<SEC-DOCUMENT>0001055726-20-000048.txt : 20200810
<SEC-HEADER>0001055726-20-000048.hdr.sgml : 20200810
<ACCEPTANCE-DATETIME>20200810154748
ACCESSION NUMBER:		0001055726-20-000048
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200810
DATE AS OF CHANGE:		20200810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		201089118

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-6302010q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:4C2F7DB8F2745B3CA27B296B6AC4DFBD,x:11bccee559de4a49a441dcb75b033f36-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:sheci="http://fasb.org/stm/sheci/2020-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2020-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2020-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2020-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2020-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2020-01-31" xmlns:equity="http://fasb.org/dis/equity/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ides="http://fasb.org/dis/ides/2020-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2020-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2020-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2020-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2020-01-31" xmlns:ei="http://fasb.org/dis/ei/2020-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2020-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2020-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2020-01-31" xmlns:srt-all="http://fasb.org/srt-all/2020-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2020-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2020-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2020-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2020-01-31" xmlns:se="http://fasb.org/dis/se/2020-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2020-01-31" xmlns:hco="http://fasb.org/dis/hco/2020-01-31" xmlns:soi="http://fasb.org/stm/soi/2020-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2020-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2020-01-31" xmlns:spc="http://fasb.org/stm/spc/2020-01-31" xmlns:ts="http://fasb.org/dis/ts/2020-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:rd="http://fasb.org/dis/rd/2020-01-31" xmlns:sr="http://fasb.org/dis/sr/2020-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2020-01-31" xmlns:guar="http://fasb.org/dis/guar/2020-01-31" xmlns:te="http://fasb.org/dis/te/2020-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2020-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:ni="http://fasb.org/dis/ni/2020-01-31" xmlns:dr="http://fasb.org/dis/dr/2020-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2020-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2020-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2020-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2020-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2020-01-31" xmlns:iago="http://fasb.org/dis/iago/2020-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2020-01-31" xmlns:con="http://fasb.org/dis/con/2020-01-31" xmlns:leas="http://fasb.org/dis/leas/2020-01-31" xmlns:com="http://fasb.org/stm/com/2020-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:inv="http://fasb.org/dis/inv/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2020-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2020-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2020-01-31" xmlns:oi="http://fasb.org/dis/oi/2020-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2020-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2020-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:cn-part="http://fasb.org/cn-part/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2020-01-31" xmlns:srt-std="http://fasb.org/srt-std/2020-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2020-01-31" xmlns:re="http://fasb.org/dis/re/2020-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ir="http://fasb.org/dis/ir/2020-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2020-01-31" xmlns:soc="http://fasb.org/stm/soc/2020-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2020-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2020-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2020-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2020-01-31" xmlns:regop="http://fasb.org/dis/regop/2020-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2020-01-31" xmlns:ero="http://fasb.org/dis/ero/2020-01-31" xmlns:ino="http://www.inovio.com/20200630" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2020-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2020-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invco="http://fasb.org/dis/invco/2020-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2020-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2020-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2020-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2020-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2020-01-31" xmlns:aro="http://fasb.org/dis/aro/2020-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2020-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2020-01-31" xmlns:pay="http://fasb.org/dis/pay/2020-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2020-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2020-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2020-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2020-01-31" xmlns:eps="http://fasb.org/dis/eps/2020-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2020-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2020-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:crcrb="http://fasb.org/dis/crcrb/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2020-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2020-01-31" xmlns:lea="http://fasb.org/dis/lea/2020-01-31" xmlns:disops="http://fasb.org/dis/disops/2020-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2020-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2020-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2020-01-31" xmlns:nt="http://fasb.org/dis/nt/2020-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2020-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2020-01-31" xmlns:cce="http://fasb.org/dis/cce/2020-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2020-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2020-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2020-01-31" xmlns:acec="http://fasb.org/dis/acec/2020-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2020-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2020-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2020-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2020-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2020-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2020-01-31" xmlns:ru="http://fasb.org/dis/ru/2020-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2020-01-31" xmlns:foct="http://fasb.org/dis/foct/2020-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2020-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2020-01-31" xmlns:diha="http://fasb.org/dis/diha/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ap="http://fasb.org/dis/ap/2020-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:eui="http://fasb.org/dis/eui/2020-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:AmendmentFlag" id="Fact-FB458C139E05CB4215F07A9E0A82058A-wk-Fact-FB458C139E05CB4215F07A9E0A82058A" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-29F90C69A8EE4A6804DF7A9E0ABD05FD-wk-Fact-29F90C69A8EE4A6804DF7A9E0ABD05FD">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-33FD3EDBDB9B711D49C47A9E0AC0D495-wk-Fact-33FD3EDBDB9B711D49C47A9E0AC0D495">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-92BF7CC8BB8FA1501E227A9E0AA09E4E-wk-Fact-92BF7CC8BB8FA1501E227A9E0AA09E4E">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-294FEC1FAC2272B17E107A9E0AB306A1-wk-Fact-294FEC1FAC2272B17E107A9E0AB306A1">0001055726</ix:nonNumeric><ix:nonFraction decimals="0" unitRef="usd" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" name="ino:CollaborativeAgreementFundingReceived" id="Fact-C6023C4FCFA867982FE986AC7FEF9DB2-wk-Fact-C6023C4FCFA867982FE986AC7FEF9DB2">0</ix:nonFraction><ix:nonNumeric contextRef="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" id="Fact-1280E348174B39C2F6397AD749CC0EF9-wk-Fact-1280E348174B39C2F6397AD749CC0EF9">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" name="ino:CollaborativeArrangementTerm" id="Fact-F93F8A3AD1253A5A02B77ACAFE59DA3C-wk-Fact-F93F8A3AD1253A5A02B77ACAFE59DA3C">P5Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" id="Fact-5940286619FA582B94BE7A9E0AB3D38C-wk-Fact-5940286619FA582B94BE7A9E0AB3D38C">0.06</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q2YTD_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="Fact-F92331A0F68BEDF2A7BC7A9E0A77561B-wk-Fact-F92331A0F68BEDF2A7BC7A9E0A77561B">P1Y</ix:nonNumeric><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-3519EE79828E1EAB699FA66FB714DAD4-wk-Fact-3519EE79828E1EAB699FA66FB714DAD4">26944620</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-BAB2C0F4BA90E8C0E7C2A66FAF8605A0-wk-Fact-BAB2C0F4BA90E8C0E7C2A66FAF8605A0">14585653</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-49A09E6BE4DDB1D0179CA66FB1F251AA-wk-Fact-49A09E6BE4DDB1D0179CA66FB1F251AA">0</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-1A85EDE3919AB04C39C4A66FB47C2DB0-wk-Fact-1A85EDE3919AB04C39C4A66FB47C2DB0">0</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-57A56E0EBE5A00BE9F90A66FAD616EE4-wk-Fact-57A56E0EBE5A00BE9F90A66FAD616EE4">8456</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-450595384C4496DD13A2A66FA403D9D2-wk-Fact-450595384C4496DD13A2A66FA403D9D2">10770319</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-3330195FA2E12BA52803A66FAB26A0DD-wk-Fact-3330195FA2E12BA52803A66FAB26A0DD">1580192</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-44ED07BD57A0A7C58EFCA66FA7C22766-wk-Fact-44ED07BD57A0A7C58EFCA66FA7C22766">0</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-2D92F0A3D160BA7CCDB2A66F53C4EE69-wk-Fact-2D92F0A3D160BA7CCDB2A66F53C4EE69">32622537</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-01B321C801547C9C017CA66F45211140-wk-Fact-01B321C801547C9C017CA66F45211140">14585653</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-158979117164AB4363D1A66F49F6FCDE-wk-Fact-158979117164AB4363D1A66F49F6FCDE">4962364</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-A0FD3014CA1AC2E32B2AA66F4ED44E24-wk-Fact-A0FD3014CA1AC2E32B2AA66F4ED44E24">1009450</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-C4825AC303551AFF9384A66F422ECF26-wk-Fact-C4825AC303551AFF9384A66F422ECF26">3309</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-4938A161BD19B142DCBFA66F37D95833-wk-Fact-4938A161BD19B142DCBFA66F37D95833">9193096</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-AABB3F09D8E7D7CE00D5A66F3D944DA1-wk-Fact-AABB3F09D8E7D7CE00D5A66F3D944DA1">2868665</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-19B467D591FA63F8B538A66F3A514205-wk-Fact-19B467D591FA63F8B538A66F3A514205">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-36BE240D32E4C40F760F7A9E0A69B6F2-wk-Fact-36BE240D32E4C40F760F7A9E0A69B6F2">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-8D3E88DAFC5DD09869967A9E0A6A4226-wk-Fact-8D3E88DAFC5DD09869967A9E0A6A4226">0.001</ix:nonFraction><ix:nonFraction decimals="7" unitRef="number" contextRef="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-71FC66547215A9F88C8B7A9E0AB35B8F-wk-Fact-71FC66547215A9F88C8B7A9E0AB35B8F">0.1858045</ix:nonFraction><ix:nonFraction decimals="10" unitRef="number" contextRef="D2019Q3Aug1Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-ABACCD3791E8172FF66E7A9E0AAED6DF-wk-Fact-ABACCD3791E8172FF66E7A9E0AAED6DF">0.0003517658</ix:nonFraction><ix:nonFraction decimals="10" unitRef="number" contextRef="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-128D08EE868916305EF47A9E0AAA6F58-wk-Fact-128D08EE868916305EF47A9E0AAA6F58">0.0002110595</ix:nonFraction><ix:nonFraction decimals="10" unitRef="number" contextRef="D2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-631B00DDD3C35FE3AAB57A9E0AA8E632-wk-Fact-631B00DDD3C35FE3AAB57A9E0AA8E632">0.0003579611</ix:nonFraction><ix:nonFraction decimals="10" unitRef="number" contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-7DA61F3652A57BFE63327A9E0AAEF62E-wk-Fact-7DA61F3652A57BFE63327A9E0AAEF62E">0.0002147766</ix:nonFraction><ix:nonFraction decimals="10" unitRef="number" contextRef="D2020Q2Aug01_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-B7CEE9999956A604D0887A9E0AA0BEA1-wk-Fact-B7CEE9999956A604D0887A9E0AA0BEA1">0.0002756873</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-7F638E84BAB17FDFDE417A9E0AB3B276-wk-Fact-7F638E84BAB17FDFDE417A9E0AB3B276">0.01</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-6F771BB2D53F089145127AE2FD95882F-wk-Fact-6F771BB2D53F089145127AE2FD95882F">P2Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-2099AE7C872E7367B0E17A9E0A69CD4B-wk-Fact-2099AE7C872E7367B0E17A9E0A69CD4B">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-E59F987B7BD4C3E0DF977A9E0A6A9CD0-wk-Fact-E59F987B7BD4C3E0DF977A9E0A6A9CD0">0.001</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-2E496096F745EDE869FF867954C558C5-wk-Fact-2E496096F745EDE869FF867954C558C5">31000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-A568BB507C5B333180DD86797E9D709F-wk-Fact-A568BB507C5B333180DD86797E9D709F">63000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="ino-20200630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Aug07">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1June01_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_OwnershipAxis_ino_VGXAnimalHealthIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:VGXAnimalHealthIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2005Q1Jan31_us-gaap_BusinessAcquisitionAxis_ino_InovioAsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:InovioAsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2005-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2009Q2_us-gaap_BusinessAcquisitionAxis_ino_VgxPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:VgxPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2009-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q2Apr_us-gaap_BusinessAcquisitionAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-26</xbrli:startDate>
			<xbrli:endDate>2019-12-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan02_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-19</xbrli:startDate>
			<xbrli:endDate>2019-03-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Aug01_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-01</xbrli:startDate>
			<xbrli:endDate>2020-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-26</xbrli:startDate>
			<xbrli:endDate>2019-12-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Aug1Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan1_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Apr_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-03</xbrli:startDate>
			<xbrli:endDate>2020-04-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q2May_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-05-01</xbrli:startDate>
			<xbrli:endDate>2015-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2010Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-01-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb20_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Nov1Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-01</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2013Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_SanDiegoOfficeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_PlymouthMeetingPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3Sept1Sept30_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1March1March31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Aug1Aug30_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-08-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-11</xbrli:startDate>
			<xbrli:endDate>2018-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_INO4800Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3Aug7_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-08-07</xbrli:startDate>
			<xbrli:endDate>2015-08-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA2000DeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Jan1Jan31_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct1Oct31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec31_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb1Feb28_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan31_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan31_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-01</xbrli:startDate>
			<xbrli:endDate>2020-06-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2July1toJuly31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-07-01</xbrli:startDate>
			<xbrli:endDate>2020-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Aug10_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2Aug1toAug10_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-01</xbrli:startDate>
			<xbrli:endDate>2020-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2July1toJuly31_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-07-01</xbrli:startDate>
			<xbrli:endDate>2020-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="day">
		<xbrli:measure>ino:day</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="investment">
		<xbrli:measure>ino:investment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="krw">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>ino:product</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s7071FB3A94B35145B6AF2B3266F708E1"></a></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.33333333333333%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d5937929e489-wk-Fact-EB3C09FF76E6D2B4A5C57B0907D73F81" name="dei:DocumentType" contextRef="FD2020Q2YTD"><span style="font-size:14pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:14pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d5937929e506-wk-Fact-D791840516AA4A716EC57B0DEF959ECE" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">      </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> FOR THE QUARTERLY PERIOD ENDED </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d5937929e518-wk-Fact-A1C783ED84FBAA4768C27B0FA4CE541D" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q2YTD" format="ixt:datemonthdayyearen">JUNE 30, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">OR</span></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d5937929e537-wk-Fact-5CD63F4E256C8BCD4F9E7B0ECEC1E333" name="dei:DocumentTransitionReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">COMMISSION FILE NO.&#160;</span><span><ix:nonNumeric id="d5937929e550-wk-Fact-795EC545147CF8B54AEB7B109FAA3975" name="dei:EntityFileNumber" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">001-14888</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:248px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:248px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;"><img src="inoviologosw.jpg" alt="inoviologosw.jpg" style="height:64px;width:204px;"></img></div><div style="line-height:120%;text-align:center;font-size:13pt;"><span style="font-family:inherit;font-size:13pt;">&#160;</span><span><ix:nonNumeric id="d5937929e574-wk-Fact-8EAFF210DA38E98B88BA7B1283063A8D" name="dei:EntityRegistrantName" contextRef="FD2020Q2YTD"><span style="font-size:12pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:13pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:3%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d5937929e595-wk-Fact-01EF7FD1235DBA5423147B1BFCE353E0" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d5937929e605-wk-Fact-1A9191B4FFDB4AE0EC9A7B1CE7B70BF3" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q2YTD">33-0969592</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span><ix:nonNumeric id="d5937929e648-wk-Fact-1E05D7B71FA77655E2F5DB64CC9E22DA" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">660 W. GERMANTOWN PIKE, SUITE 110 </span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span><ix:nonNumeric id="d5937929e654-wk-Fact-F6BBEC5BE0E385D037F1DB64E7FC11B3" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">PLYMOUTH MEETING</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d5937929e659-wk-Fact-88B140FBDB80A869704F32AA35424DFC" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">PA</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">  </span><span><ix:nonNumeric id="d5937929e664-wk-Fact-1759C1EF8B7AB8DAB4642EA711C88AC5" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">19462</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (</span><span><ix:nonNumeric id="d5937929e677-wk-Fact-0F497D56D00097F116FE7B1F74D6EB4B" name="dei:CityAreaCode" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">267</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d5937929e682-wk-Fact-D277D0D2EE0AAF97D93C7B202324DFE5" name="dei:LocalPhoneNumber" contextRef="FD2020Q2YTD"><span style="font-size:9pt;font-weight:bold;">440-4200</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.93548387096774%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:43%;"></td><td style="width:15%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Title of Each Class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Trading Symbol(s)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d5937929e722-wk-Fact-5F7643A56F5B44F08F7C7B242B32CAD7" name="dei:Security12bTitle" contextRef="FD2020Q2YTD">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d5937929e727-wk-Fact-0522E6E83EF2426E07A07B242BFF78D0" name="dei:TradingSymbol" contextRef="FD2020Q2YTD">INO</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d5937929e732-wk-Fact-C91557AC81DD7B3872D87B242AF74055" name="dei:SecurityExchangeName" contextRef="FD2020Q2YTD" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.33333333333333%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d5937929e754-wk-Fact-31AF117066E0707F13C27B4DF862DAD1" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q2YTD"><span style="font-size:9pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9746;</span><span style="font-family:inherit;font-size:9pt;">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d5937929e768-wk-Fact-9C5EC16805C54F0FFFBA7B4EA4A9FAE5" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q2YTD"><span style="font-size:9pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9746;</span><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:21%;"></td><td style="width:3%;"></td><td style="width:51%;"></td><td style="width:22%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Large&#160;accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d5937929e812-wk-Fact-6CD2C12CA68F1B4CB1297B4F687417B2" name="dei:EntityFilerCategory" contextRef="FD2020Q2YTD" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9746;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d5937929e869-wk-Fact-1D7D08BCA9385A0638897B4FBDF64EDF" name="dei:EntitySmallBusiness" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d5937929e921-wk-Fact-17BDD8E1DFF195D3AC607B4FE4E7E701" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d5937929e934-wk-Fact-212D751AC3B38E42AEB17B507D1BF4E9" name="dei:EntityShellCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;">        &#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9746;</span></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:9pt;"><span style="font-family:Wingdings;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was </span><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937929e946-wk-Fact-4B87D4801886FC17D73C7B50B4EACEE5" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2Aug07" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">167,520,435</ix:nonFraction></span></span><span style="font-family:inherit;font-size:9pt;"> as of </span><span style="font-family:inherit;font-size:9pt;">August&#160;7, 2020</span><span style="font-family:inherit;font-size:9pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:248px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:248px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s1AB2ECC29EE55CB395222A750C42996D"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 10-Q</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Quarterly Period Ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:83%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;" href="#s1221512018B15444AFFF718DB1F4DFA8"><span style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Part I.  Financial Information</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s1221512018B15444AFFF718DB1F4DFA8"> 1</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s1221512018B15444AFFF718DB1F4DFA8"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;1. Financial Statements</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s1221512018B15444AFFF718DB1F4DFA8"> 1</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D7F44D4AA865B3E8F0333D535EE51C4"><span style="font-family:inherit;font-size:10pt;">a) Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s2D7F44D4AA865B3E8F0333D535EE51C4"> 2</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE3361340D99592ABA108DAC31B6F400"><span style="font-family:inherit;font-size:10pt;">b) Condensed Consolidated Statements of Operations</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sCE3361340D99592ABA108DAC31B6F400"> 3</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;padding-left:16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC4000BB091EB51CBA84334B00C023A5D"><span style="font-family:inherit;font-size:10pt;">c) Condensed Consolidated Statements of Comprehensive Loss</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sC4000BB091EB51CBA84334B00C023A5D"> 4</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD90B4CDB0442533BBDCF74508B8DF3BC"><span style="font-family:inherit;font-size:10pt;">d) Condensed Consolidated Statements of Stockholders' Equity</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD90B4CDB0442533BBDCF74508B8DF3BC"><span style="font-family:inherit;font-size:10pt;">5</span></a></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF08BCF4571825C2B85B5A070B2B6BC67"><span style="font-family:inherit;font-size:10pt;">e) Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sF08BCF4571825C2B85B5A070B2B6BC67"> 7</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7327FF5A78C65B64855FAEC7CED643A7"><span style="font-family:inherit;font-size:10pt;">f) Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s7327FF5A78C65B64855FAEC7CED643A7"> 9</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s3080E15B106953F4957DD2D2BDCA1AF5"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s3080E15B106953F4957DD2D2BDCA1AF5"> 32</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s9925388AFB9256B2B863C5EFFA684F14"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s9925388AFB9256B2B863C5EFFA684F14"> 37</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sC42EAD319146535BAA0CB62342DAD4B5"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;4. Controls and Procedures</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sC42EAD319146535BAA0CB62342DAD4B5"> 38</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;" href="#sFCE84EC98CBC5C1EBE706630F89FDAB0"><span style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Part II.  Other Information</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sFCE84EC98CBC5C1EBE706630F89FDAB0"> 39</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sB0415D0CF1E454ACA468388AF40406E4"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;1. Legal Proceedings</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sB0415D0CF1E454ACA468388AF40406E4"> 39</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s1A885C5BEE545FC19984C3BA88359DA6"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;1A. Risk Factors</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s1A885C5BEE545FC19984C3BA88359DA6"> 39</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s2219AA4CA0455699A368E8E29B4DBCE1"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s2219AA4CA0455699A368E8E29B4DBCE1"> 59</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9A470E5F1CFD57C285DA2E389A0A14D9"><span style="font-family:inherit;font-size:10pt;">Item&#160;3. Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s9A470E5F1CFD57C285DA2E389A0A14D9"> 59</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7F1B10C7A39F5028B2078CCC1AA5EE2A"><span style="font-family:inherit;font-size:10pt;">Item&#160;4. Mine Safety Disclosures</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s159AECE47CC9539B844C5C7534326CF9"> 59</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s159AECE47CC9539B844C5C7534326CF9"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;5. Other Information</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s159AECE47CC9539B844C5C7534326CF9"> 59</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sFB507579071A5812955FA13557B72D6A"><span style="font-family:inherit;font-size:10pt;vertical-align:middle;">Item&#160;6. Exhibits</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#sFB507579071A5812955FA13557B72D6A"> 59</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:middle;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;" href="#s30DE353666CA5D649B004951779A97C1"><span style="font-family:inherit;font-size:10pt;font-weight:bold;vertical-align:middle;">Signatures</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:middle;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;vertical-align:middle;" href="#s30DE353666CA5D649B004951779A97C1"> 61</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s1221512018B15444AFFF718DB1F4DFA8"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Part I.  Financial Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 1</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2D7F44D4AA865B3E8F0333D535EE51C4"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90338164251207%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e664-wk-Fact-B5F429C7F247C59B8C357A9E0AB79C8F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">215,432,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e683-wk-Fact-B85135F763B9B23904917A9E0AD2BD18" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">22,196,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e698-wk-Fact-22755D6E0E1ADE4277BD7A9E0AB3DE60" name="us-gaap:ShortTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">156,231,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e717-wk-Fact-641EE90B79DEE0169BE07A9E0A8C5D50" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">67,338,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e737-wk-Fact-80B405605EBB14D2720B7A9E0AD5B154" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,513,159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e756-wk-Fact-CFA3AADD1F88FDD9BE7D7A9E0AA01E4C" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">700,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e776-wk-Fact-9169CBB8F9706E1FC1D07A9E0A8C1B64" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">482,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e795-wk-Fact-E165221EDA5822F98E1F7A9E0A77CB30" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,332,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e815-wk-Fact-8D842E33379021BC0B267A9E0AB3BCAF" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,591,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e834-wk-Fact-5809192925EBB0014C5C7A9E0A825EEC" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,584,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e854-wk-Fact-850FAFF0888D6FD6D88A7A9E0AB71C42" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,811,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e873-wk-Fact-90C0DFEB55A5784BF0107A9E0A997250" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,050,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e893-wk-Fact-4FE8509ACA8B0BF915497A9E0AC6E6FA" name="us-gaap:AssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">382,062,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e912-wk-Fact-C8089D2D407F81CC051B7A9E0AD62A62" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">94,200,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Fixed assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e933-wk-Fact-CC6E538F644D87E5F08B7A9E0AB2BC85" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">11,323,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e952-wk-Fact-E4B130F5D5F400D50B007A9E0A774C26" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">12,773,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e972-wk-Fact-8A28232C2C60F1912CD07A9E0AAE4AA2" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">17,327,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e991-wk-Fact-3FC076352E6AF30B7CC57A9E0AA027F3" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,315,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Investment in Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1011-wk-Fact-9A69A48397097CEDABCE7A9E0AB741B7" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,717,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1030-wk-Fact-4F29B005F4C5B28C95A57A9E0A8CDF6B" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1050-wk-Fact-5AEF9FB28C71FDB93E127A9E0AD48F24" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,420,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1069-wk-Fact-41EFE250074670975DCF7A9E0A824ADF" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,693,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1089-wk-Fact-4C743719408FD2CB5FDF7A9E0A77B25E" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,513,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1108-wk-Fact-45EAD88160297DD80C547A9E0AC8ABE1" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,513,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1128-wk-Fact-C65939662370B8EEC6307A9E0AA05F7A" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">13,265,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1147-wk-Fact-81BBDBBC0C581B27C0517A9E0AAAD232" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">13,783,009</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1167-wk-Fact-719B448B303ED3E0AF3D7A9E0AC00167" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,555,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1186-wk-Fact-F2054E4E12CF12A0AE9C7A9E0AAAF842" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,672,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1211-wk-Fact-F5342BBC550BD31D10937A9E0AC8FF80" name="us-gaap:Assets" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">443,185,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1230-wk-Fact-757BCCF52DBBEFB538267A9E0A8C0D4F" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">143,951,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1332-wk-Fact-DD8CAA388F5B176B6AF77A9E0ABC2395" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">17,216,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1351-wk-Fact-46AD4C82266089489CCA7A9E0AB3A4D9" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">18,237,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses due to affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1367-wk-Fact-DE1EE51FC7708321A9F97A9E0A952F5E" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">511,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1386-wk-Fact-ED0A47C95B0971A1BD867A9E0AAAFD54" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">729,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued clinical trial expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1406-wk-Fact-E527A2F043CA74790D487A9E0AA0C6CE" name="ino:AccruedClinicalTrialExpenseCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,870,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1425-wk-Fact-7E592572087026714D727A9E0AA0A448" name="ino:AccruedClinicalTrialExpenseCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,049,727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1445-wk-Fact-3803BD82D685E9C6CA747A9E0AAE5349" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">14,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1464-wk-Fact-39CE463B497631DDEE0B7A9E0AAE7A91" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">92,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1484-wk-Fact-BCB20AA4AF0A3A754D8C7A9E0A82392F" name="ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">94,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1503-wk-Fact-A06FF84A0DEBADD056957A9E0AD52417" name="ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">31,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1523-wk-Fact-2AB65C70DCF3DADCE7897A9E0AB7809D" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,200,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1542-wk-Fact-7BF8BE87B83EF5C9F8C77A9E0A957CBB" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,074,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Grant funding liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1562-wk-Fact-E5BEF5FDADEB5510EF707A9E0A823385" name="ino:DeferredGrantFundingCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,330,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1581-wk-Fact-D1B95A791DEBA27573497A9E0A99E205" name="ino:DeferredGrantFundingCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,065,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Grant funding liability from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1601-wk-Fact-7641B35BEF281F48A72B7A9E0A950D58" name="ino:DeferredGrantFundingFromAffiliateCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">742,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1620-wk-Fact-8FD047B20B2189DD9E897A9E0A8CA808" name="ino:DeferredGrantFundingFromAffiliateCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">708,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1640-wk-Fact-8C0B6FE7BA2E661F296E7A9E0AC8950E" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">37,981,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1659-wk-Fact-480432A460080A33E9BE7A9E0AAD5C50" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">31,989,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1679-wk-Fact-6ABCC36353F99DA2F28C7A9E0A6ECB79" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">86,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1698-wk-Fact-74782474F022BE31003E7A9E0A773630" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">101,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible senior notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1718-wk-Fact-BED82455FD7C256849307A9E0A8245E4" name="us-gaap:ConvertibleDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">65,844,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1737-wk-Fact-F18E478FA649FDDDC4CD7A9E0A99A3A4" name="us-gaap:ConvertibleDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">64,180,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1757-wk-Fact-992D364C2B8C78E8FCAA7A9E0AD1B17B" name="us-gaap:ConvertibleDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">13,718,528</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1776-wk-Fact-0252681AD3E7D65B43FA7A9E0A949252" name="us-gaap:ConvertibleDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">12,842,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liability </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1797-wk-Fact-71A405789FCF965068E97A9E0A9F36A0" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">119,796,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1816-wk-Fact-E29CDF0F4FA32DB2C7667A9E0AC0FD18" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">8,819,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liability, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1836-wk-Fact-BA02CD1A6B2124CED8577A9E0AB3A86D" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">19,261,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1855-wk-Fact-6C7815B0B45AE7CEB8E07A9E0AC8ED39" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">20,409,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1875-wk-Fact-34C6D0F72A1D3DBB66037A9E0AA0D358" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">32,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1894-wk-Fact-18C37B30657B2F0C08537A9E0AA0F87A" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">32,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Grant funding liability from affiliated entity, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1914-wk-Fact-F4C6ACAD4A1EC9A8F34B7A9E0A8C8E59" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">37,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1933-wk-Fact-FD9457B7E9460DC76CCC7A9E0AA0CF2D" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">135,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1953-wk-Fact-CCCA586843F80F4887217A9E0AAEB840" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">66,629</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1972-wk-Fact-B8E18732E77361FCE05F7A9E0AB75597" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">36,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e1992-wk-Fact-DCD84296D0787D1AE1F47A9E0A7C6FC8" name="us-gaap:Liabilities" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">256,824,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2011-wk-Fact-363D40E7E1FEFC6436A07A9E0AC826B4" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">138,546,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2072-wk-Fact-86CA08EE2365E74922EA7A9E0AC0A4C6" name="us-gaap:PreferredStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2091-wk-Fact-812AAD7F1AAA83ABA6617A9E0A995A4B" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2111-wk-Fact-37E5D18AE2BC3FADEE107A9E0A8BE9A6" name="us-gaap:CommonStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">158,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2130-wk-Fact-3D85BD481A7BC97F73997A9E0AD43294" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">101,361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2150-wk-Fact-06AD46CB46D4F61005E57A9E0AAA1460" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,087,745,242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2169-wk-Fact-0527B72EC87861F5924F7A9E0A95787B" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">742,646,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d5937166e2189-wk-Fact-E782D6A385EB18BA267F7A9E0AA0D156" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">901,029,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d5937166e2209-wk-Fact-4D93FAE553BAC9B796A17A9E0A82CE26" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">739,785,655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d5937166e2231-wk-Fact-BBD9A44C6062C07033B97A9E0AB79942" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">610,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2251-wk-Fact-9558CF511ED1CEA8F6FD7A9E0A8C8616" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">472,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2271-wk-Fact-68113EC39852FA0B6A167A9E0A6E2ED4" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">186,264,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2290-wk-Fact-86F3026D0C8E2019A1F57A9E0A8C0CE9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,435,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2310-wk-Fact-5CAF4CBB6F9966C2D2317A9E0AAA63C0" name="us-gaap:MinorityInterest" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">96,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2329-wk-Fact-DA3B3372DE1E773E23AE7A9E0AC8CE8B" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,969,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2349-wk-Fact-5CB95FF0F6D850B0EA7D7A9E0A7CE12E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">186,360,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2368-wk-Fact-E52BD533C888BDEDC4CA7A9E0A820848" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,404,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2393-wk-Fact-CDFD50F21C1C77D594AF7A9E0A7C44E4" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">443,185,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d5937166e2412-wk-Fact-E345D87F83E18A01174F7A9E0AA96257" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">143,951,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 2</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCE3361340D99592ABA108DAC31B6F400"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.89888776541962%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e759-wk-Fact-5397989B1CF5012AA1D97A9E0A99B49C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">74,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e778-wk-Fact-942EB1FC23DD15DC2D747A9E0AAEEAE2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">64,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e797-wk-Fact-7AC3A1A2F0B21CDFED4F7A9E0A76ECEB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">145,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e817-wk-Fact-031CED6F9D6616B97CB07A9E0A6418D6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,834,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e832-wk-Fact-E337AEC5E0218183FC667A9E0AAA0E25" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">95,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e851-wk-Fact-80C6D9154F2E7D774A997A9E0AC869CA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">71,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e870-wk-Fact-9F4FB82A9529BF8A25427A9E0AD38689" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,267,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e890-wk-Fact-3901CF19CBAEE67CA2B57A9E0AC74736" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">126,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Miscellaneous revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e910-wk-Fact-02E1EEF55F57280EBAD37A9E0AA00510" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">97,939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e929-wk-Fact-A7DD9AAFC242D6D24F257A9E0AAA3527" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e948-wk-Fact-F2AE288F8AE918C282B37A9E0A6C45BD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">181,587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e968-wk-Fact-2514372CF84B044105277A9E0A82D3E9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e988-wk-Fact-8181045FB2D5BBFD40F77A9E0AC0A69B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">267,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1007-wk-Fact-2D819B14A5BD48FDE9EA7A9E0AA01CA2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">135,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1026-wk-Fact-2C54494AA51BF8DE41827A9E0A647627" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,594,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1046-wk-Fact-529C9D6DF745C442E0EA7A9E0A69672B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,965,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1148-wk-Fact-34828E2DBB79987F4F147A9E0A826779" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">22,376,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1167-wk-Fact-4707659EAC753569DCD97A9E0A762179" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">22,486,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1186-wk-Fact-05D34F7B29C4B06D23C37A9E0AD7533A" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">41,487,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1206-wk-Fact-32E77F4C6FA9F0C290107A9E0AD1077B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">46,876,155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1226-wk-Fact-51B697B3F647FD45F6877A9E0A804DA4" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">11,071,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1245-wk-Fact-D5E4CA0A306477375EFE7A9E0A7C38B7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,850,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1264-wk-Fact-A01D2DDD373661DFBEED7A9E0A6E171B" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">18,519,864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1284-wk-Fact-516319F9C3421F75652A7A9E0A6E716D" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">12,825,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1304-wk-Fact-D20B379FC7A10480FC797A9E0AAEDEF7" name="us-gaap:OperatingExpenses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">33,448,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1323-wk-Fact-892E00232E3DDFDD0D917A9E0AD1B9CD" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">28,336,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1342-wk-Fact-2A79128E1B564AE3E0287A9E0A825912" name="us-gaap:OperatingExpenses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">60,007,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1362-wk-Fact-F8F4ECB4626311584AEC7A9E0A5B9796" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">59,701,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1383-wk-Fact-BB7575C02FC8367B2B8C7A9E0AB32D2E" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">33,180,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1403-wk-Fact-65880E4C64076DA065547A9E0AA0676A" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">28,200,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1423-wk-Fact-5607D61E32628041E2F97A9E0A82FB5B" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">58,413,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1444-wk-Fact-78F0AF1B8ABE920AE47E7A9E0A7C916F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">56,735,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (expense):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1547-wk-Fact-17289C6F2CCE315BB79B7A9E0AD4229B" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,067,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1566-wk-Fact-07D426C922D44378F7F67A9E0A95C187" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">755,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1585-wk-Fact-3B2898B631BE5396592E7A9E0A675F93" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,483,968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1605-wk-Fact-4D6CACF8755F709FB51F7A9E0AC07FE8" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,380,864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1625-wk-Fact-B42926336E54E395B3587A9E0A828958" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,846,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1645-wk-Fact-BBFA072347E4F5FD50867A9E0A9907E6" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,194,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1665-wk-Fact-01420528B290DB0BA08E7A9E0AC7E155" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,650,396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1686-wk-Fact-7C9E674D30A9691AF1EA7A9E0AC06095" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,851,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1707-wk-Fact-9CFDDC363EE9F2089C6A7A9E0AC82645" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">97,755,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1727-wk-Fact-E2A7C8DDCA8FD8DE8D207A9E0A95365B" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1746-wk-Fact-B36C921F513672FD83B77A9E0A829735" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">110,976,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1767-wk-Fact-CA024247493179FF658D7A9E0A5C1108" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain (loss) on investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1787-wk-Fact-113AA4A5981CA1A97F7E7A9E0ADB123B" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">3,883,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1807-wk-Fact-1B02F38CB709DCF929277A9E0A8CB520" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">173,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1827-wk-Fact-F6A96CD149825F66836E7A9E0A687A78" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">9,298,443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1847-wk-Fact-7B02690ADD5F499786EB7A9E0A7675EF" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">923,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on available-for-sale equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1868-wk-Fact-A2C0E810F9983D999694C68174900613" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,358,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1887-wk-Fact-1919C2E0721664E4A31CC68174802C2E" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1906-wk-Fact-03A8CDF73C455A25ECEAC6817471A4EE" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">691,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1927-wk-Fact-214C17302A7475DFC8E4C6817461C36A" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1947-wk-Fact-8080E9ED2F65335F3AAF7A9E0AA0D74B" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">152,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e1967-wk-Fact-18D3D19F2D16B7B91D717A9E0AAE5C92" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">127,512</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e1986-wk-Fact-8C3EE42EFD32D31303AD7A9E0AAA51BD" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">577,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2007-wk-Fact-8330B459248481A5B7DA7A9E0A69CBCB" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">91,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on deconsolidation of Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2027-wk-Fact-86455AB158D98870D471B5AD1CEDF3BA" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,121,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2046-wk-Fact-5542E897F448A1923749B5AD1D3B3DCB" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2065-wk-Fact-1C6B1ABCAC3AF68762C3B5AD1D1C2DDE" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,121,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2085-wk-Fact-2A7A5A93E33A9116A997B5AD1CFCCD3C" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before income tax benefit and share in net loss of Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2105-wk-Fact-6E759A4A4A24FFBA58C77A9E0AB71446" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">128,270,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2125-wk-Fact-C1CA3FB12484A2FC315E7A9E0AD618BE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,685,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2145-wk-Fact-40D906C4DB33251217797A9E0A77074C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">161,406,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2166-wk-Fact-620F7169BD916F6534B87A9E0A611874" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">59,037,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2187-wk-Fact-6126A7889CE8C630441D7A9E0A7C0F7A" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2206-wk-Fact-E094A47ECD978A8181417A9E0ADAFBBC" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">106,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2225-wk-Fact-E15FFB41D0B7DFB45B297A9E0A8209DB" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2245-wk-Fact-828C1BF01D374D2EB79B7A9E0AB30A91" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">169,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share in net loss of Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2266-wk-Fact-45EE2BA3BC2E5391D93ACA2EC20B0E71" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">901,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2286-wk-Fact-A435345325A3F06BB8F4CA2EC2116DBB" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2305-wk-Fact-EF138DCEFC740125876BCA2EC22EBAFA" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">901,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2326-wk-Fact-44606EA1753EB9F33325CA2EC21E6825" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2346-wk-Fact-8B1E762B05FFF8DE6BCE7A9E0AC0D2CC" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">129,172,466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2366-wk-Fact-8B633C1C3465A33D73D87A9E0AC8A85C" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,579,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2386-wk-Fact-724D940E836D918EC5557A9E0A8A3844" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">162,307,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2407-wk-Fact-343497D076BA424517FF7A9E0A7CB9DD" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">58,867,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2428-wk-Fact-6343067E5D0BBCBCABC67A9E0AD387E5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">469,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2447-wk-Fact-EE590DE7892298537C2D7A9E0A7B9F79" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">191,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2466-wk-Fact-C7B4ADA5D00C5E9D2D837A9E0A62DF4C" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,063,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2486-wk-Fact-FE0B41372E6C00AA56BF7A9E0A6E4D8E" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">261,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2511-wk-Fact-0C228D272FE150AEBE1E7A9E0ADA1F0E" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">128,703,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2531-wk-Fact-1668132808B558ABAC4B7A9E0AA0FC0D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,387,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2551-wk-Fact-F45C1800BCB88D52B1317A9E0A827962" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">161,244,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2572-wk-Fact-406064D56F47A34D437D7A9E0A66E3BE" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">58,606,488</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2675-wk-Fact-C0824A96B5664703EE677A9E0A8C7B90" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2695-wk-Fact-A330C279F4DFA6C5C7DD7A9E0A994E78" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2715-wk-Fact-EC5D8D5AD459F31D28A07A9E0AD3ED82" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941018e2736-wk-Fact-36A08A29D20BF8D9AD617A9E0AAE6E76" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average number of common shares outstanding </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2834-wk-Fact-9B7AEB5286B0773A421C7A9E0AD1B583" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">155,807,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2853-wk-Fact-8B9E1D92FB1E4E52C6587A9E0AD6CA2B" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">98,083,896</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2872-wk-Fact-5059CC009BF30E64113D7A9E0A7CA4E7" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">140,215,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941018e2892-wk-Fact-3AB26B4EF87638DACBBB7A9E0A8C3C4E" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">97,795,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 3</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC4000BB091EB51CBA84334B00C023A5D"></a></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e678-wk-Fact-8B1E762B05FFF8DE6BCE7A9E0AC0D2CC" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">129,172,466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e698-wk-Fact-8B633C1C3465A33D73D87A9E0AC8A85C" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,579,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e718-wk-Fact-724D940E836D918EC5557A9E0A8A3844" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">162,307,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e739-wk-Fact-343497D076BA424517FF7A9E0A7CB9DD" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">58,867,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e837-wk-Fact-67FB19C5658A41A4DB917A9E0A6B74AA" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">846,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e856-wk-Fact-9E551AB1B561B6265C727A9E0A6AD8EB" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">441,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e875-wk-Fact-ABCA954AA2943B00B3337A9E0A8C4C51" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,082,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e896-wk-Fact-0CCA1FECC682BCDEDC667A9E0A8286FC" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,260,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e916-wk-Fact-B4DA8D25E0BD00539BE37A9E0A682F9F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">128,325,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e936-wk-Fact-E887D7E6E8EFB3F574247A9E0A5C2B7D" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,137,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e956-wk-Fact-AB6AEAA2B62DA33955B17A9E0A779D70" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">163,390,508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e977-wk-Fact-22E1D03ABEE6CA1D4EB87A9E0A996D29" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">57,607,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e998-wk-Fact-1C8CDA9A98C3F362693C7A9E0A64D065" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">469,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e1017-wk-Fact-5AE888941C00FF49486E7A9E0A6799C1" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">191,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e1036-wk-Fact-D46CDB551264B484C0317A9E0A6EEBF1" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,063,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5941860e1056-wk-Fact-2B29D087E62AE011DD8C7A9E0A778FD0" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">261,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e1081-wk-Fact-1A6CBC43E1D4B2DA84157A9E0A5A0E4D" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">127,856,159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e1101-wk-Fact-9D7CDE46F545F7911FA57A9E0A662A86" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">28,945,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e1121-wk-Fact-0ABE52FCF8B0E5BAC0727A9E0A6E2C87" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">162,326,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5941860e1142-wk-Fact-7FFE1636A383422B96827A9E0A9999D2" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">57,345,766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD90B4CDB0442533BBDCF74508B8DF3BC"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="34"></td></tr><tr><td style="width:25%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three and Six Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number<br/>of&#160;shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number<br/>of shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional<br/>paid-in<br/>capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-<br/>controlling<br/>interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br/>stockholders&#8217;<br/>equity</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1045-wk-Fact-5CC82674A68F0AF5D76A7A9E0AAA91E7" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1064-wk-Fact-8B53D56C577DDB290A1A7A9E0AA0CD95" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1078-wk-Fact-B745093D47A23E37D49A7A9E0AAA1162" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,361,034</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1098-wk-Fact-28B80BD7100592D3F4807A9E0AA978D3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">101,361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1117-wk-Fact-A3B4BEA7BAAF1921359C7A9E0AAA0469" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">742,646,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e1136-wk-Fact-92F377F5D91BA236C84E7A9E0AA0CF02" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">739,785,655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1157-wk-Fact-44CB4474409AF4DC26357A9E0AA08137" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">472,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1176-wk-Fact-A73F466444E25F134ADF7A9E0AAAD4C4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,969,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1195-wk-Fact-E52BD533C888BDEDC4CA7A9E0A820848" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,404,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1244-wk-Fact-55740840BFF999B1856F7A9E0AA91916" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">43,148,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1259-wk-Fact-E9236AD4D76D1906133A7A9E0AA0AAB8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">43,149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1278-wk-Fact-AB09D0F216E901493EE07A9E0AA0C435" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">208,198,784</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1355-wk-Fact-1F989506E10EB29909887A9E0AA0807C" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">208,241,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1409-wk-Fact-233861547A023E485F1C7A9E0AA05431" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,405,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1424-wk-Fact-A22F4A17715082043BC47A9E0AAA3AD2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1443-wk-Fact-477A4138DC0EADD311C97A9E0AA050D6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,099,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1520-wk-Fact-1974322FBCC23FAA7CE47A9E0AA0C544" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,100,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1608-wk-Fact-25A04BF2F7E42FA778E67A9E0AA0FF88" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,017,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e1666-wk-Fact-BD80268B1A26C4902A0A7A9E0AAAFC30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">16,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1686-wk-Fact-EF1CE2F849827C55271F7A9E0AA0908D" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,001,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Acquisition of non-controlling interest in Geneos</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1832-wk-Fact-B59C8ACB69E2F4D9FFF07A9E0AA09DA1" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,169,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e1851-wk-Fact-F5EBCDFE098D7783DFC17A9E0AA9294D" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="FD2020Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,169,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e1958-wk-Fact-8989B98C7724DE7B592E7A9E0AA00A76" name="us-gaap:ProfitLoss" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">32,541,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e1998-wk-Fact-3FA0C7623A999179EA9D7A9E0AA0C627" name="us-gaap:ProfitLoss" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">594,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2018-wk-Fact-FAFE1B00E0ADE484470C7A9E0AA04365" name="us-gaap:ProfitLoss" contextRef="FD2020Q1QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">33,135,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized loss on short-term investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2146-wk-Fact-F960792843D7ECE464C47A9E0AA0051E" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,929,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2185-wk-Fact-50D54C3E52BE7C947D287A9E0AAA175F" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q1QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,929,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2207-wk-Fact-B6BD397850B75058FA207A9E0AA0E03C" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2226-wk-Fact-068726A30F6DE766949F7A9E0AA0487D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2240-wk-Fact-FCD2D0E03E3134E0337A7A9E0AA08737" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">145,915,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2260-wk-Fact-A6E7B9B53727572A6C3E7A9E0AAAF8D5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">145,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2279-wk-Fact-A4A9589E6A64A44E45417A9E0AAA8A24" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">957,962,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2298-wk-Fact-9FA7570DD7034994AB407A9E0AA0F1F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">772,326,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2319-wk-Fact-761EC99F1D954F300B917A9E0AA022AD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,456,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2339-wk-Fact-19634179A581FFA88A5A7A9E0AAA9F22" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,529,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2358-wk-Fact-1D72D17ED8C384CADADB7A9E0AA08A50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">187,854,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2408-wk-Fact-E08F60D03348EA55F8CB6234F42CFFA8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,041,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2423-wk-Fact-52AE17FE1C84A34225376234F662C2FF" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">12,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2442-wk-Fact-E9116AB88787D2498C376234F8792AE5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">121,706,881</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2519-wk-Fact-DA474D49CA166FF25F53C73372FF3B1C" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">121,718,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2540-wk-Fact-94B4CD9EF83A7315A6546D37E2288214" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2574-wk-Fact-299B95A4595AD5B9B1BC6D39FA7CD2DD" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2589-wk-Fact-DA739648DB2063A78F686D39FA1C15D0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e2608-wk-Fact-9E7AFB6C853D9B2708A86D39F9E6DB5B" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2686-wk-Fact-FD03A5034A6AAD50413D6D39F9D754BF" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2740-wk-Fact-EE4C3530AAAEF38DBFC562358610BDBC" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">794,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2755-wk-Fact-C879D131D98C80C202D86235885ACA00" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2774-wk-Fact-6FDC00020770244A60A962358A4CA12A" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,421,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2851-wk-Fact-0658181458AC8CB8CEE0C73373DDA1EF" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,422,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2939-wk-Fact-EE2199398AF034E1E54D6235A8E602AB" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,654,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e2997-wk-Fact-41A0DF2B3810C795C29B6236242935FF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">8,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3016-wk-Fact-F333AAAE842C52EBA710C73374D1B793" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,662,435</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Acquisition of non-controlling interest in Geneos</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3162-wk-Fact-5B850B0400469C83F030623625D5F123" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">209,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3181-wk-Fact-AD7FDE38B5F98BE91448C73375CE437B" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">209,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Deconsolidation of Geneos</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3327-wk-Fact-B9A7C770598A5C6D6951B9340DDFEBD9" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,181,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3347-wk-Fact-51EC36A49F9EE79CE199B9340DDAF568" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,181,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3455-wk-Fact-FE6B4EBCF9AD7157F5AB6235CF4F8263" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">128,703,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3495-wk-Fact-CAFD250E143120245735623627523B1B" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">469,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3515-wk-Fact-8B1E762B05FFF8DE6BCE7A9E0AC0D2CC" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">129,172,466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized gain on short-term investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3643-wk-Fact-0C0C57F617063CC7C3986235F801C832" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">846,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3681-wk-Fact-67FB19C5658A41A4DB917A9E0A6B74AA" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">846,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3702-wk-Fact-10F0CA1F70AB195D48D9C725D1633798" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3721-wk-Fact-63AC4A8821DB7AC8B79CC725D391019D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3735-wk-Fact-8D82D6C014CEE982F064C725D5A32B8C" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">158,756,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3755-wk-Fact-0F378E5CA7F8F692E17BC725D7EA4B39" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">158,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3774-wk-Fact-16FC987C32D64BE4FF69C725DA11C050" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,087,745,242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3793-wk-Fact-5130DAE7A8CB1C4DAABDC725DC27386C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">901,029,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e3814-wk-Fact-A4D25134E98A472FE4A7C725DE4F5A86" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">610,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3834-wk-Fact-886C76E88194244FBD5CC725E060C473" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">96,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e3853-wk-Fact-5CB95FF0F6D850B0EA7D7A9E0A7CE12E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">186,360,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 5</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="34"></td></tr><tr><td style="width:25%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="33" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three and Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number<br/>of&#160;shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number<br/>of shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional<br/>paid-in<br/>capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-<br/>controlling<br/>interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br/>stockholders&#8217;<br/>equity</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4435-wk-Fact-1F55077CE86F84CE29017A9E0AC0FB53" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4454-wk-Fact-9C96E73FA6A741FAA7DB7A9E0A6E9367" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4468-wk-Fact-281E7DB76665A68A68337A9E0A6E4E3F" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">97,225,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4488-wk-Fact-C19B6547F924259ACA2E7A9E0A77B99F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">97,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4507-wk-Fact-00C0E15BD60C2EC424247A9E0A95ABEF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">707,794,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e4526-wk-Fact-7E294594D29BA0539DB67A9E0A946292" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">620,426,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e4547-wk-Fact-A485D6E7D062035A482E7A9E0A95E811" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">528,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4567-wk-Fact-D716A5F25B64534CAD197A9E0ABFE86B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">96,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4586-wk-Fact-C30DFEF65987A4CD37DC7A9E0AC0B144" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">87,032,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4635-wk-Fact-29CDFA2C1F21413AB5557A9E0ABFBFD9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">183,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4650-wk-Fact-1850E66948F7218B36737A9E0AC0F80F" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4669-wk-Fact-025FE3EDEF6BEDA37D907A9E0AC0B3F5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">907,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4746-wk-Fact-05033509A8D5D6EA8E237A9E0AC0D3A5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">907,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4800-wk-Fact-49F5827193D890D0DA7E7A9E0A7C463C" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">525,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e4815-wk-Fact-F610B2291F15FD9D5DA57A9E0AC01108" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e4834-wk-Fact-EF96FDD53A864AFFA0787A9E0AC084C1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">719,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e4912-wk-Fact-13C59194C2CC8674D1BA7A9E0AB70917" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">719,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Equity component of issuance of convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5001-wk-Fact-E4DD0D26D2F40ED2767F7A9E0AB7BF61" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">15,752,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5078-wk-Fact-7AEEDC621C2AF8CEE0847A9E0A7B404A" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">15,752,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5166-wk-Fact-770AF1C0914D18D99C487A9E0A95A492" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,432,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5243-wk-Fact-563CCC41B4D79F28ED717A9E0A7CC8F4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,432,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Acquisition of non-controlling interest in Geneos</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5389-wk-Fact-AB56AB5FE7B2752414C47A9E0A7758AA" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,030,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5408-wk-Fact-47AA577AB82605E48C4E7A9E0A778D24" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,030,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e5515-wk-Fact-26395D0E849CDBFD14DD7A9E0A6E3333" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,219,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e5555-wk-Fact-7BE1849F67E1BC0CF9587A9E0A77E887" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">69,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e5575-wk-Fact-334C729ABAE3A94A3BAC7A9E0AC016CD" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,288,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized gain on short-term investments, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5703-wk-Fact-73CFD768988C28A8D69F7A9E0AC01A72" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">819,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5741-wk-Fact-03999D7C96199095294C7A9E0AB73C22" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">819,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5763-wk-Fact-530CE40F6CD9D9EB8D367A9E0A776D0B" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5782-wk-Fact-36F8E7A6812C3B6FAE1A7A9E0A7770C8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5796-wk-Fact-26D8BB15FF8682C302D97A9E0AB7A626" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">97,934,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5816-wk-Fact-E2FD1BB0AF315E34CD257A9E0ABFDC5D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">97,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5835-wk-Fact-64927817944104159D427A9E0A7CEF08" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">727,166,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e5854-wk-Fact-A8F929A81618FB265C677A9E0AC0403F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">649,645,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5875-wk-Fact-892FCF07AE8C7606828E7A9E0ABFC8F4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">290,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5894-wk-Fact-563809DD0A10BF2510347A9E0A77EFD7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,056,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5913-wk-Fact-88ED1F66E2914D3E8E0F7A9E0AC06FB7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">80,966,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5962-wk-Fact-F80C94ECBA067608AF797A9E0AD21CCC" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">476,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5977-wk-Fact-E95763C9F447FEEE23317A9E0AC82BFA" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e5996-wk-Fact-7B808BBF90155D129ABF7A9E0AB74B16" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,388,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6073-wk-Fact-F8E4871120A4131072727A9E0A8CFC4E" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,388,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6127-wk-Fact-CA9034344C0E3CB5A2687A9E0AC81CB1" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">173,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6142-wk-Fact-DC908574B7EC9C8112D57A9E0A61276A" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6161-wk-Fact-CCD29EBE5EF8275B699B7A9E0A641EFA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">81,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6239-wk-Fact-0D3078A616CC274D64607A9E0A8CC748" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">81,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6328-wk-Fact-9244E0548D10CE627E627A9E0A657077" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,345,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6386-wk-Fact-77F47FCDB34BAD7462ED7A9E0A95DECB" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">9,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6405-wk-Fact-80588F81CCF4B9A53DA77A9E0AB7818C" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,355,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of acquisition of non-controlling interest in Geneos</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6551-wk-Fact-506C5C8AB1BF575CBE9A7A9E0A9E9520" name="us-gaap:MinorityInterestDecreaseFromRedemptions" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">13,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6571-wk-Fact-21E67173D7ABB4895DC57A9E0A77985D" name="us-gaap:MinorityInterestDecreaseFromRedemptions" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">13,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6679-wk-Fact-D6F67FD9C232A43F03A07A9E0AD4D93A" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,387,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6719-wk-Fact-83F75C1F1302DB981FF67A9E0AD293F3" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">191,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e6739-wk-Fact-8B633C1C3465A33D73D87A9E0AC8A85C" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">29,579,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unrealized gain on short-term investments, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6867-wk-Fact-CF038FCCE1DA44E528367A9E0AC8E2BB" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">441,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6905-wk-Fact-9E551AB1B561B6265C727A9E0A6AD8EB" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">441,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6926-wk-Fact-A0F787AC2551CB7718447A9E0AAA6284" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6945-wk-Fact-552127C891AA874075137A9E0AB38758" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6959-wk-Fact-5E54CCE7C8876BC0FA1B7A9E0A6EFC54" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">98,584,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6979-wk-Fact-54ECE5E589379227E34A7A9E0AC8369B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">98,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e6998-wk-Fact-543C280079B0E34D2F417A9E0A95C813" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">731,819,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5952269e7017-wk-Fact-5857DE0DCFB350862CDE7A9E0A6811C9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">679,032,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e7038-wk-Fact-E087819D7378836EC0477A9E0A94CC21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">731,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e7057-wk-Fact-6988B851739F07FB1DB97A9E0AC0611C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,861,169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5952269e7076-wk-Fact-46F7B54F71EC00AE914A7A9E0A8238CB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">56,478,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF08BCF4571825C2B85B5A070B2B6BC67"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.5959595959596%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e625-wk-Fact-724D940E836D918EC5557A9E0A8A3844" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">162,307,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e645-wk-Fact-343497D076BA424517FF7A9E0A7CB9DD" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">58,867,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e702-wk-Fact-34D13E0208503EEB8A847A9E0A8C6B2A" name="us-gaap:Depreciation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,608,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e721-wk-Fact-21CE3FB3F5F70E09D50F7A9E0A828EE1" name="us-gaap:Depreciation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,863,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e741-wk-Fact-CC8382A34D939ABE3AD27A9E0A95DC86" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">273,540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e760-wk-Fact-1DE57BB47FA6464896947A9E0A8AEDD1" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">533,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e780-wk-Fact-502CE2DB216FE8810F617A9E0A8265A5" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">110,976,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e799-wk-Fact-6A424A95CDC63D7FB4177A9E0A958D14" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e819-wk-Fact-E95B646F90A0F0C2F8A07A9E0A8283FD" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">7,663,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e838-wk-Fact-7B863868C0F1092A9B107A9E0A7C0B12" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,787,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e858-wk-Fact-D3C3E1BE64889ECC0AA67A9E0A95C65D" name="ino:NonCashInterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,013,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e877-wk-Fact-35F82F69228166F2805D7A9E0A8C5469" name="ino:NonCashInterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,851,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of premiums on investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e897-wk-Fact-81BC3F35A758C5EA44907A9E0A82B70B" name="ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e916-wk-Fact-320AFF56ABAB50DDFD537A9E0A8A33EC" name="ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,962</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e937-wk-Fact-936365A1603A00BF78A07A9E0A77E158" name="us-gaap:GainLossOnInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">576,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e956-wk-Fact-4FD3D33811B9B9FD44A77A9E0A8CD9B9" name="us-gaap:GainLossOnInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">93,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e977-wk-Fact-AB18DB30CB4E31AF0CDC7A9E0A7C9FDB" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,713,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e997-wk-Fact-3D66F93847A45B19F72D7A9E0A82D9E4" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on deconsolidation of Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1017-wk-Fact-1C6B1ABCAC3AF68762C3B5AD1D1C2DDE" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,121,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Gain) loss on equity investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1056-wk-Fact-F6A96CD149825F66836E7A9E0A687A78" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">9,298,443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1076-wk-Fact-7B02690ADD5F499786EB7A9E0A7675EF" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">923,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share of net loss in Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1096-wk-Fact-EF138DCEFC740125876BCA2EC22EBAFA" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">901,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized loss on available-for-sale equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1134-wk-Fact-D5EBAD64EDF3D8CF47BEC73AA436043C" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">691,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1153-wk-Fact-D17E91ADC394CF28A1ECC73AA43931A6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash lease expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1173-wk-Fact-98050C693EC67F885628C739E4CA5924" name="ino:OperatingLeaseNonCashLeaseExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">517,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1192-wk-Fact-433B0D213B66352FB7417A9E0A990465" name="ino:OperatingLeaseNonCashLeaseExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">412,533</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax benefit from other unrealized gains on short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1212-wk-Fact-93E40E1E9CDFB50D24537A9E0A8C0CAF" name="ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1231-wk-Fact-40DB89C8779B39B97F627A9E0A8C96CE" name="ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">335,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized transaction loss on foreign-currency denominated debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1252-wk-Fact-CBFEA3691B35245D89E77A9E0A7C9E8C" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">474,071</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1272-wk-Fact-2E3E06381D937FADFE8A7A9E0A82DACB" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1333-wk-Fact-0485142760E8DEC30AF97A9E0A8A86F8" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,813,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1353-wk-Fact-4A86B085665AA37C96907A9E0A8C9113" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">3,186,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1374-wk-Fact-9D4331999282F4C786FC7A9E0A8CB700" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">865,832</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1393-wk-Fact-846A86999B1751DB6C9F7A9E0A7C33BB" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">258,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1414-wk-Fact-37F779E4CF87441A751F7A9E0A8C7DF0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,084,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1434-wk-Fact-B1826368CCEED9DB5F497A9E0A8CE194" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">902,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1455-wk-Fact-2B971AE324A30CA00FB27A9E0A7CFE75" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,330,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1475-wk-Fact-A103F5BB4E6E37BB28647A9E0A820171" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">20,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1495-wk-Fact-F60E6B6856C375F34C7D7A9E0A82B88F" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">116,242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1514-wk-Fact-AB6BC2E6CFCD763E9D127A9E0A957F9D" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">183,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1535-wk-Fact-0461FA4E9F9A415853BD7A9E0A8257C9" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">732,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1555-wk-Fact-CF5C7014EB7D7CD940BC7A9E0A81A953" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">9,187,074</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1576-wk-Fact-2A049DA934D062221E5F7A9E0A8CA13E" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,882,486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1595-wk-Fact-7B5DA793502F3F1B3A117A9E0A82139D" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,033,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses due to affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1616-wk-Fact-98E7052BE1D003C84E407A9E0A8CCAD3" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1635-wk-Fact-3F5E21763C12457351097A9E0A8B15F3" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">324,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1656-wk-Fact-AC39457126688F71488D7A9E0A82B0B2" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">92,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1676-wk-Fact-24A0A3C64E3D48A36FD87A9E0A81FEAB" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">137,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1697-wk-Fact-509AF0E8D9A4130555437A9E0A820932" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1716-wk-Fact-A4456FD7CC07F444FA7D7A9E0A7797E9" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1736-wk-Fact-EBF6B8ED220F0ABAD5AF7A9E0A77A0A6" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,022,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1756-wk-Fact-98051B0BEF0CB8EE5C777A9E0A775E56" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">786,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant funding liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1777-wk-Fact-5F5D69679E42C759FBFF7A9E0A8CA564" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,265,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1796-wk-Fact-185FE11363C79DDEA0F77A9E0A7C0AD5" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,695,191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant funding liability from affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1818-wk-Fact-679EF76E74FF37E043227A9E0A7C0167" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">63,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1838-wk-Fact-A1308A65DEC17859857F7A9E0A81481C" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">817,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e1858-wk-Fact-4D8C13925052064452717A9E0A776E96" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">29,686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1877-wk-Fact-BF26611D1527597954F97A9E0A8C96D2" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">34,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1898-wk-Fact-EE777CAFB8055345DBCE7A9E0A771D95" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">52,604,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1918-wk-Fact-729A417EDB2C0D9F7A9C7A9E0A8260CC" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">56,379,331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e1980-wk-Fact-7A0B11809B3DDF0F8B767A9E0A808D5F" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">138,698,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2000-wk-Fact-7F0A78CB72AEC6A4D0517A9E0A8C887D" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">73,698,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from sale or maturity of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2021-wk-Fact-EE29008DD9C2D2AFAB037A9E0A8C43B5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">47,455,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2040-wk-Fact-0A17F421C52CDAE422627A9E0A82D0C2" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">46,688,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of capital assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2060-wk-Fact-AA815A51D19EE8C93BA87A9E0A7748B6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">176,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2080-wk-Fact-1998A852B2B4EB18A3757A9E0A8CAEFB" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">739,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease in cash resulting from the deconsolidation of Geneos</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2101-wk-Fact-CC04C69C640920B961F7C2EC6074D84D" name="us-gaap:CashDivestedFromDeconsolidation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,774,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2121-wk-Fact-2931D0175966252E0331C2EC607948AB" name="us-gaap:CashDivestedFromDeconsolidation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2141-wk-Fact-E9D782A89A78C9776C007A9E0A7C22D0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">94,194,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2161-wk-Fact-E46D9A3B207BD93729E07A9E0A82D3A9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">27,749,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of convertible senior notes </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2223-wk-Fact-0655A3AEEC624CCC11FF7A9E0A8235B4" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2242-wk-Fact-D39F53763674CF25457C7A9E0A8C480D" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">75,658,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2263-wk-Fact-854B2CC0E8EF24F4D2227A9E0A7782DC" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">329,960,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2282-wk-Fact-965E5F19B60CFB5971977A9E0A956B2E" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,296,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from stock option exercises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2302-wk-Fact-DEAD6FA4DFFC89812EF07A9E0A8C2356" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">9,599,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2321-wk-Fact-64AA7153B4B520D156287A9E0A7C76E5" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">92,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes paid related to net share settlement of equity awards </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2341-wk-Fact-B358549C857D1C773EA17A9E0A820E56" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,076,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2361-wk-Fact-06E17591F7970DED4C627A9E0A7C9C3E" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">892,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition of non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2382-wk-Fact-72A857BA54D204DA2C157A9E0A8CFD5A" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,379,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2401-wk-Fact-54956FA0A0024C7084D27A9E0A8CC5FC" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,016,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from Geneos issuance of note payable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2421-wk-Fact-C5471799D45A19E3F81BB943645697ED" name="us-gaap:ProceedsFromNotesPayable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">171,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2440-wk-Fact-E79E60FF6738F3CB8CF3B9436453E168" name="us-gaap:ProceedsFromNotesPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2460-wk-Fact-907D41E0277B773B6DB87A9E0A82E1EA" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">340,035,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2479-wk-Fact-98E6DC4CEE7957B240507A9E0A82E49E" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">80,171,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2499-wk-Fact-E48F06EFF697BCF2D7617A9E0A6BFDBA" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2518-wk-Fact-DB35360C092CE69A19087A9E0AA0150A" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase (Decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2538-wk-Fact-9D1ABEBA09C67668321B7A9E0A8C7F12" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">193,236,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d5944595e2557-wk-Fact-8583E522D1E91D8EFF947A9E0A8CB86A" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">3,957,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2578-wk-Fact-455A97A81EB672F5A28B7A9E0A82DDA6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">22,196,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2597-wk-Fact-09933A06CBA20E52C4E17A9E0A8C23AA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">23,693,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and cash equivalents, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2622-wk-Fact-1FA4F5FA0E5005CAB89A7A9E0A8CD80F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">215,432,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2641-wk-Fact-2C6246B95544F8F0E59A7A9E0A9560BF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">19,735,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosures:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts accrued for purchases of property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2744-wk-Fact-928E870750022F02333A7A9E0A954E1C" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2763-wk-Fact-91BDEBBC40357B370C8E7A9E0A7CF88E" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 7</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:center;padding-left:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.5959595959596%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2799-wk-Fact-2A45146916AA3BDE51D47A9E0A823A95" name="us-gaap:InterestPaidNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,636,454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2818-wk-Fact-B45701514A9FCA675A857A9E0A8C7C29" name="us-gaap:InterestPaidNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2838-wk-Fact-2F4807573DCE81DD2DED7A9E0A82E472" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d5944595e2857-wk-Fact-E1A28AFAE6A117D0D8197A9E0A772D76" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">14,634,769</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7327FF5A78C65B64855FAEC7CED643A7"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div><a id="s82DC7B547CDE5F1FA1A5AFAB0DBFF253"></a></div><div style="line-height:174%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NatureOfOperations" id="TextSelection-EEE35599712FB1E694E87A9E0AE48AA6-0-wk-Fact-C2D75917D30928A63F3D7A9E0A7619FC" continuedAt="TextSelection-EEE35599712FB1E694E87A9E0AE48AA6-1" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EEE35599712FB1E694E87A9E0AE48AA6-1"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's novel DNA medicines are made using its proprietary SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio's hand-held CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of Inovio&#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> smart delivery device in more than 6,000 administrations across more than 2,000 patients.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="line-height:120%;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div><div><a id="s7056B2EAAEFC591FBBF0EA56F5A42C37"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="TextSelection-04CEC7F0627D57E5B2437A9E0AE40A10-0-wk-Fact-975168F60E160CCB9A847A9E0A82042C" continuedAt="TextSelection-04CEC7F0627D57E5B2437A9E0AE40A10-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-BAA0D62BB201EAD0D8657A9E0AE461C8-0-wk-Fact-69ADF505756D13D53A647A9E0A7CBE5E" continuedAt="TextSelection-BAA0D62BB201EAD0D8657A9E0AE461C8-1" escape="true"><ix:continuation id="TextSelection-04CEC7F0627D57E5B2437A9E0AE40A10-1" continuedAt="TextSelection-04CEC7F0627D57E5B2437A9E0AE40A10-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statements of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;12, 2020. The balance sheet at December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BAA0D62BB201EAD0D8657A9E0AE461C8-1"><ix:continuation id="TextSelection-04CEC7F0627D57E5B2437A9E0AE40A10-2"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June of 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e525-wk-Fact-161E191D10CDD2BDF4977A9E0A82EDE8" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="FI2020Q2_srt_OwnershipAxis_ino_VGXAnimalHealthIncMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e529-wk-Fact-1679AA4A0D82B306F8B2B5C00889233D" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="I2020Q1June01_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">47</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio incurred a net loss attributable to common stockholders of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e536-wk-Fact-CC3398B8277D3F0F083BCAF3CE664C82" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">128.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e540-wk-Fact-B9C787DE1D3620A14DEECAF3DED82B99" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">161.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively. Inovio had working capital of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e548-wk-Fact-6DB40BD4C58FBEEF9F1A7A9E0A7C5E67" name="us-gaap:Capital" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">344.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e552-wk-Fact-15A4169B632E82E8B475CAF611C7359A" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">901.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e561-wk-Fact-B016282C54122AA1FF357A9E0A81A4F0" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">371.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#8220;Sales Agreement&#8221; and collectively, the &#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e572-wk-Fact-94CA27B45B4EF438D0157A9E0A7C427E" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e576-wk-Fact-AF10AFE32AC0B77167D3CAFCAE9CE5B0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">330.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e584-wk-Fact-35904BD94A7B338A94DC7A9E0A820DB1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e588-wk-Fact-FA16ECBC31FAB5C4CB267A9E0A80F0B7" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e593-wk-Fact-C78378166FAA8702300F7A9E0A82A6A7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e597-wk-Fact-FCBEBA70BCB704FEC2C17A9E0A820F3F" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from the private placement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e601-wk-Fact-C2CEE7B649395CE241E77A9E0A82E675" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="krw" decimals="INF" scale="9" format="ixt:numdotdecimal">18</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e605-wk-Fact-1974E1ACA335AB62B70D7A9E0A7C9255" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e609-wk-Fact-F5BAD24F5632E5DCF14F7A9E0A818799" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e613-wk-Fact-2DE58C4CE99DF181141C7A9E0A82B144" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from the private placement of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e618-wk-Fact-9501506516B877FCEF277A9E0A828953" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="krw" decimals="INF" scale="9" format="ixt:numdotdecimal">4.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952356e622-wk-Fact-FB325C8CFDF98209AECF7A9E0A82FC5D" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952356e626-wk-Fact-6A9717410DB3891EBB417A9E0A800406" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s condensed consolidated financial statements as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s71265D617B12534798170FE5FE696986"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-0-wk-Fact-5FB466AA029B5312040C7A9E0A6E2021" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-1" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="TextSelection-7CDE2F624EA9C51FE2FB7A9E0AE4A26C-0-wk-Fact-669364000A0A6DC228477A9E0A6CC4CB" continuedAt="TextSelection-7CDE2F624EA9C51FE2FB7A9E0AE4A26C-1" escape="true"><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-1" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the </span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-2" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-3"><ix:continuation id="TextSelection-7CDE2F624EA9C51FE2FB7A9E0AE4A26C-1"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-B108F6938EBAEB15D7E07A9E0AE43EAD-0-wk-Fact-C49653E79E1A0CB5A8EB7A9E0A6E7B59" continuedAt="TextSelection-B108F6938EBAEB15D7E07A9E0AE43EAD-1" escape="true"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-3" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-4"><ix:continuation id="TextSelection-B108F6938EBAEB15D7E07A9E0AE43EAD-1"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2020Q2YTD" name="ino:GrantPolicyPolicyTextBlock" id="TextSelection-16AB06A42F2C225DAA6E7A9E0AE4723D-0-wk-Fact-E7B539D75D21B39E0C3F7A9E0A6E6D71" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-46A459929D5790F7D7187A9E0AE495F0-0-wk-Fact-7F11A84463F813CA68877A9E0A6D070B" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-5E927334E3B8DE3BB1B37A9E0AE444B0-0-wk-Fact-691C974F82F7C1228B3B7A9E0A6EEBA3" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="TextSelection-0F5E9B8028616F725E5E7A9E0AE57577-0-wk-Fact-C39C72D6CE1CE4FDBE2C7A9E0A6EDD22" continuedAt="TextSelection-0F5E9B8028616F725E5E7A9E0AE57577-1" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful lives ranging from </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5952684e613-wk-Fact-9AFB85614822685E339F7A9E0A6C7103" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">18</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-4" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-5"><ix:continuation id="TextSelection-0F5E9B8028616F725E5E7A9E0AE57577-1" continuedAt="TextSelection-0F5E9B8028616F725E5E7A9E0AE57577-2"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the license has an alternative future use. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952684e631-wk-Fact-F59CE66D22E73784D0C3CB8620972677" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5952684e635-wk-Fact-E996B05427A9433E0B36CB8641A2882A" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, identifying no impairment.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-0F5E9B8028616F725E5E7A9E0AE57577-2">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DerivativesPolicyTextBlock" id="TextSelection-5B2800C75B75A0D0205E7A9E0AE568AC-0-wk-Fact-033E6AE5CAE4790D48D07A9E0A6E3CC9" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#8217;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-20F5F0DE404AD87633E87A9E0AE51492-0-wk-Fact-DD8CDCF9AB35F5BD101D7A9E0A6E5009" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive gain (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="TextSelection-27C200BF283D8356CE949AA3C4D33625-0-wk-Fact-DC6A99016BE6997B94789AA3D52D44FA" continuedAt="TextSelection-27C200BF283D8356CE949AA3C4D33625-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities (VIE)</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-5" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-6"><ix:continuation id="TextSelection-27C200BF283D8356CE949AA3C4D33625-1"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" id="TextSelection-3725B4FC06399928A0DEC7EF616B56F0-0-wk-Fact-1F2BA0E1B0EDA8EDC443C7EF72BA23E2" continuedAt="TextSelection-3725B4FC06399928A0DEC7EF616B56F0-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Investments</span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-3725B4FC06399928A0DEC7EF616B56F0-1" continuedAt="TextSelection-3725B4FC06399928A0DEC7EF616B56F0-2"><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-6" continuedAt="TextSelection-448809A51589D3FCA4217A9E0AE413F1-7"><span style="font-family:inherit;font-size:10pt;">Under Accounting Standards Codification ("ASC") Topic 321, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Securities,</span><span style="font-family:inherit;font-size:10pt;"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement,</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-3725B4FC06399928A0DEC7EF616B56F0-2"><ix:continuation id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-7"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation></ix:continuation>&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s66C3773C9B3B57C0B2534767A0C2862E"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-0-wk-Fact-BB61076DD932C15AE62E7A9E0A66B0EF" continuedAt="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-1" escape="true">Impact of Recently Issued Accounting Standards </ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-5EAF48230E91DE9255507A9E0AE5A937-0-wk-Fact-F6BC150CAA512D70A9537A9E0A657D7B" continuedAt="TextSelection-5EAF48230E91DE9255507A9E0AE5A937-1" escape="true"><ix:continuation id="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-1" continuedAt="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-2"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Recently Adopted</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2019-12. </span><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption.  As of June 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended June 30, 2020. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-13</span><span style="font-family:inherit;font-size:10pt;">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-13</span><span style="font-family:inherit;font-size:10pt;">. In August 2018, the FASB issued ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#8217;s fair value classifications).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-18</span><span style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:inherit;font-size:10pt;">, which clarified the interaction between Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;">, and Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 14</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-5EAF48230E91DE9255507A9E0AE5A937-1" continuedAt="TextSelection-5EAF48230E91DE9255507A9E0AE5A937-2"><ix:continuation id="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-2" continuedAt="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-3"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU 2017-04.</span><span style="font-family:inherit;font-size:10pt;"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-5EAF48230E91DE9255507A9E0AE5A937-2"><ix:continuation id="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-3">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s065681260FB75C71BCB646282134890F"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-68640F496F7E8B2B6AB47A9E0AE59F5D-0-wk-Fact-BC9C29EC4411B85B9C8B7A9E0A95C2D0" continuedAt="TextSelection-68640F496F7E8B2B6AB47A9E0AE59F5D-1" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><ix:continuation id="TextSelection-68640F496F7E8B2B6AB47A9E0AE59F5D-1"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized total revenue under collaborative research and development and other agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e494-wk-Fact-78F52E742CDD803A87777A9E0A999925" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">64,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e498-wk-Fact-FB7C85247D4C6CC28B54CB8ED5C77938" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e502-wk-Fact-D17DB0C393F844AC72C17A9E0A95B4D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">74,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e506-wk-Fact-0D0C9DBC32B0CCF20B03CB8F9B7823E7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">146,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from AstraZeneca and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e511-wk-Fact-80264DFCF9B102DEEFFE7A9E0A95AE09" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">129,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e515-wk-Fact-67C50948170A246D5BF1CB8FB1DD5EFB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">244,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from various other contracts. Of the total revenue recognized during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e523-wk-Fact-6DEE0A5F5CFEED7B66EE7A9E0A996444" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">66,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5952758e527-wk-Fact-3AECEC8197A78137AFC3CB8FFB384546" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">124,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were in deferred revenue as of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Performance obligations are generally satisfied within </span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;"> months of the initial contract date.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s208C13D16F475C48921BE685A47F3789"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="TextSelection-424C74FC42A40F0F16D37A9E0AE543C8-0-wk-Fact-23B849B3DCE987A4DBE27A9E0A62653F" continuedAt="TextSelection-424C74FC42A40F0F16D37A9E0AE543C8-1" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-424C74FC42A40F0F16D37A9E0AE543C8-1" continuedAt="TextSelection-424C74FC42A40F0F16D37A9E0AE543C8-2"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of mutual funds, corporate debt securities and certificates of deposit. Short-term investments at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gross realized gain on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e492-wk-Fact-0D2F4ABDE3049F5812067A9E0A63BAE2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">585,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e496-wk-Fact-73159D33925CDA9B6FA07A9E0A6314CF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">635,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and gross realized loss on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e501-wk-Fact-70AB3506BA8AEB80EFB97A9E0A64CB40" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">686,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e505-wk-Fact-A99A4E95104D6470ABAA7A9E0A65E4ED" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gross realized gain on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e513-wk-Fact-A4C7A90FA06EE856D514CBFD94304AFB" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">157,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e517-wk-Fact-3546C8141D5BC378E6B9CBFDA2E79201" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">175,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and gross realized loss on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e521-wk-Fact-99AD94CE8843D942CE6FCBFDF5C12C13" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">29,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e526-wk-Fact-691699AD468164C095C9CBFE073601C2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">82,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5953814e534-wk-Fact-93DA9A10D0E7F08B9A5C7A9E0A63C974" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$(<ix:nonFraction id="d5953814e538-wk-Fact-DF21F1796711DB2682B27A9E0A625423" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="0" sign="-" format="ixt:numdotdecimal">691,000</ix:nonFraction>)</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e542-wk-Fact-1919C2E0721664E4A31CC68174802C2E" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> material unrealized gain or loss on available-for-sale equity securities recorded during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e563-wk-Fact-82B5C2FCA186F54F10D27A9E0A624EEE" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2020Q2" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> available-for-sale securities in an unrealized loss position, of which </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e567-wk-Fact-02ECA8245A67930DA9667A9E0A658C58" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" contextRef="FI2020Q2" unitRef="investment" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> were in such position for longer than </span><span style="font-family:inherit;font-size:10pt;">12 months</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="TextSelection-2AAF76CD0D33E03A305A7A9E0AE59AE4-0-wk-Fact-716A95CCB962A9F16C507A9E0A645882" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:26%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e839-wk-Fact-4494E0CF77B2B1AEE5EC7A9E0AA023AF" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">149,641,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e858-wk-Fact-1D83E42E13032FF10FFB7A9E0AA0069B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,180,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5953814e878-wk-Fact-D00682F5C449982A4BA37A9E0A9E0525" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,871,643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e898-wk-Fact-52A2CB83325C4E33AC6B7A9E0A9965D3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">148,949,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e923-wk-Fact-E4F4E4BDC17AF7A1B59B7A9E0A9F714E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,625,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e942-wk-Fact-56B516C4CEFC8F787C797A9E0AA0F51A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">14,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5953814e962-wk-Fact-B6753EE32B8A48F478D77A9E0A998C06" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">376,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e982-wk-Fact-F7B4649CA688F7383CFE7A9E0A9909D9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,262,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1012-wk-Fact-822D37D5815DC93652687A9E0AA086FE" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1031-wk-Fact-B4EC0247987CF9824BCB7A9E0A9F28B2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">38,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5953814e1051-wk-Fact-3E8815CDC159AB7822617A9E0AAD8348" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1071-wk-Fact-C9D91B14EB70A10B41CD7A9E0A994853" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,018,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1106-wk-Fact-5AB671D4E44C2C2E25977A9E0A9E944D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">157,266,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1125-wk-Fact-3370CC47ACE03752F3837A9E0AA01D34" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,232,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5953814e1145-wk-Fact-F1A5CBDF774E5D62BD4F7A9E0AA0CA71" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,268,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1165-wk-Fact-A06ACD39110EEBADF5C57A9E0AA06CD9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">156,231,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:26%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1413-wk-Fact-DC6BC041A639938CF36F7A9E0AAE4BB6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">66,599,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1432-wk-Fact-0D2BD68350B4D242697D7A9E0A6577A0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">754,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5953814e1452-wk-Fact-488F795CD093CF3B6B487A9E0A64A489" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">15,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5953814e1472-wk-Fact-D507E39043A5C18C73D07A9E0A645336" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">67,338,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 15</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-424C74FC42A40F0F16D37A9E0AE543C8-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s4047196D21855ED1B3919651168CBDBD"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-53869378AAD98ABAA9677A9E0AE60AEA-0-wk-Fact-9367D2FA4D95909406A47A9E0A6C8AC7" continuedAt="TextSelection-53869378AAD98ABAA9677A9E0AE60AEA-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-53869378AAD98ABAA9677A9E0AE60AEA-1" continuedAt="TextSelection-53869378AAD98ABAA9677A9E0AE60AEA-2"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-77FD3E0BB0D8CAD2DF577A9E0AE6F82C-0-wk-Fact-4DBDEAA5B1352E0C2BBE7A9E0A6EDA67" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e891-wk-Fact-0A5FB0442A4AF184CB367A9E0AAEE6D0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">148,949,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e910-wk-Fact-43F386B0E22A57550B7475C975277B56" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">148,949,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e929-wk-Fact-C365E334FA5EAA105CCE7A9E0AAE0710" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e949-wk-Fact-0C8A835731D29287F1BD7A9E0AB25B4B" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e969-wk-Fact-641DB5FDA78FA49422077A9E0AB3DE13" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,262,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e988-wk-Fact-F7B4649CA688F7383CFE7A9E0A9909D9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,262,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1007-wk-Fact-90E04F8995A97FB571FB7A9E0AAD3760" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1027-wk-Fact-82F3F83DF517DB712DE47A9E0AB30416" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1047-wk-Fact-901D25371EC029C1E9C87A9E0AAEF552" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,018,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1066-wk-Fact-6C645D29B5F48E546F387A9E0AAE9651" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1085-wk-Fact-D3940C3ADAA46FCC9AD07A9E0AAD044B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,018,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1105-wk-Fact-955801D7D99A6231F95D7A9E0AAE2AFB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1125-wk-Fact-4BBE3CA2A9EFFCFA4BC57A9E0AAE3C77" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">17,327,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1144-wk-Fact-F3D8DFBBAA43639195987A9E0AB344BF" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">17,327,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1163-wk-Fact-1B2EE00BF1D6CFB9F2F17A9E0AB36BE5" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1183-wk-Fact-7B9CB54ED4FF1EC8D7547A9E0AAED4A8" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1208-wk-Fact-481D1BF02C39C52309637A9E0AAE855E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">173,558,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1227-wk-Fact-24C80DBD8C18A42FB0D07A9E0AAA157F" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">170,540,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1246-wk-Fact-131FA152537FEB7505C07A9E0AAE94D8" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,018,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1266-wk-Fact-A0DC5DB198FEBAFE232A7A9E0AB3EC25" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability (Note 9)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1368-wk-Fact-5CDB0560629BA3C54D3F7A9E0AB2D8D2" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">119,796,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1387-wk-Fact-AA6E01C2DC24ABEC714C7A9E0AAEF63A" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1406-wk-Fact-6DCD31D302C45E96A6507A9E0AAA35DF" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1421-wk-Fact-71A405789FCF965068E97A9E0A9F36A0" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">119,796,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1447-wk-Fact-3AD23F9F61EEB1D72B9A7A9E0AAABD87" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">119,796,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1466-wk-Fact-1E7D79DC31128DCAC9E87A9E0AAE441C" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1485-wk-Fact-465C6A3242B86560FBBB7A9E0AAEFB0E" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1505-wk-Fact-D806E0592D2B4D817B1C7A9E0AAEAD87" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">119,796,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1911-wk-Fact-11CC37B33DD383C690EB7A9E0AB7F3F5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,349,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1930-wk-Fact-E5547CBFD459FF219A717A9E0AB7452E" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,349,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1949-wk-Fact-83AE90C8BEDCCA1181957A9E0AB7FBAE" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1969-wk-Fact-5CDCB2639382CD47C3A97A9E0AB752D1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e1984-wk-Fact-F95CD5A8AEF2FE7BB7D27A9E0AB79385" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">67,338,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2003-wk-Fact-5998FE16CECEE2E51A357A9E0AB7B03B" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">67,338,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2022-wk-Fact-5D72A74E2E1EA98A41D47A9E0AB77876" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2042-wk-Fact-D855A798D8BEAA4ED5F67A9E0ABD96A5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2062-wk-Fact-0942D10774DC0C35039A7A9E0AB72BE0" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,315,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2081-wk-Fact-582A189EEEE8CC7800E27A9E0AB76EC3" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,315,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2100-wk-Fact-1EC49968D09D18CFC1847A9E0AC0A31A" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2120-wk-Fact-3D9E9D3DA5D33963515C7A9E0AB7350B" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2145-wk-Fact-95B90F95DB02E3D747307A9E0ABF04BD" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">76,003,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2164-wk-Fact-06B1DAF18DB8CB75D47C7A9E0ABD272A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">76,003,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2183-wk-Fact-1A1C67BA21A86433D7A07A9E0AC02818" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2203-wk-Fact-28250B9D20DDAE72F42B7A9E0AB7CC12" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability (Note 9)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2305-wk-Fact-17E85C625225E9A2561A7A9E0AB7CF51" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">8,819,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2324-wk-Fact-598D13EC030744A662C47A9E0AB76B81" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2343-wk-Fact-6CBCCAFB9AB876BB1CDC7A9E0ABD873E" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2363-wk-Fact-B5BB6D20CC0278AEDEE37A9E0ABF1EE9" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">8,819,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2383-wk-Fact-C8E46BA198917C0122197A9E0AC03044" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">8,819,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2402-wk-Fact-1126117CE61C585A135F7A9E0AC0C2D7" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2421-wk-Fact-0BBDBE6ECB096C669AF07A9E0AB7547D" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2441-wk-Fact-F41FD2250A81AA6D0A1C7A9E0AC01619" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">8,819,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 16</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-53869378AAD98ABAA9677A9E0AE60AEA-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 assets at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of mutual funds and corporate debt securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investments in affiliates, GeneOne and PLS. The Company accounts for its investment in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2466-wk-Fact-4FED942634A32EE4D86A7A9E0A6DABA9" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,644,155</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> common shares of GeneOne based on the closing price of the shares on the Korean Stock Exchange on the applicable balance sheet date. The Company accounts for its investment in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2470-wk-Fact-65CFFBBA0A658E4BCE197A9E0A6E99A4" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">597,808</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> common shares of PLS based on the closing price of the shares on the Korea New Exchange (KONEX) Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of operations as a gain (loss) on investment in affiliated entities. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 assets at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of certificates of deposit held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no Level 3 assets at June 30, 2020.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 liabilities held as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 9 below for more information). The derivative liability was recorded at fair value of $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2535-wk-Fact-11D03DB8B15CD8A098677A9E0A6EFF80" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> include the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-F7F6BB0AE3474CCEB7617A9E0AE60529-0-wk-Fact-E062F940EE18DE36529E7A9E0A6DFB6B" escape="true"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company's derivative liability for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2582-wk-Fact-07FB481B70CB58C9427D7A9E0AB3C0BF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="3" format="ixt:numdotdecimal">8,819,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2597-wk-Fact-79997E2A31AB6E949FBB7A9E0AB389C6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q2YTD" unitRef="usd" decimals="0" scale="3" sign="-" format="ixt:numdotdecimal">110,976,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5956226e2622-wk-Fact-CE49F2424707F988BAD97A9E0AB39090" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="3" format="ixt:numdotdecimal">119,796,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:81%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sC43A28B926D153B2B3E303C0CAB10EA2"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-0-wk-Fact-1A1302981E562C03AF197A9E0AC895AC" continuedAt="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-0-wk-Fact-6E9B98B86E8C324A073A7A9E0AC8121A" continuedAt="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-1" escape="true"><ix:continuation id="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-1" continuedAt="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-2"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 17</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-2" continuedAt="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-3"><ix:continuation id="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-1" continuedAt="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-2"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:18%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Yrs)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite lived:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e964-wk-Fact-6FCA4FAEAAEF7A0F679A7A9E0AD16368" name="us-gaap:GoodwillGross" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,513,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1003-wk-Fact-4C743719408FD2CB5FDF7A9E0A77B25E" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,513,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1022-wk-Fact-E85299F3B15040B3EACB7A9E0AC8CF32" name="us-gaap:GoodwillGross" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,513,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1061-wk-Fact-45EAD88160297DD80C547A9E0AC8ABE1" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,513,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Definite lived:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5957868e1209-wk-Fact-74DC273150855FA4FE217A9E0AC8D637" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" format="ixt-sec:duryear">10</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1219-wk-Fact-A7C5476E8FE72899FC847A9E0AD2176F" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,323,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1238-wk-Fact-1EBB2D4E1536F7554B3F7A9E0AC8EF7E" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,262,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1259-wk-Fact-BE3322F8A0DC94B5B0767A9E0AC812EA" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">61,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1278-wk-Fact-DC102C30330EA3EAEE4C7A9E0AC8CA19" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,323,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1297-wk-Fact-8A3CDE53D9C12F80FC0D7A9E0AC804B3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,248,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1318-wk-Fact-33D9C7FF37EF102801157A9E0AC8C573" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">75,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bioject(b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5957868e1338-wk-Fact-E66FA02379F8C1BE4DD37A9E0AC86B37" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" format="ixt-sec:duryear">12</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1348-wk-Fact-C7B68773A0F9F9058A4A7A9E0AC8F9B0" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,100,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1367-wk-Fact-7A12C676EE0CF77E4C9E7A9E0AC7948C" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,322,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1388-wk-Fact-CA8B13A8C6FF7D9193C47A9E0AD35A9E" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,777,778</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1407-wk-Fact-B68E5FC2D663407841DD7A9E0AC8F7FF" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,100,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1426-wk-Fact-17D9E91BBB63095EB5F87A9E0AC81AB9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,175,556</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1447-wk-Fact-A472282AAC02DB80FBD37A9E0AD33F06" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,924,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other(c)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5957868e1467-wk-Fact-C1C0BCC66325B8AEF88D7A9E0AC8D585" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" format="ixt-sec:duryear">18</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1477-wk-Fact-6F62184BFB207B4801FA7A9E0AC896EE" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,050,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1496-wk-Fact-5FB1BE66AA96D98047017A9E0AC8C8C4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,468,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1517-wk-Fact-A20170F7BC3CA9428FAE7A9E0AD04688" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">581,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1536-wk-Fact-F820370AA155801F44AA7A9E0AC8ECAA" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,050,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1555-wk-Fact-3C612EE5EA8C287383747A9E0AD32656" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,356,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1576-wk-Fact-912BB2971A5EFBD951727A9E0AC8F3FA" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">693,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5957868e1596-wk-Fact-799E27F019D51E3A49C77A9E0AC81415" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember" format="ixt-sec:duryear">11</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1606-wk-Fact-D0235F73CB75C5490E4A7A9E0AC8241B" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,473,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1625-wk-Fact-ADFC3CD13F212B7737F87A9E0AC85F6A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">7,053,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1646-wk-Fact-6DA1C84F27F8329B754C7A9E0AD1DC9E" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,420,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1665-wk-Fact-590963AC9CC2758C484D7A9E0AC8F71A" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">10,473,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1684-wk-Fact-CB01B0E36DFBAA84A8AB7A9E0AC82DCC" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,779,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1705-wk-Fact-48EADEBAEBBAC695A8627A9E0AD03665" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,693,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total goodwill and intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1740-wk-Fact-6CA3319B32DE5B2976497A9E0AC84F1F" name="ino:GoodwillAndIntangibleAssetsGross" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">20,987,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1759-wk-Fact-ADFC3CD13F212B7737F87A9E0AC85F6A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">7,053,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1780-wk-Fact-43F07945AB4E755C5AD37A9E0AC8D14B" name="ino:GoodwillAndIntangibleAssetsNet" contextRef="FI2020Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">13,933,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1799-wk-Fact-7195F991D22858B1F7D37A9E0AC8D37A" name="ino:GoodwillAndIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">20,987,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5957868e1818-wk-Fact-CB01B0E36DFBAA84A8AB7A9E0AC82DCC" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">6,779,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1839-wk-Fact-1B43DBC3A85BD5BF327E7A9E0AC84562" name="ino:GoodwillAndIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">14,207,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1856-wk-Fact-3152C31AB36F1459A8F07A9E0AD6D581" name="us-gaap:Goodwill" contextRef="I2005Q1Jan31_us-gaap_BusinessAcquisitionAxis_ino_InovioAsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1860-wk-Fact-179BEE3F36AC230DCAF07A9E0AC88D41" name="us-gaap:Goodwill" contextRef="I2009Q2_us-gaap_BusinessAcquisitionAxis_ino_VgxPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1864-wk-Fact-5F9FF89932371013BC057A9E0AD4052E" name="us-gaap:Goodwill" contextRef="I2016Q2Apr_us-gaap_BusinessAcquisitionAxis_ino_BiojectMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">400,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-2" continuedAt="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-3"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(c)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</span></div></ix:continuation></td></tr></table></ix:continuation><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-3" continuedAt="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-4"><span style="font-family:inherit;font-size:10pt;">Aggregate amortization expense on intangible assets for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1909-wk-Fact-401E1D417AA9AA64FF6C7A9E0AD1F02A" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">137,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1913-wk-Fact-3680A69259BB21A8D043CC23193C3898" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">274,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Aggregate amortization expense on intangible assets for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1921-wk-Fact-53690A0BFFFB312DC1A57A9E0AD0FF99" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">267,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1926-wk-Fact-2102BA72EDCEF274785CCC276839A0E2" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">533,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Estimated aggregate amortization expense is $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1930-wk-Fact-08524591938D0E98918F7A9E0AC8CA8A" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">274,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the remainder of fiscal year </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5957868e1938-wk-Fact-0DDB6AD792D7C03541177A9E0AD4B866" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">520,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1946-wk-Fact-D533F1316E8523C6CF577A9E0AD5BA11" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">493,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1955-wk-Fact-3DC86B5B41A7D6F1E31D7A9E0AC855DB" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">276,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1963-wk-Fact-E54E905758CC11E89EEE7A9E0AD26101" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">253,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5957868e1972-wk-Fact-E873293D92DBA2EB0DA97A9E0AD0F917" name="ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2025</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-4"> and subsequent years combined.</ix:continuation> </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE4259AF0128F5A9496DC246F268B4EC5"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-0-wk-Fact-643C19BBA5936129F5B37A9E0A958602" continuedAt="TextSelection-D31D03989F47F5E906B07A9E0AE62965-1" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-1" continuedAt="TextSelection-D31D03989F47F5E906B07A9E0AE62965-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 19, 2019 and March 1, 2019, the Company completed a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e481-wk-Fact-6DE987EB25033AE986B27A9E0AB3ECDB" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">78.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e485-wk-Fact-893FC2AC66BAF2C13D457A9E0A6EF966" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e492-wk-Fact-92EFB16E3F11575832F77A9E0A6E89C8" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e496-wk-Fact-33DDD402148868EEF1837A9E0A9F9EDB" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.38</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e503-wk-Fact-64DC5335DAB3D2420A8E7A9E0AA07DC8" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="FD2020Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on (i) each of at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e507-wk-Fact-9D16EA84804FA19252947A9E0A6E9E6B" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e511-wk-Fact-EF555D9213E020E22F697A9E0A9E8210" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e515-wk-Fact-C52B0B63E6B98CF1FD6F7A9E0A995AD1" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 18</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-2" continuedAt="TextSelection-D31D03989F47F5E906B07A9E0AE62965-3"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applies. Therefore, the Notes issuance proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e525-wk-Fact-69667C0046E0B7BC6EC07A9E0A9FB9D1" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">78.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e529-wk-Fact-C873BB42C29EEB6B2BDB7A9E0AA0327D" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e533-wk-Fact-DFB6C8B3C30953EF87B77A9E0AA0E4B8" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><ix:continuation id="TextSelection-41E36BA1A1274B7569327A9E0AE6B38C-0" continuedAt="TextSelection-1007DC471688854A54BE7A9E0AE6D104-0"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the Notes at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e574-wk-Fact-41ECC1E92A72F3CF0A087A9E0A8C9222" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">78,500,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt discount on the liability component</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5959237e589-wk-Fact-E5308E5F3450417FFAF27A9E0A8C7339" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">12,619,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5959237e610-wk-Fact-94259F879A9C70B201847A9E0A8CBA08" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,736,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e631-wk-Fact-BC1EA8D6F080C71CE52B7A9E0A8C3FE8" name="ino:DebtinstrumentAccruedInterest" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,700,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e656-wk-Fact-CDD93674B1142736C1DA7A9E0A8CD017" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">65,844,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e671-wk-Fact-38F2B6C6F69C47155DCA7A9E0A95348D" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e675-wk-Fact-E1BDC8C53C4E05E5FDE27A9E0A9573DA" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">13.1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e683-wk-Fact-307CAD249B5BB11C178A7A9E0AA0ACCD" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e687-wk-Fact-2BDD0ED8E796ECF26D21DA5D004CB4A0" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of interest expense related to the Notes, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e692-wk-Fact-B547A363BD41659CE95E7A9E0A6E0266" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e696-wk-Fact-8BB635B0816635B8D925DA5ED389F201" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. For the three and six months ended June 30, 2019,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e700-wk-Fact-8CB9ADF44851BF79BB329AA7603E89EE" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e704-wk-Fact-31BC1E76E0FFF992EFF69AA78DD7C8F3" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of interest expense related to the Notes, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e708-wk-Fact-A036C9CFE438B77502259AA7E68AF271" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e712-wk-Fact-77BAE9287B01E87DE1349AA8110389C5" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there had not been any conversions or redemptions of the Notes. As described in Note 18 below, subsequent to June 30, 2020, certain holders converted a portion of the Notes into shares of the Company's common stock.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">August 2019 Convertible Bonds </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e729-wk-Fact-414254C0E53F377081DB7A9E0AAEE863" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="krw" decimals="INF" scale="9" format="ixt:numdotdecimal">18</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e733-wk-Fact-5794EC9E132BEDA59D997A9E0A6EEC42" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e737-wk-Fact-0AB7B8A67585E8A019F37A9E0A9997F5" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ Market of the Korea Exchange (KOSDAQ) in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e744-wk-Fact-1EB9C9C52160CEC7F5B07A9E0AAEE91B" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. As described in Note 18 below, on August 1, 2020 the August 2019 Bonds were converted in full. The initial conversion rate was </span><span style="font-family:inherit;font-size:10pt;">211.0595</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to an initial conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e756-wk-Fact-0B2135EE08B6C013B0557A9E0A9F99D1" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset on each three month anniversary thereafter to the then current market price if the current market price was lower than the conversion price then in effect; subject to a maximum conversion rate of </span><span style="font-family:inherit;font-size:10pt;">351.7658</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e769-wk-Fact-F8FBBB4499A93C61287A7A9E0A6E9793" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2019Q3Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.40</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rates as of July 30, 2019). The conversion rate as of the date of conversion on August 1, 2020 was </span><span style="font-family:inherit;font-size:10pt;">275.6873</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW </span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e781-wk-Fact-C5F442922F55B8A355067A9E0AAE4D35" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2020Q1Jan02_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.14</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of January 2, 2020).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e788-wk-Fact-5D0F8A6DB0957F35D5817A9E0A6E75B3" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 19</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-3" continuedAt="TextSelection-D31D03989F47F5E906B07A9E0AE62965-4"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><ix:continuation id="TextSelection-1007DC471688854A54BE7A9E0AE6D104-0"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the August 2019 Bonds at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e830-wk-Fact-9214840F0C97EE3BD2A07A9E0AC6BC88" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">14,993,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt discount </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5959237e845-wk-Fact-2F60E8CF7EFD219AF6FA7A9E0AC83DD2" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,600,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5959237e866-wk-Fact-55754A9712D1E400C0ED7A9E0AC7B913" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">211,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the August 2019 Bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e887-wk-Fact-C99AE589B27F26680D277A9E0AC75190" name="ino:DebtInstrumentAccretionOfPremium" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">519,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e907-wk-Fact-C6F18092E13039B3DA087A9E0AC82083" name="ino:DebtinstrumentAccruedInterest" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">37,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e932-wk-Fact-B61069E80DFEDF28693E7A9E0AC0DA59" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">9,738,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e948-wk-Fact-2C8D75E8B1EA54F8C6077A9E0AA0BA54" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e952-wk-Fact-2FD50B134AD6ACCF14887A9E0A6E9F93" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">29.4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e960-wk-Fact-B8FDD2285700213E72327A9E0A9547EC" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">672,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e964-wk-Fact-E51722B461BD88E876A9DA69DAD8C75E" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively, of interest expense related to the August 2019 Bonds, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e969-wk-Fact-7123DDD00732AB4723187A9E0A99E1FE" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">37,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e973-wk-Fact-3F65131A6AF011185206DA6A18A4038B" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there had not been any conversions or redemptions of the August 2019 Bonds.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The derivative liability was valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e984-wk-Fact-F215CD6C6EA9F961CDF77A9E0A6E63C7" name="us-gaap:DerivativeLiabilities" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The change in fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e992-wk-Fact-E7DC4040BBA5E0C6FF637A9E0A6EDDDF" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e996-wk-Fact-82F6EF0E007BF2CEFF8A47F5803F4EF7" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">111.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively.  As a result of the conversion in full of the August 2019 Bonds in August 2020, the derivative liability will be eliminated during the quarter ended September 30, 2020.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">December 2019 Convertible Bonds </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1016-wk-Fact-B592CF0463652986ECCE7A9E0A998C21" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="krw" decimals="INF" scale="9" format="ixt:numdotdecimal">4.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1020-wk-Fact-AB95D0CF9482A80B3E407A9E0A6E2CFA" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1024-wk-Fact-45DCACA0DC38E8367EEC7A9E0AAAE146" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1031-wk-Fact-E5024AF1946963B8F2A37A9E0A99084A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1035-wk-Fact-BF037FF87BBE8489B0367A9E0A6E429F" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.00</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate is </span><span style="font-family:inherit;font-size:10pt;">214.7766</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of Bonds (equivalent to an initial conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1047-wk-Fact-7EC2820419B0D2DCA7D77A9E0A6EA19A" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed </span><span style="font-family:inherit;font-size:10pt;">357.9611</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1060-wk-Fact-4001488C138B4E497C647A9E0AA07DC1" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.40</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of December&#160;19, 2019).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1067-wk-Fact-BF037FF87BBE8489B0367A9E0A6E429F" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.00</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1071-wk-Fact-21FB564FA514FF63A4677A9E0A995C72" name="ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 20</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-4" continuedAt="TextSelection-D31D03989F47F5E906B07A9E0AE62965-5"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ConvertibleDebtTableTextBlock" id="TextSelection-65FFFD9604645778B8557A9E0AE7ABDB-0-wk-Fact-4459FFEA662B608ACFAE7A9E0A95877D" continuedAt="TextSelection-41E36BA1A1274B7569327A9E0AE6B38C-0" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the December 2019 Bonds at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1115-wk-Fact-8EF1D7BEEEE6C05F7BD57A9E0A826368" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">3,915,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5959237e1130-wk-Fact-7BD56DFE31F8EF5E8C3A7A9E0A8C84CE" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">40,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the December 2019 Bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1151-wk-Fact-1CC865EA57C3E24D17627A9E0A7C34EB" name="ino:DebtInstrumentAccretionOfPremium" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">95,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1171-wk-Fact-7056B40410C5E8F00B707A9E0A7CFDF2" name="ino:DebtinstrumentAccruedInterest" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">9,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1196-wk-Fact-6F1D9D694B0AF5F530667A9E0A8C66F3" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,979,780</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1211-wk-Fact-25153DF71950DDA73C1C7A9E0AA006AE" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">6.2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1219-wk-Fact-7C2C630487F77CDF3D3B7A9E0AA9148C" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">60,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1223-wk-Fact-961D587C06F041DFDC6ADA6F475E0877" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">122,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of interest expense related to the December 2019 Bonds, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1227-wk-Fact-D33EB49A759CE8F102FF7A9E0AA914E5" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959237e1232-wk-Fact-E59859001DEEED711A19DA6F814655F8" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there had not been any conversions or redemptions of the December 2019 Bonds.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="TextSelection-B767703AE7EEB4731F717A9E0AE6436F-0-wk-Fact-0FE092F311C4D9FCEB997A9E0AA09DAA" continuedAt="TextSelection-B767703AE7EEB4731F717A9E0AE6436F-1" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, future minimum payments due under the Company's convertible debt instruments are as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Notes (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">August 2019 Bonds (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 2019 Bonds (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1380-wk-Fact-C16F2EC116BB73D4DC5A7A9E0A60537E" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,551,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1399-wk-Fact-9842DB26FD0B2929D7BA7A9E0A61B9C4" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1419-wk-Fact-88C50DC057644C2388F37A9E0A5CEF7D" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1438-wk-Fact-BABF1AB021D7195055AA7A9E0A5EE49A" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,646,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1458-wk-Fact-03BED33154CEFEFE80217A9E0A5CDFCE" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,103,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1477-wk-Fact-4B4A17D0A733063E7E447A9E0A622DB9" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1496-wk-Fact-CFB14B87FC84702D37F17A9E0A5E2753" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">39,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1516-wk-Fact-6D0C6AA7214645C4B6E17A9E0A605AE6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,292,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1541-wk-Fact-23F6033F861EB24F4BD57A9E0A5D6C25" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,103,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1560-wk-Fact-078B0159A76389D2C9C87A9E0A60A9DA" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1579-wk-Fact-3142D7B3E0D3DE8750C57A9E0A5A7D9D" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">39,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1599-wk-Fact-D83B46DEA9CEDE90BEBF7A9E0A622EDC" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,292,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1624-wk-Fact-7B5C399671FEEE7ED0877A9E0A5FB663" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,103,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1643-wk-Fact-39144F9BDF91A45EC49E7A9E0A5E675A" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1662-wk-Fact-EA21551B274AEB2BC7E67A9E0A60C9E5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">39,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1682-wk-Fact-AAD679230AEBFC6E161B7A9E0A5B1548" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,292,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1707-wk-Fact-E53B4FAA5024236B08247A9E0A5FC98A" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">81,051,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1726-wk-Fact-499A03C6656ED1A74DF67A9E0A62ACFE" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">19,270,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1745-wk-Fact-9A357E0C8183DD4B0F6C7A9E0A5CAD6B" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,040,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1765-wk-Fact-F0A3B10215B450756A477A9E0A5F7127" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">105,361,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1795-wk-Fact-FE7E21EB133A755394EA7A9E0A604063" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">98,911,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1814-wk-Fact-696646C3A3FED59F83FF7A9E0A5F5076" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">19,795,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1834-wk-Fact-92F259E397717E48239B7A9E0A5B34EA" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">5,177,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1853-wk-Fact-712148F3B898E0BFBB9F7A9E0A5EB0CD" name="us-gaap:LongTermDebt" contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">123,883,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1862-wk-Fact-630DA27F33B822D3967B7A9E0A990152" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per year. </span></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection-B767703AE7EEB4731F717A9E0AE6436F-1"><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><ix:continuation id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-5" continuedAt="TextSelection-D31D03989F47F5E906B07A9E0AE62965-6"><span style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1869-wk-Fact-D38AB644048FDF107F247A9E0A6EBF37" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959237e1873-wk-Fact-6BB04B5B776840209D237A9E0A6E39F5" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-6"> at maturity.</ix:continuation> </span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s8970F49E5D1F53648F82E4C48883FCBF"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-0-wk-Fact-85049DDA3760433CCF437A9E0A5AB6B4" continuedAt="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfStockByClassTextBlock" id="TextSelection-179744D9ACF492497AEE7A9E0AE77C9D-0-wk-Fact-A0B498A56C4CA21BF0557A9E0A6E54EA" escape="true"><ix:continuation id="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-1" continuedAt="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-2"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company's authorized and issued common and preferred stock as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:42%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding as of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common Stock, par value $0.001 per share</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e647-wk-Fact-8102D8ACF421541B83527A9E0AB3A666" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2020Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">600,000,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e661-wk-Fact-E5E585E140C889F8D4737A9E0AAE4D72" name="us-gaap:CommonStockSharesIssued" contextRef="FI2020Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">158,756,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e675-wk-Fact-0BB8FF2CC65EBA33F1B07A9E0AA9190F" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">158,756,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e689-wk-Fact-F1C5069E1DA4D22D58157A9E0AB3E2E5" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,361,034</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e705-wk-Fact-1A7B8E12EB3751E49D317A9E0AB21B16" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e719-wk-Fact-0774657E97380A0FCA317A9E0AAEF0E4" name="us-gaap:PreferredStockSharesIssued" contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e733-wk-Fact-EF0E2EA9D90E578AE0877A9E0AB79949" name="us-gaap:PreferredStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e747-wk-Fact-A0C3EF77CB746A9B50347A9E0AB33FB9" name="us-gaap:PreferredStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 21</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-2" continuedAt="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-3"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2020, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e769-wk-Fact-89B99B229A575FCD76CC32D615186B6F" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e773-wk-Fact-4DE922F4A38634B2DCEF32D765FCC7AC" name="us-gaap:ConversionOfStockSharesIssued1" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,147</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e783-wk-Fact-3F8B0B09F5A21458F6167A9E0A6EAE91" name="ino:StockSalesAgreementMaximumAuthorizedAmount" contextRef="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e787-wk-Fact-3F8B0B09F5A21458F6167A9E0A6EAE91" name="ino:StockSalesAgreementMaximumAuthorizedAmount" contextRef="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e791-wk-Fact-CD2A17E699909BB30F517A9E0A5ADE61" name="ino:StockSalesAgreementMaximumAuthorizedAmount" contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. As of March 31, 2020, there was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e795-wk-Fact-DA67B4009DA981CC98A4734DD6C60FDE" name="ino:StockSalesAgreementRemainingAuthorizedAmount" contextRef="FI2020Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="font-family:inherit;font-size:11pt;">.  </span><span style="font-family:inherit;font-size:10pt;">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e804-wk-Fact-D1717B9AF451F8B34905955F9ADF1212" name="ino:StockSalesAgreementMaximumAuthorizedAmount" contextRef="D2020Q2Apr_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the New Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent is entitled to compensation for its services in an amount equal to up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e808-wk-Fact-8BBD58145CDC20A99D4B7A9E0A6EE571" name="ino:StockSalesAgreementAgentFee" contextRef="D2020Q2Apr_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2020, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e815-wk-Fact-57DDFD426DBE114886297A9E0A6E9E04" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">43,148,952</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e819-wk-Fact-4CA8AA30E928DDEA2DE87A9E0A5BE2F2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.92</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, resulting in aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e823-wk-Fact-2ED49395FBEF378E3C4C7A9E0A667C16" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">208.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.  As of March 31, 2020, there was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e827-wk-Fact-DA67B4009DA981CC98A4734DD6C60FDE" name="ino:StockSalesAgreementRemainingAuthorizedAmount" contextRef="FI2020Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> remaining capacity under the Prior Sales Agreement.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2020, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e834-wk-Fact-26D1D2E250985A76A02923B7AD4257AA" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,041,178</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e838-wk-Fact-E59562E026C4FF00CF5223B8B7C4EC52" name="ino:StockSaleAgreementWeightedAveragePricePerShare" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.26</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, resulting in aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e842-wk-Fact-DB2FA92EA3C9C83325B423B8E8B84EBB" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. As of June 30, 2020, the Company may sell up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5959682e846-wk-Fact-338B8FEB7D829A8C2AC395C4DCF9DC9F" name="ino:StockSalesAgreementMaximumAuthorizedAmount" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">126.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in gross proceeds of shares of Common Stock under the New Sales Agreement before it would be required to file a new prospectus supplement with the SEC to sell additional shares pursuant to the New Sales Agreement. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options and Restricted Stock Units</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e872-wk-Fact-2F3A82B0D9827B0D71AB7A9E0A608C79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">18,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e876-wk-Fact-59339BF02B2E57A984367A9E0A5C3978" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" contextRef="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock unless the Company's Board of Directors determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e880-wk-Fact-A1EACF7CB9C03DC04AE67A9E0A5F8848" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e888-wk-Fact-BDE9B4803CDF5A65E79E7A9E0A5DC1DF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">18,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e897-wk-Fact-403EAF7FE11C359155EC7A9E0A5F2220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,953,960</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock available for future grant under the 2016 Incentive Plan, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e901-wk-Fact-59B289083AB5F40DB29D7A9E0A5AEE99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,868,665</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e905-wk-Fact-7CCD42BF894C4A75AC1D7A9E0A5FA468" name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,733,501</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5959682e909-wk-Fact-5E3AFEBB625C170BF1D57A9E0A5D8128" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> and have a maximum contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5959682e913-wk-Fact-B0A24935DE26B38BC5087A9E0A5B269D" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-3" continuedAt="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-4"><span style="font-family:inherit;font-size:10pt;">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had options outstanding to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5959682e925-wk-Fact-EFE60B992CCCAC7AD87D7A9E0A6EA45A" name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,459,595</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5959682e929-wk-Fact-407946925ED904AAD4C67A9E0A6E18B1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> and have a maximum contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5959682e933-wk-Fact-8A5C6429C06A8FF539E67A9E0A6EB1AF" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-4">.</ix:continuation> </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s3734B00207935CFA8FD71E12C4396ED3"></a></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11.  <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-4064C9A59F0E0DB9C1857A9E0AE7F1A2-0-wk-Fact-44DF6E4A93B48F212D307A9E0A99235B" continuedAt="TextSelection-4064C9A59F0E0DB9C1857A9E0AE7F1A2-1" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="TextSelection-4064C9A59F0E0DB9C1857A9E0AE7F1A2-1" continuedAt="TextSelection-4064C9A59F0E0DB9C1857A9E0AE7F1A2-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 22</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-4064C9A59F0E0DB9C1857A9E0AE7F1A2-2"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are anti-dilutive.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-BEE5F8513FADFD15BB437A9E0AE797AF-0-wk-Fact-8C732ED8D5C8FED41BEF7A9E0A99C697" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Common Stock Equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e623-wk-Fact-9F522DDE7E0B3BE55A007A9E0AD7F9D5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,193,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e637-wk-Fact-0D5B6FAA93EB9AC1CC917A9E0AD772F4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,770,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e652-wk-Fact-92E7E7488B7028453C0E7A9E0AD3DEC5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,868,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e666-wk-Fact-882AE9FAD820A26CFCC57A9E0AD8C027" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,580,192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible preferred stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e681-wk-Fact-498DA62242368778D6687A9E0AD57379" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e695-wk-Fact-E256C74995688356D7D07A9E0AD6DF87" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e710-wk-Fact-6C0F9517A228FFBCC63E7A9E0AD58D82" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">14,585,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e724-wk-Fact-58939108404A5C3061877A9E0AD4631F" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">14,585,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019 Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e739-wk-Fact-3A761A7AFD59A42648127A9E0AD64194" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,962,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e753-wk-Fact-079E2EF4AD26C8A8DD307A9E0AD7AC3D" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2019 Bonds</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e768-wk-Fact-D3876F8E9C8599445D077A9E0AD859E1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,009,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e782-wk-Fact-195A3D03F0D67A99A6E97A9E0AD6233F" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e797-wk-Fact-F9BB15BC3EE3950D88A37A9E0AD758BF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">32,622,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960166e811-wk-Fact-8713A922356136E3AEBF7A9E0AD46756" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">26,944,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:73%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s73310FA724355CBE9FD361AB6CF2A447"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12.  <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-9AA2225ED8B8D2887F697A9E0AE7F6D9-0-wk-Fact-02444F5B13C1F65F6BC07A9E0A9930FB" continuedAt="TextSelection-9AA2225ED8B8D2887F697A9E0AE7F6D9-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9AA2225ED8B8D2887F697A9E0AE7F6D9-1" continuedAt="TextSelection-9AA2225ED8B8D2887F697A9E0AE7F6D9-2"><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-32FDB9D88FC57C2EF16C7A9E0AE7CAE8-0-wk-Fact-FB6D824098106B11D28D7A9E0A8C114D" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below: </span><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:58%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:2%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e598-wk-Fact-5E00FBD2821891CD8D627A9E0A6DC952" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">0.40</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e608-wk-Fact-3F8C99E2C0222C49AF707A9E0A6B169F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.31</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e618-wk-Fact-F067B2A59BCBA11CA8F67A9E0A6EB4CC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">0.67</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e628-wk-Fact-24AF11E8D937D52B67147A9E0A67EAEB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.43</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e639-wk-Fact-59031EB4AAA5A1A84CF67A9E0A6E869A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e649-wk-Fact-83AEC0E66D5099A9908C7A9E0A6C3283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e659-wk-Fact-0CCD13AADBC9796E7F087A9E0A687381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">77</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e669-wk-Fact-F9015DBAE3FE3D85D3827A9E0A694BF5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life in years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960575e680-wk-Fact-A8D48DFFA8FE3CC99AAA7A9E0A6E46D7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.9</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960575e690-wk-Fact-0A0AC3462DA2C907874F7A9E0A6E7C1F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.2</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960575e700-wk-Fact-C8426DBBD4F97FEEA3C07A9E0A65CC16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.9</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960575e710-wk-Fact-AD2BFBBCE8FE5EB1FD427A9E0A6A5B82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.2</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e721-wk-Fact-09092ACE90A9FCBEBD907A9E0A6B0D83" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e731-wk-Fact-F106C97C313C56E6628E7A9E0A778191" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e741-wk-Fact-4FC0DAB1449FFAC05C4C7A9E0A6AC653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e751-wk-Fact-736F59F4015BD5C0A7AA7A9E0A63C5DD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e772-wk-Fact-94D796D1CFAA3EE2E93D7A9E0A99A2CA" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e776-wk-Fact-5EDDB384CC2212D2CA5DCC9E06AF2269" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e780-wk-Fact-ABBA22D150109F7F01CC7A9E0A9516DD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e784-wk-Fact-53100C1A9589B3BA631ACC9E268E1BEB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in research and development expenses, and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960575e789-wk-Fact-587835243ACD5AB481977A9E0A9909F1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e793-wk-Fact-B3A761D7121A700B4A76CC9E41F2377A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in general and administrative expenses.</span></div><div style="line-height:120%;padding-bottom:4px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e804-wk-Fact-DE219A05CE30D92B6ED57A9E0A9977F1" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e808-wk-Fact-C06FB2BDB5D8C82C2B32CC9E5ACDA947" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e812-wk-Fact-07AE2B4BFE766B39A00A7A9E0A8C7C52" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e816-wk-Fact-D5BA67A694F6DBD1BEB4CC9E88EC41E0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in research and development expenses, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e821-wk-Fact-2733C2031938D543E5817A9E0A992670" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">877,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e825-wk-Fact-C7F5C62355986591C4CCCC9EA1E590AB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in general and administrative expenses.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e836-wk-Fact-FB35123AD8D17825E0437A9E0A8CC195" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960575e840-wk-Fact-E6CC39F852B562A693FC7A9E0A8CFBB3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2020Q2YTD" format="ixt-sec:duryear">2.3</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e847-wk-Fact-177A65E57C78AF5961597A9E0A8CBD38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.52</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e851-wk-Fact-84A13C630AAE3079C137CC9EC9CA7FB9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.19</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for employee and director stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e859-wk-Fact-AB996FDA6E36950811497A9E0AA08C1B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.44</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e863-wk-Fact-AF9C7B3AA7BB98A04C71CC9EE52F7C8D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for employee and director stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 23</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-9AA2225ED8B8D2887F697A9E0AE7F6D9-2"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e879-wk-Fact-98A30F3B6A947386A7317A9E0A9E05D5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960575e883-wk-Fact-97B0CB2821FB8446D7D47A9E0A9F3285" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.3</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years.  </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e890-wk-Fact-893DA43AE56D720A8FF47A9E0A95813E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e894-wk-Fact-97B5D6660A4247304CF4CCA10C5C39FE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.12</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for restricted stock units granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e902-wk-Fact-85A47F6CBE094CC7FC687A9E0A999DC7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.90</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e906-wk-Fact-E8CED0A1DA6AA8F03655CCA122D511BC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.42</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for restricted stock units granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e922-wk-Fact-D36DAA79DF854F5628807A9E0AA079C4" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">224,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e926-wk-Fact-3809629ECAE06E08023BCCA181C5986E" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">607,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e934-wk-Fact-83792F58FCE80780001F7A9E0A955E9C" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">207,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960575e939-wk-Fact-4ABF36CB146E13F48F76CCA19B8264F1" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">480,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s205C8663FD345A3B91327BEF3D03F005"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13.  <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="TextSelection-AFD77B342EDF79C915907A9E0AE7FDB2-0-wk-Fact-CEB7A002264221E0378F7A9E0AB76CF0" continuedAt="TextSelection-AFD77B342EDF79C915907A9E0AE7FDB2-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-AFD77B342EDF79C915907A9E0AE7FDB2-1" continuedAt="TextSelection-AFD77B342EDF79C915907A9E0AE7FDB2-2"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">GeneOne Life Sciences </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company owns </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960755e482-wk-Fact-F8CFB47D0C020E88D5357A9E0AB33D52" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,644,155</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in GeneOne as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to GeneOne. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2010, the Company entered into a collaboration and license agreement (the &#8220;GeneOne Agreement&#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#8220;Product&#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e497-wk-Fact-7463A4FFA93E00731E1E7A9E0AC08669" name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="D2010Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into a collaborative development and license agreement (the &#8220;Hep Agreement&#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#8217;s SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> therapeutic vaccines for hepatitis B and C infections (the &#8220;Hep Products&#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5960755e512-wk-Fact-E17A293539A0F2C5A12B7A9E0ABD7B1E" name="ino:CollaborativeArrangementTerm" contextRef="FD2013Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" format="ixt-sec:duryear">20</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years after the effective date.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960755e519-wk-Fact-524E88B0EE3805AF93D07A9E0AB3143C" name="ino:MilestoneBasedOwnershipTarget" contextRef="D2015Q2May_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960755e526-wk-Fact-FDC73C8D379BE0DADBFD7A9E0ABF12D8" name="ino:MilestoneBasedOwnershipTarget" contextRef="D2016Q1Jan_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized from GeneOne consisted of patent and device maintenance fees. For both the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019, the Company recognized revenue from GeneOne of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e537-wk-Fact-2C053DC305747435DF527A9E0ABE7619" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">31,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e541-wk-Fact-3BEF76E2FD8573BD63E0DACA923B2F34" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">63,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e548-wk-Fact-8D55D1925ABB6BA3A29D7A9E0A5CA7BE" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e552-wk-Fact-DD1D63CC602F60A06C0EDACB237932D6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e560-wk-Fact-4886DFE63788FBFC83097A9E0AAE72B6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">727,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e564-wk-Fact-483998F500B8DE03E681DACB674CCE1A" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 24</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-AFD77B342EDF79C915907A9E0AE7FDB2-2"><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e584-wk-Fact-713B9D003C310CC1B0F87A9E0A60B7CD" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">3,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e588-wk-Fact-E57D64A1ACFC715DA0937A9E0AB3748D" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">128,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e592-wk-Fact-021E85B01FC77E52362D7A9E0AC085EE" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">26,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e597-wk-Fact-7ED1C013C7FB4DE5A4517A9E0AB7CAE4" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">511,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to GeneOne and its subsidiaries. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e609-wk-Fact-5DC04AA97B98D9DC3F9C7A9E0AB739C1" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">238,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e613-wk-Fact-B6206FE34F55AFE71CCF7A9E0AB3F419" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">284,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of prepayments made to GeneOne were classified as long-term other assets on the Company's condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Plumbline Life Sciences, Inc.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company owns </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960755e624-wk-Fact-2FC2C3439865109A7B5A7A9E0AB35275" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">597,808</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960755e636-wk-Fact-B5E93B7D72FC5407655B7A9E0A5A6F35" name="ino:InvestmentOwnedAdditionalSharesAcquired" contextRef="I2020Q1Feb20_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">202,050</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company held a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5960755e644-wk-Fact-C6F305AA3A508F2479377A9E0AB7E9C2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ino_PlumblineLifeSciencesMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">19.9</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in PLS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized from PLS consists of milestone, license and patent fees. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from PLS of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e655-wk-Fact-78F52E742CDD803A87777A9E0A999925" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">64,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e659-wk-Fact-FB7C85247D4C6CC28B54CB8ED5C77938" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e663-wk-Fact-21B5A47B727A7B2FEFD47A9E0AB29E56" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e667-wk-Fact-3A3FCEFB5F6C0A380E27DACFEA5CD424" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">64,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e684-wk-Fact-2179A8D4C5FD227EB5D07A9E0AC088BE" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">13,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e688-wk-Fact-BACEB4B139C893189AC67A9E0AB75CD9" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2019Q4_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">589,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to PLS.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Wistar Institute</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e701-wk-Fact-A6CE516580DC46B8B1CB7A9E0AB7545F" name="ino:CollaborativeAgreementExpensesToReimburse" contextRef="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year term of the agreement.  The Company will have the exclusive right to in-license new intellectual property developed under the agreement.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Company received a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e712-wk-Fact-094E4F81A7E7355B95587A9E0AB7654C" name="ino:CollaborativeAgreementAwardedAmount" contextRef="D2016Q4Nov1Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through December 2020. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2020.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e726-wk-Fact-309EFA9A54C7289C4EF67A9E0A5ACF03" name="ino:GrantProceedsReceived" contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">73,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e730-wk-Fact-697ABEB68958FAD76EB8DAD53183C671" name="ino:GrantProceedsReceived" contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">691,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e738-wk-Fact-FB28F817AFBF654410B77A9E0AB3FE79" name="ino:GrantProceedsReceived" contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">368,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e743-wk-Fact-2427B9B814A4BD8A2420DAE099E73522" name="ino:GrantProceedsReceived" contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense from Wistar. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e754-wk-Fact-1D30B4BC11F3EDD226377A9E0AB332F7" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">408,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e758-wk-Fact-BBD1613425E147075025DAE1243BEC09" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">770,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Research and development expenses recorded from Wistar for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e766-wk-Fact-C5CBBBB5095C6C0D57527A9E0AB719D8" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">170,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e771-wk-Fact-7D27A680B428F7F768D4DAE15971C5EB" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">458,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e783-wk-Fact-A1B0F201C5B50DFB98777A9E0ABF0E0D" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">370,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e787-wk-Fact-D46064FEA832B62566CA7A9E0AB7A3B4" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">616,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e791-wk-Fact-63DED656E2AE8830658B7A9E0AB3EBF0" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">486,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e796-wk-Fact-F06BB725760EA3DFF3927A9E0A5A80C4" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">219,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to Wistar. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5960755e804-wk-Fact-3FEC4E9BFA89F5D2323D7A9E0AB70872" name="ino:DeferredGrantFundingFromAffiliate" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">780,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2EE2B40AF72C5F56B63B4E477BA4D385"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">14.  <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-90504A64C5ED0CF295FD7A9E0AE8B342-0-wk-Fact-E12EB0CDD60B325E827C7A9E0AC8F354" continuedAt="TextSelection-90504A64C5ED0CF295FD7A9E0AE8B342-1" escape="true">Leases                                                  </ix:nonNumeric></span></div><ix:continuation id="TextSelection-90504A64C5ED0CF295FD7A9E0AE8B342-1" continuedAt="TextSelection-90504A64C5ED0CF295FD7A9E0AE8B342-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e480-wk-Fact-248A6D923A8BC7255A757A9E0AC87957" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" contextRef="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_SanDiegoOfficeMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">82,200</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office, laboratory, and manufacturing space in San Diego, California and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e484-wk-Fact-CBB199FD9AD9273653F07A9E0AC8999F" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" contextRef="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_PlymouthMeetingPennsylvaniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">57,360</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June 30, 2020 of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961176e488-wk-Fact-1839C25D9971683AE28C7A9E0AD8791C" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="FI2020Q2_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">3.4</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961176e492-wk-Fact-3900A44CBD413886EB1F7A9E0AC8D769" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="FI2020Q2_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">9.5</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years, which represent the non-cancellable periods of the leases.  The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performed an evaluation of its contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 25</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-90504A64C5ED0CF295FD7A9E0AE8B342-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-F18FB0C7B857557126967A9E0AE7FF08-0-wk-Fact-8E8E0BA65B6945A59F9D7A9E0ADAB11D" escape="true"><div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e541-wk-Fact-C0D26FF0D6FDF32D8A727A9E0A7CBAF2" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">1,956,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e556-wk-Fact-CEC704E86323980F3B7B7A9E0A82978F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">3,968,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e576-wk-Fact-5BEFC935AF5F95AF7BD87A9E0A9FD3D3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">4,045,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e596-wk-Fact-E37001C484122066E9357A9E0AAE5F47" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">4,023,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e616-wk-Fact-61D8113C1F2BF1955E587A9E0AD9D328" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">3,001,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e636-wk-Fact-8C0AF24D23C992D977B57A9E0AAAF8D2" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">12,951,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total remaining lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e656-wk-Fact-585B3C30C92C0BBD27F17A9E0AA030C6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">29,944,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5961176e676-wk-Fact-C79AF067F2EE8FC6A5637A9E0A6E5A9E" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">8,482,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e697-wk-Fact-A8CD8C79B50B67606CEB7A9E0AA084B0" name="us-gaap:OperatingLeaseLiability" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">21,462,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,201,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e743-wk-Fact-E29516213BEEECD0CDF47A9E0A6E1A09" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">19,261,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961176e780-wk-Fact-F77604C2037C6781A8B07A9E0A6E54DD" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2020Q2" format="ixt-sec:duryear">7.8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961176e800-wk-Fact-B52C41EA4005AF3F83B27A9E0AC0BCF6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2020Q2" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease costs included in operating expenses in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961176e827-wk-Fact-9B363F29C1E2D974B6647A9E0AC8B4DF" name="us-gaap:LeaseCost" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">814,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961176e831-wk-Fact-9A472DCEB420BCB94E7D7A9E0AD83CC9" name="us-gaap:LeaseCost" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961176e839-wk-Fact-2D628770368B95A701CDCCABB9A0F2B3" name="us-gaap:LeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">835,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961176e844-wk-Fact-842C47D7486DF57C6AB4CCABC3992FD2" name="us-gaap:LeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s4BEC70F6D4C359969EFC8DBA14EBF4A8"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">15. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-D004398605F1673618287A9E0AE8579E-0-wk-Fact-15FD6452A45B2150BA517A9E0AC701B0" continuedAt="TextSelection-D004398605F1673618287A9E0AE8579E-1" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D004398605F1673618287A9E0AE8579E-1" continuedAt="TextSelection-D004398605F1673618287A9E0AE8579E-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ApolloBio Corporation </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961322e485-wk-Fact-A355CF9AC4F67481E3C17A9E0A5A2825" name="ino:CollaborationAgreementTerritoryExpansionOptionPeriod" contextRef="D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> following the effective date of the ApolloBio Agreement.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the ApolloBio Agreement, the Company received proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e492-wk-Fact-16694E0B7569FE7C1A3C7A9E0ADB3EDE" name="ino:ProceedsFromCollaborativeAgreement" contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in March 2018 which comprised the upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e496-wk-Fact-6A751668088BA90997197A9E0A5D3EFF" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> less </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e500-wk-Fact-007F08F2B90B2285EC077A9E0AC8FB3D" name="ino:CollaborativeAgreementCorporateIncomeTax" contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in foreign income taxes and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e504-wk-Fact-81503AEC5D2C70C9CB1E7A9E0AC8C45D" name="ino:CollaborativeAgreementForeignNonIncomeTaxes" contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e508-wk-Fact-F1178953E420B4464B4B7A9E0A5DDF6D" name="ino:CollaborativeAgreementAdvisoryFees" contextRef="FI2018Q1_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">960,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e515-wk-Fact-9B4EAD573A049FD111037A9E0ADAB267" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 26</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-D004398605F1673618287A9E0AE8579E-2" continuedAt="TextSelection-D004398605F1673618287A9E0AE8579E-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961322e522-wk-Fact-2142D0C074492ABD56347A9E0AD9EE1F" name="ino:CollaborationAgreementRoyaltyPeriod" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the terms of the ApolloBio Agreement under Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e529-wk-Fact-35FF7398C7C6DF3380E97A9E0AD93B07" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961322e536-wk-Fact-9474CFBD6F948E28C8A37A9E0AD746CC" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> after the effective date for any reason upon </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5961322e540-wk-Fact-558D498719E12CD8DFCD7A9E0A5AC7B0" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days written notice to the Company.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Topic 606, the entire transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e547-wk-Fact-7685B81EE0FA033175A77A9E0A582BF0" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e551-wk-Fact-7685B81EE0FA033175A77A9E0A582BF0" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as revenue under collaborative research and development arrangements on the condensed consolidated statement of operations during the three months ended June 30, 2018.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e561-wk-Fact-E755B02308B0B0A37ACF7A9E0AC79A62" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" contextRef="D2015Q3Sept1Sept30_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e565-wk-Fact-DE11E47CB97CCF6CCDD47A9E0ADB466B" name="ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and potential future commercial event-based payments totaling up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e569-wk-Fact-F3D8598BACD499C3B0687A9E0ADADBB7" name="ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.  </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Within the broader collaboration, AstraZeneca had rights to co-develop up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961322e577-wk-Fact-69674F2F3D3F70CBE3B77A9E0AC88B3F" name="ino:NumberOfAdditionalProducts" contextRef="D2015Q3Aug7_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company had recognized all of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e584-wk-Fact-1FD5EE01C25D2F31A73B7A9E0AC8E9CB" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" contextRef="D2017Q4Dec31_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e596-wk-Fact-D17DB0C393F844AC72C17A9E0A95B4D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">74,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e600-wk-Fact-0D0C9DBC32B0CCF20B03CB8F9B7823E7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">146,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from AstraZeneca primarily for manufacturing services. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e609-wk-Fact-EC67BEA0873B9A0BBA027A9E0AD9C483" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">62,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e613-wk-Fact-AF43E6AC109AEC4022B1DAF6DBD36C40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from AstraZeneca primarily from a milestone achieved in the first quarter of 2019 triggered by the initiation of a Phase 2 portion of an ongoing clinical trial in the third major indication, as well as for manufacturing services.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Coalition for Epidemic Preparedness Innovations </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e623-wk-Fact-CEBD04ED20BF17B1CE237A9E0ADAC005" name="ino:CollaborativeAgreementFundingToBeReceived" contextRef="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of costs over a </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 27</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-D004398605F1673618287A9E0AE8579E-3" continuedAt="TextSelection-D004398605F1673618287A9E0AE8579E-4"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company received funding of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e638-wk-Fact-47FAC92972A8BABF7A257A9E0A58E7A8" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e642-wk-Fact-FEF66BA3710C7B3648E9DAF7E7820DE4" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the CEPI Lassa fever and MERS grants and recorded such amounts as contra-research and development expense. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company received funding of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e650-wk-Fact-44D493987DF53EA985A47A9E0A5BAA6C" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e655-wk-Fact-653F353DA4D16B30EBB8DAF812794BEA" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively, related to these grants and recorded such amounts as contra-research and development expense. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e663-wk-Fact-4F08B9AD0331F472BBA07A9E0A5D5D06" name="ino:DeferredGrantFundingCurrent" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, CEPI awarded the Company a grant of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e670-wk-Fact-80D91AFDEE9EFAC9690E7A9E0A583AA2" name="ino:CollaborativeAgreementFundingToBeReceived" contextRef="D2020Q1Jan1Jan31_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e674-wk-Fact-B7A12509B755EF1501548691F74311F0" name="ino:CollaborativeAgreementFundingToBeReceived" contextRef="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e678-wk-Fact-1985CD01B0797A49DEFA86926D8EB401" name="ino:CollaborativeAgreementFundingToBeReceived" contextRef="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP, for the intradermal delivery of INO-4800, and a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e686-wk-Fact-759B5FD4C77628CB0A8D86927DFBFF01" name="ino:CollaborativeAgreementFundingToBeReceived" contextRef="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_INO4800Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to support large-scale manufacturing of INO-4800. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company received funding of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e695-wk-Fact-230ACFBF61FD5C9ACCF2DB01A7CBC5A7" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e699-wk-Fact-DDEECE6F7ED8DAEDC769DB01CB734F24" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e707-wk-Fact-EFC641F7F7875A7D01D686A6F0C8FE55" name="us-gaap:AccountsReceivableRelatedParties" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e711-wk-Fact-27892B35973B81407CC47A9E0AC83A5A" name="ino:DeferredGrantFundingCurrent" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">101,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> recorded deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bill &amp; Melinda Gates Foundation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e722-wk-Fact-B8E89B064A1FD95EDA137A9E0ADA6E6C" name="ino:CollaborativeAgreementFundingReceived" contextRef="D2018Q4Oct1Oct31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to advance the development of DNA-encoded monoclonal antibody technology (&#8220;dMAb&#8221;) to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e726-wk-Fact-B4791A7932D854B016477A9E0A58EA7B" name="ino:CollaborativeAgreementFundingReceived" contextRef="D2019Q3Aug1Aug30_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the project. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e734-wk-Fact-148B34CAEB69123C61857A9E0A5EA0B3" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">36,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e738-wk-Fact-16EA60F4F5D04B4D8DC47A9E0A615A69" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">170,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e747-wk-Fact-F77874FCDCCCF1189E35DAF88B1157F6" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">698,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e751-wk-Fact-541AF140D91275E2BC31DAF8A4274B01" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense related to the Gates dMAb grant. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e759-wk-Fact-16CF675DC66693F9ACFA7A9E0A5A01FF" name="ino:DeferredGrantFundingCurrent" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">858,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, Gates awarded and funded the Company a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e766-wk-Fact-C1C56E89EADA9F728EDD7A9E0ADACA8E" name="ino:CollaborativeAgreementFundingReceived" contextRef="D2020Q1March1March31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to accelerate the development of the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP device for the intradermal delivery of INO-4800. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e778-wk-Fact-1EB064CECB8875D8F9F87A9E0AD9F11B" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">850,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e782-wk-Fact-34C2398ECB9FF07A54BBDAF8DFFBD47E" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">913,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense and had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e787-wk-Fact-DD4E11BB82CF5D80C1197A9E0A5A4E44" name="ino:DeferredGrantFundingCurrent" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> recorded as deferred grant funding on the condensed consolidated balance sheet related to this Gates grant. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Department of Defense (DoD) </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the U.S. Department of Defense (the "DoD"), to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e809-wk-Fact-ABB7540E6887F65E9A93333F391BEC1F" name="ino:CollaborativeAgreementFundingReceived" contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;2000 device and accessories. The CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961322e825-wk-Fact-CB2FAA47E1C6CB9E37A8334DAE60BEB8" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA2000DeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-D004398605F1673618287A9E0AE8579E-4" continuedAt="TextSelection-D004398605F1673618287A9E0AE8579E-5"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961322e836-wk-Fact-78A154EBB79557ECEE8886AB86453B00" name="ino:CollaborativeAgreementFundingReceived" contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> contra-research and development expense </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961322e840-wk-Fact-2DA793D2C02C1BD2F0B786B2C3974FA9" name="ino:DeferredGrantFundingCurrent" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D004398605F1673618287A9E0AE8579E-5">r deferred grant funding recorded related to these agreements with the DoD.</ix:continuation> </span></div><div><a id="sCA19009CB10C57AD9AC5BB0A5C0E2B85"></a></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">16. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-CE9B970C11B1A31B0F9B7A9E0AE8C117-0-wk-Fact-897560D370AC1C21A93C7A9E0A99653D" continuedAt="TextSelection-CE9B970C11B1A31B0F9B7A9E0AE8C117-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="TextSelection-CE9B970C11B1A31B0F9B7A9E0AE8C117-1" continuedAt="TextSelection-CE9B970C11B1A31B0F9B7A9E0AE8C117-2"><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 28</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-CE9B970C11B1A31B0F9B7A9E0AE8C117-2"><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets. The Company will continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows.</span></div></ix:continuation><div><a id="s8F7E90B702955BE7855B44CEA8559E2E"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">17. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-0-wk-Fact-A84DEFC9673103B5B47F7A9E0AA0BE1C" continuedAt="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-1" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-1" continuedAt="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-2"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In  August 2016, the Company formed Geneos, to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;preferred stock financing. The Company invested&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e473-wk-Fact-507C9F7E36E28ECCF54DB5D15F1C2C6E" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" contextRef="D2019Q1Feb1Feb28_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;in the preferred stock financing, which was led by an outside investor.  Following this transaction, the Company held&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e477-wk-Fact-4E75F54FC22289D9A3FBB5D3FDD60925" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="I2019Q1_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">61</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, Geneos completed the second closing of the&#160;preferred stock financing, in which the Company invested &#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e488-wk-Fact-560ADAD6C7B3B8B98F53B5D357164091" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" contextRef="I2020Q1Jan31_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">800,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. Following this transaction, as of March 31, 2020, the Company held&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e492-wk-Fact-7E93A967A4934BB0A255B5D3E0EBB475" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="I2020Q1Jan31_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, Geneos closed an additional&#160;preferred stock financing round, in which the Company invested </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e499-wk-Fact-23261FB82E5E2A4DAB82B5D268935B00" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">800,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">.  Following this transaction, the Company no longer held a controlling financial interest as the Company, retaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e503-wk-Fact-927800823B9D2D66B5ADB5D3CF8F5FA9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q2_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">47</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding equity of Geneos on an as-converted to common stock basis.  This transaction triggered a VIE reconsideration. Based on the Company&#8217;s assessment, Geneos is a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company is not the primary beneficiary of Geneos as it does not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e507-wk-Fact-657DDE81CBAB573A3AFAB5E29189E510" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e511-wk-Fact-CCA5A389BCB403E5A9CCC3B5DE89E6A4" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  <ix:continuation id="TextSelection-41E3CA43BF157B08A488C3B673FA0A3B-0" continuedAt="TextSelection-41E3CA43BF157B08A488C3B673FA0A3B-1">The following table shows the amounts related to the deconsolidation accounting: </ix:continuation></span></div><ix:continuation id="TextSelection-41E3CA43BF157B08A488C3B673FA0A3B-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital (excluding cash) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5962107e542-wk-Fact-C91505256F440C965673D5FE71D2832A" name="ino:WorkingCapitalExcludingCash" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">59,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note Payable </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e558-wk-Fact-F89771DD528A676AD04DD5FE71CA3399" name="us-gaap:NotesPayable" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">171,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed Assets, net of accumulated depreciation </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5962107e578-wk-Fact-0D77FB22A0212498A4DAD5FE71BC87B0" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">16,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying value of noncontrolling interest </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e599-wk-Fact-A4819508852C8052572ED5FE71C12672" name="us-gaap:MinorityInterest" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,181,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of investment in Geneos retained</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e619-wk-Fact-A0614790ECE1A493203FD5FE71CFB17E" name="us-gaap:RetainedInterestFairValueDisclosure" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,618,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on deconsolidation of Geneos </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5962107e639-wk-Fact-4399E8D95BD28694E26AD5FE71C59BB7" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">4,121,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease in cash resulting from the deconsolidation of Geneos</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e665-wk-Fact-258D3AD6E17F7A183D21C385E1C4BCC1" name="us-gaap:CashDivestedFromDeconsolidation" contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,774,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EquityMethodInvestmentsTextBlock" id="TextSelection-1F3F93048F091C2AC1F3B5E762D4875E-0-wk-Fact-94DFAFBD66184AE19316B5E873F80BF3" continuedAt="TextSelection-41E3CA43BF157B08A488C3B673FA0A3B-0" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 1, 2020, the fair value of the Company&#8217;s </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e679-wk-Fact-927800823B9D2D66B5ADB5D3CF8F5FA9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q2_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">47</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> retained investment in Geneos is shown in the table below.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Geneos Share Class</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e766-wk-Fact-3B117D94BDC59945A124D5FE6C553710" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e785-wk-Fact-7E75D590FB3BFC0AA9B9D5FE6C2AB73C" name="us-gaap:SharePrice" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="3" scale="0" format="ixt:numdotdecimal">0.273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e804-wk-Fact-01D4D005AEFB5A12844BD5FE6C5FAD00" name="us-gaap:EquityMethodInvestments" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">819,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e819-wk-Fact-624C20EC412F0DC007EAD5FE6C3B7588" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,113,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e838-wk-Fact-8CDB8229E58438B9FF67D5FE6C6EEB43" name="us-gaap:SharePrice" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="usdPerShare" decimals="3" scale="0" format="ixt:numdotdecimal">1.325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e857-wk-Fact-B8A29F80105F102E9040D5FE6C02A200" name="us-gaap:EquityMethodInvestments" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,799,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e872-wk-Fact-04A061448DA4E7EC7169D5FE6C67B512" name="us-gaap:InvestmentOwnedBalanceShares" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,113,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e911-wk-Fact-8356ECEDC1AF70311C04D5FE6C662C60" name="us-gaap:EquityMethodInvestments" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">3,618,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of Geneos preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of preferred stock financing for Geneos on June 1, 2020.  The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for Geneos&#8217; common stock.  Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving Geneos&#8217; own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 29</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-2" continuedAt="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on Geneos&#8217; total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of Geneos&#8217; estimated time to their next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="TextSelection-793EB679FDB1E094B822B9750C0D5558-0-wk-Fact-CB1080A7B83836A3DC81B975185D1F00" continuedAt="TextSelection-793EB679FDB1E094B822B9750C0D5558-1" escape="true">The assumptions used in the fair value calculation as of June 30, 2020 are presented below:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-793EB679FDB1E094B822B9750C0D5558-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:80%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5962107e951-wk-Fact-7EA825B6342334BEC47FD5FE788E91EB" name="ino:AlternativeInvestmentMeasurementInputTerm" contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">2.92</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e962-wk-Fact-DB642F9C83EA37B42984D5FE7854667E" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5962107e973-wk-Fact-1687BD3A4B9627D358F5D5FE78381FB4" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.46</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enterprise value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e984-wk-Fact-0EA52C6A7C17054E6316D5FE78759923" name="ino:EquityMethodInvestmentEnterpriseValue" contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,966,531</ix:nonFraction></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations.  The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly.  There were </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon deconsolidation, the Company recorded its preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020.  The Company has determined that its preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through June 30, 2020 was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e1006-wk-Fact-B2F167FF135C2BA7FCC6C815484ED97C" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-3" scale="0" sign="-" format="ixt:numdotdecimal">902,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">.  Of this amount, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e1010-wk-Fact-82B097A575D4F71E4D69C830D6B3B51D" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="0" sign="-" format="ixt:numdotdecimal">819,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> has been allocated to the equity method investment, thereby reducing the balance to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e1014-wk-Fact-13DCDEB2D211BDD52014C854DD8B7C78" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> as of June 30, 2020.  The remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e1018-wk-Fact-B1CD07794888A4D6BA2FC8155E91A409" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-3" scale="0" sign="-" format="ixt:numdotdecimal">83,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> loss has been allocated to the Company&#8217;s preferred stock investment in Geneos. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continues to exclusively license its SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">immunotherapy and CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.  </span></div></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><ix:continuation id="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-3" continuedAt="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-4"><span style="font-family:inherit;font-size:10pt;">As of June 30, 2020 the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5962107e1036-wk-Fact-96288B69F20DC5676735B97BDF03D65C" name="us-gaap:DueFromRelatedParties" contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">97,000</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-4"> recorded as a receivable from Geneos.</ix:continuation>  </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE6D675B63920580D8DEE4D957C17D4C1"></a></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">18. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-FFFEAC34978965D51A797A9E0AE858FA-0-wk-Fact-238A2F1006E1F302CA027A9E0AC0493E" continuedAt="TextSelection-FFFEAC34978965D51A797A9E0AE858FA-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FFFEAC34978965D51A797A9E0AE858FA-1" continuedAt="TextSelection-FFFEAC34978965D51A797A9E0AE858FA-2"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, certain holders converted an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961486e485-wk-Fact-580DF1531D9633AFE384956A9C69310D" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2020Q2July1toJuly31_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Notes into an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961486e489-wk-Fact-38DD321D4148EA71A8F59570CE173A2B" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2020Q2July1toJuly31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,546,074</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock.  </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2020, the holders converted all of the August 2019 Bonds into an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961486e496-wk-Fact-459BB0D1A28F9545F54686BE0CB0C455" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2020Q2Aug1toAug10_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,962,364</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, leaving </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5961486e500-wk-Fact-3A9C63823F16ED97463D9AACD0E30CD2" name="us-gaap:LongTermDebt" contextRef="I2020Q2Aug10_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> further August 2019 Bonds outstanding. The conversion rate as of the date of conversion </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 30</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-FFFEAC34978965D51A797A9E0AE858FA-2"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">on August 1, 2020 was </span><span style="font-family:inherit;font-size:10pt;">275.6873</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW </span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5961486e515-wk-Fact-C5F442922F55B8A355067A9E0AAE4D35" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2020Q1Jan02_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.14</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of January 2, 2020).</span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 31</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3080E15B106953F4957DD2D2BDCA1AF5"></a></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC, on March 12, 2020 (our &#8220;2019 Annual Report&#8221;). Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2019 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibody product candidates, or dMABS, may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare proposals; and the impact of COVID-19 on us and our third-party contractors and suppliers.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC71E617E85235D4D84BB90693756E40D"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">General</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, we have demonstrated that a DNA medicine can be delivered directly into cells in the body via our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our novel DNA medicine candidates are made using our proprietary SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our hand-held CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 32</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> smart device in more than 6,000 administrations across more than 2,000 patients.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our corporate strategy is to advance, protect, and provide our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 30, 2020, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$901.0 million</span><span style="font-family:inherit;font-size:10pt;">. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impacts of COVID-19 on Our Business</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic has had a number of significant impacts on our business during 2020.  Most notably, in the United States, South Korea and China, we have accelerated the clinical development of INO-4800, our DNA vaccine candidate matched to the outbreak strain of SARS-CoV-2, the virus that causes COVID-19. In January, we received initial grant funding from CEPI to advance INO-4800 into preclinical studies and clinical development through Phase 1 human testing. We had previously been awarded grants from CEPI for the development of other DNA vaccines against Lassa fever and Middle East Respiratory Syndrome, MERS, which is also caused by a coronavirus like COVID-19. We commenced a Phase 1 clinical trial in the United States in April, and in June we reported positive interim data from the first two cohorts of the trial. In addition, INO-4800 was selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a national program aiming to provide substantial quantities of safe, effective COVID-19 vaccine for Americans by January 2021. We recently expanded our Phase 1 trial to add older participants in additional cohorts and plan to initiate a Phase 2/3 efficacy trial subject to FDA concurrence.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have also initiated clinical trials of INO-4800 in South Korea and China. In April, CEPI awarded us a grant of $6.9 million to work with International Vaccine Institute and the Korea National Institute of Health to conduct a Phase 1/2 trial, which is the first COVID-19 vaccine clinical trial approved in South Korea. In China, we are collaborating with Beijing Advaccine Biotechnology Co. to conduct a Phase 1 trial, the initiation of which was approved by regulatory authorities in July. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In parallel with our accelerated clinical development efforts, we have engaged a network of partners for the planned large-scale manufacturing of INO-4800 if it achieves regulatory approval. In March, the U.S. Department of Defense, or DoD, awarded Ology Bioservices Inc. a contract to manufacture INO-4800 for the DoD to be used in upcoming clinical trials. In April, we entered into an agreement with the German contract manufacturer Richter-Helm BioLogics GmbH &amp; Co. KG and expanded our preexisting manufacturing partnership to support large-scale manufacturing of INO-4800. In March, we also received a grant from the Bill and Melinda Gates Foundation for accelerated testing and scale up of our CELLECTRA 3PSP proprietary smart device for the intradermal delivery of INO-4800. In June, the DoD awarded us $71 million to support the large-scale manufacture of CELLECTRA 3PSP and the procurement of CELLECTRA 2000 devices that are used to deliver INO-4800 intradermally.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With this growing coalition of partners and funders, and with our existing capacity and current and planned contract resources, we are seeking to produce up to one million doses of INO-4800 by the end of 2020 and 100 million doses in 2021. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 33</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operationally, we have not experienced significant disruptions to date as a result of the COVID-19 pandemic.  In response to the outbreak, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. We have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, our liquidity has also not been negatively impacted by the pandemic. During 2019, we raised a total of $94.1 million in net proceeds from the issuances of convertible notes and bonds, which allowed us to continue the funding of our clinical development programs. In addition, during the six months ended June 30, 2020, we have raised an additional $330.0 million from the sale of shares of our common stock, which has further enhanced our liquidity and capital resources. As of June 30, 2020, our cash and cash equivalents and short-term investments were $371.7 million, compared to $89.5 million as of December 31, 2019. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are closely monitoring the impact of the COVID-19 pandemic on our employees, collaborators and service providers. The extent to which the pandemic will impact our business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain. For additional information on the potential effects of the COVID-19 pandemic on our business, financial condition and results of operations, see the &#8220;Risk Factors&#8221; section below in Part II, Item 1A of this Form 10-Q.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6428A1B063695ACDA390BC7B514EC369"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no significant changes to our critical accounting policies since December 31, 2019, other than our adoption of Accounting Standards Update ("ASU") No. 2016-13,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326),</span><span style="font-family:inherit;font-size:10pt;"> on</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">January 1, 2020. For a description of our critical accounting policies that affect our significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2019 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2019 Annual Report. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0C4C06D7F63D53EFBF3CCD207B03D15F"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding recent accounting pronouncements is contained in Note&#160;4 to the Condensed Consolidated Financial Statements, included in this Quarterly Report.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sD3E8DAFDD6AB51CFB12A5EED680CAC83"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue. </span><span style="font-family:inherit;font-size:10pt;">Total revenue was </span><span style="font-family:inherit;font-size:10pt;">$267,000</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.6 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, as compared to </span><span style="font-family:inherit;font-size:10pt;">$136,000</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$3.0 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The decrease in revenue for the six-month period year over year was primarily due to less revenue recognized from our collaboration with AstraZeneca, offset by milestone revenue earned from our affiliated entity PLS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses. </span><span style="font-family:inherit;font-size:10pt;">Research and development expenses for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were $</span><span style="font-family:inherit;font-size:10pt;">22.4 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$41.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, as compared to </span><span style="font-family:inherit;font-size:10pt;">$22.5 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$46.9 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The decrease for the three-month period year over year was primarily due to an increase in contra-research and development expense recorded from grant agreements of $6.6 million, offset by an increase in drug manufacturing expenses related to our COVID-19 and VGX-3100 clinical trials of $3.9 million and increases in device inventory expense of $1.0 million and expensed engineering equipment of $769,000, among other variances. The decrease for the six-month period year over year was primarily due to an increase in contra-research and development expense recorded from grant agreements of $7.6 million, a decrease in clinical trial expenses related to our GBM and bladder cancer trials of $2.2 million and lower employee compensation expense of $1.4 million. These were offset by an increase in drug manufacturing and clinical trial expenses of $3.7 million related to COVID-19 and an increase in R&amp;D expenses incurred by our subsidiary Geneos of $1.1 million, among other variances.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contributions received from current grant agreements and recorded as contra-research and development expense were </span><span style="font-family:inherit;font-size:10pt;">$9.1 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$14.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> as compared to </span><span style="font-family:inherit;font-size:10pt;">$2.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The increase for the three-month period year over year was primarily due to increases of $5.8 million, $850,000 and $595,000 earned under grants from CEPI, Gates and MCDC, respectively, for our INO-4800 and device development activities, partially offset by a decrease of $662,000 earned from the Gates grant related to our dMAb technology, among other variances. The increase for the six-month period year over year was primarily due to increases of $8.1 million, $1.2 million and $913,000 earned from the CEPI, MCDC and Gates grants, respectively, related to our INO-4800 and device development activities, partially offset by a decrease of $1.7 million earned from the Gates grant related to our dMAb technology, among other variances.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expenses. </span><span style="font-family:inherit;font-size:10pt;">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $</span><span style="font-family:inherit;font-size:10pt;">11.1 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$18.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, as compared to </span><span style="font-family:inherit;font-size:10pt;">$5.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$12.8 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The increase for the three-month period year over year was primarily related to an increase in legal expenses of $1.8 million related to the legal proceedings described elsewhere in this report, an increase in expenses for work performed related to corporate marketing and communications of $1.6 million, and higher employee and consultant stock-based compensation expense of $897,000, among other variances. The increase for the six-month period year over year was primarily related to an increase in expenses for work performed related to corporate marketing and communications of $2.8 million, an increase in legal expenses of $1.4 million, and higher employee and consultant stock-based compensation expense of $1.2 million, among other variances. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation. </span><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$3.4 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$7.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Of these amounts, </span><span style="font-family:inherit;font-size:10pt;">$1.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$4.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in research and development expenses, and </span><span style="font-family:inherit;font-size:10pt;">$1.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$3.0 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in general and administrative expenses. Total employee and director stock-based compensation expense for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$3.1 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$6.3 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Of these amounts, </span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$4.2 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in research and development expenses, and </span><span style="font-family:inherit;font-size:10pt;">$877,000</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in general and administrative expenses. The year over year increase was primarily related to a higher weighted average grant date fair value for the awards granted in 2020, offset in part by an option modification expense recorded in the second quarter of 2019.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest income. </span><span style="font-family:inherit;font-size:10pt;">Interest income for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$1.1 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, as compared to </span><span style="font-family:inherit;font-size:10pt;">$755,000</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The increase was related to higher interest earned on our short-term investment holdings.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense. </span><span style="font-family:inherit;font-size:10pt;">Interest expense for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$2.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$5.7 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, as compared to </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The increase was due to higher interest expense recorded for our 6.5% convertible senior notes due 2024, or the Notes, which were issued during the first quarter of 2019, as well as interest expense from our August 2019 Bonds and our December 2019 Bonds, which were issued during the third and fourth quarters of 2019, respectively.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Change in fair value of derivative liability.</span><span style="font-family:inherit;font-size:10pt;"> The change in fair value of derivative liability for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$97.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$111.0 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. We determined that our August 2019 Bonds included an embedded conversion feature that is considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion feature was revalued at the end of each reporting period with&#160;the resulting changes in fair value reflected in the condensed consolidated&#160;statements of operations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gain (loss) on investment in affiliated entities. </span><span style="font-family:inherit;font-size:10pt;">The gain (loss) results from the change in the fair market value of the investments in GeneOne and PLS for a loss of </span><span style="font-family:inherit;font-size:10pt;">$3.9 million</span><span style="font-family:inherit;font-size:10pt;"> and gain of </span><span style="font-family:inherit;font-size:10pt;">$9.3 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> as compared to a loss of $</span><span style="font-family:inherit;font-size:10pt;">173,000</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;">923,000</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. We record our investments in GeneOne and PLS at their market values based on the closing prices of those securities on the applicable stock exchange at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net unrealized gain (loss) on available-for-sale equity securities. </span><span style="font-family:inherit;font-size:10pt;">The net unrealized gain (loss) on available-for-sale equity securities for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$4.4 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$(691,000)</span><span style="font-family:inherit;font-size:10pt;">, respectively, results from a change in the fair market value of the investments as of June 30, 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gain on deconsolidation of Geneos. </span><span style="font-family:inherit;font-size:10pt;">The gain recorded represents the excess of the fair value of our retained noncontrolling investment in Geneos and the carrying amount of the noncontrolling interest over the carrying amount of Geneos' assets and liabilities as of June 1, 2020, the date of deconsolidation. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Share in net loss of Geneos.</span><span style="font-family:inherit;font-size:10pt;"> The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax benefit/(Provision for income taxes). </span><span style="font-family:inherit;font-size:10pt;">The income tax benefit of </span><span style="font-family:inherit;font-size:10pt;">$107,000</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$170,000</span><span style="font-family:inherit;font-size:10pt;"> recorded for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, reflected our application of the intraperiod tax allocation rules under which we are required to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income (loss) related to unrealized gains on our short-term investments. There was no income tax benefit or provision recorded for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA81D48578D54595AB03F724572F6804E"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Working Capital and Liquidity</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and short-term investments of $</span><span style="font-family:inherit;font-size:10pt;">371.7 million</span><span style="font-family:inherit;font-size:10pt;"> and working capital of $</span><span style="font-family:inherit;font-size:10pt;">344.1 million</span><span style="font-family:inherit;font-size:10pt;">, as compared to $</span><span style="font-family:inherit;font-size:10pt;">89.5 million</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;">62.2 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, as of December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The increase in cash and short-term investments during the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to the net proceeds from the sale of our common stock under at-the-market, or ATM, sales agreements, offset by expenditures related to our research and development activities, clinical trials and various general and administrative expenses related to legal, consultants, accounting and audit, and corporate development.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was $</span><span style="font-family:inherit;font-size:10pt;">52.6 million</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;">56.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Net cash used in operating activities for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of net loss of&#160;</span><span style="font-family:inherit;font-size:10pt;">$162.3 million</span><span style="font-family:inherit;font-size:10pt;">, less use of net cash in operating assets and liabilities of&#160;$</span><span style="font-family:inherit;font-size:10pt;">913,000</span><span style="font-family:inherit;font-size:10pt;"> partially offset by net non-cash adjustments of&#160;$</span><span style="font-family:inherit;font-size:10pt;">110.6 million</span><span style="font-family:inherit;font-size:10pt;">.  The primary non-cash adjustments to net loss included the increase in fair value of derivative liability of </span><span style="font-family:inherit;font-size:10pt;">$111.0 million</span><span style="font-family:inherit;font-size:10pt;">, stock-based compensation of&#160;$</span><span style="font-family:inherit;font-size:10pt;">7.7 million</span><span style="font-family:inherit;font-size:10pt;">, interest expense of </span><span style="font-family:inherit;font-size:10pt;">$3.0 million</span><span style="font-family:inherit;font-size:10pt;"> and depreciation and amortization of </span><span style="font-family:inherit;font-size:10pt;">$1.9 million</span><span style="font-family:inherit;font-size:10pt;">, offset by gain on investment in affiliated entities of </span><span style="font-family:inherit;font-size:10pt;">$9.3 million</span><span style="font-family:inherit;font-size:10pt;">, gain on deconsolidation of Geneos of $</span><span style="font-family:inherit;font-size:10pt;">4.1 million</span><span style="font-family:inherit;font-size:10pt;"> and acquisition of investment in our affiliated entity PLS of $</span><span style="font-family:inherit;font-size:10pt;">1.7 million</span><span style="font-family:inherit;font-size:10pt;"> through the settlement of accounts receivable with additional shares of PLS common stock. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> consisted of net loss of&#160;$</span><span style="font-family:inherit;font-size:10pt;">58.9 million</span><span style="font-family:inherit;font-size:10pt;">,&#160;less use of net cash in operating assets and liabilities of&#160;$</span><span style="font-family:inherit;font-size:10pt;">10.5 million</span><span style="font-family:inherit;font-size:10pt;">, partially offset by net non-cash adjustments of&#160;$</span><span style="font-family:inherit;font-size:10pt;">12.9 million</span><span style="font-family:inherit;font-size:10pt;">. The primary non-cash expenses added back to net loss included stock-based compensation of&#160;$</span><span style="font-family:inherit;font-size:10pt;">6.8 million</span><span style="font-family:inherit;font-size:10pt;">, interest expense of </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;"> and depreciation and amortization of&#160;$</span><span style="font-family:inherit;font-size:10pt;">2.4 million</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was </span><span style="font-family:inherit;font-size:10pt;">$94.2 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$27.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </span><span style="font-family:inherit;font-size:10pt;">$340.0 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$80.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The variance was primarily due to the significantly higher net proceeds from the sale of common stock under the ATM sales agreement as well as proceeds from stock option exercises in 2020, offset by the net proceeds received from the issuance of Notes in the first quarter of 2019 (described below).</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Notes and Bonds</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, we completed a private placement of our 1.0% convertible bonds due December 2024, or the December 2019 Bonds, to an institutional investor in Korea for an aggregate principal amount of 4.7 billion Korean Won (KRW) (approximately USD $4.1 million based on the exchange rate on the date of issuance). Net proceeds from the offering were $4.0 million, after deducting the offering expenses payable by us. See Note 9 to the condensed consolidated financial statements included in this report for further discussion. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In the third quarter of 2019, we completed a private placement of aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) of August 2019 Bonds issued to institutional investors led by Korea Investment Partners. Net proceeds from the offering were $14.5 million, after deducting the offering expenses payable by us. See Note 9 to the condensed consolidated financial statements included in this report for further discussion. </span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">In August 2020, all holders of the August 2019 Bonds converted principal amount of 18.0 billion KRW (approximately USD $15.0 million based on the exchange rate on June 30, 2020) into 4,962,364 shares of our common stock.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, we completed a private placement of $78.5 million aggregate principal amount of Notes, sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 36</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">offering were $75.7 million, after deducting the initial purchasers' discount and offering expenses payable by us. See Note 9 to the condensed consolidated financial statements included in this report for further discussion. In July 2020, certain holders of the Notes converted principal amount of $19.1 million into an aggregate of 3,546,074 shares of our common stock.</span></div><div style="line-height:174%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Common Stock</span></div><div style="line-height:120%;padding-bottom:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with an outside placement agent, or the Placement Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the year ended December&#160;31, 2019, we sold 3,340,678 shares of common stock under the Sales Agreement for aggregate net proceeds of $9.1 million. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2020, we entered into amendments to the&#160;Sales Agreement to increase the amount of our common stock that could be sold through the Placement Agent under the Sales Agreement to an aggregate offering price of up to $250.0 million. During the three months ended March 31, 2020, we sold 43,148,952 shares of common stock under the Sales Agreement for aggregate net proceeds of $208.2 million. Following these sales, there was no remaining capacity under this Sales Agreement.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 3, 2020, we entered into a new sales agreement, or the New Sales Agreement, with the same Placement Agent to sell shares of our common stock. On that same day, we filed a prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for aggregate gross proceeds of up to $150.0 million. On May 12, 2020 we filed an additional prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for an additional $100.0 million of gross proceeds, bringing the maximum gross proceeds of sales under the New Sales Agreement to $250.0 million. Through the date of this report, we have sold 12,041,178 shares of common stock under the New Sales Agreement for aggregate net proceeds of $121.7 million.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the six months ended June 30, 2020, stock options to purchase 1,649,874 shares of common stock were exercised for aggregate net proceeds to us of $9.6 million. During the six months ended June 30, 2019, stock options to purchase 33,594 shares of common stock were exercised for aggregate net proceeds of $92,000.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of $</span><span style="font-family:inherit;font-size:10pt;">901.0 million</span><span style="font-family:inherit;font-size:10pt;">. We expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. If these activities are successful and if we receive approval from the FDA to market any of our DNA vaccines, DNA immunotherapies or dMAB product candidates, then we will need to raise additional funding to market and sell the approved vaccine products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date this Quarterly Report is filed.</span></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s9925388AFB9256B2B863C5EFFA684F14"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities.  Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The interest rate on our indebtedness, consisting of the Notes and Bonds, is fixed and not subject to fluctuations in interest rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 37</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The investment in affiliated entities represents our ownership interest in the Korean-based companies, GeneOne and PLS. We report these investments at fair value on the condensed consolidated balance sheet using the closing price of GeneOne and PLS shares of common stock as reported on the date of determination on the Korean Stock Exchange and Korea New Exchange Market, respectively.</span></div><div style="line-height:120%;padding-top:18px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operated primarily in the United States and most transactions during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of the issuance of the August 2019 and December 2019 Bonds, which are denominated in South Korean Won, and the valuation of our equity investments in GeneOne and PLS, each of which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sC42EAD319146535BAA0CB62342DAD4B5"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> at the reasonable assurance level. </span></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 38</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFCE84EC98CBC5C1EBE706630F89FDAB0"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Part II. Other Information</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div><a id="sB0415D0CF1E454ACA468388AF40406E4"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March&#160;12, 2020, a purported shareholder class action complaint,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</span><span style="font-family:inherit;font-size:10pt;">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for&#160;COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff.&#160; On August 3, 2020, the plaintiff filed an amended complaint, naming us and three of our officers as defendants.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 20, 2020, a purported shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Behesti v. Kim, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Beheshti</span><span style="font-family:inherit;font-size:10pt;"> action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Isman v. Benito</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">et al. </span><span style="font-family:inherit;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Devarakonda et al. v Kim, et. al</span><span style="font-family:inherit;font-size:10pt;">.&#160; The complaints assert substantially similar claims as the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Beheshti</span><span style="font-family:inherit;font-size:10pt;"> action and name our current directors as defendants.&#160; The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Devarakonda</span><span style="font-family:inherit;font-size:10pt;"> complaint also names one of our former directors as a defendant.&#160; On July 21, 2020, the court consolidated the three derivative cases under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In re Inovio Pharmaceuticals, Inc. Derivative Litigation</span><span style="font-family:inherit;font-size:10pt;">.&#160; The consolidated action is stayed pending resolution of a forthcoming motion to dismiss the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">McDermid</span><span style="font-family:inherit;font-size:10pt;"> securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 7, 2020, a fourth shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fettig v. Kim et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> &#160;</span><span style="font-family:inherit;font-size:10pt;">The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We intend to defend these actions vigorously.</span></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">VGXI Litigation </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them.  The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI.  On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020.  On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment.  The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us.  Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI.  On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing.  A trial date for the litigation has not been set.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1A885C5BEE545FC19984C3BA88359DA6"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2019 Annual Report, which we filed with the SEC on March 12, 2020 in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 39</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our common stock could decline. You should also consider the more detailed description of our business contained in our 2019 Annual Report. </span></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Industry</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, a novel strain of coronavirus, since named SARS-CoV-2, causing the disease known as COVID-19, was reported in China. Since then, COVID-19 has spread globally, resulting in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &#8220;pandemic&#8221; in March 2020 and United States also declaring a national emergency. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines could be negatively affected by COVID-19, which could then materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as local jurisdictions continue to put restrictions in place, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital, including a potential secondary listing of our equity securities on the KOSDAQ Market of the Korea Exchange. Although we have raised a substantial sum of funds from the sale of our common stock in the public markets in 2020, there can be no guarantee that we will be able to continue to so, which could negative affect our future liquidity. In addition, if a global economic recession results following the spread of COVID-19, its impact could materially affect our business and the value of our common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The continued spread of COVID-19 globally could also adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, the COVID-19 outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to enroll in trials, patients withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of patients to comply with clinical trial protocols as quarantines and travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. These restrictions may delay the conduct of multiple clinical trials including our Phase 1 through 3 clinical trials.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain and cannot be predicted with confidence.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have experienced significant operating losses to date; as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, our accumulated deficit was approximately $</span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">901.0 million</span><span style="font-family:inherit;font-size:10pt;">. We have generated limited revenues, primarily consisting of license revenue, grant funding and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 40</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine, DNA immunotherapy and dMAB product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, during 2020, numerous purported shareholder class action complaints have been filed against us, naming us and our executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of our INO-4800 vaccine candidate against COVID-19 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. For example, in June 2020 we filed a lawsuit against VGXI, one of our contract manufacturers, seeking to compel VGXI to facilitate the transfer of manufacturing methods, using VGXI&#8217;s technology, which would for the large-scale manufacture of INO-4800 by other third-party contract manufacturers that we have engaged and are seeking to engage. In July 2020, VGXI filed a counterclaim against us alleging that we had breached our contract with them, among other claims. Even though we intend to vigorously defend ourselves in the shareholder class action and the litigation with VGXI, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our consolidated financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAB and electroporation equipment. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developing our electroporation-based DNA delivery technology; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or monoclonal antibody products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our human vaccine programs, which includes our COVID-19 vaccine candidate INO-4800, and our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates, including INO-4800. The success of our efforts to develop and commercialize our product candidates, including INO-4800, could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of a COVID-19 vaccine candidate, like INO-4800, on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all</span><span style="font-family:inherit;font-size:9pt;">.  </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 41</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our substantial indebtedness could limit the cash flow available for our operations and could expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, we sold $78.5 million aggregate principal amount of 6.50% convertible senior notes due 2024, or the Notes, as well as $4.1 million aggregate principal amount of 1.0% convertible bonds due December 2024, or the December 2019 Bonds.  We also sold $15.0 million of convertible bonds in August 2019 which we fully converted into shares of our common stock in August 2020. A portion of the Notes were also converted into shares of our common stock in July 2020, although the substantial majority of the Notes remain outstanding. We may incur additional indebtedness to meet our future financing needs. Our existing indebtedness and potential future indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increasing our vulnerability to adverse economic and industry conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limiting our ability to obtain additional financing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limiting our flexibility to plan for, or react to, changes in our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">diluting the interests of our existing stockholders if we issue additional shares of our common stock upon conversion of any convertible debt, such as the Notes and the December 2019 Bonds, in accordance with their respective terms; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the Notes and the December 2019 Bonds and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The conditional conversion features of the Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert their Notes into shares of our common stock at any time during specified periods at their option. If one or more of the holders of the Notes elects to convert their Notes, unless we satisfy our conversion obligation by delivering only shares of our common stock, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. The conditional convertibility of the Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conversion of the Notes and/or the December 2019 Bonds will dilute the ownership interest of existing stockholders, and may otherwise depress the price of our common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#231f20;">The conversion of some or all of the Notes and/or December 2019 Bonds will dilute the ownership interests of existing stockholders to the extent we deliver shares of our common stock upon conversion of any of the Notes. The Notes may become in the future convertible at the option of the holders of the Notes prior to November 1, 2023 under certain circumstances as provided in the indenture governing the Notes. The December 2019 Bonds may become in the future convertible at the option of the holders of the December 2019 Bonds starting December 31, 2020. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 42</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need substantial additional capital to develop our DNA vaccine, DNA immunotherapy and dMAB programs and electroporation delivery technology.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the progress of our current and new product development programs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the progress, scope and results of our pre-clinical and clinical testing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the time and cost involved in obtaining regulatory approvals; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of manufacturing our products and product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">debt service obligations on the Notes</span><span style="font-family:inherit;font-size:10pt;color:#231f20;"> and the December 2019</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;color:#231f20;">Bonds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">competing technological and market developments; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability and costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility and turmoil, particularly in light of the COVID-19 pandemic, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, as we have done in 2020 through our &#8220;at-the-market&#8221; sales agreement, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face intense and increasing competition and many of our competitors have significantly greater resources and experience. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 43</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to enter into agreements with other highly-regarded organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A small number of licensing partners and government contracts account for a substantial portion of our revenue. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 44</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses related to corporate transactions, including ones not fully completed; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">addition or termination of clinical trials or funding support; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any intellectual property infringement lawsuit in which we may become involved; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any legal claims that may be asserted against us or any of our officers; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">debt service obligations on the Notes and the December 2019 Bonds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the fair value of our investments, including investments in affiliated entities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 45</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate that our electroporation equipment or product candidate's clinical and other benefits outweigh its safety risks; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Delays in the commencement or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining regulatory approval to commence a clinical trial; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 46</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future bans or stricter standards imposed on clinical trials of gene-based therapy; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collecting, reviewing and analyzing our clinical trial data; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">global unrest, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unforeseen safety issues; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lack of adequate funding to continue the clinical trial. </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 47</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">issue Warning Letters or untitled letters; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impose civil or criminal penalties; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend regulatory approval; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend any ongoing clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refuse to approve pending applications or supplements to applications filed by us; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impose restrictions on operations, including costly new manufacturing requirements; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seize or detain products or require us to initiate a product recall. </span></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="line-height:120%;padding-bottom:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAB candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for our product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impairment of our business reputation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">costs of related litigation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">distraction of management's attention from our primary business; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or other claimants; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 48</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">loss of revenues; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to commercialize our products. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently do not have a sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any of our products for which we receive regulatory approval does not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to provide acceptable evidence of safety and efficacy; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the relative convenience and ease of administration; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of any actual or perceived adverse side effects; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">availability of alternative treatments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pricing and cost effectiveness; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 49</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably.&#160;In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA.   Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. Under the Consolidated Appropriations Act of 2016, the excise tax was suspended through December&#160;31, 2017, and under the continuing resolution on appropriations for fiscal year 2018, or 2018 Appropriations Resolution, signed by President Trump on January&#160;22, 2018, was further suspended through December&#160;31, 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expanded the entities eligible for discounts under the Public Health program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 50</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">created a licensure framework for follow on biologic products.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. On January 31, 2019, the U.S. Department of Health and Human Services, Office of Inspector General, proposed modifications to the federal healthcare program Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. While some of these and other proposed measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to set a price we believe is fair for our products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to generate revenues and achieve or maintain profitability; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability of capital; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain timely approval of our products. </span></div></td></tr></table><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 51</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-left:64px;padding-top:6px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Physician Payments Sunshine Act, created under the ACA, which requires pharmaceutical companies to record any transfers of value made to doctors and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and to annually report such data to CMS;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 52</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we have in the past relied on VGXI to manufacture DNA plasmids for our product candidates, including our COVID-19 vaccine candidate INO-4800. Due to the urgency of the COVID-19 pandemic, we previously announced our goal of having up to one million doses of INO-4800 available by the end of 2020. VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have sought to engage additional third-party contract manufacturers to support the large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure this additional manufacturing capacity on commercially reasonable terms, if at all. In addition, VGXI has to date refused to permit the transfer of its proprietary methods and technology to third parties for the potential manufacture of INO-4800, something we believe VGXI is contractually obligated to do under our agreement with them. If we are unable to compel VGXI to provide the requested manufacturing methods, it could impair our ability to effectively engage additional third-party manufacturers or could delay the expected timeline for manufacturing sufficient quantities of INO-4800, either of which would adversely affect our commercialization plans and could also harm our reputation.    </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, any delay or interruption in the supply of clinical trial supplies for INO-4800 or any of our other product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">exposure to unknown liabilities; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">higher than expected acquisition and integration costs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased amortization expenses; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 53</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability to retain key employees of any acquired businesses. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption in or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information, and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us.</span></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2017, the Tax Cuts and Jobs Act of 2017 was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code.&#160;The new federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions).&#160;Notwithstanding the reduction in the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 54</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected.&#160;In addition, it is uncertain if and to what extent various states will conform to the federal tax law.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pending patent applications may not result in issued patents; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may not develop or acquire additional proprietary technologies that are patentable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our trademarks may be invalid or subject to a third party's prior use; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 55</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 56</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our common stock may be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price may be highly volatile and can be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of INO-4800 as a potential vaccine candidate against COVID-19;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuating public or scientific interest in the potential for COVID-19 and other pandemic or other applications for our vaccine or other product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in our operating results; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements of technological innovations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">new products or services that we or our competitors offer; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory developments in the United States and other countries; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">negative perception of gene-based therapy; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additions or departures of key personnel; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales or other transactions involving our common stock; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in our capital structure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales or other transactions by executive officers or directors involving our common stock; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in accounting principles; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">global unrest, terrorist activities, and economic and other external factors; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">catastrophic weather and/or global disease pandemics, such as the recent COVID-19 outbreak. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 outbreak during 2020. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 57</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the elimination of cumulative voting. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 58</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2219AA4CA0455699A368E8E29B4DBCE1"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s9A470E5F1CFD57C285DA2E389A0A14D9"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s7F1B10C7A39F5028B2078CCC1AA5EE2A"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s159AECE47CC9539B844C5C7534326CF9"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sFB507579071A5812955FA13557B72D6A"></a></div><div style="line-height:120%;padding-bottom:4px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-align:center;text-decoration:underline;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a200622dodnatickotaagr.htm"><span style="font-family:inherit;font-size:10pt;">10.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a200622dodnatickotaagr.htm"><span style="font-family:inherit;font-size:10pt;">Other Transaction Authority For Prototype Agreement dated June 22, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (filed herewith).#</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a200618dodnatickawarde.htm"><span style="font-family:inherit;font-size:10pt;">10.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a200618dodnatickawarde.htm"><span style="font-family:inherit;font-size:10pt;">Award Agreement dated June 18, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (filed herewith).#</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-63020x10qex311.htm"><span style="font-family:inherit;font-size:10pt;">31.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-63020x10qex311.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-63020x10qex312.htm"><span style="font-family:inherit;font-size:10pt;">31.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-63020x10qex312.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-63020x10qex321.htm"><span style="font-family:inherit;font-size:10pt;">32.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-63020x10qex321.htm"><span style="font-family:inherit;font-size:10pt;">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB2ECC29EE55CB395222A750C42996D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="padding-top:10px;text-align:left;padding-left:17px;text-indent:-16px;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because such portions, indicated by asterisks, are both not material and would likely cause competitive harm to the Registrant if publicly disclosed. The Registrant hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 60</span></div></div><hr style="page-break-after:always"></hr><div><a id="s30DE353666CA5D649B004951779A97C1"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        INOVIO PHARMACEUTICALS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:5%;"></td><td style="width:40%;"></td><td style="width:4%;"></td><td style="width:51%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August&#160;10, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">J. Joseph Kim</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;font-style:italic;">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:28px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:28px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:28px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:28px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August&#160;10, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Peter Kies </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;font-style:italic;">Chief Financial Officer                                                                         (Principal Financial and Accounting Officer)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 61</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a200622dodnatickotaagr.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4E760F06E02E13DB47399C70A7F8C3DA"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:184px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;[***]&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I)&#160;IS NOT MATERIAL AND (II)&#160;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:184px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OTHER TRANSACTION AUTHORITY FOR PROTOTYPE AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:162px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BETWEEN</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:170px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inovio Pharmaceuticals, Inc. (Awardee) 660 W Germantown Pike Ste 110 Plymouth Meeting, PA, 19462-1111</font></div><div style="line-height:120%;text-align:center;padding-left:162px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">And</font></div><div style="line-height:120%;text-align:center;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NATICK CONTRACTING DIVISION (Government)</font></div><div style="line-height:120%;text-align:center;padding-left:253px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">110 Thomas Johnson Dr. Frederick, MD 21702</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:240%;text-align:left;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date: 22 June 2020 Agreement No.: [***]</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:14px;text-indent:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Total Amount of the Agreement: $[***]</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:14px;text-indent:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:14px;text-indent:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:14px;text-indent:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:14px;text-indent:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:14px;text-indent:21px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awardee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ J. Joseph Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lawrence Mize</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signature</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. Joseph Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lawrence Mize</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Printed Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Printed Name</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agreement Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/20/2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/20/2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:8px;text-indent:312px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">A</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Appendices and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s5B6B880562F3CAAFA1579C70A8194CCA"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Other Transaction Authority for Prototype Agreement is entered into between the United States of America, hereinafter called the &#8220;Government&#8221;, pursuant to and under U.S. Federal law, and Inovio Pharmaceuticals, Inc. a small business, non-traditional defense contractor, hereinafter called the &#8220;Awardee&#8221;. The United States of America and Awardee are sometimes referred to herein individually as a &#8220;Party&#8221; and collectively as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Awardee is eligible for an Other Transaction Authority for Prototype Agreement in accordance with 10 USC &#167; 2371b(d)(1)(A) as amended by the National Defense Authorization Act for Fiscal Year 2018 as they are non-traditional defense contractor;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, in accordance with 10 U.S.C. 2371b, The Department of Defense currently has authority to award &#8220;other transactions&#8221; (OTs) in certain circumstances for prototype projects that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the Armed Forces. To the maximum extent practicable, competitive procedures shall be used when entering into agreements to carry out projects under subsection (a);</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the parties are developing a prototype only for use with Inovio's approved products and under Inovio&#8217;s regulatory filings, whereby such protoype can generally be described as a proof of concept, model, reverse engineering to address obsolescence, pilot, novel application of commercial technologies for defense purposes, agile development activity, creation, design, development, demonstration of technical or operational utility, or combinations of the foregoing;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:240%;text-align:left;padding-left:12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, this Agreement meets the criteria for a prototype project; NOW THEREFORE, the Parties have agreed as follows:</font></div><div style="line-height:126%;padding-top:1px;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ARTICLE 1. Scope.</font></div><div style="line-height:120%;text-align:justify;padding-left:12px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Other Transaction Authority for Prototypes Agreement (the &#8220;Agreement&#8221;) is entered into between the Government and the Awardee on the Effective Date set forth above. For the avoidance of doubt, this Agreement is entered into pursuant to 10 U.S.C.</font></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#167; 2371b and is not a procurement contract governed by the Federal Acquisition Regulation (FAR), a grant, or cooperative agreement. The FAR and the Defense Federal Acquisition Regulation Supplement (DFARS) apply only as specifically referenced herein. This Agreement is not intended to be, nor will it be construed as, forming, by implication or otherwise, a partnership, a corporation, or other business organization. This Agreement is not subject to the Bayh-Dole Act, 35 U.S.C. &#167;&#167; 200- 12.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:12px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">B.</font><font style="font-family:inherit;font-size:12pt;">The Parties agree that the sole purpose of this Agreement is for the development of an FDA approved next generation electroporation device and array for DNA Vaccine delivery of INO-4800 against COVID-19, with demonstrated capability to be produced at a large scale, as well as full automation for production of the device arrays, (hereinafter referred to as the "Prototype Project"). The Awardee shall develop the Prototype as described in the Awardee&#8217;s Statement of Work (SOW), which is incorporated herein and attached hereto as Appendix A. For purposes of clarity, this Agreement does not contemplate Government use of the Prototype while it is an investigational device. Any subsequent Government purchase of the Prototype or the FDA-cleared device, including a follow-on contracting action under 10 USC 2371b(f), shall specify the terms of Government use, which shall be conducted</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s61E839D76EF28641EB859C70A8624567"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under Inovio&#8217;s regulatory filings or under the terms of the FDA&#8217;s clearance and consistent with the product labeling. No further use is permitted without Inovio&#8217;s explicit prior written consent, whereby any such permitted use shall be negotiated by the parties and subject to a future agreement.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:12px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">C.</font><font style="font-family:inherit;font-size:12pt;">The prototype will be deemed successful where the Awardee&#8217;s efforts meet the key technical requirements and are sufficient to meet an FDA compliant final report(s) that supports the completion of a human clinical trial(s). Follow on production pursuant to 10 USC 2371b is anticipated to be [***], which the Parties agree to negotiate such terms in good faith pursuant to a separate agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ARTICLE 2. Term and Termination.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Term: The Term of this Agreement commences upon the Effective Date and extends through final payment. This Agreement is anticipated to end [***], subject to completion of the project(s). A transaction for a prototype project is complete upon the written determination of the appropriate official for the matter in question that efforts conducted under a Prototype OT: (1) met the key technical goals of a project, or (2) accomplished a particularly favorable or unexpected result that justifies the completion of the prototype.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Termination for Convenience: The Government may terminate this Agreement for any or no reason by providing at least thirty (30) calendar days&#8217; prior written notice to the Awardee. The Government and Awardee will negotiate in good faith a reasonable and timely adjustment of all outstanding issues between the Parties as a result of termination by the Government for convenience, consistent with the terms of this Agreement.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Termination for Cause: If the Awardee materially fails to comply with the provisions of this Agreement, the Other Transaction Agreement Officer (OTAO), after issuance of a cure notice and failure of the Awardee to cure the defect within ten (10) business days or the time allowed by the OTAO after Awardee&#8217;s receipt of the cure notice, whichever is longer, may take one or more of the following actions as appropriate:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">i.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">temporarily withhold payments pending correction of the deficiency,</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:65px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">disallow all or part of the cost of the activity or action not in compliance,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:86px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:65px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">wholly or partly suspend or terminate this Agreement,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:65px;"><font style="font-family:inherit;font-size:12pt;">iv.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">withhold further funding,</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:65px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">v.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">require Awardee to pay repurchase costs as defined in Article 2C1, Repurchase Against vi. Contractors Account, or</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:65px;"><font style="font-family:inherit;font-size:12pt;">vi.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">take any other legally available remedies.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:29px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Repurchase Against Contractors Account.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">When the Prototype is still required after termination, the AO shall repurchase the same or a similar prototype against the Contractor&#8217;s account as soon as practicable. The AO shall repurchase at as reasonable a price as practicable, considering the quality and delivery requirements.          The AO may repurchase a quantity in excess of the undelivered quantity terminated for          cause when the excess quantity is needed, but excess cost may not be charged against the</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s5BAF356697C55F8B03BA9C70A89966DD"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Contractor for more than the undelivered quantity terminated for cause (including variations in quantity). The AO will make a decision whether or not to repurchase before issuing the termination notice.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If repurchase is made at a price over the price of the Prototype terminated, the AO shall, after completion and final payment of the repurchase contract or agreement, make written demand on the Contractor for the total amount of the excess, giving consideration to any increases or decreases in other costs such as transportation, discounts, etc. If the Contractor fails to make payment, the AO shall follow the procedures in FAR subpart 32.6 for collecting contract debts due the Government.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">b.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If this Agreement is terminated for Cause, Awardee will grant the Government a non- exclusive, paid up, license to the Awardee and subawardee patents and documentation necessary for the purpose of developing the Prototype solely for use with the INO-4800 product for COVID-19 and shall only be conducted under Inovio&#8217;s regulatory filings and solely for the pandemic period as applicable in the United States. No further use is permitted without Inovio&#8217;s explicit prior written consent, whereby any such permitted use shall be negotiated by the parties and subject to a future agreement. The Awardee shall provide the Government or its designee with a non-exclusive, paid up, license to any patent, copyright, technical data or regulatory information held by the Awardee that relates to the technology to permit the Government to pursue commercialization of the technology with a third party solely for use with the INO-4800 product for COVID-19 and shall only be conducted under Inovio&#8217;s regulatory filings and solely for the pandemic period as applicable in the United States. No further use is permitted without Inovio&#8217;s explicit prior written consent, whereby any such permitted use shall be negotiated by the</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">parties and subject to a future agreement, on terms to be agreed between the Parties and subject to rights granted or held by third parties. The terms of this section and the obligations herein will be included in any exclusive license given by the Awardee to a third party for any intellectual property covered by this Agreement, on terms to be agreed between Awardee and such third party. This clause will survive the acquisition or merger of the Awardee by or with a third party.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding this Article 2.C, the Government's rights and Awardee's obligations under this paragraph will cease to exist if the Government terminates this Agreement for any reason other than for Awardee's failure to materially comply with the terms of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Survival: In the event of Termination, all rights, obligations, and duties hereunder, which by their nature or by their express terms extend beyond the expiration or termination of this Agreement, including but not limited to warranties, indemnifications, intellectual property (including rights to and protection of Intellectual Property and Proprietary Information), and product support obligations shall survive the expiration or termination of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3. Project Management.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">Program Governance: The Awardee is responsible for the overall management of the project development program and related program decisions. The Government will have continuous involvement with the Awardee. The Awardee shall provide access to project results in accordance with the Awardee&#8217;s Project Timeline located in Appendix A.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sBC8446375DC267B5D1439C70A8D16136"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-left:24px;padding-top:4px;text-align:left;text-indent:0px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">Project Managers: The Awardee and the Government will each designate a Project Manager responsible for facilitating the communications, reporting, and meetings between the Parties. Each Party will also designate an alternate to the Project Manager, in case the primary Project Manager is unavailable. See Project Manager/Alternate Project Manager point of contact information for each respective party below:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14.5pt;"><font style="font-family:inherit;font-size:14.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Awardee Project Managers</font></div><div style="line-height:120%;padding-left:29px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.29175475687104%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:54%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Primary Project Manager:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alternate Project Manager:</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:228px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Government Project Managers (GPM)</font></div><div style="line-height:120%;padding-left:29px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.29175475687104%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:51%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Primary Project Manager:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alternate Project Manager:</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;padding-top:4px;text-align:left;text-indent:0px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:12pt;">Key Personnel: The Awardee's organization shall be established with authority to effectively develop the Prototype. This organization shall become effective upon execution of this Agreement and its integrity shall be maintained until completion or acceptance of the effort by the Government. The key personnel listed in Appendix C are considered to be critical to the successful performance of this Agreement. Prior to replacing these key personnel, the Awardee shall provide written notification to the OTAO. The Awardee shall demonstrate that the qualifications of the proposed substitute personnel are generally equivalent to or better than the qualifications of the personnel being replaced.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:20px;">D.</font><font style="font-family:inherit;font-size:12pt;">Subaward Approval: Modifications to subawards and/or new subcontracts under this Agreement after the Effective Date that could reasonably impact the technical approach proposed and accepted by the Government require the approval of the OTAO prior to being executed.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">E.</font><font style="font-family:inherit;font-size:12pt;">The OTAO has assigned an Agreements Officer&#8217;s Representative (AOR) for this agreement. The Awardee will receive a copy of the written designation outlining the roles and responsibilities of the AOR and specifying the extent of the AOR&#8217;s authority to act on behalf of the OTAO. The AOR is not authorized to make any commitments or changes that will affect price, quality, quantity, delivery, or any other term or</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF3BB67F67B450FC22F059C70A8EEA3DB"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">condition of the contract.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4. Agreement Administration.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In no event shall any understanding or agreement, modification, change order, or other matter in deviation from the terms of this Agreement between the Awardee and a person other than the OTAO be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the OTAO.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Government Representatives:</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Transaction Agreements Officer [***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Transaction Agreement Specialist [***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreements Officer&#8217;s Representative [***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:138%;padding-top:4px;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Awardee Representatives:</font></div><div style="line-height:138%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s4247BF009CCC4E0F34B69C70A8F74F1D"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:138%;padding-top:4px;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:138%;text-align:left;padding-left:29px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;" href="#"><font style="font-family:inherit;font-size:12pt;">[***]</font></a></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:138%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:138%;text-align:left;padding-left:29px;font-size:12pt;"><a style="font-family:inherit;font-size:12pt;" href="#"><font style="font-family:inherit;font-size:12pt;">[***]</font></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5. Performance Objectives and Changes.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Statement of Work (SOW): The SOW, Appendix A, describes the scope of activities that will be undertaken by the Awardee to achieve the objective.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Recommendations for Modifications: At any time during the term of this Agreement, progress or results may indicate that a change in the SOW would be beneficial to the project objectives. Recommendations for modifications, including justifications to support any changes to the SOW, will be documented in a letter and submitted by Awardee to the GPM with a copy to the OTAO. This letter will detail the technical, chronological and financial impact, if any, of the proposed modification to the project. Any resultant modification is subject to the mutual agreement of the Parties. The Government is not obligated to pay for additional or revised costs unless and until this Agreement is formally revised by the OTAO and made part of this Agreement. Any modification to this Agreement to account for recommended changes in the SOW or Payable Milestones will be considered a supplemental agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Review of Recommendations: The OTAO will be responsible for the review and verification of any recommendations to revise or otherwise modify the Agreement, the SOW, the milestone payments, or other proposed changes to the terms and conditions of this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Minor Modifications: The Government may make minor or administrative Agreement modifications unilaterally (e.g., changes in the paying office or appropriation data, changes to Awardee personnel proposed by Awardee, etc.).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amending the Agreement: The Government will be responsible for effecting all modifications to this Agreement, with the concurrence of the Awardee for modifications that are not minor or administrative. Administrative and material matters under this Agreement will be referred to OTAO.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s76E82AD408CB7DFF40F09C70A9169B92"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Modification Communications: No other communications, whether oral or in writing, that purport to change this Agreement are valid.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Government Property: If applicable, terms and conditions applicable to Government Property shall be incorporated through Appendix D.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:34px;text-indent:-7px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">E. Disputes: For any disagreement, claim, or dispute arising under this Agreement, the parties shall communicate with one another in good faith and in a timely and cooperative manner. Whenever disputes, disagreements, or misunderstandings arise, the parties shall attempt to resolve the issue by discussion and mutual agreement as soon as practicable. Failing resolution by mutual agreement, the aggrieved party shall request a resolution in writing from the OTAO. The OTAO will review the matter and render a decision in writing within sixty (60) calendar days. Thereafter, either party may pursue any right or remedy provided by law in a court of competent jurisdiction as authorized by 28</font></div><div style="line-height:120%;text-align:left;padding-left:34px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">U.S.C. 1491. Alternately, the parties may agree by mutual consent to explore and establish and Alternate Disputes Resolution procedure to resolve this dispute. The Awardee shall proceed diligently with performance under this agreement pending resolution of the dispute.</font></div><div style="line-height:120%;text-align:left;font-size:15pt;"><font style="font-family:inherit;font-size:15pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:34px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6. Inspection/Acceptance</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:36px;padding-top:13px;text-align:left;text-indent:0px;"><font style="padding-top:13px;text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">Inspection: The Government has the right to inspect and test all work called for by this Agreement, to the extent practicable at all places and times, including the period of performance, and in any event before acceptance. The Government may also inspect the premises of the Awardee or any subawardee engaged in performance. The Government shall perform inspections and tests in a manner that will not unduly delay the work. If the Government performs any inspection or test on the premises of the Awardee or a subawardee, the Awardee shall furnish and shall require subawardees to furnish, at no increase in price, all reasonable facilities and assistance for the safe and convenient performance of these duties. Except as otherwise provided in the Agreement, the Government shall bear the expense of Government inspections or tests made at other than the Awardee&#8217;s or subawardee&#8217;s premises.</font></div><div style="line-height:120%;padding-left:36px;padding-top:13px;text-align:left;text-indent:0px;"><font style="padding-top:13px;text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">The Government shall inspect/accept or reject the work as promptly as practicable after completion/delivery, unless otherwise specified in the Agreement. Government failure to inspect and accept or reject the work shall not relieve the Awardee from responsibility, nor impose liability on the Government, for nonconforming work. Work is nonconforming when it is defective in material or workmanship or is otherwise not in conformity with Agreement requirements. The Government has the right to reject nonconforming work. Inspection/Acceptance of the Prototype performed should not exceed 90 days after completion</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s657AE7369F2B3CE8AB5C9C70A946EDC7"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7. Financial Matters</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">This Agreement is an expenditure type Other Transaction Authority agreement. The payments provided under this Agreement are intended to compensate the Awardee on a cost basis for performance under this Agreement. The Awardee shall provide its best efforts to complete a prototype project based on the estimated cost. Payments are based on amounts generated from the Awardee&#8217;s financial or cost records.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">Payment. Payments are based on amounts generated from the Awardee&#8217;s financial or cost records. The Awardee shall be reimbursed for each element identified in the awarded cost proposal, executed and accomplished in accordance with the performance schedule set forth in Appendix B. The schedule is predicated upon the Government's fiscal year, which begins on October 1 of each year, and ends on September 30 of the subsequent calendar year.</font></div><div style="line-height:120%;text-align:left;font-size:14.5pt;"><font style="font-family:inherit;font-size:14.5pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:12pt;">Obligation. Under no circumstances shall the Government's financial obligation exceed the amount obligated in this Agreement or by amendment to the Agreement. The amount of Government funds obligated by this Agreement and available for </font><font style="font-family:inherit;font-size:11pt;">payment is set forth in the supplemental PD2 version of the agreement, and any subsequent modifications. The Government may incrementally fund this agreement.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">D.</font><font style="font-family:inherit;font-size:12pt;">The Government is not obligated to provide payment to the Awardee for amounts in excess of the amount of obligated funds allotted by the Government.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">E.</font><font style="font-family:inherit;font-size:12pt;">The Government shall pay the Awardee, upon submission of proper invoices, the costs stipulated in this Agreement for work delivered or rendered and accepted, less any deductions provided in this Agreement. Unless otherwise specified, payment shall be made upon acceptance of any portion of the work delivered or rendered for which a price is separately stated in the Agreement. Payments will be made within thirty</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(30) calendar days of receipt of a request for payment.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">F.</font><font style="font-family:inherit;font-size:12pt;">Prior written approval by the OTAO, or the AOR, is required for all travel directly and identifiably funded by the Government under this agreement. The Awardee shall present to the OTAO or AOR, an itinerary for each planned trip, showing the name of the traveler, purpose of the trip, origin/destination, dates of travel, and estimated cost broken down by line item as far in advanced of the proposed travel as possible, but no less than two weeks before travel is planned to commence. In the event that emergency travel is required (e.g. in the event of an outbreak) that would make two weeks&#8217; notice impractical, travel requests may be submitted to the Government for an expedited</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s3CD9D38021E70267D1789C70A98C452E"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:34px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">review. Emergency travel requests shall be labelled as such and shall include a brief summary of the emergency situation and rationale for expedited review.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:34px;"><font style="font-family:inherit;font-size:12pt;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (MAY 2013)</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Definitions. As used in this clause--</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Department of Defense Activity Address Code (DoDAAC) is a six position code that uniquely identifies a unit, activity, or organization.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Document type means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Local processing office (LPO) is the office responsible for payment certification when payment certification is done external to the entitlement system.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Electronic invoicing. The WAWF system is the method to electronically process vendor payment requests and receiving reports, as authorized by DFARS 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">WAWF access. To access WAWF, the Awardee shall (i) have a designated electronic business point of contact in the System for Award Management at https://www.acquisition.gov; and (ii) be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this website.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">WAWF training. The Awardee should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the "Web Based Training" link on the WAWF home page at https://wawf.eb.mil/.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">WAWF methods of document submission. Document submissions may be via Web entry, Electronic Data Interchange, or File Transfer Protocol.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">WAWF payment instructions. The Awardee must use the following information when submitting payment requests and receiving reports in WAWF for this Agreement:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">i.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Document type. The Awardee shall use the following document type: Voucher</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s53BC8E5E67B77ECD5B419C70A99AB35F"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ii.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Inspection/acceptance location. The Awardee shall select the following inspection/acceptance location(s) in WAWF, as specified by the contracting officer.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">iii.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Document routing. The Awardee shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Routing Data Table</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:53px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.77272727272728%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Field Name in WAWF</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:46px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Data to be entered in WAWF</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Payment request and supporting documentation. The Awardee shall ensure a payment request includes appropriate contract line item and subline item descriptions of the work performed or supplies delivered, costs, fee (if </font><font style="font-family:inherit;font-size:11pt;">applicable), and all relevant back-up documentation in support of each payment request.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">WAWF email notifications. The Awardee shall enter the email address identified below in the "Send Additional Email Notifications" field of WAWF once a document is submitted in the system.</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s2122156CCA14A5D46ACF9C70A9BD3F71"></a></div><div style="line-height:112%;text-align:left;padding-left:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:112%;text-align:left;padding-left:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:112%;text-align:left;padding-left:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:128%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:128%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:46px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font><font style="font-family:inherit;font-size:12pt;color:#0000ff;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="s17ADE3B523BFE8E1CE3D9C70A9EF6A57"></a></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:38px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:22px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WAWF point of contact.</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Awardee may obtain clarification regarding invoicing in WAWF from the following contracting activity's WAWF point of contact.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For technical WAWF help, contact the WAWF helpdesk at 866-618-5988.</font></div><div style="line-height:120%;text-align:left;padding-left:146px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(End of Clause)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA2FC1DE909D1BE8AA33E9C70AA0E677F"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-left:24px;padding-top:4px;text-align:left;text-indent:0px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">H.</font><font style="font-family:inherit;font-size:12pt;">Comptroller General Access to Records: To the extent that the total Government payments under this Agreement exceed $5,000,000, the Comptroller General, at its discretion, shall have access to and the right to examine records of any Party to the Agreement or any entity that participates in the performance of this Agreement that directly pertain to, and involve transactions relating to, the Agreement for a period of three</font></div><div style="line-height:120%;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3) years after final payment is made. This requirement shall not apply with respect to any Party to this Agreement or any entity that participates in the performance of the Agreement, or any subordinate element of such Party or entity, that has not entered into any other agreement (contract, grant, cooperative agreement, or &#8220;other transaction&#8221;) that provides for audit access by a government entity in the year prior to the date of this Agreement. This paragraph only applies to any record that is created or maintained in the ordinary course of business or pursuant to a provision of law. The terms of this paragraph shall be included in all sub-agreements to the Agreement other than sub-agreements with a component of the U.S. Government. The Comptroller General may not examine records pursuant to a clause included in an agreement more than three years after the final payment is made by the United States under the agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARTICLE 8. Report and Data Requirements</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">A.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Weekly Teleconferences and Communication</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Awardee shall conduct weekly teleconferences with the Government throughout the performance of the Agreement to discuss tasks accomplished and direction for the upcoming tasks. The Government anticipates reducing the teleconferences once enrollment executes and again after completion of the trial. Awardee shall provide agendas and read-ahead material as required two days prior to the meetings and shall provide minutes of each meeting to the Government. Awardee shall include key subcontractors as attendees at these teleconferences when applicable. The Awardee shall provide meeting minutes within [***] after each formal scheduled meeting/teleconference conducted with JPEO EB.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarterly Progress Reports</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall submit a Quarterly Progress report within [***] after the end of each quarter of performance. The Quarterly Progress report shall contain the technical progress made during the previous quarter and the updated resource loaded Integrated Master Schedule (IMS) in Microsoft Project format. The schedule update shall include the explanation for any changes in the schedule, and drivers for the changes, as applicable. The report should also address any concerns that would impact the performance, schedule, or cost planned for the effort. The Awardee shall report risk matrix</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s0027577C7D75E71F63969C70AA3EBE55"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">format to include risk mitigation strategies. Note: Any identified changes require formal notification to the OTAO in accordance with the Agreement provisions.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, the Quarterly Progress Report shall contain regular status updates of all Intellectual Property (IP) license(s) related to the effort to ensure that all license(s) are in good standing as the project progresses. In the event of any change in IP license(s) status or potentially imminent change in status, the Awardee shall immediately contact the OTA and GPM in writing.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Government will have [***] to respond to the report with any comments and the Awardee will have [***] to revise the deliverable or respond to those comments.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quarterly Financial Status Report</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall submit a Quarterly Financial Status Report no later than [***] after the end of each quarter of performance. The Government will have [***] to respond to the report with any comments and the Awardee will have [***] to revise the deliverable or respond to those comments. Reports will cover work performed every three (3) months for the duration of the Period of Performance (PoP).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, the Quarterly Financial Status Report shall include quarterly expenditure forecasts with both the quarterly planned accrual and the cumulative total. Expenditure forecast submissions shall include analysis of the cost drivers for Estimate to Complete changes, if any, from the previous projection. The Awardee shall provide all submissions in Excel format, including all formulas.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">D.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Expenditure Forecasts</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall submit the first expenditure forecast within thirty (30) calendar days after receiving the project award. An updated forecast shall be submitted within [***] of any project modifications that modify the PoP or the cost of the prototype. Expenditure forecast submissions shall include analysis of the cost drivers for Estimate to Complete changes, if any, from the previous projection. The Awardee shall provide all submissions in Excel format, including all formulas.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Final report</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A Final Report shall be prepared at the end of the effort by the Awardee. The Final Report shall narrate a complete summary of the project execution and associated results obtained. The narration will include outstanding problems and their potential solutions, problems solved during the course of the agreement, and the solutions to the solved problems. The Final Report shall demonstrate how the prototype was developed and advanced.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7CAAD2FDF86F0FB784789C70AA61A9C6"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall submit a Draft Final Report by the [***] following the end of the project. The Government shall provide comments to the Awardee by the [***] following receipt of the Awardee&#8217;s Draft Final Report. The Awardee shall submit the Final Report on the [***] after receipt.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">F.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Ad Hoc Meetings</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to the monthly meetings and written quarterly program updates, additional ad hoc meetings to address specific issues or to convey time- sensitive updates or scientific data related to the program will be held.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:29px;"><font style="font-family:inherit;font-size:12pt;">G.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Patents - Reporting of Subject Inventions</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes of this paragraph, &#8220;Subject Invention&#8221; is defined as any invention, discovery, or improvement of the Awardee, whether or not patentable, that are conceived of or first actually reduced to practice in the performance of work under this Agreement. The Awardee shall report any OTA Inventions in accordance with the terms and conditions of this Other Transaction Agreement (OTA).</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">H. All documentation submitted to the government must have quality oversight from an independent quality group not reporting to the executing management group (for example; clinical trials group, data management group, etc)</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:44px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:29px;"><font style="font-family:inherit;font-size:11pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Miscellaneous Data Submissions</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If applicable, the Awardee must submit to the Government all Point Papers, Briefings, Technical Performance Plans (TPP), Program Development Plans (PDP), Regulatory Strategy, Technology Transfer Report and Gap Analysis, Formulation Development, Feasibility and Optimization Reports, United States Army Medical Research and Material Command Animal Care and Use Review Office (USAMRMC ACURO) Approvals, Human Resources Operations Branch (HROB) Approvals, Technical Presentations and Publications, and any formal technical reports that have been prepared for eventual submission to FDA or other regulatory agencies. Examples include the following reports related to: pharmaceutical development, manufacturing development, manufacturing validation, completed batch records, certificates of analysis, analytical development and validation, drug substance and product stability, nonclinical testing, and clinical testing. Examples include clinical performance and clinical quality documentation.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:29px;"><font style="font-family:inherit;font-size:11pt;">J.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:126%;text-align:left;font-size:11pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">Work Breakdown Structure</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Three-level WBS with costs and schedule (top level is program, level two (2) is phase, level three (3) are major tasks). For WBS level two (2), show breakdown for labor, material, and other indirect costs.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WBS shall be updated annually or [***] after a Statement of Work modification. Government review/approval is [***] after receipt of first submittal. Provide changes to draft within [***] of such request. Provide final document within [***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sDDF8F451C0E574674F369C70AA92BD31"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">after approval of changes is received.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:29px;"><font style="font-family:inherit;font-size:11pt;">K.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Integrated Master Schedule</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall provide within [***] after project award an IMS in Microsoft Project format. Any updates to the IMS shall be included in the monthly progress reports.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Submission shall be [***] after the end of each month of performance. The Government will have [***] to respond to the report with any comments and the performer will have [***] to revise the deliverable or respond to those comments.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:29px;"><font style="font-family:inherit;font-size:11pt;">L.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Incident Report.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall report any incident to the Government that could result in more than a one month delay in schedule from the most recent IMS critical path delivered to the Government. Telephonically contact the GPM within one day of incident. A written summary report shall be submitted within [***] of an incident, to include, what happened, what was the impact, if there are any available corrective actions and a time line for when the corrective actions would be in place.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:29px;"><font style="font-family:inherit;font-size:11pt;">M.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quality Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Awardee shall submit a quality agreement within 90 days of award for Government review. Upon acceptance the agreement is to be executed by both parties. This document must flow down to all subawards.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9. Most Favored Customer</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">For a period of six (6) years from the Effective Date, Awardee agrees that it shall not offer, sell or otherwise provide the production model of the Prototype to any entity at a price lower than that offered to the DoD. In the event that Awardee sells the production model of the Prototype at a lower unit price than that price sold to the DoD, Awardee shall immediately notify the OTAO in writing of the lower price. For prior purchases, the Awardee shall reimburse the DoD, the difference between the lower price sold to the other customer(s) and the price sold to the DoD multiplied by the number of items sold. Such reimbursement shall occur within [***] of the Awardee discovering that the lower price was given to another customer. Notwithstanding the foregoing, the parties may agree to apply the difference in price paid by the other customer(s) and DoD into additional quantities required by the DoD.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">If Awardee develops a like product (commercialized version or derivative of the production model of the Prototype) with similar capability and intended application, but at a lower unit price ("Like Product") regardless of quantity, Awardee shall make the DoD aware of that similar product and the technical and price differences between that product and</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s760A56C173C22BC808899C70AAB353C6"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Prototype. Such notification shall be made to the OTAO in writing, of which email is an acceptable form, within [***] of such offering. Awardee agrees that no entity shall receive a lower price for any Like Product than the DoD for like purchase quantities..</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 10. Confidential Information</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Definitions</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;Disclosing Party&#8221; means the Government or the Awardee who discloses Confidential Information as contemplated by the subsequent Paragraphs.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;Receiving Party&#8221; means Government or the Awardee who receives Confidential Information disclosed by a Disclosing Party.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;Confidential Information&#8221; means information and materials of a Disclosing Party which are designated as confidential or as a Trade Secret in writing by such Disclosing Party, whether by letter or by use of an appropriate stamp or legend, prior to or at the same time any such information or materials are disclosed by such Disclosing Party to the Receiving Party. Notwithstanding the foregoing, materials and other information which are orally, visually, or electronically disclosed by a Disclosing Party, or are disclosed in writing without an appropriate letter, stamp, or legend, shall constitute Confidential Information or a Trade Secret (as defined below) if such Disclosing Party, within thirty (30) calendar days after such disclosure, delivers to the Receiving Party a written document or documents describing the material or information and indicating that it is confidential or a Trade Secret, provided that any disclosure of information by the Receiving Party prior to receipt of such notice shall not constitute a breach by the Receiving Party of its obligations under this Paragraph. &#8220;Confidential Information&#8221; includes any information and materials considered a Trade Secret by the Awardee. &#8220;Trade Secret&#8221; means all forms and types of financial, business, scientific, technical, economic, or engineering or otherwise proprietary information, including, but not limited to, patterns, plans, compilations, program devices,  formulas, designs, prototypes, methods, techniques, processes, procedures, programs, or codes, whether tangible or intangible, and whether or how stored, compiled, or memorialized physically, electronically, graphically, photographically, or in writing if &#8211;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:17px;">(a)</font><font style="font-family:inherit;font-size:12pt;">The Disclosing Party thereof has taken reasonable measures to keep such information secret; and</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:17px;">(b)</font><font style="font-family:inherit;font-size:12pt;">The information derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable through proper means by, the public.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE9CB49F388FDD4C0AA9A9C70AAE6FB40"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-left:24px;padding-top:4px;text-align:left;text-indent:0px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">B.</font><font style="font-family:inherit;font-size:12pt;">Exchange of Information: The Government shall not be obligated to transfer Confidential Information independently developed by or on behalf of the Government absent an express written agreement between the Parties involved in the exchange providing the terms and conditions for such disclosure.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">C.</font><font style="font-family:inherit;font-size:12pt;">Authorized Disclosure: The Receiving Party agrees, to the extent permitted by law, that Confidential Information shall remain the property of the Disclosing Party (no one shall disclose unless they have the right to do so), and that, unless otherwise agreed to by the Disclosing Party, Confidential Information shall not be disclosed, divulged, or otherwise communicated by it to third parties or used by it for any purposes other than in connection with specified project efforts and the licenses granted in Article 11, Intellectual Property Rights, and Article 12, Data Rights, provided that the duty to protect such &#8220;Confidential Information&#8221; and &#8220;Trade Secrets&#8221; shall not extend to materials or information that:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(a)</font><font style="font-family:inherit;font-size:12pt;">Are received or become available without restriction to the Receiving Party under a proper, separate agreement,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(b)</font><font style="font-family:inherit;font-size:12pt;">Are not identified with a suitable notice or legend per Article 12 entitled "Confidential Information" herein,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(c)</font><font style="font-family:inherit;font-size:12pt;">Are lawfully in possession of the Receiving Party without such restriction to the Receiving Party at the time of disclosure thereof as demonstrated by prior written records,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(d)</font><font style="font-family:inherit;font-size:12pt;">Are or later become part of the public domain through no fault of the Receiving Party,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(e)</font><font style="font-family:inherit;font-size:12pt;">Are received by the Receiving Party from a third party having no obligation of confidentiality to the Disclosing Party that made the disclosure,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(f)</font><font style="font-family:inherit;font-size:12pt;">Are developed independently by the Receiving Party without use of Confidential Information as evidenced by written records,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:21px;">(g)</font><font style="font-family:inherit;font-size:12pt;">Are required by law or regulation to be disclosed; provided, however, that the Receiving Party has provided written notice to the Disclosing Party promptly so as to enable such Disclosing Party to seek a protective order or otherwise prevent disclosure of such information.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">D.</font><font style="font-family:inherit;font-size:12pt;">Return of Proprietary Information: Upon the request of the Disclosing Party, the Receiving Party shall promptly return all copies and other tangible manifestations of the Confidential Information disclosed. As used</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sCA5835DF825B35DC31929C70AB06D1CE"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in this section, tangible manifestations include human readable media as well as magnetic and digital storage media.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">E.</font><font style="font-family:inherit;font-size:12pt;">Term: The obligations of the Receiving Party under this Article shall continue for a period of seven (7) years from conveyance of the Confidential Information.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:18px;">F.</font><font style="font-family:inherit;font-size:12pt;">The Government shall flow down the requirements of this Article 10 to their respective personnel, member entities, agents, and Awardees (including employees) at all levels, receiving such Confidential Information under this Agreement..</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 11. Intellectual Property Rights</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">Background IP and Materials. The Awardee and the Government each retain any intellectual property (IP) rights to their own materials, data, technology, information, documents, or know-how&#8212;or potential rights, such as issued patents, patent applications, invention disclosures, or other written documentation&#8212;that exist prior to execution of this Agreement or are developed outside the scope of this Agreement (&#8220;Background IP&#8221;). Additionally, no party to the Agreement will enter into an agreement with any contract manufacturer or other third party whereby the third party will obtain rights in OTA Inventions or Study Data, as those terms are defined in this Agreement, absent the mutual consent of the parties to the awarded contract, however any party having an existing agreement with Inovio shall not be subject to this requirement.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">Awardee&#8217;s Background IP. Awardee warrants that it has filed patent application(s) or is the assignee of issued patent(s) directed to a device previously provided to the Government and hereby incorporated as Attachment 1 which contain claims that are related to research contemplated under this Agreement. No license(s) to any patent applications or issued patents shall be granted under this Agreement to the Government, and the application(s) and any continuing applications (except for continuing applications pursuant to this agreement) identified to the Government are specifically excluded from the definitions of "OTA Invention" contained in this Agreement: Background</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:12pt;">Patent Indemnity. The Awardee shall indemnify the Government and its officers, employees and agents against liability, including costs, for actual or alleged direct or contributory infringement of, or inducement to infringe, any United States or foreign patent, trademark or copyright, arising out of this Agreement, provided the Awardee is reasonably notified of such claims and proceedings.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sFE887C79CCF674A9D51C9C70AB381207"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-left:24px;padding-top:4px;text-align:left;text-indent:0px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">D.</font><font style="font-family:inherit;font-size:12pt;">Patent Prosecution. Awardee agrees to take responsibility for the preparation, filing, prosecution, and maintenance of any and all patents and patent applications listed as Awardee Background IP that are relevant to the work performed under this Agreement. Awardee shall keep the Government reasonably advised on the status of Awardee Background IP by providing an annual report on the status of Awardee Background IP. Prior to acting on a decision by Awardee to abandon or not file in any country a patent or patent application covering an OTA Invention, which is defined below, Awardee shall so inform the Government in a timely manner to allow Awardee to thoughtfully consider the Government's comments regarding such a proposed decision. Nothing in this ARTICLE shall restrict the Government in its preparation, filing, prosecution and maintenance of a patent or patent application covering an OTA Invention.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">E.</font><font style="font-family:inherit;font-size:12pt;">Patent Enforcement. Awardee will have the first option to enforce any patent rights covering an OTA Invention owned jointly by the Parties or solely by Awardee, at Awardee&#8217;s expense. If Awardee chooses not to exercise this option, the Government may enforce patent rights covering a joint OTA Invention only with Awardee&#8217;s prior written approval.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">F.</font><font style="font-family:inherit;font-size:12pt;">Ownership. Ownership of any invention, regardless of whether it is not patentable, or is patentable under U.S. patent law that is conceived or first reduced to practice under this Agreement (&#8220;OTA Invention&#8221;) will follow inventorship in accordance with U.S. patent law. The Bayh-Dole Act, 35</font></div><div style="line-height:120%;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">U.S.C. &#167;&#167; 200-212 does not apply to this Agreement and, as such, title to inventions will belong to the inventor or via assignment of ownership to the inventor-organization. The Parties represent and warrant that each inventor is obligated to assign and will assign his or her rights in any such inventions to his or her employing organization. If either an Awardee employee or a Government employee makes a sole OTA Invention, the entire rights to that OTA Invention will be respectively assigned to the Awardee or the Government. If an Awardee employee and a Government employee jointly make an OTA invention, it will be owned jointly by the Awardee and the Government. Ownership of inventions made in whole or in part with subawardee or collaborator employees, including employees of </font><font style="font-family:inherit;font-size:11pt;">other components of the Government, will be determined solely pursuant to an agreement between the Awardee and the applicable subawardee or collaborator.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">G.</font><font style="font-family:inherit;font-size:12pt;">Patent Applications. The Parties will respectively have the option to file a patent application claiming any OTA Invention made solely by their respective employees. The Parties will consult with each other regarding the options for filing a patent application claiming a joint OTA Invention. Within thirty (30) calendar days of being notified of the discovery of an OTA invention or filing a patent application covering an OTA Invention, each Party will provide notice of such discovery or filing to the other Party. The Parties will reasonably cooperate with each other in the</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF697366B81248CE0EAA59C70AB5B3A12"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">preparation, filing, and prosecution of any patent application claiming an OTA Invention. Any Party filing a patent application will bear expenses associated with filing and prosecuting the application, as well as maintaining any patents that issue from the application, unless otherwise agreed by the Parties.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">H.</font><font style="font-family:inherit;font-size:12pt;">Licenses. Upon the Awardee's request, the Government agrees to enter into good faith negotiations with the Awardee regarding the       Awardee's receipt of a nonexclusive commercialization license covering the Government's interest in any OTA Invention made in whole by a Government employee. Any OTA Invention made solely by an Awardee employee is subject to a nonexclusive, nontransferable, irrevocable, paid- up license for the Government to practice and have practiced the OTA Invention with "Unlimited rights," as this term is defined in DFARS 252.227-7013a)(16), as if this regulation were applicable to inventions, rather than technical data.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">I.</font><font style="font-family:inherit;font-size:12pt;">Executive Order No. 9424 of 18 February 1944 requires all executive Departments and agencies of the Government to forward through appropriate channels to the Commissioner of Patents and Trademarks, for recording, all Government interests in patents or applications for patents.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 12. Data Rights</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">All data generated in connection with the performance of this Agreement, or that arises out of the use of any materials or enabling technology provided or used by the Awardee in the performance of this Agreement, other Awardee materials or Awardee confidential information, whether conducted by the Government or the Awardee (collectively, the "Study Data"), shall be owned by the Awardee. The Government shall  have the right to use, modify, reproduce, release, perform, display, or disclose data first produced in the performance of this Agreement within the Government and otherwise for "Unlimited rights," as this term is defined in DFARS 252.227-7013(a)(16). The Government may, under a separate agreement or by modification to this agreement, obtain any rights to use or disclose the Awardee&#8217;s material or data to the extent that such material or data was produced outside the scope of this Agreement.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the above, as a result of this Agreement, the Government shall obtain "Unlimited rights," as this term is defined in DFARS 252.227-7013(a)(16) specific to any data generated under this agreement.</font></div><div style="line-height:120%;text-align:left;font-size:17pt;"><font style="font-family:inherit;font-size:17pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">The Awardee agrees to retain and maintain in good condition until seven (7) years after completion or termination of this Agreement, all data generated under this Agreement. In the event of exercise of the</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s171F21DED960B0EE300F9C70AB8C5D2C"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Government's rights as potentially granted under paragraph 2.C, the Awardee agrees to deliver at no additional cost to the Government, all data, in Awardee's possession and developed under this Agreement, necessary to develop the Prototype within sixty (60) calendar days from the date of the written request.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:12pt;">Marking of Data: The Awardee will mark any data delivered under this Agreement with the following legend:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"Use, duplication, or disclosure is subject to the restrictions as stated in Agreement No. [***] between the Government and the Awardee."</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any rights that the Awardee or the Government may have in data delivered under this Agreement, whether arising under this Agreement or otherwise, will not be affected by Awardee's failure to mark data pursuant to this Article.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D. All Technical Data and Software (each term as defined under DFARS 252.227- 7013) which shall be delivered under this Agreement with less than unlimited rights shall be identified in reasonable specificity and particular rights granted (Government Purpose, Limited or Restricted (all as defined in DFARS 252.227-7013)) prior to entering into the Agreement. All other Technical Data and Software developed under funding of this agreement shall be delivered with unlimited rights as provided for within this Article.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 13. Regulatory Rights</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:29px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">This Agreement includes research with an investigational drug, biologic or medical device that is regulated by the U.S. Food and Drug Administration (FDA) and requires FDA pre-market approval or clearance before commercial marketing may begin. It is expected this</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement will result in the FDA clearance and commercialization of product(s) as set forth in this agreement (the &#8220;Technology&#8221;). The Awardee will serve as the Sponsor of the Regulatory Application (an Investigational New Drug Application (IND), Investigational Device Exemption (IDE), New Drug Application (NDA), Biologics License Application (BLA), Premarket Approval Application (PMA), or 510(k) Pre-Market Notification Filing (510(k)) or another regulatory filing submitted to FDA) that controls research under this agreement. The Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR</font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20) has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:29px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">The Senior Director Medical Regulatory (SDMR) is the JPEO-CBRND and DTRA-JSTO representative for all regulatory and quality activities. The Awardee shall coordinate with the SDMR prior to communicating or meeting</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s98D65F5D912E51C334249C70ABAD1B95"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">with the FDA, or other regulatory authorities, as appropriate. .</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:29px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:12pt;">The Awardee shall invite the SDMR to all FDA meetings and regulatory discussions applicable to this OTA Project.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With respect to any products under this Agreement regulated by the FDA for which the Awardee serves as Sponsor, the Awardee agrees to the following:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:60px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">The Awardee shall provide to the Government all data, including top- line summaries and key conclusions from all studies, supporting the regulatory filing and commercial approval to the extent that such data, summaries, and conclusions are funded under this Agreement. In addition, the Awardee will offer the Government the opportunity to review and provide comments on a final draft of regulatory submissions which include data funded under this Agreement. The Government will review any such submissions promptly upon receipt. The Awardee shall reasonably consider any comments provided by the Government, and prior to submission shall provide notification to the Government of any additional edits or revisions. The Awardee shall keep the Government reasonably apprised of planned FDA meetings and post-meeting outcomes relating to activities funded under this Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:60px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Communications. The Awardee shall provide the Government with all communications and summaries thereof, both formal and informal, to or from FDA regarding the regulatory submissions subject to this Agreement and ensure that the Government representatives are invited to participate in any formal Sponsor meetings with the FDA. The Awardee shall use its best efforts to ensure that the Government representatives are invited to participate in any informal Sponsor meetings with the FDA so long as the Awardee has 48 hour advance notice of such Sponsor meeting from the FDA prior to the scheduled meeting time.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:60px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:12pt;">Non-compliance with section (C)(1)(i) or (C)(1)(ii) may result in termination of the agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Product Development Failure. Certain product development failures may trigger certain remedies in Section (3) below for the Government advanced developer funding the development of the work in this Agreement. This remedy is not available to the Government for any cause outside of the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:89px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:65px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">if this agreement is terminated for nonperformance; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s0DC0831806B5DA4CA7E99C70ABE1E383"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:89px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:65px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Contractor gives notice, required to be submitted to the Government no later than 30 business days, of any formal management decision to terminate this product development effort pre-market or to file for Federal bankruptcy protection.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If any of the product development failures listed in section (b) occur, the Awardee, upon the request of the Government:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:89px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:58px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shall transfer possession, ownership and sponsorship or holdership of any Regulatory Application submitted solely for approval of the Technology (including any associated expedited review designation, priority review voucher, or marketing exclusivity eligibility or award), regulatory correspondence, and supporting regulatory information related to the Technology to the Government or its designee;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:89px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:58px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shall provide DoD or its designee with a letter (&#8220;Reference Letter&#8221;) providing permission to reference any Regulatory Application submitted to the FDA for a combination drug-device product that includes the Technology;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:89px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:58px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shall inform FDA of the transfer of sponsorship or holdership of the Regulatory Application transferred under section (c)(i) above or the Reference Letter issued under section (c)(ii) above; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:93px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:62px;"><font style="font-family:inherit;font-size:12pt;">iv.</font></div></td><td style="vertical-align:top;padding-left:6.666666666666667px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-6.666666666666667px;"><font style="font-family:inherit;font-size:12pt;">shall negotiate in good faith a non-exclusive license, at customary industry rates and under reasonable terms and conditions, to any patent, copyright or other intellectual property owned or controlled by the Awardee, developed prior to or outside the scope of this agreement, or any technical data that is necessary for the Government to pursue commercialization of this technology with a third party for sale to the Government or otherwise.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:29px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">D.</font><font style="font-family:inherit;font-size:12pt;">Awardee shall submit to the Government, within thirty (30) days of contract award, a fully executed sponsor authorization letter enabling FDA to disclose information to the JPEO-CBRND and its government support contractors related to the Technology under Public Law 115-92. A Template of the letter is available upon request. JPEO-CBRND shall submit the executed letter to the FDA only if the Technology becomes a DoD medical product priority under Public Law 115-92.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:29px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">E.</font><font style="font-family:inherit;font-size:12pt;">This Article 13 will survive the acquisition or merger of the Awardee by or with a third party. This Article will also be included in any subcontracts/sub agreements relating to the development of the Technology. This Article will survive the expiration of this agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 14. Foreign Access to Data.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sFE83CED342074BE7AD4B9C70AC01CB97"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Export Compliance: The Parties will comply with any applicable U.S. export control statutes or regulations in performing this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 15. Scientific Publications and Press Releases.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">A.</font><font style="font-family:inherit;font-size:12pt;">The Parties shall jointly agree on a publication plan for the Study Data derived from studies executed under this Agreement. This publication plan will identify key new Data to be disclosed or presented and the target date for finalizing any related scientific abstract or manuscript. As part of its Quarterly Program Reviews, the Awardee will share the publication plan with the Government.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">B.</font><font style="font-family:inherit;font-size:12pt;">The Parties will jointly develop each abstract or manuscript and agree on the authorship and the content of the final draft to be submitted; provided that authorship for each abstract and manuscript will be determined based on  whether a particular individual made a significant contribution to the conceptualization, design, execution, or interpretation of a research study, as authorship is defined in the fifth edition of the Guidelines and Policies for the Conduct of Research in the Intramural Research Program at NIH, available at: https://oir.nih.gov/sites/default/files/uploads/sourcebook/documents/ethical_cond uct/gui delines-conduct_research.pdf.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;padding-right:20px;">C.</font><font style="font-family:inherit;font-size:12pt;">Prior to submission for publication, the Parties shall provide drafts of proposed publications to the authors of such publications for review and comment, and shall provide copies to non-authors for viewing purposes. Review periods are ten (10)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">business days for abstracts, or less than ten (10) business days if agreed by Project Managers and in order to meet publication submission deadlines. Review periods are twenty (20) calendar days for manuscripts. Contributing parties shall be appropriately accredited in any publication.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:20px;">D.</font><font style="font-family:inherit;font-size:12pt;">The Parties will jointly agree on whether to issue one or more press releases related to the resulting Data. If all Parties agree that one or both Parties will issue a press release, each Party will also have the right to review and agree on the content in advance of its publication. Other parties, if any, contributing to the studies, will have review rights and will be appropriately accredited in the press release. For data generated in studies executed by Awardee outside the scope of this Agreement, the Awardee, at its sole discretion, may issue a press release related to such data.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 16. Miscellaneous Clauses.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:16px;">A.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Consent.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Nothing in the terms of this Agreement constitutes express or implied Government authorization and consent for Awardee or its</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7F1726484746E2C673CC9C70AC4C481A"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">subawardee(s) to utilize, manufacture or practice inventions covered by United States or foreign patents in the performance of work under this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:16px;">B.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patent Infringement.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Each Party will advise the other Party promptly and in reasonable written detail, of each claim or lawsuit of patent infringement based on the performance of this Agreement. When requested by either Party, all evidence and information in possession of the Party pertaining to such claim or lawsuit will be provided to the other at no cost to the requesting Party.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:16px;">C.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Limitation of Liability.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">In no event will either Party be liable to the other Party or any third party claiming through such Party for any indirect, incidental, consequential or punitive damages, or claims for lost profits, arising under or relating to this Agreement, whether based in contract, tort or otherwise, even if the other Party has been advised of the possibility of such damages.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:16px;">D.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosure of Information.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Subject to Article 10, the Awardee shall not release to anyone outside the Awardee&#8217;s organization any unclassified information, regardless of medium (e.g., film, tape, document), pertaining to any part of this Agreement or any program related to this Agreement, unless (i) the OTAO has given prior written approval or (ii) the information is otherwise in the public domain before the date of release. For purposes of this clause, Awardee&#8217;s Organization includes entities identified as Collaborators in Appendix A Table 1.</font></div><div style="line-height:120%;padding-left:24px;padding-top:4px;text-align:left;text-indent:0px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:16px;">E.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Force Majeure.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Neither Party will be liable to the other Party for failure or delay in performing its obligations hereunder if such failure or delay arises from circumstances beyond the control and without the fault or negligence of the Party (a Force Majeure event). Examples of such circumstances are: authorized acts of the government in either its sovereign or contractual capacity, war, insurrection, freight embargos, fire, flood, or strikes. The Party asserting Force Majeure as an excuse must take reasonable steps to minimize delay or damages caused by unforeseeable events.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:16px;">F.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">If any provision of this Agreement, or the application of any such provision to any person or set of circumstances, is determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by law.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:22px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Choice of Law.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">This Agreement and the resolution of disputes hereunder will be governed, construed, and interpreted by the statutes, regulations, and/or legal precedent applicable to the Government of the United States of America. Unless explicitly stated, the Parties do not intend that this Agreement be subject to the Federal Acquisition Regulation either directly or indirectly or by operation of law. When a specific FAR requirement is incorporated by reference in this</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s771FEA840F4330BDDE0E9C70ACB2D99C"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:32px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement, the text of the clause alone will apply without application or incorporation of other provisions of these regulations.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Order of Precedence.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">In the event of a conflict between the terms of this Agreement and the attachments incorporated herein, the conflict shall be resolved by giving precedence in descending order as follows: (i) the Articles of this Agreement, and</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Appendices to the Agreement.</font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a200618dodnatickawarde.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE324ED2D5D8DE956CC539C76519AE377"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.2</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;[***]&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I)&#160;IS NOT MATERIAL AND (II)&#160;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.</font></div><div style="line-height:120%;text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:15.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.66197183098592%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:2%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:16%;"></td><td style="width:5%;"></td><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:6%;"></td></tr><tr><td colspan="4" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AWARD/CONTRACT</font></div></td><td colspan="10" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:152px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)</font></div></td><td colspan="2" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">RATING</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PAGE   OF  PAGES</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2. CONTRACT </font><font style="font-family:inherit;font-size:6pt;">(Proc.  [***].)  </font><font style="font-family:inherit;font-size:8pt;">NO.</font></div><div style="padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3. EFFECTIVE DATE</font></div><div style="padding-left:105px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18 Jun 2020</font></div></td><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4. REQUISITION/PURCHASE REQUEST/PROJECT  NO.</font></div><div style="padding-left:4px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">[***]</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5. ISSUED BY   CODE</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">W911QY</font></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6. ADMINIST ERED BY  </font><font style="font-family:inherit;font-size:6pt;">(If other than Item 5)   </font><font style="font-family:inherit;font-size:8pt;">CODE</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:190px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">W6QK ACC-APG NATICK                        110 THOMAS JOHNSON DR SUITE #240 FREDERICK MD 21702</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="padding-left:13px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">See Item 5</font></div></td></tr><tr><td colspan="12" rowspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7. NAME AND ADDRESS OF CONTRACTOR   </font><font style="font-family:inherit;font-size:6pt;">(No., street, city, county, state and zip code)</font></div><div style="padding-left:2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">INOVIO PHARMACEUTICALS, INC. [***]                            </font></div><div style="padding-left:2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">660 W GERMANTOWN PIKE STE 110 PLYMOUTH MEETING PA 19462-1111</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8. DELIVERY</font></div><div style="padding-left:13px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[   ]  FOB ORIGIN   [ X ]  OTHER   </font><font style="font-family:inherit;font-size:6pt;">(See below)</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">9. DISCOUNT FOR PROMPT PAYMENT</font></div></td></tr><tr><td colspan="4" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;padding-left:1px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">10. SUBMIT INVOICES   1</font></div><div style="padding-top:4px;padding-left:4px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(4 copies unless otherwise specified)</font></div><div style="padding-left:2px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">TO THE ADDRESS SHOWN IN:</font></div></td><td colspan="3" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;padding-left:5px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">ITEM</font></div><div style="font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="padding-left:33px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">Block 12</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">CODE   43MD0</font></div></td><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">FACILITY CODE</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11. SHIP TO/MARK FOR   CODE</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12. PAYMENT WILL BE MADE BY   CODE</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">[***]</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="padding-left:88px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">See Schedule</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-left:1px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">DEFENSE FINANCE AND ACCOUNTING SERVICE</font></div><div style="padding-top:1px;padding-left:1px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">DFAS-INDY VP GFEBS   8899 E 56TH STREET INDIANAPOLIS IN 46249-3800</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;padding-left:20px;text-indent:-20px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION:</font></div><div style="padding-left:8px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[  X ] 10 U.S.C. 2304(c)(   2    )  [   ] 41 U.S.C. 253(c)(   )</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14. ACCOUNTING AND APPROPRIATION DATA</font></div><div style="padding-top:6px;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">See Schedule</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15A. ITEM NO.</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:77px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15B. SUPPLIES/ SERVICES</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15C. QUANTITY</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:14px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15D. UNIT</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15E. UNIT PRICE</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:18px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15F. AMOUNT</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:15pt;"><font style="font-family:inherit;font-size:15pt;"><br></font></div><div style="padding-top:13px;padding-left:54px;font-size:15.5pt;"><font style="font-family:inherit;font-size:15.5pt;">SEE SCHEDULE</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="19" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-top:1px;text-align:left;padding-left:404px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15G. TO TAL AMOUNT OF CONTRACT   $16,570,397.00</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:11.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.66197183098592%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:2%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:16%;"></td><td style="width:5%;"></td><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:6%;"></td></tr><tr><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:268px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16. TABLE  OF  CONTENTS</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(X)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SEC.</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DESCRIPTION</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PAGE(S)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(X)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SEC.</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:142px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DESCRIPTION</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PAGE(S)</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:105px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PARTI - THE SCHEDULE</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:122px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PARTII - CONTRACT CLAUSES</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">A</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SOLICITATION/ CONTRACT  FORM</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">I</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">CONTRACT  CLAUSES</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9 - 23</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">B</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SUPPLIES OR SERVICES AND PRICES/ COSTS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2 - 4</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:33px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PART III &#8211; LIST OF DOCUMENTS, EXHIBITS AND O THER ATTACH.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">C</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DESCRIPTION/ SPECS./ WORK STATEMENT</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">J</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">LIST  OF ATTACHMENTS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">D</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PACKAGING AND MARKING</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:70px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">PART IV - REPRESENTATIO NS AND INSTRUCTIO NS</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">E</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">INSPECT ION AND ACCEPTANCE</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">K</font></div></td><td colspan="9" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:90px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">REPRESENT ATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DELIVERIES OR PERFORMANCE</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:5px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">X</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:10px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">G</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">CONTRACT  ADMINISTRATION DATA</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">L</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">INST RS., CONDS., AND NOTICES TO OFFERORS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">H</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">SPECIAL CONTRACT  REQUIREMENTS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:10px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">M</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">EVALUATION FACTORS FOR AWARD</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="19" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:46px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;text-decoration:underline;">CONTRACTING OFFICE R WILL COMP LETE ITEM 17 (SEAL ED-BID OR NEGOTIATED P ROCUREMENT) OR 18 (SEAL ED-BID P ROCUREME NT) AS AP P LICABLE</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:4px;padding-left:1px;text-indent:-2px;font-size:8pt;"><font style="font-family:inherit;font-size:6pt;">17. [ </font><font style="font-family:inherit;font-size:8pt;">X</font><font style="font-family:inherit;font-size:6pt;">] CONTRACTOR'S NEGOTIATED AGREEMENT   </font><font style="font-family:inherit;font-size:6pt;text-decoration:underline;">Contractor is required to sign this</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:6pt;text-decoration:underline;">docum e nt and return1   copies to issuing office.)</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;&#160;Contractor agrees to furnish and deliver all</font></div><div style="padding-top:1px;padding-left:1px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this  contract shall be subject to and governed by the following documents: (a) this award/contract,</font></div><div style="padding-left:2px;text-indent:-2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein.</font></div><div style="padding-left:2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(Attachments are listed herein.)</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;padding-left:2px;text-indent:-2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">18. [    ]  SEALED-BID AWARD   (Contractor is not required to sign this document.)</font></div><div style="padding-left:116px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="padding-top:2px;padding-left:2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Your bid on Solicitation Number</font></div><div style="padding-left:114px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="padding-left:2px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the terms listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government's solicitation and your bid, and (b) this award/contract. No further contractual document is necessary. (Block 18 should be checked only when awarding a sealed-bid contract.)</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19A. NAME AND TITLE OF SIGNER    </font><font style="font-family:inherit;font-size:6.5pt;">( Type or print)</font></div></td><td colspan="12" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20A. NAME OF CONTRACTING OFFICER</font></div><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="padding-left:2px;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;">TEL:   EMAIL:</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19B. NAME OF CONTRACTOR</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">BY </font><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="padding-top:1px;padding-left:48px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(Signature of person authorized to sign)</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19C. DATE SIGNED</font></div></td><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20B. UNITED STATES OF AMERICA</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="padding-top:1px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">BY </font><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="padding-top:1px;padding-left:102px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(Signature of Contracting Officer)</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20C. DATE SIGNED</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sF5539714998C6BF9DBB29C7651BA9045"></a></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:8px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">AUTHORIZED FOR LOCAL REPRODUCTION</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:8px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Previous edition is NOT usable</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:6pt;">STANDARD FORM 26 (REV. 5/2011)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:8px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Prescribed by GSA &#8211; FAR (48 CFR) 53.214(a)</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sEE7DC402A57DBB5667B39C7651EACAD1"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:38px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section B - Supplies or Services and Prices</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:12.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42647058823529%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:10%;"></td><td style="width:21%;"></td><td style="width:14%;"></td><td style="width:11%;"></td><td style="width:25%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITEM NO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SUPPLIES/SERVICES</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QUANTITY</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNIT</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNIT PRICE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:74px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMOUNT</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$[***]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CELLECTRA 2000 Devices and Accessories FFP</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Government is purchasing Cellectra 2000 Devices and Accessories to be used to inject the INO-4800 vaccine, provided by Inovio, into Phase 3 COVID-19 clinical trial subject being performed under Inovio's IND. Upon Completion of the Phase 3 trials, Inovio shall ship the devices and remaining accessories to the Government. The Government shall use any device and/or accessory only for use with INO-4800 for COVID-19 and shall only be conducted under Inovio&#8217;s regulatory filings. No further use is permitted without Inovio&#8217;s explicit prior written consent. Equipment costing for this award does not reflect expected final commercial pricing and is based on a direct cost for labor and materials plus an indirect cost rate only.</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PURCHASE REQUEST NUMBER: [***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:537px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:424px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET AMT&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITEM NO&#160;&#160;&#160;&#160;SUPPLIES/SERVICES&#160;&#160;&#160;&#160;QUANTITY&#160;&#160;&#160;&#160;UNIT&#160;&#160;&#160;&#160;UNIT PRICE&#160;&#160;&#160;&#160;AMOUNT</font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0001AA&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;$[***]&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:537px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:424px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET AMT&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sE5D8AEF63BF3F0CDC0569C76520CE310"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">$[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB25E2743A47C9047CF1D9C76523F084E"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITEM NO&#160;&#160;&#160;&#160;SUPPLIES/SERVICES&#160;&#160;&#160;&#160;QUANTITY&#160;&#160;&#160;&#160;UNIT&#160;&#160;&#160;&#160;UNIT PRICE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMOUNT [***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$[***]&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:533px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:420px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET AMT&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sFB7ED5BEE3278E5D54329C765261AB6F"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">$[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sE98DF5553563A0F510BC9C765294FCF2"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14.5pt;"><font style="font-family:inherit;font-size:14.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITEM NO&#160;&#160;&#160;&#160;SUPPLIES/SERVICES&#160;&#160;&#160;&#160;QUANTITY&#160;&#160;&#160;&#160;UNIT&#160;&#160;&#160;&#160;UNIT PRICE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMOUNT [***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$[***]&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:533px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:420px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET AMT&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s548012597125BF918F439C7652B2D9FA"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">$[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE223836891D63EBF382C9C7652E50863"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITEM NO&#160;&#160;&#160;&#160;SUPPLIES/SERVICES&#160;&#160;&#160;&#160;QUANTITY&#160;&#160;&#160;&#160;UNIT&#160;&#160;&#160;&#160;UNIT PRICE&#160;&#160;&#160;&#160;AMOUNT</font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;$[***]&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:537px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:424px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET AMT&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s47FF5B394C4B3D2EE60B9C765305F777"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">$[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sCC021C659F947C7308439C7653371542"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42647058823529%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:9%;"></td><td style="width:21%;"></td><td style="width:14%;"></td><td style="width:11%;"></td><td style="width:24%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ITEM NO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SUPPLIES/SERVICES</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QUANTITY</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNIT</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNIT PRICE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:82px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMOUNT</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$[***]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:537px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:5.5pt;"><font style="font-family:inherit;font-size:5.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:424px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET AMT&#160;&#160;&#160;&#160;$[***]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s5515FD64C5BEEEC61A929C76535AB9FD"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">$[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB2778025A72C6632EA2B9C76538DE53C"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section D - Packaging and Marking</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">PRESERVATION AND PACKING</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Contractor shall provide its standard preservation and packing in all shipments.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sC3B6F59883FCA14C73AB9C7653AD4EA6"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INSPECTION AND ACCEPTANCE TERMS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Supplies/services will be inspected/accepted at:</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9296066252588%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:31%;"></td><td style="width:24%;"></td><td style="width:23%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CLIN   INSPECT AT</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:62px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INSPECT BY</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ACCEPT AT</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:5px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ACCEPT BY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr></table></div></div><div style="line-height:110%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7F55CCC630AA9CE617B49C7653E16034"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DELIVERY INFORMATION</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:56px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">CLIN</font></div></td><td style="vertical-align:top;padding-left:517.3333333333334px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-517.3333333333334px;"><font style="font-family:inherit;font-size:10pt;">DELIVERY DATE&#160;&#160;&#160;&#160;QUANTITY&#160;&#160;&#160;&#160;SHIP TO ADDRESS&#160;&#160;&#160;&#160;DODAAC / CAGE</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s1EB5DB75D72BD2DD14059C7654000E7C"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sEB02C0CCDB4D998F58D99C765432148A"></a></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sDF0EF7903408A6455A1A9C765455A887"></a></div><div style="line-height:115%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:115%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="s43854D01CF2562D3ABD99C765487B60D"></a></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s0146F78B599970A327309C7654A8451E"></a></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sD9EF6D2E23E77EAFFC589C7654D85700"></a></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s18BAE5FD718D9D8EA8629C7654F9356D"></a></div><div style="line-height:115%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="s69DEAA65FAE293E040EA9C76552CAF4A"></a></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s1061FFAA2C23203316389C76554D59B3"></a></div><div style="line-height:115%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]&#160;&#160;&#160;&#160;[***]&#160;&#160;&#160;&#160;[***]</font></div><div style="line-height:115%;text-align:left;padding-left:317px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s33322DB2EB1C9803E43F9C76558134BA"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ACCOUNTING AND APPROPRIATION DATA</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">AA: 09720202021013000018170552520255&#160;&#160;&#160;&#160;S.0074658.1.1.8.1&#160;&#160;&#160;&#160;6100.9000021001 COST CODE: AHPDD</font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">AMOUNT: $[***]</font></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:65.76763485477179%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:10%;"></td><td style="width:21%;"></td><td style="width:43%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;padding-left:4px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">ACRN</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="padding-left:4px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;padding-left:9px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">CLIN/SLIN</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="padding-left:9px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;padding-left:22px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">CIN</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="padding-left:22px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;padding-left:40px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">AMOUNT</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="padding-left:40px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">$[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">$[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">$[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">$[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">[***]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;">$[***]</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s69F2E92099506BBE38A49C7655A08EEC"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section I - Contract Clauses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CLAUSES INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sEDF11AC9DE95AC4674369C7655D26904"></a></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.203-12</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Limitation On Payments To Influence Certain Federal Transactions</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.204-19</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Incorporation by Reference of Representations and Certifications.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.204-21</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Basic Safeguarding of Covered Contractor Information Systems</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.204-23</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.204-25</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.209-10</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Prohibition on Contracting With Inverted Domestic Corporations</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:240%;text-align:justify;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JUN 2020 DEC 2014 JUN 2016 JUL 2018</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:240%;text-align:justify;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AUG 2019 NOV 2015</font></div><div style="line-height:240%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sDFB43ABC6FF91080E7429C7655F365FE"></a></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.211-8&#160;&#160;&#160;&#160;Time of Delivery&#160;&#160;&#160;&#160;JUN 1997</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.211-8 Alt I&#160;&#160;&#160;&#160;Time of Delivery (Jun 1997) Alternate I&#160;&#160;&#160;&#160;APR 1984</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.211-17&#160;&#160;&#160;&#160;Delivery of Excess Quantities&#160;&#160;&#160;&#160;SEP 1989</font></div><div style="line-height:115%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.216-18&#160;&#160;&#160;&#160;Ordering&#160;&#160;&#160;&#160;OCT 1995</font></div><div style="line-height:115%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.216-19&#160;&#160;&#160;&#160;Order Limitations&#160;&#160;&#160;&#160;OCT 1995</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.216-20&#160;&#160;&#160;&#160;Definite Quantity&#160;&#160;&#160;&#160;OCT 1995 52.222-1&#160;&#160;&#160;&#160;Notice To The Government Of Labor Disputes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FEB 1997 52.223-6&#160;&#160;&#160;&#160;Drug-Free Workplace&#160;&#160;&#160;&#160;MAY 2001 52.232-39&#160;&#160;&#160;&#160;Unenforceability of Unauthorized Obligations&#160;&#160;&#160;&#160;JUN 2013</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s3AFA14A3A7CC6EBC5C5E9C7656262926"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">52.232-40</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Providing Accelerated Payments to Small Business Subcontractors</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">DEC 2013</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="s38E3AE77AD9A7D5C233E9C7656479262"></a></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.233-3&#160;&#160;&#160;&#160;Protest After Award&#160;&#160;&#160;&#160;AUG 1996 52.233-4&#160;&#160;&#160;&#160;Applicable Law for Breach of Contract Claim&#160;&#160;&#160;&#160;OCT 2004 52.243-1&#160;&#160;&#160;&#160;Changes--Fixed Price&#160;&#160;&#160;&#160;AUG 1987</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.246-2&#160;&#160;&#160;&#160;Inspection Of Supplies--Fixed Price&#160;&#160;&#160;&#160;AUG 1996</font></div><div style="line-height:115%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.246-16&#160;&#160;&#160;&#160;Responsibility For Supplies&#160;&#160;&#160;&#160;APR 1984</font></div><div style="line-height:115%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.247-1&#160;&#160;&#160;&#160;Commercial Bill Of Lading Notations&#160;&#160;&#160;&#160;FEB 2006</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.247-34&#160;&#160;&#160;&#160;F.O.B. Destination&#160;&#160;&#160;&#160;NOV 1991</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.249-8&#160;&#160;&#160;&#160;Default (Fixed-Price Supply &amp; Service)&#160;&#160;&#160;&#160;APR 1984</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.249-14&#160;&#160;&#160;&#160;Excusable Delays&#160;&#160;&#160;&#160;APR 1984</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s4CF469A8A73A08EF71E59C76567AD316"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">252.203-7000</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Requirements Relating to Compensation of Former DoD Officials</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">SEP 2011</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="s7334013D01B5D57D5B8C9C76569AD199"></a></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.203-7002&#160;&#160;&#160;&#160;Requirement to Inform Employees of Whistleblower Rights&#160;&#160;&#160;&#160;SEP 2013 252.203-7003&#160;&#160;&#160;&#160;Agency Office of the Inspector General&#160;&#160;&#160;&#160;AUG 2019</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.204-7000&#160;&#160;&#160;&#160;Disclosure Of Information&#160;&#160;&#160;&#160;OCT 2016</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s2F27F994D8FAA1AF44899C7656CC8014"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">252.204-7002</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Payment For Contract Line or Subline Items Not Separately Priced</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">APR 2020</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sF1BB5B5BB638C32143D29C7656EE4B31"></a></div><div style="line-height:114%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.204-7003&#160;&#160;&#160;&#160;Control Of Government Personnel Work Product&#160;&#160;&#160;&#160;APR 1992</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.204-7006&#160;&#160;&#160;&#160;Billing Instructions&#160;&#160;&#160;&#160;OCT 2005</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s6C3A9EF0DB5F3BE348D49C765720F91B"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">252.204-7012</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Safeguarding Covered Defense Information and Cyber Incident Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">DEC 2019</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="s52F2AE47373DD90D0DBD9C7657417688"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">252.204-7015</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Notice of Authorized Disclosure of Information for Litigation MAY 2016 Support</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s41F904BD67CC39C3E0E69C7657722B62"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:118px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">252.204-7018</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Prohibition on the Acquisition of Covered Defense Telecommunications Equipment or Services</font></div></td></tr></table><div style="line-height:114%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">DEC 2019</font></div><div style="line-height:114%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><div><a name="sF674E8E42B8DFAD4AE829C76579C0C55"></a></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.205-7000&#160;&#160;&#160;&#160;Provision Of Information To Cooperative Agreement Holders DEC 1991</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s214FB1D8627C94A0A85C9C7657C7DF84"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:13pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.72727272727273%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:67%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.209-7004</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subcontracting With Firms That Are Owned or Controlled By MAY 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Government of a Country that is a State Sponsor of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Terrorism</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.211-7003</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item Unique Identification and Valuation   MAR 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.211-7005</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substitutions for Military or Federal Specifications and   NOV 2005</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Standards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.217-7027</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Definitization   DEC 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.217-7028</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Over And Above Work   DEC 1991</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.222-7006</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restrictions on the Use of Mandatory Arbitration Agreements DEC 2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.225-7012</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preference For Certain Domestic Commodities   DEC 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.225-7025</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restriction on Acquisition of Forgings   DEC 2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.225-7041</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Correspondence in English   JUN 1997</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.225-7048</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Export-Controlled Items   JUN 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.232-7010</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Levies on Contract Payments   DEC 2006</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.232-7017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerating Payments to Small Business Subcontractors--   APR 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prohibition on Fees and Consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.243-7001</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pricing Of Contract Modifications   DEC 1991</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.243-7002</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Requests for Equitable Adjustment   DEC 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.244-7000</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subcontracts for Commercial Items   JUN 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12.5pt;"><font style="font-family:inherit;font-size:12.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CLAUSES INCORPORATED BY FULL TEXT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.212-4&#160;&#160;&#160;&#160;CONTRACT TERMS AND CONDITIONS-- COMMERCIAL ITEMS (OCT 2018)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:10px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(a)</font><font style="font-family:inherit;font-size:10pt;">Inspection/Acceptance. The Contractor shall only tender for acceptance those items that conform to the requirements of this contract. The Government reserves the right to inspect or test any supplies or services that have been tendered for acceptance. The Government may require repair or replacement of nonconforming supplies or reperformance of nonconforming services at no increase in contract price. If repair/replacement or reperformance will not correct the defects or is not possible, the Government may seek an equitable price reduction or adequate consideration for acceptance of nonconforming supplies or services. The Government must exercise its post- acceptance rights (1) within a reasonable time after the defect was discovered or should have been discovered; and</font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) before any substantial change occurs in the condition of the item, unless the change is due to the defect in the item.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:10px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(b)</font><font style="font-family:inherit;font-size:10pt;">Assignment. The Contractor or its assignee may assign its rights to receive payment due as a result of performance of this contract to a bank, trust company, or other financing institution, including any Federal lending agency in accordance with the Assignment of Claims Act (31 U.S.C. 3727). However, when a third party makes payment (e.g., use of the Governmentwide commercial purchase card), the Contractor may not assign its rights to receive payment under this contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:10px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(c)</font><font style="font-family:inherit;font-size:10pt;">Changes. Changes in the terms and conditions of this contract may be made only by written agreement of the parties.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:10px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(d)</font><font style="font-family:inherit;font-size:10pt;">Disputes. This contract is subject to 41 U.S.C. chapter 71, Contract Disputes'', as amended (41 U.S.C. 601-613). Failure of the parties to this contract to reach agreement on any request for equitable adjustment, claim, appeal or action arising under or relating to this contract shall be a dispute to be resolved in accordance with the clause at FAR 52.233-1, Disputes, which is incorporated herein by reference. The Contractor shall proceed diligently with performance of this contract, pending final resolution of any dispute arising under the contract.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Definitions. The clause at FAR 52.202-1, Definitions, is incorporated herein by reference.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:10px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(f)</font><font style="font-family:inherit;font-size:10pt;">Excusable delays. The Contractor shall be liable for default unless nonperformance is caused by an occurrence beyond the reasonable control of the Contractor and without its fault or negligence such as, acts of God or the public</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB61EB3E51A1519A533B59C76583FB152"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enemy, acts of the Government in either its sovereign or contractual capacity, fires, floods, epidemics, quarantine restrictions, strikes, unusually severe weather, and delays of common carriers. The Contractor shall notify the Contracting Officer in writing as soon as it is reasonably possible after the commencement or any excusable delay, setting forth the full particulars in connection therewith, shall remedy such occurrence with all reasonable dispatch and shall promptly give written notice to the Contracting Officer of the cessation of such occurrence.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invoice.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contractor shall submit an original invoice and three copies (or electronic invoice, if authorized) to the address designated in the contract to receive invoices. An invoice must include--</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Name and address of the Contractor;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Invoice date and number;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Contract number, line item number and, if applicable, the order number;</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Description, quantity, unit of measure, unit price and extended price of the items delivered;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Shipping number and date of shipment, including the bill of lading number and weight of shipment if shipped on Government bill of lading;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Terms of any discount for prompt payment offered;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:32px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Name and address of official to whom payment is to be sent;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name, title, and phone number of person to notify in event of defective invoice; and</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Taxpayer Identification Number (TIN). The Contractor shall include its TIN on the invoice only if required elsewhere in this contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Electronic funds transfer (EFT) banking information.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contractor shall include EFT banking information on the invoice only if required elsewhere in this contract.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">If EFT banking information is not required to be on the invoice, in order for the invoice to be a proper invoice, the Contractor shall have submitted correct EFT banking information in accordance with the applicable solicitation provision, contract clause (e.g., 52.232-33, Payment by Electronic Funds Transfer&#8212;System for Award Management, or 52.232-34, Payment by Electronic</font></div><div style="line-height:114%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Funds Transfer--Other Than System for Award Management), or applicable agency procedures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(C)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">EFT banking information is not required if the Government waived the requirement to pay by EFT.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Invoices will be handled in accordance with the Prompt Payment Act (31 U.S.C. 3903) and Office of Management and Budget (OMB) prompt payment regulations at 5 CFR part 1315.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(h)</font><font style="font-family:inherit;font-size:10pt;">Patent indemnity. The Contractor shall indemnify the Government and its officers, employees and agents against liability, including costs, for actual or alleged direct or contributory infringement of, or inducement to infringe, any United States or foreign patent, trademark or copyright, arising out of the performance of this contract, provided the Contractor is reasonably notified of such claims and proceedings.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment.--</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Items accepted. Payment shall be made for items accepted by the Government that have been delivered to the delivery destinations set forth in this contract.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s33C1FEC012B16E6784A09C7658737DBF"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Prompt payment. The Government will make payment in accordance with the Prompt Payment Act (31 U.S.C. 3903) and prompt payment regulations at 5 CFR part 1315.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Electronic Funds Transfer (EFT). If the Government makes payment by EFT, see 52.212-5(b) for the appropriate EFT clause.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Discount. In connection with any discount offered for early payment, time shall be computed from the date of the invoice. For the purpose of computing the discount earned, payment shall be considered to have been made on the date which appears on the payment check or the specified payment date if an electronic funds transfer payment is made.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Overpayments. If the Contractor becomes aware of a duplicate contract financing or invoice payment or that the Government has otherwise overpaid on a contract financing or invoice payment, the Contractor shall--</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Remit the overpayment amount to the payment office cited in the contract along with a description of the overpayment including the--</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:21px;">(A)</font><font style="font-family:inherit;font-size:10pt;">Circumstances of the overpayment (e.g., duplicate payment, erroneous payment, liquidation errors, date(s) of overpayment);</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affected contract number and delivery order number, if applicable;</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(C)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Affected line item or subline item, if applicable; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(D)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractor point of contact.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Provide a copy of the remittance and supporting documentation to the Contracting Officer.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">All amounts that become payable by the Contractor to the Government under this contract shall bear simple interest from the date due until paid unless paid within 30 days of becoming due. The interest rate shall be the interest rate established by the Secretary of the Treasury as provided in 41 U.S.C.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7109,  which is applicable to the period in which the amount becomes due, as provided in (i)(6)(v) of this clause, and then at the rate applicable for each six-month period as fixed by the Secretary until the amount is paid.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Government may issue a demand for payment to the Contractor upon finding a debt is due under the contract.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Final decisions. The Contracting Officer will issue a final decision as required by 33.211 if--</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contracting Officer and the Contractor are unable to reach agreement on the existence or amount of a debt within 30 days;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contractor fails to liquidate a debt previously demanded by the Contracting Officer within the timeline specified in the demand for payment unless the amounts were not repaid because the Contractor has requested an installment payment agreement; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contractor requests a deferment of collection on a debt previously demanded by the Contracting Officer (see 32.607-2).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">If a demand for payment was previously issued for the debt, the demand for payment included in the final decision shall identify the same due date as the original demand for payment.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s635AB6643320FA8C32A69C76589A19FC"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts shall be due at the earliest of the following dates:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The date fixed under this contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The date of the first written demand for payment, including any demand for payment resulting from a default termination.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The interest charge shall be computed for the actual number of calendar days involved beginning on the due date and ending on--</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The date on which the designated office receives payment from the Contractor;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The date of issuance of a Government check to the Contractor from which an amount otherwise payable has been withheld as a credit against the contract debt; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The date on which an amount withheld and applied to the contract debt would otherwise have become payable to the Contractor.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The interest charge made under this clause may be reduced under the procedures prescribed in 32.608-2 of the Federal Acquisition Regulation in effect on the date of this contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(j)</font><font style="font-family:inherit;font-size:10pt;">Risk of loss. Unless the contract specifically provides otherwise, risk of loss or damage to the supplies provided under this contract shall remain with the Contractor until, and shall pass to the Government upon:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Delivery of the supplies to a carrier, if transportation is f.o.b. origin; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Delivery of the supplies to the Government at the destination specified in the contract, if transportation is f.o.b. destination.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes. The contract price includes all applicable Federal, State, and local taxes and duties.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(l)</font><font style="font-family:inherit;font-size:10pt;">Termination for the Government's convenience. The Government reserves the right to terminate this contract, or any part hereof, for its sole convenience. In the event of such termination, the Contractor shall immediately stop all work hereunder and shall immediately cause any and all of its suppliers and subcontractors to cease work. Subject to the terms of this contract, the Contractor shall be paid a percentage of the contract price reflecting the percentage of the work performed prior to the notice of termination, plus reasonable charges the Contractor can demonstrate to the satisfaction of the Government using its standard record keeping system, have resulted from the termination. The Contractor shall not be required to comply with the cost accounting standards or contract cost principles for this purpose. This paragraph does not give the Government any right to audit the Contractor's records. The Contractor shall not be paid for any work performed or costs incurred which reasonably could have been avoided.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(m)</font><font style="font-family:inherit;font-size:10pt;">Termination for cause. The Government may terminate this contract, or any part hereof, for cause in the event of any default by the Contractor, or if the Contractor fails to comply with any contract terms and conditions, or fails to provide the Government, upon request, with adequate assurances of future performance. In the event of termination for cause, the Government shall not be liable to the Contractor for any amount for supplies or services not accepted, and the Contractor shall be liable to the Government for any and all rights and remedies provided by law. If it is determined that the Government improperly terminated this contract for default, such termination shall be deemed a termination for convenience.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(n)</font><font style="font-family:inherit;font-size:10pt;">Title. Unless specified elsewhere in this contract, title to items furnished under this contract shall pass to the Government upon acceptance, regardless of when or where the Government takes physical possession.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(o)</font><font style="font-family:inherit;font-size:10pt;">Warranty. The Contractor warrants and implies that the items delivered hereunder are merchantable and fit for use for the particular purpose described in this contract.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s1A43F84E7D82247759849C7658AACB3C"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(p)</font><font style="font-family:inherit;font-size:10pt;">Limitation of liability. Except as otherwise provided by an express warranty, the Contractor will not be liable to the Government for consequential damages resulting from any defect or deficiencies in accepted items.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(q)</font><font style="font-family:inherit;font-size:10pt;">Other compliances. The Contractor shall comply with all applicable Federal, State and local laws, executive orders, rules and regulations applicable to its performance under this contract.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(r)</font><font style="font-family:inherit;font-size:10pt;">Compliance with laws unique to Government contracts. The Contractor agrees to comply with 31 U.S.C. 1352 relating to limitations on the use of appropriated funds to influence certain Federal contracts; 18 U.S.C. 431 relating to officials not to benefit; 40 U.S.C. chapter 37, Contract Work Hours and Safety Standards; 41 U.S.C.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">chapter 87, Kickbacks; 41 U.S.C. 4712 and 10 U.S.C. 2409 relating to whistleblower protections; 49 U.S.C. 40118, Fly American; and 41 U.S.C. chapter 21 relating to procurement integrity.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(s)</font><font style="font-family:inherit;font-size:10pt;">Order of precedence. Any inconsistencies in this solicitation or contract shall be resolved by giving precedence in the following order: (1) the schedule of supplies/services; (2) The Assignments, Disputes, Payments, Invoice, Other Compliances, Compliance with Laws Unique to Government Contracts, and Unauthorized Obligations paragraphs</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of this clause; (3) the clause at 52.212-5; (4) addenda to this solicitation or contract, including any license agreements for computer software; (5) solicitation provisions if this is a solicitation; (6) other paragraphs of this clause; (7) the Standard Form 1449; (8) other documents, exhibits, and attachments; and (9) the specification.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(t)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserved.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(u)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unauthorized Obligations.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Except as stated in paragraph (u)(2) of this clause, when any supply or service acquired under this contract is subject to any End User License Agreement (EULA), Terms of Service (TOS), or similar legal instrument or agreement, that includes any clause requiring the Government to indemnify the Contractor or any person or entity for damages, costs, fees, or any other loss or liability that would create an Anti-Deficiency Act violation (31 U.S.C. 1341), the following shall govern:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Any such clause is unenforceable against the Government.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Neither the Government nor any Government authorized end user shall be deemed to have agreed to such clause by virtue of it appearing in the EULA, TOS, or similar legal instrument or agreement. If the EULA, TOS, or similar legal instrument or agreement is invoked through an ``I agree'' click box or other comparable mechanism (e.g.,</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">``click-wrap'' or ``browse-wrap'' agreements), execution does not bind the Government or any Government authorized end user to such clause.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Any such clause is deemed to be stricken from the EULA, TOS, or similar legal instrument or agreement.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Paragraph (u)(1) of this clause does not apply to indemnification by the Government that is expressly authorized by statute and specifically authorized under applicable agency regulations and procedures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(v) Incorporation by reference. The Contractor's representations and certifications, including those completed electronically via the System for Award Management (SAM), are incorporated by reference into the contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:241px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(End of Clause)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.212-5&#160;&#160;&#160;&#160;CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT STATUTES OR EXECUTIVE ORDERS--COMMERCIAL ITEMS (JUN 2020)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s3B7946C3A89800EF4B549C7658BA49FC"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(a)</font><font style="font-family:inherit;font-size:10pt;">The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract by reference, to implement provisions of law or Executive orders applicable to acquisitions of commercial items:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (JAN 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (Jul 2018) (Section 1634 of Pub. L. 115-91).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (AUG 2019) (Section 889(a)(1)(A) of Pub. L. 115-232).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:240%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (Nov 2015). (5) 52.233-3, Protest After Award (AUG 1996) (31 U.S.C. 3553).</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6) 52.233-4, Applicable Law for Breach of Contract Claim (OCT 2004) (Public Laws 108-77 and 108-78 (19</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.C. 3805 note)).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(b)</font><font style="font-family:inherit;font-size:10pt;">The Contractor shall comply with the FAR clauses in this paragraph (b) that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items: (Contracting Officer check as appropriate.)</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;(1) 52.203-6, Restrictions on Subcontractor Sales to the Government (JUN 2020), with Alternate I (Oct 1995) (41 U.S.C. 4704  and 10 U.S.C. 2402).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (2) 52.203-13, Contractor Code of Business Ethics and Conduct (JUN 2020) (41 U.S.C. 3509).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(3) 52.203-15, Whistleblower Protections under the American Recovery and Reinvestment Act of 2009 (JUN 2010) (Section 1553 of Pub. L. 111-5). (Applies to contracts funded by the American Recovery and Reinvestment Act of 2009.)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X  (4) 52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (JUN 2020) (Pub. L. 109- 282) (31 U.S.C. 6101 note).</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(5) [Reserved]</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:124%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;(6) 52.204-14, Service Contract Reporting Requirements (Oct 2016) (Pub. L. 111-117, section 743 of Div. C).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;(7) 52.204-15, Service Contract Reporting Requirements for Indefinite-Delivery Contracts (Oct 2016) (Pub.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">L. 111-117, section 743 of Div. C).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(8) 52.209-6, Protecting the Government's Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment. (JUN 2020) (31 U.S.C. 6101 note).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X&#160;&#160;&#160;&#160;(9) 52.209-9, Updates of Publicly Available Information Regarding Responsibility Matters (OCT 2018) (41</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.C. 2313).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(10) [Reserved]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(11)(i) 52.219-3, Notice of HUBZone Set-Aside or Sole-Source Award (MAR 2020) (15 U.S.C. 657a).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB416C8984A92149B75F49C7658FB91C3"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAR 2020) of 52.219-3.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(12) (i) 52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (MAR 2020) (if the offeror elects to waive the preference, it shall so indicate in its offer) (15 U.S.C. 657a).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAR 2020) of 52.219-4.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(13) [Reserved]</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(14)(i) 52.219-6, Notice of Total Small Business Set-Aside (MAR 2020) (15 U.S.C. 644).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAR 2020).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(15)(i) 52.219-7, Notice of Partial Small Business Set-Aside (MAR 2020) (15 U.S.C. 644).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAR 2020) of 52.219-7.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (16) 52.219-8, Utilization of Small Business Concerns (OCT 2018) (15 U.S.C. 637(d)(2) and (3)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(17)(i) 52.219-9, Small Business Subcontracting Plan (JUN 2020) (15 U.S.C. 637(d)(4)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (NOV 2016) of 52.219-9.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(iii) Alternate II (NOV 2016) of 52.219-9.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(iv) Alternate III (JUN 2020) of 52.219-9.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(v) Alternate IV (JUN 2020) of 52.219-9.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(18) 52.219-13, Notice of Set-Aside of Orders (MAR 2020) (15 U.S.C. 644(r)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(19) 52.219-14, Limitations on Subcontracting (MAR 2020) (15 U.S.C. 637(a)(14)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(20) 52.219-16, Liquidated Damages&#8212;Subcontracting Plan (Jan 1999) (15 U.S.C. 637(d)(4)(F)(i)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(21) 52.219-27, Notice of Service-Disabled Veteran-Owned Small Business Set-Aside (MAR 2020) (15</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.C. 657f).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (22) (i) 52.219-28, Post Award Small Business Program Rerepresentation (MAR 2020) (15 U.S.C. 632(a)(2)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAR 2020) of 52.219-28.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(23) 52.219-29, Notice of Set-Aside for, or Sole Source Award to, Economically Disadvantaged Women- Owned Small Business (EDWOSB) Concerns (MAR 2020) (15 U.S.C. 637(m)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(24) 52.219-30, Notice of Set-Aside for, or Sole Source Award to, Women-Owned Small Business Concerns Eligible Under the Women-Owned Small Business Program (MAR 2020) (15 U.S.C. 637(m)).</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(25) 52.219-32, Orders Issued Directly Under Small Business Reserves (MAR 2020) (15 U.S.C. 644(r)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(26) 52.219-33, Nonmanufacturer Rule (MAR 2020) (15 U.S.C. 637(a)(17)).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (27) 52.222-3, Convict Labor (JUN 2003) (E.O. 11755).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X  (28) 52.222-19, Child Labor--Cooperation with Authorities and Remedies (JAN 2020) (E.O. 13126).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s975513B7ACB1F9507F619C765907010D"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (29) 52.222-21, Prohibition of Segregated Facilities (APR 2015).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (30)(i) 52.222-26, Equal Opportunity (SEPT 2016) (E.O. 11246).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (FEB 1999) of 52.222-26.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (31)(i) 52.222-35, Equal Opportunity for Veterans (JUN 2020) (38 U.S.C. 4212).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (JUL 2014) of 52.222-35.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (32)(i) 52.222-36, Equal Opportunity for Workers with Disabilities (JUN 2020) (29 U.S.C. 793).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (JUL 2014) of 52.222-36.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (33) 52.222-37, Employment Reports on Veterans (JUN 2020) (38 U.S.C. 4212).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (34) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (DEC 2010) (E.O. 13496).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (35)(i) 52.222-50, Combating Trafficking in Persons (JAN 2019) (22 U.S.C. chapter 78 and E.O. 13627).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAR 2015) of 52.222-50 (22 U.S.C. chapter 78 and E.O. 13627).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (36) 52.222-54, Employment Eligibility Verification (OCT 2015). (E. O. 12989). (Not applicable to the acquisition of commercially available off-the-shelf items or certain other types of commercial items as prescribed in 22.1803.)</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(37)(i) 52.223-9, Estimate of Percentage of Recovered Material Content for EPA&#8211;Designated Items (MAY 2008) (42 U.S.C. 6962(c)(3)(A)(ii)). (Not applicable to the acquisition of commercially available off-the-shelf items.)</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAY 2008) of 52.223-9 (42 U.S.C. 6962(i)(2)(C)). (Not applicable to the acquisition of commercially available off-the-shelf items.)</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(38) 52.223-11, Ozone-Depleting Substances and High Global Warming Potential Hydrofluorocarbons (JUN 2016) (E.O. 13693).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(39) 52.223-12, Maintenance, Service, Repair, or Disposal of Refrigeration Equipment and Air Conditioners (JUN 2016) (E.O. 13693).</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:119%;padding-top:4px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(40) (i) 52.223-13, Acquisition of EPEAT&#174; Registered Imaging Equipment (JUN 2014) (E.O.s 13423 and 13514).</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (OCT 2015) of 52.223-13.</font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(41)(i) 52.223-14, Acquisition of EPEAT&#174; Registered Televisions (JUN 2014) (E.O.s 13423 and 13514).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;(ii) Alternate I (JUN 2014) of 52.223-14.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(42) 52.223-15, Energy Efficiency in Energy-Consuming Products (DEC 2007) (42 U.S.C. 8259b).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(43)(i) 52.223-16, Acquisition of EPEAT&#174;-Registered Personal Computer Products (OCT 2015) (E.O.s 13423 and 13514).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (JUN 2014) of 52.223-16.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA8E61A9265E1299107E89C765914DBF5"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (44) 52.223-18, Encouraging Contractor Policies to Ban Text Messaging While Driving (JUN 2020) (E.O. 13513).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(45) 52.223-20, Aerosols (JUN 2016) (E.O. 13693).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(46) 52.223-21, Foams (JUN 2016) (E.O. 13693).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(47)(i) 52.224-3, Privacy Training (JAN 2017) (5 U.S.C. 552a).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (JAN 2017) of 52.224-3.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(48) 52.225-1, Buy American--Supplies (MAY 2014) (41 U.S.C. chapter 83).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(49)  (i) 52.225-3, Buy American--Free Trade Agreements--Israeli Trade Act (MAY 2014) (41 U.S.C. chapter 83, 19 U.S.C. 3301 note, 19 U.S.C. 2112 note, 19 U.S.C. 3805 note, 19 U.S.C. 4001 note, Pub. L. 103-182, 108-77,</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108-78, 108-286, 108-302, 109-53, 109-169, 109-283, 110-138, 112-41, 112-42, and 112-43.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (MAY 2014) of 52.225-3.</font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(iii) Alternate II (MAY 2014) of 52.225-3.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(iv) Alternate III (MAY 2014) of 52.225-3.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(50) 52.225-5, Trade Agreements (OCT 2019) 19 U.S.C. 2501, et seq., 19 U.S.C. 3301 note).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (51) 52.225-13, Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(52) 52.225-26, Contractors Performing Private Security Functions Outside the United States (OCT 2016)</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Section 862, as amended, of the National Defense Authorization Act for Fiscal Year 2008; 10 U.S.C. 2302 Note).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(53) 52.226-4, Notice of Disaster or Emergency Area Set-Aside (NOV 2007) (42 U.S.C. 5150</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(54) 52.226-5, Restrictions on Subcontracting Outside Disaster or Emergency Area (NOV 2007) (42 U.S.C. 5150).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(55) 52.229-12, Tax on Certain Foreign Procurements (JUN 2020).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(56) 52.232-29, Terms for Financing of Purchases of Commercial Items (FEB 2002) (41 U.S.C. 4505, 10</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.C. 2307(f)).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(57) 52.232-30, Installment Payments for Commercial Items (JAN 2017) (41 U.S.C. 4505, 10 U.S.C. 2307(f)).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (58) 52.232-33, Payment by Electronic Funds Transfer&#8212;System for Award Management (OCT 2018) (31 U.S.C. 3332).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(59) 52.232-34, Payment by Electronic Funds Transfer&#8212;Other than System for Award Management (JUL 2013) (31 U.S.C. 3332).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(60) 52.232-36, Payment by Third Party (MAY 2014) (31 U.S.C. 3332).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (61) 52.239-1, Privacy or Security Safeguards (AUG 1996) (5 U.S.C. 552a).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X (62) 52.242-5, Payments to Small Business Subcontractors (JAN 2017)(15 U.S.C. 637(d)(13)).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7309C81217DEB29C58119C765935AB32"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(63)(i) 52.247-64, Preference for Privately Owned U.S.-Flag Commercial Vessels (FEB 2006) (46 U.S.C. Appx. 1241(b) and 10 U.S.C. 2631).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(ii) Alternate I (APR 2003) of 52.247-64.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">(iii) Alternate II (FEB 2006) of 52.247-64.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:18px;">(c)</font><font style="font-family:inherit;font-size:10pt;">The Contractor shall comply with the FAR clauses in this paragraph (c), applicable to commercial services, that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items: (Contracting Officer check as appropriate.)</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(1) 52.222-41, Service Contract Labor Standards (AUG 2018) (41 U.S.C. chapter 67).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(2) 52.222-42, Statement of Equivalent Rates for Federal Hires (MAY 2014) (29 U.S.C. 206 and 41 U.S.C. chapter 67).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(3) 52.222-43, Fair Labor Standards Act and Service Contract Labor Standards--Price Adjustment (Multiple Year and Option Contracts) (AUG 2018) (29 U.S.C. 206 and 41 U.S.C. chapter 67).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(4) 52.222-44, Fair Labor Standards Act and Service Contract Labor Standards--Price Adjustment (MAY 2014) (29 U.S.C 206 and 41 U.S.C. chapter 67).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(5) 52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment--Requirements (MAY 2014) (41 U.S.C. chapter 67).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(6) 52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services--Requirements (MAY 2014) (41 U.S.C. chapter 67).</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(7) 52.222-55, Minimum Wages Under Executive Order 13658 (DEC 2015) (E.O. 13658).</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(8) 52.222-62, Paid Sick Leave Under Executive Order 13706 (JAN 2017) (E.O. 13706).</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(9) 52.226-6, Promoting Excess Food Donation to Nonprofit Organizations (JUN 2020) (42 U.S.C. 1792).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comptroller General Examination of Record. The Contractor shall comply with the provisions of this paragraph</font></div></td></tr></table><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(d)</font><font style="font-family:inherit;font-size:10pt;">if this contract was awarded using other than sealed bid, is in excess of the simplified acquisition threshold, as defined in FAR 2.101, on the date of award of this contract, and does not contain the clause at 52.215-2, Audit and Records--Negotiation.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Comptroller General of the United States, or an authorized representative of the Comptroller General, shall have access to and right to examine any of the Contractor's directly pertinent records involving transactions related to this contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contractor shall make available at its offices at all reasonable times the records, materials, and other evidence for examination, audit, or reproduction, until 3 years after final payment under this contract or for any shorter period specified in FAR Subpart 4.7, Contractor Records Retention, of the other clauses of this contract. If this contract is completely or partially terminated, the records relating to the work terminated shall be made available for 3 years after any resulting final termination settlement. Records relating to appeals under the disputes clause or to litigation or the settlement of claims arising under or relating to this contract shall be made available until such appeals, litigation, or claims are finally resolved.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">As used in this clause, records include books, documents, accounting procedures and practices, and other data, regardless of type and regardless of form. This does not require the Contractor to create or maintain any record that the Contractor does not maintain in the ordinary course of business or pursuant to a provision of law.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s467B6265419190C559C39C76596732F4"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(e)</font><font style="font-family:inherit;font-size:10pt;">(1) Notwithstanding the requirements of the clauses in paragraphs (a), (b), (c), and (d) of this clause, the Contractor is not required to flow down any FAR clause, other than those in this paragraph (e)(1)in a subcontract for commercial items. Unless otherwise indicated below, the extent of the flow down shall be as required by the clause&#8212;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(i)</font><font style="font-family:inherit;font-size:10pt;">52.203-13, Contractor Code of Business Ethics and Conduct (JUN 2020) (41 U.S.C. 3509).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(ii)</font><font style="font-family:inherit;font-size:10pt;">52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (JAN 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(iii)</font><font style="font-family:inherit;font-size:10pt;">52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (Jul 2018) (Section 1634 of Pub. L. 115-91).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(iv)</font><font style="font-family:inherit;font-size:10pt;">52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (AUG 2019) (Section 889(a)(1)(A) of Pub. L. 115-232).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(v)</font><font style="font-family:inherit;font-size:10pt;">52.219-8, Utilization of Small Business Concerns (Oct 2018) (15 U.S.C. 637(d)(2) and (3)), in all subcontracts that offer further subcontracting opportunities. If the subcontract (except subcontracts</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to small business concerns) exceeds the applicable threshold specified in FAR 19.702(a) on the date of subcontract award, the subcontractor must include 52.219-8 in lower tier subcontracts that offer subcontracting opportunities.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.222-21, Prohibition of Segregated Facilities (Apr 2015).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">52.222-26, Equal Opportunity (Sep 2016) (E.O. 11246).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.222-35, Equal Opportunity for Veterans (JUN 2020) (38 U.S.C. 4212).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">52.222-36, Equal Opportunity for Workers with Disabilities (JUN 2020) (29 U.S.C. 793).</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.222-37, Employment Reports on Veterans (JUN 2020) (38 U.S.C. 4212).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(xi)</font><font style="font-family:inherit;font-size:10pt;">52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) (E.O. 13496). Flow down required in accordance with paragraph (f) of FAR clause 52.222-40.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(xii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">52.222-41, Service Contract Labor Standards (Aug 2018), (41 U.S.C. chapter 67).</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(xiii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(A) 52.222-50, Combating Trafficking in Persons (JAN 2019) (22 U.S.C. chapter 78 and E.O. 13627).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">(B) Alternate I (March 2, 2015) of 52.222-50 (22 U.S.C. chapter 78 and E.O. 13627).</font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(xiv)</font><font style="font-family:inherit;font-size:10pt;">52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment--Requirements (May 2014) (41 U.S.C. chapter 67.)</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(xv)</font><font style="font-family:inherit;font-size:10pt;">52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services--Requirements (May 2014) (41 U.S.C. chapter 67)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(xvi)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">52.222-54, Employment Eligibility Verification (Oct 2015) (E. O. 12989).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(xvii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">52.222-55, Minimum Wages Under Executive Order 13658 (Dec 2015) (E.O. 13658).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(xviii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">52.222-62</font><font style="font-family:inherit;font-size:10pt;">, Paid Sick Leave Under Executive Order 13706 (Jan 2017) (E.O. 13706).</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:22px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(xix)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">(A) </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">52.224-3</font><font style="font-family:inherit;font-size:10pt;">, Privacy Training (Jan 2017) (</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">5 U.S.C. 552a</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF4A32D796ABDC71960439C7659894DF1"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B) Alternate I (Jan 2017) of </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">52.224-3</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-left:8px;padding-top:5px;text-align:left;text-indent:0px;"><font style="padding-top:5px;text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(xx)</font><font style="font-family:inherit;font-size:10pt;">52.225-26, Contractors Performing Private Security Functions Outside the United States (Oct 2016) (Section 862, as amended, of the National Defense Authorization Act for Fiscal Year 2008; 10 U.S.C. 2302 Note).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(xxi)</font><font style="font-family:inherit;font-size:10pt;">52.226-6, Promoting Excess Food Donation to Nonprofit Organizations. (JUN 2020) (42 U.S.C. 1792). Flow down required in accordance with paragraph (e) of FAR clause 52.226-6.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:16px;">(xxii)</font><font style="font-family:inherit;font-size:10pt;">52.247-64, Preference for Privately-Owned U.S. Flag Commercial Vessels (Feb 2006) (46 U.S.C. Appx 1241(b) and 10 U.S.C. 2631). Flow down required in accordance with paragraph (d) of FAR clause 52.247-64.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">(2)</font><font style="font-family:inherit;font-size:10pt;">While not required, the Contractor may include in its subcontracts for commercial items a minimal number of additional clauses necessary to satisfy its contractual obligations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(End of clause)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.252-2&#160;&#160;&#160;&#160;CLAUSES INCORPORATED BY REFERENCE (FEB 1998)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:14px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:8px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:8px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:105%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Insert one or more Internet addresses]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(End of clause)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Definitions. As used in this clause&#8212;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Department of Defense Activity Address Code (DoDAAC)&#8221; is a six position code that uniquely identifies a unit, activity, or organization.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Document type&#8221; means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Local processing office (LPO)&#8221; is the office responsible for payment certification when payment certification is done external to the entitlement system.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Payment request&#8221; and &#8220;receiving report&#8221; are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s96BA948C994F155E40719C7659BA36B0"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Electronic invoicing. The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:8px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">WAWF access. To access WAWF, the Contractor shall&#8212;</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Have a designated electronic business point of contact in the System for Award Management at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">https://www.sam.gov</font><font style="font-family:inherit;font-size:10pt;">; and</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Be registered to use WAWF at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">https://wawf.eb.mil/</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">following the step-by-step procedures for self-registration available at this web site.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">WAWF training. The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF. Both can be accessed by selecting the &#8220;Web Based Training&#8221; link on the WAWF home page at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">https://wawf.eb.mil/</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">WAWF methods of document submission. Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">WAWF payment instructions. The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">(1)</font><font style="font-family:inherit;font-size:10pt;">Document type. The Contractor shall submit payment requests using the following document type(s):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:8px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For cost-type line items, including labor-hour or time-and-materials, submit a cost voucher.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:8px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">For fixed price line items&#8212;</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">COMBO INVOICE AND RECEIVING REPORT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">For services that do not require shipment of a deliverable, submit either the Invoice 2in1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:8px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:8px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">For customary progress payments based on costs incurred, submit a progress payment request.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:8px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">For performance based payments, submit a performance based payment request.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:8px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For commercial item financing, submit a commercial item financing request.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">(2)</font><font style="font-family:inherit;font-size:10pt;">Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Note: The Contractor may use a WAWF &#8220;combo&#8221; document type to create some combinations of invoice and receiving report in one step.]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:8px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">(3)</font><font style="font-family:inherit;font-size:10pt;">Document routing. The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB0F776DBD45CA94326B29C7659DB667D"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:261px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Routing Data Table*</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.95824634655533%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Field Name in WAWF</font></div></td><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data to be entered in WAWF</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:3px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #efefef;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px solid #a0a0a0;border-right:1px solid #a0a0a0;border-top:3px solid #a0a0a0;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:1px solid #efefef;border-top:3px solid #a0a0a0;"><div style="text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #efefef;border-right:1px solid #a0a0a0;border-top:1px solid #efefef;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:2px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:22px;">(4)</font><font style="font-family:inherit;font-size:10pt;">Payment request. The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receiving report. The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:25px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WAWF point of contact.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity&#8217;s WAWF point of contact.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:28px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:10px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:10pt;">Contact the WAWF helpdesk at 866-618-5988, if assistance is needed.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:261px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(End of clause)</font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ino-63020x10qex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s196FC654124053048275311C073B4F59"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of CEO Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as Adopted Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, J. Joseph Kim, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:47%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J. J</font><font style="font-family:inherit;font-size:7pt;">OSEPH</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">J. Joseph Kim</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ino-63020x10qex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s79A63671A7D85321B0C8877C8ABABA8A"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of CFO Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as Adopted Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Peter Kies, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:47%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;P</font><font style="font-family:inherit;font-size:7pt;">ETER</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Peter Kies</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ino-63020x10qex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s67D73461F40D514F9D30F6F797721A41"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. Section&#160;1350, </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Adopted Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge: </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:47%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J. J</font><font style="font-family:inherit;font-size:7pt;">OSEPH</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">J. Joseph Kim</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">President, Chief Executive Officer and Director</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;P</font><font style="font-family:inherit;font-size:7pt;">ETER</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Peter Kies</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">Chief Financial Officer</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ino-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20200630" xmlns:ino="http://www.inovio.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BasisOfPresentation" roleURI="http://www.inovio.com/role/BasisOfPresentation">
        <link:definition>2102100 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationDetails" roleURI="http://www.inovio.com/role/BasisOfPresentationDetails">
        <link:definition>2402402 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationPolicies" roleURI="http://www.inovio.com/role/BasisOfPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2120100 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2420401 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1006000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2110100 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails">
        <link:definition>2410403 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2410402 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleOfMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails">
        <link:definition>2410404 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2310301 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>2103100 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPoliciesDetails" roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Critical Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.inovio.com/role/FairValueMeasurements">
        <link:definition>2108100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>2408402 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails">
        <link:definition>2408404 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2408403 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.inovio.com/role/FairValueMeasurementsTables">
        <link:definition>2308301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2122100 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDeconsolidationAccountingDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails">
        <link:definition>2422403 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncFairValueAssumptionsDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails">
        <link:definition>2422405 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncInvestmentInGeneosDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails">
        <link:definition>2422404 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2422402 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2322301 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets">
        <link:definition>2109100 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails">
        <link:definition>2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails">
        <link:definition>2409402 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2309301 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactOfRecentlyIssuedAccountingStandards" roleURI="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards">
        <link:definition>2105100 - Disclosure - Impact of Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2121100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.inovio.com/role/Leases">
        <link:definition>2119100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.inovio.com/role/LeasesNarrativeDetails">
        <link:definition>2419402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryOfFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails">
        <link:definition>2419403 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.inovio.com/role/LeasesTables">
        <link:definition>2319301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>2112100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails">
        <link:definition>2412402 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperations" roleURI="http://www.inovio.com/role/OrganizationAndOperations">
        <link:definition>2101100 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2118100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2418401 - Disclosure - Related Party Transactions  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2106100 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2406401 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestments" roleURI="http://www.inovio.com/role/ShortTermInvestments">
        <link:definition>2107100 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsNarrativeDetails" roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails">
        <link:definition>2407402 - Disclosure - Short-term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails">
        <link:definition>2407403 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsTables" roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables">
        <link:definition>2307301 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>2113100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationDetails">
        <link:definition>2413402 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>2313301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2111100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2411403 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails">
        <link:definition>2411402 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2311301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>2123100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>2423401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ino_A2007IncentivePlanMember" name="A2007IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_A2016IncentivePlanMember" name="A2016IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_A6.50ConvertibleSeniorNotesDue2024Member" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_AccruedClinicalTrialExpenseCurrent" name="AccruedClinicalTrialExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_AfterJanuary22020ConversionPriceMember" name="AfterJanuary22020ConversionPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_AfterJuly22020ConversionPriceMember" name="AfterJuly22020ConversionPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_AlternativeInvestmentMeasurementInputTerm" name="AlternativeInvestmentMeasurementInputTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_ApolloBioMember" name="ApolloBioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_AstraZenecaMember" name="AstraZenecaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_August2019ConvertibleBondsMember" name="August2019ConvertibleBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_BillAndMelindaGatesFoundationMember" name="BillAndMelindaGatesFoundationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_BiojectMember" name="BiojectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CELLECTRA2000DeviceMember" name="CELLECTRA2000DeviceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CoalitionforEpidemicPreparednessInnovationsMember" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" name="CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" name="CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementRoyaltyPeriod" name="CollaborationAgreementRoyaltyPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementTerritoryExpansionOptionPeriod" name="CollaborationAgreementTerritoryExpansionOptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementAdvisoryFees" name="CollaborativeAgreementAdvisoryFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_CollaborativeAgreementAwardedAmount" name="CollaborativeAgreementAwardedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementCorporateIncomeTax" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementExpensesToReimburse" name="CollaborativeAgreementExpensesToReimburse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementFundingReceived" name="CollaborativeAgreementFundingReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementFundingToBeReceived" name="CollaborativeAgreementFundingToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeArrangementTerm" name="CollaborativeArrangementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" name="ContractWithCustomerLiabilityAffiliatedEntityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_ConvertibleBondsMember" name="ConvertibleBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DebtInstrumentAccretionOfPremium" name="DebtInstrumentAccretionOfPremium" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DebtInstrumentConvertibleInternalRateOfReturn" name="DebtInstrumentConvertibleInternalRateOfReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" name="DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DebtinstrumentAccruedInterest" name="DebtinstrumentAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_December2019ConvertibleBondsMember" name="December2019ConvertibleBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DeferredGrantFundingCurrent" name="DeferredGrantFundingCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredGrantFundingFromAffiliate" name="DeferredGrantFundingFromAffiliate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredGrantFundingFromAffiliateCurrent" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_DepartmentOfDefenceMember" name="DepartmentOfDefenceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_EquityMethodInvestmentEnterpriseValue" name="EquityMethodInvestmentEnterpriseValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_GeneOneLifeSciencesMember" name="GeneOneLifeSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_GeneosTherapeuticsInc.Member" name="GeneosTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_GoodwillAndIntangibleAssetsGross" name="GoodwillAndIntangibleAssetsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_GoodwillAndIntangibleAssetsNet" name="GoodwillAndIntangibleAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_GrantPolicyPolicyTextBlock" name="GrantPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_GrantProceedsReceived" name="GrantProceedsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_INO4800Member" name="INO4800Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_InitialConversionPriceMember" name="InitialConversionPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_InovioAsMember" name="InovioAsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" name="InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_InvestmentOwnedAdditionalSharesAcquired" name="InvestmentOwnedAdditionalSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_LassaFeverAndMERSVaccineMember" name="LassaFeverAndMERSVaccineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_LicensewithAffiliatedEntitiesMember" name="LicensewithAffiliatedEntitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" name="MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_MilestoneBasedOwnershipTarget" name="MilestoneBasedOwnershipTarget" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_MutualFundsMember" name="MutualFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_NewSalesAgreementMember" name="NewSalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NonCashInterestExpense" name="NonCashInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_NonEmployeeMember" name="NonEmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NumberOfAdditionalProducts" name="NumberOfAdditionalProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLeaseNonCashLeaseExpense" name="OperatingLeaseNonCashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_OtherCounterpartyMember" name="OtherCounterpartyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_PlumblineLifeSciencesMember" name="PlumblineLifeSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_PlymouthMeetingPennsylvaniaMember" name="PlymouthMeetingPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_PriorSalesAgreementMember" name="PriorSalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ProceedsFromCollaborativeAgreement" name="ProceedsFromCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_RelatedPartyTransactionsTextualAbstract" name="RelatedPartyTransactionsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_SARSCoV2COVID19VaccineMember" name="SARSCoV2COVID19VaccineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_SalesAgreementsMember" name="SalesAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_SanDiegoOfficeMember" name="SanDiegoOfficeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSalesAgreementAgentFee" name="StockSalesAgreementAgentFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" name="TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_VGXAnimalHealthIncMember" name="VGXAnimalHealthIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_VgxPharmaceuticalsMember" name="VgxPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_WorkingCapitalExcludingCash" name="WorkingCapitalExcludingCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ino-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentation" xlink:href="ino-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentationDetails" xlink:href="ino-20200630.xsd#BasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentationPolicies" xlink:href="ino-20200630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:href="ino-20200630.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:href="ino-20200630.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ino-20200630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:href="ino-20200630.xsd#ConvertibleDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:href="ino-20200630.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:href="ino-20200630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:href="ino-20200630.xsd#CriticalAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:href="ino-20200630.xsd#CriticalAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:href="ino-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:href="ino-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:href="ino-20200630.xsd#GeneosTherapeuticsInc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards" xlink:href="ino-20200630.xsd#ImpactOfRecentlyIssuedAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:href="ino-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:href="ino-20200630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:href="ino-20200630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:href="ino-20200630.xsd#LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:href="ino-20200630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:href="ino-20200630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="ino-20200630.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:href="ino-20200630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationAndOperations" xlink:href="ino-20200630.xsd#OrganizationAndOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:href="ino-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="ino-20200630.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:href="ino-20200630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ino-20200630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestments" xlink:href="ino-20200630.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:href="ino-20200630.xsd#ShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="ino-20200630.xsd#ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:href="ino-20200630.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:href="ino-20200630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:href="ino-20200630.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:href="ino-20200630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:href="ino-20200630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:href="ino-20200630.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:href="ino-20200630.xsd#StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:href="ino-20200630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:href="ino-20200630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:href="ino-20200630.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisOfPresentationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisOfPresentationPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_02ec7b38-4afa-636c-3b62-de1bd1bf96c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:to="loc_us-gaap_MinorityInterest_02ec7b38-4afa-636c-3b62-de1bd1bf96c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac757736-b2b3-41b4-5596-13d65c8f73d5" xlink:to="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_355fc088-038d-3905-0784-91db0d020a77" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_355fc088-038d-3905-0784-91db0d020a77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_844e7c43-dfe0-790d-4f5e-8b1150390e12" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_PreferredStockValue_844e7c43-dfe0-790d-4f5e-8b1150390e12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b9335989-b665-3beb-a2a7-fb509dac64bf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b9335989-b665-3beb-a2a7-fb509dac64bf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_cbfdef0d-4eb0-77bb-ab8b-7d8bdf053005" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_cbfdef0d-4eb0-77bb-ab8b-7d8bdf053005" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2630c4c7-5991-34ac-57a3-7a9e1d539254" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2630c4c7-5991-34ac-57a3-7a9e1d539254" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9c3d7122-75d0-d4e2-bab1-85e33c60c552" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9c3d7122-75d0-d4e2-bab1-85e33c60c552" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_549f70e3-80c7-e52a-155f-7a9e1d877181" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_549f70e3-80c7-e52a-155f-7a9e1d877181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5d89653-9412-3469-28ee-c3579ebc0767" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5d89653-9412-3469-28ee-c3579ebc0767" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_c83b6817-0868-0dc5-c885-7a9e1d6ae33d" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_ino_DeferredGrantFundingCurrent_c83b6817-0868-0dc5-c885-7a9e1d6ae33d" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b396fdb-eb23-f2a2-e68f-7a9e1d8dc244" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b396fdb-eb23-f2a2-e68f-7a9e1d8dc244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c26fd986-9c22-6850-c06e-2e4754d9df6f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c26fd986-9c22-6850-c06e-2e4754d9df6f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e498812a-ea06-2933-72f6-8e959ed1c719" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e498812a-ea06-2933-72f6-8e959ed1c719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ee1cf6a2-027c-8fc3-c914-7a9e1d742fd2" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ee1cf6a2-027c-8fc3-c914-7a9e1d742fd2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_f51cc7f9-f9da-2e46-79a2-7e0156450268" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_ConvertibleDebt_f51cc7f9-f9da-2e46-79a2-7e0156450268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2107189c-f25f-5667-a3b4-dbf4394a5e32" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2107189c-f25f-5667-a3b4-dbf4394a5e32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33b4d214-779b-2177-f7ba-19f0abb03b76" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33b4d214-779b-2177-f7ba-19f0abb03b76" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_ee7ebc9e-e7d0-b854-3e89-7a9e1d28380e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_ee7ebc9e-e7d0-b854-3e89-7a9e1d28380e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_ed718549-1cfe-f993-f4cb-ef808ccb9104" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_ed718549-1cfe-f993-f4cb-ef808ccb9104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_ff686380-cb66-3f62-443b-907a193effe8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_EquityMethodInvestments_ff686380-cb66-3f62-443b-907a193effe8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a63bfe00-8c71-75eb-c989-1230f0c1a19e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe7a6688-63e6-c3a8-34a9-6a59f12ca16e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe7a6688-63e6-c3a8-34a9-6a59f12ca16e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_06529ffd-62cf-ac47-b8f8-c38a666da5ee" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_06529ffd-62cf-ac47-b8f8-c38a666da5ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a217bad1-c076-d01c-43fb-4959b256b731" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a217bad1-c076-d01c-43fb-4959b256b731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_48d97f34-0a5c-c855-1d88-050ad7d70f97" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_48d97f34-0a5c-c855-1d88-050ad7d70f97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1280953b-4e55-e1d6-0c4b-6dfd4307a698" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1280953b-4e55-e1d6-0c4b-6dfd4307a698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_1d03c0f5-2631-323d-1589-8c39d4694344" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_1d03c0f5-2631-323d-1589-8c39d4694344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_b545f23f-bf59-d4ef-c917-eb5b8df27e85" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_b545f23f-bf59-d4ef-c917-eb5b8df27e85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7fd6a784-2a6d-75d2-7b24-d11d64876f63" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7fd6a784-2a6d-75d2-7b24-d11d64876f63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_d984ce6b-cdb9-1fec-8206-6ecde8a57fc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_d984ce6b-cdb9-1fec-8206-6ecde8a57fc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_1b48be7e-8ead-597a-6f58-97801493268f" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_1b48be7e-8ead-597a-6f58-97801493268f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_b4594c91-bfbf-17e4-6af1-43d13a6c52ac" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_Depreciation_b4594c91-bfbf-17e4-6af1-43d13a6c52ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b9d0680b-19c9-6dd3-9b2a-1297536be3c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b9d0680b-19c9-6dd3-9b2a-1297536be3c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_c33114bd-415a-c55a-e520-5de3f074e449" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_c33114bd-415a-c55a-e520-5de3f074e449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NonCashInterestExpense" xlink:label="loc_ino_NonCashInterestExpense_596057c3-8256-069e-93a2-7a9e1d78c383" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_NonCashInterestExpense_596057c3-8256-069e-93a2-7a9e1d78c383" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_66598960-2026-5e41-c3e5-7a9e1d2f0e02" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_66598960-2026-5e41-c3e5-7a9e1d2f0e02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_455e03f5-a15c-e45e-dbed-b386cb838666" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_GainLossOnInvestments_455e03f5-a15c-e45e-dbed-b386cb838666" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_3b30a6a5-38e1-f27b-eb19-7a9e1d4930b9" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_3b30a6a5-38e1-f27b-eb19-7a9e1d4930b9" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_ee733737-9f1b-1777-008b-7a9e1d71a010" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_ee733737-9f1b-1777-008b-7a9e1d71a010" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_4847EC307186EF7654F29C7021509A74" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_4847EC307186EF7654F29C7021509A74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_753ca67e-e0b1-89f6-0f4c-664d01a2b0f7" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_753ca67e-e0b1-89f6-0f4c-664d01a2b0f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_4bf22407-489a-db73-9376-d35874de9524" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_4bf22407-489a-db73-9376-d35874de9524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a606b8-7e33-f76c-e640-a59fba42c06a" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a606b8-7e33-f76c-e640-a59fba42c06a" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_fdb6634e-53f7-20c3-731f-7a9e1d521ae8" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_fdb6634e-53f7-20c3-731f-7a9e1d521ae8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5efc4af8-bdb4-9fc6-04da-b12facfc424c" xlink:type="locator" />
    <link:calculationArc order="16" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5efc4af8-bdb4-9fc6-04da-b12facfc424c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5dd5b086-49e7-fe47-c325-776c1b6828fe" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5dd5b086-49e7-fe47-c325-776c1b6828fe" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_59198d86-0856-2c66-d54d-7a9e1d7d65b6" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_59198d86-0856-2c66-d54d-7a9e1d7d65b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_47bbef15-f7e2-5c8f-dee3-e319c4d8727e" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_47bbef15-f7e2-5c8f-dee3-e319c4d8727e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_afeb5653-dd4e-f1f9-0e15-665d77599c63" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_afeb5653-dd4e-f1f9-0e15-665d77599c63" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_c2f6e20c-f7cd-9421-0d70-7a9e1d213fd4" xlink:type="locator" />
    <link:calculationArc order="21" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_c2f6e20c-f7cd-9421-0d70-7a9e1d213fd4" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_a6fbecc9-ccd8-ab44-e209-7a9e1d739e86" xlink:type="locator" />
    <link:calculationArc order="22" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_a6fbecc9-ccd8-ab44-e209-7a9e1d739e86" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_da48be13-fe22-7466-1a86-7a9e1d9a62b5" xlink:type="locator" />
    <link:calculationArc order="23" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_da48be13-fe22-7466-1a86-7a9e1d9a62b5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_a3413e5c-1edb-70c9-ff10-7a9e1d644f7e" xlink:type="locator" />
    <link:calculationArc order="24" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_a3413e5c-1edb-70c9-ff10-7a9e1d644f7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_093f89d5-9d1d-a871-86aa-9403fcf30357" xlink:type="locator" />
    <link:calculationArc order="25" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_093f89d5-9d1d-a871-86aa-9403fcf30357" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_OperatingLeaseNonCashLeaseExpense" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_82c8e01b-4012-b653-1825-7a9e1d3cca66" xlink:type="locator" />
    <link:calculationArc order="26" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_82c8e01b-4012-b653-1825-7a9e1d3cca66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_db1ebd38-aa6d-5af7-743b-bd61e9637a33" xlink:type="locator" />
    <link:calculationArc order="27" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_db1ebd38-aa6d-5af7-743b-bd61e9637a33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_3646ea00-f9ba-9334-36e4-77e2e11ff3d8" xlink:type="locator" />
    <link:calculationArc order="28" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_3646ea00-f9ba-9334-36e4-77e2e11ff3d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_61b20b47-ad8c-4810-f94d-4e2e9b69a931" xlink:type="locator" />
    <link:calculationArc order="29" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_61b20b47-ad8c-4810-f94d-4e2e9b69a931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75dcfd3d-3d98-a274-6983-66b5cde008e2" xlink:type="locator" />
    <link:calculationArc order="30" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75dcfd3d-3d98-a274-6983-66b5cde008e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fb4920-0b72-7fd0-429d-d910e936dd99" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fb4920-0b72-7fd0-429d-d910e936dd99" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:to="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21e78629-41be-59b9-6de7-6a506ab18f9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b648d0ef-16fe-7d60-a025-6e0cc8ac751c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21e78629-41be-59b9-6de7-6a506ab18f9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8d46be56-f4eb-8e22-ebfd-f7827a406c06" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8d46be56-f4eb-8e22-ebfd-f7827a406c06" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:to="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:to="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_922daf79-4589-2010-458b-2bc250462d25" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_922daf79-4589-2010-458b-2bc250462d25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c156c847-bbc0-f5d6-c7be-d450851582a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c156c847-bbc0-f5d6-c7be-d450851582a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_26dd6f54-ff36-2514-c7c3-79c67c5774ff" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_InterestIncomeOperating_26dd6f54-ff36-2514-c7c3-79c67c5774ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_70961961-6a13-30f4-732a-8e29cef0bea0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_InterestExpense_70961961-6a13-30f4-732a-8e29cef0bea0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_831204c8-a383-c6e4-c75c-44e9b1e283d8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_831204c8-a383-c6e4-c75c-44e9b1e283d8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_ee733737-9f1b-1777-008b-7a9e1d71a010" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_ee733737-9f1b-1777-008b-7a9e1d71a010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5d028922-d070-82e0-ad36-97267b622d4c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5d028922-d070-82e0-ad36-97267b622d4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_61b20b47-ad8c-4810-f94d-4e2e9b69a931" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_61b20b47-ad8c-4810-f94d-4e2e9b69a931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75dcfd3d-3d98-a274-6983-66b5cde008e2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82a1dba8-8b5a-130a-edce-afbb0d3a199c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75dcfd3d-3d98-a274-6983-66b5cde008e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63bbe84c-b938-87b9-5103-68b80738d584" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63bbe84c-b938-87b9-5103-68b80738d584" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_07f72461-1cfc-5fb5-6e43-57a569e5cc5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_07f72461-1cfc-5fb5-6e43-57a569e5cc5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2687778d-de2e-ec86-99ca-07a7c84f6557" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2687778d-de2e-ec86-99ca-07a7c84f6557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_beea53c5-84dc-71c1-587d-d2a3828d4dec" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_beea53c5-84dc-71c1-587d-d2a3828d4dec" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_ec3628a9-13d2-69bf-16f9-7a9e1d6e30bd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_ec3628a9-13d2-69bf-16f9-7a9e1d6e30bd" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_a638834d-0545-c99f-65d9-7a9e1d4fccd1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_ino_DebtinstrumentAccruedInterest_a638834d-0545-c99f-65d9-7a9e1d4fccd1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_675259d5-1955-ca95-e3dd-f8737788a08c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_675259d5-1955-ca95-e3dd-f8737788a08c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3277d04c-55b4-8a89-a6de-301442f4acca" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3277d04c-55b4-8a89-a6de-301442f4acca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_48f78b57-30c2-4d9a-4535-7f0247d4e88b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_48f78b57-30c2-4d9a-4535-7f0247d4e88b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_037ce1e1-bf34-7d9f-964d-e1eb24c269e0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_037ce1e1-bf34-7d9f-964d-e1eb24c269e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6751af82-9c67-ff0a-0222-bc23a551c471" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_95efea61-67de-e4d2-2a62-71c1dca5646f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6751af82-9c67-ff0a-0222-bc23a551c471" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0aee1c19-f77f-655a-b96e-557260095c84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_88da5cea-7ea1-ec46-7d8e-822e6c2e193d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_88da5cea-7ea1-ec46-7d8e-822e6c2e193d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_94f6a7df-136b-0f93-234f-a6f9faabdf3c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_94f6a7df-136b-0f93-234f-a6f9faabdf3c" xlink:to="loc_us-gaap_DerivativeLiabilities_34294b8c-6491-36d6-dd54-7604deaf3d1f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_de2be270-37a2-d88c-7bb8-7a9e1d580d6e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_de2be270-37a2-d88c-7bb8-7a9e1d580d6e" xlink:to="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_ccb0b8c5-cf2f-c901-e2fb-8292251574a1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:to="loc_us-gaap_GoodwillGross_ccb0b8c5-cf2f-c901-e2fb-8292251574a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_de2be270-37a2-d88c-7bb8-7a9e1d580d6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46346561-8cfb-ab6e-79bb-c44fc2165bf6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46346561-8cfb-ab6e-79bb-c44fc2165bf6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_097cbdee-f90d-7331-468c-cf3193d6f1a6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c124af4a-c1a7-5bd7-f6b9-0a8199d145c1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_097cbdee-f90d-7331-468c-cf3193d6f1a6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_9a441977-858a-e8af-96aa-7a9e1d24949a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_9a441977-858a-e8af-96aa-7a9e1d24949a" xlink:to="loc_us-gaap_GoodwillGross_ccb0b8c5-cf2f-c901-e2fb-8292251574a1" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_9a441977-858a-e8af-96aa-7a9e1d24949a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46346561-8cfb-ab6e-79bb-c44fc2165bf6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_a8b66d7f-72c7-4ff2-7f1f-84b93ba048de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5d89653-9412-3469-28ee-c3579ebc0767" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a8b66d7f-72c7-4ff2-7f1f-84b93ba048de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5d89653-9412-3469-28ee-c3579ebc0767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a8b66d7f-72c7-4ff2-7f1f-84b93ba048de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43bc6b71-af9e-673d-6993-b6a02f1641e8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43bc6b71-af9e-673d-6993-b6a02f1641e8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5204522-5767-9cc8-bd20-39f37a077136" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5204522-5767-9cc8-bd20-39f37a077136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5b3c8073-78d2-1d8d-4a57-09d002ab65a0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5b3c8073-78d2-1d8d-4a57-09d002ab65a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_006a0126-4f87-3b72-3a02-6e918f06be6c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_006a0126-4f87-3b72-3a02-6e918f06be6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e274b476-0799-2889-05dd-d2465fdd0c72" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e274b476-0799-2889-05dd-d2465fdd0c72" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_BDAE89AAE84AB39B22342F49F23EBE62" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ace8d124-6d5c-421d-3a79-a2bec1d408ae" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_BDAE89AAE84AB39B22342F49F23EBE62" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/OrganizationAndOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a837b31e-1400-d592-c167-ead1d80d260e" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a837b31e-1400-d592-c167-ead1d80d260e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ef772ef-d0a5-977b-06d1-931f4da1f4a0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ef772ef-d0a5-977b-06d1-931f4da1f4a0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ino-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentation" xlink:href="ino-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentationDetails" xlink:href="ino-20200630.xsd#BasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentationPolicies" xlink:href="ino-20200630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:href="ino-20200630.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:href="ino-20200630.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ino-20200630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:href="ino-20200630.xsd#ConvertibleDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:href="ino-20200630.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:href="ino-20200630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:href="ino-20200630.xsd#CriticalAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:href="ino-20200630.xsd#CriticalAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:href="ino-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:href="ino-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:href="ino-20200630.xsd#GeneosTherapeuticsInc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards" xlink:href="ino-20200630.xsd#ImpactOfRecentlyIssuedAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:href="ino-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:href="ino-20200630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:href="ino-20200630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:href="ino-20200630.xsd#LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:href="ino-20200630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:href="ino-20200630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="ino-20200630.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:href="ino-20200630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationAndOperations" xlink:href="ino-20200630.xsd#OrganizationAndOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:href="ino-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="ino-20200630.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:href="ino-20200630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ino-20200630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestments" xlink:href="ino-20200630.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:href="ino-20200630.xsd#ShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="ino-20200630.xsd#ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:href="ino-20200630.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:href="ino-20200630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:href="ino-20200630.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:href="ino-20200630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:href="ino-20200630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:href="ino-20200630.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:href="ino-20200630.xsd#StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:href="ino-20200630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:href="ino-20200630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:href="ino-20200630.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:to="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:to="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_1C5251C2D4453FEFB427BC7D05418A29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_1C5251C2D4453FEFB427BC7D05418A29" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_VGXAnimalHealthIncMember" xlink:label="loc_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:to="loc_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_AD2CDA96582C4D27A236BC7D0543D714" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_AD2CDA96582C4D27A236BC7D0543D714" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_3F760C484F223131F8C5BC7D0543C7B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:to="loc_ino_August2019ConvertibleBondsMember_3F760C484F223131F8C5BC7D0543C7B5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_F7D20A935AC314D9130CBC7D05439445" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:to="loc_ino_December2019ConvertibleBondsMember_F7D20A935AC314D9130CBC7D05439445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_EF3FDE8F16F90B11CCA4BC7D0544AFE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF" xlink:to="loc_us-gaap_ConvertibleDebtMember_EF3FDE8F16F90B11CCA4BC7D0544AFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:to="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:to="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_194AF3912E49EA8A5D22BC7D0544F950" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C" xlink:to="loc_us-gaap_CommonStockMember_194AF3912E49EA8A5D22BC7D0544F950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SalesAgreementsMember" xlink:label="loc_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38" xlink:to="loc_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E6B0CB4A4A7F36D708C7BC7D0547CE27" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E6B0CB4A4A7F36D708C7BC7D0547CE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_724379E533AC006963CEBC7D0547E936" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_724379E533AC006963CEBC7D0547E936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0A5662FA38809E08114DBC7D05475026" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0A5662FA38809E08114DBC7D05475026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_FB8A5F31180D13E05E14BC7D0547E6B5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_FB8A5F31180D13E05E14BC7D0547E6B5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisOfPresentationPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AstraZenecaMember" xlink:label="loc_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_BillAndMelindaGatesFoundationMember" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DepartmentOfDefenceMember" xlink:label="loc_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:to="loc_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:to="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:to="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LassaFeverAndMERSVaccineMember" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SARSCoV2COVID19VaccineMember" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_INO4800Member" xlink:label="loc_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CELLECTRA2000DeviceMember" xlink:label="loc_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ProceedsFromCollaborativeAgreement" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementCorporateIncomeTax" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementAdvisoryFees" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementRoyaltyPeriod" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NumberOfAdditionalProducts" xlink:label="loc_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementFundingToBeReceived" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementFundingReceived" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_D7B990BB338D5079D661BC1FABA8CBE7" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_DeferredGrantFundingCurrent_D7B990BB338D5079D661BC1FABA8CBE7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:to="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:to="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_43DC896320B99DF74E80BC7D05BE58BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_43DC896320B99DF74E80BC7D05BE58BF" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ConvertibleBondsMember" xlink:label="loc_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:to="loc_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:to="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2D1996C18B1BD6BD0421BC7D05C41365" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_DerivativeLiabilities_2D1996C18B1BD6BD0421BC7D05C41365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:to="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:to="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:to="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:to="loc_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E90F7E803C3C104DFF14CA24947AA44F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E90F7E803C3C104DFF14CA24947AA44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="loc_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_064882EBA22BAAB45235CA24947CB127" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_064882EBA22BAAB45235CA24947CB127" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_755A812CA244C8BC1B97CA24947D4378" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_755A812CA244C8BC1B97CA24947D4378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:to="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:to="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_F99CBD9FEE791A1B9531B92D69E5E4E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_PreferredStockMember_F99CBD9FEE791A1B9531B92D69E5E4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6FAFEF187DC2E5AD0D12B92D69E56CC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_CommonStockMember_6FAFEF187DC2E5AD0D12B92D69E56CC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BBA447EC5A113FE8E3A4B92D69E5D4D2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BBA447EC5A113FE8E3A4B92D69E5D4D2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:to="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_72EE5B5F5E329BC575E4A643FA16EEE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_72EE5B5F5E329BC575E4A643FA16EEE3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_8395B448B31C94162DD3A643FA169E52" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:to="loc_ino_August2019ConvertibleBondsMember_8395B448B31C94162DD3A643FA169E52" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_619368AFCCDFE0D00972A643FA167348" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:to="loc_ino_December2019ConvertibleBondsMember_619368AFCCDFE0D00972A643FA167348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_80D0DD3B61FA00D5CA80A643FA16A914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_80D0DD3B61FA00D5CA80A643FA16A914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3688FB4D5F65B453522BA643FA17511F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_LongTermDebt_3688FB4D5F65B453522BA643FA17511F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:to="loc_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:to="loc_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="loc_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="loc_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:to="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:to="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InitialConversionPriceMember" xlink:label="loc_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="loc_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AfterJanuary22020ConversionPriceMember" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AfterJuly22020ConversionPriceMember" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:to="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:to="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:to="loc_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_EEB35974C139D378DC912E9F708614C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5" xlink:to="loc_us-gaap_ConvertibleDebtMember_EEB35974C139D378DC912E9F708614C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:to="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_D5FD00AC3F4E825661FC2E9F7087656E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_D5FD00AC3F4E825661FC2E9F7087656E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_00C297372193D4408D512E9F7087C150" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:to="loc_ino_August2019ConvertibleBondsMember_00C297372193D4408D512E9F7087C150" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_C6804768086CEB866D582E9F7087801F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:to="loc_ino_December2019ConvertibleBondsMember_C6804768086CEB866D582E9F7087801F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4CECDA26059C7EB54F472E9F70892E06" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4CECDA26059C7EB54F472E9F70892E06" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_3D817B3DDA04E5F9AC8C2E9F7089913E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_3D817B3DDA04E5F9AC8C2E9F7089913E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:to="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:to="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:to="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:to="loc_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_832906190D582BECABF6CB7E042E2BA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:to="loc_srt_MaximumMember_832906190D582BECABF6CB7E042E2BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_BA9CAB6509D40DA9407BC7EFA9CADB1F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_BA9CAB6509D40DA9407BC7EFA9CADB1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:to="loc_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_FCE58F98ACAC77CCD8A6C9B427720999" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_FCE58F98ACAC77CCD8A6C9B427720999" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:to="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:to="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_795CAAD3A1EE29CFA3D3C9B42771EA4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC" xlink:to="loc_us-gaap_CommonStockMember_795CAAD3A1EE29CFA3D3C9B42771EA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_FCE58F98ACAC77CCD8A6C9B427720999" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3385B16ED440DE327BFBC9B427739A7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3385B16ED440DE327BFBC9B427739A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="loc_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:to="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_WorkingCapitalExcludingCash" xlink:label="loc_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:to="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_8B50ABC9D2D8C4798668BC216322CEF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_8B50ABC9D2D8C4798668BC216322CEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AlternativeInvestmentMeasurementInputTerm" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_EquityMethodInvestmentEnterpriseValue" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:to="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:to="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_90B97A783EFBF174FA93C9E6D7B27D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:to="loc_us-gaap_CommonStockMember_90B97A783EFBF174FA93C9E6D7B27D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:to="loc_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:to="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_D9BB10A12E5A9158DE0CC9E6D7B3795F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_D9BB10A12E5A9158DE0CC9E6D7B3795F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_B86221EB6E79D2BBB4E2CA2492AB36C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_B86221EB6E79D2BBB4E2CA2492AB36C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:to="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:to="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_491E0542606122BF6AA8CA2492ABB314" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_491E0542606122BF6AA8CA2492ABB314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:to="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:to="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DD3423F0476EEEFB119CCA2492ACA1AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:to="loc_us-gaap_CommonStockMember_DD3423F0476EEEFB119CCA2492ACA1AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D5BE9C98157EBF12B767CA2492AC116B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:to="loc_us-gaap_PreferredStockMember_D5BE9C98157EBF12B767CA2492AC116B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4A085CDA6B52E12248DCCA2492AE81DC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_EquityMethodInvestments_4A085CDA6B52E12248DCCA2492AE81DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:to="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:to="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC" xlink:to="loc_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="loc_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InovioAsMember" xlink:label="loc_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="loc_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_VgxPharmaceuticalsMember" xlink:label="loc_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="loc_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_4409B477C715B496CB68CC035FB1D314" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="loc_ino_BiojectMember_4409B477C715B496CB68CC035FB1D314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:to="loc_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:to="loc_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2745CD7AF5D6B719EE9FCC035FB38921" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2745CD7AF5D6B719EE9FCC035FB38921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:to="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:to="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:to="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B37727F2F3F26F63DB3B3278C4B3D4AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:to="loc_srt_MinimumMember_B37727F2F3F26F63DB3B3278C4B3D4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DDFC7D0630FE6A2E169A3278C4B35C04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:to="loc_srt_MaximumMember_DDFC7D0630FE6A2E169A3278C4B35C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SanDiegoOfficeMember" xlink:label="loc_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:to="loc_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlymouthMeetingPennsylvaniaMember" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:to="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_C32A572B18AD68B340DAA643F9CAD60D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_C32A572B18AD68B340DAA643F9CAD60D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_9493922370B7F2BF5D05A643F9CABE9D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:to="loc_ino_August2019ConvertibleBondsMember_9493922370B7F2BF5D05A643F9CABE9D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_998E81F53A0194D4FBDAA643F9CA76D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:to="loc_ino_December2019ConvertibleBondsMember_998E81F53A0194D4FBDAA643F9CA76D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/OrganizationAndOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_2517E2E5D887EC870E5A9C6514ACC479" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:to="loc_ino_PlumblineLifeSciencesMember_2517E2E5D887EC870E5A9C6514ACC479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:to="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:to="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:to="loc_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:to="loc_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_7C4CF7099E7F1A8EE3EA9C3ABD2339CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047" xlink:to="loc_ino_PlumblineLifeSciencesMember_7C4CF7099E7F1A8EE3EA9C3ABD2339CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_12E9F4F2789183A13C429C3ABD2448BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_12E9F4F2789183A13C429C3ABD2448BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeArrangementTerm" xlink:label="loc_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MilestoneBasedOwnershipTarget" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_7B989179A17FCD8D2CD79C3ABD25B918" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_7B989179A17FCD8D2CD79C3ABD25B918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InvestmentOwnedAdditionalSharesAcquired" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_99A247A96952D8A9BFB59C3ABD26529A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_99A247A96952D8A9BFB59C3ABD26529A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementExpensesToReimburse" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementAwardedAmount" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GrantProceedsReceived" xlink:label="loc_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliate" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:to="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:to="loc_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AstraZenecaMember" xlink:label="loc_ino_AstraZenecaMember_1FD0704E32E59AAB72D83361BDB1214A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:to="loc_ino_AstraZenecaMember_1FD0704E32E59AAB72D83361BDB1214A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_OtherCounterpartyMember" xlink:label="loc_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:to="loc_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="loc_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_28EFCFCB7B82265A7CD73361BD820677" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_28EFCFCB7B82265A7CD73361BD820677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_915A6F61C0054D486BB43361BD82B0D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="loc_us-gaap_CertificatesOfDepositMember_915A6F61C0054D486BB43361BD82B0D7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_EmployeesAndDirectorsMember" xlink:label="loc_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:to="loc_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:to="loc_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:to="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:to="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:to="loc_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PriorSalesAgreementMember" xlink:label="loc_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:to="loc_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NewSalesAgreementMember" xlink:label="loc_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:to="loc_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:to="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:to="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A2016IncentivePlanMember" xlink:label="loc_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:to="loc_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A2007IncentivePlanMember" xlink:label="loc_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:to="loc_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:to="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:to="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_83626D07ADE26E37D1E97A9E604BF450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_83626D07ADE26E37D1E97A9E604BF450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_459CB0C5607154BC0637C9EAF3592343" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20" xlink:to="loc_ino_August2019ConvertibleBondsMember_459CB0C5607154BC0637C9EAF3592343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_2271A94DC6C8FF017D0CC9EAF35B7748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F" xlink:to="loc_us-gaap_ConvertibleDebtMember_2271A94DC6C8FF017D0CC9EAF35B7748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:to="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:to="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_954DFF3B5D2F8A73B0BDC9EAF35BCB46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE" xlink:to="loc_us-gaap_CommonStockMember_954DFF3B5D2F8A73B0BDC9EAF35BCB46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690" xlink:to="loc_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_8A4B735F241198ECF161C9EAF35E7DAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_8A4B735F241198ECF161C9EAF35E7DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4779263F4994C6597A4BC9EAF3645890" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4779263F4994C6597A4BC9EAF3645890" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ino-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:to="lab_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:to="lab_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:to="lab_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:type="arc" />
    <link:label id="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049_verboseLabel_en-US" xlink:label="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prior Sales Agreement</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049_label_en-US" xlink:label="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049_documentation_en-US" xlink:label="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_PriorSalesAgreementMember" xlink:label="loc_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:to="lab_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:type="arc" />
    <link:label id="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E_terseLabel_en-US" xlink:label="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Sales Agreement</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E_label_en-US" xlink:label="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E_documentation_en-US" xlink:label="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_NewSalesAgreementMember" xlink:label="loc_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:to="lab_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:to="lab_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:to="lab_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:type="arc" />
    <link:label id="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_A2016IncentivePlanMember" xlink:label="loc_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:to="lab_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:type="arc" />
    <link:label id="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_A2007IncentivePlanMember" xlink:label="loc_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:to="lab_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="lab_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:type="arc" />
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:type="arc" />
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:type="arc" />
    <link:label id="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agent fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4_label_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:to="lab_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:type="arc" />
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:type="arc" />
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement weighted average price per share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:type="arc" />
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:type="arc" />
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D_terseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of potential shares authorized for issuance under share based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:type="arc" />
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:type="arc" />
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment  award maximum contractual term.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Fair Value of the Company's Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:to="lab_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amortization expense on intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated aggregate amortization expense for remainder of 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated aggregate amortization expense for 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated aggregate amortization expense for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated aggregate amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated aggregate amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:type="arc" />
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0_terseLabel_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated aggregate amortization expense for 2025</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0_label_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0_documentation_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:to="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:to="lab_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:to="lab_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E" xlink:to="lab_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="lab_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:to="lab_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:to="lab_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:to="lab_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:type="arc" />
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:type="arc" />
    <link:label id="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2019 Convertible Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:to="lab_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:type="arc" />
    <link:label id="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2019 Convertible Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:to="lab_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="lab_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:type="arc" />
    <link:label id="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_InitialConversionPriceMember" xlink:label="loc_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:to="lab_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:type="arc" />
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288_terseLabel_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After January 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288_label_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288_documentation_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_AfterJanuary22020ConversionPriceMember" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:to="lab_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:type="arc" />
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B_terseLabel_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After July 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B_label_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B_documentation_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_AfterJuly22020ConversionPriceMember" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:to="lab_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9_label_en-US" xlink:label="lab_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:to="lab_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312_terseLabel_en-US" xlink:label="lab_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312_label_en-US" xlink:label="lab_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:to="lab_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440_label_en-US" xlink:label="lab_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:to="lab_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="lab_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, carrying amount of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A_label_en-US" xlink:label="lab_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:to="lab_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:to="lab_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:to="lab_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:type="arc" />
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, internal rate of return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:to="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:type="arc" />
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, required bondholder approval, percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:to="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:to="lab_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:type="arc" />
    <link:label id="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_EmployeesAndDirectorsMember" xlink:label="loc_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:to="lab_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:type="arc" />
    <link:label id="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3_label_en-US" xlink:label="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:to="lab_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:to="lab_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:to="lab_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:to="lab_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA_label_en-US" xlink:label="lab_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="lab_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_454A02F5106BE72121433278C64F0B60_terseLabel_en-US" xlink:label="lab_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_454A02F5106BE72121433278C64F0B60_label_en-US" xlink:label="lab_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:to="lab_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:to="lab_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:to="lab_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:to="lab_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199_label_en-US" xlink:label="lab_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:to="lab_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0_label_en-US" xlink:label="lab_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:to="lab_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:to="lab_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:to="lab_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:to="lab_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:to="lab_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:to="lab_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:to="lab_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF_label_en-US" xlink:label="lab_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:to="lab_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:to="lab_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC_label_en-US" xlink:label="lab_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:to="lab_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95_label_en-US" xlink:label="lab_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:to="lab_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A_label_en-US" xlink:label="lab_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:to="lab_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:to="lab_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:to="lab_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC_label_en-US" xlink:label="lab_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:to="lab_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:to="lab_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:to="lab_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68_label_en-US" xlink:label="lab_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:to="lab_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21_label_en-US" xlink:label="lab_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:to="lab_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:to="lab_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:to="lab_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:to="lab_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:to="lab_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:to="lab_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:to="lab_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:type="arc" />
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:to="lab_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="lab_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:type="arc" />
    <link:label id="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F_negatedTerseLabel_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Working capital (excluding cash)</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F_label_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F_documentation_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_WorkingCapitalExcludingCash" xlink:label="loc_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:to="lab_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B_label_en-US" xlink:label="lab_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:to="lab_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:to="lab_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of investment in Geneos retained</link:label>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F_label_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Interest, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:to="lab_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54" xlink:to="lab_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="lab_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:to="lab_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="lab_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:to="lab_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550" xlink:to="lab_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:to="lab_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816_label_en-US" xlink:label="lab_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:to="lab_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3_label_en-US" xlink:label="lab_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:to="lab_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:type="arc" />
    <link:label id="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ConvertibleBondsMember" xlink:label="loc_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:to="lab_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:to="lab_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="lab_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="lab_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:to="lab_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:type="arc" />
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:to="lab_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:to="lab_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D_label_en-US" xlink:label="lab_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:to="lab_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192_label_en-US" xlink:label="lab_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:to="lab_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:type="arc" />
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:type="arc" />
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D_verboseLabel_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D_label_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Affiliated Entity, Current</link:label>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D_documentation_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:to="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:to="lab_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:to="lab_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:to="lab_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25_label_en-US" xlink:label="lab_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:to="lab_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:to="lab_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:to="lab_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:to="lab_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:to="lab_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:to="lab_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A" xlink:to="lab_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D" xlink:to="lab_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364_label_en-US" xlink:label="lab_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:to="lab_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:type="arc" />
    <link:label id="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF_terseLabel_en-US" xlink:label="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF_label_en-US" xlink:label="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF_documentation_en-US" xlink:label="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_NonCashInterestExpense" xlink:label="loc_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:to="lab_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:type="arc" />
    <link:label id="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D_terseLabel_en-US" xlink:label="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums on investments</link:label>
    <link:label id="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D_label_en-US" xlink:label="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income Accrued On Short Term Investments Certificates Of Deposit</link:label>
    <link:label id="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D_documentation_en-US" xlink:label="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Income Accrued On Short Term Investments Certificates Of Deposit</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:to="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:to="lab_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:type="arc" />
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5_negatedLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294_terseLabel_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294_label_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294_documentation_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_OperatingLeaseNonCashLeaseExpense" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:to="lab_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:type="arc" />
    <link:label id="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from other unrealized gains on short-term investments</link:label>
    <link:label id="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4_label_en-US" xlink:label="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments</link:label>
    <link:label id="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4_documentation_en-US" xlink:label="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:to="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized transaction loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Geneos issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:to="lab_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC_label_en-US" xlink:label="lab_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:to="lab_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:to="lab_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:to="lab_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:type="arc" />
    <link:label id="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE_label_en-US" xlink:label="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE_documentation_en-US" xlink:label="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:to="lab_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:to="lab_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability (Note 9)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:to="lab_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input, expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input, price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input, risk free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:type="arc" />
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205_terseLabel_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, measurement input, expected term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205_label_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205_documentation_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_AlternativeInvestmentMeasurementInputTerm" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:to="lab_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:type="arc" />
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:type="arc" />
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302_verboseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Enterprise value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_EquityMethodInvestmentEnterpriseValue" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:to="lab_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:to="lab_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6_label_en-US" xlink:label="lab_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:to="lab_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in equity method investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:to="lab_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:to="lab_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="lab_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:to="lab_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:to="lab_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56_label_en-US" xlink:label="lab_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:to="lab_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of non-controlling interest in Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of acquisition of non-controlling interest in Geneos</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:to="lab_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1" xlink:to="lab_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:type="arc" />
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB_verboseLabel_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB_label_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB_documentation_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable securities and fair value measurements.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares held in an affiliated entity (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advances to Affiliates, Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:to="lab_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:type="arc" />
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00_terseLabel_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00_label_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00_documentation_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_GrantPolicyPolicyTextBlock" xlink:label="loc_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:to="lab_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Intangible Assets by Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:type="arc" />
    <link:label id="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753_label_en-US" xlink:label="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753_documentation_en-US" xlink:label="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:to="lab_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:type="arc" />
    <link:label id="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604_terseLabel_en-US" xlink:label="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604_label_en-US" xlink:label="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604_documentation_en-US" xlink:label="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_AstraZenecaMember" xlink:label="loc_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:to="lab_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:type="arc" />
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:type="arc" />
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_BillAndMelindaGatesFoundationMember" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:type="arc" />
    <link:label id="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DepartmentOfDefenceMember" xlink:label="loc_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:to="lab_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:to="lab_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:to="lab_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:to="lab_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:to="lab_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="lab_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:type="arc" />
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_LassaFeverAndMERSVaccineMember" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:type="arc" />
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_SARSCoV2COVID19VaccineMember" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:type="arc" />
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:type="arc" />
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:type="arc" />
    <link:label id="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A_terseLabel_en-US" xlink:label="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A_label_en-US" xlink:label="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A_documentation_en-US" xlink:label="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_INO4800Member" xlink:label="loc_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:to="lab_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:type="arc" />
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CELLECTRA 2000 Device</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E_label_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E_documentation_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CELLECTRA2000DeviceMember" xlink:label="loc_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:to="lab_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Territory expansion option period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F_label_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:to="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:type="arc" />
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds received in upfront payment</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ProceedsFromCollaborativeAgreement" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementCorporateIncomeTax" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign non-corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementAdvisoryFees" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementRoyaltyPeriod" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anticipated development and regulatory event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:to="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anticipated commercial event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:to="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:type="arc" />
    <link:label id="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711_terseLabel_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional products to be developed</link:label>
    <link:label id="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711_label_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Additional Products</link:label>
    <link:label id="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711_documentation_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Additional Products</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_NumberOfAdditionalProducts" xlink:label="loc_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:to="lab_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementFundingToBeReceived" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94_verboseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Funding received for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementFundingReceived" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:to="lab_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:to="lab_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:type="arc" />
    <link:label id="lab_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:to="lab_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:type="arc" />
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual maturity (less than)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Market Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:type="arc" />
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:type="arc" />
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:type="arc" />
    <link:label id="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_SanDiegoOfficeMember" xlink:label="loc_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:to="lab_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:type="arc" />
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_PlymouthMeetingPennsylvaniaMember" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:type="arc" />
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF_label_en-US" xlink:label="lab_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:to="lab_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:type="arc" />
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:to="lab_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:type="arc" />
    <link:label id="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:to="lab_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:type="arc" />
    <link:label id="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_OtherCounterpartyMember" xlink:label="loc_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:to="lab_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from deferred revenue beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:to="lab_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:type="arc" />
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of premium associated with the Bonds</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656_label_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:to="lab_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:type="arc" />
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14_terseLabel_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14_label_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14_documentation_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:to="lab_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630_label_en-US" xlink:label="lab_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:to="lab_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE_label_en-US" xlink:label="lab_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:to="lab_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:type="arc" />
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on deconsolidation of investment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:to="lab_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:type="arc" />
    <link:label id="lab_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797_label_en-US" xlink:label="lab_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:to="lab_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:to="lab_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:type="arc" />
    <link:label id="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100_terseLabel_en-US" xlink:label="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100_label_en-US" xlink:label="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100_documentation_en-US" xlink:label="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:to="lab_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:type="arc" />
    <link:label id="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C_verboseLabel_en-US" xlink:label="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inovio AS</link:label>
    <link:label id="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C_label_en-US" xlink:label="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inovio As [Member]</link:label>
    <link:label id="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C_documentation_en-US" xlink:label="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inovio AS.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_InovioAsMember" xlink:label="loc_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:to="lab_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:type="arc" />
    <link:label id="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44_verboseLabel_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">VGX</link:label>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44_label_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VGX Pharmaceuticals [Member]</link:label>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44_documentation_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VGX pharmaceuticals.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_VgxPharmaceuticalsMember" xlink:label="loc_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:to="lab_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087_label_en-US" xlink:label="lab_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:to="lab_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:to="lab_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:type="arc" />
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and intangible assets, gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:type="arc" />
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and intangible assets, net book value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1" xlink:to="lab_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA_label_en-US" xlink:label="lab_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:to="lab_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:type="arc" />
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:to="lab_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="lab_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:to="lab_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:to="lab_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:to="lab_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:to="lab_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income tax benefit and share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:to="lab_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:to="lab_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:type="arc" />
    <link:label id="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2_terseLabel_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VGX Animal Health, Inc</link:label>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2_label_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VGX Animal Health, Inc [Member]</link:label>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2_documentation_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VGX Animal Health, Inc [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_VGXAnimalHealthIncMember" xlink:label="loc_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:to="lab_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:type="arc" />
    <link:label id="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agreements</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614_label_en-US" xlink:label="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614_documentation_en-US" xlink:label="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_SalesAgreementsMember" xlink:label="loc_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:to="lab_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:to="lab_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Capital_71023990FF924834A79DBC7D05468E66_terseLabel_en-US" xlink:label="lab_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_us-gaap_Capital_71023990FF924834A79DBC7D05468E66_label_en-US" xlink:label="lab_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Banking Regulation, Total Capital, Actual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:to="lab_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:to="lab_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:type="arc" />
    <link:label id="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11_terseLabel_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GeneOne Life Sciences</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11_label_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11_documentation_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:to="lab_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:type="arc" />
    <link:label id="lab_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723_terseLabel_en-US" xlink:label="lab_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723_label_en-US" xlink:label="lab_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:to="lab_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:type="arc" />
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:type="arc" />
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6_verboseLabel_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6_label_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6_documentation_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related party transactions.</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="lab_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment received for license granted</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeArrangementTerm" xlink:label="loc_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:to="lab_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:type="arc" />
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B_terseLabel_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone-based ownership target</link:label>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B_label_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone-Based Ownership Target</link:label>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B_documentation_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone-Based Ownership Target</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_MilestoneBasedOwnershipTarget" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:to="lab_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923_terseLabel_en-US" xlink:label="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liability</link:label>
    <link:label id="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923_label_en-US" xlink:label="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Other Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:to="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:type="arc" />
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D_terseLabel_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned, additional shares acquired (in shares)</link:label>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D_label_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Additional Shares Acquired</link:label>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D_documentation_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Owned, Additional Shares Acquired</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_InvestmentOwnedAdditionalSharesAcquired" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:to="lab_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementExpensesToReimburse" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementAwardedAmount" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:type="arc" />
    <link:label id="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7_label_en-US" xlink:label="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_GrantProceedsReceived" xlink:label="loc_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:to="lab_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable/accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliate" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ino-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentation" xlink:href="ino-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentationDetails" xlink:href="ino-20200630.xsd#BasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/BasisOfPresentationPolicies" xlink:href="ino-20200630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:href="ino-20200630.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:href="ino-20200630.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ino-20200630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="ino-20200630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:href="ino-20200630.xsd#ConvertibleDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:href="ino-20200630.xsd#ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:href="ino-20200630.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:href="ino-20200630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:href="ino-20200630.xsd#CriticalAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:href="ino-20200630.xsd#CriticalAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:href="ino-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="ino-20200630.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:href="ino-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:href="ino-20200630.xsd#GeneosTherapeuticsInc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:href="ino-20200630.xsd#GeneosTherapeuticsIncTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="ino-20200630.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards" xlink:href="ino-20200630.xsd#ImpactOfRecentlyIssuedAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:href="ino-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:href="ino-20200630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:href="ino-20200630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:href="ino-20200630.xsd#LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:href="ino-20200630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:href="ino-20200630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="ino-20200630.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:href="ino-20200630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationAndOperations" xlink:href="ino-20200630.xsd#OrganizationAndOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:href="ino-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="ino-20200630.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:href="ino-20200630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ino-20200630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestments" xlink:href="ino-20200630.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:href="ino-20200630.xsd#ShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="ino-20200630.xsd#ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:href="ino-20200630.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:href="ino-20200630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:href="ino-20200630.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:href="ino-20200630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:href="ino-20200630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:href="ino-20200630.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:href="ino-20200630.xsd#StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:href="ino-20200630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:href="ino-20200630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:href="ino-20200630.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4B67F568D589F35D43917A9E603F7A04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4B67F568D589F35D43917A9E603F7A04" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EEB5D5DE4C91F0014F9B7A9E603FF4DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_52A59B3BA6875B7FC793BC7D05401A24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_52A59B3BA6875B7FC793BC7D05401A24" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_411A80350C7291DE35A5BC7D0541C909" xlink:to="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_1C5251C2D4453FEFB427BC7D05418A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_1C5251C2D4453FEFB427BC7D05418A29" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_VGXAnimalHealthIncMember" xlink:label="loc_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2DB039543A8A58CF1B7CBC7D05414353" xlink:to="loc_ino_VGXAnimalHealthIncMember_2C328D52AF184BEF8179BC7D0542D3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_44BC992A0DB411F38FC4BC7D05426F81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_AD2CDA96582C4D27A236BC7D0543D714" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_AD2CDA96582C4D27A236BC7D0543D714" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_3F760C484F223131F8C5BC7D0543C7B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:to="loc_ino_August2019ConvertibleBondsMember_3F760C484F223131F8C5BC7D0543C7B5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_F7D20A935AC314D9130CBC7D05439445" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A0B6FB9C6A0757AF1AABC7D054266E8" xlink:to="loc_ino_December2019ConvertibleBondsMember_F7D20A935AC314D9130CBC7D05439445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8AE851AE8137152C754DBC7D05434CD1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_EF3FDE8F16F90B11CCA4BC7D0544AFE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_917106BB57D816263A33BC7D05433CFF" xlink:to="loc_us-gaap_ConvertibleDebtMember_EF3FDE8F16F90B11CCA4BC7D0544AFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0AE8763D8A2CB82CF715BC7D0544E59F" xlink:to="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_194AF3912E49EA8A5D22BC7D0544F950" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D755CE2CCFBB299EE1CBBC7D0544556C" xlink:to="loc_us-gaap_CommonStockMember_194AF3912E49EA8A5D22BC7D0544F950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D97A29ACB87E3D045C6CBC7D05452CFB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SalesAgreementsMember" xlink:label="loc_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187CF3EB17A99380E0E1BC7D05452F38" xlink:to="loc_ino_SalesAgreementsMember_BA7ABB13CEBDB66E3159BC7D0545D614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_55A1290EE3A769AD1DDEBC7D0541B572" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_D3C87DB91A7061BDFF6FBC7D054639E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_NetIncomeLoss_D4BFD64FF489B12D6A8DBC7D05464B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital" xlink:label="loc_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_Capital_71023990FF924834A79DBC7D05468E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8316F110E87028268EB6BC7D05463909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_E7B044AE29142E911BCCBC7D0546A10A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E6B0CB4A4A7F36D708C7BC7D0547CE27" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E6B0CB4A4A7F36D708C7BC7D0547CE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_724379E533AC006963CEBC7D0547E936" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_724379E533AC006963CEBC7D0547E936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0A5662FA38809E08114DBC7D05475026" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0A5662FA38809E08114DBC7D05475026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_FB8A5F31180D13E05E14BC7D0547E6B5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_829289A18A666B33C86CBC7D05458837" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_FB8A5F31180D13E05E14BC7D0547E6B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisOfPresentationPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_81EC3DEA26BFFD42DCE5D8E268C75B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A26A8491343B1747FFD1D8E268C80019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_997220A2A436EEA100BAD8E268C8C77E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GrantPolicyPolicyTextBlock" xlink:label="loc_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_ino_GrantPolicyPolicyTextBlock_9367C5709484D9A9B66DD8E268C85E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9B0DB4C438A1ACD06BFFD8E268C98D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2F7A2FB1E76B68A9E132D8E268C9FE7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_B322D2468B62E137473DD8E268C9B501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_BB7E0C34AE4E2885CBA8D8E268CAD44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_E99640D8950E057F9C0FD8E268CA1C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_C5B1E0FDEC2B70365399D8E268CA0D3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_7DD8559518A1F57E8BC4D9163C833011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4D39F9181B4FE38E34B7D8E268C79AC0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12A1FF94500AFDBE35B7D8E268CBFAAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C65F582CF006720FCA4D7A9E5F7802ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C65F582CF006720FCA4D7A9E5F7802ED" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6D362564A624DBA8876A7A9E5F7813C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83C54099366E9623EEF2BC1FAB9E3648" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83C54099366E9623EEF2BC1FAB9E3648" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_B2A7AB83CF29D4B75EF2BC1FAB9EC9D7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_ApolloBioMember_45742E343BD74C667ABABC1FAB9F9753" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AstraZenecaMember" xlink:label="loc_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_AstraZenecaMember_7902F4248E61914D2894BC1FAB9F0604" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_FCE836DE63A7445BC7B8BC1FAB9F9095" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_BillAndMelindaGatesFoundationMember" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_6A60473B0E8AC0A3399BBC1FABA0ABB0" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DepartmentOfDefenceMember" xlink:label="loc_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B8B8B296BC247460657FBC1FAB9F2A6F" xlink:to="loc_ino_DepartmentOfDefenceMember_FA91D07E08BC630309BDBC1FABA014D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B1880CAEFB02FA5B93ABBC1FABA0F85A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DB2E5AA75BE661D527A5BC1FABA11F6F" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9C984067810445611496BC1FABA13B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C4DC8B5559108A94AEDEBC1FABA13F31" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25F0226F6AFD70909418BC1FABA2D7A4" xlink:to="loc_us-gaap_ForeignCountryMember_A13DA322CE9286A7FA69BC1FABA21E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_D46C1FAD0DB04BE33A94BC1FABA2398B" xlink:to="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LassaFeverAndMERSVaccineMember" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_6346F3FFCAD70C42AAAEBC1FABA3B17E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SARSCoV2COVID19VaccineMember" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_6F36C0E39160988881B7BC1FABA33C24" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_AF6AB5F785744B25760DBC1FABA4C462" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7A72512C2F8486C49FA6BC1FABA42946" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_INO4800Member" xlink:label="loc_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_INO4800Member_B2A2534824771CD4263ABC1FABA4A67A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CELLECTRA2000DeviceMember" xlink:label="loc_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AEEC2B571125E90A674BBC1FABA22B5E" xlink:to="loc_ino_CELLECTRA2000DeviceMember_F7B33022218E37045FA9BC1FABA4070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2FFEF96F347D962A6683BC1FAB9E4E1B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_7920347BA625151CF2E4BC1FABA4DC2F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ProceedsFromCollaborativeAgreement" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_170FD2FDBB22F4F1D7BBBC1FABA55BD6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_339A1F9051B5CD9C3F7BBC1FABA5C0A2" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementCorporateIncomeTax" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_8A4BE84AFF7011598416BC1FABA596B8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_2543089980A961300866BC1FABA53B1C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementAdvisoryFees" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_F376C1405FE9D982583BBC1FABA5A564" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_18A8CC45C4EF942AE05FBC1FABA6239E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementRoyaltyPeriod" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_E12383D66A7D0A6D06B2BC1FABA619E8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_DC86C01E4017D86ED3D7BC1FABA6ACB9" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_C05A0A698A165AF82781BC1FABA68FD6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_94DEAFDBD1BF9E720B8ABC1FABA7F79A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_CEFE74D30C2B1B4A02D0BC1FABA7FD03" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NumberOfAdditionalProducts" xlink:label="loc_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_NumberOfAdditionalProducts_59877164EDF1EFA6B7F4BC1FABA71711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1C40EBE67B6F4E6398A3BC1FABA70B05" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementFundingToBeReceived" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_848C72AEECF851BBEDAEBC1FABA739E5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_16A516A11E4A7DF58321BC1FABA75974" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementFundingReceived" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_D0D9CDB98C30C78C8BDEBC1FABA8AC94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_FCAD77D0803B4BDB6B8DBC1FABA8CCFD" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_75F0CBB02B23A396B9A3BC1FABA8D314" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_D7B990BB338D5079D661BC1FABA8CBE7" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C00AEF8D0BD283E4A189BC1FABA4378A" xlink:to="loc_ino_DeferredGrantFundingCurrent_D7B990BB338D5079D661BC1FABA8CBE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_106EF87E1DD7FC34AE5EBC7D05BBF07D" xlink:to="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:to="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_70324ADC570AA9B59FB4BC7D05BDE987" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_43DC896320B99DF74E80BC7D05BE58BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_43DC896320B99DF74E80BC7D05BE58BF" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ConvertibleBondsMember" xlink:label="loc_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FBCB642B8350ED3EA9E5BC7D05BDD6F7" xlink:to="loc_ino_ConvertibleBondsMember_89377A5E78CDA1EC1E0ABC7D05BE7DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E38AA4181F7470C32786BC7D05BC07F3" xlink:to="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:to="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384E0DE7F46D37EC8CB4BC7D05BF2193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_ShortTermInvestments_B5381B16313BA9372546BC7D05BFAC5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_F28701B15F983FA3A1C2BC7D05BFA00D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_BF64007DDEDD1D4F1796BC7D05BF552D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B23A490C2A13E1D1579BBC7D05C0594C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_342376CEE08988F41573BC7D05C09B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A82B8364FB2A139374A8BC7D05BF6D99" xlink:to="loc_us-gaap_AssetsCurrent_4E00154040B39D49C7D9BC7D05C00CA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1B8D50A12B7EE798AC6ABC7D05C0E550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_774651B78BB7CAA8600FBC7D05C05043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_EquityMethodInvestments_00CC614351E274E0446FBC7D05C088A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CD2B8C58C6EB725DD58EBC7D05C17AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_Goodwill_F5CC4AE20FE76496F29DBC7D05C1713D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95D08B7403CB6A52A43BBC7D05C11090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0760D5A3208FD23D18E8BC7D05C19ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E92BBEE46E19BAC81D9ABC7D05BEBAF1" xlink:to="loc_us-gaap_Assets_3D1F0E8EF12243866503BC7D05C1D192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E482A4DE7B186789433DBC7D05BE275B" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_60D0B86293D76C4EE80DBC7D05C27B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_D79F8E037E004C179B12BC7D05C2FB22" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_9867E02A82E7D20F5ACDBC7D05C3D364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9E073F626BFEEBCC0536BC7D05C37622" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_73E5A607AD76C6100945BC7D05C3830D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_EC2D352323F0DC654822BC7D05C37287" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_DeferredGrantFundingCurrent_117C924222ED75B00A5CBC7D05C3BE0E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_AE13E9517254067BF789BC7D05C3959E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5C445AC84FD86F6BD8F2BC7D05C20CFC" xlink:to="loc_us-gaap_LiabilitiesCurrent_2378F6B8293CEAA34380BC7D05C4E4B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_EFD52DDF2268FA2E5BE8BC7D05C4C51A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_ConvertibleDebt_CEFE078961D9ED82C3FDBC7D05C44D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2D1996C18B1BD6BD0421BC7D05C41365" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_DerivativeLiabilities_2D1996C18B1BD6BD0421BC7D05C41365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_C384BE5DFDEAEFF46468BC7D05C4B32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8B2F682FB6B5A78BDBD0BC7D05C46635" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_1DF039C946DDA4247CCDBC7D05C5F590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_506567CB87066A43845FBC7D05C5D08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_Liabilities_AE121123EED0F86626FABC7D05C59D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_PreferredStockValue_F799D1993F4D077E71A2BC7D05C50246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_CommonStockValue_33C267288EF517ABF18ABC7D05C6EF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C8AD50CD8E4B1A606130BC7D05C6322A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44E3292D63B038584C46BC7D05C6295C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D3709C222AF6F8F8EAE5BC7D05C6C821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_StockholdersEquity_4EACA5E08003F6DF7B15BC7D05C6253A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_MinorityInterest_7F090F8A95AD46E7FB80BC7D05C727AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_C240BF59916F36FD93ECBC7D05C58901" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5BF471CDE945F4EDD5EABC7D05C76319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_CC3C1034938412E37AC1BC7D05C2A4A5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_141B62A0358D7E364FC6BC7D05C7AA8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:to="loc_us-gaap_ProfitLoss_AEB8080F8F3D966E54C2D8E268E5992D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_Depreciation_A8FEB099295BC143CFFCD8E268E68364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_24899E7A86C3E015E461D8E268E6F87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_17985EE4D1FFC062CA3DD8E268E62DAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A24C507611F9496AE092D8E268E66BE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_ShareBasedCompensation_A24C507611F9496AE092D8E268E66BE9" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NonCashInterestExpense" xlink:label="loc_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_ino_NonCashInterestExpense_46C152417C372239229CD8E268E73FAF" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_A81C4F4BFBC90E2F1A95D8E268E7E28D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_GainLossOnInvestments_55AA8710A76546BB0CC4D8E268E7FF5C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_4A2C3536A4C79AF80EBFD8E268E755A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_1188DC19760D63CF958AD8E268E79DF3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_1188DC19760D63CF958AD8E268E79DF3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1CB9F3FE93036B22B287D8E268E79FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_D73DB468F3B68E94C8BBD8E268E82343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1D95FD9191E3EF1CE8EAD8E268E8CE7E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_OperatingLeaseNonCashLeaseExpense" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_8876694B3AD4E23F64C8D8E268E8A294" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_E45828ED16D3C35A2BC8D8E268E833F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5135856D477E9E68B2B0D8E268E8E488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_193832CC967068C90B37D8E268E6C234" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D81CF32588D552F69D1D8E268E977AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9FFE94F6996A67C00667D8E268E9C9E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520B0DE1979D13EA740CD8E268E95E67" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_D89714F178DB69EE742DD8E268E95239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78BE8C52A995637F5285D8E268E927FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_EF7F0B5B0CBC3E7209BDD8E268E94B67" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_C9B8A8BDBCA7F3540BD8D8E268EAA753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_220247059AAF29B6591DD8E268EA15E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_344E0C5BF2A8B2CC895ED8E268EA4A5C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_E3836FA631F670626BE3D8E268EA04EF" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_C91A5936459ED6CE265DD8E268EA4CE9" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_FC5A2E10FA4600103515D8E268EAAF5A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_A5BD04F9A0EF460B2512D8E268EB7DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D5CA9CB3D7D947F18367D8E268E86E50" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8DF8E034446DDA0CFEBBD8E268EBDC2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F84EE19F0DE9C032BD3ED8E268E50BAE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E29DEDE6ABD25CAB6656D8E268EB6110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_F0181764F282A3869E1DD8E268EBC018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_888D4E9A0E2633B824E2D8E268EC0D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3039CCC0BCE2EACBDBB7D8E268ECDDE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3D53E5AFCA9266D2222BD8E268EC47C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3D53E5AFCA9266D2222BD8E268EC47C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6C7C84B21E30F9FB0F15D8E268EBFAC7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C5F88ACB8C72A84B028D8E268EC9A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_EAFD4EF2F8C2EC2A079CD8E268EC574E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8DA366A5276D1392CF03D8E268ED5A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_83C9832E5CEC94C94362D8E268ED3057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_F0D7231B366719930246D8E268ED9381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_E291C705BC90C4A099E1D8E268ED6A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9D63E3D0DA5501BFBF2ED91687B149A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E1FFBBA2AC68AF9E8AB3D8E268EC0444" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9314660CE2E55CC00251D8E268ED084E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_AB06EDB11BCDF98E20A3D8E268EE6E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F5BD1CEB7CD42075F0C7D8E268EE3295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13683635760FD84A5208D8E268EE1BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FD40A176276109FAEA50D8E268EE62A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D5CB1C22C695F6EDEBD8E268E5B229" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1761806E2F0BEDF290B7D8E268EEB949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:to="loc_us-gaap_InterestPaidNet_7B97F4C0246AE67B75A8D8E268EFD94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8CBFBD87A4DB0719A648D8E268EEC68A" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22A79994ECAB6C850B53D8E268EF3E52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:to="loc_us-gaap_ProfitLoss_7F88DD40916349A25BE475AA0F3FEB88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_197FC9216E8AA3B1CADB75AA0F3FAA1D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1B8336124D20185A6CA175AA0F3F41F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_D9BEEC8121BF6511973075AA0F3F38A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_29DB128019DBEC2DBEED75AA0F3F42E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C25F186E1015D60B149C75AA0F3F142E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F98A01423BE6CA9B456975AA0F3FADC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B0075C6EFF0F9BD4F90DCA249477C7F1" xlink:to="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:to="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B163807252203519956BCA2494783E8E" xlink:to="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:to="loc_us-gaap_LicenseMember_72F9B4C9A4581E380B5BCA249478A2DA" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_6365F3D2166D84E5C55DCA2494798D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E207D034321CDD7080C2CA2494785517" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_BF9A40434598B2535A3CCA2494799844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FF07B047A45FBC4E804ECA249477DE95" xlink:to="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E90F7E803C3C104DFF14CA24947AA44F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_EF816C79258D440DED8FCA2494790384" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E90F7E803C3C104DFF14CA24947AA44F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7AE759A3F504F7443C55CA24947A0A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0E3A572BE6CC0B2837C2CA24947B8AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_71B584309CEF841E89EACA24947AEA30" xlink:to="loc_us-gaap_OperatingExpenses_EC5B19B181E7AF32367ECA24947B8410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_OperatingIncomeLoss_B863F212AFCC9FB7C9C9CA24947B9EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_InterestIncomeOperating_E742EA27F7B5CF6036DACA24947BB72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_InterestExpense_6C5014EB4511925D3162CA24947C21EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_064882EBA22BAAB45235CA24947CB127" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_064882EBA22BAAB45235CA24947CB127" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_A38C4AAE383005BDB19CCA24947C842F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_C591CED25ECFC69DC374CA24947C5E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0FB8D08B99B2E095FBDCCA24947C510F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_99E10660995274052EB7CA24947D7714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8B93DA2DEB0EAAC8A7EBCA2FB12809BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9B9F67A7DA496C039202CA24947D7E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_755A812CA244C8BC1B97CA24947D4378" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_755A812CA244C8BC1B97CA24947D4378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_ProfitLoss_7532230DCD980F062B5ACA24947D4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6F72290721DB85871E4DCA24947EFEB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2484BEADF8FBD95E2C4CCA24947BFF95" xlink:to="loc_us-gaap_NetIncomeLoss_08025446C47922FFAF55CA24947EF7AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_37D9B820590D82091B67CA24947E5CC8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_EA585AD8D5F039766864CA24947EAC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6E96CC80C3E4DE46CE1ECA2494797F14" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A3CB02E2398FACED7720CA24947EA381" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78D74B814106E625A6D4CA24947EF655" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9A166DF1096C1920038FB92D69E5644E" xlink:to="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F2E65AFC773D7B34A84FB92D69E5ACED" xlink:to="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_F99CBD9FEE791A1B9531B92D69E5E4E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_PreferredStockMember_F99CBD9FEE791A1B9531B92D69E5E4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6FAFEF187DC2E5AD0D12B92D69E56CC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_CommonStockMember_6FAFEF187DC2E5AD0D12B92D69E56CC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_511EDC26045DC9F22B3BB92D69E52E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_RetainedEarningsMember_92BB8BE7235BF7282303B92D69E57513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8B1A6901E4E00DF2F767B92D69E5EE87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47D3CDCCDA875F05AA9BB92D69E5257A" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6AF08543F1ABC118F910B92D69E5B358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_231796BAE07F072A7F85B92D69E59F9D" xlink:to="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_SharesIssued_2E0F45992E32AEDAB7DCB92D69E58F56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_AE09BD60AA3239E9EDE9B92D69E518AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A29A7039DEC4AF999631B92D69E54B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_849006226A8DEB73BC77B92D69E5E659" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_FBAB1D24BE5376BF8197B92D69E5D336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9835104C67A865472C66B92D69E504C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6479EEA2A6C2F7C0CEC1B92D69E5ADE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AE1F380F793BB68C7CF0B92D69E52D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C0D2E79648E1DAE875DDB92D69E5CD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_569BA639FD98BEE799BDB92D69E5BC2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_554CB9F55CF54C798DE8B92D69E5EDF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_309B8D9BBCECF19B0F01B934110F5774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7E3697BBAD036CC9103EB92D69E523BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_ProfitLoss_8C80C60EDD8898F84771B92D69E5C9C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BBA447EC5A113FE8E3A4B92D69E5D4D2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_BBA447EC5A113FE8E3A4B92D69E5D4D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_SharesIssued_00BAC3F473A4EFA032DFB92D69E5BEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CB4F7FE81447911E4E10B92D69E5DFE7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BC6B91CF36DC1CE30761B92D69E5AF20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4943E90D65FFC40D48087A9E60D6FA97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4943E90D65FFC40D48087A9E60D6FA97" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_D0CE8E6948C42A4B10FB7A9E60D68A56" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EAD9510D58350DB287F0A643FA14443F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EAD9510D58350DB287F0A643FA14443F" xlink:to="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:to="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_91F5F47AE96735410DFEA643FA1571B3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_72EE5B5F5E329BC575E4A643FA16EEE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_72EE5B5F5E329BC575E4A643FA16EEE3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_8395B448B31C94162DD3A643FA169E52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:to="loc_ino_August2019ConvertibleBondsMember_8395B448B31C94162DD3A643FA169E52" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_619368AFCCDFE0D00972A643FA167348" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E1C95A526193BDCE51EEA643FA1555B6" xlink:to="loc_ino_December2019ConvertibleBondsMember_619368AFCCDFE0D00972A643FA167348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1C06BAF575B5CB66101CA643FA14B735" xlink:to="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_80D0DD3B61FA00D5CA80A643FA16A914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_80D0DD3B61FA00D5CA80A643FA16A914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4CD994E0737A61C5A525A643FA17CAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_086BEAA6D59F3236DE8CA643FA176B23" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_526867058B730F9FF451A643FA175656" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_ino_DebtinstrumentAccruedInterest_D558C10F96F18F02ECAEA643FA177A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3688FB4D5F65B453522BA643FA17511F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_567D197A79C423A7EAECA643FA16A444" xlink:to="loc_us-gaap_LongTermDebt_3688FB4D5F65B453522BA643FA17511F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B9774219837A88A6516FC948A14B018E" xlink:to="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC11C9BA1BBCD54CDB9EC94F14BEEAFC" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_A91A719D16650D0990A5C94F14C8C470" xlink:to="loc_us-gaap_SubsequentEventMember_61A83D782E7614515FECC94F37DF31A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_68C37DD92958CB555F1BC948A14BC1D6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B51CC222B23A4F55837EC948A14B590D" xlink:to="loc_us-gaap_ConvertibleDebtMember_9D4ABCE947D04CAE75D1C948A14CD5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_DBBB93C258DBC73CDBB1C948A14C56C0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_524C2D7E236ED1B3E1E6C948A14CA562" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="loc_ino_August2019ConvertibleBondsMember_939FB4A524AC11DB82D4C948A14D4163" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6B2CAA87BD26E373B758C948A14C0EF5" xlink:to="loc_ino_December2019ConvertibleBondsMember_24E6F68F2D1A5614DC05C948A14D1CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_6E88B0C99AEFA9FE520FC948A14D52BF" xlink:to="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InitialConversionPriceMember" xlink:label="loc_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="loc_ino_InitialConversionPriceMember_4D474AF755EA237500A5C948A14DE8ED" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AfterJanuary22020ConversionPriceMember" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_FB91FFCC34BD962A14A2C948A14E7288" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AfterJuly22020ConversionPriceMember" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_22C05BBFA0CAF1FE648DC948A14D3147" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_76833C18B4F3D72E6A67C948A14EBC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9AEAA754F1887E600DCBC948A14ED6B9" xlink:to="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9E16A4EBC889254A1F5DC948A14E3312" xlink:to="loc_srt_MaximumMember_FA8CACF3C9E24840CC53C948A14F2440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622CC571D6A0C3C1EF26C948A14BF67A" xlink:to="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_66CFBD09913FC096B41EC948A14F8772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9CEFF7471F594268E3E1C948A14FB92D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3CB952FAECB9CB6C15FEC948A14FDDE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_CAEE3E931D4A65869B85C948A150C824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_E4007CBD134C7D2C6325C948A150D1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_9DEBDE2929B693390B41C948A1508C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6B6220C0038A6FE63ABEC948A1507AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0B4C466C9915CB887D1AC948A1504274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_B830819F68AE8A29F0CBC948A15050F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_999AD1D67920496FEDE5C948A151BDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_AB5FAA3B077BEEEF2066C948A1515123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E43397AD41120B411A06C948A151FDE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0605C73A6707A0FBA292C948A151BE3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_InterestExpense_D910D5B98EF8CCB40D8CC948A151C16A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_InterestExpenseDebt_EBE467FB8A36D34E96BBC948A1517116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_DerivativeLiabilities_F77566E3560D48C2006EC948A15107DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_4D55114822C368EADE25C948A1527EB3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_BCF8FD6B8654E60AF612C948A15249FC" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C3A7091DC900CCFE1D8EC948A14FE3C3" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_D3C6A17DBD8AA1AEE174C948A15205EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D618FB284DAD2F5EB62E2E9F7085ED64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D618FB284DAD2F5EB62E2E9F7085ED64" xlink:to="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F8415A31B896C7C4ACA42E9F70856230" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_EEB35974C139D378DC912E9F708614C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_DA37EEFB7528837595E52E9F70867BC5" xlink:to="loc_us-gaap_ConvertibleDebtMember_EEB35974C139D378DC912E9F708614C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:to="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_77E078E267FD170E6F082E9F7086895B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_D5FD00AC3F4E825661FC2E9F7087656E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_D5FD00AC3F4E825661FC2E9F7087656E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_00C297372193D4408D512E9F7087C150" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:to="loc_ino_August2019ConvertibleBondsMember_00C297372193D4408D512E9F7087C150" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_C6804768086CEB866D582E9F7087801F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D65B6D56614AE9A6FD042E9F708793EB" xlink:to="loc_ino_December2019ConvertibleBondsMember_C6804768086CEB866D582E9F7087801F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_75E52C9FB4AAC040819E2E9F708534E5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3098EC814B0AEF2453892E9F70887811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B7EA06EF7FAD93CAFCAF2F1EA91DF055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D09B58474833C1F725982E9F7088015A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_A7319B7BEB8EAF15A9A72F1E012EED94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_97D41169CD463101FF242F1E0914D43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_LongTermDebt_34DCB43CAFEF6E2C83A22E9F708912A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4CECDA26059C7EB54F472E9F70892E06" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4CECDA26059C7EB54F472E9F70892E06" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_3D817B3DDA04E5F9AC8C2E9F7089913E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4B9108AB9CD67E20BC992E9F7087D7FB" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_3D817B3DDA04E5F9AC8C2E9F7089913E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_CFE4C24B60259B6FFA967A9E6041EBF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CFE4C24B60259B6FFA967A9E6041EBF2" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_F5EE4605D68B95EEFB0E7A9E604244DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CFE4C24B60259B6FFA967A9E6041EBF2" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0B217929AD415C2CA5FF7A9E6042E1FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_DocumentType_454A02F5106BE72121433278C64F0B60" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_DocumentQuarterlyReport_C67D2D74BB90D25F072E3278C64F6357" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_DocumentPeriodEndDate_58FF2895CAF6663D10253278C65034D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_DocumentTransitionReport_CD84E5AD3D9F406C6D0E3278C650F8A2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityFileNumber_0F431D5E5EB660A17D1B3278C650B199" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityRegistrantName_407178869920567CEEEE3278C650BEB0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityIncorporationStateCountryCode_A9B790D5D1582ECB3AF03278C6500AAD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityTaxIdentificationNumber_F898F10B96194E9F07AD3278C6505517" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityAddressAddressLine1_5E6A155F19F92671C67E3278C651E8AE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityAddressCityOrTown_E90D9D390CE655B916AF3278C651204E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityAddressStateOrProvince_73064321E550DD3D20E63278C651FC50" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityAddressPostalZipCode_CE6780BEF14C9945E5163278C651D877" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_CityAreaCode_E5AD6AD52786ACD039203278C65134FF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_LocalPhoneNumber_42CACE99ECCFE52B6B3F3278C651B980" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_Security12bTitle_85D5C418CA4B6BBB02BA3278C65153FC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_TradingSymbol_E8974E67C7850B6FBE7D3278C652BA95" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_SecurityExchangeName_8DF96C7335CAA92C7ECF3278C652F37A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityCurrentReportingStatus_F0E725944E9030E6BB2B3278C6522F46" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityInteractiveDataCurrent_1086E3C91906579ABD533278C652F19B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityFilerCategory_5377F3F89DECD5D782083278C652E9EC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntitySmallBusiness_9904FD1C10E539A238C23278C652DBFC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityEmergingGrowthCompany_02D5EAAA49C0D5F588243278C6521BFD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityShellCompany_2AC5F2487F055DFBF7383278C6537A68" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8473265E8B41050EF17C3278C653D01D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_AmendmentFlag_1A9C73FC9DAC7796088C3278C653AE21" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_DocumentFiscalYearFocus_C19E5D711B7D469DF2293278C653DD7B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_DocumentFiscalPeriodFocus_B3A4206128A10E7EBD843278C6535508" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_EntityCentralIndexKey_53A49F29DAF83079F1803278C653B86E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C4F8EF1A7699E69EE7E23278C64F1EDA" xlink:to="loc_dei_CurrentFiscalYearEndDate_240E56C5F52B2E45A28B3278C654E4D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F0CEE39B5D81AEE7860A7A9E60AD655A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F0CEE39B5D81AEE7860A7A9E60AD655A" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6F7982A20537FA845FD37A9E60AD2259" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C4FADDD22DF0839C424ECB7E042EF3F1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:to="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6DC6C35A7B2C1148223ACB7E042E425D" xlink:to="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:to="loc_srt_MinimumMember_63DB81519D84A28A8ECBCB7E042E80BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_832906190D582BECABF6CB7E042E2BA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45A153104AB532EB908FCB7E042EB2A2" xlink:to="loc_srt_MaximumMember_832906190D582BECABF6CB7E042E2BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8244512F6772A5EC8AC1CB7E042E2CC5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_775E7E6BC37FC30D8526CB7E042E79A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_73AEFBC33BFCD15C629ACB7E042E1DA0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_44FD157244405D05C000CB7E042EB528" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D5ABBFDFB4BD39694D2B7A9E5F50A4AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D5ABBFDFB4BD39694D2B7A9E5F50A4AD" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_DA31C8D02475DF23897A7A9E5F50E128" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CE8D5AC5DD3F2F2F43CDC7EFA9C63DAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CE8D5AC5DD3F2F2F43CDC7EFA9C63DAD" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2AAD9E7CB27B826C3DE9C7EFA9C6FBA1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_89BB92BDCF58316A1165C7EFA9C65A68" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_81D534EA7993E6C0AA48C7EFA9C656DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E6421423193797AE6E71C7EFA9C798A2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_us-gaap_MoneyMarketFundsMember_897950830CF6F7D4DA45C7EFA9C7742B" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_ino_MutualFundsMember_D4264E6A766F30E52648C7EFA9C722EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3D8DD23738B3D1DBA682C7EFA9C84FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E048C28225FBA607329FC7EFA9C7D966" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2E6A2CDF23DACFB98D23C7EFA9C8A6B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_02F907FFDA35D17DB37BC7EFA9C871DE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_221AD755492B5B5928B1C7EFA9C8BD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_44B3F6EAB3B748A1B12DC7EFA9C99296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1707101372A12D46BF13C7EFA9C8FBD0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_698F7F52222848A60372C7EFA9C90755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_62D55E31329D4ECBAC48C7EFA9C613E7" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_AD594C9C53AF6DBB7014C7EFA9C95E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79DD121D2BE608D9EF88C7EFA9CA9C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_BA9CAB6509D40DA9407BC7EFA9CADB1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_BA9CAB6509D40DA9407BC7EFA9CADB1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CFC56B52B8621E87741CC7EFA9C911AE" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_CA6DE88B06698106F5A6C7EFA9CA00EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_A88F27833C986726709FC7EFA9C92038" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:to="loc_us-gaap_DerivativeLiabilities_0DE34C3458E3A0A166ACC7EFA9CA2296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_A1DBEEC1B966475C7FEAC7EFA9CAB858" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5F9219FCB7786AF437B7C7EFA9CB7F69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E101035C12FEDE4BCA8F9C3ABDB0AE69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E101035C12FEDE4BCA8F9C3ABDB0AE69" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BE8E4DCFDA1913FADF959C3ABDB01D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57B0310CC2BB301BC7AE9C3ABDB09E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_A4E21E97A746B28C68749C3ABDB0FAD5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB9D19E18B078C5064AF9C3ABDB0C339" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A7E24451D744B2931A8CC9B4277069B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A7E24451D744B2931A8CC9B4277069B1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2BF5EA4E6B35FE4261E9C9B42770B9F9" xlink:to="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_795CAAD3A1EE29CFA3D3C9B42771EA4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_36FF6DD0F71E2250BD83C9B42770F5BC" xlink:to="loc_us-gaap_CommonStockMember_795CAAD3A1EE29CFA3D3C9B42771EA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4DD0900210594F6ABDA1C9B42771477D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8E7FEC3CCCC4687488F9C9B427723CB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D5577868915DD9859397C9B427711F3D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_75A0A7B135F8A63CB6EDC9B427723ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_FCE58F98ACAC77CCD8A6C9B427720999" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1ED8CAE3A11BD6D9248CC9B4277069ED" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_FCE58F98ACAC77CCD8A6C9B427720999" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_FCE58F98ACAC77CCD8A6C9B427720999" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_E8A77923997ED02D4FDEC9B4277201D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3385B16ED440DE327BFBC9B427739A7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3385B16ED440DE327BFBC9B427739A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_EF90FD1C16D1A95A54ABC9B4277262AB" xlink:to="loc_us-gaap_DerivativeLiabilities_34A771FBD183E0D5BE11C9B427736207" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C875145D737E9D571871CC035FE27747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63FD0A38DFB1E00AA370CC035FE1E623" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D1323788BA4B3D1A46A1CC035FE2D5CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_8CEFA1E0E4BBCA5CA9CA7A9E60AB6D73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_8CEFA1E0E4BBCA5CA9CA7A9E60AB6D73" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F9CB278219E6ED698ED77A9E60AB1641" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_F15457BF06015FB9C07ED5FEFEB912E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_F15457BF06015FB9C07ED5FEFEB912E3" xlink:to="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:to="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6B6B415ACB6F3C09AA79D5FEFEBAA770" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_16ADE5D17C9F2780F8D5D5FEFEBA6B6D" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_C8DAF9F9242364BD2004D5FEFEBA1B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_F433A69472D590078CD3D5FEFEBAFD49" xlink:to="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_WorkingCapitalExcludingCash" xlink:label="loc_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_ino_WorkingCapitalExcludingCash_8731F9B8807795579738D5FEFEBB193F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_NotesPayable_9F3D75A96FAAD8081A9CD5FEFEBBB08B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ADB013AD2B440DC5B671D5FEFEBBB0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_MinorityInterest_907BAABB34D436A8B596D5FEFEBC8D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_28570D2A424A3209F281D5FEFEBC340F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_400F35DDFD39950021A7D5FEFEBC40E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_C3BD26E94327E4524EF1D5FEFEBB589C" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_2AFF2D204714C5B2E388D5FEFEBC0D5F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3FC4EF32874A7EA7B79EBC1FAB7F95DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3FC4EF32874A7EA7B79EBC1FAB7F95DB" xlink:to="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:to="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_486560F1EA53E96BD048BC214A80825C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_8B50ABC9D2D8C4798668BC216322CEF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4047F57FDE9A99C45A22BC214A81EAD7" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_8B50ABC9D2D8C4798668BC216322CEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F7EA9EA8492525A98B13BC1FAB81ADC4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_CF8B779910DED2994AB9BC1FAB823D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_EE8E57B990F291B5BD56BC1FAB82ADD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_E9232534321F3DEC56F1BC1FAB8186EE" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D6D6A8A393758206431ABC1FAB82166B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_FA78D564076BC573E72BBC1FAB7FDA30" xlink:to="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AlternativeInvestmentMeasurementInputTerm" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_8EB961A5E41DCFEB6E27BC1FAB847205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_2DBA0095A24E250467DDBC6EFAB7936A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_EquityMethodInvestmentEnterpriseValue" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_CF6EB5D75A446252666BBC1FAB831312" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_66EA58D0A18C23499502BC2DD52A7302" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_74D31A8B69AA5E63E26FC9E6D7B1268F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_74D31A8B69AA5E63E26FC9E6D7B1268F" xlink:to="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6D2C933AFDC25FADFF5FC9E6D7B2E755" xlink:to="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_90B97A783EFBF174FA93C9E6D7B27D10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:to="loc_us-gaap_CommonStockMember_90B97A783EFBF174FA93C9E6D7B27D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B9C73D35BCBC5FF21A07C9E6D7B229A1" xlink:to="loc_us-gaap_PreferredStockMember_B1AAE386B2DAD3FA36ADC9E6D7B20A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:to="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_54DA0F95416D1C4193B9C9E6D7B3218F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_D9BB10A12E5A9158DE0CC9E6D7B3795F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78C9709B35B26F3E734AC9E6D7B31941" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_D9BB10A12E5A9158DE0CC9E6D7B3795F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_13F48EBB511CB8F50070C9E6D7B1CFE5" xlink:to="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_F55C244771BA3EA15A45C9E6D7B4F9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_SharePrice_3650397ACC3505F79727C9E6D7B406E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_690C32B691A1E0F94439C9E6D7B48AC7" xlink:to="loc_us-gaap_EquityMethodInvestments_49C715F2D7D61234094AC9E6D7B5DD5D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_903DAA69DE55AD0EDEEDCA2492A9B2D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_903DAA69DE55AD0EDEEDCA2492A9B2D0" xlink:to="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_49D91C96109A23B7E517CA2492AAF328" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_B86221EB6E79D2BBB4E2CA2492AB36C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_170EF52CE7E1D6DD0709CA2492AA825C" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_B86221EB6E79D2BBB4E2CA2492AB36C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_C5667AAA7C18DEADB427CA2492ABB630" xlink:to="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_283DE9E9280656F21B04CA2492ABF5DE" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_B86221EB6E79D2BBB4E2CA2492AB36C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8E517649720F682FF883CA2492AC293C" xlink:to="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DD3423F0476EEEFB119CCA2492ACA1AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:to="loc_us-gaap_CommonStockMember_DD3423F0476EEEFB119CCA2492ACA1AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D5BE9C98157EBF12B767CA2492AC116B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B28BB5451B14CF62B48ECA2492AC67DB" xlink:to="loc_us-gaap_PreferredStockMember_D5BE9C98157EBF12B767CA2492AC116B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8CB58C0D62A44ABBD36CCA2492A9AEE6" xlink:to="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_670A8D8CC8AB68C8154BCA2492AD6010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_44B7A3688F97C26D90F0CA2492ADD529" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_8F9B76E6C43A4F752D9ACA2492ADE8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1FBFEF7465D7F485DF22CA2492AD4E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_344DFFE371334D060923CA2492AE3B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_BC5D0111FB8CB4640C95CA2492AE022B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C8A041A1159749899ED0CA2492AE67A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4A085CDA6B52E12248DCCA2492AE81DC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_EquityMethodInvestments_4A085CDA6B52E12248DCCA2492AE81DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_582FE3CC2526FE297EBECA2492ADFB96" xlink:to="loc_us-gaap_DueFromRelatedParties_E847905A813AF63A03E5CA2492AE211A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_514BBC07291E95A06E5BC9ED54600661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_A72793B30B164CBA1D97C9ED545FA72F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_857C621B7F4A0C2302B5C9ED5460D8CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62106110A1ECF8886F817A9E5FE5869B" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EDE213F3949BDF2DE01A7A9E5FE5B191" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5E4243992A8CB944C84D2E9F70B5A7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0C9C89CE6215B0194E822E9F70B6FD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7EE0302BBF24AF4D624D2F040AD12D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_C06724B25818406C9DA82E9F70B61304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_49F8C14D53E1E55453AC2E9F70B6A54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_45593FA9342E0528B9BE2E9F70B6D36C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8A93C3044C691411E11B2E9F70B5B1F3" xlink:to="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_B593BC1FCC9E7C4803672F04E0A017C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C6D97120D0A693110C8CCC035FAE2B56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C6D97120D0A693110C8CCC035FAE2B56" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5C7870B6E59566CF4C65CC035FAE2748" xlink:to="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A3FC4FBD46F5A6D36480CC035FAFA4BC" xlink:to="loc_srt_WeightedAverageMember_039E698BC4F0FA150307CC035FAF8797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972EFD67256768277189CC035FAF093F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="loc_us-gaap_LicensingAgreementsMember_C527477304ED1B1EB8AACC035FB01C6D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_650E332E7E6D7BCF9F78CC035FAFDF72" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1DC334CB8C61203FFF7ECC035FB0FA08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_008B676417AA9C2D3D4ECC035FB0CC85" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InovioAsMember" xlink:label="loc_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="loc_ino_InovioAsMember_A7BA0453D8BDCAA60CFBCC035FB16B1C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_VgxPharmaceuticalsMember" xlink:label="loc_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="loc_ino_VgxPharmaceuticalsMember_F0104EDCC5D767669F2ECC035FB1AA44" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1CB8EF7A640F08C5E918CC035FB04B4B" xlink:to="loc_ino_BiojectMember_DCF9D75A720446D8CD71CC035FB0B100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6A73E6268F6588AB2793CC035FAED418" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_B86A9566C83269BB6A49CC035FB1ED2D" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:to="loc_us-gaap_GoodwillGross_B4FF7A066834B8DE352DCC035FB27087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_35D406EC0E9DCF8E92A0CC035FB215F4" xlink:to="loc_us-gaap_Goodwill_DD39B9B71BD17488076CCC035FB2D09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2745CD7AF5D6B719EE9FCC035FB38921" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2745CD7AF5D6B719EE9FCC035FB38921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9C043D80E0A744124A4BCC035FB38B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_359D7D15C3F1805D3D71CC035FB37B3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FC8240C135FD8F054481CC035FB22718" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C0284AB205B1E0498264CC035FB3B8A5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_E02606D7A5B21ABDFE73CC035FB3AA42" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1C3B796E5DA0CD2BEAAECC035FB1E0D0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_12A706DE9328A5B1A1F5CC035FB3765F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8F8DE0604940A12BF055CC035FB7D566" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8F8DE0604940A12BF055CC035FB7D566" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51163473BB8984AE9086CC035FB709E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7BFCC03927A2F86C22FA7A9E6043D7E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7BFCC03927A2F86C22FA7A9E6043D7E1" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_59F378D1060A8FB2806F7A9E60448265" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9858A68CB7B61C2A7EC97A9E60520D6C" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7DCC269C01E645CC34C27A9E60521C77" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_8F4EB3A2F8EDF72810617A9E60231BBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8F4EB3A2F8EDF72810617A9E60231BBF" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9ECDB51C35BD44A39B3A7A9E60248C5F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_E95889B2A56E347EB2913278C4B21357" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_E95889B2A56E347EB2913278C4B21357" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:to="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E02B91BCEA7997374F283278C4B2A657" xlink:to="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B37727F2F3F26F63DB3B3278C4B3D4AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:to="loc_srt_MinimumMember_B37727F2F3F26F63DB3B3278C4B3D4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DDFC7D0630FE6A2E169A3278C4B35C04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1B82619A0D00E6CE04673278C4B2ECDD" xlink:to="loc_srt_MaximumMember_DDFC7D0630FE6A2E169A3278C4B35C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_CB41E8A06FA5DB59F2313278C4B3B357" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SanDiegoOfficeMember" xlink:label="loc_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:to="loc_ino_SanDiegoOfficeMember_5D25A2DDD73A276F67193278C4B4ADFE" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlymouthMeetingPennsylvaniaMember" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_166DCFBADE33576497C93278C4B3543C" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_6680AB726D57863334B13278C4B413F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_D3BB11C7ECD511414CE03278C4B27394" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_1782D71BE49DEAB7EE393278C4B431D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_us-gaap_LeaseCost_0FBE052B0820F80C56AB3278C4BA8ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_BE1B3BFF6DA36949106A3278C4B46BC7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5B2510938072AEB184FD32A446375C08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7287FDEA9FF97743D132D8E2674E1D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8E7729092714D51F0586D8E2674E5648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_72E30AB76AA390CFAB57D8E2674E9A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0B2A67BC75F4A0B44D28D8E2674E4CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3FFCCBBEA85EBC07DB5ED8E2674F477A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_F5260602708A44B4C1BDD8E2674FE314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AE67AFD1A87437705105D8E2674F7D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D37E6E4B25A10468CF76D8E2674F4ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_OperatingLeaseLiability_B374CF1B6180CA281721D8E2674F6406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_59A7C23FB0B41926C85DD8E2674F779A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_FF4BC6C5A89A5FEC36B2D8E267500F74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311691BA1FF61E669999D8E26750C81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9BD6F295704D16DF7490D8E2674D5DC9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_D77C8F044FDAE1BA6786D8E267504C01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90C8D9E815C19061721B7A9E60A9DA3A" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_FDA6BB65BF561ABF27627A9E60A9A1B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7192248B90C983204CFC7A9E5F77CFF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7192248B90C983204CFC7A9E5F77CFF9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9FC3AEE4213F172ACED07A9E5F77BA31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_939D1B920E5299A22D06A643F9C96550" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:to="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_18ABA834C81C79D96542A643F9C9BA25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_C32A572B18AD68B340DAA643F9CAD60D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_C32A572B18AD68B340DAA643F9CAD60D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_9493922370B7F2BF5D05A643F9CABE9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:to="loc_ino_August2019ConvertibleBondsMember_9493922370B7F2BF5D05A643F9CABE9D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_998E81F53A0194D4FBDAA643F9CA76D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69E44B531E253064F8FEA643F9CA03BF" xlink:to="loc_ino_December2019ConvertibleBondsMember_998E81F53A0194D4FBDAA643F9CA76D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EF781D0642AC95E7D56BA643F9CB16B9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CD10B4C5D10CA9F551C4A643F9CB1668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_WarrantMember_F7172EB48F23772AE07DA66F3B605816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_AB23BA5DEA6B353E72CFA643F9CB5B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_A40EF7DF53BE21B75F9CA643F9CC005A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_24829A5E5B78460A9FC2A643F9CBAF5E" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_692F77A471AA6FAF208EA643F9CC9DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C7F4CE9D17F8E02A724A643F9C9B1F9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_988C14A9584149E237D1A643F9CC0CE7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7A20FB9EA9E406D7F289A643F9CCB089" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4CDF728F55835D595AE47A9E603B528C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4CDF728F55835D595AE47A9E603B528C" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_294CD50760814473CDDA7A9E603B9CD1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationAndOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C3F22370202DEA50BE7A7A9E60587769" xlink:to="loc_us-gaap_NatureOfOperations_7AE144071BCD9D990CD77A9E6058C33C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_AB2294A1DD857BB18A397A9E5F50C6F0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1802C10002246284574D7A9E5F505283" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_5F047AF5A8341FA7852B9C3ABD21F794" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_5F047AF5A8341FA7852B9C3ABD21F794" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D5F8939EB3CE1486E7559C64D83C4305" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_7C4CF7099E7F1A8EE3EA9C3ABD2339CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7AAFC96258A27C5ED37C9C64D8479E8C" xlink:to="loc_ino_PlumblineLifeSciencesMember_7C4CF7099E7F1A8EE3EA9C3ABD2339CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8C5AFAD195210910E6F79C3ABD22BCCB" xlink:to="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:to="loc_ino_GeneOneLifeSciencesMember_E719C1AFA9048DD7ABA39C3ABD22CA11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3CA98C3F38CF1105A8EF9C3ABD222A2C" xlink:to="loc_srt_DirectorMember_E45AB6376E58BC1DA13F9C3ABD22C723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1104E869A3CA2BE6D68F9C3ABD230FE5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_406B60C69522D9E4EAF49C3ABD234047" xlink:to="loc_ino_PlumblineLifeSciencesMember_7C4CF7099E7F1A8EE3EA9C3ABD2339CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_99A5D969C1DF8D1942259C3ABD23658B" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_DFB4B470E28848C96BDF9C3ABD24065F" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_7AAA87A6FEBA8DDBB5219C3ABD245EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9A14C5DE02AD9F1DE79F9C3ABD21DFBC" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_E90D9C4E5AE40E7239739C3ABD24206E" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_12E9F4F2789183A13C429C3ABD2448BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_12E9F4F2789183A13C429C3ABD2448BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_C5C4E81C88241E6FB8BA9C3ABD256C3D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeArrangementTerm" xlink:label="loc_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_CollaborativeArrangementTerm_742CF78320FA2EBDC0F39C3ABD251F43" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MilestoneBasedOwnershipTarget" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_MilestoneBasedOwnershipTarget_A5186A34B79752423FBC9C3ABD25B82B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7B57DB588E117013ACD09C3ABD257FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_A581E397C9A43BB311AA9C3ABD25D4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_7B989179A17FCD8D2CD79C3ABD25B918" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_7B989179A17FCD8D2CD79C3ABD25B918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_BC9D7C51F5F13A96D3AB9C3ABD264923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_83719771D147186969959C3ABD268651" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_InvestmentOwnedAdditionalSharesAcquired" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_InvestmentOwnedAdditionalSharesAcquired_AFFBD8A619DE2B0B9DCF9C3ABD26650D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_99A247A96952D8A9BFB59C3ABD26529A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_99A247A96952D8A9BFB59C3ABD26529A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementExpensesToReimburse" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_08DBEF1F38C63AE29F0C9C3ABD266B89" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_CollaborativeAgreementAwardedAmount" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_3718FF088CBD9BBD94B19C3ABD26F08F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_GrantProceedsReceived" xlink:label="loc_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_GrantProceedsReceived_B5247916CC5622655CF89C3ABD27FDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8BB103BD87D4800289829C3ABD275C23" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DeferredGrantFundingFromAffiliate" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_0A3B51DA74247C21E17D9C3ABD24A5E6" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_1497A32B18D46B2C7F469C3ABD27CE00" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FEC2ED308B84393A5E877A9E605A686E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FEC2ED308B84393A5E877A9E605A686E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_33ACE9E1331EE4A15ECD7A9E605BC0F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EBAD43C9D9D1EA409B6F3361BDB15D3D" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:to="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_BA8CBDF05D6CC82162463361BDB1EED9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:to="loc_ino_PlumblineLifeSciencesMember_AD5DD4D1E7B1708A6D343361BDB13FF4" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_AstraZenecaMember" xlink:label="loc_ino_AstraZenecaMember_1FD0704E32E59AAB72D83361BDB1214A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:to="loc_ino_AstraZenecaMember_1FD0704E32E59AAB72D83361BDB1214A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_OtherCounterpartyMember" xlink:label="loc_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CABF2B516AB9DE9A8C593361BDB131F2" xlink:to="loc_ino_OtherCounterpartyMember_9F728B0970C73CF7CCBE3361BDB1B4E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F3D3191348E4259924683361BDB10BC7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3C53B26CA06693EFF1353361BDB165D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_38D5032DD802200A2E5D3361BDB1E84A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_598002CD2196BF0D53953361BDB1FCDB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_31389C263B243F2397217A9E605EF308" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_31389C263B243F2397217A9E605EF308" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4E33F12D16614D879CF97A9E605F7E0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FD29EF75A0C194F3220DC01B4F50E043" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FD29EF75A0C194F3220DC01B4F50E043" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_401559541D9B97400C2AC01B4F509AF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FD29EF75A0C194F3220DC01B4F50E043" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_BACF05ACDDA1F9C48F9AC01B4F5165F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FD29EF75A0C194F3220DC01B4F50E043" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_CF58F3B19AD1C157FAA0C01B4F511B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FD29EF75A0C194F3220DC01B4F50E043" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_CBD0465B6E84AFDABF96C01B4F5142B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FD29EF75A0C194F3220DC01B4F50E043" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0A2BFB3493ED2A678025C01B4F519D98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42932F3A2526254079413361BD8266F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42932F3A2526254079413361BD8266F4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D48289FE17DA3A082EA13361BD82894E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="loc_ino_MutualFundsMember_8123C783D09666FDAAE73361BD822C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_28EFCFCB7B82265A7CD73361BD820677" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_28EFCFCB7B82265A7CD73361BD820677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_915A6F61C0054D486BB43361BD82B0D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52714E3E2522E9C2B6E83361BD82F5D3" xlink:to="loc_us-gaap_CertificatesOfDepositMember_915A6F61C0054D486BB43361BD82B0D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67937A2D2414C49F174E3361BD82609E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_5F6E2BF9C3A296BEF9FC3361BD82B789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20286BBA74EB8B3E11173361BD825F25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6433A4B097463255B4303361BD8248E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88C979DAD29A760E7A5B3361BD822CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7E5DB56AA26CF9A0C2C3361BD82F423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_F55C6BF66BA7E9B1E32E3361BD82520A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1BF226BB687D5EBBD24D3361BD822210" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02E0E671D8094FF1B8DFCB7E040FE29A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_DDBB92E6161B812D1EAECB7E040FE263" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5B0B52A88F836991059D7A9E60603411" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5B0B52A88F836991059D7A9E60603411" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_E2B3612E7916BCA6A39A7A9E60600D70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C2EA913391D7264E14B95A264D84ACA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_50DA22DF106272AEB61B95A264D86B6D" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_EmployeesAndDirectorsMember" xlink:label="loc_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:to="loc_ino_EmployeesAndDirectorsMember_EC090E690799D87B0B4495A264D8E3D1" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_A0FAF26A6B6A67DE0AFC95A264D8E4D8" xlink:to="loc_ino_NonEmployeeMember_583B5B29542F620BCC8995A264D812C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7CDA469D90E8B60FCFDE95A264D8CCB9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17909B51EAFB475B640095A264D801BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2FF4C7C5224F8092035095A264D8C000" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8EC6A7048B3790A702C895A264D834E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0925A962002528138BC795A264D86993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_554BFB6962F29BA2D85895A264D81B91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5DD2720F123F5665757295A264D8245F" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88B5BEE123B97A84FADF95A264D8669B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0B326A84567A0AEED64795A264D88693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6153F29BD1F276AE8C9395C4DCBF80FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F2C085812338A1BB3A7595A264D80586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_274B343F8AE1628D4A2295A264D8AF11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_56C16DBAFEDC67BAA1CE95A264D855B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8CC1FF8B577F5E4ECB6C95A264D8BAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensation_5ACAE0EA6D4C0C8DE0F795A264D801A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BF18DF6AEBB07C4B283895A264D8C83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_E000BD3D879A543769FC95A264D85B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46939CC00D2AE232736A95A264D8CCA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BA3C9F8D42E1C9F13F595A264D81C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EB732E560623519D222795A264D8CBA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FC19925F882FB2E2EC7795A264D89C6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_734023C5EC9AC08F39777A9E60B1C397" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_734023C5EC9AC08F39777A9E60B1C397" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C763E2528E44070772477A9E60B10423" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_06D3E78D5751324FA24E7A9E60AF9C60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_06D3E78D5751324FA24E7A9E60AF9C60" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6B2DD612A2F01604AAAF7A9E60AF4DFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4E03359BB5DCFB33D4CA9C3ABD568B8B" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20347D279E6AA316CC899C3ABD57DF08" xlink:to="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:to="loc_us-gaap_CommonStockMember_6F5F39FC40E0CEACD1F29C3ABD57A335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A7DCC2439B77D0F5A0AF9C3ABD57863A" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_21B2C1B3E06BF7F243559C3ABD580EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8704FEB692E1D47E69CA9C3ABD585E8A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_PriorSalesAgreementMember" xlink:label="loc_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:to="loc_ino_PriorSalesAgreementMember_29F689E843BB7CB109EE9C3ABD58D049" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NewSalesAgreementMember" xlink:label="loc_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DF1D7614A942F70250B49C3ABD58B41A" xlink:to="loc_ino_NewSalesAgreementMember_D36C1F79BDD29E6113519C3ABD58C67E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1FF1B71B325C038E1DD39C3ABD58B6D2" xlink:to="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A2016IncentivePlanMember" xlink:label="loc_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:to="loc_ino_A2016IncentivePlanMember_D07BAAF7E54AD5A877E29C3ABD5983FE" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_A2007IncentivePlanMember" xlink:label="loc_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_EDECE84F9232709ECED59C3ABD5945BC" xlink:to="loc_ino_A2007IncentivePlanMember_C59C1E538A7B426F40D59C3ABD59D925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2094DF37BF9C4D3053739C3ABD561E34" xlink:to="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_CE32A6D487A8B88484809C3ABD5A4A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_F2457EF31577C3C12FA19C3ABD5AC86F" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20C002191A7056504E419C3ABD5A1698" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_AA95CA565768352F7DE49C3ABD5A3CDA" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSalesAgreementAgentFee_9052FCE4684AA14BF0849C3ABD5A24C4" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1772DD8F182EEDD4BE199C3ABD5A89DD" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_876521418BDDBA1FEACB9C3ABD5B51B5" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_2E2058F3EE3A04D2E0269C3ABD5B8220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_CAA949F2FC0F99E626889C3ABD5B1A03" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_8813D4B4A0795E5D63089C3ABD5BA08D" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_D9997038EDD5C25A99FD9C3ABD5B65CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D560F4F539CFE0CAE6B49C3ABD5B3EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8201D1D2FAD019C77CA79C3ABD5CD5F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_C951E2B57D8D800A0CE49C3ABD5C5235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02B5EBD6BC500358F9539C3ABD5C8764" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3FF44119272AB47F3CC29C3ABD591570" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_1315FD91839CA9500FBE9C3ABD5CE444" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_BE72CF9EBF0F0D05168C7A9E604A1BC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_BE72CF9EBF0F0D05168C7A9E604A1BC2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6FDF2665C10DCBD5AE347A9E604A5EEE" xlink:to="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_83626D07ADE26E37D1E97A9E604BF450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D630996190BC74492DF77A9E604ADE4A" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_83626D07ADE26E37D1E97A9E604BF450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_20BB704586BD351E2C637A9E604A85CD" xlink:to="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AF9F446726E9B8E9D7A47A9E604B2C18" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75C5EEACB0D5183DDD5F7A9E604B51CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DCB782CEEBA72EF4CE507A9E604C88F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7E67B3E67B93FD037C3C7A9E604CAF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_EAE3F9AB1516F4D7EB9E7A9E604C9294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829DB40C8450BF20D9AD7A9E604C907E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8AB9C3BAD2125CFADDB67A9E604CB1EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0982AFF929DC0D446ACC7A9E604CE208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5BEE592C1B4656F0AC5D7A9E604B70F2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_DA785A60FBC25BD1B3DF7A9E604CD93F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6836EE1BF22EA2398695CC82C2172FAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6836EE1BF22EA2398695CC82C2172FAA" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_CFA10D36C457BEBDBB71CC82C21742D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E10F4B5FD5EEE95FF9C17A9E604671E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E10F4B5FD5EEE95FF9C17A9E604671E6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_DE2BE3C39B5DB9AD0F637A9E60463B47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_90EF1C0AB883DAB6A2BEC9EAF3580F54" xlink:to="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_399B604922872ABE6572C9EAF358DB21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20" xlink:type="arc" />
    <link:loc xlink:href="ino-20200630.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_459CB0C5607154BC0637C9EAF3592343" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0317A944DF3618009C3DC9EAF3588D20" xlink:to="loc_ino_August2019ConvertibleBondsMember_459CB0C5607154BC0637C9EAF3592343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_550DDB79ED798AEB9B64C9EAF359CB06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_2271A94DC6C8FF017D0CC9EAF35B7748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FCA48C0FC9BB405AC411C9EAF359108F" xlink:to="loc_us-gaap_ConvertibleDebtMember_2271A94DC6C8FF017D0CC9EAF35B7748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E9A185BEA71257A776CDC9EAF35B701B" xlink:to="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_954DFF3B5D2F8A73B0BDC9EAF35BCB46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1DA1795C299B597F6144C9EAF35BFEFE" xlink:to="loc_us-gaap_CommonStockMember_954DFF3B5D2F8A73B0BDC9EAF35BCB46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_088382605AF87606D378C9EAF35CEFBB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_925A8FFBA1664DE68E44C9EAF35C2690" xlink:to="loc_us-gaap_SubsequentEventMember_A4D8E228982107ACD1DCC9EAF35CFE2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_DC8D25D617CB5AA2E8D3C9EAF3586755" xlink:to="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_8A4B735F241198ECF161C9EAF35E7DAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_8A4B735F241198ECF161C9EAF35E7DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_98ED508FBD3BEF53ACEFC9EAF363FC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_BE7EC8D28D8CBC3761B2C9EAF3631B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_LongTermDebt_852AF1DA14020BCDAE31C9EAF3644719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4779263F4994C6597A4BC9EAF3645890" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_D1B990C9850FA286E40CC9EAF35DCA45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4779263F4994C6597A4BC9EAF3645890" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>inoviologosw.jpg
<TEXT>
begin 644 inoviologosw.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B^?;RU6OU//9KPL''4\LT<?3SQQU=9-QSRW'/'/+<
M>] ?01<2L:]P<+CXV:Q,75ST^)D:<?5QQSQU3-SQRW/'NY;GWLO0L;IZ8B;J
MDU'@8QYXYDR^/!N7YX;DK#-SY/Y<_(Z YXBZY_FPZ1_33IS_ /#F,_\ 4K]X
M-U]+2N[1:EP$CLW+M'F<<;LWU78;+\,@.?HN'P[AX"0F"/.8>0WYX$,G2(GX
M;E^!&=W?AFY?ZC>?N7V:VH*$S.\-VI*S.S.\5F&1F=_<S]!OP[_(R ^NB\+R
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$<7>K[M
MZET1LYE]0:3S%K!9J#,:=KPY&F,!3QPV\M7@LQBUF&>+IFA,HRYC=^'Y%V?A
MVJW_ ));OU_9/U!_@L/_ +K5DSOJOB$SGV>TI^'*JIH(#./\DMWZ_LGZ@_P6
M'_W6GY);OU_9/U!_@L/_ +K6#B(#./\ )+=^O[)^H/\ !8?_ '6GY);OU_9/
MU!_@L/\ [K6#B(#./\DMWZ_LGZ@_P6'_ -UJVOW=6XN<U9LOH74.I,E/E\WD
MJ62DOY&TT33VCASN4K1%(T$<,3.$$$43=$8MT@W+<\N]$57ANZG^E^VX^Q^7
M_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %66[\[O9I-$5;>S6VN38-
M996G)#K//T9C&?26+NP!X>+Q]F Q*#4>3KS/(<P$TN'HN,HO'=MUI:TEG>N=
MX'4V VTM9:D5>SKC4+R8?1.,F<2%\@8-ZSFK<+\N>.P-<_79@<>FW:]2QSE'
MZX\T5!+;#;O-;A9W(YO-7;=M[F1GR>H,W<,YK>2R%Z<[=M_'/SFO6Y3DEGE=
MW:!I/%-O:BC.N/C[XN4Z%A6XM=ZINE5SY5R?O8]$^D:Z]GO](O>RC%>\H--+
M>R$EJW%/$-.!CV666*N,8[SGZQ3Z*,5W<YMI12Z]5MU:/A[0;-W-13=0L5;'
M1%TV+KBS^?O>&!BY\2<O>[NSA'SU2>;B!R2Z7T72Q-6.G0@&&$/-^/,Y3=F9
MY99/HI)"X;DR^1F%N!9F7-,'I>K0K0U*<$=:M #!%#$+" M^U[R=W=S(N2(G
M<G<G?E<CAQWUEQZXS\0[]4M?5U8T9?54)_\ 7M:^W8U_LP3<8_>E*EO%O%N1
MJMKWWKQ82^JH3_)3MVZ2L:_V8=5#NY2XO#CO=Y+H3%0O#G,C"[<.UV9G;EO>
M3]?R?5ZO_/S4EG9O[-V:W*U-5TYAA:(2;UC)Y*2,I*V)QH&(SW9V%QZW;J:.
MM7ZXWLV"CA&2-G.0,>NVMM%0T#O;K'2F+&9L?C9<,51[!E+/)'<P6,NO-*91
MQ]4DQSG(3@#1MU<1<@PKKA_<:=(U):]Q3J<Z90TK*T:K$JOF^59&;CZA19)4
MQ:WLC17;*-MFZC&=L81<I<ZAB9Z!D?HK+SG7MBN4<:-C^_<U*;4%MUC",7SR
MZ)2E&*;>_+D7W16::CVBM.QN3#\)X75&-9G=FZ^<=Z_T^;/U?\W]7 \/[///
M#/S<Z94<.[QS/P=VBMK;#DXA+G<A0-F(A8VR>GLSCHQ+I9^IFGLQ&PNW2Y@#
MNXLW4-X]ETH]I/'Y-<QI[=+=-J;?[4<G*BU^*CR_O+0^ &3SZ%L_N95B7X.F
MB7];?[CRB(J]$X$=/>S_ $O.Y?V*H?AO&*EOBO\ FL_^Z'^AU=/[UZK)+V>]
MS1C%R<<-6E)FX;B.'+XZ64O/CR&,")V][LW#,[NJ6&+_ .:S_P"Z'^AU=CV9
MW_ZGS?\ \1G_ /IL8J-[1_\ RS3O]%#_ ']I;-[BWXC7^W74W^FBID5#=W%O
MQ&O]NFIO]-%3(JL/B;_[0ZS_ /B&3_O&60X(_P #Z9_J6-_NHA>'7E%HIM)2
M0[T+*>N=I#71"0\U"P--G!RY$J^#H/YN[^1MU^?2[,S\<>:^%V>]:9C4NI*>
MBX*4V4R=Z.T^**#I]9F>C4FN303,1"TAO7KR/ ;.TDD@C#TRR&#KC_;RR'KG
M:'W4F?KZ0U.-<6-V=Q:IBL=6=FXY;I<XC(6YY9B;GSY9=Q]TUC?7.T7I7WOZ
MKCM2W7X)F9O"Q4L?+\^]N9F9V;S=W;RX96A\>?9ZX5X]\-8:7Q-IU>3]"T*&
M5IN?7RU:CI.:M/A*.1@97*Y5-RC!7TR4\?*A%5Y%-L%%*@7$W#>/KG%N1@Y/
M,J\C,LJ=E;2LK4\B47.MM27,HK=*491?:46NA[FZ>S^.U10FQ&8KR0S0R&,,
M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/B
M:EU#3Q&.OY;(SQU<?C*5K(7K,I,$5>G2@.S:GD(G81"&"(Y#)W9A$7=W9F5*
MO=3O4-Y<OJ7.Y/!:ZS.#PEW*6Y\1B*L.-:#'XQY2&C7%K&/EGZAKC&4KRR&;
MS%([NW+"TXW?:]I1M*[=5M$4+'1E]P)I:UD8C9I(=-XXH)<H4C-R01WYI:F.
M;EQ:Q#+= >L(YQ:HP@,X_P DMWZ_LGZ@_P %A_\ =:?DEN_7]D_4'^"P_P#N
MM8.(@,X_R2W?K^R?J#_!8?\ W6GY);OU_9/U!_@L/_NM8.(@,X_R2W?K^R?J
M#_!8?_=:?DEN_7]D_4/^"P_^ZU@XN6:#T1D=39O$:=Q$/CY3.9&IBZ$7!.Q6
MKLP01.?2SDT8.?B2N+.XQ 9,S\<("V/W.VLMTM:8#46N-PM6YC.XRY;BPVEJ
M5\:$<'%!SDS&58:M."21Y+)U\?5<S9HWIY!WC-IHC"9U=2[#[18_06C=-Z.Q
M;-ZGI[$T\<TO2P%;GAB;UR]*+.[-/?ME/<GX?CQ9SZ>!X9NVD 1$0!$1 %AS
MW@6O\SI;9O7NH-/9"?$YK%XB*QC\C6:)YZLSY&E$\D;31RQ.[QR&#L<9CP3^
M2S&6!7>@?$'N9]@X?PKCT!5'_)+=^O[)^H/\%A_]UI^26[]?V3]0?X+#_P"Z
MU@XB SC_ "2W?K^R?J#_  6'_P!UI^26[]?V3]0?X+#_ .ZU@XB SC_)+=^O
M[)^H/\%A_P#=:?DEN_7]D_4'^"P_^ZU@XB NF=T7O1JK7>U,^<UAF[>?RPZL
MS5$;]T:XS-4KUL8<$#-6@KQ=$932N/SOJY-^2?RXE$4-O<8_$I8^W?4'[TPZ
MF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1%XY0'E%A'V@^\0VEVU>:OGM55+>6AZA/ X%QS.8&06
M?YS8KU#**A([\-QD)ZG'6)/P#]30@;[]_)JK)^/4V]TO3TU6)G"+*Y^0,QEW
M%^KYZ-"#P\73DZ7'B(YLJ &+EXL@ET,!:+RF6JT8)+5VS7IUHFZI;%J:.O!&
M+>;E)+*01@S-[W(F91P[U][7LGHPYJH:E?563A=Q*CI. LM&)LS^4F69XL*+
ML3>')''D);$1^4D#>?%03=OM%Z\UY8.SK'5N=U 1D1>!>OR_!\/6[.0U<5!X
M.+IQN[,_A5*<$7+<]'/+KIAD!/GO+W]>L+[RU]"Z1P^G:Y,0CD<_+-G<IQSR
M,L52L=#&U)6;@7"=\M&7M/Y.X],5^\';5W5UWXH:FUSG[=.9RZ\95N'B\20G
MYO%)CL9ZI5GB_I0LQSL/R<<+%Q$!_ QB/N%F_69F_P!"_M$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'\D+/[V9_UVY7=&U'
M:*UYH4V/2&KL_I\&+K>KC\C.&.D/EW<IL9(4F.F)^7Y*6J9<$3<^T_/3*(":
M_9[OS]T<(\,&JL3I_6=$/*25XI<#FB%FZ1Z;U+UC&ET^1.TN&*25V=BL!RYC
M+-LSWU>SFI/!@SUC*:(O2O''TYNE)9QOB'PW_.N+&W##$)<\SWXZ4(1\'(8<
MDP4ZD0&Q@T7N#@=24H\CI[,XO.4)18X[F)OULA6,2YZ7::K+*'GP_'M-[N%S
M!:Z/0FY&HM+7!R&FL[F-/WA?EK>&R5O&SN_RL9U)HGD$F;I,).L#'V3$A=V4
MMNPW??;GZ;\"KJ^GC=>8\'83GL-'A,YX;-QY7Z%8J$IMPSL4^+(S]II)'(FD
M "W>BC&[/O>V[.Z[:"M8S1Z-R\K1B6-U;X&/A>8N&<*^7":7$S Y\M$1VJ\I
MCT.=>(R\)I,JUF.:,)89 EBD%CCEB(9(Y )N1,#!W$A)O-B%W9V\V= ?NB(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"HM=YM\?>YOV<J_@/$J]*J+7>;?'WN;]
MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
M+X3R3WLAXC-U/!8KPN<@5XG6": (B( B(@"Y5H71F0U)F\/I[$PE8R>=R='$
M8^$6YZ[>1LQU8.?Z4!.5CE-^!CC$Y#<0$B;BJG6[C/LVOGM9Y?<7(5NK&Z.A
M;'XB26/F.?465AD&>2$G\G/%8OEY?T0GE:KB_P!'P!9?V&VAQV@=&Z<T=BA9
MJ6G\77H 3,S//.+/+<MGY-S+=N26+<Q.W4<LQD7).[KMM$0!$1 $1$ 1$0!$
M1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B M_=QC\
M2EC[=]0?O3#J9)0V]QC\2EC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 7']5:JQN#QUW+YB]6QN+QM>6W?OW)1@K5:\(]
M4DLLINPB(M^V3NPBSD[,_P _7VOL-I?#Y#4&H,C5Q.&Q5:2Y?OW)&B@KPQ-R
M[N[^T<AOQ'!!$)SV)CC@@CDED 'IK=X=WCF;WER9XC&>L8?;[&VG/&8II#"S
MF9(O9CRV=828))7?JDI8_@H,?&8\O-;8[#@=H]XYWI64W0FMZ0T9-8Q.W@$4
M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!03][WW>S:OQMC<_1U'G
M5>%I]6H\=6 GDU%AJH\M;AA!G:3,8F'K/D6:6_CP*NY235:413L+QP@-;>SL
M[,[>;/YL[>[A_<O*FH[WCL$?,!GCW"TM3)M&ZGOG\)U8 ;P=.:@L]4IQB ,S
MPXO+F,L]1W%XJMWQJ77$$^.@>%= $1$ 1$0'AVY\G]WRJVUW-/;5+6NESV[U
M#;<]3Z-J0-BIYS9Y,QI<&&O6X=WZY+>$(8Z5KJY(ZDM"9BD-[/A5)EVOL;O)
MF=OM6X+6.!E>/)8*]';CC<B&&Y7\X[N.M,)#UU<A4.6K./O89/$#B2,"$#8<
MHNH]B-Y\-N%I'!:RP$K2XS.T8[48N_,M6=G*&[0L-PW3:Q]R.>G8'AF:6$W'
MD7%W[<0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %1:[S
M;X^]S?LY5_ >)5Z546N\V^/O<W[.5?P'B4!@HB(@"(B *17NE?IB]L_[?J[^
M#W5RCJ4BO=*_3%[9_P!OU=_![JY 7>T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$
M5'?1?$#J3[,Z2_&3'*F,KG/?1?$#J3[,Z2_&3'*F,@"(B (B( KM/='?$)HK
M^['X9O*DLKM/='?$)HK^['X9O("2=$1 $1$ 1$0!$1 %^4T0R 49@)@8D!@;
M,0&!-TD)"[.Q"3.[$+^3L[L[.OU1 5!N]>[O,MMLR>N=)4S?0N?N&]RG7B=X
M]*9>R3F]9V!NF+#9"0B?&D[#'3GZL<[B)41DAH6QFUQHG%:DP^2P&<HP9+$9
M>G/0R%&R/7#8JV >.0";R<2X?JCD!QDBD898C"0!)J0O;[[$F5V6U?)C^+%S
M2>6*6UI7-2-U>L56?F7&W9!9A'*XUR:.=ND&M0/!=C%FF..(#!-$1 $1$ 1$
M0'U<'G+N,NU,EC;4]'(X^S#<HW:LI0V:ENM(,M>Q!*#L4<L,@B8$SMP[?4\G
MNG]VSV]J>\NE_5<H<%37>GXHXM04!>,!R,+<1PZ@QT(]+M4MNXC<A$!:A?>2
M#AZ\E26:DVNUMD=Z=0;>:GQ6KM+V_4\QB9G.)R8BKVJ\C=%K'WHA(?'HW8N8
MK$/4SNSC)&031Q2 !L.D6,/9([4^GMWM'4=58*1HIG$*N;Q)DSV\)F B K5"
MPS>9QLY>)3LLS1VZI13BPDYQ1Y/( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>&[
MJ?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O^,F90$A2(B (B( B(@"(B (B( B(
M@"(B (B( B(@"+QRNCMY^TKH3;VJ]K6.J,7@QZ/$CKV)WER%@?/CU3&51GR-
MHB=G86KUI')V?AGX?CTXF'=D61JHJLNMF]H5U0E99)_",()R;_!'X9.553"5
MMUD*JXK>5EDXPA%?&4I-12_%G>2*"+=OOQ=.0/+7T'I3(YR07(8\EGI!PU N
M'<6ECIQ>M9&6-_9,1G&C*3<A($1>8QZZ[[S[>?4Q'QJ&OIRJ;\M4TSCX:(@W
MG[KMLK^4=^'9BYO,#NW+1A[E+VA^ W$&8E.VFG K>W7,LY9M?Z&J-ML7\K(U
M_B1!Q'X[Z!I^\8VW9UB^[AUJ4-^W\M;*JIKYURG_ !1;=MW8:\92SRQ01 SD
M<DT@1Q@+>\B,W819OE=W9F^JL=-8=L?:G N8Y7</2-<XWXDACSE&W8C?AGZ9
M*]*6Q.!<.SL)1L3L_+-PZIF;B[EYS/$YYS-97,DQ=3?"F0MWF$W\^H LS2A'
M\O\ 0Q%F\^&9= 96ZS<\<,WUF9;_ $>SK14M\O5+)OUCCX\:TOPLLLLYO^CC
M^!&MGM)WWMK$TFNN/W9Y.3*QO\:ZJJE'\%;(N0:F[V[8;&.3%K([O3^BQF%S
M-X7\V;D7BH^U[^?)O<SO[F6 O;5[U/8_<;;36NAJTFJ)K>=P%Z'#W"TZ\=>I
MGZXO;P-J5[-J"8(X,M6I33%&#&T'B,SL?+-68OV^7?\ \5\$R7WRO ;0[:K<
M>Z6;=5=5.FV,[JXJ5=D7":]RB+6\6U]H_*[QFU>^$H.K!C"<91E%46R;C);-
M/GO?1I[?9,S*_:-PW1&\U;(M*X"\K!#7<&DZ6<V!WM"[@QN_2[LS\<<LWN7L
MMVE<"WOK93W_ -3UO_5K!\S_ )?47J2$JK0_N6OA/_\ RFN_A^FKMO\ =%-<
MWV9.%\IMVUYW5OI',E%=?1>X]DOZC/>#M+:;?CJ;(1^7+]=5B9G^H_A2R>?U
M..6^J[*4OL"]ZCMIM_C\]@]593*U\?8N097&RUL)EK[#:FA&M>@>.M5,HVZ*
M]67KXZ"+K87ZF=WK8F2]4R6R<$_W./@+AW5<?6=%RN),/,QU?",):EC9&-;7
M?5.F==]5VGRLG#::G%1N@U.NN3D]C8?"?V?-"X.XBQ.)M%MU2&?B0R:E3?EU
MW8=]673.BVK(J^C1MG#::L@H7UN-M=<VWR[.UMVNNVCV8]X<%&P:ZCP>K,96
MFFT]G,CIW4-48C)FD+$Y0FQS$6/NR (F+^))1E+URM&9#+#8AGT[O_I:8'JV
M\S3'AR%C+QNGD2=NL3*%NH2XY%_+J%V+CSX4:YEPO1,_[Z^WB?["%7$-BR*.
M(*\+)BMG9+1W:[=MN1VSKU.E.<$N5356[CLI=(Q2M/K/$"U"]9-N+75<X\MD
ML>3BKDDE%V1FI[RBERJ2<9<NT9-J,>6:GL^=L,=L-40:ATYG:-RE*XQ9K"/=
M:*IF<?R_5%*!N(QVX&)Y:%IQ\2O,W2_57EGBDM&;=]N?:74F(QN7J[@Z0I#D
MH(Y1Q^5U)A<;E:LIOT'4N4+5Z.Q#9BE8HW'H<9'9CA*2(XY"UX?KD@/R)DS_
M ">?/^GE?N&IKD?F,K/Q\A1QDWZS\B_/\N'6K\,^R+XA</TV8VG:OPMK&,WS
M55ZC;JVFRKENMY1ECX.I*/.M^:M;P<MI*46Y\V9X7XPR-,C955%743?.J;9-
M*NQ]Y5RBMTI_>BULW[RV?-S;(9NT7M\_NUWHU_UM3X1__P">7$=?[C;5:JPN
M1T_G-5Z*R.)RM:2I<JRZDPA"8'YB8%Z[U16()&&>M/&XS5[$<<\)A+&!-KMX
M=QLA%[@IGQ\AUW9O=\OAR1_YG9?7BWGO1^^G0+W>X)@_;X\8_+ZWR?*[^Y>/
M6/"'Q?@IUU\+<*9\))PE&KB:R,;(R6S369IN-O%I[-22W6_0V>[Q2S)QE#]&
MXUD)Q<91ED2Y91:V:DI5;--/9I]&NA-?O?MW6VZU7:PU3/XK4> L==G"9?'9
M2A?&?'D?#09!JD\K5LA4=_ L!)T--TC:@9XI6$.K(]6OALGC\_I_+-1R^-L1
MW*%JM*WC5[$;N[/[/D0&+E%-$7,<T)G%() 9"HMXNT+;C9N,94=_E?QI19_K
M\,+\?K<O]3E>S_/.7@9^,53]WRV)N.?UF#S_ %O+]I5+U/V+_&F6?+-T[A#2
M,'>WGA6N*-,MC#9\RY9_2:9^Y+K"3]^,=DVY)MP]DTYTISECXL*H>9SU0^D*
M3H>^Z4+-X2VB_L-^]%);MR7,[G>V'>X;?SZ8Q]O53Y''ZG&!HLIB\?C+-R":
M["/0=FA9%AKC4NNWCPQ6)XY*SR/7E(_"\>3K[6G?-X*/K#3>B\O?+Z$9\W?I
MXN-G9OHVKTFRTD@._N$I:Y.S]3]#MT/3KN=K+.@WSFAB ?CWR1W)F_7X&Y!Y
M<>7'/[;MY+@&8[5VL9&<8KM.HWU*N/KL_P"T5EK)C]7EB9_?Y\/PI=A[-GM*
M:E7"CZ1P-P]M'DEDV94LBYI+;GFZL/6JW9)==ZZH1W>^T.C6ZRXNXONKC7"[
M!QG&*B[57&5D]DDY2<XY$.9]VXPBM^R1:#W([TK=+/#+#C;&-TM6D9Q?X(IC
M-<8'Y9V:]D?6GC=V\FD@A@F!^2"0"Z>(L=Q-Z,%CKEW)ZEU#4^%;\TEJ_/<M
MM;R]ZP?!'-9%BFO3RR>7!S,[EPPL[\,S0MZIWDU/DF(;N>R<H$SL48VI((G9
M_P!"\==X@(?^R[.W^E=&WK+#R3\-[R(GX;Z[D[_7\W=W\_E=973?[D_Q!Q#=
M5D>(WB=GZE7"?.]-T7%GY,6]]WCY6H6+&QWL]O<T3JGMT2ZX"_@;4-3G&>KZ
MO?D)/=5Q<I0B_7R_,:KJ?I[F.OX(DWW+[P.G ,E?2N*DM2,SL.2RO,%=G_IH
M:,;O8E;Z]B6J[>[PG;@E_/8C[%6[':YUHU63)7JNC</;K%JK5=J$QPN"J3&4
MA8[!T@&*E>U!8KQ&-2E$[E!U0W<Q/' 8'9R+[L/N.M:;VV*&K-=1Y'1&UCOX
MX6S!JNI=61L[.,.GJEB(WI8V;S\34%V'PR!N,76O$96*M\O939+2VW6F<5H_
M1>%IX#3F%KA6H8ZD),(B+-USV)I".Q<N6"9Y;=ZW+-;MSD<UB:64B)[+<.>$
MWAKX35RQ>!M!P[.(^1U7<09K6J:EC-KDL;SLGG\JZ2Z2P]/AB8BE[U]+<?*G
M,'!?AI@X?+;#&4=O\;9O/(L_"<NM<9>OEJ"DNR[27%NS+V9=&[0Z-Q6A-"8>
M'#X'$QETB/MV\A<F?KN97*6R;Q;^3OS.\UJU,[D[N,4315XH88^_D1:!E95E
M]EEUTYVVVSE9999)RG.<GO*<I/=RE)MMMO=LF",5%)))))))=DEV2"(B_ ^P
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 73F^&
MQ&F=P\%9T]JC'1WJ4WMP3,S!=QUIF^=W<=:87DJ60XXZXWZ98W.O.$L$DD1]
MQHO%J.FX^91;BY5-61C7URJOHNA&RJVN:VE"R$TXRBUW31^&5BUWUSINKA;5
M9%PLKG%2A.,ELXRB]TTUZ,IK]MSL":HVMGDEL">:TC8G(<7J6M ;#7,G^<5L
MS"#&./NNQ>$Q$?JMQ^IZTK&3UXHQ9JI 11R,W4SN),_#B[?Z'8OV^6]_RLMB
M9F\%3R=.SC\C5KW:-R$Z]JG:B">M8@E'IDBFAD8@D Q=V<29V_O,J\';?[G"
M5O6M2;2Q^,#.<]G1MB=O&B%W<C^9^W8=FEB'GJ'&79FD >H:5F1_"IOY/9VS
M\CPQSLC3\>61G<!ZGD/(E@?69&=PMGVM*S,P8KGMSM)R$HK-Q(*>9CN$,O'C
MDS^DPOKMQ%X7W:=.R_3%/(P9MRGB=9Y&*_65/>613\8=;X[)I7>\RK'K'0Q5
M^NS5#KJOR\L7'4\'RN[-Y]4/^</<[=+=2Y'MGVA]>Z.,)-)ZTU3IWHZ6&/#Y
MW)4:[B+L[ =6&P-66+EN7BEA.(^.#!V\EW/E\-;Q]NS0OU9Z5ZI-)7MT[<,D
M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
MN?T+OST\/Y/U*IR,7/QZ[(RHS,7(KC93;%UY&/?5.*E"R$US5V0G%IQG%N,H
MM--HTVC+E%IQG*,EVG&3B_WQV:_@2-;7=]MV@\)X-:UG\3JR/K8!#/Z?HE:-
MG9A",;6&'$2$75QQ),%B4GZNLB=V<<DM[.V7KS>FO@X-3UL?AJ.,'QRPN$*W
MZA9R,GE\(7'M2R23V((OG-<')X*K'.4 ]<TAE$]V==NH[LAY&7@[$%@ZP0/]
M%6(1;J.029G&4V/V/D$'Y9^HGZ9!V:'$U>&X:5P]_P#2\M[OUW_]EQY]M[Q?
MT]:G;PIH&!1BV8EG)JN530L>>1D[*7T6%<5&*Q:$XRLLY-[[7M!^36IW_MF\
M19U]<\:S+OEBK;S8V3E/S'%J2BY3;ERII-KFVDUU326_KYS*P8NJ48D(=(\R
M&[\,S,W+\N_EPS-YN_U/-UF5V NW?V>MMJEK*:DRV:/6N4<X+%_YE\G:IXN@
MTO 8W&6*D=DG";I&S=N.$7K!=$7LQPB)0<[X;LE?GEQ=.5W@ N+DP_\ 6FW_
M % $W_5@_'BNS-UF/1]"Q=6.HNSMP_\ +ZZDWV4/8^JJTVOB'B2.17G9T8W:
M?BP<:K<;&LCNLK(5E=FU^1%ITU<J=-&TI-V6\E/FT?6+</(CE5U4SG!-51OA
M*<8)]/,C&,X>_MTBVWLF]ENUM>;Q_?-]G>?IYUT5?J/H_-6#SD'3[O;+JH>S
M&W/F7N][KD)=[]V<V]^YN*_Q+,?[N5#*S!]9?;T-MW8SUX8(V(*\;L]F=F_H
M8>]@#GEBED]PMYL+<F7+#P5I^)O"7AK2,'*U/4-1S<3!PZI77W66X[48Q[)+
MZ-S3LG)JNJN"<[+)1KA%SDDY%K\6<U1YIU8NR[M0M7[EYK[^B_ NG[^][IH$
M]*VOYE>;AU3J6\4N/IV(:=R.CA3./V\I;*[6@"P=9C%ZE.-I6GL]+3L, 2<P
M2Q89KQVLKGR;*6[TYV[EC(B-J6Y;ED*62:=YV)C,Y"(G=VX'G@&9N&;BVV^W
MU7%TX1"(8:]>,6$&^HS-\K^9&3^9&[N1.[D[N[NN&;X[T5,!0.:1^H_.*I4!
M^#L3=+\"W]+&/T4LC^0"WN<G$2X]\7\9ZKQAQ-3I_"\=0A&67Y&DTU7..:N:
M6T;)VT>5&.1-+S;K(N->-6FO,\NMV/2.(.),G5;86Y,8\J3ACXT$^1<WVI.,
MF]YS^])M[12CT2.F;F3T'3U_2QVX.H+FF]%//Z]D+&,QF0R^2EQXL\HXW'5,
M=7L21S6Y6]2"Y,(UZ4+2V".:6*.":?G#^D$=F31&$QNGM)X'7<F&PM*"CC<=
MAM+TZ<4%:")Q",/A?,XTC-W%O%FF-Y9YI7FFDD,Y9&IFZSU#>S-Z?(Y"5YK,
M[\N_N",&=^B&(/<$4;/P _KD3D3D3\JV VQ^:C5N+Q\@.5."5LCD?J/3I&$A
M0OY>ZS+X58N."Z)3('8A9=I>+]&QL'A"C5N-]0R,A\,</?2M6LQ<A0QKKL#"
MY\S(@IU*V[)R76X0G.Q.RR25<*W8XO\ ;%XGQ.#M&U+4[(T4X^%BY&?FW<F]
MGE8]<KG34W)1V]WEJ@HISLDEU;BE8*[3N_0;HZMOZTKT\CCJ&6@H'C<=E6KQ
MY"E1BHUXH8+L-.YD*4-K@>JP%2W/"\CN32F[D3XNW:WO\EV?=J^]F9F9O=PW
MDS?M>3<?K>2XE>JK^3C6>([-3U'/U*U<MNH9N5FV04G)0GE7V7R@I/9R47/E
MBWLVDMS^=3B+C_*U_6=3UO-EOEZKG9.=?L_=C/)ME;Y</V*E)5UKIM",5V.K
M[M7W^7\OY?R=<"U!>I8^O/>R3S#CJ<96K[UFC]8:E WB6_5VE(8O'\ 3\)I2
M&/Q.GK)AY=NWKM;WK"/MJ:D^#M(2TXS<)LQ;K4AXXZG@BD:W:;ZO3)%7\$O+
MCHE)O+EE+/@7P-9Q7Q;PYP[!2:U?5\'$O<=^:O"E=&6?>MNNV/@PR+WLM^6M
MDO>#VA3U[B#1='ANUJ&H8N/9MWACRM4LJSIUVIQHVVO;T@^Q91VH])X[/)4Z
M.-NZ3W0TG6HU:U*)KF!T_D*D,%:"*&(8&P&I\I:*&,!:,6*G#)\[?YRPN#GG
MIMOWZO9:U,P^!NGC<.9\=,6IL=F-/&[DS/Q_RG1@ 7;GS8S%FX?ZCK6=KRR_
MJ1S/9QX?FMJ)9V(DDHQKOA.N*71+ENILGT6R7UB/Z2,?7+8*,%&ODBE&*46M
MHI;)+E:222V2V-O%MGOMHG6D#VM'ZPTOJFN+#US:=SV*S4<?5]"TA8ZU8:,G
M_I9.DF?R=F=G9=JK3HXJW-1N0Y"A--0R%9^JM?HS24[U<N6?JKW*Y1V(3\F=
MBBE!_)GY\E)/L3WQ/:2V[\"+![J9W(TJ_##C-6^KZMI&#.SE'(6<CM9!F/AA
M*2&_!88>?#GC+VE'^L>S+?%.6GZI5:_2O+IG1M\O-IE>I/YNJ"_=N\E5Q#%_
M;JDOG%J7\&H_ULV@Z*FAV:?2J;8>!3W?VWAE^A&?/;>6#B9V]EBD?3>H+LI!
MTLQ/TQ:AE\0B;@86'A[&G90[S[8W>F.&/0>O<7;RTC TFFLLTV U/!*3L'A%
MA<O'4MV?GG,86,>-VE8(">I:L /6H6XD\--;TI2GEX%ODQ?7)I2OQTO1RMJY
ME6GZ*U5R]'%/H9?'U&FS91FM_P!5^[+]SVW_ "W,^T1%HA[0B(@"(B (B( B
M(@"(B (B( B(@"(B *G)WR_9L?16Z4FI*%;P\%KVN68C*,.F*#/P$T&<JOTL
MPB4SO5R@>[Q"O6!%G\ R>XVH[.]#[-3[E;2YRM2@:74&G.-38#CCK.QC1(K]
M$7XY=\CBRN5HP=V#ULJLAOQ%R@*02+PS_P G\G_;;Y'7E $1$ 1$0$J'=!]I
M+Y@MV:6+NV?"P6NH8]-W@,^F"/*'.,FG[I<\-XL=PI<<#N_'AY6;EG)@Z;H"
MUN4<I@0G&9Q2 0G'+&3A)'(#L021F+L0&!,Q 8NQ"3,[.SLKZ/86[1T6ZFV6
MG-5O*!Y,J_P9J",.!>#/XU@AR E&W]#]8+P[T(\#S6MP&+=!@@,O$1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %3E[Y?M*OK7=*33-"?
MQ,%H"%\1&P2=4-K.V6CL9NVPMP/YG+U?$CRSD,E"T8&\<XL-G[MC]H&#;#;?
M5&L3>-[F/QTD.&@EY<+6=NL]7$0&+$!%$]V2*2PPD)-6BF<'8F94%\AD;%RQ
M8N6YI+-NW/-:M6)7ZI;%FQ(4UB>1^&9Y)I3.0WX;DB=_)N&8#TT1$ 1$0!$7
MAR9F=W\F9N7=_<S-[W0$I_="=FQM?;LTLI>K-/@]!!7U-?\ $!RA/*#.0Z<J
MGY./B%?@ER,8$[,8XF7Z)A("NA*,7NE^S8^WNTF*LWJ[P9[6GAZIRPR"XS0P
MW(1^!J4K%P8%6Q?@22PDS/!;LV@=NIB<I.D 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!8%=Z!\0>YGV#A_"N/6>JP*[T#X@]S/L'#^%<>@*,B(B (B( B(@+?W<8_$
MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
MW6=N>MV?]!"Q/[V(@X;G[;)=^K_@0Q/5]=XAO4<?S:JD^CAO6H+?OTVC#Y2D
M^9_-G0O:4V@QFGK,%["F88^Y(44E.0_$>K88>OF W?K>O*+$[ ;D41L[,9 8
MB&+\4QQR1RQD4<L1M)%+&11RQ2-[CBD!Q.,V?S8P<29_-G7+-8:[RF=F:;(V
M2E87?PH1;HKP,_R11MY<NWT4A.4A-QU'PS,W#E]2R'#^'DX^'13EWO)OKCM*
MYMN4ENW%2DTG.44U%S:WEMN]WU<U_8O[^S?C:$:N-R&5_FH:6K,P#@=<9"Y/
MDHH6Z6:#':P<+V9IL LX0_"$6:K5V(1CI/%&$*N/=A+OH=E=]GJXK&YGYD=;
M6&=FT3JR:M1R=J4(_$E'!VVE^#\^(#U'T8^9[K1 <LU&$ /IUF2_>O8.*2.:
M,Y(IH9(YH9HC*.6&:(F..6*0'$XY8S83CD!Q,"9B%V)F=1)QGX,:-JZE9"E8
M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
MX3/>&#,,6<QP$="Y(X\>>3QO-=W=N&DQ;.1$=AF: M $1$ 1$0!6V^Y![2/S
M3;>6]"9"P\F5T'9Z*32%S)+IK*2S6,>S._+F./M^N8\?<T54*,+-P+$]219J
M]WQVD/YENZNG-1V9V@PMLST_J1R)QB;!Y>2$)[$WF+=&.MPTLIR[^SZER[./
M4) 7NT7\@3$S.+LXNS.SL[.SL_FSL[>3L[>Y_E9?T@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B+^2)F9W=V9F;EW?R9F9N7=W]S,S?+[D!#CWTW:5?1
M^V8:3Q\_1F]?63QAL+LQU].U!:;,V?)^1>R3T\7&SLW4%VQ(Q<UR$J?S+/SO
M+NTB6YF[6H,C6G:7 X*3YFM.B)=494<81!;NB_N)\EDWN6Q,1;\RE4B+J>'K
M+ 1 $1$ 1$0!<FT3H^_J'-8C3^+A*?)YW*4,/CX1;GQ+N2M14ZPO\C#XLPN9
M$[" ,1FXB+NW&5.7W&_9M;4.N,KN%D*W5C-$P#4Q1R SQ3ZCRT,P$<3O[Y,7
MB_$DD?R>,\E3(>2=^@"S)V?]G,=M]HO3>C,4(M3T_BX*3&+<>L6?:GOW3\F=
MY;]^:S=F)V9REG,G\W==PHB (B( B(@"(B (B( B(@"(B (B( B(@"P*[T#X
M@]S/L'#^%<>L]5@5WH'Q![F?8.'\*X] 49$1$ 1$0!$1 6_NXQ^)2Q]N^H/W
MIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B *";OS^T>
MV"T5B=NZ,_3D=:6/7LH /[46GL-8AE8979^0'(93U>.)G'B:.E=%B9HC$IV'
M?CS^3Y?K?75$+O!NT-_-,W8U3J"O-XV'JVRP.GR8G>,L-AY):T%F+GCB/(3^
MLY(&80?HMBQMUL3N!A:B(@"(B (B^[I?3-_-Y/'8;%USMY/+WZ>,Q]6-N3L7
M;]B.K5A%OJR32@/+NPBSN1.PL[L!/+W&'98;*Y[*[K96NQTM///@],M(S])Y
MNW7#X4R -T\&^/QMAJ<3N3@TN1G)A>:N!Q6CET/V9-BZ&VN@]-:*QS"\6$QX
M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M * KOUNS;\+:6PFY6.@9[VE[#8C.O&')S8+*2-ZI9,A9W?X,RG0#<MPT&3L2
M$3-"(O/JN [I[<X[5^F\[I;+Q^)C<_BKV)N"W3UC#=KG \L3DQ,$\#F,T$G2
M[QS1A(S<BR UUJ+G6Y^W61TAJ/.:6RX=&2T_E+F*N<,XC))4F*-IXV?S:*Q&
MP6(N?/PY0YX?EFX*@"(B (B("U?W$O: ?,:*S^W]Z;KNZ1R#9'%,1<D6 S3N
M10BWF_%#+16W<G=F:+(58@%AB=3PJC1W9>_+[?;R:3R$\WA8G-V"TOF^>>AJ
M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ
M][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z8O;/\ M^KO
MX/=7("[VB(@"(B (B( B(@"(B (B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y
M[Z+X@=2?9G27XR8Y4QD 1$0!$1 %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_
M#-Y 23HB( B(@"(B (B( B(@"(B (B( B(@"(B +CNKM)XW/8R_A<Q2@R&*R
ME2:ED*5D.N"U5L \<T,@_4(2?AV=B%^" A(6=N1(@*-G>$=AS);+:M*M$UFY
MHW-R6+&ELO*S&_@B75+AK\H"(?">-$P$BZ8VNUGCMQ +O/%#@$M@YVC>SWI[
M<_264TAJ2NTE*_$[UK0 #V\5D(Q+U/*4#+^AVZDK]8^X)HWDKS,4$TH%1?[3
M'9RU#M7K#*:/U'"_K%$VDI9".*2.EFL9-[53*8\C;VX)PY"4&(RJ6X[%*9_&
MKF@.@T1$ 1$0!$1 =E[.[NY[0>I<3JW3-PJ.8PUD+%>3S>&>/GBQ1N1,XM/1
MNP]5>W [LTD1NXD$@QR!>7[&_:RP.\6C*6I\005[T?%/4&&(^;.%R\8L\U:1
MG\SJSMQ9Q]IN0LU) Y<;$=F"&@ZLMNQCVO,[LUK&OJ3%M-<QE@1IZBP+3O%!
MF<8YL3BS$_@AD:C\S8VV8\P2O)"1C6M6AD OM(NNMI]U<%K;3V+U1IJ]'D<-
MEZP6:EB/R)F?V9()XOHH+5:5C@M5Y&:2">,XS;D5V*@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E
M^VX^Q^7_ !DS*H\J\-W4_P!+]MQ]C\O^,F90$A2(B (B( B(@"(B (B(#$WM
MT;J%HS:77.=BE\&U'A+%"C)R[.U_+.&+J.#MPXR--;$HR^0V%U4 [&6T;:XW
M1T/I8HW.K=S,4]YFXX;&8B&;+Y!B=_99CIT)8F8O(SD")N2,1>P#WYFN"H[9
MZ<P44C@6?UA6.P#$[-+0P^,R-J0"9O(F'(RXJ5N7=A*,787+AQPA[C+;D+VO
M-4ZGDC8AP&GH\?6-QY8+6;MB\A"[_02-5Q\@=7T7AS2 WLD7-GO#N?Z*X/U7
M4U[MM[O\J?JG&,<3&_'DR)SE^#>WJ0OQ9#Z=K^#A]ZZE5SQ^3;ON_I4QBOQ1
M:+CC$1$19A$6819FX9A9N&9OJ,S>3,NJ-V=A]&:[I^H:PTQA=15F$AC;*48+
M,M=B=G+U6R0>LU2=V9W*M+$[NWFZ[:15GQ\FRJ<;*ISKLB]XV5RE"<7\8RBU
M)/YIDR6U0G%PG&,X26SC**E%KX.+337R:(%=\>X:T/DRGO;>ZES6CKAL[ABL
MB3:@T]UMYLT3S^%FZC$[OUD64O0B+"$%2%F?F'[>KNTM]=O2FFGTL>J\-%UE
M\,:1E;,1^$')=5G$\19NJ[1MUF3XZ:J'F+6S=O.[6BF'AKQWU[3^6-MT-0I7
M3DS(N5FW[.1!PN<OG;*U?&+(QXB\'=$U!2;QOHUC^_C[16_SJDI5[?*$8/X-
M&NF+,UBEDJWJ\E:U$71-!-%)7L0G[W":"41DB-O)W&01+AV\O<O2O:0I7!?H
M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
M&6ZUI&CM<:BTEEZFI](YG):?SN/-C@R&)M25;+"W#$!/&_38KR#R%FG8&:K;
MA(HK$$L9$!3V[4^D&ZU@TJ]+4&@<9J#5<0!%3S\&4DQ&+MM[0G9RF'BHV9&G
MC=A=X\?;KP6^HF;U#H9Y?RXP]G[-INYM&:S,>R72BVRNO(QTWZSL<*[:X_KI
MQL2Z.N6SF_STGQ,Q?*_]8-8\X1ZVQC*55FWPC%2G";V^SLXOTDND2V-+*("1
MF0@ "Y&1$PB(BW)$1.[,(LS.[N[\,S.[J,CM*][?LYMQ)9QWPX6K]15V,2P6
MDA')/#,/EX-_+B0X:A)U>102W3N@W!O4<'8E5KW^[;6\6[4L@:GU7>JX:3R'
M3.GRFPN 8.KJ$;-6I*TV4<>!=CRMBZT9#U0C#U$SXT4M*4J8MXKQCT_H69N6
MX^3CW-_+R6V<)^S7!<MNL9;D^C^BX;Y8?':S)LCS27I*-=4/V;=MFXZXJ]H.
MBERJTZGS)]E9:N9OYQJA+I\4YR:^,"3?M"]\GO)KT[%+3/JFW> D=QBCPK';
MU'+$XN!>N9ZTW0'7RY .+QV..!WZ7LV7 )GC";2LMFS8R65M6+=ZY*\]R_?L
M2V[MR8N'.>U:L')9LRD[>U++(9EY<EY<OS71^)R^H<A'A=(Z?RNH<K-PT='"
MX^UD[?3R(O(<=6*5X(0<A\6Q-X<$(^U+* <DTP79][C_ %_J4J^0W(SU?16-
M)VDEPN,\'-:CG#AG\$[0S-A\4?+^<S%F';I(/5?;&<)EMS.&>%*.1O$T].*V
MK@N?*O2[;QBK,J_K]^?-%-^].*(HA'BGBBW>$;W5O]NQ\M5>[Z[;N-%?3[L?
M>V72+[$+7K]&J4<, ///(8Q0QB#R22RF["$<40,YR2&3LP +$1$_##SPRD&[
M/W=B;T[E%!:+"?,3IV7@FS6JF*G+)&_F[T,"!/F;!<.)#)9K4*9B_P [MR$)
M K0_9S[O_:G:X8IM,Z5HGF CZ#U)EP'+:@/GS/P\C<&0Z02/P\D&.&G ;B#G
M&3@+MF8H+XK]I2V?-5HV(JH]4LK,2E9_.KQX2\N+7H[9VIKO4B6N%_9YQ:G&
M[5,B65:MFZJFU7OWVE9)*37Q5<:VMNDV1#]F[N8]J=$G!D=11V]PL[&\<OK&
MHAA'"U9@=B_,&GZPC5<.IA+G*S969B%WCEBC)XE+7C<=7J5X:M2"&K5KQA#7
MK5XHX(((8Q88XH88A".*,!9A",!$0%F9F9F7O(JY:[Q+GZG;YV?EW94_3S)[
MPAOZ5UK:NM?LUQBOD3]I.B8F#7Y6)CU8\/55Q2<OG.7VIOYR;81>.5'[VJ.\
MRVGVG&S4S&>#-:DKL8MI331P93-M,(\C#>$)@J8AR]G_ )ULU"Z28Q V7ETK
M1\K.NCCX>/;DW2[5TPE.6W;F>RVC%>LI-1CW;2/3FY]&-6[<BVNFN/>=DE%?
M@M^[^"6[?HC)+M)[RUMOM#:EU?:<'^!L9--5CDY<;&1F<:V,JNS.+EZS?FKP
M]+.//7]$/T3:]'=S5UG+Y6U-9G*Q-):LV[DYNY'9R5R8[%VQ(3_12'-(74[^
M?6\COYDZE"[:?>EZQW@Q-C'38FEI72,%^&SCL+6GDO9*[=@"<*T^6RA!7"<8
M!G*<:5:G!5CF".0WL2UX9FAWE9W=W=W=R=W=W?EW)_-W=_E=W?E^?>ZN1X4<
M"WZ)BW?3(PAFY5D960C*-GE4UQ^JJE.+<7/FG;*?)*4>L5NW$KCQ[Q95J614
ML:3GC40DH2:<599-^_-)[/EVC",>9)^[)^J/BRA^TO0D!?9E!>A*'\O\ZF.J
M9IU4_P#CY'/-D-I;FN]::4T7CP,K>I]08O"BX,[O#!=M1QW+A=+.XPX^CZS>
MLFS/X=>M+)P_1PME1I33-3"XO&XBA'X5'%4:F.IQ,PMX=:E!'6@'@1$>6BC%
MGX%FYY=F95&_1]>SE\.:^U'N-=KN]'1./CQ6)EDCYCDU!GXIQL% ;LXO-C</
M#(T_#L<89FMY.,S\7!%4'V@N(UD:E1@0>\,"KFL_UC)4+)+X>[3&G\)2FNA8
M'PST[R\2>3)>]DSVC_HZFXI_G-S^6RBT$1% !)(1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!1X=ZAMF^I]D=71QQ]=K"#1U)4X;DQ/#VHYK+@W
M#\D>..["_N]F4N'9U(>N/ZKTU5S.+R.(O!XE+*T;>.MQ^7)UKM>2M.+<L[,[
MQR%P_#\/PZRV@ZF\+-Q,N.^^-DTW[+U5=D9./^TDTUZI['AU/#61C7T/M=39
M7U]'.#BG^3:?Y&L_R%7PK-B/Y FD9F_[/6_3_FX=?W5J'*;11MR9,3LWEY,+
M<O\ Z%V=OAM_<TKJK.8#(CTWL1D+>.M>RXB<]"Q+2EDC8N7\*62N4L3\EU1F
M),[L[._6> SHTK\%@V9P8G&1G;EO#D9Q?GR=O9Y8OJ\,NC5$H6.#4N:N;C)2
MB^DH2V::^3333^!3'.\V,;5&&]M<9[5OHW.">T'\'S+8^-EL;8C8F.-W;AV?
MY>6?R]WO]W/^=7Y.ZIWQ;7NQ.@\E)-XU_#XP=*91W?F0;VFN,6SS<NY^+/3A
MJ6B*3@I?':;S&07>EFXXZ^/N",B;ZSL__C^M[UVQLKO=N+M;=+(;?ZKR>%CD
MF&Q<QD4WK6"R1@+!SDL+9\7'V9'B;P6LO -V*-W&O:A?@FU?Q1\,GKF#"G&M
MKJR*+O-IE;S.MIPE"=4I14IP4]X/F49[."W6W5>GP^\6*-.RI?3*;:XVU^79
M%;=U).,X\S49<NTEMS+I)O==GL!$5;OLZ=_=#UP8S=G2<M N!C+5.E6.W3<_
M)G._@+#^N50X8G*7'W,B1&[ -*(&*1IW]F>T+HC<+'_">B]3XC4-5NGQFQ]R
M.2U4(QZQCOT2<;M"4@X,8K=>$RC<9 $HR$GI1Q/P#JVCR:SL*VNO?97P2MQY
M;]MKJ^:";_4FXV+U@F6QT+BS3]2@I8>57:]MW7ORVK\:Y;2V7ZR3C\&SN5?G
M+&)B0$+$),XD)-U"0NW!"3.SL[.WDXOY.W++^^5Y6G&Q$9_:,[IC9O<3QK18
M$](9N3J(<WHTJV(F>5W<NJUCBK6,/=$B_HOCX]YW!R:*Q!([2#!YO]W)^[&D
M?'O:'NT=PL7$Y&-2$X,+J2.$6=^7I7K XZZ0BSN05,B-F1^D*U.:0NAK>:*3
M>%_%[7=*Y8U9;R*(_P#NV9OD5<OZL9.2NKC\(U6PC\C1>(O#C2-34O/Q80LE
MWNH2JLW^+23KF_BYPDW^1KN=3AE]/WSP^J<+D<)DX^>NAF:%G'VV$7Z7(8K4
M<1F#$SMX@,<?4SLQ.[.R^+8Q.-OB_#B+DWF)<.S\_)SQ[OUVX6P-W6V0T?KK
M'EBM8Z9PFI:!?0P9C'5KO@&WF,M66:,IJE@']J.Q5DAGB+VHY!+S4*?:"[A?
M2F2\>_MGJ:]I"Z_688;,C+G,!*3N[C#'8\:++XP?/I:=Y<J$8,S-2,N35C>%
M_:-TS)Y:]3ILT^Q]';%/(QF_CO"*OKW?HZK(Q];-NI '$/L^9=#E;I.3YB75
M5-JJSUZ<LGY,_P >:#?I'T((-B^U/NSM1X46A]79"KBH6XCT_><<MIUA=^7&
M+%7'D@IB3]3O\'E4-R(CZNM^IIK.S[W^>.E:&CNOI&;"V.KIES^D1L9#$NW'
M]&EPEN:;+TQ8GX>*M;S)] ];$1$T+1!;\=AK>;:TI9=0Z1OY##1%P^H=.1S9
MW#,'F[26Y*<)6L9&[,S/+DZE2%C(8AE*0Q%\ M=[Y:<Q%<WO-ZQ=Z7>.A5Z7
ML&7R>+S[%<'=O,Y>GR^A _H7WG5.">&N)*GDJO%O=G7Z;A60A=S/UG;2VIS7
MZN1"S9]X[KIKFB\4<6Z+D0PW3D7]5&./97*46ETWY+-N2'9N=<X12Z\VV[-A
M#MGVN-LM88.SJ/3FN-.Y'#4*LEW)6WR$-,\55B!Y)I<O4O\ JMW$M#&SG,.1
MK53B;SD$551[U;TBT[P7] =G>\\=0_&IYS=%X9HY90Y**2MH:*;PCB$B9^K4
MUJ$PDA?JPD!>)!E8ZLFYF[N4SLTS=3T*,C%%\'TY9 BD@=V?PKACT/=9^D7<
M9A\'J;J"$'Y765+%22MU/S''_3E\O_=;Y?U_=]=:GPQ[/^E:?F2RK[;-0A!I
MXV/D5P5=;_6O4?=R9)[<B<*ZUWE5-[<MF:.(\NW%K>177C72C]:JK'-)_JQ?
MW7^LHRGUZ1FUU?I-XD\LAD1S3SRRV)YI#*266>>0IIY[$LA$<LLTLAS332$<
MDLIG)(1F;N_TN@*X.3NW+,[D;\,S,S<O^L+>]_J_Z/IF(0CT@S-]5_+EW^J[
M_P#A[F^HI\.XB[KD]Y]9AN)K7%M+M;HF\$@5KU?Q*>L]453CEKX9HI1\*YA<
M8_YJSSNTM>>4:V'DCE"S>&O+O$O$6-I6%?GY<^6FB.^RVY[)OI736GWLLEM&
M*[+K*348R:\F-3*^<807?^I=W+X)?\=2P!Z/AW=D^T^W4VX6JZ+U]>;E0UK@
M5IP<;& T< C/AL7(Q"QQWLD9EF<FWDP--0HN#'0DEGL,KPS>[CRX^1O=^TO*
MYL\3\19&JYV1GY+^MR)\W*M^6N"2C75#?KR55J,([]6EO+>3;<CXV/&J$:X]
MHK;\7ZM_-OJ$1%@3]PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B *-CO5NS3_-(VFRS4X'ES^DC?5.#\-F>64J%>8,E0;RZC"[C)++#
M$+MU6X:<G!%" O).O#MS[_-G^1 :V\29V9V\V=F=G^L_FR\K-_O$>S:.UNZN
MH-/U(/ PE]PU#IP1C\.$,-EI9W"K![A>/'7(+F-$0X8 J W''#OA @"(B (B
M(#W<9DK%*S6NU)2@MT[$%NK.#\'#9K2A/7F!_D**6,#%VX=G%N'97YNQQV@Z
MVZ&V^E]90N#6<C1\#+P#PSU,WCY#HY:N0?1 +7()):_4PO+3EKV!;PY@=Z!B
MG[[BGM+/B]29O;')3]-'44$F>P#R2\!%F\>$<>0HQ@7+=>2QO%L.EP9BQ,HN
MTASAT@6E41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!T%VHM]:6VN@M3:T
MN^$387'224X)7=AN92=QJXNEPQ"1>MWYJ\+L)"709.SMQRU '.YRYE+U[)Y"
M<[60R=RUD+]J1^9+-V]/):MV)'^4YK$LDA/_ $Q.K!G?O]I4;>2T_M7CK'5'
MB_"U/J08I/)KUF":'"49V']%#2FL9$HC=FZ;E&=P=_!,:[R (B( B(@"\._'
MF_DS>;_6;Y77E9>]A/LY2;I;H:9TN<9EBAMAEM12"Q<!@,7)'9OQ.8\>&60X
MCQD4G+.$MP9!8G#I<"T)W0W9K+0&T]#(Y"N4.?UO*VI,B,@LTE:C*'AX*D_D
MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!<+W&U]CM+8#-:ER\S5\7@<5?R]^7WN-7'U
MI+,W0+>9RD$;A%$/)RRD$8"YDS/S10*]^EVEGPND\+MKCI^+^KY2R><8"=BK
MZ?Q,\+UH)69V_P"=LKT^'SUB\.*N"8BY1$X%:C>O=?(ZZU;J+6&5=_7]0Y2S
MD90=^KP(Y'8*E07;R\.E3CKTXF;@6C@%@9A9F;K!$0!$1 $1$ 5KWN->S6VG
M]$Y3<3(0<9/6TPU,61M[4&G,3/-&)1\^8MD\F\\\SMY2PT\>_'$;$5:#8'9Z
M_N!K736B\:Q^M:ARL%%Y(VY*M49CLY*Z_D3,%#&P6[AN[.S! [NS^Y]@1H71
MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB + KO0/B#W,^P</X5QZSU6!7>@?$'N9]@X?PKCT!1D1$0!$1 $1$!;^[C'X
ME+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B (B(
M"!OOW=A7RVB<!N!3@Z[6DLDV-RD@CR8X3.F$,<I\>\*V7"C'QQ[+7CD=Q #=
M54UL1-Y=L*.M=*:ATGDA9Z6H,3=Q<Q$+'X7K4)!%8$7=N3K3>'/'P[.QQB[.
MS^:U\6MM'9#3N9R^G\M"5?)X/)WL1D(2]\=S'69*D[,[>1@\D1%'(/(21N,D
M;N!"[@<81$0!$1 %:][C'M&MG=#Y7;R]8ZLCHJRUO& ;MU2Z=S,\THM%R7)M
MC\HUJ*5F%F@BMT1ZG\41&J$LP^P;VCRVLW0TWJ>60AQ!V6P^HA;GA\%E#C@N
MS.+?1O0+P<D <.YE38!X(A)@+YJ+\:]B.:,)8C"6*4!DCDC(3CDC,6(# Q=Q
M,#%V(2%W$A=G9W9U^R (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"P6[QSM&_S,
MMIM2YJM/ZOFLG ^G=.D+LTHYC+PS0Q686=VYDQU4;63'R-F]39S @8F?.E5%
M.^T[2HZKW%JZ)Q]AI<3H"&6&WX9<Q2ZDR<<$N0ZG'V9#QU0*M'WD]>R5^#V)
M/'% 0L"/#,S>YF9O[W^?^^OZ1$ 1$0!$7\D3,SN_DS,[N_U&;WN@)QNXOV$;
M.[@Y?75N'KIZ)QSU\>9?0MG<]%8J,8^YG.MB1R O]$P>N1DXL3QDULQ1[=U_
MV>GVZV>TY1LP>!F-0"^J\VQ!T3-=S,-<J\$S<\M)3Q<./ID!,+@4!"0"?7S(
M2@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q
M*O2JBUWFWQ][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z
M8O;/^WZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F=)?
MC)CE3&5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265VGNC
MOB$T5_=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/XDC$A(39B F<2
M$F9Q(7;AQ)G\G9VY9V?R=G=G51'O8>[Q_F<98]=Z/I,.A,Y:_-U&L!=&ELS9
MD=W@8&Y&/"Y&0NK'.+C'2L/)CO#BA]1\2WBN+ZUT7B]1XC(X'-TH,EB<M3GH
M9"C9!CALU; .$L9MY.SNS\@8N)QFPR1D)B),!KET6>?> ]B'*;+:N.D(SV](
M9F2>QI3,2>V4M<>DI<5>D86$<IC>MHY.69K=?PKL;-XDL4.!B (B( B(@"^G
MA<U<QMRID<?9GI7Z%F"Y2N5I'BL5;5:09H+$$H\$$L4H"8$WN)F7S$0%UONT
MNWM4WCTQZAEI(*^O=/5H@S],.F,<G69Q@AU!0AYY]7LD\87HA9QI7S\+RAGJ
MN<FJUX&R^\FH-O\ 4V*U;I>YZEF<1/XT!F+G6L1%[-BC>A$XWL4+L75!;@:2
M,CB)WCDBF&.4+SO9$[5FGMX-'4]58(VAF8FIYS$&?5:PF7CC [%&?D8WDCZ9
M!FIVA!HK=62.:/AW,  RB1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L]I3
M\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_P!+]MQ]C\O^,F95'E7A
MNZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 %_+CS[_ '?4_P W
M\F7](@(1NW7W.^ UR5S5&W/J.E=6RN5BWBB$H-.9^9W(I3*. 2^!LC-SSZU5
MA.G8E%FM5@.:6\%6G>38K/:3R]G3VL,+=P>:J._SJW$\921]72%FI.W,%ZE*
M[.\5BO)-7DX=F-C$A'8GKI??+L]:.W(PYX/66#J9FEQ)ZN<HE'=H2RBPE8QU
M^%PMT;'L@[R5Y0<GC#Q&-A85./ ?C7F:<H8NH*>=A1VC&7,OI5$>R4)R>UT(
MKHJ[6FELH6PC%0<=<3>'M&7S78SCCY#W;6WU-C_:BEO7)OO.":?5RA)O<UQ^
M4TU8I\D[>+"S_P!%!G=F;_MC[P?Z[\C\C$Z^2+>Y63^U/W)^J=/O8RFV5L]7
M8EG,WP5^6K5U+5BX<G:"8AJX[,"#-PXCZE</V1AJVI"=08:YVCM8N]8QN4Q]
MW!9>J739H7JLM6>,N7;Y]5G&.06=Q+ID!F ^.1<V\VM+H7%.GZK5YN!E5W;+
M>=>_+=5\K*9;60ZO9-QY9/[,I+J0;K&@Y6%-PR:95[]%+O7/^98MXRZ==D^9
M>J78ZWT_I$[HC)RY [^YO<SL_#L_'RM]?_Q7:=/3E.D+/,0L[?H6X=_V_J?R
M\EUG%7RV(<WB<O!/Z,H_GD)LS<=1"WM _'O=V!^/<3LN/9/4%F?ES/C_ +O/
M^;EW6ZT:A5""3BXR71I+HW\5^/S_ (]R,-4TG.R+G%Y$88_390W4]OA)=MUV
MWCONMFVNR[7S.OJ]42"!A#WM[/#D_P"W[_[RZ5SNNK5AR8"<6\_:?S?^][O[
M[O\ K+X%DG=W=_-_JKXLW_FO/=J<Y](^ZM_3O^_T_+]YG-(X8Q<?9J"G/UG/
MJW\^NY\FY.<C]1D1D_O<G=W_ /J^M[ES'05!_P T62;R?B /K^?7(_[7$;-_
M]]RN$6/=_?\ ]"[NT_CO5Z->/C@G!I#_ ._+P;_WN6']I8G-MVC\Y/;\N[_L
M7YF;U?(\NCE71V-1Z=/=75[?P7X,]@P7IFW]YU]20/K+TS%8V$MC7*Y_\?(^
M88?^RQ@W-S/K-XH0?F&H/A,WO9Y>>92_O\ WU&'GY799"ZMS+4*,T_EXG#A"
MS_+*3<!Y?*PO[3MY<LW'RK#RT3OU.[NY/R[N_F[N[^;O]5^>>7^59W3J]_??
MX+^U_EV_,WOA7$W<KY+I'W(?-O[3_)=-_F_@?#L-_+^^OBROQYM[+\^]G=O\
M[>:^W8]W\OKKG>W>VDN;F:29I H [LY@["<YL[?.XW=GX%O/KD;W<=(^T_(Y
MRM&^W9E=%<K;9*$(+=M_U+XM^B.H?ABY#YQ6K4;M[O#L3!^MQTFWU&_O,OJU
MMT]1U'^<9O("S>X9)WL W_Z.PTH?M=/G_>4EVE]BM-PU^NUB*4D;-YO/'XIG
MY>YR-W(G?ZO4L,.TOHG3V*L59,-&U*6R<K3T0D*2%HQ%G:Q&!N10^T[1N#$T
M9\LX@+@?/J\I)=4OW?\ T-7T'CW U+->%7BVR?O;6RKJG3O%.34O><H[I=-H
MR2Z;M>G$\3VH-45G9II*=X6XY\>J$<A?_?U7A%OVH_\ 0NX=/=L*L[B.4PT\
M3<MU38^P$S-]=H+'@%PWO?\ -#OQ[A=_?@H?O7CE?G+'@^\5^73_ .AO-_#^
M'9WHC%_&&]>WY1:7[TR7C2.]VF,PX!5RL$4Q^ZO<?U.9R?\ 0BT_0)ER_#-&
M9<O]#RLF-O\ <C4.EK89#36<RV!NB76UG$Y"S0,BXXY-Z\D8RLX^RXRL8N/L
MNSL_"K_XO%3WIXJM6%YYYBZ8XAXY)_-W\R=A$6;ER(B$19G<G9N765^E\%N=
MI>NUG'"=ZC"W7)0:8<E" ,WFSU#*.P(,S>;T29P9G+EFY=_#DZ7"R,H-1G&2
MVE79%2BU\))IIKY..QJ.JZ%CXTH.&=7CV2>]4<BV%4F^RY;$XM/?HO=ZOION
M6V>SGWV&ML$]>EN#CH=9XT7CCDR=*.MB=111,[L4I!#'#B<C*P.SC&<..*5X
MV:2TQF<RL'=G?M::#W1H/<TAG(+DT8==S$V6:IFL?YL+^N8V0O& &)V%K$7C
M5#)V\.P?++7*;:]JS#91XZF7#X&OD[1L<A$>/FEY87$;#LQ5G=_<-IA!N>CQ
MR)AZLT]':NR6$R%/,X/)6L9DJ9M/2R6.L'!9A)V\CAGA=GZ#%^"'EXI0)P,2
M G9X+XQ\$--S%*>+#]&Y3W:=,?[UL?PGCIJ,%Z<U#KVWW<)OH9?3N.-3TV:J
MS8RR*O\ .OZWE_6KOZ^9^$W/?MS0-A0SKRJW79*[ZJS3*##[OU_6:74$4>M,
M/1,K52)Q$>O/X:FTAW(P-G*3(86NU@8C%I,3*\,UV6PUH?7.&U+B:&=T_E*&
M:PV3KQVL?E,9:BN4;E>1N0E@L0$<9B_N=F+D"9P-A,79JH\4\%ZAH]OE9M#C
M&3:JOAO/'NVZ_5V;)<VW5UR4;(KK*"31,^B:_BZA5YN-9S;?;KELK*W\)PW>
MWR:WC+[LF<K1$6JF9"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(N$;B;DX#26)M9W4V7Q^#P],>JSD,E9CK5H^
M>>D>N1VZY3X=HX8V.60O9C G\E^E54[)1A",ISFU&$(1<I2DWLHQBDVVWT22
MW;['TLLC&+E)J,8IN4I-*,4NK;;Z))=6WT1S;E<6UEKG"Z=H2Y7/97'X;&P^
M4M[)W(*-42Z2)@\:P<8/(8@3QQ"[R2<.P"3^2KS=J+OTQ,K.(V@Q(RL[G$VK
MM1U)0CX\A:QB<!(\,Y._F<,N9\+H=A>?%2,Y1M!YN'NOJO7>3^%]7Y_)Z@R'
M+O'-D+!2QUF+ABCI518:M&)V$6>.K!")=(]3.[<J?.#_ &?-3S5&[49K3*'L
MU7*/F9DE\ZMXQIW[?6S\R+[TLA?B[QLT_ YJ\.#S[E]Y2\O&B_\ 2[2E;MW^
MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 5=#OX.S6\]+3FZ>-KL\E OF:U,X#[15+)^-@KQ\-Y!5M>
MMT)R)R)_7Z3"PA";JQ>NJ=\MI,=KS1^H]'Y5OS%J'$W,;)(S<G6EGB?U6[#S
MY>/1M-#<@ZF<?&@#J$AY%P->*BY?N#H3):7SN8TYF(? RF"R5O%WXO/AK-.8
MX3(.>'>*7I:6)W9G*(P=V9WX7$$ 1$0!$1 9&=DK?NSMEN+I;6D!R-!BL@(9
M2&-_SWA+P%2RU4A]TG53FDEA$F)@MPUYQ9I(8W:_CA<Q6R%.I?IS!8IWJT%R
MI8C)CCGK68@F@EC(7<2"6(Q,"9W8A=G9W9:X)7 >Y7[2;:OVR?2-VQXF9V]D
M@Q; ;_/3T[;:8\#*W/T4588+6+#A_G<=&$2$1*)S F/1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 >K=NQ5H9K$\@0P5XI)II9'88XHH@<Y)#)_(0 !(B=_)A9W=4
M(NVMVAI]T=R]4:M*0RQT]^6AI^(W_.^GL<9U<4W2SNP26H!^$+(,1B-NY.(2
M'&(.K/\ WQO:2?0^U%K!8^SX.>UY,^ J.!<308ANB;4%H6;VFZZ'_)@2-TO%
M+D@F _$B$2IKL@"(B (B( B+[FF-,Y#-Y+'X;$UCNY3+7:V-QU2/Z.Q=NS!7
MK0L[^0L<T@"1O[(#R9.PB[L!8?[ASLW#+)J/=3(5V=H#DTIILY1=R:1XZ]K.
MWH&?AF'HEJ8V.<6)W)LC78@Z)1.RJND^SELI0VZT1IO1F.Z2@P.,AJRSB+#Z
MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'A4Q.]_[-GS!;L7,M2K^#@]?!8U)2<&
MXA#+/,PZBJCPS,)M=FAR) W(L.4CZ'9OG<=SQ1E][%V:WW#VERT]*MZQG]&M
M)JC#C'%XMF>.E"7POCX.GYXYW,8TQ1P@QO8MUJD;1N?08 4HT7AG9V9V\V?S
M9_K+R@"(B (B( B(@"(B (B("2[NHNS7_-$W;Q$UV#Q<!HUX]49=B%BBFGIR
MM\"T3ZO9<;.3&*::-Q)I:E.S"3,TG4-V)10]SWV:FT'M34S-VOX6>U[)#J.\
M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B<H B(@"(B (B( B(@"(B (B( B(@"
M(O'* \HO2R.2K4X)+5NQ#5K0CUS6+,L<$$0-PW5++*0QQCR[-U$3-]=8$;U]
MZYV:]NCFAUGOAMKA+< /))CI-4XRYE7 >KEXL3CIKF2GX<7'B"K(77P''4[,
MX$@B*O#K;TIOL78GJ:GN+J#49@Y"X8+;C7_#D+FSL$^9T]AJLHNX,P2Q3G";
M2 02$'40]&VO2]NR7&1B%?=F=A^A./048A)Y<^QXV<B-N?=[8!^MQYH"T@BJ
MQT_2_.R@<8%-0W;@E)O;B^8>M*T;\\.WB1Y[I-F]_(MYM\G/DNX-'^E:=C3)
MFPW=9:PT\+N[>)F-M]9S@S,[<$[8#%9R3AV?EN <N&?D6?AG L>(HNMG>^N[
M)^O3@ATUOUMW-:LFT5?'Y7,MIG*S2/U/T1XG4\6'R1$S"[NS5?9;S+AG;F27
M3FK,5F*[6\1DL?E:A>0VL;<KWJ[^7/#3U9)8G\O/R+W(#D")RB (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
M0?$\7QH_HNGP_+J?/! =)]I;XN-?_:3JK\!7U"SZ/K_T4W&^V'"?@F13N;EZ
M.^:+3FH-/^L>I_#N$RN'];\'UCU7X3H3TO6? \6'Q_ \?Q?!\:+Q.GH\6/JZ
MFPM[OOL'ML3BM1XSYJGU5\/Y"E?\=\(V$]4]3J%5\+PVR^6\?Q.KQ.OKAZ..
MGH+Z) 2$*J=VL]/7>S)VC\1N-@*ICI+55F;*24H6^=G5N'##K+"1MR =8RS-
ME\=&Y"$4EBG%PT5;J*UBL.>V_P!CK%;UZ.'2]^_\"W:F2K97#YT*(Y&;&6X1
MD@F9JKVJ+V*]RG//6G@];A$NJ*?EY:\3B! Q!9D[6':<@E#Q;>VVC68Q(HY(
MJ[Z:Q,Y2@[Q2"SM9U7G"C$QE$)RQC^V+CCAB&U5'&("("+"(LPB(LS"(BW#"
MS-Y,S,W#,WDS+!'L%=A3%[&8#+8ROE_FCRV;R?KV0SLF,'%2'6A@C@H8V*HU
M[(^'6I\6)N7MF4UBW/(3 /AQQYXH"$/O[OB@TS]TO#_BKK-9Y]WI\2.V/VIX
MW_4)?+[>W8V;?#2&,TH^HWTQ\':EIZB]?;$?#/C>J8K,XSU/U7X3Q7A^)\+^
M-X_K!]'J_A^ 7B^)%WSV>MI/F"T1IC1OPA\*_,YB:V+^$?5?4?7/5V=O']4]
M9M^K]?/]"]9GZ?\ XA(#N1$1 $1$ 1$0!$1 $1$ 6D7[8'QO[N?=5W(_'3.+
M=T+2+]L#XW]W/NJ[D?CIG$!CNMCWZ&O\0&Y'W7;WXI:66N$6Q[]#7^(#<C[K
MM[\4M+("WJB(@"(B (B( B(@"(B (B( M:/Z8G3 .U'HZ83!Y)]B]+#)"+#X
M@-7UUN3X<Q\/U.T[3%&#D+?G8V$BZ7$-ENM7EZ6GN%%FNU]9QT3LY:1VLT'I
MVQP/'3/8N:GU8P$_N(O5]45SY;W 8#\B K.K,#N\?IA-@ONX[0_PB:<6'ZSW
M[JS15C47:;[/V)JB13'N_H3)<!T\^%I[/5-26'?J\NGU?$2]7'M=//3P_#L!
MN>41$!#WW[7;CDV![-.O-78ZUZKJK.10:&T20OQ)\T^J1GK0V8O<[/B,7%E<
M\;BXFT.+D>(O%Z&?4'Q1L B#<NPLP\D[D3\-QR3OYN3^]W?S=_-U=-],K[43
MY37VU>SE.P)UM*X&[K_.0CY]&5U'/8PF" R$N&DBQF-R\Q02 \@17JLPN$=A
MO&I;( KNGH@O=R5<SEM2=I;4^/&>+35V]HG;,+,;]$69DH0_-;JBLQ<-))7H
M9%M,TK LX0G8U!$Q%8%_5J3.*PU[)6Z>,QE<[>3R=RIC<94C$CDM9'(6(Z="
MM& ^T1V+<T,("/FY&S,MU-V!^RGC-D-G-O-J\3& P:/TW2Q]J0&C_-F8FZ[^
M>R)E&$8239+-V\A?GFZ!>::R<IMUF3H#+Q$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$!5=]*K[N.MNCLJ^\&#IL^M]E*N0R]@X0)Y<MM]8\*;5&.G:-G>4L0U:'4.
M/DD$FJM4R<(G!#D;<BUF#/S[EO6=0X"GE:%[%Y&M%<Q^2IV:%^I8C&6"U3N0
M'7M5IXC8@DAG@DDBD A<3 G$F=G=GTM?>"]E*;8[>S<O:B1I?5M':HMT\,<[
MD<DVF[T<.7TS,<AB!S$6!R&/$[! #V)!.;I'KX8##M;([T1#MLGK7974&SV7
MME-FMGLL!8@9CZI)-$:LGO9#$A&[\$\6*R\.9Q@QMUM5JACPZ@BEKPAK<5/A
MZ-#VFVVU[7.AH;%AX,7N/C<SMKD>J7PX"ES+5LMA"FY+I<OAW!4*U?V")YKC
M1#T#-(; ;8!$1 %I^._,[)8[,=J7=72U2L-7!YG,?-]IJ*/^A1X76QSY8JT8
ML #''1S+Y>A!%'UA#6K01>(\@2 &X'5'/TR[LC>MX3:S?3'U2*;!V[6V^J9P
M%N/@G,R2YC2\\Q.3.P4<U'EZ<0@!N1Y\C+HCB(D!0;4W7H[/:I+:?M:;;7)[
M+5\)KHLCMGJ'K( B.GJJ.*3$'))()='J^J\9I^9G#IDD$3K 7YH=GA%7N8W+
M7<?9JY'&69*62QUJMD,;=A+IFI9&C/';HVX2;GIEK6H89XWX?@XQ?S]S@;V1
M%B-V">TU5WEV7VRW/J] OK31F"S5Z&/EAIYB>C$&;H,SF9?F'+QW:C.Y$Y#"
MQ=3L3.^7* (B( B(@"(O5O7H:T$UFQ($->O%)//-(3!'%#$#R2R2$_D(1@)$
M1/Y,+.[H"@)Z9;VLWR&J=J-D<=<=ZVGJ&3W%U54!VZ3RN6XP6D6F9Q8A.EC(
MM43#TD4<@Y8'+B2NS-246=/>:]JJ?>S?_=C<LY2DHY_6.4KZ=$NIF@TE@IGP
M6E8A I)1B*3"8^I=MC"30R9&Y=LQBWCOS@L@,X^[0[*LF]V_NU.U_@/8HZFU
M93+/"P=8!I?"1S:@U-),/DSPOA,7=@(2(!E.>.!C$Y@=;H+'T(:L$%6O&,5>
MM#'!!$'T,<,(#'%&/O?I !$6Y^1E0(]#4[([9#4VZ>^5^N3PZ>JU=M--S$#>
M'\(Y2*GJ+5!PG[7,L&/^9N(_Z&<<=[@2,)Y!'8!(#@^YFWN,U;IS/:6S, V<
M3J+#Y'"9* Q$QEI92I+3LCTFQ"[^%,73RSLQ,S_(RTF/:3V'RNUNXFNMMLW$
M<63T)JS.Z6L=8R#ZQ'B,C/5I7XO%$3.KD\>%3)TI^.FQ3N06 <@D$GW@RUK_
M *7MV0VT;OKI3=7'U'BQ6[FFI:V3G 6:)]7Z(]2HV?%Z!]FQ=T]D<*<1SR==
MD,=:& 'CH3.(%2]6B_1,^V V@NTA8VZR-@XL)O)IZUB*K$7%>+5^EX+>H,*1
M]<@QQ/D,5%G\<T@@<MBZ6*J-Y&*JZ+M38K>/*[=ZWT?K_!.39C16IL+J?'L!
M/&4L^&OPW"JM(+L4;788Y:9R"[$$=@W%V=F= ;QQ%U7L9N[B-P-%:1UW@)VM
M8/6>F<'JG$6&$@\7'9[&5LI3-P+VXS\"T#212<21'U1R,QB3+M1 $1$ 1$0!
M$7QM19^KBL?>REZ48*.-IV;]R<N&&&K3A.Q8E)W=FXCBC,G\_<R UR?IA/:J
M;5&]VB-JJ5IY*&U^E9<ME8 .(HH]3:X*K8$9&!O%"W5T_C,=(\<K\!7RD<D7
ME:D5119,]M'M%6]W=WMS-SKDQ3EK?6V?SE,B\3YWAI;LE?3U6,92*0(*6GZV
M,I5XS=SC@KQ@?M,_.,R D![JKLKS[U=HK:';L(GEH936.-RNHWZ"((M)Z7/Y
MI-1O(XBXQ^M8W&2XNN<O$3WLA3A)R*48SW-->O'#&$40!'%$ QQQQBP!'& L
M(  BS"("+,(BS,S,S,S<,J!GH9O93>]J'=O>R_59Z^$JXS;735HF%W?)7PBU
M'JUHB9^H'KX]]*QFQ-TR->\N7AY:_P H B(@"TK?>/?3&=H3[N^\?\(^I5NI
M%I6^\>^F,[0GW=]X_P"$?4J PS6PF]"U^+#?'[I.#_%*DM>RMA-Z%K\6&^/W
M2<'^*5) 72D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 4[/3.OB-VC^[&'XAZ
MR6NB6Q=],Z^(W:/[L8?B'K):Z) 91]AOX[=F_NJ[>?C;B%NS5I,NPW\=NS?W
M5=O/QMQ"W9J (B( B(@"(B (B( B(@"(B *DSZ:??C;0>PE5^AYI-=:KL-[0
M^(,<.F8XRX#Z/H,IPZB;@6(!9^7=N+LRUX/IF6^-?([H[1;=UK'B2Z8T=F-4
MY:NS<C7GU/E(\=B"<O<TLE;!90CC^C&-X3)A"6-Y *9J^=F/SI:_8\W[F2^B
MNX>SOM)>U_N%H+0F,C\3(:TUKI72M4>'=F/.YRCCCFD^08:T-B6S8D)VCAKP
MRS2D,49DP&Z;[+T11[9[=@;=)AH72($+^\2' 8\2;R^H[.R[T7SL/BH*%2K1
MJ@T5:E7@J5XV]T<%>,880;ZP1@(M^LOHH JR_I:_TH&3^Z-M[^%I59H59?TM
M?Z4#)_=&V]_"TJ U>Z^=F/SI:_8\_P"Y$OHKYV8_.EK]CS_N1(#>]U_Z''_W
M!_U67[+\:_\ 0X_^X/\ JLOV0!$1 :^+TTSXPM@OM-U]^&],*E8KJ?IIGQA;
M!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN @
M/FY?$5;]2U1O5H;E*[7FJ7*EF()JUJK9C*"Q6L0R,4<T$\1G%+%()!)&1 3.
M+\+5E^D'=R]<[,^N"UMHRGXFR.O,L0:?:%I"?0VH;$,MNQHR^Y=3-CYV@M7=
M*V^MF.D$^'D 9\7%->VHRZ7[0_9]TGNKHK4>WNN<3!F]+:JQLV+RV/G9O;AE
MX*.Q7D<2>O=ISC%<HVP;Q:MR"&Q&['&R T>Z\?K.[.SL[$).)"[/R+B3.SB0
MOPXD+L0NS.SL[,ZDP[UKNR-7=E?=.YH3/>L9/3>3CFR^WVL"B 8-4:;\=X6\
M=X>8*^H,1)T4\]CN(CCE*MDH( QN4H$<:" V1OHTG?>%N_@JVQ&Z>6EGW6TK
MC)9=+Z@R!Q]>X.D\>PBT<TS,'B:KTY7*.'(@8>+F,6$.9&2Q:BS+U[<:T7>@
MM>9O2N<P^IM,Y6Y@]1:?R-7+X3,X^3P;N,R=*09:MNO([./5&8\''()PSQ%)
M7L1RP2RQEMC^X^[WG"=JK;4;%^2GC=UM'P4J&XNFX >O$=F6)QJZHP<)R2^)
MI[.G#.40A+)+C+L5C'VQCZ:LEH";5$1 $1$ 1$0!$1 8[=K[XI=T?N=ZV_%K
M)K2#X?\ .E7]CP?N0K=\=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"@/HK;!^C$
M_2/[+?LC=/\ AFW#6I\6V#]&)^D?V6_9&Z?\,VX: GM1$0!5AO2LNV^^V/9T
M+;_%W/5]3;W7K6D(HXY&&=M'4(:]O7-KI8AD]5EHVL?I^P8=3-)J*O%(#Q3&
M[6>5JZ/2LNU%\WO:EMZ3JSO+B]H],XS28 W+1AG,R$6I,\[>?09^'<P]>20/
M-BJO7D=CKD  5IEX(F9G=W9F9G=W=^&9F][N_P C-\KKRLU.[C[+_P#-IWXV
MHVM.(Y:>K]7TJV7 &9W^9[%06=0:E)V?] .G\1DGDX\VCZG;A^'8#8J^C!]W
MU7V=[/6,UOE*(PZWWJ@QNM<M8ECZ;=72TE>271&$+J;JBBKXJ]+F)(.?*]F[
M;R<$S1Q61UZ&+QE>E5K4ZL005:D$-6M#&S#'#7KQC%#$ MY"$<8" LWDS,S,
MO?0!$1 $1$ 1$0!$1 $1$ 1$0!$1 12]]CV-(-].S5N7HT*D5K.T,--J[1Y&
M!G+7U7I:&;)XPJOA1RS-/=CCM8EQB%GL09&>I(7@6)F?3Q5IVECCE%G89 "1
MF?WLQBQ,S_)SP_GQY+>[*LEF?1)^R+<N6[C4]QZ36[5BTU/'ZWDJ4*C6)CF:
MK1JAC'"M3K]?@UH!=VA@ (V=^GEP-7ZMA/Z&;VBSR>W.[&U=F8S/1NJL;JS&
M1./ 18O6M.>"=@-WY,BS&G[\L@#[,32QDXB4W5)F3^5%>R-_2;I??_-_NQ2#
M]W7W)6RO9>U+G]5;7'K0,CJ7!AI_*Q:BU,6:HS4H;\&1@D"L5*NX6Z\\!##/
MXC]$-JW&P/XSD($O*(B (B( B(@"(B (B( B(@,;NV3\4&ZOW-]<_BQE%I#\
M/^=*O['@_<A6[P[9/Q0;J_<WUS^+&46D/P_YTJ_L>#]R% ?16V8]&D^DFV3_
M &/KC^$C6"U,ZVS'HTGTDVR?['UQ_"1K! 3L(B( B(@"(B (B( B(@"(B (B
M(#74^F$=BFOIC<W1.^.'IA7I[ET#TMJR2(789M6Z6I1/AK\PB'2UG(:6C]0.
M4Y&>6#3M4 BZHII#IRK;&>DH]FB/<KLC;B]%9K&5T"6.W*P;L#G-%=TO)*.0
M]781(FEMZ<R&=QI./#M#>F\W9W$M3DS\LSMYL_F@.5Z$UWD]+9[ ZIPLIP9G
M2^<P^I<1-$?AR193 9*ME\>82</X9#<IPNQLSN+^TWFRW:79BWSQNYVW6A]Q
M,03%C=:Z5P>IJG2W2PQ9C'P7?#Z7.1P>(I2B<",C!P<3?J9UI UM#O1.]]SU
M7V2\1INS8\:YMMK#5NE1$B.26/%7LI)JG$ 9F1?.X8,_+2J1CTA!3I5X  8X
M@Y LQ(B( M7)Z65].%DON9: _=-0+:-K5R>EE?3A9+[F6@/W34" K5*U9Z'U
M]-#J;[CNH_QGT>JJ:M6>A]?30ZF^X[J/\9]'H#9B+K7>+9_36X&EL[HO6&(I
MY[3&I<;9Q.:Q-Z)I:UVC:!PDC,7\Q,?*2&8'&6"8(YH3"6,";LI$!I]>^)[J
MC4W91W0ETS<.;*Z"U*=[*;:ZJD9W?)X:*87FPF4-AZ0U)IP9Z];)@SN-ZL=/
M,0, 7):U2)E;I3O">P9HKM'[7Y[;'6\!#5R(-;PN:K1PEE-,:AJB;XO/XHY@
MD$;-.4G&:$F\*[2EM4)V>&R:U"/;2['6M]@]R=1[7[@8]Z>=P%ABKW(A?X-U
M#A++D>(U)A9NHQFQF5K,T@AXA3T+0VL7>&*_1LP@!CIIG4V2PF2Q^9PN0N8G
M,8B[6R6*RN.L'5OX[(TI@L5+M.S$['#8KS $D9L_'+<$Q Y"^U4[@SOEL?VH
MMOBPFIIHJ>\V@J&/K:VH]$->'4M0Q>M3USA(86"+U3*R0&.8H0Q1? F9>2NT
M(8ZUB9[6J07?W9;[3VL]F=?:;W+V_P F6*U1I>\%NH9.14LA5)Q&_A,O +MZ
MYALQ58Z61JN[.\1M/ <-N"M8A W>2*/;NRN\6T9VG-K,1N+I,_5;;O\ !FK-
M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 5?STH?Z23=G[)[7_ ,+&B58#5?STH?Z23=G[)[7_ ,+&B4!JDE\W,_G2
MU^QYOW,E])?-S/YTM?L>;]S) ;QKLW_%WH+[2]+?@.BHGO2#.[L#M"=GG4=;
M$8X;NX.WT5O7.@7C;B[9R&,J2'EM/5I/_P#)L3'/CHX)/G$N2;&2R/$5>*S!
M+#V;_B[T%]I>EOP'17<[MSY(#1&12B8B8^8DS$W+.S\/Y^;.S.S_ %6=F=G\
MG9G9?HI_O2/.[GFV&[0>9S&(I>#M[NS-<UII,X@%H,;EISB+5^G#<.&$ZF9G
MDRM%B$'/%Y>M"+SRT+4Y0 H#9B^BD=XE%N=LI+L_G;SR:RV3@H8NE'.?SW(;
M=W'GATK9K=3\S!@?5)M.6A%R>G#5Q#S-$%^J)VJUIH^ZE[=]_LX[ZZ(W-A,R
MP5:^&#UQ2'EVO:'S<T%;4'2#.S';Q<+1YS',[MU7\9! 1-#/-SN0-,ZDH9G'
M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
MMTOR8SZ9S6#M/(8 [RS3 W6T?B'8;6K ]' [V2CV<-U;FF-<WPH[3[HE3HY[
M(RA*<>E=55?S/I_4TOAGQ'B9PEDP^H92AE>M6EH93K@K8RXT^TSQ^0@MUX+5
M6>&S5LPQV*UFO*$T%BO, R0SP31D4<L,L9#)%)&1 8$)"3B[.@/<1$0!$1 $
M1$ 1$0!$1 %7*](C[H[7_:KTOMK4VTLZ0IZAT7J3+7;D^K\MD\34DPN5Q)59
M:]6;%X+.RR6'O0TIBCE@AC\.(B\1R815C5$!K(_RH'VL?Z][(_?KJ[_ATN^.
MRQZ*=VHM%;H;:ZRRN;V=^"M(;@Z+U1E&QVK]46+YXS3^I,;E<A%2@L:!JP36
MY:52>*O%-:KQ'*8B<T0NYCL9$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!:1?M@?&_NY]U7<C\=,XMW0M(OVP/C?W<^ZKN1^.F<0&.ZV/?H
M:_Q ;D?==O?BEI9:X1;'OT-?X@-R/NNWOQ2TL@+>J(B (B( B(@"(B (B( B
M(@/3R%^"I!-:M315ZU:*2Q8GG,8H8((0*26:60W$(XXHQ(Y#-V$ %R)V9G=:
M7CO)^U''O5OUNKN?6DDEQ>J=6W9<"4A2$[Z<QD<.&P!AXHC)''8Q>.K6PA,!
M*!K'@N+/&ZO!^D]]\_BM"Z0S'9SVYRXVMP]9X^7'[@9''6!<=$Z/OP=%S%32
MQ\D.HM45)BIPUHS"7'8D[EVR\<LU"*?7.B+"S"S,S#Y,S-PS,WN9F^1F9 ?T
MK$GHM.Q9ZS[7VE\B=<I:6WFE-5:XLRL+N%:P$-/3.,<C^A&26WJ-QC!_:DC"
M<@9VA,@KMK9&^B*=AN?0VS6H-X\U3*OF=X\A V$\83":/0NEIK]+$RM$;NT<
M>8R]C,Y6*81![N/DQDQ>)!'4D<"W&B+Y^6NM6JV;#NS-!7FF=R=F%FBC(W<G
M?R9FZ>7=_)F0&G][]#>4M>]KK?;/M9>U6@U?#IG'&Q$\4>/T?A,5IF** '\H
MH_'QEF:0 $6*W/:G)GEFE,XH5S;<S7LNJ]3ZGU5,[O+JG4NH-2R\^3]>H,O<
MRY,[/P_+/<X?R9^6\V;W+A* FC]'J[.\.Y/:\VDQ]N$)\?I3(7MQ;T4@]<9M
MHVLUW%N3.[")0Z@FP]J,G8V\2N L+&0&.W-6NN]#'VL]?WAWCUD<8F&E]NL#
M@(B(6=X;.LM13W6,'<'Z3*OHRQ%U,8%X9R@PF)DX;%% $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!:XCTQ?LXQ8'>W;[<RG T<.X.ASP>7..(0"3.:*OFU:S-*W
MG+:N8/-5:C,7+C5P43#PPNMCNJ@WIDVVH7]@MN=5\,\NF-UZ5'EOHFKZETWG
MZYN[]+^QZQCZHNW6/MG'[)>\0-<0N5:#W%R6C\_@-88:5X<OI'.X;5.)F8G%
MXLGIS)U<S0-B'VAZ;=*)W<>";CEGY9EQ5?E/$T@'&7T)@0/^L3.+_P"9T!O3
M=$:MJ9_"XC/4"<J.:Q>/R](G]Y5,E4AN5R?ZY0S [_77*%&OW.FYLNL.RUL-
MJ&Q-X]F[MGI>.U)U$7%FACXL?/$Y'P3^#)5*+GW>QY>7"DH0!1U][-V28]\.
MSMNMMP,<9Y/+Z6N7M-R2"S^KZJP#AG=-S,709QB67QU6O9*(?$*G/9A9B:4A
M*11$!HD'"0'<)HI()HR*.:O,!1S5YXR>.:O/&;,<<\$HE%-&;,82 0FS$SLO
M"EH[\OLEOLQVI=U]+5ZS5L'FLT^OM+"+<1O@-;/)F/!B;J,FCQN;/-84?$=I
M";&-*[.,@D42Z V+GH=7:W+4FT>OMG\C88\AMAJ:OF\()F+2'I/70W+00Q@[
MO)-\&:DQ6=::0?G=>KDL36>./V#GN*+5'>C.=K@-K.U=H_'W[95<#NK6L;:9
M%G-@@++Y>2.UHXYFX=S.745:OAZP,XMX^;$RYZ!XVN* (B( B(@"A7](*[8D
MVR_96W(S>,LO6U-JBK5V^TL82O#-#E-86!Q=S(0FPR.TN%P)YC-0BX/'-8Q\
M%64H@L/*$U"UY/ICO; +,[B[=;'XZ=BH:+P3Z]U(P.W#ZAU.=S&8.D?DQM)C
ML#0M7Y1?F(X]043!WEAE8 *8,,0Q@$8-P("("WOX$69F;E_/R9OE7\V)ACC.
M0N>F,",N/?TB+D_'U^&7[*2?N@>Q['OMVC]KMN[M4+N L9P=1:MK3")03Z3T
ML+9G,5+(FXA)6R;5Z^(L1=0G-!D)(XG:4@=@-G+W'_8^_F(=F3;#1UFJ-7.W
ML,.K]5"T;QREJ35KMFL@%CJCCE>:D%FOC&:9GDAAHPU6?PX $99%X9>4 5?_
M -)?[(H[J=E+7%^K5:QGMKFCW.PY!!XU@:^FXYCU+%"_6#Q--I>;+O(3-([C
M"PM$9./%@!?)SV$JY.C=QMV$;%+(5+%&W ;,035;<)U[$1B3.)#)%(8$SL[.
MSNSL[>2 T4K.S^;>[ZWN?GSY_;_^KR19;=O7LNV-E-Z=S=J9XY(X]$ZMOXW&
M>(\A%)I^V$.8TQ.QROXLHV-.9+%3#/+Q).Q^,;,1NL24!LX_1-.V''N!V;Y-
MO;ED9,]LOFSTW) 4XR6/F5SA6LSI*YX7+SQU'!LOAJTDSNTD^!NQ0<15Q ;1
MJU=?HJ7:Y_F==IVOHV[9\'";QX&QI.4#?YT6I,*UG/:7,N98XPD(1S>/A,AD
M,Y,B%:('DL-SM%$ 1$0!$1 % GZ2EVKY-K.R9N &.N>J:@W"]0VWPI!,T5@8
MM3V!@U%8K\?/7DKZ6CS1 <3B<$QPS=8,'*GL6NH],:[6)Y_=C;O9NC/)\';?
MZ8EUCG(Q-VAFU-K&:2GC898W]\V(T]BCGBD%^D@U+*!,1Q-X8%.01869F9F9
MF9F9FX9F;R9F;Y&9O<R_B>88P.0O(8P(R?W\"+.3^3>?N;Y%^JD1[IGLGCO=
MVC=I]N;-;UK$9/4T.7U)"XL<9Z8TO%+J'-Q6!)Q8JURMCFQLX]0/(-WP@,99
M(W0&ST[C?LB#LMV7]J]*6*7J6=R6!@UCJN(@<)_FDU>(YR_#:8P&5IZ VH,:
M<<CD\#4FKQDT,48#+6OY 6%F%FX869F;ZC,W#-_>7]( B(@"TK?>/?3&=H3[
MN^\?\(^I5NI%I6^\>^F,[0GW=]X_X1]2H##-;";T+7XL-\?NDX/\4J2U[*OU
M^AR[I:8T]MIO7#G]1X'!RV=Q<++7BS&7Q^,DGB'2E,"EACNV(3EC8V<',&<>
MMG'GJ9V8"\*BZ4_GE=N?T_Z*^^K!?^O3^>5VY_3_ **^^K!?^O0'=:+I3^>5
MVY_3_HK[ZL%_Z]/YY7;G]/\ HK[ZL%_Z] =UHNE/YY7;G]/^BOOJP7_KT_GE
M=N?T_P"BOOJP7_KT!W6BZ4_GE=N?T_Z*^^K!?^O3^>5VY_3_ **^^K!?^O0'
M=:+I3^>5VY_3_HK[ZL%_Z]/YY7;G]/\ HK[ZL%_Z] =UHNE/YY7;G]/^BOOJ
MP7_KT_GE=N?T_P"BOOJP7_KT!W6BZ4_GE=N?T_Z*^^K!?^O3^>5VY_3_ **^
M^K!?^O0'=:+BFDM=X3/P26L%F<5FJT4CPRV,1D*F2@CF86-XI)J<TT82,!"7
MAD3%TD+\<.W/*T 1$0%.STSKXC=H_NQA^(>LEKHEL7?3.OB-VC^[&'XAZR6N
MB0&4?8;^.W9O[JNWGXVXA;LU:3+L-_';LW]U7;S\;<0MV:@"(B (B( B(@"(
MB (B( B+BNM]<X73.)OY[465QV#PF*KE;R66RUR"ACJ-8'9BFM7+1QP01]1"
M+%(8]1D(#R1"S@?AN%K_  VE,!F]4:BR-7#Z?TYB<CG<WE;THP4\;B<34FO9
M&]:F-V"*O4J033S&3LP@!._N6F@[R?MBV=_M]-R-VI@F@IZISK!I^G.1/)1T
MKA*=;!::K.!!%X!R8G'5[UJNT4?1D+MPI&.Q)--+/5Z07Z08.^@W-F=F;ENM
MM'7M$&K-3E#ZM8W*M4YP.M5QH&[V:NB:T\366*:.O<U%8&O++%7Q4 Q9*IJ@
M"M1>B9=B.SN!O]>W5R-(STOLWB3L5;<L)>K6-<ZE@L8_#U:\SD,9V<9AFS&2
MM +3O4:QBSF"$KM.0JV&QVR>J-R=8Z;T!HK%39O5>K<I!A\'C(.>9[4PG+)-
M/(PGZO1H58K&0R=PA>.ECJMFW+[$)+<$=UAW?6"[,^S&E]L<5)%?RE:%\KK'
M/QQE$6HM7Y(0ES638#.0H:@S"-+%UNMVJXRI4A?F09)# D51$0!5E_2U_I0,
MG]T;;W\+2JS0JR_I:_TH&3^Z-M[^%I4!J]U\[,?G2U^QY_W(E]%?.S'YTM?L
M>?\ <B0&][K_ -#C_P"X/^JR_9?C7_H<?_<'_59?L@"(B U\7IIGQA;!?:;K
M[\-Z85*Q74_33/C"V"^TW7WX;TPJ5B FP]'0^G/V0^R>J/Q'U*MN M1_Z.A]
M.?LA]D]4?B/J5;<! $1$!'CWG'=R:+[3VUN5V\U7''4OMSD=(:ICK1S9/2.I
M(0=JF5H$7!%!,+E2RU'K&+)8R>Q5EX)XI(M1#VJNRWK39;<#4FVFO\6>+U-I
MF])5G'I/U/)TG,_@[/8>8V9K>%S-41N8ZR#N_AF5>PT5VO:KP[NQ5_\ O[.Y
MCQ?:CT&.<TU7KTMY]"X^_+HG)%,U2#45.3P[5S16;E?YR=7)25P?#7K;?\B9
M4O%">O0O98; &J/65?8G[96MM@MRM-[H:"OR5LQ@;3>N8X[$\.+U-A)_8RFF
ML[%"_3:Q>2@=V;Q(Y2H7HZ>6J UZA6,<;]3:9R6$R>1PN9H6\5F,/>M8O+8N
M_"5>[CLC1F.O<I6X#]J*>O.!QF/FSNW4!$!"3_$0&Z:[OSMW:)[1FV& W-T/
M:YIY2%H,OAISC?*:8U!7$1RNG\M'&1,%NA8=Q"4>8+M4H+U4Y*UB,WS66H)[
MFKO9=2=E'<R+. ][+;;ZEDK4-Q])0%XGKF/ V&'46(KR&$0ZEP0.9U"8X?A&
MD5C%V9'"2L4&VTVGW6T[KK36#UCI++4\[IG4F-JY?"9>A)XM2_C[D;2P3Q%P
MQ#R+],D4@A-#*)PS1QRQF @=A(B( B(@"(B QV[7WQ2[H_<[UM^+636D'P_Y
MTJ_L>#]R%;OCM??%+NC]SO6WXM9-:0?#_G2K^QX/W(4!]%;8/T8GZ1_9;]D;
MI_PS;AK4^+;!^C$_2/[+?LC=/^&;<- 3VHB(#TLED8:E>>W9D&*O5AEL3RES
MTQ0P 4DLA<,[]( )$_#._#>Y:13M4;N6M?[I;F:[N$1V=9;@ZSU,;E(4O3'F
M=19&]5@ R=W:"K4EKU:L;/T0U888(Q&*,!;<5=XQN>>BM@]Y]61\]>GML=:Y
M4>D1,N:>G[\G(B0D).W'+,XNSO\ (M*G1@>*"&)_-XXHP=_JN ,+O^V[(#VE
M;B]#P[/T&?WZUUN%;@:0=OM!?!^+.2+J"++:TR#59K$,O3\[MP8C$W:OD;<U
M,K9$@+K$AJ.K8>>A?;=#7VBWFU=TBYYG=.EIMBY9R8-,Z,P.3<>.>1%RU;R_
MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 6H%[^_P"G'[0'VY5/Q8P"V_2U O?W_3C]H#[<JGXL8! 1$J\'
MZ%-_TC[2'V%VE_?VY*H^*\'Z%-_TC[2'V%VE_?VY* OVHB( N&[B_P#1[._8
M;*?O&=<R7#=Q?^CV=^PV4_>,Z T6&'_.E7]CP?N0KZ*^=A_SI5_8\'[D*^B@
M-J%Z*U])KHC[9]?_ (UY%6+E71]%:^DUT1]L^O\ \:\BK%R (B(#7P^DZ=Q\
M&D;F7[2NTN&&+2^2M-;W8TMBZO3%@,G<E=I=>XZM W3%B<G9DC^:F"*$8J%^
M0\^9#7M9.2"E;RMZUGL#2RE&YC,E4KW\=D*L]*]1MPA8JW*=J(H;%:S!*)1S
M03PF<4L4@D!@1"3.SNM5MW_?<O7>R_KIM3Z/J6+.R6N<A8/35GJ.P6C,U*16
M)]$Y.1PZXJ@ 7B:5NV9)"O4(Y:$L\E['F4X%>Y79O1@.^Y^9RWB^S/NSFY3P
MF2MO7VCU/E;3R1X2W, N&WMZU,[O#BK<P2R:3FGD*.I;G/3P'%5DPM:*DROT
MBE.,XY(SDBEBD":*:*0XIH9HC:2*:&6,ADBFBD$9(I8R&2*01D A,6)@-[8B
MJK>C=]]RV^FFHMG-S,FS[P:*Q,18[+6W",MQ=*TN*X9,3ZOGVIL)$U:'4D;A
M')?":OFH!G>7)^J6J4 1$0!$1 $1$!KT?32/C-V'^T76OX?P:I>JZ%Z:1\9N
MP_VBZU_#^#5+U 38^CD_3L["_977'\%6O%MOUJ0/1R?IV=A?LKKC^"K7BVWZ
M (B( M6AZ5U]./J#[GFWW[VRBVEZU:'I77TX^H/N>;??O;*("M\K7GH=_P!,
MYK'[C&?_ !OT4JH:M+>B-:UPV![2>K[N=R^+PM,]GL[7CM9;(5,;7DG+5FC3
M& )KDT,9S$$<AM$).;A&9L/2!.P&S:1=*?SRNW/Z?]%??5@O_7I_/*[<_I_T
M5]]6"_\ 7H#NM%TI_/*[<_I_T5]]6"_]>G\\KMS^G_17WU8+_P!>@.ZT72G\
M\KMS^G_17WU8+_UZ?SRNW/Z?]%??5@O_ %Z [K1=*?SRNW/Z?]%??5@O_7I_
M/*[<_I_T5]]6"_\ 7H#NM%TI_/*[<_I_T5]]6"_]>G\\KMS^G_17WU8+_P!>
M@.ZT72G\\KMS^G_17WU8+_UZ?SRNW/Z?]%??5@O_ %Z [K1=*?SRNW/Z?]%?
M?5@O_7I_/*[<_I_T5]]6"_\ 7H#NM%U_I'=C2VH)I:V!U+I_-V((O'G@Q&9Q
MV2FAA<VC::6*G9F..)S(0\0Q8',F'GEV9^P$ 7Y3P!+&<4H!)%(!1R1R"QA(
M!LXF!@3.) 0NXD),[$SNSL[.OU1 :A3OR.[DN=FS?S4FGZM2:/06L;-_6>W%
MQP/U?X"R5TY;VGAF?D9+.DLA8?%&#D4WP86'N3<%>\X>EN4N]#[M+1':CVSN
MZ#U8/J.4JG+D]&:JKQ#)D=*:B:$HX,A69^/'IV!XJY?'&319"B1Q$X3!!-%J
M;>W%V%-R.SQKN[M_N9A2QN3B\6;$9:NTDN U5B@-ACS&G<@0"%NJ;''ZU6?I
MNXR<_5;\$,O1X@&'SLSL[.W+/Y.S^;.S_([*QQW1?I'&Y?9NJ8[0VK:-K=#:
M2H4-:EA+&2:OJC1E#K$3CTCE+@S5[6.JQ.1T]+90ZU$79JE#*X:L3/%7(1 ;
MDKL1][EV?>T%7KCMQN-@[6?EK':GT3F+4.#UO2BB+HG.;3.1DAR,\%<G!IKN
M/CN40::N[V6:>+JDF6B3K320S0V8))8+-:8+%:S7DD@LUK$1,<5BM8B()J\\
M1LQQ30F$D9,Q 3.S*9'LM>D ]K/:5ZE;#;K7M4X2H(@VG-QJ5;66-EC'GIC+
M(W/5]5UV9W(G>EJ6H4A$[S/([#P!MVT5#?L^>FA2A'#!NOLF<D@@ 393;O/P
MF$A\MXL[874OJKP"[<N%8<U:=N/:LOSPIKMA?2C.Q[K=X(;NN<SM[?G/H:EN
M'I?)X>./Z%NJ?.8QLWI:$>2X;Q,\)%P1"+@+D@+#2+&;9_MH;1[@0P6-$;F:
M%U3':=AK-A-48>]-.[\<>%7AME.?5U"PN,;L3OPSNLF4 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!:1?M@?&_NY]U7<C\
M=,XMW0M(OVP/C?W<^ZKN1^.F<0&.ZV/GH:[?_J_[D/\ )_->O^?ZVDM*\_WE
MK@UV5HS>C6FFZTM/36L]7Z;ISS/9GIZ>U1G<'5FLN 1O8FKXN_4AEG>...-Y
MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
MW>Z+2$?SUFZW]E7<[_*%K#_?*?SUFZW]E7<[_*%K#_?* W>Z+2$?SUFZW]E7
M<[_*%K#_ 'RG\]9NM_95W._RA:P_WR@-WNBTA'\]9NM_95W._P H6L/]\I_/
M6;K?V5=SO\H6L/\ ?* W>ZXYF-8XC'"19#*8ZB(,[F5R]5JB+#SU.3SR@PL/
M#\N_''#\^Y:22QVHMTI1Z9=T-RY0Y8NF37^KC'J;EF?@LR[<MR[,_'/#O]5=
M9:GUMG,XQ-G,[G,XQ%UD.;S63RXN?4Y];CD;5D>KK=SZN.KJ?JYY\T!MZ>TM
MWY/93VI"R&I=Z-'WLI5ZQ/3VD+XZUU TP ,GJ\N,TNV4DH2D!"8?"A48S9QX
MD?J'FH]WD7I<NL=85+^E.SQIZSM_B+(2UK&X>HWAL:SGB-S!RT[A87DQNG7*
M/IDBR.1L93(,1<!C\=+$TLM,Z&$(Q8(P$ ;W" L(MSYOPPLS-R_+^[Y5^B ]
M[*Y2U?MV\A?MVK^0R%J>]D,A>LS7+]^]:D*:U=O7+,DMFW;LS&<UBS8EDGFE
M(I)9#(G=>BBEC[K;N;]VNU9G #2E,]-[?U)SBU#NAF*4TFGL=X/0\U#"Q,4+
MZFS_  8M'C:,PUJI.TF6O4(NEI0/R[G7NN]0=J?=K':5AAM5= 8"Q1RNYNHX
MA(8L;I_Q7D;"U+'#A\/:E&"7'XV-G<JL)6<K(+Q4ACGV].B-%XK3>&Q.GL'1
MKXS"X+&TL1B<=4C&&K0QN.K1U*5.O$#,,<->O#'%&(MPPBS+%SL(=@[;OLZ;
M?8W;K;C$M0QE5_6\IDK#M-F=2YJ:,!NYW.779CM7[9 +,/LUJ5<(:-&&O3@A
MA#,Q %C?VQ]4E@]H=U<T+F)8?;?7&4$HQ$C8L?IC*6V<!/V"-GAY$2]EWX9_
M+E9(+#[O#/B!WQ^X_N9^)>;0&E!Q0NU6LS^]J\+/^NT8LO?7J8]_G$']JC_U
M&7MH"_MZ%;I@ TCO]F^1>6YJ[1F(=O:ZVAQ6!R%Z)G_0=/B9N=QX;JZG/J=Q
MZ&:[TJ:'H7UFL^S^\T(L/K@;K4Y9R8.#>M+HK3XU6*7CVQ:6&XXQ]3^&Y&7#
M>)R]R] $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!5V?2HM+A?[%VX-LNGJP>I=L
M\I'U=7/7+N#IW"OX?3Y=7AY<W=C]GHZ_T?0K$R@7])LFA#L2[RO.+$)'MY&#
M.#'Q8EW1T7'6+A_<X6"B(3_ZMV8VX<>4!J=T1$!MAO1E<Z>0[%6STDG/-5]<
M8L.6%N(L3N#JG&0BW3[Q:*J#"[^TXLSG[3NIZE7W]%T^DFVI^RVZ'\*FLU8(
M0!$1 4<_3,>R<=G [4;W8ZJ1/A<G?VZU/-%&[O'1SL19C3=RP01^Q##DL9D<
M:\\Y]'K.6Q]>/I.5A.@VMRSWM/9._FV]G3=?;N"K':R^6TI?NZ;C.+Q2'5&#
M%LSIXH!ZP8;!92C6AAD<F\(Y6D\^GA:9ZI8:6*.5FX:2,#9OE;J%BX?CY6YX
M= <JT?K'(:<S.&U'B3>++:=R^+U!BI!)P>/)82_7RE F-G9QXMU(7<A<29O-
MB9^';=D]DO?_ !FZNV.@=R,/*$V.UMI/!ZC@>-VXC+)X^"Q8K&+.[Q35+)35
M;$!\2UYX9()1"6,Q;2*+91^B#]JJ'579]SNU]FT\F6VEU9?&"M)*)2QZ9UM:
MNZCQ<D<7'7'4;+GJ*K"1D['+6GCC80A86 MFHB( B(@/0RF3K4JUB[<GBJU*
MD$UJU9G,8H*]:O&4L\\TANP1Q11 4DAD[" "Y$[,SK2M]OSM56-[MZ-R=U)C
ME*OJ_5%^[AHYNL3KZ;JDV/TW7>,W<H''"5*4DL'EX5F6=N&?EFV;7I'?:_?:
M#LJ:[FI7'J:BW!]7VSTX\<OAV7M:HBM#EIX.!)W]1TS4S=Z1G%@(8&A<P*8"
M6IECC$!$!;@1%A%F]S,S<,S?69O)OK(#^U>_]#2['S!%NCOSDJA>):>';'2=
MB0'8/4J\M+/:NGKGUN!O9R$6 I2<QC)"6*D$3<+,@M1 8)#<0AB.>:0ACA@B
M%REGFD)@A@B%F=SEFD(8XP%G(C(19G=V9;E+NCNR!%L5V=-K=M^@6R>,T['E
M-23,/!VM4ZEL3ZBU%,;N 2.(97)V:M49&<Z]&M4J,_AUP9@)'D1$ 1$0&O.]
M,<['P837^W.^&.J]%?6V,ET)J:>*+@#SVFX9LEI^Q.8 P^LV\%)D:@G+(4LM
M?"PQ1LT5-^*8"V\'?W]C9M[NR[N/IVK6:QJ'3=(-P-).P"<T>H-(1SWQC@<N
M7 LEB2RV$F>-BE*GE+,4+>+(+MJ&H)AD )!\QD$3%^./9)F)O+Y/)_<@.=;:
M;CY31NIM-:QP<A0YO2&HL%JO#2@[,<>6TWE:F:QQ@3L3"0W*4+L_2_'OX=;M
M3LY[UXO<C0.C-?X66.;%:RTSA=249(G=X_ R]""Z("Y>U\[>5XGZO:Y!V?S6
MCV6RQ]$2[67S8=GK+;97[;S97:/5-^E2BEE$IFTIJJ:?46(Z <BF]5J9*SG,
M?7(^(XXJT=. 0AK # 6OT1$ 1$0'HY/)5Z=:Q<MSQ5JM2&6S9L3F,4->O!&4
MLTTTANP1Q11B4DAD[" "Y$[,W*TJ_;Y[4\V]N].YFZLCR-6UEJS)7\-%()1G
M7TU6-L=IF XC,WAF' T\>=N-G$?79+)M''U] [0+TA?M@-LWV5=Q,I5MO4U!
MK.&';72S@3#,>9U?%9KV9(&)G8SQVGJV=S!QNSL=?&S,_DM2!%$("("W @+"
M+?4$6X9OVF9D!_:O&>AH]D<;&8W5WSR%9R;'5JVV.F)I ?H&6X5'4>J[$!$+
M@<KQPZ<I]8.$M8&LQ<E'=D%J-TTO0!'TD70+ET@W)%PW/2+?*1>X6^5W9EN&
M>Y'['P;']F3:[1DU>.#.6L(VK=6&'2Y6-3ZND?.9+Q#80>1J(VZ^'JD8#*-#
M&U(I&8XW0$KB(B (B( M*WWCWTQG:$^[OO'_  CZE6ZD6E;[Q[Z8SM"?=WWC
M_A'U*@,,UZMBC#*[/+#'(X^3.8";LS^]FZF?A>TO5GNPQ.S2S11N[<LTD@ [
MM]5F)VY;]9 >O\#5/ZEK_P"!C_V4^!JG]2U_\#'_ +*\_#%3^JJ_^'B_VD^&
M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B +2+]L#XW]W/NJ[D?CIG%NZ%I%^V!\;^[GW5=R/
MQTSB QW6Q[]#7^(#<C[KM[\4M++7"+8]^AK_ ! ;D?==O?BEI9 6]41$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 %A]V].Q9I/M!;5:LVJUC$38S4='BGD8!C>
M_@,Y4)K&%U!C2D Q"]BKX1608A>.Q$TU.<3K6)HSS!1 :2+M?=D_66Q^X^J-
MK]>4"I:ATQ>.!YFC,*69Q<KO)B=0XDSY\?%9JET6ZIB<CPD4U&P0W*EJ*/&Q
M;9WOQNYEP':KT*%G%>IX3=[2%6W-H;4TK/'#>C,"EFTCJ PY\3!Y6P,11V""
M2?#W1"Y4(8Y+L-K5/;H[6ZET/J/-:/UE@\AIK56G;LF.SF!RL/@7L=<B\WCE
M%G()8I!<9JMNN<M2[6.*U4FFKRQR$!V!V8.T[K?9O76 W'V[S4N"U5IVRTU.
MR+%+4NUC</7</F*;'&&2PN4B#U?(X^8F&:-QEB."W!6LP;5WNA^^@VZ[5>E8
M/4;%/36Z.*HC+K';JS<$KU,XC&&;,:?*;PILWIBQ(41PY&")Y*!68J&5CK76
MZ9-1,N>[6[J:FT/J'%:MT;GLKI?4^#L-:Q.=PER2CDJ$[>3O%/$_M12#[%BM
M,,M6U$[PV898B(' WF:*E+W5OI9VG-00XW17:;AATIJ'B.K7W3Q=4 T=EB88
M@&75&,K_ #_2MZ8_$.6Y1KV=.OSU&^&!@B.YEHK6V&U)B<?GM/97'YS"96M'
M<QF6Q-ROD,=?J2MS'8IW:LDM>Q";?0R12$+NSMSRSL@.4(B( B(@"(B (B<H
M B_*:<(P*20QCCC$CD,R80  9R(S(G81$69W(G=F9F=W=F\U5Z[T+TH;:'9P
M<AI/:MZ^[^XP1VZ[RXBY"6@M,W82:$?A_44,I/D[/BN9QXK3D5\G&O+\(WL4
M,M(K@$U_;S[P?;'LXZ'M:ZW,SL>/J,Y5L+A:O19U#JC*^&4D6)T_BV,9KUHV
M%SFE]BI0KB=N_8K5HSD;4Z]Y?WENX/:EW%DU[KDAQU&C!-C=&Z+HW)[6$T9A
M99O'DJTRD&$+N7OD,!Y_/O4JV,Q)5IQO#7H8_'4ZO2':Y[96Y>^VLKFN]TM4
MW=3Y^SUQ51D8:V(P= C8@Q&G</!TTL/C(ND&\&N#SVC!K62LWKQRVI,8T 7(
M=(Z1RNH,MC,#@<;=S.<S=^KB\-B,; =J_D\E=E&&I2IUXV<Y9YY281%F81;D
MS(8P,Q^%##)+)%##')--/+'!!!!&<T\\\QC%#!!#$)2S3S2D$4,,0%)+(0QQ
MB1DS/L??1RNX3+9ZI1WSWCQ0MNOE:<CZ1TO<%C_F;X>["\<EJZ#$\):SR]:0
M@MOQ+\ 8^1L=7E&Y9RCH"4SN-^ZIH=EG:&MB,@%2UN5K#U//;D9BN[2C\*M6
MZ:FG:%AV9SP^FHI9J=3I88[-N7(9)Q\2\;O-&B( B(@"(B (B(#^2%B9Q)F=
MG9V=G;EG9_)V=G\G9V\G9_>M.[WUW91+9GM0[N:-AJG6PUO4+ZRTP[@0PSZ?
MUK &H87K$XB!Q4<G;RN%/PA"*.UBK,,8#'&'.XD5%/TS7LH!ZGM)OA1K?/(;
M]W;#4<\8-R4-^K>U+IB2P3<D4<,^-S]6$B8(HI;[1N1RVXA8"AVK9GH@W:K^
M9'?O5FV5VTT6+W7TB$]&&23HC/5.AY;=^DT(ESU6;.#RV=$HP8"ECJ"<AN-6
M.-5,UW_V4>T'E=IMS]O]SL*QR9'0>KL)J:*J,SUVR-;'7(SR>&EF%G>.MG,2
M5[#6BX=QK7I7%NIF=@+#7I:W:^;7?:+Q^W&-MC-A-GM-5L?<"&5SA/66J0AS
M>9Z^B4H3DQV&?3U >8QGJVBRM<R]H@"K,NXNT/O3E=R-?:UW S9F>5UIJC-:
MDN,<CRE"^4O2V*]-I79GD#'U"KT(C=F<X:T9.S.[KIU 6&O1A>R1_-0[56G<
MO=J-9P.T^(N[AY$I8AEK-EZ\L&(TK7DZQ>/UA\ID),I4!^)6/#26H?SH?&U6
M53_T1/LBAHWL^Y?=&[4:+,[PZDL6Z]B0>)BTEI"Q>P.#B$NIW]5FR+9_)P"X
MBY?"!3,YQRQ.UL! $1$ 1$0!$1 $1$ 6IQ]))[(DFTW:NUO+5J%7TYN97H[D
MZ=D"%XZOB9<"HZFHQ&,8P//3U)C[]J:",BEAJ93'36!%[<92[8Y5$?3 NR'\
MU6R&E]W,=4"3*;4ZHKU<Q.POX[:-UD<6'M<$W/,534GS.6)0Z6$8#LV3D$:W
M28&M]4WOH[7:W#:'M7;>W+UMJF!U[ZSMAG3.0XX&#5<]+X#EL=/D81ZGHX6(
M?$XCB>QZP9B$)<PA+^XK$\)QSU9SJVZ\D=BI9B)QEK6H#&:M9B(78AEKSA'-
M&0NQ"8"0NSLR O8^F8]K0?\ ^E&QE"PSR'ZUN?J> )"?HK1E=T[I2&>+Z!_6
M;8:AMQ$[M+"^,%V9PL,ZHEK-[O%.V]G.T1NQFMT]05_4KF4Q6F\1!1\0)6IU
M,!A:N/(1**.&'\UY$<CDW:*&,0>\\;L1@4AX0H"3[N9>R0.]O:8VJT/:K-:P
MD6>#5NJ(C 9(3TYH_IS=V"P,C/$5:_:@HXNQ'([>+#?.*/F4P9]QDJ)7H:/9
M < W3WXR-7SLM!MAI.P8EY58):>?U?/ 7+QDUF]%IVD?DTL)8J4>?#LNRO:H
M B(@"(B (B( M*WWCWTQG:$^[OO'_"/J5;J1:5OO'OIC.T)]W?>/^$?4J PS
M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0%.STSKXC=H_NQA^(>LEKHEL7?3.OB-VC^[&'XAZR6N
MB0&4?8;^.W9O[JNWGXVXA;LU:3+L-_';LW]U7;S\;<0MV:@"(B (B( B(@"(
MB (B( B(@"UB_I>.)BK=K3'31]77?V8T/;GZGY9I0U+KZBW0W#=(^!2A=V?G
MV^LN>"9FV="UI?IA^'*'M-Z-OO&XC?V:P58)')G:5\;JW61R"(\^R\+9.-R?
MANKQAX=^E^ *H:L;^BGYH*G;'TW&;DWK^@-?4AZ69V(WK8RR+%S[A_,W/+<O
MU,+<<.ZKD*:[T=/5?P3VS=E'<PC'*9+4>%,CX9G:YI'.3Q@SO)&S%+8IP1A]
M&Y&0@T9$3.(&W!9>41 %67]+7^E R?W1MO?PM*K-"K+^EK_2@9/[HVWOX6E0
M&KW7SLQ^=+7['G_<B7T5\[,?G2U^QY_W(D!O>Z_]#C_[@_ZK+]E^-?\ H<?_
M '!_U67[( B(@-?%Z:9\86P7VFZ^_#>F%2L5U/TTSXPM@OM-U]^&],*E8@)L
M/1T/IS]D/LGJC\1]2K;@+4?^CH?3G[(?9/5'XCZE6W 0!$1 $1$ 1$0!$1 $
M1$!U3OCLEI?<C2&H="ZTP]3/:6U1C9\5F<3=B"6"U5G9G8F8Q+PK-:88K=*T
M'$U.Y!!;KF$\,9CJ0.]^[JW5/92W/L:7R!3Y;0VH);N2VWU<8.P9C"QRB1XG
M(GYA'J73X3P5,M%RPW0\#+UA&"X4%;<*K!/O%^[\T-VE=L<SMMKBJS#9$KVG
M,_!$!9726I8(90QNH,3*_#C-6*0HK=4B]7R6/EM8ZV)U[)L@-+VN<;8[FZ@T
M5J3!:OTGE;6#U-IG*T\U@<O2,H[-#)4)6FKS XD/7&3L\5FN;O#;JR3U9Q."
M:0"[B[8G9$UML3N-J/:_<&@-+46G; ,T\#2OC,WBK(O)C-082Q-'&=O$92!G
MD@E<6.">.U0L,%RE8B#&5 ;4_L)][AI[M6=EG<S*2%0Q.Y^EMM=6T-Q](UY"
M;U*\>F<N%3/XJ&9_'ETYJ 8)+5"7F9J5D;>'L3R6J!R2:I_#_G2K^QX/W(5D
MIV9^U'K7:+45K4^ALHV-R&1T_G=*9>":,K&.S.G=1T),?E,5E*;21-:@(3CM
MU7<Q.ID:M2W&3O"\<F.U:!HHXXAY<8P",7?CEV 6%G?AF;GAO/AF;GY$!^RV
MP?HQ/TC^RW[(W3_AFW#6I\6V#]&)^D?V6_9&Z?\ #-N&@)[41$ 1$0%5+TH7
MNF+.\^WE3=_0F+>WN5M;2LED:%.!Y+VK= <36\EBX0B%Y+.4P-E_AG#@3&YP
M/EZ$3#)?C(=9S'()B)"[$),Q"3>YQ=N6=OK.WFRWN:UM?I)/<93;19O*;\;4
M89FVGSUL;.M,#CH2Z=O-0Y&WX<F3AKQCX<&CLY<L0"#1,$>#R\Y5S <?=JE5
M J1JWQZ./W]];:&:CL1O1F8:FUMR:P^B=:Y6VX0;?Y*U-')\ 9>>;F*OHW(S
M26K%:_--%#IN^3PR,^*O=>+J#KP[,[.SMRS^3L_N=G]_+?*R WM-2W%8BBG@
MECF@FC"6&:(QDBFBD%CCEBD!R"2.0'8P,'<2%V(7=G9>PM7YW-?I(>MNSU%C
M]O\ <R'*[B;/PE!6QXQSA8UAH*HS]!!I^6W)&.:P<(.QAIZ_<A.F,;QX>Y!$
M0TBV-/92[8^V>]^EJVL=KM78G5N#G&-ICH3\7<99D#K>AF<9*T=_$9"+@AEI
M9"O!.) 7 D+=3@9-(B( B(@"(B (B( B+%[M9=M#;#8W2\^K]T]8XC26%B"=
MZ[WYNK(96>N F=+!XFNTN3S60+KC$*6-JV;#G+$S@WB"[@9/22" N9$PB+.1
M$3LPB(MR1$[NS,S,W+N_DS>;^2U^'I'W?_4-:5<UV>-C<W'=TO.UK%[I:[QD
MAO7SOAS/!:T5IB[&0QV<.?ARQ:ES$#S5<K#(V)Q\TE5[\LN%??%^DMZVWY@R
M&W^TL69VWVHL.<&2N2S!4USK:K[0>!DYZ,\PZ<P<[.QRXC'7)+UX>F+)WQKO
M8QTE7, 81819A$69A%F9F9F;AF9F\F9F\F9O<@/+,S,S,W#-Y,S>3,WN9F^1
MF_O,I1.[+[KK5W:.O:YO4?7\1H;;?2.=U)JG5$%09V+*T\1:O:?TCB_&"2*?
M,9NS",MGIBL_!F&BL7)H?&L8V.SCEV'.Q1KKM";DX3:_;VD$^:RO-K(9*TTG
MP3IC 02PQ9'4N<EB$SBQM#QXQ&,!*Q?N2UZ%0#L6 9MM-V6^[[T/L#L1;VCT
M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
M:9E_:F,[C3NU[/::WUPVGLA2.;;W1KT]6[DV2 VJ286O:9L=IJ286Z?6M67H
M"HM68AEDQ-;-6 Z/52D8#87^CR]D>;9[LI[<8G(TRI9_5U>QN+J.&4!"P&2U
MAX-VK!9Z")BEH8*/#XUG=V(8J40&S$#LIM5^<40@(@ B  +   S"(B+,PB(L
MS,(BS,PLS,S,W#-QPOT0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 6D7[8'QO[N?=5W(_'3.+=T+2+]L#XW]W/NJ[D?CIG$!CNMCWZ&O\0&Y'W7;
MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
MGWZU]*!1RZ^UW)&;<&$FM-3F!-]0A+*N)-Y-Y.SMY+B&3UOG;S.-[/9Z^+MP
MXW\WE;HNS,[,SC:MS,[,Q$S-QPS$3-]$7(&Z(W;[PC8K0413:RW@VWTV @1\
M976."K2$P-RXQPE=>:65_(0AB Y9#<0C C(6>'C?[TJ_LC:/CGCT]J74NY>2
MB&1@JZ.TEFX:)SASTQOG=35,#B9(Y&;V;5"?(5^29G/ECZ-6?%2AC)S"&(#?
MWD,8B3_+RY,W+OSY\N_O\U[* MW=LCTO[>;5K6L7L]H_3VUV'E:2(<[FO_LO
MUI)&3NS25A(JFFL*;QNX$!4-02L;!/7O5C;PVJR;U;XZRW(U#;U;N!JC.:RU
M+=<O'S.H+\V0ML!2'+ZO6\5_!H4ADD,HJ&/BJT8'(O!K1L[LNK%^<LH@+F9"
M CYN1.PBS?7=_)D!^BRS[%?8BW'[0.N\;M]MG@ILOEKDE>3)Y V>/"Z7P\DX
MPV=0:BODXQ4\=3#Q)1A8BO9*2)Z6+KVKAC$I1NZT]'AWH[1MBCG\S3O;6;6'
M+&<VL-1XF>/+YVJQ,\H:-T[<*G9R#2#UQQYR\T&$BE;JA?*/%-6;93=A?L ;
M7=G71E?1.U^G:^(I/X4^8RTK!9U!J;)1Q-$65U%ER ;.2N$+.,3&XUJ<3^KT
M:]:N(Q,!T!W3?=1Z%[*.WS:6TX3YK56:>"]KK6]NO%#D=2Y6,9/#CCCC;BC@
M\6TTM;"XP3D>O7=YK4UJ_/:M32F21"8D!LQ"3.)"3,XD)-P0NS^3L[<L[.WF
MSNWN7Z+P@-'!OE@BQ6NM=XLQ<"QNN-8X\@=F%P>EJ7*5G!Q$B$>GPNGI$B%N
M.&=V9G73V8_.EK]CS_N1+-_O(-.CB.T7V@<6 >'%0WQW:KP"PQBS5AU]J JK
ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
MM7)Z65].%DON9: _=-0+:-K5R>EE?3A9+[F6@/W34" K5*U9Z'U]-#J;[CNH
M_P 9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@"(B (B( B(@"JL^DA
M]R'_ #=]-EO#MECN=XM%8J0,AB*K5XFW&TK49ISQDO7&QRZGP<<<TVF)6L1-
M;BFNX6P-@[&+DH6IEXX0&B3DC,#..0#BDB,XI8I0.*6&6(WCEAFBD$9(IHI!
M*.6*01DCD$@,1,79OX5WGTGSN0AP<^6[36TN&D?%W;$=C=S2F*J%(&.M3.,!
M;@XRI7%WAI3%X(:NKPQ>#7D?YHR\&-\S,](5G9V9V\V?S0'E>']SKRO#^YT!
MN<NZ=^E8[-/W -F_X.M.+/\ 6 '=._2L=FG[@&S?\'6G%G^@,8^V=VHL%LKM
M7KK=/4DC#BM%:>O9@XNERDOW0%H,3BJX,0==K+Y:>EC*HN<8O8MQ]<L0=4@:
M6_=[=7-:[U;JC7&HY_6=0:QU#E]3YJ?J<V/)9J]-?LB!%[3PPG-ZO79_H*\4
M0>3"S-=Q],2[?+<:*[-V"M\O,-7<7<+P96<6KQ3V*VC,%8%A?VY[E>]J&Q&\
M@20A1PLA1R0WA)J)2 *^=Z'5V#Y*]+7?:+SM)A?*.6WVWYR@WB/CZ,PVM8YB
M%W;J:"YDQQV$@=G'J/"Y%R$HRK2*CMM!M)G]?:LTUH?2M1[NI-7YO':>PE;I
MD(3R&3L!6BDF\())1JU6,K=R0(S>&G!/-TDT;LMTMV.NS%@MF-KM"[7:<%O@
MK1.F\7@H[#QC'+D;52L W\M:$.6];RMY[&0M.SNWCV38>!860&2J(B (B( B
M(@"(B (B( B(@"(B +6V^ES]AD=#[QZ<WFPU HL%N[0DH:AGACXJP:[TO4J0
M,4SMRT5G/:<]6L1]3BUH\'D91!Y([$DFR245??2=A<>T)V==P-"5*D-G5-;&
MR:HT(4H@Q1ZRT[%+?P]>.<N"K?"SA-A)YA,1&MDIO&:2#Q(9 -/&N4Z&UQEM
M,9S"ZFP-LJ.<TYE\9GL-=!R9ZN5P]V'(4)_8(2<8[5>)Y!$A<X^H.6ZEQ@XY
M (HYH9:\\1G%/7G HIZ\\1/'-7GB-F.*>"43BFB-F..4" V8A=F_E ;J#N\>
MV%B-^]F-O]UL1TQCJK 5I\K19^3Q.HZ;EC]28>5ND'YQN;JWJT4C@ V:P07(
M6>O8B(LT%K]?0]>WS)B]3:T[.N?NM\&Z@JRZ]T ,\ILU;-T'AJZNPU<"<HG'
M*T9<?FZT<?@N$^-S$A^LG=#P-@4@"(B (B( B(@"(B *OYZ4/]))NS]D]K_X
M6-$JP&J_GI0_TDF[/V3VO_A8T2@-4DOFYG\Z6OV/-^YDOI+YN9_.EK]CS?N9
M(#>-=F_XN]!?:7I;\!T5W0NE^S?\7>@OM+TM^ Z*[H0!$1 $1$ 1$0$=G>L]
MA/']H[8G7.UMEP@RF3HQY3262(8G+$ZQP<C9'3UUGE=@:"2["V/R(N<3SXF]
M?K--!XWC!IO-2Z:R.$R>3PF8IRX[,87)7\-E\?.SC-0RN*MS8_(T9F=FXEJ7
M:\]>3R^BC?CRX6]66M>]+/[O*/;G=S$;V:=QW@:7WB*Q7U(]6N\=/'[C8BK"
M<LDY!S%'9U=A@/)APT;V[V$SEN03LR333 5,$1$!YZ3=V&.,YI#<0BAB%SEF
ME-V&.&(&\SEE-QCC!O,S)A;S=EMV.XC[N<>S9V?]/::RE< UWJJ0M:;A3LS=
M0ZART$ P8<"<1D]6T[B8*&'C$O([5:[=8(CNR1C1;]&6[N<M[=_J>L<[CGL[
M?[,G0U9EBL1-)0R>KRF<]&X&039X[#Q6:]C45J#@ACCQ--K/$=V&.QM.T 1$
M0!$1 $1$ 1$0&CGW^^,#<#[?=:_C/E5U.NV-_OC W ^WW6OXSY5=3H#9*^AJ
M_2T;C?=_U)_!GM,K;:J2>AJ_2T;C?=_U)_!GM,K;: (B(#%_MO?$MN]]R_7_
M .*F66D>P_YTJ_L>#]R%;N'MO?$MN]]R_7_XJ99:1[#_ )TJ_L>#]R% ?15K
MONW_ $H:[V>ME=$;/1;+U]5QZ,AS<(Y\]<GB#R'PSJ7,ZB<GQS:8R#5O5WR[
MU.&N3>(T'C>QXGAA5$1 7F_RZKD?U.U7_*7)_$M/RZKD?U.U7_*7)_$M49$0
M%YO\NJY']3M5_P I<G\2T_+JN1_4[5?\I<G\2U1D1 7F_P NJY']3M5_RER?
MQ+3\NJY']3M5_P I<G\2U1D1 7F_RZKD?U.U7_*7)_$M/RZKD?U.U7_*7)_$
MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
MGY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_P"N>R_W[ZF_B GY4,[6?]<]E_OW
MU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B K\/=6=F#4FR_9\VNVOU?+BIM2:-T
MY'B,K+A+4]W%G9CLV9>JG:LTZ$\T3A*#]4M2 F+D>GRY>05$ 1$0$!WI!/=;
M[A]JS;;0VD-N,MHO$973.OAU5>FUMD\YB\?-CVTUGL*\-2;!:;U-9.YZQE8)
M&CFIP0>#'*_K#2, '4Y_*<_:G_3GL!]^.XO_  D6RW1 :[#LW^B5=IC2&XN@
M-6Y35^Q<V,TKK;2NI,C#0U9K^:_-0P>=HY.Y%2AL;65*\MN2O5D"M'/:K0G,
MX#)8A BE'8GHB (B( B(@"(B (B( B(@"(B *-KO:NP-%VE=B=8[5QV:./SF
M0"EE](Y;)/.%'%:LP=D+V&M73K5KEF.A-($N.R1UJMBPV-O7&@A.5Q922H@-
M:1^4Y^U/^G/8#[\=Q?\ A(GY3G[4_P"G/L__ 'X[B_\ "1;+=$!%'W,O9:WC
MV2V.P&U&\N4T3G,EHJS<QFE<QHG-9[+P3:/.5[>*QV4?/Z6TO/7NX,IY\35]
M6AN0S8FMCRDE"R$S'*XB( H>N_*[O[6O:8V'N;7Z!R.E\5J&QJO2V=CMZOO9
M;'89JF#N26;,1V<+@]0W6L2B0C (XXHW=R>26-F;JF%1 :TC\IS]J?\ 3GV?
M_OQW%_X2+U[GH;_:GEAEB^;7L_CXL9Q]7S8;BOT]8N//'\R5N>.>>.6Y]W*V
M7Z(#\X1<0$7]["+/Q[N69F\O=_H9?HB( B(@*LOI"W<D[M]K#5.V.<VVSNW6
M(JZ+P&IL5E8M<9K4V*GGL9K(XBY6/'C@=':HCEACCQTHSO8DJ&QF#1A(/435
MXORG/VI_TY[ ??CN+_PD6RW1 46>Z=]&;[0.Q?:#VYW6UAJ?9R_IO2-W,V,I
M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>ino-6302010q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ino="http://www.inovio.com/20200630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20200630.xsd" xlink:type="simple"/>
    <context id="FD2020Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q2Aug07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2020Q1June01_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_OwnershipAxis_ino_VGXAnimalHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:VGXAnimalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2005Q1Jan31_us-gaap_BusinessAcquisitionAxis_ino_InovioAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:InovioAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-01-31</instant>
        </period>
    </context>
    <context id="I2009Q2_us-gaap_BusinessAcquisitionAxis_ino_VgxPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:VgxPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-06-30</instant>
        </period>
    </context>
    <context id="I2016Q2Apr_us-gaap_BusinessAcquisitionAxis_ino_BiojectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="I2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="I2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="I2020Q1Jan02_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="I2019Q3Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2020Q2Aug01_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="D2019Q3Aug1Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q1Jan1_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q2Apr_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q2May_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2010Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="I2020Q1Feb20_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2016Q4Nov1Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="FD2013Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_SanDiegoOfficeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_PlymouthMeetingPennsylvaniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q3Sept1Sept30_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q1March1March31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q3Aug1Aug30_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-11</startDate>
            <endDate>2018-04-11</endDate>
        </period>
    </context>
    <context id="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_INO4800Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q3Aug7_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-07</startDate>
            <endDate>2015-08-07</endDate>
        </period>
    </context>
    <context id="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA2000DeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q1Jan1Jan31_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2018Q4Oct1Oct31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec31_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="I2019Q1_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="D2019Q1Feb1Feb28_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="I2020Q1Jan31_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q1Jan31_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="D2020Q2July1toJuly31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="I2020Q2Aug10_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="D2020Q2Aug1toAug10_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-10</endDate>
        </period>
    </context>
    <context id="D2020Q2July1toJuly31_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>ino:investment</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <unit id="product">
        <measure>ino:product</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2020Q2YTD"
      id="Fact-FB458C139E05CB4215F07A9E0A82058A-wk-Fact-FB458C139E05CB4215F07A9E0A82058A">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q2YTD"
      id="Fact-29F90C69A8EE4A6804DF7A9E0ABD05FD-wk-Fact-29F90C69A8EE4A6804DF7A9E0ABD05FD">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q2YTD"
      id="Fact-33FD3EDBDB9B711D49C47A9E0AC0D495-wk-Fact-33FD3EDBDB9B711D49C47A9E0AC0D495">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q2YTD"
      id="Fact-92BF7CC8BB8FA1501E227A9E0AA09E4E-wk-Fact-92BF7CC8BB8FA1501E227A9E0AA09E4E">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q2YTD"
      id="Fact-294FEC1FAC2272B17E107A9E0AB306A1-wk-Fact-294FEC1FAC2272B17E107A9E0AB306A1">0001055726</dei:EntityCentralIndexKey>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="0"
      id="Fact-C6023C4FCFA867982FE986AC7FEF9DB2-wk-Fact-C6023C4FCFA867982FE986AC7FEF9DB2"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      id="Fact-1280E348174B39C2F6397AD749CC0EF9-wk-Fact-1280E348174B39C2F6397AD749CC0EF9">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeArrangementTerm
      contextRef="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      id="Fact-F93F8A3AD1253A5A02B77ACAFE59DA3C-wk-Fact-F93F8A3AD1253A5A02B77ACAFE59DA3C">P5Y</ino:CollaborativeArrangementTerm>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="Fact-5940286619FA582B94BE7A9E0AB3D38C-wk-Fact-5940286619FA582B94BE7A9E0AB3D38C"
      unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="FD2020Q2YTD_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      id="Fact-F92331A0F68BEDF2A7BC7A9E0A77561B-wk-Fact-F92331A0F68BEDF2A7BC7A9E0A77561B">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="Fact-3519EE79828E1EAB699FA66FB714DAD4-wk-Fact-3519EE79828E1EAB699FA66FB714DAD4"
      unitRef="shares">26944620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="Fact-BAB2C0F4BA90E8C0E7C2A66FAF8605A0-wk-Fact-BAB2C0F4BA90E8C0E7C2A66FAF8605A0"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="Fact-49A09E6BE4DDB1D0179CA66FB1F251AA-wk-Fact-49A09E6BE4DDB1D0179CA66FB1F251AA"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="Fact-1A85EDE3919AB04C39C4A66FB47C2DB0-wk-Fact-1A85EDE3919AB04C39C4A66FB47C2DB0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact-57A56E0EBE5A00BE9F90A66FAD616EE4-wk-Fact-57A56E0EBE5A00BE9F90A66FAD616EE4"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact-450595384C4496DD13A2A66FA403D9D2-wk-Fact-450595384C4496DD13A2A66FA403D9D2"
      unitRef="shares">10770319</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact-3330195FA2E12BA52803A66FAB26A0DD-wk-Fact-3330195FA2E12BA52803A66FAB26A0DD"
      unitRef="shares">1580192</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"
      decimals="0"
      id="Fact-44ED07BD57A0A7C58EFCA66FA7C22766-wk-Fact-44ED07BD57A0A7C58EFCA66FA7C22766"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="Fact-2D92F0A3D160BA7CCDB2A66F53C4EE69-wk-Fact-2D92F0A3D160BA7CCDB2A66F53C4EE69"
      unitRef="shares">32622537</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="Fact-01B321C801547C9C017CA66F45211140-wk-Fact-01B321C801547C9C017CA66F45211140"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="Fact-158979117164AB4363D1A66F49F6FCDE-wk-Fact-158979117164AB4363D1A66F49F6FCDE"
      unitRef="shares">4962364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="Fact-A0FD3014CA1AC2E32B2AA66F4ED44E24-wk-Fact-A0FD3014CA1AC2E32B2AA66F4ED44E24"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact-C4825AC303551AFF9384A66F422ECF26-wk-Fact-C4825AC303551AFF9384A66F422ECF26"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact-4938A161BD19B142DCBFA66F37D95833-wk-Fact-4938A161BD19B142DCBFA66F37D95833"
      unitRef="shares">9193096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact-AABB3F09D8E7D7CE00D5A66F3D944DA1-wk-Fact-AABB3F09D8E7D7CE00D5A66F3D944DA1"
      unitRef="shares">2868665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"
      decimals="0"
      id="Fact-19B467D591FA63F8B538A66F3A514205-wk-Fact-19B467D591FA63F8B538A66F3A514205"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-36BE240D32E4C40F760F7A9E0A69B6F2-wk-Fact-36BE240D32E4C40F760F7A9E0A69B6F2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-8D3E88DAFC5DD09869967A9E0A6A4226-wk-Fact-8D3E88DAFC5DD09869967A9E0A6A4226"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="7"
      id="Fact-71FC66547215A9F88C8B7A9E0AB35B8F-wk-Fact-71FC66547215A9F88C8B7A9E0AB35B8F"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2019Q3Aug1Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="10"
      id="Fact-ABACCD3791E8172FF66E7A9E0AAED6DF-wk-Fact-ABACCD3791E8172FF66E7A9E0AAED6DF"
      unitRef="number">0.0003517658</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="10"
      id="Fact-128D08EE868916305EF47A9E0AAA6F58-wk-Fact-128D08EE868916305EF47A9E0AAA6F58"
      unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="10"
      id="Fact-631B00DDD3C35FE3AAB57A9E0AA8E632-wk-Fact-631B00DDD3C35FE3AAB57A9E0AA8E632"
      unitRef="number">0.0003579611</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="10"
      id="Fact-7DA61F3652A57BFE63327A9E0AAEF62E-wk-Fact-7DA61F3652A57BFE63327A9E0AAEF62E"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2020Q2Aug01_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="10"
      id="Fact-B7CEE9999956A604D0887A9E0AA0BEA1-wk-Fact-B7CEE9999956A604D0887A9E0AA0BEA1"
      unitRef="number">0.0002756873</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="Fact-7F638E84BAB17FDFDE417A9E0AB3B276-wk-Fact-7F638E84BAB17FDFDE417A9E0AB3B276"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-6F771BB2D53F089145127AE2FD95882F-wk-Fact-6F771BB2D53F089145127AE2FD95882F">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact-2099AE7C872E7367B0E17A9E0A69CD4B-wk-Fact-2099AE7C872E7367B0E17A9E0A69CD4B"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact-E59F987B7BD4C3E0DF977A9E0A6A9CD0-wk-Fact-E59F987B7BD4C3E0DF977A9E0A6A9CD0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="Fact-2E496096F745EDE869FF867954C558C5-wk-Fact-2E496096F745EDE869FF867954C558C5"
      unitRef="usd">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="Fact-A568BB507C5B333180DD86797E9D709F-wk-Fact-A568BB507C5B333180DD86797E9D709F"
      unitRef="usd">63000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:DocumentType
      contextRef="FD2020Q2YTD"
      id="d5937929e489-wk-Fact-EB3C09FF76E6D2B4A5C57B0907D73F81">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q2YTD"
      id="d5937929e506-wk-Fact-D791840516AA4A716EC57B0DEF959ECE">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q2YTD"
      id="d5937929e518-wk-Fact-A1C783ED84FBAA4768C27B0FA4CE541D">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q2YTD"
      id="d5937929e537-wk-Fact-5CD63F4E256C8BCD4F9E7B0ECEC1E333">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q2YTD"
      id="d5937929e550-wk-Fact-795EC545147CF8B54AEB7B109FAA3975">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q2YTD"
      id="d5937929e574-wk-Fact-8EAFF210DA38E98B88BA7B1283063A8D">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q2YTD"
      id="d5937929e595-wk-Fact-01EF7FD1235DBA5423147B1BFCE353E0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q2YTD"
      id="d5937929e605-wk-Fact-1A9191B4FFDB4AE0EC9A7B1CE7B70BF3">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q2YTD"
      id="d5937929e648-wk-Fact-1E05D7B71FA77655E2F5DB64CC9E22DA">660 W. GERMANTOWN PIKE, SUITE 110 </dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q2YTD"
      id="d5937929e654-wk-Fact-F6BBEC5BE0E385D037F1DB64E7FC11B3">PLYMOUTH MEETING</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q2YTD"
      id="d5937929e659-wk-Fact-88B140FBDB80A869704F32AA35424DFC">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q2YTD"
      id="d5937929e664-wk-Fact-1759C1EF8B7AB8DAB4642EA711C88AC5">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q2YTD"
      id="d5937929e677-wk-Fact-0F497D56D00097F116FE7B1F74D6EB4B">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q2YTD"
      id="d5937929e682-wk-Fact-D277D0D2EE0AAF97D93C7B202324DFE5">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD"
      id="d5937929e722-wk-Fact-5F7643A56F5B44F08F7C7B242B32CAD7">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD"
      id="d5937929e727-wk-Fact-0522E6E83EF2426E07A07B242BFF78D0">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q2YTD"
      id="d5937929e732-wk-Fact-C91557AC81DD7B3872D87B242AF74055">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q2YTD"
      id="d5937929e754-wk-Fact-31AF117066E0707F13C27B4DF862DAD1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q2YTD"
      id="d5937929e768-wk-Fact-9C5EC16805C54F0FFFBA7B4EA4A9FAE5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q2YTD"
      id="d5937929e812-wk-Fact-6CD2C12CA68F1B4CB1297B4F687417B2">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q2YTD"
      id="d5937929e869-wk-Fact-1D7D08BCA9385A0638897B4FBDF64EDF">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q2YTD"
      id="d5937929e921-wk-Fact-17BDD8E1DFF195D3AC607B4FE4E7E701">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q2YTD"
      id="d5937929e934-wk-Fact-212D751AC3B38E42AEB17B507D1BF4E9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2Aug07"
      decimals="INF"
      id="d5937929e946-wk-Fact-4B87D4801886FC17D73C7B50B4EACEE5"
      unitRef="shares">167520435</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e664-wk-Fact-B5F429C7F247C59B8C357A9E0AB79C8F"
      unitRef="usd">215432713</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e683-wk-Fact-B85135F763B9B23904917A9E0AD2BD18"
      unitRef="usd">22196097</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e698-wk-Fact-22755D6E0E1ADE4277BD7A9E0AB3DE60"
      unitRef="usd">156231102</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e717-wk-Fact-641EE90B79DEE0169BE07A9E0A8C5D50"
      unitRef="usd">67338017</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e737-wk-Fact-80B405605EBB14D2720B7A9E0AD5B154"
      unitRef="usd">3513159</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e756-wk-Fact-CFA3AADD1F88FDD9BE7D7A9E0AA01E4C"
      unitRef="usd">700073</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e776-wk-Fact-9169CBB8F9706E1FC1D07A9E0A8C1B64"
      unitRef="usd">482373</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e795-wk-Fact-E165221EDA5822F98E1F7A9E0A77CB30"
      unitRef="usd">1332044</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e815-wk-Fact-8D842E33379021BC0B267A9E0AB3BCAF"
      unitRef="usd">4591966</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e834-wk-Fact-5809192925EBB0014C5C7A9E0A825EEC"
      unitRef="usd">1584598</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e854-wk-Fact-850FAFF0888D6FD6D88A7A9E0AB71C42"
      unitRef="usd">1811140</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e873-wk-Fact-90C0DFEB55A5784BF0107A9E0A997250"
      unitRef="usd">1050140</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e893-wk-Fact-4FE8509ACA8B0BF915497A9E0AC6E6FA"
      unitRef="usd">382062453</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e912-wk-Fact-C8089D2D407F81CC051B7A9E0AD62A62"
      unitRef="usd">94200969</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e933-wk-Fact-CC6E538F644D87E5F08B7A9E0AB2BC85"
      unitRef="usd">11323531</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e952-wk-Fact-E4B130F5D5F400D50B007A9E0A774C26"
      unitRef="usd">12773017</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e972-wk-Fact-8A28232C2C60F1912CD07A9E0AAE4AA2"
      unitRef="usd">17327569</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e991-wk-Fact-3FC076352E6AF30B7CC57A9E0AA027F3"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1011-wk-Fact-9A69A48397097CEDABCE7A9E0AB741B7"
      unitRef="usd">2717241</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1030-wk-Fact-4F29B005F4C5B28C95A57A9E0A8CDF6B"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1050-wk-Fact-5AEF9FB28C71FDB93E127A9E0AD48F24"
      unitRef="usd">3420311</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1069-wk-Fact-41EFE250074670975DCF7A9E0A824ADF"
      unitRef="usd">3693851</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1089-wk-Fact-4C743719408FD2CB5FDF7A9E0A77B25E"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1108-wk-Fact-45EAD88160297DD80C547A9E0AC8ABE1"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1128-wk-Fact-C65939662370B8EEC6307A9E0AA05F7A"
      unitRef="usd">13265144</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1147-wk-Fact-81BBDBBC0C581B27C0517A9E0AAAD232"
      unitRef="usd">13783009</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1167-wk-Fact-719B448B303ED3E0AF3D7A9E0AC00167"
      unitRef="usd">2555782</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1186-wk-Fact-F2054E4E12CF12A0AE9C7A9E0AAAF842"
      unitRef="usd">2672024</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1211-wk-Fact-F5342BBC550BD31D10937A9E0AC8FF80"
      unitRef="usd">443185402</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1230-wk-Fact-757BCCF52DBBEFB538267A9E0A8C0D4F"
      unitRef="usd">143951597</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1332-wk-Fact-DD8CAA388F5B176B6AF77A9E0ABC2395"
      unitRef="usd">17216875</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1351-wk-Fact-46AD4C82266089489CCA7A9E0AB3A4D9"
      unitRef="usd">18237258</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1367-wk-Fact-DE1EE51FC7708321A9F97A9E0A952F5E"
      unitRef="usd">511953</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1386-wk-Fact-ED0A47C95B0971A1BD867A9E0AAAFD54"
      unitRef="usd">729729</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1406-wk-Fact-E527A2F043CA74790D487A9E0AA0C6CE"
      unitRef="usd">6870450</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1425-wk-Fact-7E592572087026714D727A9E0AA0A448"
      unitRef="usd">4049727</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1445-wk-Fact-3803BD82D685E9C6CA747A9E0AAE5349"
      unitRef="usd">14853</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1464-wk-Fact-39CE463B497631DDEE0B7A9E0AAE7A91"
      unitRef="usd">92353</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1484-wk-Fact-BCB20AA4AF0A3A754D8C7A9E0A82392F"
      unitRef="usd">94275</ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent>
    <ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1503-wk-Fact-A06FF84A0DEBADD056957A9E0AD52417"
      unitRef="usd">31775</ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1523-wk-Fact-2AB65C70DCF3DADCE7897A9E0AB7809D"
      unitRef="usd">2200459</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1542-wk-Fact-7BF8BE87B83EF5C9F8C77A9E0A957CBB"
      unitRef="usd">2074842</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1562-wk-Fact-E5BEF5FDADEB5510EF707A9E0A823385"
      unitRef="usd">10330235</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1581-wk-Fact-D1B95A791DEBA27573497A9E0A99E205"
      unitRef="usd">6065212</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1601-wk-Fact-7641B35BEF281F48A72B7A9E0A950D58"
      unitRef="usd">742875</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1620-wk-Fact-8FD047B20B2189DD9E897A9E0A8CA808"
      unitRef="usd">708425</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1640-wk-Fact-8C0B6FE7BA2E661F296E7A9E0AC8950E"
      unitRef="usd">37981975</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1659-wk-Fact-480432A460080A33E9BE7A9E0AAD5C50"
      unitRef="usd">31989321</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1679-wk-Fact-6ABCC36353F99DA2F28C7A9E0A6ECB79"
      unitRef="usd">86641</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1698-wk-Fact-74782474F022BE31003E7A9E0A773630"
      unitRef="usd">101567</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5937166e1718-wk-Fact-BED82455FD7C256849307A9E0A8245E4"
      unitRef="usd">65844260</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5937166e1737-wk-Fact-F18E478FA649FDDDC4CD7A9E0A99A3A4"
      unitRef="usd">64180325</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember"
      decimals="0"
      id="d5937166e1757-wk-Fact-992D364C2B8C78E8FCAA7A9E0AD1B17B"
      unitRef="usd">13718528</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember"
      decimals="0"
      id="d5937166e1776-wk-Fact-0252681AD3E7D65B43FA7A9E0A949252"
      unitRef="usd">12842592</us-gaap:ConvertibleDebt>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1797-wk-Fact-71A405789FCF965068E97A9E0A9F36A0"
      unitRef="usd">119796000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1816-wk-Fact-E29CDF0F4FA32DB2C7667A9E0AC0FD18"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1836-wk-Fact-BA02CD1A6B2124CED8577A9E0AB3A86D"
      unitRef="usd">19261354</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1855-wk-Fact-6C7815B0B45AE7CEB8E07A9E0AC8ED39"
      unitRef="usd">20409922</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1875-wk-Fact-34C6D0F72A1D3DBB66037A9E0AA0D358"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1894-wk-Fact-18C37B30657B2F0C08537A9E0AA0F87A"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1914-wk-Fact-F4C6ACAD4A1EC9A8F34B7A9E0A8C8E59"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1933-wk-Fact-FD9457B7E9460DC76CCC7A9E0AA0CF2D"
      unitRef="usd">135000</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1953-wk-Fact-CCCA586843F80F4887217A9E0AAEB840"
      unitRef="usd">66629</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e1972-wk-Fact-B8E18732E77361FCE05F7A9E0AB75597"
      unitRef="usd">36943</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e1992-wk-Fact-DCD84296D0787D1AE1F47A9E0A7C6FC8"
      unitRef="usd">256824933</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2011-wk-Fact-363D40E7E1FEFC6436A07A9E0AC826B4"
      unitRef="usd">138546739</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2072-wk-Fact-86CA08EE2365E74922EA7A9E0AC0A4C6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2091-wk-Fact-812AAD7F1AAA83ABA6617A9E0A995A4B"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2111-wk-Fact-37E5D18AE2BC3FADEE107A9E0A8BE9A6"
      unitRef="usd">158756</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2130-wk-Fact-3D85BD481A7BC97F73997A9E0AD43294"
      unitRef="usd">101361</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2150-wk-Fact-06AD46CB46D4F61005E57A9E0AAA1460"
      unitRef="usd">1087745242</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2169-wk-Fact-0527B72EC87861F5924F7A9E0A95787B"
      unitRef="usd">742646785</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2189-wk-Fact-E782D6A385EB18BA267F7A9E0AA0D156"
      unitRef="usd">-901029768</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2209-wk-Fact-4D93FAE553BAC9B796A17A9E0A82CE26"
      unitRef="usd">-739785655</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2231-wk-Fact-BBD9A44C6062C07033B97A9E0AB79942"
      unitRef="usd">-610030</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2251-wk-Fact-9558CF511ED1CEA8F6FD7A9E0A8C8616"
      unitRef="usd">472608</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2271-wk-Fact-68113EC39852FA0B6A167A9E0A6E2ED4"
      unitRef="usd">186264200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2290-wk-Fact-86F3026D0C8E2019A1F57A9E0A8C0CE9"
      unitRef="usd">3435099</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2310-wk-Fact-5CAF4CBB6F9966C2D2317A9E0AAA63C0"
      unitRef="usd">96269</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2329-wk-Fact-DA3B3372DE1E773E23AE7A9E0AC8CE8B"
      unitRef="usd">1969759</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2349-wk-Fact-5CB95FF0F6D850B0EA7D7A9E0A7CE12E"
      unitRef="usd">186360469</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2368-wk-Fact-E52BD533C888BDEDC4CA7A9E0A820848"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q2"
      decimals="0"
      id="d5937166e2393-wk-Fact-CDFD50F21C1C77D594AF7A9E0A7C44E4"
      unitRef="usd">443185402</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="0"
      id="d5937166e2412-wk-Fact-E345D87F83E18A01174F7A9E0AA96257"
      unitRef="usd">143951597</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="0"
      id="d5941018e759-wk-Fact-5397989B1CF5012AA1D97A9E0A99B49C"
      unitRef="usd">74102</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="0"
      id="d5941018e778-wk-Fact-942EB1FC23DD15DC2D747A9E0AAEEAE2"
      unitRef="usd">64283</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="0"
      id="d5941018e797-wk-Fact-7AC3A1A2F0B21CDFED4F7A9E0A76ECEB"
      unitRef="usd">145602</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="0"
      id="d5941018e817-wk-Fact-031CED6F9D6616B97CB07A9E0A6418D6"
      unitRef="usd">2834995</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember"
      decimals="0"
      id="d5941018e832-wk-Fact-E337AEC5E0218183FC667A9E0AAA0E25"
      unitRef="usd">95146</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember"
      decimals="0"
      id="d5941018e851-wk-Fact-80C6D9154F2E7D774A997A9E0AC869CA"
      unitRef="usd">71390</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember"
      decimals="0"
      id="d5941018e870-wk-Fact-9F4FB82A9529BF8A25427A9E0AD38689"
      unitRef="usd">1267272</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember"
      decimals="0"
      id="d5941018e890-wk-Fact-3901CF19CBAEE67CA2B57A9E0AC74736"
      unitRef="usd">126970</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="0"
      id="d5941018e910-wk-Fact-02E1EEF55F57280EBAD37A9E0AA00510"
      unitRef="usd">97939</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="0"
      id="d5941018e929-wk-Fact-A7DD9AAFC242D6D24F257A9E0AAA3527"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="0"
      id="d5941018e948-wk-Fact-F2AE288F8AE918C282B37A9E0A6C45BD"
      unitRef="usd">181587</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="0"
      id="d5941018e968-wk-Fact-2514372CF84B044105277A9E0A82D3E9"
      unitRef="usd">3614</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e988-wk-Fact-8181045FB2D5BBFD40F77A9E0AC0A69B"
      unitRef="usd">267187</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1007-wk-Fact-2D819B14A5BD48FDE9EA7A9E0AA01CA2"
      unitRef="usd">135673</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1026-wk-Fact-2C54494AA51BF8DE41827A9E0A647627"
      unitRef="usd">1594461</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1046-wk-Fact-529C9D6DF745C442E0EA7A9E0A69672B"
      unitRef="usd">2965579</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1148-wk-Fact-34828E2DBB79987F4F147A9E0A826779"
      unitRef="usd">22376575</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1167-wk-Fact-4707659EAC753569DCD97A9E0A762179"
      unitRef="usd">22486266</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1186-wk-Fact-05D34F7B29C4B06D23C37A9E0AD7533A"
      unitRef="usd">41487763</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1206-wk-Fact-32E77F4C6FA9F0C290107A9E0AD1077B"
      unitRef="usd">46876155</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1226-wk-Fact-51B697B3F647FD45F6877A9E0A804DA4"
      unitRef="usd">11071510</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1245-wk-Fact-D5E4CA0A306477375EFE7A9E0A7C38B7"
      unitRef="usd">5850101</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1264-wk-Fact-A01D2DDD373661DFBEED7A9E0A6E171B"
      unitRef="usd">18519864</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1284-wk-Fact-516319F9C3421F75652A7A9E0A6E716D"
      unitRef="usd">12825129</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1304-wk-Fact-D20B379FC7A10480FC797A9E0AAEDEF7"
      unitRef="usd">33448085</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1323-wk-Fact-892E00232E3DDFDD0D917A9E0AD1B9CD"
      unitRef="usd">28336367</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1342-wk-Fact-2A79128E1B564AE3E0287A9E0A825912"
      unitRef="usd">60007627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1362-wk-Fact-F8F4ECB4626311584AEC7A9E0A5B9796"
      unitRef="usd">59701284</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1383-wk-Fact-BB7575C02FC8367B2B8C7A9E0AB32D2E"
      unitRef="usd">-33180898</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1403-wk-Fact-65880E4C64076DA065547A9E0AA0676A"
      unitRef="usd">-28200694</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1423-wk-Fact-5607D61E32628041E2F97A9E0A82FB5B"
      unitRef="usd">-58413166</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1444-wk-Fact-78F0AF1B8ABE920AE47E7A9E0A7C916F"
      unitRef="usd">-56735705</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1547-wk-Fact-17289C6F2CCE315BB79B7A9E0AD4229B"
      unitRef="usd">1067399</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1566-wk-Fact-07D426C922D44378F7F67A9E0A95C187"
      unitRef="usd">755330</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1585-wk-Fact-3B2898B631BE5396592E7A9E0A675F93"
      unitRef="usd">1483968</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1605-wk-Fact-4D6CACF8755F709FB51F7A9E0AC07FE8"
      unitRef="usd">1380864</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1625-wk-Fact-B42926336E54E395B3587A9E0A828958"
      unitRef="usd">2846641</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1645-wk-Fact-BBFA072347E4F5FD50867A9E0A9907E6"
      unitRef="usd">2194783</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1665-wk-Fact-01420528B290DB0BA08E7A9E0AC7E155"
      unitRef="usd">5650396</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1686-wk-Fact-7C9E674D30A9691AF1EA7A9E0AC06095"
      unitRef="usd">2851031</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1707-wk-Fact-9CFDDC363EE9F2089C6A7A9E0AC82645"
      unitRef="usd">-97755000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1727-wk-Fact-E2A7C8DDCA8FD8DE8D207A9E0A95365B"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1746-wk-Fact-B36C921F513672FD83B77A9E0A829735"
      unitRef="usd">-110976977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1767-wk-Fact-CA024247493179FF658D7A9E0A5C1108"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1787-wk-Fact-113AA4A5981CA1A97F7E7A9E0ADB123B"
      unitRef="usd">-3883176</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1807-wk-Fact-1B02F38CB709DCF929277A9E0A8CB520"
      unitRef="usd">-173212</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1827-wk-Fact-F6A96CD149825F66836E7A9E0A687A78"
      unitRef="usd">9298443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1847-wk-Fact-7B02690ADD5F499786EB7A9E0A7675EF"
      unitRef="usd">-923315</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1868-wk-Fact-A2C0E810F9983D999694C68174900613"
      unitRef="usd">4358634</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1887-wk-Fact-1919C2E0721664E4A31CC68174802C2E"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1906-wk-Fact-03A8CDF73C455A25ECEAC6817471A4EE"
      unitRef="usd">-691458</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e1927-wk-Fact-214C17302A7475DFC8E4C6817461C36A"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e1947-wk-Fact-8080E9ED2F65335F3AAF7A9E0AA0D74B"
      unitRef="usd">-152102</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e1967-wk-Fact-18D3D19F2D16B7B91D717A9E0AAE5C92"
      unitRef="usd">127512</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e1986-wk-Fact-8C3EE42EFD32D31303AD7A9E0AAA51BD"
      unitRef="usd">-577602</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2007-wk-Fact-8330B459248481A5B7DA7A9E0A69CBCB"
      unitRef="usd">91673</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2027-wk-Fact-86455AB158D98870D471B5AD1CEDF3BA"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2046-wk-Fact-5542E897F448A1923749B5AD1D3B3DCB"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2065-wk-Fact-1C6B1ABCAC3AF68762C3B5AD1D1C2DDE"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2085-wk-Fact-2A7A5A93E33A9116A997B5AD1CFCCD3C"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2105-wk-Fact-6E759A4A4A24FFBA58C77A9E0AB71446"
      unitRef="usd">-128270709</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2125-wk-Fact-C1CA3FB12484A2FC315E7A9E0AD618BE"
      unitRef="usd">-29685847</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2145-wk-Fact-40D906C4DB33251217797A9E0A77074C"
      unitRef="usd">-161406113</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2166-wk-Fact-620F7169BD916F6534B87A9E0A611874"
      unitRef="usd">-59037514</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2187-wk-Fact-6126A7889CE8C630441D7A9E0A7C0F7A"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2206-wk-Fact-E094A47ECD978A8181417A9E0ADAFBBC"
      unitRef="usd">-106771</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2225-wk-Fact-E15FFB41D0B7DFB45B297A9E0A8209DB"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2245-wk-Fact-828C1BF01D374D2EB79B7A9E0AB30A91"
      unitRef="usd">-169571</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2266-wk-Fact-45EE2BA3BC2E5391D93ACA2EC20B0E71"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2286-wk-Fact-A435345325A3F06BB8F4CA2EC2116DBB"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2305-wk-Fact-EF138DCEFC740125876BCA2EC22EBAFA"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2326-wk-Fact-44606EA1753EB9F33325CA2EC21E6825"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2346-wk-Fact-8B1E762B05FFF8DE6BCE7A9E0AC0D2CC"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2366-wk-Fact-8B633C1C3465A33D73D87A9E0AC8A85C"
      unitRef="usd">-29579076</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2386-wk-Fact-724D940E836D918EC5557A9E0A8A3844"
      unitRef="usd">-162307870</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2407-wk-Fact-343497D076BA424517FF7A9E0A7CB9DD"
      unitRef="usd">-58867943</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2428-wk-Fact-6343067E5D0BBCBCABC67A9E0AD387E5"
      unitRef="usd">-469407</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2447-wk-Fact-EE590DE7892298537C2D7A9E0A7B9F79"
      unitRef="usd">-191850</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2466-wk-Fact-C7B4ADA5D00C5E9D2D837A9E0A62DF4C"
      unitRef="usd">-1063757</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2486-wk-Fact-FE0B41372E6C00AA56BF7A9E0A6E4D8E"
      unitRef="usd">-261455</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2511-wk-Fact-0C228D272FE150AEBE1E7A9E0ADA1F0E"
      unitRef="usd">-128703059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2531-wk-Fact-1668132808B558ABAC4B7A9E0AA0FC0D"
      unitRef="usd">-29387226</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2551-wk-Fact-F45C1800BCB88D52B1317A9E0A827962"
      unitRef="usd">-161244113</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2572-wk-Fact-406064D56F47A34D437D7A9E0A66E3BE"
      unitRef="usd">-58606488</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d5941018e2675-wk-Fact-C0824A96B5664703EE677A9E0A8C7B90"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d5941018e2695-wk-Fact-A330C279F4DFA6C5C7DD7A9E0A994E78"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d5941018e2715-wk-Fact-EC5D8D5AD459F31D28A07A9E0AD3ED82"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d5941018e2736-wk-Fact-36A08A29D20BF8D9AD617A9E0AAE6E76"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941018e2834-wk-Fact-9B7AEB5286B0773A421C7A9E0AD1B583"
      unitRef="shares">155807054</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941018e2853-wk-Fact-8B9E1D92FB1E4E52C6587A9E0AD6CA2B"
      unitRef="shares">98083896</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941018e2872-wk-Fact-5059CC009BF30E64113D7A9E0A7CA4E7"
      unitRef="shares">140215158</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941018e2892-wk-Fact-3AB26B4EF87638DACBBB7A9E0A8C3C4E"
      unitRef="shares">97795910</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941860e678-wk-Fact-8B1E762B05FFF8DE6BCE7A9E0AC0D2CC"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941860e698-wk-Fact-8B633C1C3465A33D73D87A9E0AC8A85C"
      unitRef="usd">-29579076</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941860e718-wk-Fact-724D940E836D918EC5557A9E0A8A3844"
      unitRef="usd">-162307870</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941860e739-wk-Fact-343497D076BA424517FF7A9E0A7CB9DD"
      unitRef="usd">-58867943</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941860e837-wk-Fact-67FB19C5658A41A4DB917A9E0A6B74AA"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941860e856-wk-Fact-9E551AB1B561B6265C727A9E0A6AD8EB"
      unitRef="usd">441545</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941860e875-wk-Fact-ABCA954AA2943B00B3337A9E0A8C4C51"
      unitRef="usd">-1082638</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941860e896-wk-Fact-0CCA1FECC682BCDEDC667A9E0A8286FC"
      unitRef="usd">1260722</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941860e916-wk-Fact-B4DA8D25E0BD00539BE37A9E0A682F9F"
      unitRef="usd">-128325566</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941860e936-wk-Fact-E887D7E6E8EFB3F574247A9E0A5C2B7D"
      unitRef="usd">-29137531</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941860e956-wk-Fact-AB6AEAA2B62DA33955B17A9E0A779D70"
      unitRef="usd">-163390508</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941860e977-wk-Fact-22E1D03ABEE6CA1D4EB87A9E0A996D29"
      unitRef="usd">-57607221</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941860e998-wk-Fact-1C8CDA9A98C3F362693C7A9E0A64D065"
      unitRef="usd">-469407</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941860e1017-wk-Fact-5AE888941C00FF49486E7A9E0A6799C1"
      unitRef="usd">-191850</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941860e1036-wk-Fact-D46CDB551264B484C0317A9E0A6EEBF1"
      unitRef="usd">-1063757</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941860e1056-wk-Fact-2B29D087E62AE011DD8C7A9E0A778FD0"
      unitRef="usd">-261455</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5941860e1081-wk-Fact-1A6CBC43E1D4B2DA84157A9E0A5A0E4D"
      unitRef="usd">-127856159</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5941860e1101-wk-Fact-9D7CDE46F545F7911FA57A9E0A662A86"
      unitRef="usd">-28945681</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5941860e1121-wk-Fact-0ABE52FCF8B0E5BAC0727A9E0A6E2C87"
      unitRef="usd">-162326751</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5941860e1142-wk-Fact-7FFE1636A383422B96827A9E0A9999D2"
      unitRef="usd">-57345766</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e1045-wk-Fact-5CC82674A68F0AF5D76A7A9E0AAA91E7"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5952269e1064-wk-Fact-8B53D56C577DDB290A1A7A9E0AA0CD95"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e1078-wk-Fact-B745093D47A23E37D49A7A9E0AAA1162"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e1098-wk-Fact-28B80BD7100592D3F4807A9E0AA978D3"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e1117-wk-Fact-A3B4BEA7BAAF1921359C7A9E0AAA0469"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e1136-wk-Fact-92F377F5D91BA236C84E7A9E0AA0CF02"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e1157-wk-Fact-44CB4474409AF4DC26357A9E0AA08137"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e1176-wk-Fact-A73F466444E25F134ADF7A9E0AAAD4C4"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="0"
      id="d5952269e1195-wk-Fact-E52BD533C888BDEDC4CA7A9E0A820848"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e1244-wk-Fact-55740840BFF999B1856F7A9E0AA91916"
      unitRef="shares">43148952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e1259-wk-Fact-E9236AD4D76D1906133A7A9E0AA0AAB8"
      unitRef="usd">43149</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e1278-wk-Fact-AB09D0F216E901493EE07A9E0AA0C435"
      unitRef="usd">208198784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q1QTD"
      decimals="0"
      id="d5952269e1355-wk-Fact-1F989506E10EB29909887A9E0AA0807C"
      unitRef="usd">208241933</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e1409-wk-Fact-233861547A023E485F1C7A9E0AA05431"
      unitRef="shares">1405114</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e1424-wk-Fact-A22F4A17715082043BC47A9E0AAA3AD2"
      unitRef="usd">1405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e1443-wk-Fact-477A4138DC0EADD311C97A9E0AA050D6"
      unitRef="usd">3099298</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1QTD"
      decimals="0"
      id="d5952269e1520-wk-Fact-1974322FBCC23FAA7CE47A9E0AA0C544"
      unitRef="usd">3100703</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e1608-wk-Fact-25A04BF2F7E42FA778E67A9E0AA0FF88"
      unitRef="usd">4017761</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e1666-wk-Fact-BD80268B1A26C4902A0A7A9E0AAAFC30"
      unitRef="usd">-16208</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1QTD"
      decimals="0"
      id="d5952269e1686-wk-Fact-EF1CE2F849827C55271F7A9E0AA0908D"
      unitRef="usd">4001553</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e1832-wk-Fact-B59C8ACB69E2F4D9FFF07A9E0AA09DA1"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="FD2020Q1QTD"
      decimals="0"
      id="d5952269e1851-wk-Fact-F5EBCDFE098D7783DFC17A9E0AA9294D"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e1958-wk-Fact-8989B98C7724DE7B592E7A9E0AA00A76"
      unitRef="usd">-32541054</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e1998-wk-Fact-3FA0C7623A999179EA9D7A9E0AA0C627"
      unitRef="usd">-594350</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q1QTD"
      decimals="0"
      id="d5952269e2018-wk-Fact-FAFE1B00E0ADE484470C7A9E0AA04365"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e2146-wk-Fact-F960792843D7ECE464C47A9E0AA0051E"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q1QTD"
      decimals="0"
      id="d5952269e2185-wk-Fact-50D54C3E52BE7C947D287A9E0AAA175F"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e2207-wk-Fact-B6BD397850B75058FA207A9E0AA0E03C"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5952269e2226-wk-Fact-068726A30F6DE766949F7A9E0AA0487D"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e2240-wk-Fact-FCD2D0E03E3134E0337A7A9E0AA08737"
      unitRef="shares">145915100</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e2260-wk-Fact-A6E7B9B53727572A6C3E7A9E0AAAF8D5"
      unitRef="usd">145915</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e2279-wk-Fact-A4A9589E6A64A44E45417A9E0AAA8A24"
      unitRef="usd">957962628</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e2298-wk-Fact-9FA7570DD7034994AB407A9E0AA0F1F6"
      unitRef="usd">-772326709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e2319-wk-Fact-761EC99F1D954F300B917A9E0AA022AD"
      unitRef="usd">-1456930</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e2339-wk-Fact-19634179A581FFA88A5A7A9E0AAA9F22"
      unitRef="usd">3529199</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1"
      decimals="0"
      id="d5952269e2358-wk-Fact-1D72D17ED8C384CADADB7A9E0AA08A50"
      unitRef="usd">187854103</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e2408-wk-Fact-E08F60D03348EA55F8CB6234F42CFFA8"
      unitRef="shares">12041178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e2423-wk-Fact-52AE17FE1C84A34225376234F662C2FF"
      unitRef="usd">12041</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e2442-wk-Fact-E9116AB88787D2498C376234F8792AE5"
      unitRef="usd">121706881</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e2519-wk-Fact-DA474D49CA166FF25F53C73372FF3B1C"
      unitRef="usd">121718922</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e2540-wk-Fact-94B4CD9EF83A7315A6546D37E2288214"
      unitRef="shares">-14</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e2574-wk-Fact-299B95A4595AD5B9B1BC6D39FA7CD2DD"
      unitRef="shares">5147</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e2589-wk-Fact-DA739648DB2063A78F686D39FA1C15D0"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e2608-wk-Fact-9E7AFB6C853D9B2708A86D39F9E6DB5B"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e2686-wk-Fact-FD03A5034A6AAD50413D6D39F9D754BF"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e2740-wk-Fact-EE4C3530AAAEF38DBFC562358610BDBC"
      unitRef="shares">794986</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e2755-wk-Fact-C879D131D98C80C202D86235885ACA00"
      unitRef="usd">795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e2774-wk-Fact-6FDC00020770244A60A962358A4CA12A"
      unitRef="usd">4421449</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e2851-wk-Fact-0658181458AC8CB8CEE0C73373DDA1EF"
      unitRef="usd">4422244</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e2939-wk-Fact-EE2199398AF034E1E54D6235A8E602AB"
      unitRef="usd">3654289</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e2997-wk-Fact-41A0DF2B3810C795C29B6236242935FF"
      unitRef="usd">8146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e3016-wk-Fact-F333AAAE842C52EBA710C73374D1B793"
      unitRef="usd">3662435</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e3162-wk-Fact-5B850B0400469C83F030623625D5F123"
      unitRef="usd">209971</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e3181-wk-Fact-AD7FDE38B5F98BE91448C73375CE437B"
      unitRef="usd">209971</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e3327-wk-Fact-B9A7C770598A5C6D6951B9340DDFEBD9"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e3347-wk-Fact-51EC36A49F9EE79CE199B9340DDAF568"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e3455-wk-Fact-FE6B4EBCF9AD7157F5AB6235CF4F8263"
      unitRef="usd">-128703059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e3495-wk-Fact-CAFD250E143120245735623627523B1B"
      unitRef="usd">-469407</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e3515-wk-Fact-8B1E762B05FFF8DE6BCE7A9E0AC0D2CC"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e3643-wk-Fact-0C0C57F617063CC7C3986235F801C832"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5952269e3681-wk-Fact-67FB19C5658A41A4DB917A9E0A6B74AA"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e3702-wk-Fact-10F0CA1F70AB195D48D9C725D1633798"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5952269e3721-wk-Fact-63AC4A8821DB7AC8B79CC725D391019D"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e3735-wk-Fact-8D82D6C014CEE982F064C725D5A32B8C"
      unitRef="shares">158756411</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e3755-wk-Fact-0F378E5CA7F8F692E17BC725D7EA4B39"
      unitRef="usd">158756</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e3774-wk-Fact-16FC987C32D64BE4FF69C725DA11C050"
      unitRef="usd">1087745242</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e3793-wk-Fact-5130DAE7A8CB1C4DAABDC725DC27386C"
      unitRef="usd">-901029768</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e3814-wk-Fact-A4D25134E98A472FE4A7C725DE4F5A86"
      unitRef="usd">-610030</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e3834-wk-Fact-886C76E88194244FBD5CC725E060C473"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="0"
      id="d5952269e3853-wk-Fact-5CB95FF0F6D850B0EA7D7A9E0A7CE12E"
      unitRef="usd">186360469</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e4435-wk-Fact-1F55077CE86F84CE29017A9E0AC0FB53"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5952269e4454-wk-Fact-9C96E73FA6A741FAA7DB7A9E0A6E9367"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e4468-wk-Fact-281E7DB76665A68A68337A9E0A6E4E3F"
      unitRef="shares">97225810</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e4488-wk-Fact-C19B6547F924259ACA2E7A9E0A77B99F"
      unitRef="usd">97226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e4507-wk-Fact-00C0E15BD60C2EC424247A9E0A95ABEF"
      unitRef="usd">707794215</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e4526-wk-Fact-7E294594D29BA0539DB67A9E0A946292"
      unitRef="usd">-620426436</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e4547-wk-Fact-A485D6E7D062035A482E7A9E0A95E811"
      unitRef="usd">-528867</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e4567-wk-Fact-D716A5F25B64534CAD197A9E0ABFE86B"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="0"
      id="d5952269e4586-wk-Fact-C30DFEF65987A4CD37DC7A9E0AC0B144"
      unitRef="usd">87032407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e4635-wk-Fact-29CDFA2C1F21413AB5557A9E0ABFBFD9"
      unitRef="shares">183200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e4650-wk-Fact-1850E66948F7218B36737A9E0AC0F80F"
      unitRef="usd">183</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e4669-wk-Fact-025FE3EDEF6BEDA37D907A9E0AC0B3F5"
      unitRef="usd">907147</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e4746-wk-Fact-05033509A8D5D6EA8E237A9E0AC0D3A5"
      unitRef="usd">907330</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e4800-wk-Fact-49F5827193D890D0DA7E7A9E0A7C463C"
      unitRef="shares">525000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e4815-wk-Fact-F610B2291F15FD9D5DA57A9E0AC01108"
      unitRef="usd">525</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e4834-wk-Fact-EF96FDD53A864AFFA0787A9E0AC084C1"
      unitRef="usd">-719922</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e4912-wk-Fact-13C59194C2CC8674D1BA7A9E0AB70917"
      unitRef="usd">-719397</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e5001-wk-Fact-E4DD0D26D2F40ED2767F7A9E0AB7BF61"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e5078-wk-Fact-7AEEDC621C2AF8CEE0847A9E0A7B404A"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e5166-wk-Fact-770AF1C0914D18D99C487A9E0A95A492"
      unitRef="usd">3432796</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e5243-wk-Fact-563CCC41B4D79F28ED717A9E0A7CC8F4"
      unitRef="usd">3432796</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e5389-wk-Fact-AB56AB5FE7B2752414C47A9E0A7758AA"
      unitRef="usd">3030107</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e5408-wk-Fact-47AA577AB82605E48C4E7A9E0A778D24"
      unitRef="usd">3030107</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e5515-wk-Fact-26395D0E849CDBFD14DD7A9E0A6E3333"
      unitRef="usd">-29219262</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e5555-wk-Fact-7BE1849F67E1BC0CF9587A9E0A77E887"
      unitRef="usd">-69605</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e5575-wk-Fact-334C729ABAE3A94A3BAC7A9E0AC016CD"
      unitRef="usd">-29288867</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e5703-wk-Fact-73CFD768988C28A8D69F7A9E0AC01A72"
      unitRef="usd">819177</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d5952269e5741-wk-Fact-03999D7C96199095294C7A9E0AB73C22"
      unitRef="usd">819177</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e5763-wk-Fact-530CE40F6CD9D9EB8D367A9E0A776D0B"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5952269e5782-wk-Fact-36F8E7A6812C3B6FAE1A7A9E0A7770C8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e5796-wk-Fact-26D8BB15FF8682C302D97A9E0AB7A626"
      unitRef="shares">97934010</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e5816-wk-Fact-E2FD1BB0AF315E34CD257A9E0ABFDC5D"
      unitRef="usd">97934</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e5835-wk-Fact-64927817944104159D427A9E0A7CEF08"
      unitRef="usd">727166934</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e5854-wk-Fact-A8F929A81618FB265C677A9E0AC0403F"
      unitRef="usd">-649645698</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e5875-wk-Fact-892FCF07AE8C7606828E7A9E0ABFC8F4"
      unitRef="usd">290310</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e5894-wk-Fact-563809DD0A10BF2510347A9E0A77EFD7"
      unitRef="usd">3056771</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="0"
      id="d5952269e5913-wk-Fact-88ED1F66E2914D3E8E0F7A9E0AC06FB7"
      unitRef="usd">80966251</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e5962-wk-Fact-F80C94ECBA067608AF797A9E0AD21CCC"
      unitRef="shares">476600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e5977-wk-Fact-E95763C9F447FEEE23317A9E0AC82BFA"
      unitRef="usd">476</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e5996-wk-Fact-7B808BBF90155D129ABF7A9E0AB74B16"
      unitRef="usd">1388510</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5952269e6073-wk-Fact-F8E4871120A4131072727A9E0A8CFC4E"
      unitRef="usd">1388986</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e6127-wk-Fact-CA9034344C0E3CB5A2687A9E0AC81CB1"
      unitRef="shares">173761</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e6142-wk-Fact-DC908574B7EC9C8112D57A9E0A61276A"
      unitRef="usd">174</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e6161-wk-Fact-CCD29EBE5EF8275B699B7A9E0A641EFA"
      unitRef="usd">-81433</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5952269e6239-wk-Fact-0D3078A616CC274D64607A9E0A8CC748"
      unitRef="usd">-81259</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e6328-wk-Fact-9244E0548D10CE627E627A9E0A657077"
      unitRef="usd">3345378</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e6386-wk-Fact-77F47FCDB34BAD7462ED7A9E0A95DECB"
      unitRef="usd">9817</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5952269e6405-wk-Fact-80588F81CCF4B9A53DA77A9E0AB7818C"
      unitRef="usd">3355195</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e6551-wk-Fact-506C5C8AB1BF575CBE9A7A9E0A9E9520"
      unitRef="usd">13569</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5952269e6571-wk-Fact-21E67173D7ABB4895DC57A9E0A77985D"
      unitRef="usd">13569</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e6679-wk-Fact-D6F67FD9C232A43F03A07A9E0AD4D93A"
      unitRef="usd">-29387226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e6719-wk-Fact-83F75C1F1302DB981FF67A9E0AD293F3"
      unitRef="usd">-191850</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5952269e6739-wk-Fact-8B633C1C3465A33D73D87A9E0AC8A85C"
      unitRef="usd">-29579076</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e6867-wk-Fact-CF038FCCE1DA44E528367A9E0AC8E2BB"
      unitRef="usd">441545</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5952269e6905-wk-Fact-9E551AB1B561B6265C727A9E0A6AD8EB"
      unitRef="usd">441545</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="INF"
      id="d5952269e6926-wk-Fact-A0F787AC2551CB7718447A9E0AAA6284"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5952269e6945-wk-Fact-552127C891AA874075137A9E0AB38758"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5952269e6959-wk-Fact-5E54CCE7C8876BC0FA1B7A9E0A6EFC54"
      unitRef="shares">98584371</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5952269e6979-wk-Fact-54ECE5E589379227E34A7A9E0AC8369B"
      unitRef="usd">98584</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="d5952269e6998-wk-Fact-543C280079B0E34D2F417A9E0A95C813"
      unitRef="usd">731819389</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="d5952269e7017-wk-Fact-5857DE0DCFB350862CDE7A9E0A6811C9"
      unitRef="usd">-679032924</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="d5952269e7038-wk-Fact-E087819D7378836EC0477A9E0A94CC21"
      unitRef="usd">731855</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="d5952269e7057-wk-Fact-6988B851739F07FB1DB97A9E0AC0611C"
      unitRef="usd">2861169</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="0"
      id="d5952269e7076-wk-Fact-46F7B54F71EC00AE914A7A9E0A8238CB"
      unitRef="usd">56478073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e625-wk-Fact-724D940E836D918EC5557A9E0A8A3844"
      unitRef="usd">-162307870</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e645-wk-Fact-343497D076BA424517FF7A9E0A7CB9DD"
      unitRef="usd">-58867943</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e702-wk-Fact-34D13E0208503EEB8A847A9E0A8C6B2A"
      unitRef="usd">1608060</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e721-wk-Fact-21CE3FB3F5F70E09D50F7A9E0A828EE1"
      unitRef="usd">1863225</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e741-wk-Fact-CC8382A34D939ABE3AD27A9E0A95DC86"
      unitRef="usd">273540</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e760-wk-Fact-1DE57BB47FA6464896947A9E0A8AEDD1"
      unitRef="usd">533126</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e780-wk-Fact-502CE2DB216FE8810F617A9E0A8265A5"
      unitRef="usd">110976977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e799-wk-Fact-6A424A95CDC63D7FB4177A9E0A958D14"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e819-wk-Fact-E95B646F90A0F0C2F8A07A9E0A8283FD"
      unitRef="usd">7663988</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e838-wk-Fact-7B863868C0F1092A9B107A9E0A7C0B12"
      unitRef="usd">6787991</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e858-wk-Fact-D3C3E1BE64889ECC0AA67A9E0A95C65D"
      unitRef="usd">3013942</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e877-wk-Fact-35F82F69228166F2805D7A9E0A8C5469"
      unitRef="usd">2851031</ino:NonCashInterestExpense>
    <ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e897-wk-Fact-81BC3F35A758C5EA44907A9E0A82B70B"
      unitRef="usd">0</ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit>
    <ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e916-wk-Fact-320AFF56ABAB50DDFD537A9E0A8A33EC"
      unitRef="usd">1962</ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit>
    <us-gaap:GainLossOnInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e937-wk-Fact-936365A1603A00BF78A07A9E0A77E158"
      unitRef="usd">-576001</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e956-wk-Fact-4FD3D33811B9B9FD44A77A9E0A8CD9B9"
      unitRef="usd">93273</us-gaap:GainLossOnInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e977-wk-Fact-AB18DB30CB4E31AF0CDC7A9E0A7C9FDB"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e997-wk-Fact-3D66F93847A45B19F72D7A9E0A82D9E4"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1017-wk-Fact-1C6B1ABCAC3AF68762C3B5AD1D1C2DDE"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1056-wk-Fact-F6A96CD149825F66836E7A9E0A687A78"
      unitRef="usd">9298443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1076-wk-Fact-7B02690ADD5F499786EB7A9E0A7675EF"
      unitRef="usd">-923315</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1096-wk-Fact-EF138DCEFC740125876BCA2EC22EBAFA"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1134-wk-Fact-D5EBAD64EDF3D8CF47BEC73AA436043C"
      unitRef="usd">691458</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1153-wk-Fact-D17E91ADC394CF28A1ECC73AA43931A6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1173-wk-Fact-98050C693EC67F885628C739E4CA5924"
      unitRef="usd">517865</ino:OperatingLeaseNonCashLeaseExpense>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1192-wk-Fact-433B0D213B66352FB7417A9E0A990465"
      unitRef="usd">412533</ino:OperatingLeaseNonCashLeaseExpense>
    <ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1212-wk-Fact-93E40E1E9CDFB50D24537A9E0A8C0CAF"
      unitRef="usd">0</ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments>
    <ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1231-wk-Fact-40DB89C8779B39B97F627A9E0A8C96CE"
      unitRef="usd">-335228</ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1252-wk-Fact-CBFEA3691B35245D89E77A9E0A7C9E8C"
      unitRef="usd">474071</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1272-wk-Fact-2E3E06381D937FADFE8A7A9E0A82DACB"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1333-wk-Fact-0485142760E8DEC30AF97A9E0A8A86F8"
      unitRef="usd">2813086</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1353-wk-Fact-4A86B085665AA37C96907A9E0A8C9113"
      unitRef="usd">-3186131</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1374-wk-Fact-9D4331999282F4C786FC7A9E0A8CB700"
      unitRef="usd">-865832</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1393-wk-Fact-846A86999B1751DB6C9F7A9E0A7C33BB"
      unitRef="usd">258353</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1414-wk-Fact-37F779E4CF87441A751F7A9E0A8C7DF0"
      unitRef="usd">3084082</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1434-wk-Fact-B1826368CCEED9DB5F497A9E0A8CE194"
      unitRef="usd">902772</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1455-wk-Fact-2B971AE324A30CA00FB27A9E0A7CFE75"
      unitRef="usd">1330601</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1475-wk-Fact-A103F5BB4E6E37BB28647A9E0A820171"
      unitRef="usd">-20059</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1495-wk-Fact-F60E6B6856C375F34C7D7A9E0A82B88F"
      unitRef="usd">-116242</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1514-wk-Fact-AB6BC2E6CFCD763E9D127A9E0A957F9D"
      unitRef="usd">183091</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1535-wk-Fact-0461FA4E9F9A415853BD7A9E0A8257C9"
      unitRef="usd">-732774</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1555-wk-Fact-CF5C7014EB7D7CD940BC7A9E0A81A953"
      unitRef="usd">-9187074</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1576-wk-Fact-2A049DA934D062221E5F7A9E0A8CA13E"
      unitRef="usd">2882486</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1595-wk-Fact-7B5DA793502F3F1B3A117A9E0A82139D"
      unitRef="usd">-1033367</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1616-wk-Fact-98E7052BE1D003C84E407A9E0A8CCAD3"
      unitRef="usd">4634</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1635-wk-Fact-3F5E21763C12457351097A9E0A8B15F3"
      unitRef="usd">-324224</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1656-wk-Fact-AC39457126688F71488D7A9E0A82B0B2"
      unitRef="usd">-92426</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1676-wk-Fact-24A0A3C64E3D48A36FD87A9E0A81FEAB"
      unitRef="usd">-137046</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1697-wk-Fact-509AF0E8D9A4130555437A9E0A820932"
      unitRef="usd">62500</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1716-wk-Fact-A4456FD7CC07F444FA7D7A9E0A7797E9"
      unitRef="usd">62500</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1736-wk-Fact-EBF6B8ED220F0ABAD5AF7A9E0A77A0A6"
      unitRef="usd">-1022951</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1756-wk-Fact-98051B0BEF0CB8EE5C777A9E0A775E56"
      unitRef="usd">-786079</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1777-wk-Fact-5F5D69679E42C759FBFF7A9E0A8CA564"
      unitRef="usd">4265023</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1796-wk-Fact-185FE11363C79DDEA0F77A9E0A7C0AD5"
      unitRef="usd">-1695191</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1818-wk-Fact-679EF76E74FF37E043227A9E0A7C0167"
      unitRef="usd">-63050</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1838-wk-Fact-A1308A65DEC17859857F7A9E0A81481C"
      unitRef="usd">817125</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1858-wk-Fact-4D8C13925052064452717A9E0A776E96"
      unitRef="usd">29686</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1877-wk-Fact-BF26611D1527597954F97A9E0A8C96D2"
      unitRef="usd">-34688</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1898-wk-Fact-EE777CAFB8055345DBCE7A9E0A771D95"
      unitRef="usd">-52604208</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e1918-wk-Fact-729A417EDB2C0D9F7A9C7A9E0A8260CC"
      unitRef="usd">-56379331</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e1980-wk-Fact-7A0B11809B3DDF0F8B767A9E0A808D5F"
      unitRef="usd">138698249</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2000-wk-Fact-7F0A78CB72AEC6A4D0517A9E0A8C887D"
      unitRef="usd">73698391</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2021-wk-Fact-EE29008DD9C2D2AFAB037A9E0A8C43B5"
      unitRef="usd">47455067</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2040-wk-Fact-0A17F421C52CDAE422627A9E0A82D0C2"
      unitRef="usd">46688689</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2060-wk-Fact-AA815A51D19EE8C93BA87A9E0A7748B6"
      unitRef="usd">176534</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2080-wk-Fact-1998A852B2B4EB18A3757A9E0A8CAEFB"
      unitRef="usd">739808</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2101-wk-Fact-CC04C69C640920B961F7C2EC6074D84D"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2121-wk-Fact-2931D0175966252E0331C2EC607948AB"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2141-wk-Fact-E9D782A89A78C9776C007A9E0A7C22D0"
      unitRef="usd">-94194567</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2161-wk-Fact-E46D9A3B207BD93729E07A9E0A82D3A9"
      unitRef="usd">-27749510</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2223-wk-Fact-0655A3AEEC624CCC11FF7A9E0A8235B4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2242-wk-Fact-D39F53763674CF25457C7A9E0A8C480D"
      unitRef="usd">75658953</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2263-wk-Fact-854B2CC0E8EF24F4D2227A9E0A7782DC"
      unitRef="usd">329960855</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2282-wk-Fact-965E5F19B60CFB5971977A9E0A956B2E"
      unitRef="usd">2296316</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2302-wk-Fact-DEAD6FA4DFFC89812EF07A9E0A8C2356"
      unitRef="usd">9599514</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2321-wk-Fact-64AA7153B4B520D156287A9E0A7C76E5"
      unitRef="usd">92272</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2341-wk-Fact-B358549C857D1C773EA17A9E0A820E56"
      unitRef="usd">2076567</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2361-wk-Fact-06E17591F7970DED4C627A9E0A7C9C3E"
      unitRef="usd">892928</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2382-wk-Fact-72A857BA54D204DA2C157A9E0A8CFD5A"
      unitRef="usd">2379969</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2401-wk-Fact-54956FA0A0024C7084D27A9E0A8CC5FC"
      unitRef="usd">3016538</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2421-wk-Fact-C5471799D45A19E3F81BB943645697ED"
      unitRef="usd">171620</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2440-wk-Fact-E79E60FF6738F3CB8CF3B9436453E168"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2460-wk-Fact-907D41E0277B773B6DB87A9E0A82E1EA"
      unitRef="usd">340035391</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2479-wk-Fact-98E6DC4CEE7957B240507A9E0A82E49E"
      unitRef="usd">80171151</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2499-wk-Fact-E48F06EFF697BCF2D7617A9E0A6BFDBA"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2518-wk-Fact-DB35360C092CE69A19087A9E0AA0150A"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2538-wk-Fact-9D1ABEBA09C67668321B7A9E0A8C7F12"
      unitRef="usd">193236616</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2557-wk-Fact-8583E522D1E91D8EFF947A9E0A8CB86A"
      unitRef="usd">-3957690</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="0"
      id="d5944595e2578-wk-Fact-455A97A81EB672F5A28B7A9E0A82DDA6"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="0"
      id="d5944595e2597-wk-Fact-09933A06CBA20E52C4E17A9E0A8C23AA"
      unitRef="usd">23693633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="0"
      id="d5944595e2622-wk-Fact-1FA4F5FA0E5005CAB89A7A9E0A8CD80F"
      unitRef="usd">215432713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="0"
      id="d5944595e2641-wk-Fact-2C6246B95544F8F0E59A7A9E0A9560BF"
      unitRef="usd">19735943</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2744-wk-Fact-928E870750022F02333A7A9E0A954E1C"
      unitRef="usd">1620</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2763-wk-Fact-91BDEBBC40357B370C8E7A9E0A7CF88E"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2799-wk-Fact-2A45146916AA3BDE51D47A9E0A823A95"
      unitRef="usd">2636454</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2818-wk-Fact-B45701514A9FCA675A857A9E0A8C7C29"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5944595e2838-wk-Fact-2F4807573DCE81DD2DED7A9E0A82E472"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d5944595e2857-wk-Fact-E1A28AFAE6A117D0D8197A9E0A772D76"
      unitRef="usd">14634769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="FD2020Q2YTD"
      id="TextSelection-EEE35599712FB1E694E87A9E0AE48AA6-0-wk-Fact-C2D75917D30928A63F3D7A9E0A7619FC">Organization and Operations&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Inovio&#x201d;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's novel DNA medicines are made using its proprietary SynCon&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inovio's hand-held CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Human data to date have shown a favorable safety profile of Inovio&#x2019;s DNA medicines delivered directly into cells in the body using the CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; smart delivery device in more than 6,000 administrations across more than 2,000 patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-04CEC7F0627D57E5B2437A9E0AE40A10-0-wk-Fact-975168F60E160CCB9A847A9E0A82042C">Basis of Presentation&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the condensed consolidated statements of cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;12, 2020. The balance sheet at December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June of 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inovio incurred a net loss attributable to common stockholders of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$128.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$161.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Inovio had working capital of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$344.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;901.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$371.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#x201c;Sales Agreement&#x201d; and collectively, the &#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$121.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$330.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from a private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Korean Won (KRW) (approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; KRW (approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#x2019;s condensed consolidated financial statements as of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BAA0D62BB201EAD0D8657A9E0AE461C8-0-wk-Fact-69ADF505756D13D53A647A9E0A7CBE5E">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the condensed consolidated statements of cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;12, 2020. The balance sheet at December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June of 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inovio incurred a net loss attributable to common stockholders of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$128.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$161.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Inovio had working capital of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$344.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and an accumulated deficit of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;901.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$371.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#x201c;Sales Agreement&#x201d; and collectively, the &#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$121.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$330.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from a private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Korean Won (KRW) (approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; KRW (approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#x2019;s condensed consolidated financial statements as of and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="FI2020Q2_srt_OwnershipAxis_ino_VGXAnimalHealthIncMember"
      decimals="2"
      id="d5952356e525-wk-Fact-161E191D10CDD2BDF4977A9E0A82EDE8"
      unitRef="number">0.15</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="I2020Q1June01_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="2"
      id="d5952356e529-wk-Fact-1679AA4A0D82B306F8B2B5C00889233D"
      unitRef="number">0.47</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d5952356e536-wk-Fact-CC3398B8277D3F0F083BCAF3CE664C82"
      unitRef="usd">-128700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d5952356e540-wk-Fact-B9C787DE1D3620A14DEECAF3DED82B99"
      unitRef="usd">-161200000</us-gaap:NetIncomeLoss>
    <us-gaap:Capital
      contextRef="FI2020Q2"
      decimals="-5"
      id="d5952356e548-wk-Fact-6DB40BD4C58FBEEF9F1A7A9E0A7C5E67"
      unitRef="usd">344100000</us-gaap:Capital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q2"
      decimals="-5"
      id="d5952356e552-wk-Fact-15A4169B632E82E8B475CAF611C7359A"
      unitRef="usd">-901000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="FI2020Q2"
      decimals="-5"
      id="d5952356e561-wk-Fact-B016282C54122AA1FF357A9E0A81A4F0"
      unitRef="usd">371700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember"
      decimals="-5"
      id="d5952356e572-wk-Fact-94CA27B45B4EF438D0157A9E0A7C427E"
      unitRef="usd">121700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember"
      decimals="-5"
      id="d5952356e576-wk-Fact-AF10AFE32AC0B77167D3CAFCAE9CE5B0"
      unitRef="usd">330000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember"
      decimals="-5"
      id="d5952356e584-wk-Fact-35904BD94A7B338A94DC7A9E0A820DB1"
      unitRef="usd">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5952356e588-wk-Fact-FA16ECBC31FAB5C4CB267A9E0A80F0B7"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e593-wk-Fact-C78378166FAA8702300F7A9E0A82A6A7"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5952356e597-wk-Fact-FCBEBA70BCB704FEC2C17A9E0A820F3F"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e601-wk-Fact-C2CEE7B649395CE241E77A9E0A82E675"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e605-wk-Fact-1974E1ACA335AB62B70D7A9E0A7C9255"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e609-wk-Fact-F5BAD24F5632E5DCF14F7A9E0A818799"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5952356e613-wk-Fact-2DE58C4CE99DF181141C7A9E0A82B144"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e618-wk-Fact-9501506516B877FCEF277A9E0A828953"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e622-wk-Fact-FB325C8CFDF98209AECF7A9E0A82FC5D"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5952356e626-wk-Fact-6A9717410DB3891EBB417A9E0A800406"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-448809A51589D3FCA4217A9E0AE413F1-0-wk-Fact-5FB466AA029B5312040C7A9E0A6E2021">Critical Accounting Policies&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;Topic 606&#x201d;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the license has an alternative future use. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;8 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#x2019;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive gain (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under Accounting Standards Codification ("ASC") Topic 321, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="FD2020Q2YTD"
      id="TextSelection-7CDE2F624EA9C51FE2FB7A9E0AE4A26C-0-wk-Fact-669364000A0A6DC228477A9E0A6CC4CB">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;Topic 606&#x201d;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B108F6938EBAEB15D7E07A9E0AE43EAD-0-wk-Fact-C49653E79E1A0CB5A8EB7A9E0A6E7B59">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-16AB06A42F2C225DAA6E7A9E0AE4723D-0-wk-Fact-E7B539D75D21B39E0C3F7A9E0A6E6D71">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;</ino:GrantPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-46A459929D5790F7D7187A9E0AE495F0-0-wk-Fact-7F11A84463F813CA68877A9E0A6D070B">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2020Q2YTD"
      id="TextSelection-5E927334E3B8DE3BB1B37A9E0AE444B0-0-wk-Fact-691C974F82F7C1228B3B7A9E0A6EEBA3">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-0F5E9B8028616F725E5E7A9E0AE57577-0-wk-Fact-C39C72D6CE1CE4FDBE2C7A9E0A6EDD22">&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the license has an alternative future use. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, identifying no impairment.&lt;/span&gt;&lt;/div&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember"
      id="d5952684e613-wk-Fact-9AFB85614822685E339F7A9E0A6C7103">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-5"
      id="d5952684e631-wk-Fact-F59CE66D22E73784D0C3CB8620972677"
      unitRef="usd">3400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d5952684e635-wk-Fact-E996B05427A9433E0B36CB8641A2882A"
      unitRef="usd">3700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5B2800C75B75A0D0205E7A9E0AE568AC-0-wk-Fact-033E6AE5CAE4790D48D07A9E0A6E3CC9">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#x2019;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-20F5F0DE404AD87633E87A9E0AE51492-0-wk-Fact-DD8CDCF9AB35F5BD101D7A9E0A6E5009">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive gain (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="FD2020Q2YTD"
      id="TextSelection-27C200BF283D8356CE949AA3C4D33625-0-wk-Fact-DC6A99016BE6997B94789AA3D52D44FA">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-3725B4FC06399928A0DEC7EF616B56F0-0-wk-Fact-1F2BA0E1B0EDA8EDC443C7EF72BA23E2">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under Accounting Standards Codification ("ASC") Topic 321, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-50350BA66C3D1E71E4947A9E0AE589F7-0-wk-Fact-BB61076DD932C15AE62E7A9E0A66B0EF">Impact of Recently Issued Accounting Standards &lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Standards Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2019-12. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption.  As of June 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2016-13&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#x201c;COVID-19&#x201d;) outbreak on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-13&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#x2019;s fair value classifications).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-18&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which clarified the interaction between Topic 808, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and Topic 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU 2017-04.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;&lt;/span&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5EAF48230E91DE9255507A9E0AE5A937-0-wk-Fact-F6BC150CAA512D70A9537A9E0A657D7B">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Standards Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2019-12. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption.  As of June 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2016-13&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#x201c;COVID-19&#x201d;) outbreak on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-13&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#x2019;s fair value classifications).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-18&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which clarified the interaction between Topic 808, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and Topic 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU 2017-04.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;&lt;/span&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-68640F496F7E8B2B6AB47A9E0AE59F5D-0-wk-Fact-BC9C29EC4411B85B9C8B7A9E0A95C2D0">Revenue Recognition  &lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized total revenue under collaborative research and development and other agreements of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$64,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$74,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$146,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from AstraZeneca and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$129,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$244,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from various other contracts. Of the total revenue recognized during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$66,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$124,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, were in deferred revenue as of December 31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Performance obligations are generally satisfied within &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of the initial contract date.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-3"
      id="d5952758e494-wk-Fact-78F52E742CDD803A87777A9E0A999925"
      unitRef="usd">64000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-5"
      id="d5952758e498-wk-Fact-FB7C85247D4C6CC28B54CB8ED5C77938"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember"
      decimals="-3"
      id="d5952758e502-wk-Fact-D17DB0C393F844AC72C17A9E0A95B4D0"
      unitRef="usd">74000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember"
      decimals="-3"
      id="d5952758e506-wk-Fact-0D0C9DBC32B0CCF20B03CB8F9B7823E7"
      unitRef="usd">146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember"
      decimals="-3"
      id="d5952758e511-wk-Fact-80264DFCF9B102DEEFFE7A9E0A95AE09"
      unitRef="usd">129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember"
      decimals="-3"
      id="d5952758e515-wk-Fact-67C50948170A246D5BF1CB8FB1DD5EFB"
      unitRef="usd">244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d5952758e523-wk-Fact-6DEE0A5F5CFEED7B66EE7A9E0A996444"
      unitRef="usd">66000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d5952758e527-wk-Fact-3AECEC8197A78137AFC3CB8FFB384546"
      unitRef="usd">124000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-424C74FC42A40F0F16D37A9E0AE543C8-0-wk-Fact-23B849B3DCE987A4DBE27A9E0A62653F">Short-term Investments&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term investments at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consisted of mutual funds, corporate debt securities and certificates of deposit. Short-term investments at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded gross realized gain on investments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$585,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$635,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and gross realized loss on investments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$686,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded gross realized gain on investments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$157,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$175,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and gross realized loss on investments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$29,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$82,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$(691,000)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; material unrealized gain or loss on available-for-sale equity securities recorded during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available-for-sale securities in an unrealized loss position, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;none&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were in such position for longer than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;12 months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of available-for-sale securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;---&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149,641,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,180,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,871,643&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;148,949,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;---&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,625,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(376,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,262,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,266,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,232,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,268,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;156,231,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;---&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,599,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;754,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,338,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d5953814e492-wk-Fact-0D2F4ABDE3049F5812067A9E0A63BAE2"
      unitRef="usd">585000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d5953814e496-wk-Fact-73159D33925CDA9B6FA07A9E0A6314CF"
      unitRef="usd">635000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d5953814e501-wk-Fact-70AB3506BA8AEB80EFB97A9E0A64CB40"
      unitRef="usd">686000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d5953814e505-wk-Fact-A99A4E95104D6470ABAA7A9E0A65E4ED"
      unitRef="usd">1200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d5953814e513-wk-Fact-A4C7A90FA06EE856D514CBFD94304AFB"
      unitRef="usd">157000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d5953814e517-wk-Fact-3546C8141D5BC378E6B9CBFDA2E79201"
      unitRef="usd">175000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d5953814e521-wk-Fact-99AD94CE8843D942CE6FCBFDF5C12C13"
      unitRef="usd">29000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d5953814e526-wk-Fact-691699AD468164C095C9CBFE073601C2"
      unitRef="usd">82000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d5953814e534-wk-Fact-93DA9A10D0E7F08B9A5C7A9E0A63C974"
      unitRef="usd">4400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d5953814e538-wk-Fact-DF21F1796711DB2682B27A9E0A625423"
      unitRef="usd">-691000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5953814e542-wk-Fact-1919C2E0721664E4A31CC68174802C2E"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2020Q2"
      decimals="INF"
      id="d5953814e563-wk-Fact-82B5C2FCA186F54F10D27A9E0A624EEE"
      unitRef="investment">16</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="FI2020Q2"
      decimals="INF"
      id="d5953814e567-wk-Fact-02ECA8245A67930DA9667A9E0A658C58"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-2AAF76CD0D33E03A305A7A9E0AE59AE4-0-wk-Fact-716A95CCB962A9F16C507A9E0A645882">&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of available-for-sale securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;---&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;149,641,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,180,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,871,643&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;148,949,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;---&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,625,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(376,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,262,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,266,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,232,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,268,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;156,231,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;---&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,599,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;754,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,338,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e839-wk-Fact-4494E0CF77B2B1AEE5EC7A9E0AA023AF"
      unitRef="usd">149641400</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e858-wk-Fact-1D83E42E13032FF10FFB7A9E0AA0069B"
      unitRef="usd">1180185</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e878-wk-Fact-D00682F5C449982A4BA37A9E0A9E0525"
      unitRef="usd">1871643</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e898-wk-Fact-52A2CB83325C4E33AC6B7A9E0A9965D3"
      unitRef="usd">148949942</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5953814e923-wk-Fact-E4F4E4BDC17AF7A1B59B7A9E0A9F714E"
      unitRef="usd">4625000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5953814e942-wk-Fact-56B516C4CEFC8F787C797A9E0AA0F51A"
      unitRef="usd">14400</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5953814e962-wk-Fact-B6753EE32B8A48F478D77A9E0A998C06"
      unitRef="usd">376600</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5953814e982-wk-Fact-F7B4649CA688F7383CFE7A9E0A9909D9"
      unitRef="usd">4262800</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5953814e1012-wk-Fact-822D37D5815DC93652687A9E0AA086FE"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5953814e1031-wk-Fact-B4EC0247987CF9824BCB7A9E0A9F28B2"
      unitRef="usd">38360</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5953814e1051-wk-Fact-3E8815CDC159AB7822617A9E0AAD8348"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5953814e1071-wk-Fact-C9D91B14EB70A10B41CD7A9E0A994853"
      unitRef="usd">3018360</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2"
      decimals="0"
      id="d5953814e1106-wk-Fact-5AB671D4E44C2C2E25977A9E0A9E944D"
      unitRef="usd">157266400</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2"
      decimals="0"
      id="d5953814e1125-wk-Fact-3370CC47ACE03752F3837A9E0AA01D34"
      unitRef="usd">1232945</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2"
      decimals="0"
      id="d5953814e1145-wk-Fact-F1A5CBDF774E5D62BD4F7A9E0AA0CA71"
      unitRef="usd">2268243</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2"
      decimals="0"
      id="d5953814e1165-wk-Fact-A06ACD39110EEBADF5C57A9E0AA06CD9"
      unitRef="usd">156231102</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e1413-wk-Fact-DC6BC041A639938CF36F7A9E0AAE4BB6"
      unitRef="usd">66599219</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e1432-wk-Fact-0D2BD68350B4D242697D7A9E0A6577A0"
      unitRef="usd">754709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e1452-wk-Fact-488F795CD093CF3B6B487A9E0A64A489"
      unitRef="usd">15911</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5953814e1472-wk-Fact-D507E39043A5C18C73D07A9E0A645336"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-53869378AAD98ABAA9677A9E0AE60AEA-0-wk-Fact-9367D2FA4D95909406A47A9E0A6C8AC7">Fair Value Measurements&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;148,949,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;148,949,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,262,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,262,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,327,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,327,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;173,558,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,540,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Derivative liability (Note 9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,349,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,349,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,338,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,338,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,315,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,315,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,003,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,003,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Derivative liability (Note 9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 assets at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consisted of mutual funds and corporate debt securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investments in affiliates, GeneOne and PLS. The Company accounts for its investment in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,644,155&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; common shares of GeneOne based on the closing price of the shares on the Korean Stock Exchange on the applicable balance sheet date. The Company accounts for its investment in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;597,808&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; common shares of PLS based on the closing price of the shares on the Korea New Exchange (KONEX) Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of operations as a gain (loss) on investment in affiliated entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 assets at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consisted of certificates of deposit held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were no Level 3 assets at June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 liabilities held as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 9 below for more information). The derivative liability was recorded at fair value of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; include the Company&#x2019;s stock price on the valuation date; the expected annual volatility of the Company&#x2019;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company's derivative liability for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,976,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-77FD3E0BB0D8CAD2DF577A9E0AE6F82C-0-wk-Fact-4DBDEAA5B1352E0C2BBE7A9E0A6EDA67">&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;148,949,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;148,949,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,262,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,262,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,327,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,327,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;173,558,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,540,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,018,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Derivative liability (Note 9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,349,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,349,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,338,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,338,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,315,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,315,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,003,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,003,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Derivative liability (Note 9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e891-wk-Fact-0A5FB0442A4AF184CB367A9E0AAEE6D0"
      unitRef="usd">148949942</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e910-wk-Fact-43F386B0E22A57550B7475C975277B56"
      unitRef="usd">148949942</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e929-wk-Fact-C365E334FA5EAA105CCE7A9E0AAE0710"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e949-wk-Fact-0C8A835731D29287F1BD7A9E0AB25B4B"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5956226e969-wk-Fact-641DB5FDA78FA49422077A9E0AB3DE13"
      unitRef="usd">4262800</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5956226e988-wk-Fact-F7B4649CA688F7383CFE7A9E0A9909D9"
      unitRef="usd">4262800</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5956226e1007-wk-Fact-90E04F8995A97FB571FB7A9E0AAD3760"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      id="d5956226e1027-wk-Fact-82F3F83DF517DB712DE47A9E0AB30416"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5956226e1047-wk-Fact-901D25371EC029C1E9C87A9E0AAEF552"
      unitRef="usd">3018360</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5956226e1066-wk-Fact-6C645D29B5F48E546F387A9E0AAE9651"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5956226e1085-wk-Fact-D3940C3ADAA46FCC9AD07A9E0AAD044B"
      unitRef="usd">3018360</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="0"
      id="d5956226e1105-wk-Fact-955801D7D99A6231F95D7A9E0AAE2AFB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1125-wk-Fact-4BBE3CA2A9EFFCFA4BC57A9E0AAE3C77"
      unitRef="usd">17327569</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1144-wk-Fact-F3D8DFBBAA43639195987A9E0AB344BF"
      unitRef="usd">17327569</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1163-wk-Fact-1B2EE00BF1D6CFB9F2F17A9E0AB36BE5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1183-wk-Fact-7B9CB54ED4FF1EC8D7547A9E0AAED4A8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1208-wk-Fact-481D1BF02C39C52309637A9E0AAE855E"
      unitRef="usd">173558671</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1227-wk-Fact-24C80DBD8C18A42FB0D07A9E0AAA157F"
      unitRef="usd">170540311</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1246-wk-Fact-131FA152537FEB7505C07A9E0AAE94D8"
      unitRef="usd">3018360</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1266-wk-Fact-A0DC5DB198FEBAFE232A7A9E0AB3EC25"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1368-wk-Fact-5CDB0560629BA3C54D3F7A9E0AB2D8D2"
      unitRef="usd">119796000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1387-wk-Fact-AA6E01C2DC24ABEC714C7A9E0AAEF63A"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1406-wk-Fact-6DCD31D302C45E96A6507A9E0AAA35DF"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2"
      decimals="0"
      id="d5956226e1421-wk-Fact-71A405789FCF965068E97A9E0A9F36A0"
      unitRef="usd">119796000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1447-wk-Fact-3AD23F9F61EEB1D72B9A7A9E0AAABD87"
      unitRef="usd">119796000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1466-wk-Fact-1E7D79DC31128DCAC9E87A9E0AAE441C"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1485-wk-Fact-465C6A3242B86560FBBB7A9E0AAEFB0E"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e1505-wk-Fact-D806E0592D2B4D817B1C7A9E0AAEAD87"
      unitRef="usd">119796000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="d5956226e1911-wk-Fact-11CC37B33DD383C690EB7A9E0AB7F3F5"
      unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="d5956226e1930-wk-Fact-E5547CBFD459FF219A717A9E0AB7452E"
      unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="d5956226e1949-wk-Fact-83AE90C8BEDCCA1181957A9E0AB7FBAE"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      id="d5956226e1969-wk-Fact-5CDCB2639382CD47C3A97A9E0AB752D1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e1984-wk-Fact-F95CD5A8AEF2FE7BB7D27A9E0AB79385"
      unitRef="usd">67338017</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e2003-wk-Fact-5998FE16CECEE2E51A357A9E0AB7B03B"
      unitRef="usd">67338017</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e2022-wk-Fact-5D72A74E2E1EA98A41D47A9E0AB77876"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember"
      decimals="0"
      id="d5956226e2042-wk-Fact-D855A798D8BEAA4ED5F67A9E0ABD96A5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2062-wk-Fact-0942D10774DC0C35039A7A9E0AB72BE0"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2081-wk-Fact-582A189EEEE8CC7800E27A9E0AB76EC3"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2100-wk-Fact-1EC49968D09D18CFC1847A9E0AC0A31A"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2120-wk-Fact-3D9E9D3DA5D33963515C7A9E0AB7350B"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2145-wk-Fact-95B90F95DB02E3D747307A9E0ABF04BD"
      unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2164-wk-Fact-06B1DAF18DB8CB75D47C7A9E0ABD272A"
      unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2183-wk-Fact-1A1C67BA21A86433D7A07A9E0AC02818"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2203-wk-Fact-28250B9D20DDAE72F42B7A9E0AB7CC12"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2305-wk-Fact-17E85C625225E9A2561A7A9E0AB7CF51"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2324-wk-Fact-598D13EC030744A662C47A9E0AB76B81"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2343-wk-Fact-6CBCCAFB9AB876BB1CDC7A9E0ABD873E"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2363-wk-Fact-B5BB6D20CC0278AEDEE37A9E0ABF1EE9"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2383-wk-Fact-C8E46BA198917C0122197A9E0AC03044"
      unitRef="usd">8819023</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2402-wk-Fact-1126117CE61C585A135F7A9E0AC0C2D7"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2421-wk-Fact-0BBDBE6ECB096C669AF07A9E0AB7547D"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="d5956226e2441-wk-Fact-F41FD2250A81AA6D0A1C7A9E0AC01619"
      unitRef="usd">8819023</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="INF"
      id="d5956226e2466-wk-Fact-4FED942634A32EE4D86A7A9E0A6DABA9"
      unitRef="shares">1644155</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5956226e2470-wk-Fact-65CFFBBA0A658E4BCE197A9E0A6E99A4"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-5"
      id="d5956226e2535-wk-Fact-11D03DB8B15CD8A098677A9E0A6EFF80"
      unitRef="usd">7100000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-F7F6BB0AE3474CCEB7617A9E0AE60529-0-wk-Fact-E062F940EE18DE36529E7A9E0A6DFB6B">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company's derivative liability for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,819,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;110,976,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;119,796,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q4"
      decimals="0"
      id="d5956226e2582-wk-Fact-07FB481B70CB58C9427D7A9E0AB3C0BF"
      unitRef="usd">8819023000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d5956226e2597-wk-Fact-79997E2A31AB6E949FBB7A9E0AB389C6"
      unitRef="usd">-110976977000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2020Q2"
      decimals="0"
      id="d5956226e2622-wk-Fact-CE49F2424707F988BAD97A9E0AB39090"
      unitRef="usd">119796000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-77DD2C35116ADC30AF8E7A9E0AE647BB-0-wk-Fact-1A1302981E562C03AF197A9E0AC895AC">Goodwill and Intangible Assets&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Yrs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Indefinite lived:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Definite lived:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,323,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,262,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,323,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,248,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Bioject(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,322,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,777,778&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,175,556&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,924,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,050,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,468,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;581,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,050,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,356,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;693,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,473,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,053,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,420,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,473,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,779,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,693,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,987,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,053,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,933,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,987,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,779,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,207,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$400,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Aggregate amortization expense on intangible assets for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$137,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$274,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Aggregate amortization expense on intangible assets for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$267,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$533,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Estimated aggregate amortization expense is $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;274,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the remainder of fiscal year &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$520,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;493,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;276,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;253,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/span&gt; and subsequent years combined.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-DFCF0223239393D32F297A9E0AE6A50E-0-wk-Fact-6E9B98B86E8C324A073A7A9E0AC8121A">&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Yrs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Indefinite lived:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,513,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Definite lived:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Licenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,323,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,262,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,323,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,248,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Bioject(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,322,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,777,778&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,100,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2,175,556&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,924,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,050,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,468,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;581,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,050,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,356,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;693,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,473,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,053,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,420,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,473,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,779,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,693,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,987,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,053,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,933,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,987,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,779,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,207,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$400,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e964-wk-Fact-6FCA4FAEAAEF7A0F679A7A9E0AD16368"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1003-wk-Fact-4C743719408FD2CB5FDF7A9E0A77B25E"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1022-wk-Fact-E85299F3B15040B3EACB7A9E0AC8CF32"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1061-wk-Fact-45EAD88160297DD80C547A9E0AC8ABE1"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      id="d5957868e1209-wk-Fact-74DC273150855FA4FE217A9E0AC8D637">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="d5957868e1219-wk-Fact-A7C5476E8FE72899FC847A9E0AD2176F"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="d5957868e1238-wk-Fact-1EBB2D4E1536F7554B3F7A9E0AC8EF7E"
      unitRef="usd">1262478</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="d5957868e1259-wk-Fact-BE3322F8A0DC94B5B0767A9E0AC812EA"
      unitRef="usd">61283</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="d5957868e1278-wk-Fact-DC102C30330EA3EAEE4C7A9E0AC8CA19"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="d5957868e1297-wk-Fact-8A3CDE53D9C12F80FC0D7A9E0AC804B3"
      unitRef="usd">1248104</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="d5957868e1318-wk-Fact-33D9C7FF37EF102801157A9E0AC8C573"
      unitRef="usd">75657</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      id="d5957868e1338-wk-Fact-E66FA02379F8C1BE4DD37A9E0AC86B37">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1348-wk-Fact-C7B68773A0F9F9058A4A7A9E0AC8F9B0"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1367-wk-Fact-7A12C676EE0CF77E4C9E7A9E0AC7948C"
      unitRef="usd">2322222</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1388-wk-Fact-CA8B13A8C6FF7D9193C47A9E0AD35A9E"
      unitRef="usd">2777778</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1407-wk-Fact-B68E5FC2D663407841DD7A9E0AC8F7FF"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1426-wk-Fact-17D9E91BBB63095EB5F87A9E0AC81AB9"
      unitRef="usd">2175556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1447-wk-Fact-A472282AAC02DB80FBD37A9E0AD33F06"
      unitRef="usd">2924444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      id="d5957868e1467-wk-Fact-C1C0BCC66325B8AEF88D7A9E0AC8D585">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="d5957868e1477-wk-Fact-6F62184BFB207B4801FA7A9E0AC896EE"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="d5957868e1496-wk-Fact-5FB1BE66AA96D98047017A9E0AC8C8C4"
      unitRef="usd">3468750</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="d5957868e1517-wk-Fact-A20170F7BC3CA9428FAE7A9E0AD04688"
      unitRef="usd">581250</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="d5957868e1536-wk-Fact-F820370AA155801F44AA7A9E0AC8ECAA"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="d5957868e1555-wk-Fact-3C612EE5EA8C287383747A9E0AD32656"
      unitRef="usd">3356250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      id="d5957868e1576-wk-Fact-912BB2971A5EFBD951727A9E0AC8F3FA"
      unitRef="usd">693750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_WeightedAverageMember"
      id="d5957868e1596-wk-Fact-799E27F019D51E3A49C77A9E0AC81415">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1606-wk-Fact-D0235F73CB75C5490E4A7A9E0AC8241B"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1625-wk-Fact-ADFC3CD13F212B7737F87A9E0AC85F6A"
      unitRef="usd">7053450</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1646-wk-Fact-6DA1C84F27F8329B754C7A9E0AD1DC9E"
      unitRef="usd">3420311</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1665-wk-Fact-590963AC9CC2758C484D7A9E0AC8F71A"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1684-wk-Fact-CB01B0E36DFBAA84A8AB7A9E0AC82DCC"
      unitRef="usd">6779910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1705-wk-Fact-48EADEBAEBBAC695A8627A9E0AD03665"
      unitRef="usd">3693851</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1740-wk-Fact-6CA3319B32DE5B2976497A9E0AC84F1F"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1759-wk-Fact-ADFC3CD13F212B7737F87A9E0AC85F6A"
      unitRef="usd">7053450</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="FI2020Q2"
      decimals="0"
      id="d5957868e1780-wk-Fact-43F07945AB4E755C5AD37A9E0AC8D14B"
      unitRef="usd">13933682</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1799-wk-Fact-7195F991D22858B1F7D37A9E0AC8D37A"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1818-wk-Fact-CB01B0E36DFBAA84A8AB7A9E0AC82DCC"
      unitRef="usd">6779910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="0"
      id="d5957868e1839-wk-Fact-1B43DBC3A85BD5BF327E7A9E0AC84562"
      unitRef="usd">14207222</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="I2005Q1Jan31_us-gaap_BusinessAcquisitionAxis_ino_InovioAsMember"
      decimals="-5"
      id="d5957868e1856-wk-Fact-3152C31AB36F1459A8F07A9E0AD6D581"
      unitRef="usd">3900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="I2009Q2_us-gaap_BusinessAcquisitionAxis_ino_VgxPharmaceuticalsMember"
      decimals="-5"
      id="d5957868e1860-wk-Fact-179BEE3F36AC230DCAF07A9E0AC88D41"
      unitRef="usd">6200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="I2016Q2Apr_us-gaap_BusinessAcquisitionAxis_ino_BiojectMember"
      decimals="0"
      id="d5957868e1864-wk-Fact-5F9FF89932371013BC057A9E0AD4052E"
      unitRef="usd">400000</us-gaap:Goodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d5957868e1909-wk-Fact-401E1D417AA9AA64FF6C7A9E0AD1F02A"
      unitRef="usd">137000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d5957868e1913-wk-Fact-3680A69259BB21A8D043CC23193C3898"
      unitRef="usd">274000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d5957868e1921-wk-Fact-53690A0BFFFB312DC1A57A9E0AD0FF99"
      unitRef="usd">267000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d5957868e1926-wk-Fact-2102BA72EDCEF274785CCC276839A0E2"
      unitRef="usd">533000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5957868e1930-wk-Fact-08524591938D0E98918F7A9E0AC8CA8A"
      unitRef="usd">274000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5957868e1938-wk-Fact-0DDB6AD792D7C03541177A9E0AD4B866"
      unitRef="usd">520000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5957868e1946-wk-Fact-D533F1316E8523C6CF577A9E0AD5BA11"
      unitRef="usd">493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5957868e1955-wk-Fact-3DC86B5B41A7D6F1E31D7A9E0AC855DB"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5957868e1963-wk-Fact-E54E905758CC11E89EEE7A9E0AD26101"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="FI2020Q2"
      decimals="-5"
      id="d5957868e1972-wk-Fact-E873293D92DBA2EB0DA97A9E0AD0F917"
      unitRef="usd">1600000</ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D31D03989F47F5E906B07A9E0AE62965-0-wk-Fact-643C19BBA5936129F5B37A9E0A958602">Convertible Debt&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$78.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of the Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.38&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share), subject to adjustment upon the occurrence of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the conversion price on (i) each of at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; trading days (whether or not consecutive) during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its condensed consolidated balance sheet, and that the cash conversion guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;applies. Therefore, the Notes issuance proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$78.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$62.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The balance of the Notes at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78,500,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12,619,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,736,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,700,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,844,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of interest expense related to the Notes, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the contractual interest coupon. For the three and six months ended June 30, 2019,&#160;the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of interest expense related to the Notes, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the contractual interest coupon. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there had not been any conversions or redemptions of the Notes. As described in Note 18 below, subsequent to June 30, 2020, certain holders converted a portion of the Notes into shares of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;August 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Korean Won (KRW) (approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ Market of the Korea Exchange (KOSDAQ) in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. As described in Note 18 below, on August 1, 2020 the August 2019 Bonds were converted in full. The initial conversion rate was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;211.0595&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in principal amount (equivalent to an initial conversion price of approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset on each three month anniversary thereafter to the then current market price if the current market price was lower than the conversion price then in effect; subject to a maximum conversion rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;351.7658&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (equivalent to a conversion price of approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rates as of July 30, 2019). The conversion rate as of the date of conversion on August 1, 2020 was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;275.6873&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per KRW &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in principal amount (equivalent to a conversion price of approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of January 2, 2020).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The balance of the August 2019 Bonds at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,993,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,600,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the August 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;519,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,738,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$672,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively, of interest expense related to the August 2019 Bonds, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$37,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the contractual interest coupon. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there had not been any conversions or redemptions of the August 2019 Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The derivative liability was valued at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$119.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The change in fair value of the derivative liability was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$97.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$111.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.  As a result of the conversion in full of the August 2019 Bonds in August 2020, the derivative liability will be eliminated during the quarter ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; KRW (approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;214.7766&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; principal amount of Bonds (equivalent to an initial conversion price of approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;357.9611&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (equivalent to a conversion price of approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of December&#160;19, 2019).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#x2019;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#x2019;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The balance of the December 2019 Bonds at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,915,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,979,780&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$122,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of interest expense related to the December 2019 Bonds, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the contractual interest coupon. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there had not been any conversions or redemptions of the December 2019 Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future minimum payments due under the Company's convertible debt instruments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Convertible Notes (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;August 2019 Bonds (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 2019 Bonds (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Remainder of 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,551,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,646,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,103,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,103,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,103,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,051,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,270,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,040,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,361,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98,911,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,795,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,177,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,883,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per year. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6%&lt;/span&gt;&lt;/span&gt; at maturity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e481-wk-Fact-6DE987EB25033AE986B27A9E0AB3ECDB"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e485-wk-Fact-893FC2AC66BAF2C13D457A9E0A6EF966"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e492-wk-Fact-92EFB16E3F11575832F77A9E0A6E89C8"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5959237e496-wk-Fact-33DDD402148868EEF1837A9E0A9F9EDB"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d5959237e503-wk-Fact-64DC5335DAB3D2420A8E7A9E0AA07DC8"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e507-wk-Fact-9D16EA84804FA19252947A9E0A6E9E6B"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e511-wk-Fact-EF555D9213E020E22F697A9E0A9E8210"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e515-wk-Fact-C52B0B63E6B98CF1FD6F7A9E0A995AD1"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e525-wk-Fact-69667C0046E0B7BC6EC07A9E0A9FB9D1"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e529-wk-Fact-C873BB42C29EEB6B2BDB7A9E0AA0327D"
      unitRef="usd">62200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e533-wk-Fact-DFB6C8B3C30953EF87B77A9E0AA0E4B8"
      unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="INF"
      id="d5959237e574-wk-Fact-41ECC1E92A72F3CF0A087A9E0A8C9222"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5959237e589-wk-Fact-E5308E5F3450417FFAF27A9E0A8C7339"
      unitRef="usd">12619675</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5959237e610-wk-Fact-94259F879A9C70B201847A9E0A8CBA08"
      unitRef="usd">1736898</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtinstrumentAccruedInterest
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5959237e631-wk-Fact-BC1EA8D6F080C71CE52B7A9E0A8C3FE8"
      unitRef="usd">1700833</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5959237e656-wk-Fact-CDD93674B1142736C1DA7A9E0A8CD017"
      unitRef="usd">65844260</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e671-wk-Fact-38F2B6C6F69C47155DCA7A9E0A95348D"
      unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="3"
      id="d5959237e675-wk-Fact-E1BDC8C53C4E05E5FDE27A9E0A9573DA"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e683-wk-Fact-307CAD249B5BB11C178A7A9E0AA0ACCD"
      unitRef="usd">2100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e687-wk-Fact-2BDD0ED8E796ECF26D21DA5D004CB4A0"
      unitRef="usd">4200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e692-wk-Fact-B547A363BD41659CE95E7A9E0A6E0266"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e696-wk-Fact-8BB635B0816635B8D925DA5ED389F201"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e700-wk-Fact-8CB9ADF44851BF79BB329AA7603E89EE"
      unitRef="usd">2000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e704-wk-Fact-31BC1E76E0FFF992EFF69AA78DD7C8F3"
      unitRef="usd">2900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e708-wk-Fact-A036C9CFE438B77502259AA7E68AF271"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e712-wk-Fact-77BAE9287B01E87DE1349AA8110389C5"
      unitRef="usd">1800000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e729-wk-Fact-414254C0E53F377081DB7A9E0AAEE863"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e733-wk-Fact-5794EC9E132BEDA59D997A9E0A6EEC42"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e737-wk-Fact-0AB7B8A67585E8A019F37A9E0A9997F5"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e744-wk-Fact-1EB9C9C52160CEC7F5B07A9E0AAEE91B"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5959237e756-wk-Fact-0B2135EE08B6C013B0557A9E0A9F99D1"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2019Q3Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5959237e769-wk-Fact-F8FBBB4499A93C61287A7A9E0A6E9793"
      unitRef="usdPerShare">2.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2020Q1Jan02_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5959237e781-wk-Fact-C5F442922F55B8A355067A9E0AAE4D35"
      unitRef="usdPerShare">3.14</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e788-wk-Fact-5D0F8A6DB0957F35D5817A9E0A6E75B3"
      unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="INF"
      id="d5959237e830-wk-Fact-9214840F0C97EE3BD2A07A9E0AC6BC88"
      unitRef="usd">14993753</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e845-wk-Fact-2F60E8CF7EFD219AF6FA7A9E0AC83DD2"
      unitRef="usd">5600302</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e866-wk-Fact-55754A9712D1E400C0ED7A9E0AC7B913"
      unitRef="usd">211272</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccretionOfPremium
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e887-wk-Fact-C99AE589B27F26680D277A9E0AC75190"
      unitRef="usd">519085</ino:DebtInstrumentAccretionOfPremium>
    <ino:DebtinstrumentAccruedInterest
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e907-wk-Fact-C6F18092E13039B3DA087A9E0AC82083"
      unitRef="usd">37484</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e932-wk-Fact-B61069E80DFEDF28693E7A9E0AC0DA59"
      unitRef="usd">9738748</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e948-wk-Fact-2C8D75E8B1EA54F8C6077A9E0AA0BA54"
      unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="3"
      id="d5959237e952-wk-Fact-2FD50B134AD6ACCF14887A9E0A6E9F93"
      unitRef="number">0.294</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e960-wk-Fact-B8FDD2285700213E72327A9E0A9547EC"
      unitRef="usd">672000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e964-wk-Fact-E51722B461BD88E876A9DA69DAD8C75E"
      unitRef="usd">1300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e969-wk-Fact-7123DDD00732AB4723187A9E0A99E1FE"
      unitRef="usd">37000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e973-wk-Fact-3F65131A6AF011185206DA6A18A4038B"
      unitRef="usd">75000</us-gaap:InterestExpenseDebt>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e984-wk-Fact-F215CD6C6EA9F961CDF77A9E0A6E63C7"
      unitRef="usd">119800000</us-gaap:DerivativeLiabilities>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e992-wk-Fact-E7DC4040BBA5E0C6FF637A9E0A6EDDDF"
      unitRef="usd">97800000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e996-wk-Fact-82F6EF0E007BF2CEFF8A47F5803F4EF7"
      unitRef="usd">111000000.0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1016-wk-Fact-B592CF0463652986ECCE7A9E0A998C21"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1020-wk-Fact-AB95D0CF9482A80B3E407A9E0A6E2CFA"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d5959237e1024-wk-Fact-45DCACA0DC38E8367EEC7A9E0AAAE146"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1031-wk-Fact-E5024AF1946963B8F2A37A9E0A99084A"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1035-wk-Fact-BF037FF87BBE8489B0367A9E0A6E429F"
      unitRef="number">0.0600</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5959237e1047-wk-Fact-7EC2820419B0D2DCA7D77A9E0A6EA19A"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5959237e1060-wk-Fact-4001488C138B4E497C647A9E0AA07DC1"
      unitRef="usdPerShare">2.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1067-wk-Fact-BF037FF87BBE8489B0367A9E0A6E429F"
      unitRef="number">0.0600</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage
      contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1071-wk-Fact-21FB564FA514FF63A4677A9E0A995C72"
      unitRef="number">0.25</ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-65FFFD9604645778B8557A9E0AE7ABDB-0-wk-Fact-4459FFEA662B608ACFAE7A9E0A95877D">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The balance of the December 2019 Bonds at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,915,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(40,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,979,780&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The balance of the Notes at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78,500,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(12,619,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,736,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,700,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,844,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The balance of the August 2019 Bonds at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,993,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5,600,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the August 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;519,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,738,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="INF"
      id="d5959237e1115-wk-Fact-8EF1D7BEEEE6C05F7BD57A9E0A826368"
      unitRef="usd">3915035</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e1130-wk-Fact-7BD56DFE31F8EF5E8C3A7A9E0A8C84CE"
      unitRef="usd">40681</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccretionOfPremium
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e1151-wk-Fact-1CC865EA57C3E24D17627A9E0A7C34EB"
      unitRef="usd">95638</ino:DebtInstrumentAccretionOfPremium>
    <ino:DebtinstrumentAccruedInterest
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e1171-wk-Fact-7056B40410C5E8F00B707A9E0A7CFDF2"
      unitRef="usd">9788</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="d5959237e1196-wk-Fact-6F1D9D694B0AF5F530667A9E0A8C66F3"
      unitRef="usd">3979780</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="3"
      id="d5959237e1211-wk-Fact-25153DF71950DDA73C1C7A9E0AA006AE"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e1219-wk-Fact-7C2C630487F77CDF3D3B7A9E0AA9148C"
      unitRef="usd">60000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e1223-wk-Fact-961D587C06F041DFDC6ADA6F475E0877"
      unitRef="usd">122000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2020Q2QTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e1227-wk-Fact-D33EB49A759CE8F102FF7A9E0AA914E5"
      unitRef="usd">10000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d5959237e1232-wk-Fact-E59859001DEEED711A19DA6F814655F8"
      unitRef="usd">20000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B767703AE7EEB4731F717A9E0AE6436F-0-wk-Fact-0FE092F311C4D9FCEB997A9E0AA09DAA">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future minimum payments due under the Company's convertible debt instruments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Convertible Notes (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;August 2019 Bonds (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 2019 Bonds (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Remainder of 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,551,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,646,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,103,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,103,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,103,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,292,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,051,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,270,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,040,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,361,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98,911,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,795,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,177,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,883,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per year. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at maturity. &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1380-wk-Fact-C16F2EC116BB73D4DC5A7A9E0A60537E"
      unitRef="usd">2551000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1399-wk-Fact-9842DB26FD0B2929D7BA7A9E0A61B9C4"
      unitRef="usd">75000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1419-wk-Fact-88C50DC057644C2388F37A9E0A5CEF7D"
      unitRef="usd">20000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1438-wk-Fact-BABF1AB021D7195055AA7A9E0A5EE49A"
      unitRef="usd">2646000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1458-wk-Fact-03BED33154CEFEFE80217A9E0A5CDFCE"
      unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1477-wk-Fact-4B4A17D0A733063E7E447A9E0A622DB9"
      unitRef="usd">150000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1496-wk-Fact-CFB14B87FC84702D37F17A9E0A5E2753"
      unitRef="usd">39000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1516-wk-Fact-6D0C6AA7214645C4B6E17A9E0A605AE6"
      unitRef="usd">5292000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1541-wk-Fact-23F6033F861EB24F4BD57A9E0A5D6C25"
      unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1560-wk-Fact-078B0159A76389D2C9C87A9E0A60A9DA"
      unitRef="usd">150000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1579-wk-Fact-3142D7B3E0D3DE8750C57A9E0A5A7D9D"
      unitRef="usd">39000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1599-wk-Fact-D83B46DEA9CEDE90BEBF7A9E0A622EDC"
      unitRef="usd">5292000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1624-wk-Fact-7B5C399671FEEE7ED0877A9E0A5FB663"
      unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1643-wk-Fact-39144F9BDF91A45EC49E7A9E0A5E675A"
      unitRef="usd">150000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1662-wk-Fact-EA21551B274AEB2BC7E67A9E0A60C9E5"
      unitRef="usd">39000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1682-wk-Fact-AAD679230AEBFC6E161B7A9E0A5B1548"
      unitRef="usd">5292000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1707-wk-Fact-E53B4FAA5024236B08247A9E0A5FC98A"
      unitRef="usd">81051000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1726-wk-Fact-499A03C6656ED1A74DF67A9E0A62ACFE"
      unitRef="usd">19270000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1745-wk-Fact-9A357E0C8183DD4B0F6C7A9E0A5CAD6B"
      unitRef="usd">5040000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1765-wk-Fact-F0A3B10215B450756A477A9E0A5F7127"
      unitRef="usd">105361000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1795-wk-Fact-FE7E21EB133A755394EA7A9E0A604063"
      unitRef="usd">98911000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1814-wk-Fact-696646C3A3FED59F83FF7A9E0A5F5076"
      unitRef="usd">19795000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1834-wk-Fact-92F259E397717E48239B7A9E0A5B34EA"
      unitRef="usd">5177000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d5959237e1853-wk-Fact-712148F3B898E0BFBB9F7A9E0A5EB0CD"
      unitRef="usd">123883000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1862-wk-Fact-630DA27F33B822D3967B7A9E0A990152"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1869-wk-Fact-D38AB644048FDF107F247A9E0A6EBF37"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d5959237e1873-wk-Fact-6BB04B5B776840209D237A9E0A6E39F5"
      unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-AA568D13BAAEE1D06BBA7A9E0AE7D73C-0-wk-Fact-85049DDA3760433CCF437A9E0A5AB6B4">Stockholders&#x2019; Equity&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding as of&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;600,000,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158,756,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158,756,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,361,034&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the three months ended June 30, 2020, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s Series&#160;C preferred stock were converted into an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,147&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#x201c;Placement Agent&#x201d;) to sell shares of its common stock with aggregate gross proceeds of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which the Placement Agent would act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As of March 31, 2020, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;.  &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Under the New Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent is entitled to compensation for its services in an amount equal to up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the three months ended March 31, 2020, the Company sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,148,952&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.92&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, resulting in aggregate net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$208.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  As of March 31, 2020, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; remaining capacity under the Prior Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the three months ended June 30, 2020, the Company sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,041,178&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.26&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, resulting in aggregate net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$121.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As of June 30, 2020, the Company may sell up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$126.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in gross proceeds of shares of Common Stock under the New Sales Agreement before it would be required to file a new prospectus supplement with the SEC to sell additional shares pursuant to the New Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock unless the Company's Board of Directors determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued increased by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,953,960&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock available for future grant under the 2016 Incentive Plan, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,868,665&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares underlying outstanding but unvested restricted stock units and options outstanding to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,733,501&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and have a maximum contractual term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had options outstanding to purchase &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,459,595&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and have a maximum contractual term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-179744D9ACF492497AEE7A9E0AE77C9D-0-wk-Fact-A0B498A56C4CA21BF0557A9E0A6E54EA">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding as of&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;600,000,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158,756,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158,756,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,361,034&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q2"
      decimals="INF"
      id="d5959682e647-wk-Fact-8102D8ACF421541B83527A9E0AB3A666"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q2"
      decimals="INF"
      id="d5959682e661-wk-Fact-E5E585E140C889F8D4737A9E0AAE4D72"
      unitRef="shares">158756411</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2"
      decimals="INF"
      id="d5959682e675-wk-Fact-0BB8FF2CC65EBA33F1B07A9E0AA9190F"
      unitRef="shares">158756411</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="d5959682e689-wk-Fact-F1C5069E1DA4D22D58157A9E0AB3E2E5"
      unitRef="shares">101361034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="d5959682e705-wk-Fact-1A7B8E12EB3751E49D317A9E0AB21B16"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="d5959682e719-wk-Fact-0774657E97380A0FCA317A9E0AAEF0E4"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="d5959682e733-wk-Fact-EF0E2EA9D90E578AE0877A9E0AB79949"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="d5959682e747-wk-Fact-A0C3EF77CB746A9B50347A9E0AB33FB9"
      unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="d5959682e769-wk-Fact-89B99B229A575FCD76CC32D615186B6F"
      unitRef="shares">14</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5959682e773-wk-Fact-4DE922F4A38634B2DCEF32D765FCC7AC"
      unitRef="shares">5147</us-gaap:ConversionOfStockSharesIssued1>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="INF"
      id="d5959682e783-wk-Fact-3F8B0B09F5A21458F6167A9E0A6EAE91"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="INF"
      id="d5959682e787-wk-Fact-3F8B0B09F5A21458F6167A9E0A6EAE91"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="INF"
      id="d5959682e791-wk-Fact-CD2A17E699909BB30F517A9E0A5ADE61"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="FI2020Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="INF"
      id="d5959682e795-wk-Fact-DA67B4009DA981CC98A4734DD6C60FDE"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="D2020Q2Apr_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember"
      decimals="INF"
      id="d5959682e804-wk-Fact-D1717B9AF451F8B34905955F9ADF1212"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementAgentFee
      contextRef="D2020Q2Apr_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember"
      decimals="INF"
      id="d5959682e808-wk-Fact-8BBD58145CDC20A99D4B7A9E0A6EE571"
      unitRef="number">0.030</ino:StockSalesAgreementAgentFee>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="INF"
      id="d5959682e815-wk-Fact-57DDFD426DBE114886297A9E0A6E9E04"
      unitRef="shares">43148952</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="2"
      id="d5959682e819-wk-Fact-4CA8AA30E928DDEA2DE87A9E0A5BE2F2"
      unitRef="usdPerShare">4.92</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="FD2020Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="-5"
      id="d5959682e823-wk-Fact-2ED49395FBEF378E3C4C7A9E0A667C16"
      unitRef="usd">208200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="FI2020Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorSalesAgreementMember"
      decimals="INF"
      id="d5959682e827-wk-Fact-DA67B4009DA981CC98A4734DD6C60FDE"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember"
      decimals="INF"
      id="d5959682e834-wk-Fact-26D1D2E250985A76A02923B7AD4257AA"
      unitRef="shares">12041178</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember"
      decimals="2"
      id="d5959682e838-wk-Fact-E59562E026C4FF00CF5223B8B7C4EC52"
      unitRef="usdPerShare">10.26</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember"
      decimals="-5"
      id="d5959682e842-wk-Fact-DB2FA92EA3C9C83325B423B8E8B84EBB"
      unitRef="usd">121700000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_NewSalesAgreementMember"
      decimals="INF"
      id="d5959682e846-wk-Fact-338B8FEB7D829A8C2AC395C4DCF9DC9F"
      unitRef="usd">126400000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e872-wk-Fact-2F3A82B0D9827B0D71AB7A9E0A608C79"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e876-wk-Fact-59339BF02B2E57A984367A9E0A5C3978"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e880-wk-Fact-A1EACF7CB9C03DC04AE67A9E0A5F8848"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e888-wk-Fact-BDE9B4803CDF5A65E79E7A9E0A5DC1DF"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e897-wk-Fact-403EAF7FE11C359155EC7A9E0A5F2220"
      unitRef="shares">6953960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e901-wk-Fact-59B289083AB5F40DB29D7A9E0A5AEE99"
      unitRef="shares">2868665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      decimals="INF"
      id="d5959682e905-wk-Fact-7CCD42BF894C4A75AC1D7A9E0A5FA468"
      unitRef="shares">5733501</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      id="d5959682e909-wk-Fact-5E3AFEBB625C170BF1D57A9E0A5D8128">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember"
      id="d5959682e913-wk-Fact-B0A24935DE26B38BC5087A9E0A5B269D">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="FI2020Q2_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember"
      decimals="INF"
      id="d5959682e925-wk-Fact-EFE60B992CCCAC7AD87D7A9E0A6EA45A"
      unitRef="shares">3459595</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember"
      id="d5959682e929-wk-Fact-407946925ED904AAD4C67A9E0A6E18B1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="FD2020Q2YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember"
      id="d5959682e933-wk-Fact-8A5C6429C06A8FF539E67A9E0A6EB1AF">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4064C9A59F0E0DB9C1857A9E0AE7F1A2-0-wk-Fact-44DF6E4A93B48F212D307A9E0A99235B">Net Loss Per Share &lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,193,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,770,319&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,868,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,580,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,585,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,585,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,962,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,009,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,622,537&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,944,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BEE5F8513FADFD15BB437A9E0AE797AF-0-wk-Fact-8C732ED8D5C8FED41BEF7A9E0A99C697">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,193,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,770,319&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,868,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,580,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,585,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,585,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,962,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 2019 Bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,009,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32,622,537&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,944,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="d5960166e623-wk-Fact-9F522DDE7E0B3BE55A007A9E0AD7F9D5"
      unitRef="shares">9193096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="d5960166e637-wk-Fact-0D5B6FAA93EB9AC1CC917A9E0AD772F4"
      unitRef="shares">10770319</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d5960166e652-wk-Fact-92E7E7488B7028453C0E7A9E0AD3DEC5"
      unitRef="shares">2868665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="d5960166e666-wk-Fact-882AE9FAD820A26CFCC57A9E0AD8C027"
      unitRef="shares">1580192</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="d5960166e681-wk-Fact-498DA62242368778D6687A9E0AD57379"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="d5960166e695-wk-Fact-E256C74995688356D7D07A9E0AD6DF87"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5960166e710-wk-Fact-6C0F9517A228FFBCC63E7A9E0AD58D82"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member"
      decimals="0"
      id="d5960166e724-wk-Fact-58939108404A5C3061877A9E0AD4631F"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5960166e739-wk-Fact-3A761A7AFD59A42648127A9E0AD64194"
      unitRef="shares">4962364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember"
      decimals="0"
      id="d5960166e753-wk-Fact-079E2EF4AD26C8A8DD307A9E0AD7AC3D"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="d5960166e768-wk-Fact-D3876F8E9C8599445D077A9E0AD859E1"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember"
      decimals="0"
      id="d5960166e782-wk-Fact-195A3D03F0D67A99A6E97A9E0AD6233F"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="d5960166e797-wk-Fact-F9BB15BC3EE3950D88A37A9E0AD758BF"
      unitRef="shares">32622537</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d5960166e811-wk-Fact-8713A922356136E3AEBF7A9E0AD46756"
      unitRef="shares">26944620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-9AA2225ED8B8D2887F697A9E0AE7F6D9-0-wk-Fact-02444F5B13C1F65F6BC07A9E0A9930FB">Stock-Based Compensation&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.40%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.31%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.67%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.43%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of which $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, was included in research and development expenses, and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, was included in research and development expenses, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$877,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.52&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.19&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for employee and director stock options granted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.44&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for employee and director stock options granted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant date fair value per share was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for restricted stock units granted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.42&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for restricted stock units granted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$224,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$607,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$207,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$480,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-32FDB9D88FC57C2EF16C7A9E0AE7CAE8-0-wk-Fact-FB6D824098106B11D28D7A9E0A8C114D">&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.40%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.31%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.67%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.43%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;80%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d5960575e598-wk-Fact-5E00FBD2821891CD8D627A9E0A6DC952"
      unitRef="number">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d5960575e608-wk-Fact-3F8C99E2C0222C49AF707A9E0A6B169F"
      unitRef="number">0.0231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d5960575e618-wk-Fact-F067B2A59BCBA11CA8F67A9E0A6EB4CC"
      unitRef="number">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d5960575e628-wk-Fact-24AF11E8D937D52B67147A9E0A67EAEB"
      unitRef="number">0.0243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d5960575e639-wk-Fact-59031EB4AAA5A1A84CF67A9E0A6E869A"
      unitRef="number">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d5960575e649-wk-Fact-83AEC0E66D5099A9908C7A9E0A6C3283"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d5960575e659-wk-Fact-0CCD13AADBC9796E7F087A9E0A687381"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d5960575e669-wk-Fact-F9015DBAE3FE3D85D3827A9E0A694BF5"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d5960575e680-wk-Fact-A8D48DFFA8FE3CC99AAA7A9E0A6E46D7">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d5960575e690-wk-Fact-0A0AC3462DA2C907874F7A9E0A6E7C1F">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d5960575e700-wk-Fact-C8426DBBD4F97FEEA3C07A9E0A65CC16">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d5960575e710-wk-Fact-AD2BFBBCE8FE5EB1FD427A9E0A6A5B82">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d5960575e721-wk-Fact-09092ACE90A9FCBEBD907A9E0A6B0D83"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d5960575e731-wk-Fact-F106C97C313C56E6628E7A9E0A778191"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d5960575e741-wk-Fact-4FC0DAB1449FFAC05C4C7A9E0A6AC653"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d5960575e751-wk-Fact-736F59F4015BD5C0A7AA7A9E0A63C5DD"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember"
      decimals="-5"
      id="d5960575e772-wk-Fact-94D796D1CFAA3EE2E93D7A9E0A99A2CA"
      unitRef="usd">3400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember"
      decimals="-5"
      id="d5960575e776-wk-Fact-5EDDB384CC2212D2CA5DCC9E06AF2269"
      unitRef="usd">7100000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d5960575e780-wk-Fact-ABBA22D150109F7F01CC7A9E0A9516DD"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d5960575e784-wk-Fact-53100C1A9589B3BA631ACC9E268E1BEB"
      unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d5960575e789-wk-Fact-587835243ACD5AB481977A9E0A9909F1"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d5960575e793-wk-Fact-B3A761D7121A700B4A76CC9E41F2377A"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember"
      decimals="-5"
      id="d5960575e804-wk-Fact-DE219A05CE30D92B6ED57A9E0A9977F1"
      unitRef="usd">3100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember"
      decimals="-5"
      id="d5960575e808-wk-Fact-C06FB2BDB5D8C82C2B32CC9E5ACDA947"
      unitRef="usd">6300000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d5960575e812-wk-Fact-07AE2B4BFE766B39A00A7A9E0A8C7C52"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d5960575e816-wk-Fact-D5BA67A694F6DBD1BEB4CC9E88EC41E0"
      unitRef="usd">4200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d5960575e821-wk-Fact-2733C2031938D543E5817A9E0A992670"
      unitRef="usd">877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d5960575e825-wk-Fact-C7F5C62355986591C4CCCC9EA1E590AB"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2020Q2"
      decimals="-5"
      id="d5960575e836-wk-Fact-FB35123AD8D17825E0437A9E0A8CC195"
      unitRef="usd">9400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2020Q2YTD"
      id="d5960575e840-wk-Fact-E6CC39F852B562A693FC7A9E0A8CFBB3">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d5960575e847-wk-Fact-177A65E57C78AF5961597A9E0A8CBD38"
      unitRef="usdPerShare">9.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d5960575e851-wk-Fact-84A13C630AAE3079C137CC9EC9CA7FB9"
      unitRef="usdPerShare">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d5960575e859-wk-Fact-AB996FDA6E36950811497A9E0AA08C1B"
      unitRef="usdPerShare">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d5960575e863-wk-Fact-AF9C7B3AA7BB98A04C71CC9EE52F7C8D"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d5960575e879-wk-Fact-98A30F3B6A947386A7317A9E0A9E05D5"
      unitRef="usd">15000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d5960575e883-wk-Fact-97B0CB2821FB8446D7D47A9E0A9F3285">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d5960575e890-wk-Fact-893DA43AE56D720A8FF47A9E0A95813E"
      unitRef="usdPerShare">14.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d5960575e894-wk-Fact-97B5D6660A4247304CF4CCA10C5C39FE"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d5960575e902-wk-Fact-85A47F6CBE094CC7FC687A9E0A999DC7"
      unitRef="usdPerShare">3.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d5960575e906-wk-Fact-E8CED0A1DA6AA8F03655CCA122D511BC"
      unitRef="usdPerShare">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember"
      decimals="-3"
      id="d5960575e922-wk-Fact-D36DAA79DF854F5628807A9E0AA079C4"
      unitRef="usd">224000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember"
      decimals="-3"
      id="d5960575e926-wk-Fact-3809629ECAE06E08023BCCA181C5986E"
      unitRef="usd">607000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2QTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember"
      decimals="-3"
      id="d5960575e934-wk-Fact-83792F58FCE80780001F7A9E0A955E9C"
      unitRef="usd">207000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember"
      decimals="-3"
      id="d5960575e939-wk-Fact-4ABF36CB146E13F48F76CCA19B8264F1"
      unitRef="usd">480000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-AFD77B342EDF79C915907A9E0AE7FDB2-0-wk-Fact-CEB7A002264221E0378F7A9E0AB76CF0">Related Party Transactions&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;GeneOne Life Sciences &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company owns &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,644,155&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in GeneOne as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to GeneOne. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2010, the Company entered into a collaboration and license agreement (the &#x201c;GeneOne Agreement&#x201d;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#x201c;Product&#x201d;). As consideration for the license granted to GeneOne, the Company received an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2011, the Company entered into a collaborative development and license agreement (the &#x201c;Hep Agreement&#x201d;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#x2019;s SynCon&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; therapeutic vaccines for hepatitis B and C infections (the &#x201c;Hep Products&#x201d;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years after the effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized from GeneOne consisted of patent and device maintenance fees. For both the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and 2019, the Company recognized revenue from GeneOne of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$31,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$63,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$727,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$128,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and an accounts payable and accrued liability balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$26,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$511,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to GeneOne and its subsidiaries. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$238,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$284,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of prepayments made to GeneOne were classified as long-term other assets on the Company's condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company owns &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;597,808&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202,050&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ownership interest in PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue from PLS of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$64,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$64,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$589,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term of the agreement.  The Company will have the exclusive right to in-license new intellectual property developed under the agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the Company received a&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$73,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$691,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$368,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$408,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$770,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Research and development expenses recorded from Wistar for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$170,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$458,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$370,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$616,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and an accounts payable and accrued liability balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$486,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$219,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to Wistar. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$780,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="INF"
      id="d5960755e482-wk-Fact-F8CFB47D0C020E88D5357A9E0AB33D52"
      unitRef="shares">1644155</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="D2010Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-5"
      id="d5960755e497-wk-Fact-7463A4FFA93E00731E1E7A9E0AC08669"
      unitRef="usd">3000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <ino:CollaborativeArrangementTerm
      contextRef="FD2013Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      id="d5960755e512-wk-Fact-E17A293539A0F2C5A12B7A9E0ABD7B1E">P20Y</ino:CollaborativeArrangementTerm>
    <ino:MilestoneBasedOwnershipTarget
      contextRef="D2015Q2May_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="INF"
      id="d5960755e519-wk-Fact-524E88B0EE3805AF93D07A9E0AB3143C"
      unitRef="number">0.35</ino:MilestoneBasedOwnershipTarget>
    <ino:MilestoneBasedOwnershipTarget
      contextRef="D2016Q1Jan_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="INF"
      id="d5960755e526-wk-Fact-FDC73C8D379BE0DADBFD7A9E0ABF12D8"
      unitRef="number">0.35</ino:MilestoneBasedOwnershipTarget>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e537-wk-Fact-2C053DC305747435DF527A9E0ABE7619"
      unitRef="usd">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e541-wk-Fact-3BEF76E2FD8573BD63E0DACA923B2F34"
      unitRef="usd">63000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-5"
      id="d5960755e548-wk-Fact-8D55D1925ABB6BA3A29D7A9E0A5CA7BE"
      unitRef="usd">2200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-5"
      id="d5960755e552-wk-Fact-DD1D63CC602F60A06C0EDACB237932D6"
      unitRef="usd">2800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e560-wk-Fact-4886DFE63788FBFC83097A9E0AAE72B6"
      unitRef="usd">727000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-5"
      id="d5960755e564-wk-Fact-483998F500B8DE03E681DACB674CCE1A"
      unitRef="usd">1800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e584-wk-Fact-713B9D003C310CC1B0F87A9E0A60B7CD"
      unitRef="usd">3000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e588-wk-Fact-E57D64A1ACFC715DA0937A9E0AB3748D"
      unitRef="usd">128000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e592-wk-Fact-021E85B01FC77E52362D7A9E0AC085EE"
      unitRef="usd">26000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e597-wk-Fact-7ED1C013C7FB4DE5A4517A9E0AB7CAE4"
      unitRef="usd">511000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e609-wk-Fact-5DC04AA97B98D9DC3F9C7A9E0AB739C1"
      unitRef="usd">238000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember"
      decimals="-3"
      id="d5960755e613-wk-Fact-B6206FE34F55AFE71CCF7A9E0AB3F419"
      unitRef="usd">284000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember"
      decimals="INF"
      id="d5960755e624-wk-Fact-2FC2C3439865109A7B5A7A9E0AB35275"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <ino:InvestmentOwnedAdditionalSharesAcquired
      contextRef="I2020Q1Feb20_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember_us-gaap_InformationByCategoryOfDebtSecurityAxis_us-gaap_AvailableforsaleSecuritiesMember"
      decimals="INF"
      id="d5960755e636-wk-Fact-B5E93B7D72FC5407655B7A9E0A5A6F35"
      unitRef="shares">202050</ino:InvestmentOwnedAdditionalSharesAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="3"
      id="d5960755e644-wk-Fact-C6F305AA3A508F2479377A9E0AB7E9C2"
      unitRef="number">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-3"
      id="d5960755e655-wk-Fact-78F52E742CDD803A87777A9E0A999925"
      unitRef="usd">64000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-5"
      id="d5960755e659-wk-Fact-FB7C85247D4C6CC28B54CB8ED5C77938"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-3"
      id="d5960755e663-wk-Fact-21B5A47B727A7B2FEFD47A9E0AB29E56"
      unitRef="usd">40000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-3"
      id="d5960755e667-wk-Fact-3A3FCEFB5F6C0A380E27DACFEA5CD424"
      unitRef="usd">64000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-3"
      id="d5960755e684-wk-Fact-2179A8D4C5FD227EB5D07A9E0AC088BE"
      unitRef="usd">13000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember"
      decimals="-3"
      id="d5960755e688-wk-Fact-BACEB4B139C893189AC67A9E0AB75CD9"
      unitRef="usd">589000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-5"
      id="d5960755e701-wk-Fact-A6CE516580DC46B8B1CB7A9E0AB7545F"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="D2016Q4Nov1Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-5"
      id="d5960755e712-wk-Fact-094E4F81A7E7355B95587A9E0AB7654C"
      unitRef="usd">6100000</ino:CollaborativeAgreementAwardedAmount>
    <ino:GrantProceedsReceived
      contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e726-wk-Fact-309EFA9A54C7289C4EF67A9E0A5ACF03"
      unitRef="usd">73000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e730-wk-Fact-697ABEB68958FAD76EB8DAD53183C671"
      unitRef="usd">691000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e738-wk-Fact-FB28F817AFBF654410B77A9E0AB3FE79"
      unitRef="usd">368000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-5"
      id="d5960755e743-wk-Fact-2427B9B814A4BD8A2420DAE099E73522"
      unitRef="usd">1200000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2020Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e754-wk-Fact-1D30B4BC11F3EDD226377A9E0AB332F7"
      unitRef="usd">408000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e758-wk-Fact-BBD1613425E147075025DAE1243BEC09"
      unitRef="usd">770000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2019Q2QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e766-wk-Fact-C5CBBBB5095C6C0D57527A9E0AB719D8"
      unitRef="usd">170000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="FD2019Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e771-wk-Fact-7D27A680B428F7F768D4DAE15971C5EB"
      unitRef="usd">458000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e783-wk-Fact-A1B0F201C5B50DFB98777A9E0ABF0E0D"
      unitRef="usd">370000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e787-wk-Fact-D46064FEA832B62566CA7A9E0AB7A3B4"
      unitRef="usd">616000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e791-wk-Fact-63DED656E2AE8830658B7A9E0AB3EBF0"
      unitRef="usd">486000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e796-wk-Fact-F06BB725760EA3DFF3927A9E0A5A80C4"
      unitRef="usd">219000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d5960755e804-wk-Fact-3FEC4E9BFA89F5D2323D7A9E0AB70872"
      unitRef="usd">780000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-90504A64C5ED0CF295FD7A9E0AE8B342-0-wk-Fact-E12EB0CDD60B325E827C7A9E0AC8F354">Leases                                                  &lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company leases approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of office, laboratory, and manufacturing space in San Diego, California and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57,360&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June 30, 2020 of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years, which represent the non-cancellable periods of the leases.  The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Remainder of 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,956,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,968,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,045,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,023,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,001,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,951,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,944,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,482,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,462,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(2,201,000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,261,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$814,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$835,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_SanDiegoOfficeMember"
      decimals="0"
      id="d5961176e480-wk-Fact-248A6D923A8BC7255A757A9E0AC87957"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="FD2020Q2YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_PlymouthMeetingPennsylvaniaMember"
      decimals="0"
      id="d5961176e484-wk-Fact-CBB199FD9AD9273653F07A9E0AC8999F"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="FI2020Q2_srt_RangeAxis_srt_MinimumMember"
      id="d5961176e488-wk-Fact-1839C25D9971683AE28C7A9E0AD8791C">P3Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="FI2020Q2_srt_RangeAxis_srt_MaximumMember"
      id="d5961176e492-wk-Fact-3900A44CBD413886EB1F7A9E0AC8D769">P9Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-F18FB0C7B857557126967A9E0AE7FF08-0-wk-Fact-8E8E0BA65B6945A59F9D7A9E0ADAB11D">&lt;div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Remainder of 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,956,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,968,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,045,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,023,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,001,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,951,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,944,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,482,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,462,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(2,201,000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,261,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e541-wk-Fact-C0D26FF0D6FDF32D8A727A9E0A7CBAF2"
      unitRef="usd">1956000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e556-wk-Fact-CEC704E86323980F3B7B7A9E0A82978F"
      unitRef="usd">3968000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e576-wk-Fact-5BEFC935AF5F95AF7BD87A9E0A9FD3D3"
      unitRef="usd">4045000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e596-wk-Fact-E37001C484122066E9357A9E0AAE5F47"
      unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e616-wk-Fact-61D8113C1F2BF1955E587A9E0AD9D328"
      unitRef="usd">3001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e636-wk-Fact-8C0AF24D23C992D977B57A9E0AAAF8D2"
      unitRef="usd">12951000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e656-wk-Fact-585B3C30C92C0BBD27F17A9E0AA030C6"
      unitRef="usd">29944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e676-wk-Fact-C79AF067F2EE8FC6A5637A9E0A6E5A9E"
      unitRef="usd">8482000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e697-wk-Fact-A8CD8C79B50B67606CEB7A9E0AA084B0"
      unitRef="usd">21462000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5961176e743-wk-Fact-E29516213BEEECD0CDF47A9E0A6E1A09"
      unitRef="usd">19261000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2020Q2"
      id="d5961176e780-wk-Fact-F77604C2037C6781A8B07A9E0A6E54DD">P7Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2020Q2"
      decimals="3"
      id="d5961176e800-wk-Fact-B52C41EA4005AF3F83B27A9E0AC0BCF6"
      unitRef="number">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d5961176e827-wk-Fact-9B363F29C1E2D974B6647A9E0AC8B4DF"
      unitRef="usd">814000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d5961176e831-wk-Fact-9A472DCEB420BCB94E7D7A9E0AD83CC9"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d5961176e839-wk-Fact-2D628770368B95A701CDCCABB9A0F2B3"
      unitRef="usd">835000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d5961176e844-wk-Fact-842C47D7486DF57C6AB4CCABC3992FD2"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D004398605F1673618287A9E0AE8579E-0-wk-Fact-15FD6452A45B2150BA517A9E0AC701B0">Collaborative Agreements&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; following the effective date of the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the ApolloBio Agreement, the Company received proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in March 2018 which comprised the upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; less &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in foreign income taxes and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$960,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the terms of the ApolloBio Agreement under Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; after the effective date for any reason upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under Topic 606, the entire transaction price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as revenue under collaborative research and development arrangements on the condensed consolidated statement of operations during the three months ended June 30, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;AstraZeneca &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$125 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and potential future commercial event-based payments totaling up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$115 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Within the broader collaboration, AstraZeneca had rights to co-develop up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2017, the Company had recognized all of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenues of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$74,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$146,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from AstraZeneca primarily for manufacturing services. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenues of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$62,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from AstraZeneca primarily from a milestone achieved in the first quarter of 2019 triggered by the initiation of a Phase 2 portion of an ongoing clinical trial in the third major indication, as well as for manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$56 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of costs over a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company received funding of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the CEPI Lassa fever and MERS grants and recorded such amounts as contra-research and development expense. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company received funding of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively, related to these grants and recorded such amounts as contra-research and development expense. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2020, CEPI awarded the Company a grant of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to support large-scale manufacturing of INO-4800. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company received funding of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$101,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; recorded deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Bill &amp;amp; Melinda Gates Foundation (&#x201c;Gates&#x201d;) awarded and funded the Company a grant of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to advance the development of DNA-encoded monoclonal antibody technology (&#x201c;dMAb&#x201d;) to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the project. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$36,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$170,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$698,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, as contra-research and development expense related to the Gates dMAb grant. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$858,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2020, Gates awarded and funded the Company a grant of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; 3PSP device for the intradermal delivery of INO-4800. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$850,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$913,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, as contra-research and development expense and had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; recorded as deferred grant funding on the condensed consolidated balance sheet related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the U.S. Department of Defense (the "DoD"), to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$54.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; contra-research and development expense &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;r deferred grant funding recorded related to these agreements with the DoD.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborationAgreementTerritoryExpansionOptionPeriod
      contextRef="D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      id="d5961322e485-wk-Fact-A355CF9AC4F67481E3C17A9E0A5A2825">P3Y</ino:CollaborationAgreementTerritoryExpansionOptionPeriod>
    <ino:ProceedsFromCollaborativeAgreement
      contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e492-wk-Fact-16694E0B7569FE7C1A3C7A9E0ADB3EDE"
      unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e496-wk-Fact-6A751668088BA90997197A9E0A5D3EFF"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementCorporateIncomeTax
      contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e500-wk-Fact-007F08F2B90B2285EC077A9E0AC8FB3D"
      unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
    <ino:CollaborativeAgreementForeignNonIncomeTaxes
      contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e504-wk-Fact-81503AEC5D2C70C9CB1E7A9E0AC8C45D"
      unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
    <ino:CollaborativeAgreementAdvisoryFees
      contextRef="FI2018Q1_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e508-wk-Fact-F1178953E420B4464B4B7A9E0A5DDF6D"
      unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e515-wk-Fact-9B4EAD573A049FD111037A9E0ADAB267"
      unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      id="d5961322e522-wk-Fact-2142D0C074492ABD56347A9E0AD9EE1F">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e529-wk-Fact-35FF7398C7C6DF3380E97A9E0AD93B07"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      id="d5961322e536-wk-Fact-9474CFBD6F948E28C8A37A9E0AD746CC">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      id="d5961322e540-wk-Fact-558D498719E12CD8DFCD7A9E0A5AC7B0">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e547-wk-Fact-7685B81EE0FA033175A77A9E0A582BF0"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e551-wk-Fact-7685B81EE0FA033175A77A9E0A582BF0"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="D2015Q3Sept1Sept30_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e561-wk-Fact-E755B02308B0B0A37ACF7A9E0AC79A62"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d5961322e565-wk-Fact-DE11E47CB97CCF6CCDD47A9E0ADB466B"
      unitRef="usd">125000000</ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones>
    <ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d5961322e569-wk-Fact-F3D8598BACD499C3B0687A9E0ADADBB7"
      unitRef="usd">115000000</ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones>
    <ino:NumberOfAdditionalProducts
      contextRef="D2015Q3Aug7_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d5961322e577-wk-Fact-69674F2F3D3F70CBE3B77A9E0AC88B3F"
      unitRef="product">2</ino:NumberOfAdditionalProducts>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="D2017Q4Dec31_srt_CounterpartyNameAxis_ino_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e584-wk-Fact-1FD5EE01C25D2F31A73B7A9E0AC8E9CB"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember"
      decimals="-3"
      id="d5961322e596-wk-Fact-D17DB0C393F844AC72C17A9E0A95B4D0"
      unitRef="usd">74000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember"
      decimals="-3"
      id="d5961322e600-wk-Fact-0D0C9DBC32B0CCF20B03CB8F9B7823E7"
      unitRef="usd">146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember"
      decimals="-3"
      id="d5961322e609-wk-Fact-EC67BEA0873B9A0BBA027A9E0AD9C483"
      unitRef="usd">62000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_AstraZenecaMember"
      decimals="-5"
      id="d5961322e613-wk-Fact-AF43E6AC109AEC4022B1DAF6DBD36C40"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d5961322e623-wk-Fact-CEBD04ED20BF17B1CE237A9E0ADAC005"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e638-wk-Fact-47FAC92972A8BABF7A257A9E0A58E7A8"
      unitRef="usd">1800000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e642-wk-Fact-FEF66BA3710C7B3648E9DAF7E7820DE4"
      unitRef="usd">2900000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e650-wk-Fact-44D493987DF53EA985A47A9E0A5BAA6C"
      unitRef="usd">1500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e655-wk-Fact-653F353DA4D16B30EBB8DAF812794BEA"
      unitRef="usd">3200000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_LassaFeverAndMERSVaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e663-wk-Fact-4F08B9AD0331F472BBA07A9E0A5D5D06"
      unitRef="usd">5300000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="D2020Q1Jan1Jan31_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e670-wk-Fact-80D91AFDEE9EFAC9690E7A9E0A583AA2"
      unitRef="usd">9000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e674-wk-Fact-B7A12509B755EF1501548691F74311F0"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e678-wk-Fact-1985CD01B0797A49DEFA86926D8EB401"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="D2020Q2April1toApril30_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_INO4800Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e686-wk-Fact-759B5FD4C77628CB0A8D86927DFBFF01"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e695-wk-Fact-230ACFBF61FD5C9ACCF2DB01A7CBC5A7"
      unitRef="usd">5800000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e699-wk-Fact-DDEECE6F7ED8DAEDC769DB01CB734F24"
      unitRef="usd">8100000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e707-wk-Fact-EFC641F7F7875A7D01D686A6F0C8FE55"
      unitRef="usd">2900000</us-gaap:AccountsReceivableRelatedParties>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_srt_ProductOrServiceAxis_ino_SARSCoV2COVID19VaccineMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e711-wk-Fact-27892B35973B81407CC47A9E0AC83A5A"
      unitRef="usd">101000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="D2018Q4Oct1Oct31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e722-wk-Fact-B8E89B064A1FD95EDA137A9E0ADA6E6C"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="D2019Q3Aug1Aug30_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e726-wk-Fact-B4791A7932D854B016477A9E0A58EA7B"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e734-wk-Fact-148B34CAEB69123C61857A9E0A5EA0B3"
      unitRef="usd">36000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e738-wk-Fact-16EA60F4F5D04B4D8DC47A9E0A615A69"
      unitRef="usd">170000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e747-wk-Fact-F77874FCDCCCF1189E35DAF88B1157F6"
      unitRef="usd">698000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e751-wk-Fact-541AF140D91275E2BC31DAF8A4274B01"
      unitRef="usd">1800000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e759-wk-Fact-16CF675DC66693F9ACFA7A9E0A5A01FF"
      unitRef="usd">858000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="D2020Q1March1March31_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e766-wk-Fact-C1C56E89EADA9F728EDD7A9E0ADACA8E"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e778-wk-Fact-1EB064CECB8875D8F9F87A9E0AD9F11B"
      unitRef="usd">850000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2YTD_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-3"
      id="d5961322e782-wk-Fact-34C2398ECB9FF07A54BBDAF8DFFBD47E"
      unitRef="usd">913000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_BillAndMelindaGatesFoundationMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e787-wk-Fact-DD4E11BB82CF5D80C1197A9E0A5A4E44"
      unitRef="usd">4100000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e809-wk-Fact-ABB7540E6887F65E9A93333F391BEC1F"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA2000DeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d5961322e825-wk-Fact-CB2FAA47E1C6CB9E37A8334DAE60BEB8"
      unitRef="usd">16600000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="FD2020Q2QTD_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d5961322e836-wk-Fact-78A154EBB79557ECEE8886AB86453B00"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_DepartmentOfDefenceMember_srt_ProductOrServiceAxis_ino_CELLECTRA3PSPProprietarySmartDeviceMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d5961322e840-wk-Fact-2DA793D2C02C1BD2F0B786B2C3974FA9"
      unitRef="usd">0</ino:DeferredGrantFundingCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-CE9B970C11B1A31B0F9B7A9E0AE8C117-0-wk-Fact-897560D370AC1C21A93C7A9E0A99653D">Income Taxes &lt;div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets. The Company will continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4277FEC21D19F9304BCF7A9E0AE848A7-0-wk-Fact-A84DEFC9673103B5B47F7A9E0AA0BE1C">Geneos Therapeutics, Inc. &lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In  August 2016, the Company formed Geneos, to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;preferred stock financing. The Company invested&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;in the preferred stock financing, which was led by an outside investor.  Following this transaction, the Company held&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Consolidation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2020, Geneos completed the second closing of the&#160;preferred stock financing, in which the Company invested &#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$800,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Following this transaction, as of March 31, 2020, the Company held&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2020, Geneos closed an additional&#160;preferred stock financing round, in which the Company invested &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$800,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  Following this transaction, the Company no longer held a controlling financial interest as the Company, retaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the outstanding equity of Geneos on an as-converted to common stock basis.  This transaction triggered a VIE reconsideration. Based on the Company&#x2019;s assessment, Geneos is a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company is not the primary beneficiary of Geneos as it does not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; relates to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(59,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Note Payable &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;171,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed Assets, net of accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,181,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,618,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,121,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,774,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June 1, 2020, the fair value of the Company&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; retained investment in Geneos is shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Geneos Share Class&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;819,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,113,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,799,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,113,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,618,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of Geneos preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of preferred stock financing for Geneos on June 1, 2020.  The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for Geneos&#x2019; common stock.  Geneos&#x2019; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving Geneos&#x2019; own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#x2019;s exercise price was based on Geneos&#x2019; total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of Geneos&#x2019; estimated time to their next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#x2019;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 30, 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.46%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Enterprise value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4,966,531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock.  Since the Company&#x2019;s preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations.  The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly.  There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upon deconsolidation, the Company recorded its preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020.  The Company has determined that its preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s share of net losses of Geneos for the period from June 1, 2020 through June 30, 2020 was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$902,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  Of this amount, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$819,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been allocated to the equity method investment, thereby reducing the balance to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of June 30, 2020.  The remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$83,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss has been allocated to the Company&#x2019;s preferred stock investment in Geneos. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.  &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June 30, 2020 the Company has &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$97,000&lt;/span&gt;&lt;/span&gt; recorded as a receivable from Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="D2019Q1Feb1Feb28_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-5"
      id="d5962107e473-wk-Fact-507C9F7E36E28ECCF54DB5D15F1C2C6E"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="I2019Q1_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="2"
      id="d5962107e477-wk-Fact-4E75F54FC22289D9A3FBB5D3FDD60925"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="I2020Q1Jan31_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-3"
      id="d5962107e488-wk-Fact-560ADAD6C7B3B8B98F53B5D357164091"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="I2020Q1Jan31_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="2"
      id="d5962107e492-wk-Fact-7E93A967A4934BB0A255B5D3E0EBB475"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-3"
      id="d5962107e499-wk-Fact-23261FB82E5E2A4DAB82B5D268935B00"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q2_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="2"
      id="d5962107e503-wk-Fact-927800823B9D2D66B5ADB5D3CF8F5FA9"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-5"
      id="d5962107e507-wk-Fact-657DDE81CBAB573A3AFAB5E29189E510"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-5"
      id="d5962107e511-wk-Fact-CCA5A389BCB403E5A9CCC3B5DE89E6A4"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <ino:WorkingCapitalExcludingCash
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e542-wk-Fact-C91505256F440C965673D5FE71D2832A"
      unitRef="usd">59992</ino:WorkingCapitalExcludingCash>
    <us-gaap:NotesPayable
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e558-wk-Fact-F89771DD528A676AD04DD5FE71CA3399"
      unitRef="usd">171620</us-gaap:NotesPayable>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e578-wk-Fact-0D77FB22A0212498A4DAD5FE71BC87B0"
      unitRef="usd">16340</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MinorityInterest
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e599-wk-Fact-A4819508852C8052572ED5FE71C12672"
      unitRef="usd">3181640</us-gaap:MinorityInterest>
    <us-gaap:RetainedInterestFairValueDisclosure
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e619-wk-Fact-A0614790ECE1A493203FD5FE71CFB17E"
      unitRef="usd">3618998</us-gaap:RetainedInterestFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e639-wk-Fact-4399E8D95BD28694E26AD5FE71C59BB7"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e665-wk-Fact-258D3AD6E17F7A183D21C385E1C4BCC1"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1F3F93048F091C2AC1F3B5E762D4875E-0-wk-Fact-94DFAFBD66184AE19316B5E873F80BF3">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of June 1, 2020, the fair value of the Company&#x2019;s &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; retained investment in Geneos is shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Geneos Share Class&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;819,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,113,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,799,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,113,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,618,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The following table shows the amounts related to the deconsolidation accounting: &lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(59,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Note Payable &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;171,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed Assets, net of accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,181,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,618,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,121,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,774,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q2_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="2"
      id="d5962107e679-wk-Fact-927800823B9D2D66B5ADB5D3CF8F5FA9"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5962107e766-wk-Fact-3B117D94BDC59945A124D5FE6C553710"
      unitRef="shares">3000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="3"
      id="d5962107e785-wk-Fact-7E75D590FB3BFC0AA9B9D5FE6C2AB73C"
      unitRef="usdPerShare">0.273</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d5962107e804-wk-Fact-01D4D005AEFB5A12844BD5FE6C5FAD00"
      unitRef="usd">819000</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5962107e819-wk-Fact-624C20EC412F0DC007EAD5FE6C3B7588"
      unitRef="shares">2113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="3"
      id="d5962107e838-wk-Fact-8CDB8229E58438B9FF67D5FE6C6EEB43"
      unitRef="usdPerShare">1.325</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d5962107e857-wk-Fact-B8A29F80105F102E9040D5FE6C02A200"
      unitRef="usd">2799998</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e872-wk-Fact-04A061448DA4E7EC7169D5FE6C67B512"
      unitRef="shares">5113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestments
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="0"
      id="d5962107e911-wk-Fact-8356ECEDC1AF70311C04D5FE6C662C60"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-793EB679FDB1E094B822B9750C0D5558-0-wk-Fact-CB1080A7B83836A3DC81B975185D1F00">The assumptions used in the fair value calculation as of June 30, 2020 are presented below:&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.46%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Enterprise value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4,966,531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:AlternativeInvestmentMeasurementInputTerm
      contextRef="D2020Q2Jun01toJune01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      id="d5962107e951-wk-Fact-7EA825B6342334BEC47FD5FE788E91EB">P2Y11M1D</ino:AlternativeInvestmentMeasurementInputTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="d5962107e962-wk-Fact-DB642F9C83EA37B42984D5FE7854667E"
      unitRef="number">0.70</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="d5962107e973-wk-Fact-1687BD3A4B9627D358F5D5FE78381FB4"
      unitRef="number">0.0246</us-gaap:AlternativeInvestmentMeasurementInput>
    <ino:EquityMethodInvestmentEnterpriseValue
      contextRef="I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-3"
      id="d5962107e984-wk-Fact-0EA52C6A7C17054E6316D5FE78759923"
      unitRef="usd">4966531000</ino:EquityMethodInvestmentEnterpriseValue>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-3"
      id="d5962107e1006-wk-Fact-B2F167FF135C2BA7FCC6C815484ED97C"
      unitRef="usd">-902000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d5962107e1010-wk-Fact-82B097A575D4F71E4D69C830D6B3B51D"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d5962107e1014-wk-Fact-13DCDEB2D211BDD52014C854DD8B7C78"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="D2020Q2June2020_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember"
      decimals="-3"
      id="d5962107e1018-wk-Fact-B1CD07794888A4D6BA2FC8155E91A409"
      unitRef="usd">-83000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2020Q2_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member"
      decimals="-3"
      id="d5962107e1036-wk-Fact-96288B69F20DC5676735B97BDF03D65C"
      unitRef="usd">97000</us-gaap:DueFromRelatedParties>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-FFFEAC34978965D51A797A9E0AE858FA-0-wk-Fact-238A2F1006E1F302CA027A9E0AC0493E">Subsequent Events&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2020, certain holders converted an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of Notes into an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,546,074&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2020, the holders converted all of the August 2019 Bonds into an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,962,364&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock, leaving &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; further August 2019 Bonds outstanding. The conversion rate as of the date of conversion &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;on August 1, 2020 was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;275.6873&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares per KRW &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in principal amount (equivalent to a conversion price of approximately USD &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of January 2, 2020).&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="D2020Q2July1toJuly31_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d5961486e485-wk-Fact-580DF1531D9633AFE384956A9C69310D"
      unitRef="usd">19100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="D2020Q2July1toJuly31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d5961486e489-wk-Fact-38DD321D4148EA71A8F59570CE173A2B"
      unitRef="shares">3546074</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="D2020Q2Aug1toAug10_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d5961486e496-wk-Fact-459BB0D1A28F9545F54686BE0CB0C455"
      unitRef="shares">4962364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:LongTermDebt
      contextRef="I2020Q2Aug10_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d5961486e500-wk-Fact-3A9C63823F16ED97463D9AACD0E30CD2"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2020Q1Jan02_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d5961486e515-wk-Fact-C5F442922F55B8A355067A9E0AAE4D35"
      unitRef="usdPerShare">3.14</us-gaap:DebtInstrumentConvertibleConversionPrice1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302967016632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. GERMANTOWN PIKE, SUITE 110 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">PLYMOUTH MEETING<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,520,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302967802312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 215,432,713<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">156,231,102<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,513,159<span></span>
</td>
<td class="nump">700,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">482,373<span></span>
</td>
<td class="nump">1,332,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,591,966<span></span>
</td>
<td class="nump">1,584,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">1,811,140<span></span>
</td>
<td class="nump">1,050,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">382,062,453<span></span>
</td>
<td class="nump">94,200,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">11,323,531<span></span>
</td>
<td class="nump">12,773,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">17,327,569<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">2,717,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,420,311<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">13,265,144<span></span>
</td>
<td class="nump">13,783,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,555,782<span></span>
</td>
<td class="nump">2,672,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">443,185,402<span></span>
</td>
<td class="nump">143,951,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">17,216,875<span></span>
</td>
<td class="nump">18,237,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">511,953<span></span>
</td>
<td class="nump">729,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">6,870,450<span></span>
</td>
<td class="nump">4,049,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">14,853<span></span>
</td>
<td class="nump">92,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">94,275<span></span>
</td>
<td class="nump">31,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,200,459<span></span>
</td>
<td class="nump">2,074,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">10,330,235<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">742,875<span></span>
</td>
<td class="nump">708,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">37,981,975<span></span>
</td>
<td class="nump">31,989,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">86,641<span></span>
</td>
<td class="nump">101,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">119,796,000<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">19,261,354<span></span>
</td>
<td class="nump">20,409,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">66,629<span></span>
</td>
<td class="nump">36,943<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">256,824,933<span></span>
</td>
<td class="nump">138,546,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">158,756<span></span>
</td>
<td class="nump">101,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,087,745,242<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(610,030)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">186,264,200<span></span>
</td>
<td class="nump">3,435,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">96,269<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">186,360,469<span></span>
</td>
<td class="nump">5,404,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">443,185,402<span></span>
</td>
<td class="nump">143,951,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">65,844,260<span></span>
</td>
<td class="nump">64,180,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 13,718,528<span></span>
</td>
<td class="nump">$ 12,842,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140303044207192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
<td class="nump">$ 2,965,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,376,575<span></span>
</td>
<td class="nump">22,486,266<span></span>
</td>
<td class="nump">41,487,763<span></span>
</td>
<td class="nump">46,876,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,071,510<span></span>
</td>
<td class="nump">5,850,101<span></span>
</td>
<td class="nump">18,519,864<span></span>
</td>
<td class="nump">12,825,129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">33,448,085<span></span>
</td>
<td class="nump">28,336,367<span></span>
</td>
<td class="nump">60,007,627<span></span>
</td>
<td class="nump">59,701,284<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(33,180,898)<span></span>
</td>
<td class="num">(28,200,694)<span></span>
</td>
<td class="num">(58,413,166)<span></span>
</td>
<td class="num">(56,735,705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">1,067,399<span></span>
</td>
<td class="nump">755,330<span></span>
</td>
<td class="nump">1,483,968<span></span>
</td>
<td class="nump">1,380,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,846,641)<span></span>
</td>
<td class="num">(2,194,783)<span></span>
</td>
<td class="num">(5,650,396)<span></span>
</td>
<td class="num">(2,851,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(97,755,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,976,977)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="num">(3,883,176)<span></span>
</td>
<td class="num">(173,212)<span></span>
</td>
<td class="nump">9,298,443<span></span>
</td>
<td class="num">(923,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">4,358,634<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(691,458)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(152,102)<span></span>
</td>
<td class="nump">127,512<span></span>
</td>
<td class="num">(577,602)<span></span>
</td>
<td class="nump">91,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income tax benefit and share in net loss of Geneos</a></td>
<td class="num">(128,270,709)<span></span>
</td>
<td class="num">(29,685,847)<span></span>
</td>
<td class="num">(161,406,113)<span></span>
</td>
<td class="num">(59,037,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(901,757)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(901,757)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(129,172,466)<span></span>
</td>
<td class="num">(29,579,076)<span></span>
</td>
<td class="num">(162,307,870)<span></span>
</td>
<td class="num">(58,867,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">469,407<span></span>
</td>
<td class="nump">191,850<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">261,455<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (128,703,059)<span></span>
</td>
<td class="num">$ (29,387,226)<span></span>
</td>
<td class="num">$ (161,244,113)<span></span>
</td>
<td class="num">$ (58,606,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">155,807,054<span></span>
</td>
<td class="nump">98,083,896<span></span>
</td>
<td class="nump">140,215,158<span></span>
</td>
<td class="nump">97,795,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 74,102<span></span>
</td>
<td class="nump">$ 64,283<span></span>
</td>
<td class="nump">$ 145,602<span></span>
</td>
<td class="nump">$ 2,834,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">95,146<span></span>
</td>
<td class="nump">71,390<span></span>
</td>
<td class="nump">1,267,272<span></span>
</td>
<td class="nump">126,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Miscellaneous revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 97,939<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 181,587<span></span>
</td>
<td class="nump">$ 3,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302967897752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (129,172,466)<span></span>
</td>
<td class="num">$ (29,579,076)<span></span>
</td>
<td class="num">$ (162,307,870)<span></span>
</td>
<td class="num">$ (58,867,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">846,900<span></span>
</td>
<td class="nump">441,545<span></span>
</td>
<td class="num">(1,082,638)<span></span>
</td>
<td class="nump">1,260,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(128,325,566)<span></span>
</td>
<td class="num">(29,137,531)<span></span>
</td>
<td class="num">(163,390,508)<span></span>
</td>
<td class="num">(57,607,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">469,407<span></span>
</td>
<td class="nump">191,850<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">261,455<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (127,856,159)<span></span>
</td>
<td class="num">$ (28,945,681)<span></span>
</td>
<td class="num">$ (162,326,751)<span></span>
</td>
<td class="num">$ (57,345,766)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964979352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 87,032,407<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="nump">$ 707,794,215<span></span>
</td>
<td class="num">$ (620,426,436)<span></span>
</td>
<td class="num">$ (528,867)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">907,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">907,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(719,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="num">(719,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,432,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,432,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">3,030,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,030,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(29,288,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,219,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">819,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,934,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">80,966,251<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,934<span></span>
</td>
<td class="nump">727,166,934<span></span>
</td>
<td class="num">(649,645,698)<span></span>
</td>
<td class="nump">290,310<span></span>
</td>
<td class="nump">3,056,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">87,032,407<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="nump">707,794,215<span></span>
</td>
<td class="num">(620,426,436)<span></span>
</td>
<td class="num">(528,867)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(58,867,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">1,260,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">98,584,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">56,478,073<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 98,584<span></span>
</td>
<td class="nump">731,819,389<span></span>
</td>
<td class="num">(679,032,924)<span></span>
</td>
<td class="nump">731,855<span></span>
</td>
<td class="nump">2,861,169<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,934,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">80,966,251<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,934<span></span>
</td>
<td class="nump">727,166,934<span></span>
</td>
<td class="num">(649,645,698)<span></span>
</td>
<td class="nump">290,310<span></span>
</td>
<td class="nump">3,056,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">1,388,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">1,388,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(81,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="num">(81,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,355,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,345,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Cost of acquisition of non-controlling interest in Geneos</a></td>
<td class="num">(13,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(29,579,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,387,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">441,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">98,584,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">56,478,073<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 98,584<span></span>
</td>
<td class="nump">731,819,389<span></span>
</td>
<td class="num">(679,032,924)<span></span>
</td>
<td class="nump">731,855<span></span>
</td>
<td class="nump">2,861,169<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">208,241,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,149<span></span>
</td>
<td class="nump">208,198,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">3,100,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">3,099,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,001,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,017,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">2,169,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,169,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(33,135,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,541,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(594,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(162,307,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(1,082,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">158,756,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">186,360,469<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 158,756<span></span>
</td>
<td class="nump">1,087,745,242<span></span>
</td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="num">(610,030)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">121,718,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,041<span></span>
</td>
<td class="nump">121,706,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">4,422,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="nump">4,421,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,662,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,654,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">209,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Geneos</a></td>
<td class="num">(3,181,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,181,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(129,172,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,703,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">846,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">158,756,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 186,360,469<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 158,756<span></span>
</td>
<td class="nump">$ 1,087,745,242<span></span>
</td>
<td class="num">$ (901,029,768)<span></span>
</td>
<td class="num">$ (610,030)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302966767944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (129,172,466)<span></span>
</td>
<td class="num">$ (33,135,404)<span></span>
</td>
<td class="num">$ (29,579,076)<span></span>
</td>
<td class="num">$ (29,288,867)<span></span>
</td>
<td class="num">$ (162,307,870)<span></span>
</td>
<td class="num">$ (58,867,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,608,060<span></span>
</td>
<td class="nump">1,863,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,540<span></span>
</td>
<td class="nump">533,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,976,977<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,663,988<span></span>
</td>
<td class="nump">6,787,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013,942<span></span>
</td>
<td class="nump">2,851,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit', window );">Amortization of premiums on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,001<span></span>
</td>
<td class="num">(93,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,713,770)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entities</a></td>
<td class="nump">3,883,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,298,443)<span></span>
</td>
<td class="nump">923,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">901,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,757<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,458<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLeaseNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,865<span></span>
</td>
<td class="nump">412,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments', window );">Tax benefit from other unrealized gains on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(335,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction loss on foreign-currency denominated debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(474,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,813,086)<span></span>
</td>
<td class="nump">3,186,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865,832<span></span>
</td>
<td class="num">(258,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,084,082)<span></span>
</td>
<td class="num">(902,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,330,601)<span></span>
</td>
<td class="nump">20,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,242<span></span>
</td>
<td class="num">(183,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732,774)<span></span>
</td>
<td class="num">(9,187,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,882,486<span></span>
</td>
<td class="num">(1,033,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
<td class="num">(324,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,426)<span></span>
</td>
<td class="num">(137,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,022,951)<span></span>
</td>
<td class="num">(786,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,265,023<span></span>
</td>
<td class="num">(1,695,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,050)<span></span>
</td>
<td class="nump">817,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,686<span></span>
</td>
<td class="num">(34,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,604,208)<span></span>
</td>
<td class="num">(56,379,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,698,249)<span></span>
</td>
<td class="num">(73,698,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,455,067<span></span>
</td>
<td class="nump">46,688,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,534)<span></span>
</td>
<td class="num">(739,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774,851<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,194,567)<span></span>
</td>
<td class="num">(27,749,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,658,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,960,855<span></span>
</td>
<td class="nump">2,296,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,599,514<span></span>
</td>
<td class="nump">92,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,076,567)<span></span>
</td>
<td class="num">(892,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
<td class="nump">3,016,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Geneos issuance of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,035,391<span></span>
</td>
<td class="nump">80,171,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (Decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,236,616<span></span>
</td>
<td class="num">(3,957,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,693,633<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">23,693,633<span></span>
</td>
<td class="nump">$ 23,693,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 215,432,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,735,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,432,713<span></span>
</td>
<td class="nump">19,735,943<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,636,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,634,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Income Accrued On Short Term Investments Certificates Of Deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLeaseNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLeaseNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965224824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's novel DNA medicines are made using its proprietary SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio's hand-held CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of Inovio&#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> smart delivery device in more than 6,000 administrations across more than 2,000 patients.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964779752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statements of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;12, 2020. The balance sheet at December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June of 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;"> non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio incurred a net loss attributable to common stockholders of </span><span style="font-family:inherit;font-size:10pt;"><span>$128.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$161.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively. Inovio had working capital of </span><span style="font-family:inherit;font-size:10pt;"><span>$344.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of $</span><span style="font-family:inherit;font-size:10pt;"><span>901.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$371.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#8220;Sales Agreement&#8221; and collectively, the &#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$121.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$330.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> from a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>6.50%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>18 billion</span></span><span style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>4.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s condensed consolidated financial statements as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964737608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful lives ranging from </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>18</span></span><span style="font-family:inherit;font-size:10pt;">&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the license has an alternative future use. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $</span><span style="font-family:inherit;font-size:10pt;"><span>3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, identifying no impairment.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#8217;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive gain (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities (VIE)</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Investments</span></div><span style="font-family:inherit;font-size:10pt;">Under Accounting Standards Codification ("ASC") Topic 321, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Securities,</span><span style="font-family:inherit;font-size:10pt;"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963328712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text">Impact of Recently Issued Accounting Standards <div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Recently Adopted</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2019-12. </span><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption.  As of June 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended June 30, 2020. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-13</span><span style="font-family:inherit;font-size:10pt;">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-13</span><span style="font-family:inherit;font-size:10pt;">. In August 2018, the FASB issued ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#8217;s fair value classifications).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-18</span><span style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:inherit;font-size:10pt;">, which clarified the interaction between Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;">, and Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU 2017-04.</span><span style="font-family:inherit;font-size:10pt;"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span>("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964754344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  <div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized total revenue under collaborative research and development and other agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), </span><span style="font-family:inherit;font-size:10pt;"><span>$74,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$146,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from AstraZeneca and </span><span style="font-family:inherit;font-size:10pt;"><span>$129,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$244,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from various other contracts. Of the total revenue recognized during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$66,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$124,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were in deferred revenue as of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Performance obligations are generally satisfied within </span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;"> months of the initial contract date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965225544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of mutual funds, corporate debt securities and certificates of deposit. Short-term investments at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gross realized gain on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$585,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$635,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and gross realized loss on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$686,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded gross realized gain on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$157,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$175,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and gross realized loss on investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$29,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$82,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$(691,000)</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> material unrealized gain or loss on available-for-sale equity securities recorded during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>16</span></span><span style="font-family:inherit;font-size:10pt;"> available-for-sale securities in an unrealized loss position, of which </span><span style="font-family:inherit;font-size:10pt;"><span>none</span></span><span style="font-family:inherit;font-size:10pt;"> were in such position for longer than </span><span style="font-family:inherit;font-size:10pt;">12 months</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,641,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,180,185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,871,643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,949,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,625,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(376,600</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,262,800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,266,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,232,945</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,268,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156,231,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,599,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>754,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,338,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964487896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,949,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,949,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,262,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,262,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,327,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,327,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,558,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,540,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability (Note 9)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,349,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,349,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,338,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,338,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,315,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,315,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,003,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,003,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability (Note 9)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 assets at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of mutual funds and corporate debt securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investments in affiliates, GeneOne and PLS. The Company accounts for its investment in </span><span style="font-family:inherit;font-size:10pt;"><span>1,644,155</span></span><span style="font-family:inherit;font-size:10pt;"> common shares of GeneOne based on the closing price of the shares on the Korean Stock Exchange on the applicable balance sheet date. The Company accounts for its investment in </span><span style="font-family:inherit;font-size:10pt;"><span>597,808</span></span><span style="font-family:inherit;font-size:10pt;"> common shares of PLS based on the closing price of the shares on the Korea New Exchange (KONEX) Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of operations as a gain (loss) on investment in affiliated entities. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 assets at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of certificates of deposit held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no Level 3 assets at June 30, 2020.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 liabilities held as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 9 below for more information). The derivative liability was recorded at fair value of $</span><span style="font-family:inherit;font-size:10pt;"><span>7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> include the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company's derivative liability for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,976,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:81%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964588728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:18%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Yrs)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite lived:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Definite lived:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,323,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,262,478</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,323,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,248,104</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bioject(b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,322,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,777,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,175,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,924,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other(c)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,050,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,468,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,050,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,356,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>693,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,473,761</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,053,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,420,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,473,761</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,779,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,693,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total goodwill and intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,987,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,053,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,933,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,987,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,779,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,207,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$400,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</span></div></td></tr></table><span style="font-family:inherit;font-size:10pt;">Aggregate amortization expense on intangible assets for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$137,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$274,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Aggregate amortization expense on intangible assets for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$267,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$533,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Estimated aggregate amortization expense is $</span><span style="font-family:inherit;font-size:10pt;"><span>274,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the remainder of fiscal year </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$520,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span>493,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span>276,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span>253,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2025</span> and subsequent years combined.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964730200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 19, 2019 and March 1, 2019, the Company completed a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>$78.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$75.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>6.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.38</span></span><span style="font-family:inherit;font-size:10pt;"> per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on (i) each of at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applies. Therefore, the Notes issuance proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$78.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$62.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the Notes at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,500,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt discount on the liability component</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,619,675</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,736,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,700,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,844,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </span><span style="font-family:inherit;font-size:10pt;"><span>$18.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is </span><span style="font-family:inherit;font-size:10pt;"><span>13.1%</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of interest expense related to the Notes, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. For the three and six months ended June 30, 2019,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of interest expense related to the Notes, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there had not been any conversions or redemptions of the Notes. As described in Note 18 below, subsequent to June 30, 2020, certain holders converted a portion of the Notes into shares of the Company's common stock.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">August 2019 Convertible Bonds </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>18 billion</span></span><span style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ Market of the Korea Exchange (KOSDAQ) in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. As described in Note 18 below, on August 1, 2020 the August 2019 Bonds were converted in full. The initial conversion rate was </span><span style="font-family:inherit;font-size:10pt;">211.0595</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to an initial conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$4.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset on each three month anniversary thereafter to the then current market price if the current market price was lower than the conversion price then in effect; subject to a maximum conversion rate of </span><span style="font-family:inherit;font-size:10pt;">351.7658</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$2.40</span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rates as of July 30, 2019). The conversion rate as of the date of conversion on August 1, 2020 was </span><span style="font-family:inherit;font-size:10pt;">275.6873</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW </span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$3.14</span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of January 2, 2020).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the August 2019 Bonds at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,993,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt discount </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,600,302</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211,272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the August 2019 Bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,738,748</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.3</span></span><span style="font-family:inherit;font-size:10pt;"> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds was </span><span style="font-family:inherit;font-size:10pt;"><span>29.4%</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$672,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively, of interest expense related to the August 2019 Bonds, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$37,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$75,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there had not been any conversions or redemptions of the August 2019 Bonds.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The derivative liability was valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$119.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The change in fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$97.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$111.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively.  As a result of the conversion in full of the August 2019 Bonds in August 2020, the derivative liability will be eliminated during the quarter ended September 30, 2020.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">December 2019 Convertible Bonds </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>4.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of </span><span style="font-family:inherit;font-size:10pt;"><span>6.00%</span></span><span style="font-family:inherit;font-size:10pt;">. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate is </span><span style="font-family:inherit;font-size:10pt;">214.7766</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of Bonds (equivalent to an initial conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$4.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed </span><span style="font-family:inherit;font-size:10pt;">357.9611</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW</span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$2.40</span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of December&#160;19, 2019).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to </span><span style="font-family:inherit;font-size:10pt;"><span>6.00%</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the December 2019 Bonds at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,915,035</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40,681</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the December 2019 Bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,638</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,979,780</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is </span><span style="font-family:inherit;font-size:10pt;"><span>6.2%</span></span><span style="font-family:inherit;font-size:10pt;">. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$60,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$122,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of interest expense related to the December 2019 Bonds, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the contractual interest coupon. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there had not been any conversions or redemptions of the December 2019 Bonds.</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, future minimum payments due under the Company's convertible debt instruments are as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Notes (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">August 2019 Bonds (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 2019 Bonds (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,551,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,646,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,103,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,103,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,103,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,051,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,270,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,040,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,361,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,911,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,795,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,177,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,883,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span>6.5%</span></span><span style="font-family:inherit;font-size:10pt;"> per year. </span></div><span style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of </span><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span> at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302968127896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company's authorized and issued common and preferred stock as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:42%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding as of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common Stock, par value $0.001 per share</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600,000,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158,756,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158,756,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,361,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>5,147</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of March 31, 2020, there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="font-family:inherit;font-size:11pt;">.  </span><span style="font-family:inherit;font-size:10pt;">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the New Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent is entitled to compensation for its services in an amount equal to up to </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2020, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>43,148,952</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.92</span></span><span style="font-family:inherit;font-size:10pt;"> per share, resulting in aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$208.2 million</span></span><span style="font-family:inherit;font-size:10pt;">.  As of March 31, 2020, there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> remaining capacity under the Prior Sales Agreement.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2020, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>12,041,178</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.26</span></span><span style="font-family:inherit;font-size:10pt;"> per share, resulting in aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$121.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of June 30, 2020, the Company may sell up to </span><span style="font-family:inherit;font-size:10pt;"><span>$126.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in gross proceeds of shares of Common Stock under the New Sales Agreement before it would be required to file a new prospectus supplement with the SEC to sell additional shares pursuant to the New Sales Agreement. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options and Restricted Stock Units</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed </span><span style="font-family:inherit;font-size:10pt;"><span>18,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>2,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock unless the Company's Board of Directors determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued increased by </span><span style="font-family:inherit;font-size:10pt;"><span>2,000,000</span></span><span style="font-family:inherit;font-size:10pt;">. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>18,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>6,953,960</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock available for future grant under the 2016 Incentive Plan, </span><span style="font-family:inherit;font-size:10pt;"><span>2,868,665</span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>5,733,501</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> and have a maximum contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><span style="font-family:inherit;font-size:10pt;">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had options outstanding to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>3,459,595</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> and have a maximum contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964507672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are anti-dilutive.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Common Stock Equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,193,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,770,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,868,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,580,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible preferred stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,456</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,585,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,585,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019 Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,962,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2019 Bonds</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,009,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,622,537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,944,620</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963306920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below: </span><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:2%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.40%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.31%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.43%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life in years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was $</span><span style="font-family:inherit;font-size:10pt;"><span>3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which $</span><span style="font-family:inherit;font-size:10pt;"><span>1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in research and development expenses, and $</span><span style="font-family:inherit;font-size:10pt;"><span>1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in general and administrative expenses.</span></div><div style="line-height:120%;padding-bottom:4px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in research and development expenses, and </span><span style="font-family:inherit;font-size:10pt;"><span>$877,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, was included in general and administrative expenses.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.3 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.52</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.19</span></span><span style="font-family:inherit;font-size:10pt;"> for employee and director stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.44</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.20</span></span><span style="font-family:inherit;font-size:10pt;"> for employee and director stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span><span style="font-family:inherit;font-size:10pt;"> years.  </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share was </span><span style="font-family:inherit;font-size:10pt;"><span>$14.50</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.12</span></span><span style="font-family:inherit;font-size:10pt;"> for restricted stock units granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.90</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.42</span></span><span style="font-family:inherit;font-size:10pt;"> for restricted stock units granted during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$224,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$607,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$207,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$480,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964685384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">GeneOne Life Sciences </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company owns </span><span style="font-family:inherit;font-size:10pt;"><span>1,644,155</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in GeneOne as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to GeneOne. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2010, the Company entered into a collaboration and license agreement (the &#8220;GeneOne Agreement&#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#8220;Product&#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into a collaborative development and license agreement (the &#8220;Hep Agreement&#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#8217;s SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> therapeutic vaccines for hepatitis B and C infections (the &#8220;Hep Products&#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> years after the effective date.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized from GeneOne consisted of patent and device maintenance fees. For both the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and 2019, the Company recognized revenue from GeneOne of </span><span style="font-family:inherit;font-size:10pt;"><span>$31,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$63,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing were </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$727,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$3,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$128,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$26,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$511,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to GeneOne and its subsidiaries. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$238,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$284,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of prepayments made to GeneOne were classified as long-term other assets on the Company's condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Plumbline Life Sciences, Inc.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company owns </span><span style="font-family:inherit;font-size:10pt;"><span>597,808</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received </span><span style="font-family:inherit;font-size:10pt;"><span>202,050</span></span><span style="font-family:inherit;font-size:10pt;"> shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company held a </span><span style="font-family:inherit;font-size:10pt;"><span>19.9%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in PLS.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized from PLS consists of milestone, license and patent fees. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from PLS of </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$40,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$13,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$589,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to PLS.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Wistar Institute</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year term of the agreement.  The Company will have the exclusive right to in-license new intellectual property developed under the agreement.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Company received a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through December 2020. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2020.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$73,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$691,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$368,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense from Wistar. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$408,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$770,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Research and development expenses recorded from Wistar for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$170,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$458,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$370,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$616,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$486,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$219,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to Wistar. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$780,000</span></span><span style="font-family:inherit;font-size:10pt;"> recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963390568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases                                                  <div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>82,200</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office, laboratory, and manufacturing space in San Diego, California and </span><span style="font-family:inherit;font-size:10pt;"><span>57,360</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June 30, 2020 of </span><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span><span style="font-family:inherit;font-size:10pt;"> years, which represent the non-cancellable periods of the leases.  The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performed an evaluation of its contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,956,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,968,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,045,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,023,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,001,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,951,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total remaining lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,944,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,482,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,462,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,201,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,261,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease costs included in operating expenses in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$814,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$835,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963076056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ApolloBio Corporation </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> following the effective date of the ApolloBio Agreement.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the ApolloBio Agreement, the Company received proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in March 2018 which comprised the upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> less </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in foreign income taxes and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of </span><span style="font-family:inherit;font-size:10pt;"><span>$960,000</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;"> after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the terms of the ApolloBio Agreement under Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the </span><span style="font-family:inherit;font-size:10pt;"><span>$23.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> after the effective date for any reason upon </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days written notice to the Company.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Topic 606, the entire transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as revenue under collaborative research and development arrangements on the condensed consolidated statement of operations during the three months ended June 30, 2018.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> and potential future commercial event-based payments totaling up to </span><span style="font-family:inherit;font-size:10pt;"><span>$115 million</span></span><span style="font-family:inherit;font-size:10pt;">, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.  </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Within the broader collaboration, AstraZeneca had rights to co-develop up to </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company had recognized all of the </span><span style="font-family:inherit;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$74,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$146,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from AstraZeneca primarily for manufacturing services. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$62,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from AstraZeneca primarily from a milestone achieved in the first quarter of 2019 triggered by the initiation of a Phase 2 portion of an ongoing clinical trial in the third major indication, as well as for manufacturing services.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Coalition for Epidemic Preparedness Innovations </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$56 million</span></span><span style="font-family:inherit;font-size:10pt;"> of costs over a </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company received funding of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the CEPI Lassa fever and MERS grants and recorded such amounts as contra-research and development expense. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company received funding of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively, related to these grants and recorded such amounts as contra-research and development expense. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3</span></span><span style="font-family:inherit;font-size:10pt;"> million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, CEPI awarded the Company a grant of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP, for the intradermal delivery of INO-4800, and a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> to support large-scale manufacturing of INO-4800. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company received funding of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$101,000</span></span><span style="font-family:inherit;font-size:10pt;"> recorded deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bill &amp; Melinda Gates Foundation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> to advance the development of DNA-encoded monoclonal antibody technology (&#8220;dMAb&#8221;) to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the project. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$36,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$170,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$698,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense related to the Gates dMAb grant. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$858,000</span></span><span style="font-family:inherit;font-size:10pt;"> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, Gates awarded and funded the Company a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to accelerate the development of the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP device for the intradermal delivery of INO-4800. During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$850,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$913,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense and had </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> recorded as deferred grant funding on the condensed consolidated balance sheet related to this Gates grant. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Department of Defense (DoD) </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the U.S. Department of Defense (the "DoD"), to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$54.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;2000 device and accessories. The CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$16.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> contra-research and development expense </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span>r deferred grant funding recorded related to these agreements with the DoD.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963410200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which </span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets. The Company will continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965224824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In  August 2016, the Company formed Geneos, to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;preferred stock financing. The Company invested&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;in the preferred stock financing, which was led by an outside investor.  Following this transaction, the Company held&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>61%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, Geneos completed the second closing of the&#160;preferred stock financing, in which the Company invested &#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$800,000</span></span><span style="font-family:inherit;font-size:10pt;">. Following this transaction, as of March 31, 2020, the Company held&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>52%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2020, Geneos closed an additional&#160;preferred stock financing round, in which the Company invested </span><span style="font-family:inherit;font-size:10pt;"><span>$800,000</span></span><span style="font-family:inherit;font-size:10pt;">.  Following this transaction, the Company no longer held a controlling financial interest as the Company, retaining </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding equity of Geneos on an as-converted to common stock basis.  This transaction triggered a VIE reconsideration. Based on the Company&#8217;s assessment, Geneos is a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company is not the primary beneficiary of Geneos as it does not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital (excluding cash) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note Payable </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed Assets, net of accumulated depreciation </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying value of noncontrolling interest </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,181,640</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of investment in Geneos retained</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,618,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on deconsolidation of Geneos </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,121,075</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease in cash resulting from the deconsolidation of Geneos</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,774,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 1, 2020, the fair value of the Company&#8217;s </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> retained investment in Geneos is shown in the table below.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Geneos Share Class</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>819,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,113,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,113,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,618,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of Geneos preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of preferred stock financing for Geneos on June 1, 2020.  The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for Geneos&#8217; common stock.  Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving Geneos&#8217; own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on Geneos&#8217; total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of Geneos&#8217; estimated time to their next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 30, 2020 are presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:80%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.92</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.46%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enterprise value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$4,966,531</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations.  The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly.  There were </span><span style="font-family:inherit;font-size:10pt;">no</span><span style="font-family:inherit;font-size:10pt;"> basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon deconsolidation, the Company recorded its preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020.  The Company has determined that its preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through June 30, 2020 was </span><span style="font-family:inherit;font-size:10pt;"><span>$902,000</span></span><span style="font-family:inherit;font-size:10pt;">.  Of this amount, </span><span style="font-family:inherit;font-size:10pt;"><span>$819,000</span></span><span style="font-family:inherit;font-size:10pt;"> has been allocated to the equity method investment, thereby reducing the balance to </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;"> as of June 30, 2020.  The remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$83,000</span></span><span style="font-family:inherit;font-size:10pt;"> loss has been allocated to the Company&#8217;s preferred stock investment in Geneos. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continues to exclusively license its SynCon</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;&#160;</sup></span><span style="font-family:inherit;font-size:10pt;">immunotherapy and CELLECTRA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.  </span></div><span style="font-family:inherit;font-size:10pt;">As of June 30, 2020 the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>$97,000</span></span> recorded as a receivable from Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964774440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2020, certain holders converted an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Notes into an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>3,546,074</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock.  </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2020, the holders converted all of the August 2019 Bonds into an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>4,962,364</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, leaving </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> further August 2019 Bonds outstanding. The conversion rate as of the date of conversion </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">on August 1, 2020 was </span><span style="font-family:inherit;font-size:10pt;">275.6873</span><span style="font-family:inherit;font-size:10pt;"> shares per KRW </span><span style="font-family:inherit;font-size:10pt;">1,000,000</span><span style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to a conversion price of approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$3.14</span></span><span style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of January 2, 2020).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140303044182216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statements of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;12, 2020. The balance sheet at December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June of 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;"> non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inovio incurred a net loss attributable to common stockholders of </span><span style="font-family:inherit;font-size:10pt;"><span>$128.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$161.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively. Inovio had working capital of </span><span style="font-family:inherit;font-size:10pt;"><span>$344.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of $</span><span style="font-family:inherit;font-size:10pt;"><span>901.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of </span><span style="font-family:inherit;font-size:10pt;"><span>$371.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#8220;Sales Agreement&#8221; and collectively, the &#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of </span><span style="font-family:inherit;font-size:10pt;"><span>$121.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$330.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> from a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>6.50%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>18 billion</span></span><span style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from the private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>4.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s condensed consolidated financial statements as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantPolicyPolicyTextBlock', window );">Grants</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Intangible Assets and Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful lives ranging from </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>18</span></span><span style="font-family:inherit;font-size:10pt;">&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the license has an alternative future use. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $</span><span style="font-family:inherit;font-size:10pt;"><span>3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, identifying no impairment.</span></div>Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#8217;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive gain (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities (VIE)</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock', window );">Equity Investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Investments</span></div><span style="font-family:inherit;font-size:10pt;">Under Accounting Standards Codification ("ASC") Topic 321, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Securities,</span><span style="font-family:inherit;font-size:10pt;"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Recently Adopted</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2019-12. </span><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption.  As of June 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended June 30, 2020. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-13</span><span style="font-family:inherit;font-size:10pt;">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-13</span><span style="font-family:inherit;font-size:10pt;">. In August 2018, the FASB issued ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#8217;s fair value classifications).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-18</span><span style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:inherit;font-size:10pt;">, which clarified the interaction between Topic 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;">, and Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU 2017-04.</span><span style="font-family:inherit;font-size:10pt;"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span>("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965186456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,641,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,180,185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,871,643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,949,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,625,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(376,600</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,262,800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less than 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,266,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,232,945</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,268,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156,231,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">---</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,599,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>754,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,338,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965231016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,949,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,949,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,262,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,262,800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,327,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,327,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,558,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,540,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,018,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability (Note 9)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,349,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,349,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,338,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,338,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment in affiliated entities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,315,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,315,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,003,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,003,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability (Note 9)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of the Company's Derivative Liability</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company's derivative liability for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,819,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,976,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,796,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:81%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964423752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Summary of Intangible Assets by Major Asset Class</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:18%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Useful</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Yrs)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite lived:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill(a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,513,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Definite lived:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,323,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,262,478</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,323,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,248,104</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bioject(b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,322,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,777,778</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,100,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,175,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,924,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other(c)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,050,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,468,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>581,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,050,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,356,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>693,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,473,761</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,053,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,420,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,473,761</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,779,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,693,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total goodwill and intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,987,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,053,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,933,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,987,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,779,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,207,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$400,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(c)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140303054565704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the December 2019 Bonds at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,915,035</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40,681</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the December 2019 Bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95,638</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,979,780</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the Notes at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,500,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt discount on the liability component</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,619,675</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,736,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,700,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,844,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balance of the August 2019 Bonds at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,993,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt discount </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,600,302</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211,272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the August 2019 Bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,738,748</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, future minimum payments due under the Company's convertible debt instruments are as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Notes (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">August 2019 Bonds (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 2019 Bonds (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,551,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,646,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,103,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,103,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,103,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,292,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,051,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,270,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,040,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,361,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,911,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,795,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,177,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,883,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span>6.5%</span></span><span style="font-family:inherit;font-size:10pt;"> per year. </span></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of </span><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span><span style="font-family:inherit;font-size:10pt;"> at maturity. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302964720856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company's authorized and issued common and preferred stock as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:42%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding as of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Issued</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common Stock, par value $0.001 per share</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600,000,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158,756,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158,756,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,361,034</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302966332520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Common Stock Equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,193,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,770,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,868,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,580,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible preferred stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,456</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,585,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,585,653</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019 Bonds</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,962,364</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2019 Bonds</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,009,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,622,537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,944,620</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963041944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below: </span><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:2%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.40%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.31%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.43%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life in years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302967505336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,956,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,968,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,045,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,023,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,001,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,951,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total remaining lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,944,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,482,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,462,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,201,000</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,261,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963265624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 1, 2020, the fair value of the Company&#8217;s </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> retained investment in Geneos is shown in the table below.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Geneos Share Class</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>819,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,113,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799,998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,113,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,618,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The following table shows the amounts related to the deconsolidation accounting: <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital (excluding cash) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note Payable </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed Assets, net of accumulated depreciation </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying value of noncontrolling interest </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,181,640</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of investment in Geneos retained</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,618,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on deconsolidation of Geneos </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,121,075</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease in cash resulting from the deconsolidation of Geneos</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,774,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule Of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The assumptions used in the fair value calculation as of June 30, 2020 are presented below:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:80%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.92</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.46%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enterprise value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$4,966,531</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302967154584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,703,059<span></span>
</td>
<td class="nump">$ 29,387,226<span></span>
</td>
<td class="nump">$ 161,244,113<span></span>
</td>
<td class="nump">$ 58,606,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (739,785,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,960,855<span></span>
</td>
<td class="nump">$ 2,296,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,993,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,993,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,915,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,915,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_VGXAnimalHealthIncMember', window );">VGX Animal Health, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_VGXAnimalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_VGXAnimalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965744024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 3,420,311<span></span>
</td>
<td class="nump">$ 3,693,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302972595960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
<td class="nump">$ 2,965,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue beginning balance</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302972538984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 585,000<span></span>
</td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="nump">$ 635,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">$ 4,358,634<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (691,458)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | investment</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302968087576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 157,266,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,232,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,268,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">156,231,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">149,641,400<span></span>
</td>
<td class="nump">$ 66,599,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,180,185<span></span>
</td>
<td class="nump">754,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,871,643)<span></span>
</td>
<td class="num">(15,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">148,949,942<span></span>
</td>
<td class="nump">$ 67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">4,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(376,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 4,262,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity (less than)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">38,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 3,018,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965838696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 156,231,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">17,327,569<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">119,796,000<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">148,949,942<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">4,262,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,018,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">17,327,569<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">173,558,671<span></span>
</td>
<td class="nump">76,003,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">119,796,000<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">119,796,000<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">17,327,569<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">170,540,311<span></span>
</td>
<td class="nump">76,003,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,018,360<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">119,796,000<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">148,949,942<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">148,949,942<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">4,262,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,018,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,018,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140303051211816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 119,796,000<span></span>
</td>
<td class="nump">$ 8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Number of shares held in an affiliated entity (in shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of affiliates held for management investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302963095416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 8,819,023,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">110,976,977,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 119,796,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302969207336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2009</div></th>
<th class="th"><div>Jan. 31, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(7,053,450)<span></span>
</td>
<td class="num">(6,779,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">3,420,311<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, net book value</a></td>
<td class="nump">13,933,682<span></span>
</td>
<td class="nump">14,207,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_InovioAsMember', window );">Inovio AS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_VgxPharmaceuticalsMember', window );">VGX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(1,262,478)<span></span>
</td>
<td class="num">(1,248,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">61,283<span></span>
</td>
<td class="nump">75,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(2,322,222)<span></span>
</td>
<td class="num">(2,175,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">2,777,778<span></span>
</td>
<td class="nump">2,924,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(3,468,750)<span></span>
</td>
<td class="num">(3,356,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 581,250<span></span>
</td>
<td class="nump">$ 693,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_InovioAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_InovioAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_VgxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_VgxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302972587656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense on intangible assets</a></td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">$ 273,540<span></span>
</td>
<td class="nump">$ 533,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated aggregate amortization expense for remainder of 2020</a></td>
<td class="nump">274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense for 2021</a></td>
<td class="nump">520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense for 2022</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense for 2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense for 2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated aggregate amortization expense for 2025</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302958475544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,846,641<span></span>
</td>
<td class="nump">$ 2,194,783<span></span>
</td>
<td class="nump">$ 5,650,396<span></span>
</td>
<td class="nump">$ 2,851,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,819,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,755,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,976,977)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,619,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,619,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,993,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,993,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0003517658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds | After January 2, 2020 Conversion Price | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage', window );">Debt instrument, convertible, required bondholder approval, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0003579611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds | After July 2, 2020 Conversion Price | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Required Bondholder Approval, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302969157672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance of Convertible Bonds and Notes (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(12,619,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(1,736,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">1,700,833<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">65,844,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">14,993,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(5,600,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(211,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccretionOfPremium', window );">Accretion of premium associated with the Bonds</a></td>
<td class="nump">519,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">37,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">9,738,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">3,915,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(40,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccretionOfPremium', window );">Accretion of premium associated with the Bonds</a></td>
<td class="nump">95,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">9,788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 3,979,780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccretionOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accretion Of Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccretionOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtinstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtinstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302966587080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 26, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 65,844,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">9,738,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">3,979,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">2,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">5,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">5,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">5,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">105,361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">123,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">2,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">81,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 98,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">19,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 19,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">5,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 5,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302973718264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">158,756,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">158,756,411<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965820792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under share based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,953,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,953,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,733,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,733,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,459,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,459,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Prior Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | New Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementAgentFee', window );">Agent fee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment  award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Agent Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302967044920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">32,622,537<span></span>
</td>
<td class="nump">26,944,620<span></span>
</td>
<td class="nump">32,622,537<span></span>
</td>
<td class="nump">26,944,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">9,193,096<span></span>
</td>
<td class="nump">10,770,319<span></span>
</td>
<td class="nump">9,193,096<span></span>
</td>
<td class="nump">10,770,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">2,868,665<span></span>
</td>
<td class="nump">1,580,192<span></span>
</td>
<td class="nump">2,868,665<span></span>
</td>
<td class="nump">1,580,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">14,585,653<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,962,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302972625624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,960,855<span></span>
</td>
<td class="nump">$ 2,296,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,663,988<span></span>
</td>
<td class="nump">$ 6,787,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.52<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 14.50<span></span>
</td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">877,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
<td class="nump">2.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 224,000<span></span>
</td>
<td class="nump">$ 207,000<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302973884552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions  - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
<td class="nump">$ 2,965,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Long-term other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,672,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_InvestmentOwnedAdditionalSharesAcquired', window );">Investment owned, additional shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Payment received for license granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MilestoneBasedOwnershipTarget', window );">Milestone-based ownership target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">727,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable and accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Long-term other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">$ 368,000<span></span>
</td>
<td class="nump">691,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_InvestmentOwnedAdditionalSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Additional Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_InvestmentOwnedAdditionalSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MilestoneBasedOwnershipTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone-Based Ownership Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MilestoneBasedOwnershipTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302969222328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost | $</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302972356856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 1,956,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">3,968,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,951,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">29,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(8,482,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">21,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,200,459)<span></span>
</td>
<td class="num">$ (2,074,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 19,261,354<span></span>
</td>
<td class="nump">$ 20,409,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302958772488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 11, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th">
<div>Aug. 07, 2015 </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
<td class="nump">$ 2,965,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,330,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,330,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,330,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,065,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod', window );">Territory expansion option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds received in upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Foreign corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Foreign non-corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones', window );">Anticipated development and regulatory event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones', window );">Anticipated commercial event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfAdditionalProducts', window );">Number of additional products to be developed | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever And MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence [Member] | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence [Member] | Collaborative Arrangement, Product | CELLECTRA 2000 Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Territory Expansion Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementTerritoryExpansionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfAdditionalProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Additional Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfAdditionalProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302966939256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901,757)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(901,757)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,717,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,717,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,717,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(902,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(819,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">819,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302972410888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed Assets, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,323,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,323,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,773,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,969,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,121,075)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapitalExcludingCash', window );">Working capital (excluding cash)</a></td>
<td class="num">$ (59,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note Payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed Assets, net of accumulated depreciation</a></td>
<td class="num">(16,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="nump">3,181,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedInterestFairValueDisclosure', window );">Fair value of investment in Geneos retained</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapitalExcludingCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital, Excluding Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapitalExcludingCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInterestFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInterestFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302966932664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Investment In Geneos (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 2,717,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302965701608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details) - Geneos Therapeutics, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityMethodInvestmentEnterpriseValue', window );">Enterprise value</a></td>
<td class="nump">$ 4,966,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Measurement input, expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AlternativeInvestmentMeasurementInputTerm', window );">Equity method investment, measurement input, expected term</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Measurement input, price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Measurement input, risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.0246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AlternativeInvestmentMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AlternativeInvestmentMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentEnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentEnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140302966319848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 02, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,546,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,738,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds | Convertible Debt | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&<"W)@_;?H<3)7;YSME**"7B_'#+6<"E?@#NKX50IQ/]@F+S=?0?4$L#!!0
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M%P^G&G/GQV:?_]^SGY'!CXG .WM\Q-X7N[?ESC8W$5OIT5;:V4I';/V[<J:
M,G*PB&7*8;SLQK>U;'_/I**9NIWN3P,0PB@74O%SV R!"9VFDI[CYLBL6@JA
M]!%WYJXXNBNBU/7+HWPF]MM+NYBB),JC51DE\8MMK*F7&V+*%92^/=3TEW9%
M8G0>+(E3QQA74BCA$8H!TTPR*3U*0V!*TTPIZ7$_1X R4Y(*@9.JCNZKJ/L_
MVQ)8+3KOS0HJ7]ZXEN6]Q0A0P5-0FB@J:.(1$ )%)A*:>*DR0PQF@NI,II[_
M")!E3% VDE39T?_L@C54!:F%>9\%S\!YFF9)YH<_!+*,<\FEM_!F(5 F2:(D
M\X#S$"BT2H""%'=?']W74??_534-6=?5]HT"V'PPUW4P_Q7G%%S7F><[@H1
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MVWW=6 ,+O07 [^NJ<F\7[03'?X*X_Q]02P,$%     @ ]GT*4=YY?26N P
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MG^_ C_N4) BA4KJ'Y*B0:NU.43-$.*&*D4!8PF*7>(&C08$4BV --&[E8':
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MW^!YD"470;9MVFH]# 8-UGG9OZ8O@R,.!L \^  V#&#C :%C !\&\','A,.
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MIH=?:#W$%!?(G6Y("!>'3*77'1&-"5A)A8/3"(.MPH^MGY=+E?7!_I+U5_]
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MMRN5+E2M!>#W90649/B@%]C_[\35_P%02P,$%     @ ]GT*44&4&608"
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M?C9?O)R<8;S#&1/^?#9_,9\LND=/;IC<WJG9 3'+[63'^W,>D\DKF:QUD(R
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M5_(2M,""3"(1A<O4W0)NWHQPN_/W"T4.8P<6W%@ <ANGNR!6@=;FW;WN"+8
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MBN9]$Q$G#?U3*L??-_&AVB/'\<S?EK=+U6*_QB]Y71YT0E?7TTB.%-5UL=+
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M,%4TEN"/,%+Y=A9QWS<V-:@#H\+?G:W[Q"T[?4W#$E#O%XFBXO=BUI!@GZ1
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M!D-8H_8#G/((BG);,'>;*/F$5%!B-!-B!X:D)N>$Z%J#/(SB/5W5ALO=-:2
M]XF C HW?*YAPH.91.U5^,EKR+"1MAU/O;0?[HMVICVJMR_#-=,%)[("<S*-
MAB?' >AVVK8;JVH_X3;*4B_[94D/%&JG0.>Y4G:_<0[Z)V_^&U!+ P04
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M#$W ^$R#VZL&;;!]\KS_ U!+ P04    " #V?0I1-X<:,C(*  #W'@  &0
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M?Z BN&B\',V]CT:FRJG)4ITQ'IGG+7DTM'39*3(BFUHKJQBKZK9V19A"4\T
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M^L^!LQ8=2O"'@5E#<?4A:%9?U/?"LH;UF:Q&T]\9RIHO$BYH+,(2"//!",Y
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M[6;H:K+ED$RRJCW%G.S2'@+B><,;2<PAP;D=.3,+]#TBD^1 =D(%&UEQ!\/
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M6EJ ]W.#G&INB$'[%=FK?P-02P,$%     @ ]GT*47+]K(0>!P  IQ$  !D
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M/7R+:4CS!, ^K%J/F[S/CLE$X%8)=QQ8&!PH8[NC$&>FHYFT@9*6)P?(I)D
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M]E$#/JQ&OT].ZSK5_<FT8[DWD&OKE:[GV$%_0'!R&G6Z$)M33(I%/]S$!E=
M&K<$T3!A:.B^'QE]/7-^GC>$9UQF=KIT)8<P1D-6VMA%5-BZYZA]0'MP%$"M
MIB'4Y(R1:?B:/,C40MG0UG:=(-AN]PMC6>YM'Q%\*<T<:*Q%8P7H<&!T-ZB#
MZX8*LBU#!RV'=<,+[)$Y>T4%S]940P,N77D\5!F7_+6LW/%%5S5X)/"%]$/=
MU+^Z^>VLUF* Z%P-1'(O11:A3*H/PB3<J=^N>O.AZP]7WG\=C"1W2&L09',*
M;K;V+AV"<6:D^/<+*U5).@?9FNM<(FLK'"@A%@$HCX3!_*,];(M'/B)4?D3
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MG_]Q>7Y^]C6]]?W5U0?Z>_;U268<$M>!8>!Y.EC.6T]@M DWG:D+TQ8N>]7
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MXQ]-FZ^RV3ESE^5C8*VZ$=I78,/(58'<P?X"&]IFG3!IE"^D-/ ?9!UK8]$
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M_*C #QJ+'"5- USK9_)1S_BPJ1\%EDA=T!<O^7$)9KF[!?$^O#2@7G/8; *
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M[1S(OE'*'A678/@H+O\'4$L#!!0    ( /9]"E'Y-X&H3P0  +P,   9
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M7#L!W"\4@KW=N >&@7SV+U!+ P04    " #V?0I19V!8^JL"   !!@  &0
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MHXD4E@7] M#X -I?:>VVAD_0_53F_P!02P,$%     @ ]GT*4>WBYA;I P
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MM(=P0,,V0.XY0!8,/C\-P-FO*I:^GN5J.6L#"S:Q#/0L]R0S8;G1LWQ<IFV
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MJ]]VK$X$6Q0ORY^9$"PI#N>43&B6&\COIXR)]4G^_GWS"YO>_U!+ P04
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M._"N%ERI]O>J+_Q.A^\W[!0%WBOD>[[7LI_)H^%XT";G:>RS_V8_"D90'8'
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MVW*X#L^:;9C(\181@-7#.^7S<[COIH0';/:&-ML>\-/#^=EO$ZR=IZC(L:W
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M)ITZ8X?$D+!"F!NY^PRUH8'EBZ30Y3_956M'&#$JM)%9#<9^QO/JR>[K1+0
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MAPO=$H,P!OK]G'.UF9@ 59/=_P=02P,$%     @ ]GT*4;M_.%<5"@  W4$
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MAL.^XS!59RT[6KG0-4\HTCA"=AR9JA-U"61WU 1")PG46YVHAT!61TT@=))
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M3WPQ/X>_F6)-4'P5@A)-4/(-"$JZ!$7FVB.:H&0804F7H#@R^VF DF$ )5V
MVOPT/\DP?I(N/VU^K7]E#<,GZ=D^NL0R@YJ>9" ]29>>'@P"LZ6&)_DV\#P1
MQ@C/@;KYY;KC!&AXDO\)GB=\>N!9CW0@=)W628$Z.7J,^8L<!TCI1@9RQX%<
M,_QP&'-H"+:K#@^63 B659=;&DM8J0?D]QLF7Z/KACJ/:([$9O\ 4$L#!!0
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M.ZTZJ^0GDMJ\$DAP$:DSJK/:H<EL^.ZL=X0$X3OJ?J,%L/W7=RJ7+%.(P\*
M<+MOT+)L:<J)%KGK"IZ$-CV&&R:F#01I \SSA1#Z;6(;C;JQG/P%4$L#!!0
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M_^ SG#@NQD'8,D.5(E.[(O^L[3LK_00':CTD?DN M;,6N_SVVK\S>JJZF.#
M1J)*?:E=?>?0^L%274'=Y2LN)<S+O*.GH95\4N\%=BVMY(_:Y<_6TRSR=[H'
M_TZ/)K![-*VCVIFN^2O"!R;7$7Q[QWP%(&<8 %H6!_/%C1;;_)CW3F@MDOQR
MP]F22S, WJ^$T(\WYN1X_^>1Z?]02P,$%     @ ]GT*468"JI]*!   $A4
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M42*:D%10E@).%I>=*W@Q<S.&C.)W2G:B=@VT*?>,/>B;S]%EQ]$:D9C,I8;
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MQ"X\:L?R"RQ43NOH&%3XAFK-WD2MYD)40PFR?S$(Z99&1)6^/26QZ=OLY 3
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M]31UF<1JSQZJD[3:-=XL[^R^.LZ$R3P_OQ:%#Z68-NG&;K+2;2%66S<+Z)B
M.LMM'G>&@+[=)PWUM=AZDO@VFNOO4ES+<8XV:6G@ "S746Y4R-4>=>'V9PNT
MHCFJI[DK/N$B&TOS 01-%K&OFMO'];FU;&=@B,W'B;8#;.?]<G77*SJC>CI[
M^V,Z6K$;?2]VHQ6[43U-?2XG'\4Q:BJ4; HOO%X-=H]<</JY^PG@.I3^UNO
MB*NI+'LOGJ)\:ZR?$Y=WRW?OY_D;R)W[%_CX&@/W;_#Q+73_#A\/H?OW^/AA
M_2:^<F?]PX"1&AH#E:603Y1KQI&M:DBLW[6O+V0RSU]>CA,IDRC_../,YR(3
M4-]/DD1N+C(#Y2\>SOX'4$L#!!0    ( /9]"E&F7ZHG9@,  * ,   9
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MY&2%JU*_%]N?29-08OF6HE3N$[:U;1Q[L*R4%JP!FP@8Y?4W?FZ$. "$R0E
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M#UVHT&X"/-\J95\'KL_I^MK5?U!+ P04    " #V?0I1]E&7*!4)  "+-@
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M!B]H1Z]!_)@4*A@FU AAUQ7_^MK]T+*R1A-HAY-!'"<JZD@J][.$4" 8>*"
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M0W!(N#90[U>,R<.-/E'+CZ8G_P-02P,$%     @ ]GT*496DFS?+ P  _ T
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MFUD3"Z6P)F6N/O/]S] (J@@F/)?5+]K7ME%@H:24BA<-6#,H**O_R7.S$$<
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MSU >J*?SA3R1YC_9%K']P"+A6BJ>EF!DD,99\66/I1 U .TV -P2X+X4X)4
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MA(]T$#H ]Y><J]U$O^JJ9__X'U!+ P04    " #V?0I12.R8AL8"  !O"
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MO@C N 4T/],:7SOND6J_,:9_ 5!+ P04    " #V?0I13PNSX=,#   >$
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MDRMH;@K_R[38W:!'LF"X[*G""W9:M(R</+H [: 0^,V94A7(48AOLI0Z!Q%
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MGKO15T86^Q?1]B_1??D;4$L#!!0    ( /9]"E&8&UJ>^P$  ,LC   :
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MWNU/ZEVFST,NUYZO-5[_)ZF>SN?FZ^4ORZ^=>+]H+S@G^'?G\2]02P,$%
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ]GT*49E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #V?0I1]3MK%6P%  "(%0  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ]GT*47U4FA;T!P  =",  !@
M             ("!L T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( /9]"E%]^V8HZ0<  ! A   8              " @=H5  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #V?0I1WGE]):X#  !W
M"P  &               @('Y'0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ ]GT*4< >"AS5"@  \$   !@              ("!W2$
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /9]"E&W90^-
M.0L  $<Q   8              " @>@L  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #V?0I109099!@(  "E$0  &
M@(%7.   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ]GT*
M4<2;YJ-L#   $B(  !@              ("!I4   'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( /9]"E&GE6!C[A<  $1*   8
M      " @4=-  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /9]"E'K  6&K00  )H+   9              "
M@<.#  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ]GT*
M49,MS:U-$@  DD0  !D              ("!IX@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #V?0I1-EXYGLL(  "V&@  &0
M        @($KFP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( /9]"E&]%&SM: 0   H*   9              " @2VD  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ]GT*4;L7#D8R!@  3Q0
M !D              ("!S*@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #V?0I18.JE\C0,  !1)@  &0              @($UKP
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /9]"E%R_:R$
M'@<  *<1   9              " @:"[  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ ]GT*40!G31#]$0  :#@  !D
M ("!]<(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #V
M?0I1BI^UZ$D%  !Z"P  &0              @($IU0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /9]"E$"IW4X&@T  %PE   9
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M970R-RYX;6Q02P$"% ,4    " #V?0I11)]44CT$  "["0  &0
M    @('I& $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M /9]"E%!O_&XA@0  )P+   9              " @5T= 0!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ ]GT*46=@6/JK @   08  !D
M             ("!&B(! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #V?0I1$;)_A$P#  # !@  &0              @('\) $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /9]"E%S8.@4QP(
M .H%   9              " @7\H 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ ]GT*44D".?_H @  8 8  !D              ("!
M?2L! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #V?0I1
M[>+F%ND#  !1"   &0              @(&<+@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( /9]"E'[<7\?0P8  &TC   9
M      " @;PR 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ ]GT*40&S<^*4 @  F0<  !D              ("!-CD! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #V?0I1NH)@QV #   =#
M&0              @($!/ $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( /9]"E%V5D:71P,  )X*   9              " @9@_ 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ]GT*42-R;"@;
M!   >!   !D              ("!%D,! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #V?0I1QVVT02P'    ,0  &0
M@(%H1P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /9]
M"E&"8QE:U@(  ,\(   9              " @<M. 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ ]GT*41KI_>Z8 @  V@4  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( /9]"E$>AA/#X00  !X;   9
M  " @:QK 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M]GT*471X (WS @  9 H  !D              ("!Q' ! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #V?0I1%G(P2H,%   J&0  &0
M            @('N<P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( /9]"E%F JJ?2@0  !(5   9              " @:AY 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ]GT*4=[$Z]C=!0
M1AP  !D              ("!*7X! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " #V?0I1Q"/8YL,&  #](   &0              @($]
MA $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /9]"E&F
M7ZHG9@,  * ,   9              " @3>+ 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ ]GT*45D:UG9E P  XPH  !D
M     ("!U(X! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /9]"E%([)B&Q@(  &\(   9              "
M@3RH 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ ]GT*
M44\+L^'3 P  'A   !D              ("!.:L! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " #V?0I1^..>RW@"   \#@  #0
M        @ %#KP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /9]"E&7BKL<
MP    !,"   +              "  >:Q 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( /9]"E&2-9.CX00  ,@G   /              "  <^R 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #V?0I1F!M:GOL!  #+(P  &@
M    @ '=MP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #V?0I1=-+&8MX!  !:(P  $P              @ $0N@$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     1 !$ ),2   ?O $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>341</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Impact of Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards</Role>
      <ShortName>Impact of Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShortTermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisOfPresentationPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Critical Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPoliciesDetails</Role>
      <ShortName>Critical Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Short-term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails</Role>
      <ShortName>Convertible Debt - Balance of Convertible Bonds and Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2418401 - Disclosure - Related Party Transactions  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420401 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Investment In Geneos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-6302010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2423401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ino-6302010q.htm">ino-6302010q.htm</File>
    <File>a200618dodnatickawarde.htm</File>
    <File>a200622dodnatickotaagr.htm</File>
    <File>ino-20200630.xsd</File>
    <File>ino-20200630_cal.xml</File>
    <File>ino-20200630_def.xml</File>
    <File>ino-20200630_lab.xml</File>
    <File>ino-20200630_pre.xml</File>
    <File>ino-63020x10qex311.htm</File>
    <File>ino-63020x10qex312.htm</File>
    <File>ino-63020x10qex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>inoviologosw.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-6302010q.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 341,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-6302010q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 552,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 30,
    "http://www.inovio.com/20200630": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 40
   },
   "keyCustom": 66,
   "keyStandard": 342,
   "memberCustom": 37,
   "memberStandard": 37,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Impact of Recently Issued Accounting Standards",
     "role": "http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards",
     "shortName": "Impact of Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Revenue Recognition",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Short-term Investments",
     "role": "http://www.inovio.com/role/ShortTermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Fair Value Measurements",
     "role": "http://www.inovio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Net Loss Per Share",
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Leases",
     "role": "http://www.inovio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121100 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123100 - Disclosure - Subsequent Events",
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.inovio.com/role/BasisOfPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.inovio.com/role/ShortTermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Leases (Tables)",
     "role": "http://www.inovio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.inovio.com/role/BasisOfPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Critical Accounting Policies (Details)",
     "role": "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
     "shortName": "Critical Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Short-term Investments - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails",
     "shortName": "Short-term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails",
     "shortName": "Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails",
     "shortName": "Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
     "shortName": "Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member",
      "decimals": "0",
      "lang": null,
      "name": "ino:DebtinstrumentAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.inovio.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418401 - Disclosure - Related Party Transactions  - Narrative (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions  - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2019Q4_srt_CounterpartyNameAxis_ino_PlumblineLifeSciencesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.inovio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419403 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)",
     "role": "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420401 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember",
      "decimals": null,
      "lang": "en-US",
      "name": "ino:CollaborationAgreementTerritoryExpansionOptionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "I2019Q1_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
     "shortName": "Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member",
      "decimals": "0",
      "lang": null,
      "name": "ino:WorkingCapitalExcludingCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
     "shortName": "Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
     "shortName": "Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "I2020Q1June01_srt_CounterpartyNameAxis_ino_GeneosTherapeuticsInc.Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "D2020Q2Aug1toAug10_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423401 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "D2020Q2Aug1toAug10_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Operations",
     "role": "http://www.inovio.com/role/OrganizationAndOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Basis of Presentation",
     "role": "http://www.inovio.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Critical Accounting Policies",
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "shortName": "Critical Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-6302010q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 81,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "6.50% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AfterJanuary22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "After January 2, 2020 Conversion Price [Member]",
        "label": "After January 2, 2020 Conversion Price [Member]",
        "terseLabel": "After January 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJanuary22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AfterJuly22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "After July 2, 2020 Conversion Price [Member]",
        "label": "After July 2, 2020 Conversion Price [Member]",
        "terseLabel": "After July 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJuly22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AlternativeInvestmentMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alternative Investment, Measurement Input, Term",
        "label": "Alternative Investment, Measurement Input, Term",
        "terseLabel": "Equity method investment, measurement input, expected term"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInputTerm",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Convertible Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA2000DeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CELLECTRA 2000 Device [Member]",
        "label": "CELLECTRA 2000 Device [Member]",
        "terseLabel": "CELLECTRA 2000 Device"
       }
      }
     },
     "localname": "CELLECTRA2000DeviceMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entities",
        "verboseLabel": "Gain (loss) on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated commercial event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated development and regulatory event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborationAgreementTerritoryExpansionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Territory Expansion Option Period",
        "label": "Collaboration Agreement, Territory Expansion Option Period",
        "terseLabel": "Territory expansion option period"
       }
      }
     },
     "localname": "CollaborationAgreementTerritoryExpansionOptionPeriod",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAdvisoryFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Advisory Fees",
        "label": "Collaborative Agreement, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "CollaborativeAgreementAdvisoryFees",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementCorporateIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Corporate Income Tax",
        "label": "Collaborative Agreement, Corporate Income Tax",
        "terseLabel": "Foreign corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementCorporateIncomeTax",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementForeignNonIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Income Taxes",
        "label": "Collaborative Agreement, Foreign Non-Income Taxes",
        "terseLabel": "Foreign non-corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementForeignNonIncomeTaxes",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "verboseLabel": "Funding received for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Contract With Customer, Liability, Affiliated Entity, Current",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAffiliatedEntityCurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible Bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccretionOfPremium": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Accretion Of Premium",
        "label": "Debt Instrument, Accretion Of Premium",
        "terseLabel": "Accretion of premium associated with the Bonds"
       }
      }
     },
     "localname": "DebtInstrumentAccretionOfPremium",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleInternalRateOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Internal Rate Of Return",
        "label": "Debt Instrument, Convertible, Internal Rate Of Return",
        "terseLabel": "Debt instrument, convertible, internal rate of return"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleInternalRateOfReturn",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Required Bondholder Approval, Percentage",
        "label": "Debt Instrument, Convertible, Required Bondholder Approval, Percentage",
        "terseLabel": "Debt instrument, convertible, required bondholder approval, percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRequiredBondholderApprovalPercentage",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual maturity (less than)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DebtinstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument, Accrued Interest",
        "label": "Debt instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtinstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Convertible Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "label": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "terseLabel": "Grant funding liability from affiliated entity, net of current portion"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateNoncurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Department Of Defence [Member]",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department Of Defence [Member]"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EquityMethodInvestmentEnterpriseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Enterprise Value",
        "label": "Equity Method Investment, Enterprise Value",
        "verboseLabel": "Enterprise value"
       }
      }
     },
     "localname": "EquityMethodInvestmentEnterpriseValue",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Estimated aggregate amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneOneLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GeneOne Life Sciences [Member]",
        "label": "GeneOne Life Sciences [Member]",
        "terseLabel": "GeneOne Life Sciences"
       }
      }
     },
     "localname": "GeneOneLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, net book value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Policy [Policy Text Block]",
        "label": "Grant Policy [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantPolicyPolicyTextBlock",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "INO-4800 [Member]",
        "label": "INO-4800 [Member]",
        "terseLabel": "INO-4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.",
        "label": "Increase Decrease in Deferred Revenue From Related Parties",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParties",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.",
        "label": "Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "negatedLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_InovioAsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inovio AS.",
        "label": "Inovio As [Member]",
        "verboseLabel": "Inovio AS"
       }
      }
     },
     "localname": "InovioAsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Income Accrued On Short Term Investments Certificates Of Deposit",
        "label": "Interest Income Accrued On Short Term Investments Certificates Of Deposit",
        "terseLabel": "Amortization of premiums on investments"
       }
      }
     },
     "localname": "InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InvestmentOwnedAdditionalSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment Owned, Additional Shares Acquired",
        "label": "Investment Owned, Additional Shares Acquired",
        "terseLabel": "Investment owned, additional shares acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedAdditionalSharesAcquired",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever And MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Area leased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements with affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable securities and fair value measurements.",
        "label": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]",
        "verboseLabel": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAndFairValueMeasurementsTextualAbstract",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_MilestoneBasedOwnershipTarget": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone-Based Ownership Target",
        "label": "Milestone-Based Ownership Target",
        "terseLabel": "Milestone-based ownership target"
       }
      }
     },
     "localname": "MilestoneBasedOwnershipTarget",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Sales Agreement [Member]",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Cash Interest Expense",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfAdditionalProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Additional Products",
        "label": "Number Of Additional Products",
        "terseLabel": "Number of additional products to be developed"
       }
      }
     },
     "localname": "NumberOfAdditionalProducts",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "terseLabel": "Number of potential shares authorized for issuance under share based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLeaseNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Non-Cash Lease Expense",
        "label": "Operating Lease, Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNonCashLeaseExpense",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OtherCounterpartyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Counterparty [Member]",
        "label": "Other Counterparty [Member]",
        "terseLabel": "Other Counterparty"
       }
      }
     },
     "localname": "OtherCounterpartyMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PriorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prior Sales Agreement [Member]",
        "label": "Prior Sales Agreement [Member]",
        "verboseLabel": "Prior Sales Agreement"
       }
      }
     },
     "localname": "PriorSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ProceedsFromCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Collaborative Agreement",
        "label": "Proceeds From Collaborative Agreement",
        "terseLabel": "Proceeds received in upfront payment"
       }
      }
     },
     "localname": "ProceedsFromCollaborativeAgreement",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RelatedPartyTransactionsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transactions.",
        "label": "Related Party Transactions (Textual) [Abstract]",
        "verboseLabel": "Related-Party Transactions (Textual) [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsTextualAbstract",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "label": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "terseLabel": "SARS-CoV-2/COVID-19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Agreements [Member]",
        "label": "Sales Agreements [Member]",
        "terseLabel": "Sales Agreements"
       }
      }
     },
     "localname": "SalesAgreementsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "San Diego Office [Member]",
        "label": "San Diego Office [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoOfficeMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment  award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "terseLabel": "Maximum contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Stock sale agreement weighted average price per share"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementAgentFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sales Agreement, Agent Fee",
        "label": "Stock Sales Agreement, Agent Fee",
        "terseLabel": "Agent fee"
       }
      }
     },
     "localname": "StockSalesAgreementAgentFee",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Maximum authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments",
        "label": "Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments",
        "terseLabel": "Tax benefit from other unrealized gains on short-term investments"
       }
      }
     },
     "localname": "TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_VGXAnimalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VGX Animal Health, Inc [Member]",
        "label": "VGX Animal Health, Inc [Member]",
        "terseLabel": "VGX Animal Health, Inc"
       }
      }
     },
     "localname": "VGXAnimalHealthIncMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_VgxPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VGX pharmaceuticals.",
        "label": "VGX Pharmaceuticals [Member]",
        "verboseLabel": "VGX"
       }
      }
     },
     "localname": "VgxPharmaceuticalsMember",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_WorkingCapitalExcludingCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Working Capital, Excluding Cash",
        "label": "Working Capital, Excluding Cash",
        "negatedTerseLabel": "Working capital (excluding cash)"
       }
      }
     },
     "localname": "WorkingCapitalExcludingCash",
     "nsuri": "http://www.inovio.com/20200630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r300",
      "r302",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r487",
      "r553",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r300",
      "r302",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r487",
      "r553",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r273",
      "r277",
      "r488",
      "r552",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r273",
      "r277",
      "r488",
      "r552",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r289",
      "r300",
      "r302",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r487",
      "r553",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r289",
      "r300",
      "r302",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r487",
      "r553",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r167",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r463",
      "r465",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r15",
      "r98",
      "r448",
      "r451",
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r39",
      "r103",
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r47",
      "r48",
      "r49",
      "r537",
      "r563",
      "r567"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r107",
      "r108",
      "r109",
      "r381",
      "r558",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r332"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of issuance of convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r303",
      "r305",
      "r335",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r305",
      "r320",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Equity method investment, measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r84",
      "r215",
      "r222"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense on intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r152",
      "r156",
      "r162",
      "r188",
      "r375",
      "r386",
      "r414",
      "r511",
      "r535"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41",
      "r96",
      "r188",
      "r375",
      "r386",
      "r414"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r173",
      "r203"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r171",
      "r174",
      "r203",
      "r518"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Market Value",
        "verboseLabel": "Debt securities, available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r307",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r299",
      "r301",
      "r360",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r106",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r532",
      "r573",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Banking Regulation, Total Capital, Actual",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r86",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r419"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (Decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "terseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r94",
      "r96",
      "r129",
      "r130",
      "r131",
      "r133",
      "r135",
      "r142",
      "r143",
      "r144",
      "r188",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "verboseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r363",
      "r364",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Product"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, other shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r61",
      "r525",
      "r549"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r54",
      "r60",
      "r371",
      "r372",
      "r392",
      "r524",
      "r548"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r54",
      "r59",
      "r370",
      "r392",
      "r523",
      "r547"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r92",
      "r385",
      "r388",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities (VIE)"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r274"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r274"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r11",
      "r513",
      "r536"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r290",
      "r298",
      "r568"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r512",
      "r513",
      "r533"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Debt instrument, convertible, carrying amount of equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r33",
      "r244",
      "r247",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r430",
      "r432"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r32",
      "r236",
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r101",
      "r244",
      "r248",
      "r249",
      "r250",
      "r429",
      "r430",
      "r432",
      "r531"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r429",
      "r432"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r179",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "Gain on deconsolidation of Geneos",
        "terseLabel": "Gain on deconsolidation of Geneos",
        "verboseLabel": "Gain on deconsolidation of investment"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r27",
      "r431"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r84",
      "r226"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r42",
      "r43",
      "r411"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Derivative liability",
        "terseLabel": "Derivative liability",
        "verboseLabel": "Derivative liability (Note 9)"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r104",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r273",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r103",
      "r448",
      "r519",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r103",
      "r448",
      "r520",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount payable to related parties classified as other.",
        "label": "Due to Other Related Parties",
        "terseLabel": "Accounts payable and accrued liability"
       }
      }
     },
     "localname": "DueToOtherRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r28",
      "r103",
      "r448"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r103",
      "r448",
      "r520",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accounts payable/accrued liabilities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r114",
      "r123",
      "r125",
      "r141",
      "r193",
      "r243",
      "r251",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r26",
      "r153",
      "r186"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Geneos",
        "verboseLabel": "Investment in equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "verboseLabel": "Investment in affiliated entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r185",
      "r550"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale equity securities",
        "verboseLabel": "Net unrealized gain (loss) on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net unrealized loss on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.",
        "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule Of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r400",
      "r412",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r401",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r400",
      "r401",
      "r403",
      "r404",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r290",
      "r291",
      "r296",
      "r298",
      "r401",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r290",
      "r291",
      "r296",
      "r298",
      "r401",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r401",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r405",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of the Company's Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r407",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense for 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated aggregate amortization expense for remainder of 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Estimated aggregate amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Estimated aggregate amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Estimated aggregate amortization expense for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r221",
      "r224",
      "r489",
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r221",
      "r496"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r221",
      "r489"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net book value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r66",
      "r84",
      "r172"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r209",
      "r210",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r213",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r102",
      "r152",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income tax benefit and share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r57",
      "r84",
      "r150",
      "r186",
      "r521",
      "r545"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share of net loss in Geneos",
        "terseLabel": "Share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r353",
      "r355",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r124",
      "r125",
      "r151",
      "r341",
      "r354",
      "r356",
      "r551"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r214",
      "r219"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r56",
      "r149",
      "r428",
      "r431",
      "r526"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r67",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, contractual interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r81",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r569",
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of affiliates held for management investment companies.",
        "label": "Investments in and Advances to Affiliates, Balance, Shares",
        "verboseLabel": "Number of shares held in an affiliated entity (in shares)"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r509",
      "r528",
      "r572"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r441",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r96",
      "r157",
      "r188",
      "r376",
      "r386",
      "r387",
      "r414"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r96",
      "r188",
      "r414",
      "r515",
      "r540"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r96",
      "r188",
      "r376",
      "r386",
      "r387",
      "r414"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r234",
      "r513",
      "r536"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleBondsAndNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r105",
      "r229"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r105",
      "r229"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r105",
      "r229"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r105",
      "r229"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement input, expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Measurement input, price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement input, risk free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r40",
      "r96",
      "r188",
      "r414",
      "r514",
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Carrying value of noncontrolling interest",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r251",
      "r373",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Cost of acquisition of non-controlling interest in Geneos"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r40",
      "r64",
      "r369",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/OrganizationAndOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r51",
      "r53",
      "r58",
      "r85",
      "r96",
      "r113",
      "r119",
      "r120",
      "r121",
      "r122",
      "r124",
      "r125",
      "r132",
      "r152",
      "r155",
      "r158",
      "r161",
      "r163",
      "r188",
      "r414",
      "r522",
      "r546"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r53",
      "r124",
      "r125",
      "r378",
      "r391"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r115",
      "r116",
      "r126",
      "r127",
      "r128",
      "r194",
      "r195",
      "r284",
      "r285",
      "r286",
      "r287",
      "r331",
      "r350",
      "r351",
      "r352",
      "r493",
      "r494",
      "r495",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ImpactOfRecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r110",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r121",
      "r139",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r490",
      "r491",
      "r492",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r252",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Deconsolidation of Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r252",
      "r373",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r251",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r11",
      "r513",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r152",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r440",
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r439",
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Long-term other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r45",
      "r47"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r307",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of convertible senior notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "verboseLabel": "Payment received for license granted"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from Geneos issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r323"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Miscellaneous revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r51",
      "r53",
      "r78",
      "r96",
      "r113",
      "r124",
      "r125",
      "r152",
      "r155",
      "r158",
      "r161",
      "r163",
      "r188",
      "r370",
      "r377",
      "r379",
      "r391",
      "r392",
      "r414",
      "r527"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net loss attributable to common stockholders",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r227",
      "r542"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "negatedTerseLabel": "Fixed Assets, net of accumulated depreciation",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r297",
      "r447",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r297",
      "r447",
      "r451",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r445",
      "r446",
      "r448",
      "r452",
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r338",
      "r583"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r92",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r251",
      "r332",
      "r538",
      "r562",
      "r567"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "netLabel": "Accumulated deficit",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r114",
      "r123",
      "r125",
      "r193",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r558",
      "r560"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedInterestFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.",
        "label": "Retained Interest, Fair Value Disclosure",
        "terseLabel": "Fair value of investment in Geneos retained"
       }
      }
     },
     "localname": "RetainedInterestFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r166",
      "r272",
      "r273",
      "r488"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from related parties",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r276",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r438",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r216",
      "r220",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Intangible Assets by Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r99",
      "r449",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r307",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r94",
      "r142",
      "r143",
      "r239",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r304",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r315",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r9",
      "r516",
      "r517",
      "r534"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Critical Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r94",
      "r96",
      "r129",
      "r130",
      "r131",
      "r133",
      "r135",
      "r142",
      "r143",
      "r144",
      "r188",
      "r243",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryOfAuthorizedAndIssuedCommonAndPreferredStockDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r107",
      "r108",
      "r109",
      "r114",
      "r123",
      "r125",
      "r141",
      "r193",
      "r243",
      "r251",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r141",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r243",
      "r244",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r243",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r243",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r243",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r243",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r251",
      "r306",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r20",
      "r21",
      "r96",
      "r170",
      "r188",
      "r414"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r107",
      "r108",
      "r109",
      "r114",
      "r123",
      "r188",
      "r193",
      "r251",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r368",
      "r369",
      "r390",
      "r414",
      "r420",
      "r421",
      "r425",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r251",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r426",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r426",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r426",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r426",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisOfPresentationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r586": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r587": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r588": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r589": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001055726-20-000048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-20-000048-xbrl.zip
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M/2'.MBRDE"7PZ_M+J?"6/J6"&3Z5S*2D _7YM(;,\;=M*DUZ2ENU!$1X:;+
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M3,:C\?%"3GED=&LY-R"C9M:8(N=\<!?D_M8&/KWQ,N1GL9"U'= 20) QH5I
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M1;+O/3NF+DC9=Y'*?E5!2\O91 ?B>8G;EZ[.[,0+O5JJRHG_E.,F7B@?MNL
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MTDY;P5K#I->JWK@]'/NNK( G?X_IS+&#AZUV/_M>)%DG^ ?"WV;YY"RI&//
M9_.I^Q"VOT0)BL7L-Q86D+,2$!RK^9",D8U</\!$<E[PN!"EC],IO6'5@I[H
M_\'4'7NX8)-_@,MY<&]8G<L$-RQR,8KX5WA%@04>KF%S\#0V;YPUI\ F"YC>
M/F<'@!7P%FS1\G[P5\T?V!$7HKI"+" ):S]W%RRB@C86/#5QD,O)YLS;9F.0
M3R1=CW@A///1\4))>.L)5!KG?I,G)E%FUV\B.']I-2DV%_3K\,Q2"C;OP\>;
MYM!Q*9+@4<$=:VHP8?U$DE>B6K?"QE>Z)T79*7''&/;! ^9?![8C!+I/ U'U
M\CS>W6Q6S"E*0VJ9C;(DUZ6*6:G65*/,*^:J2K59;[V%BKG,$?.K+^#-FPU7
M2XK[6L\N9DQ@TYTXH'V<.?%<AL+[P!PE0YBSU;7(XRZLM]U:&[ID]R;N9L!*
M2DI$FTGM;'@>N6&M.3I>/1OS[-#5P?V=.4ZLX(2:(9QHBD0O /Y2[2NO:4UF
M@HFT+]X6Q_*P$)>C18%W^8NT&>Q.MD#U90*<@VLE(O$RX:HOL1F9O'+?F[N\
M'QB_,TS'C-X,;W/HN!"A8>)-O.4AUW]BM4@TB8K?S5OBL'X]7C2E-GS<Z):.
M?H1]!+"+)3?XHFYM^ !,FG>297 K@<M$\A"^//OFX*L3@98A(L YW0*"?L0%
M$RZ!(1WA$%=BW5N\LY1%Q@L6? @2=8UQ#SXW"CW%29,>U]U7^.NMY?,.?O?8
M8=-EZ[!91K'UM =OCFWM4S;Y/GANEHHD>Q2+;UGA38QXQ)HQ9B<,N42R+4)[
M9&^JI+6F+B %9]5H\87%#R&O33Y^*=7]Q,MJ7]VA*TO<H7M$SD7#]D:+F<^Z
MZ/J; ":BQ#&CB2B>>B"#J+OPXX^F]A\+>\R#2?@U.GA1<)WYYRS9-7[N^;LO
MP#VM^H/Z"3@FC0GFG[(<BJ42Q+!)#'=)):L,5\H0\Z+#-X>W[R6D'^%^7&V+
M6ABV(W/"/M_+N'YL;G;.E5\?NYLGP)431L'<M7FE #+H=;=_CG\G%ZY\+Z5;
M5SQ*S\SA^4.H)WMH0?$!%*R_VF*.T\G1N!F[H%7#$K@JO+VKVE$4\%XTCM.B
MB<H)\.2V$U!LM9A]!IQ[;))*WG0J_#-B@!'W"*+]S6AR^+#JAA.<)^'JVS""
M(O)D6Z QVK/Y%-WC'$%6G.<X,@3>;F.[2GL<MN-E/XNQ.TH9KN3-.-GB&#-<
MB![OT5.Q\W3L/P_6OH(?8$.V?QMG'_3IR*.!Y47,=^"Q/AHX["1.HH(51-WX
MLX5(5:FL%TC<%3^1-A[ZVN!&EVV!7\1"6=P;%WI^X20+J_L%# 6><W9W'B>7
ML7A70?30P\$4W,W'CC;Q7AY"@3?Y]L_B#!9\&ZX!7C&Q?VXZ? []Q-)L#O\\
MNK9=-7I]QK%ABIGM^PLV]H'.$$]8@P7A\EM15^";Q1QG>=EB7@_<,PS"&5'Y
M (4G:#!YK[)LJO4MUG-T3$>L1&JE7W2R^3%+9PE)9K)T%S++J&("^*6BE&1)
M(O8DSX\\W6K1).R%&%T:$^ AXPN%]X8!/G@]_6G[ >O,C7?,1/9"R#Z7]:7L
M]V=Z=53)4NGH2M'#Q+*GK%U+&/^B(93G'KVSW84_?1""-M:I-K,9AA1L'!F(
M&N:[C5-!Q#<;)'9B@F-H']QCA3*OYF+Z.:B0K.IS!9-O!?<"C1O>8#EL<!_H
MY>RQ44PX1.W/@,JYHK<MPI YO!2 ]1DV3J@7SJ8;N=.I2+!B*1Z'H.H99M\I
M<JE2KA;E\^SK?*^.)W:6^A*V)YM5_WMF7$:(P#2><918B7A2V,:#1%^%B$VM
M:$FB,(RWD.%HY6,_++0A.,?T11-8T0E^_15ON4J@HFA&O5)1%44NMXQ:0Y&-
M"J\2T U);S7>0I7 *\W5V<O:6QVTDX;U=UK^Z_V[]+Y"IH=0<B(7(IMES+U<
MF!1LHR=1^ DG(.S<>^:'Q&+.3[E1=FI&&1,/W!]YX@.4WZ6AE$R[G]@>4&8X
M=&I=Q*_."M^@9_!IY7@!BTU8T7! '. L:@USG%AEZEGS1D?QGM&MY=UL+-L(
MJWEXC7_<@Q*$#W7&EL<#39B(S@85#RGHC0Y+3Q=V\B(Q1D.,!7:=/"?])-B]
MFXR"):8XB41T,;DIK@F+XI0'C?AYKS9I5D4%VIUAOPPK&;GB15+K 2H&?E%>
MY43.UJBB)0R0H[>+E6:AH^V63EFDTR(CCXYQ#IGH.K)4W( V;^[V6D>=K+F]
MEKE&C 0QI+&]# :_XS8%2T F]^X"+HN11A3R+658K&%>[OAZ@NZ1=>6#%6HF
M30O>(!'#Y$.4-=@G:)R(=,<-_M!9AO5.0^[W8O[06E$.U=T6A5M >3%&?RQL
MGTU@)[VH<ITUSV9YVTM5HJL]@DY)F7WUDJBPQ]6_#T>YGNW_8)-37-\OD>LX
MM!+G2_&0S(A-)!:Y.(D"R@+Q$H_ Z-_8FEDW$?? /%%T4<1I/-N3LCPP@&PG
M;I>03,K 5)Q"<K*OY?N;,K[FKO/IA'#HW37F:4:E29-E_ !86N$P:U:^P0J]
M,<<XZM<X*;FE84EXS7,]91W06>J9L@O0JXWR@M#R"?LGK0>"XR9RNU C\8CL
M*RMY;OE.9/YQ K[Y@?63BDRJ2);QB78B0NBS(?6)/%2A)15XNT4NT:;N"(?B
MX+-X^>8BL-?Z*9^8\SXSRM'T<)XXB)VLD8<N9EN_,/WECCHVYCVM-84"79EZ
MZ+5AV<ALEAUR/O%(NMH:$].FG ?>U0F60[%O)V]/YV.3<[K\KK;(N@JGT; V
MF0F?\);VZ_9L!L8_O!U4.1\HAB'GO>O]8*_DBEFL8B6OYODTN$)F6O)Q>VQM
MG*U[OJ@*&HZBES)6/Z(6W(CO*)'^8OAO.HIR;H-P^MG*46Q<^I#RU'L+T[9'
M6&UT$SG:5TC/HQ.6\2%ZVJQ?SW8L.I7R$91Q]0 V'Q6]2Y/'.9\N$CU*J3"F
M_-6UCBSFZ'<=/V )Z*$2#$_Q)]8HV2@BJ;2R+JKL- ,+O;UC]/FY\,\/2ME$
M19\U9B]P,YT'!9+-?I+1@,U-:C$Y:DB7FORC\QD@&VG;V&J6=2U#71O?*=;B
M1PUF63]]O I.S!G9<S 6!%U@8CSO*83O9VGRGG7C6?-;,G8I[[1]@\.2UEKD
M/L2T82W&HD='O/Q??'$4_NZ-,=R8""):@2];/F8&P:(7'NZ>^TT2+6='S!T2
M=S.R[ERT57)K] "&.TN/X3*NL\99T56Q-Q_E#,Q>X9L\[,9#:FL%1;QQ\EIG
MHB@!,DE ^*"(1CAC0WX('XV9)\1G#XMN%<;P"CD4>.V!R&0KB">/X5>>,^0O
MO*AUR601++RE?LOK4B'8=)R%51I<HB-L0KW)]1?1EO T3EC!O=#H\6>0=:RQ
M.CXG;*9:V)1.'+'SY5<E%A2]2D@:AE[\/+$%_WC)FP!0FUKWK(.4S>LT*-\V
MZS*]WOW)GO%!)=,$#HU7O!&X ($5A371FLC#P#Q1E$AKYYP0U3D'V9^#.$=P
M$!SG%SFR8BMR^R C,0*0M45GK8 G"\_AU7C;/54[O$\"^Y$B"]BY$R3H5,R_
MO,?Z-, /OI#5-L.\[>/M@X]6#0%9ZL-M)V'(G@12N8<CU7?+ \:[80# /?^"
M\R8L)F7^C9#KK$PS3^K8 /X9J*6W<#,?IH-Y'S;G/"BG0FL#Q9@]6DPM+^K9
M.$[ZX-]-8VG)4)56336KS9HLJ]6JIM=4GC)J&(VZ\B921C,C '+VL<X^YH>S
MCPM[%DXHPS!)..:C1,R?*"G(4C_*I&*#[4]_SMGT9,%I'M:L8U:LMU%Y6]&H
ML'$K*I9@W&'".0O2^&L)9EP?%E-%X"=[A&H,LC7;B9OD,\Z6JS8'H-$?AZ,1
MG]/&C Z;F0%;+.(ELV27\S'A>P05&L?3_*2C!9MIS/K&P2?>8DI#S3O1@WRI
MG!_]%LFQ+\>EK>8\:#OR>$>TOHS0AB,& AP@90-#0!@FLXX$S-;1BU7&K5F^
M<?]Z2=%DP!/$$G2]885@R/BB!M +WG4ZT;5\'/9U9F.)I@M61#JB7H"AX#"G
M(%K49R+5PO>I\.KDZ\+Q\MP(97,I'>!@P6>BEL-[0.4"#N81I5J(MD:^H[_H
MJ[L03LR^-:'! ]((]W]]SFJ;C7 S-=C,;_;HQ] :_4BNEJA5269;DJ(#D-6R
MOG1J]T"H8/\,I^X]-M7VW(!7R^&#].A!94FJ%4@+@&Z X@K$[[">>HEWA8N1
MEX&"Z2,+,3D/4U%N/!1].3](@Q_X1P@3UA@4A]QC=NF81Q4,!X>'L0[OK)A;
MB'W&RI<&K28=PI$[!%0)D9S\@+Y>A'_\\*A0+BI082+F$SF3SKF+? 06-T@;
M'LW@CJ6/H5?I,SF3SQD[,GS,CF5=PPND:?N8/NU'8U?AIW8X?Y:+RYCO^06R
MR@0OD E>;V*"(6OPN0OKVK$6P:WKP0&.27<(H!-<+7)S^]GB#,O=<>#X%'[*
M(MD+AXB(61+PG7I.8 F89LY5QQW07BU9@*NH@P\,BZ9]H6NRO';02-Q)@ W<
MX2W:^99AO3[WL<);L5/0TD5P6^6<*\>)HR9KNZORW84<&^<<S(BDJCI\5PL?
M$+:I8XK.K3VT0^A:06"-;ME7G*F=Z>?)P02C3)99Y-D#.[,'@A/('NCQ$/%J
MF"F#D?X<V78BV^($D&V;##O%KIRO+5XSE5$9>Y'\P!(C*^+P.^ FZDZK[?)8
M* (E.-.U'A(A/&*-1([ IO 'Z@9Q%@<^P$3]".XE%T(7,*+>0&?F]85Q7B"#
M,-&C+UYQ-NCV^4!Y'TQ$]&Y/Z8TU9?U8O$4XO"52*@K<IQZG5&&PE6LR/*$A
M3/5(AE/<E<&\"4,VC!%3S^?J#3K%P.*;1-G+H!F$DW<I]:.H,E<DPD3GR)/'
ME\=+*D8>Y:X5T*8#N]@,76@/;-K;G>V*=/BSI-VL2N>%%?68J]4W;$-[)#2_
M5X+,4M6%P<B*SRUF20?H::$X>GY$>;0G47L5HVS6%,PG+N#?"Q^;G+R#QI(=
M:C/Z7^$TCF .R;2F6-*"685.+V\M;2"<GL:X'/LUB3-@0]_97K#@%8*!F*/&
MTL2X(8VL%3AKM_]T-AJ-V3K@7D1BK#[^P9(E/'=QP^K._O6O-K_FEU]@Y?;H
M!QFZ/_%&-W)6@R1"G)]1C';:_DP,V<D6__C7O]CJB_<@,V$KL(%__6OHN?<^
M#3^*+=SSR%$.;#S*;AO:(M4E@09/0XQER&>-"^3M0_/VH=ND6LS)@*T!VP *
M JTRRDH]A$7EQLC^.)BEJI^K)<-#6C4\8GYI,;,CH:4+-]NV >SP"!$+A]L2
M;'3XP,R>A0AG+E4K)BX3>3=QX!*4?%3*E\*:?/*RJ';-&B-^=32[.R=M9^1Z
M<]>+(.5AI\6X_&$E;QO!%<X%$?FPR U#4/M);S) RN<-4:8T8 E[X=Q7!LH[
MV^(N7I8(SRPUXQY=O9>6 Z#DYF;?N 3A;+$DOW"A'$6B=6(,:KD>_I3@G&T.
MAU46U%M&/EF54D(_]#, ,VDP/G)^0D#+%_ 2["F,9VV3:(UN9] S&@,R,'N7
M?6)TF@0^:K8'[6ZG3WKFWZ[;/;,)V@II7UY=F)=F9T#Z V-P/3#[I-LCYM_-
MQO6@_<V$7YIFKU\L-KJ7EV:OT38N2'M@PC//_GK=(7)9+J>#G=E,Q%3J55VM
M-!2CIM?*9;.EUC61B%DWU#?2N_/5"2:#?#XS20_6$<4!CZ7++;M@'VEH<M8R
M>N="K_4+82^>5>5C-4E[21LI, 4851[>@CP.B6.BJ'6/MI&YDI2WDGUGQ8OS
M>;OK&6:68XXGR]+,FV%D.'2#0JNL%"6]0*X\E^4DB#[EO2BNT1"I<&R,&?:*
M!@R>\-;2%@L^&''N!: +R^SDOYW]U4!Y)%7/L8$Y+SZMJ@IB2=/FB$9,,-!9
M^<NW=KL0EJ;"&S +8VSQ-OECTEIX(IL&2T,7N"PCRN!CF&=@;@B\2R-G5XMA
MB5R4B"0I15G1SGEQ!"L5'HW ?G.]I=P/!P-*(C,YD1?(3881;H/E:*#Y%U!'
M]-P>Q0MA:4?,&>>?[].:_7U@>Y9\ PS;5<")-6Q/]MQ'T^XK6':8-E0@?9%
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MSL\4G/>!#.<9T#9'N>RAW ;1$F)'*%H $]<PQ<84J;-&CB7O TN46L25)*E
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M)\&5-FSNR2D%+Z*$Y/CY"'[NCZ!+;Y9*RLH?OI0C )\4Z,5MSS\8R2L%U*?
M#.U&C/8!=:GY\LPH25;7TOYR]#Y!]#XA!JQHFW 3[8=O-*"8/K'D_%)J46\X
M65I3\]-"UEQ;>#ETM7^^+V:L;&3&B/#?7>\'5IVSO$9LNCN,E(\$!<0%@]7U
M"7^'Y3?FZG.6"&)_>G@]YET%7)[-IRY/->I11&C62OH5F?=[\^;]/-+MBP6L
M9=[U?9(H&>-PI93T\&UAA=#2- !>0-9C&4HBGD#.FG2$6F5B%+"J@U9)6E'
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M]AWP>8RK5D%PZ[F+FUOVLA*IN\$M&5G.4MH$V 0^DW4A<@N7!"R-+"\M=$H
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MT^3_+LP0;JQFCE<3H,PSH,N8JX^%2]3=S=))!#?<.J,H=L[C*(W2VYF5T._
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MYY^%59=R+/Q 5M6DBN38B\!2#'UD3N9@R^Z:BEM'D[8LLS0G$MPBP801$(I
M9%50"=%;X;-)""HK?(WDX\?IK;/5;FQCP@FPJ8@=#RP>I6B4=%(P?=$CH/Q@
M2B>IEP=GIYZ0;I,?TL636:C!$7F31]*?4EZ)AQ1MO"WP!%";,>Q,@_>3!%BS
MX'XV:D%"SR3.H*!0OJ)*);:&.2(OJ5GC6J6&;QD']AIOSL![B'DIY?BY&$N
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M-U%B_M:I(7B-DJP<033."Q!*]U63/#O1=5X9T3V>ZIY&4\N,\@9D3W"K:25
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M:GA-3B*D;7;Y3J5WJR%_R- ,Q UOLQMEL>ID-)U) IGX5P:;Y/FJ_W!B0T7
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M;<@R7JG%'86X6-4!TF L>$,SED*DCMZIZH.L=!"]/96/NO85&)6J@"+SA+H
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MULS)C%;'C\)=44COG)QWU^!+.7'*SZ*&H@JD[>>;;@H9EF2H@H@JG;U0_J:
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M6LT"/24O%OL^&.HR=B91X!5!=1=DK>6B4:'YC!@@1*5\,H7EF8IV/T9R?.>
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M_Z;%U3#R;G_[]U]W)^DT^.W_ 5!+ P04    " #V?0I15G,E:9@3  ".U0
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M8GBKA&!;',9HJZ^+MD)86AA5W6,A#V^-,9\N$2^YBS'+9!X]=(M@($$=&K-
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M,RU5F5Y+H]'K89JHV$M"T\R2.U3*0[[(-9Z%*Z!I7(XP5,>Y!UY6B\S3!@0
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M#\)*ZYE47O.3=Z0>E8N:@7D,)EK0>KY\^O;U]S0)@VF*-9EH;=U*H*6I,Q=
MG P0# )*8\G2*8E#U563;!O<W.W'%WL$)FH+S-Z8:/76X>H ZF)\X;Z7^V<E
M;5<)#QXO7Z/;^/3/.MXZL,F*,D.LY+BV$@)4[L(""<*#BCD*3M#.M>VX?^$)
M\%Q_(!]#GETG+%\,8I5"KJ8X6U>UHI'P0+($ICAVS'@$*HT%$[B-0EG!FUQ1
M[L=Y? 1IUA*6Q^"@]^-9NDX#5I-S[E:IO!0R,X[&39:V)';)Y0*$AN2E-S$S
MG4R#RZ;].)^/P#$-,>R+4S8@LSQM:^AL6--(Q72Y6.4,:,4B1"8X.(9+R!$2
M)8M:B"8!F?VHY(_?V=#.S/2MFEV,SP(".4E[AHK7JE_I')4K^?:94[%DL6(E
M,%I I*@:"*-55KP5E\,1E*[&\[U!Z6H;T:-8C*X\B;TO2]5JH(K6B)"4AQ"]
M!8K+&0PC"E0*,1DG=0XG_P9+7RS5%:)'DU(;X]?V$54;&ZF"$\8)ZX#AR"%D
MU#Z5)0*2R<1XE6CV#8("^-.65VW"VN>ENE># DR*996@[G!SLKC=$;&C9D6]
M,#[I!":Y"-)J!RI+ U8;0H7E3)D&)T#']3>TS4KM8WED5?\FJJ*)JK^FD8KR
M*",7"1*W%%!31<O'"%0$J*>)!H:J08/KF?TX3A^_JM_.S/2HF.7!K#R+M5WY
M6A6J#',T>ES)QDL'E!,'*88$#J4TB=Q1:T_^"G!7$_>S@G4X:GW-_ZOT99+"
M8->&=K=8Y86T(B >/N-2H3H)4"Y3$#Q2[E20S#7@@:,JV6WS0$/<>KN.=54>
M=_SW@LSS_##0=PM?;*]8>1N),L0#M<&"BI&#]27W,+-:<N43#PU,_*,>Y;7-
M*:TCV5\$_L/M=M^D635;J +GE H?05"4HJ%<1$D2:9(Q\4RT2$*<?(Z]GKBI
M.TC[RTZQY^'OAE-'DS210GI(@CJ0P1C@+N$ZDIEI'HADJL%-\Z.>O[7--*TA
M>.#-\_?C41GF]2O"J_O.:Z9\<^%*6D6D#AP,DPJ(L@DL+]FDEMG#3."FP8YS
MU,.SMJ:[5?0.G.KKCI<I0E=OI)R/UGD@7Y9D87F DY2FYQD5JO%T[?.W;31;
M*57>95*D4*Q (L=#X.DZ0SK+))&33]C7 _L< >?>KHFYP:C8;.>C>@<3:\M7
M0LI$>/%P41E0<,H$T:<(GAL5O,&?378=<U0'7]O;3EL('BB*/J79;+BX(G*>
M;],BE(BFQ7XXO1>461R0]RY);TI[TK#5BGM.G'(2N$D4<*,MN?KI=>H.83GQ
M#71=^R08Z#@X'\AF+Q>NQ[>C15:X8N#=L/K;T6WBEJ)XN=$FIMJKC9+]A7/-
M-=A,45O36@,AY36YY69.':%-WO,D3X:'NH;U0(ZY<-]?I%'*@UGAV]]':,@-
M!_].L<C+:1&8R-UKM]P-W'-P>Y4P0K]^R4NZ,O7ZC592O&'VI2:,2F+/=(/X
M1?HD/+Y]HGL\M\[/N8/V\NG\7+W2LKP&H1%K4AZNLQEMCBP"*"4BH8YYDAM$
M^E/V)"14QXB>$C_=ST75D+ON-U8)GQD31(,PUJ$JJ3F:MN5>#9=&BYBL9$WD
MV''#-X[!:XWQ/1[GK1+J76>E7YMW<2_NJ]-@511-HKP!G3B'K!6:-4H0*.D2
MO!,L$.4:<.!QHSZZY\".,#[8@;6!OK;R9K;7096C5ZK,@^19XU "!\WI]6MO
MDE'7)+D5E4^"\8Z.^?'$X6)(MSCN+_[6-5#)E(-PV8"/7J"Q%% 5$=&!IRR[
M@-\QT2121#T)KNL<T^.K=ZLK.;AT5G[B0P^%ZS18R1BE)T:!L$E#3D)#X$R"
MQJV >F68R4WR&#P)#W[O$+>VQZZH>8DU!SA#%Y.!&VX_)MRKC4I::DW$H1$C
M%;"@4'^5!<VE;R<JZ1NX[6D_.9^.LE&VB^K)2*T6+-*U+55">Y\RE:BC)E8.
MU3/$E#A.!+5!1*.9;B*G[%/@M/ZP/1Z_;7UY=R]^V]I2Y7+RLCSN'B-.0J;9
M DD(D5(R:BVM#4TNVS'RM/FM;6Q;VQ"OK>&/Z6L:S5,Q17:*K -;J@++*J$E
M@\LJ1+""42!1D^LS>\IS;.!!8T_F)* ?;%MCH:U)/A^\\;PVI6H;S59.99]"
ML!!"-."\$(!X7)_#:FZ3::!YL2<15'XDH%OBM,%HW2N@FQ_ZV+N-*KIR$XQR
MM$D8 RU0SZ0.U<[ET*Q3S#=(G,&>1+AY'ZAVRC#WO&UM<,^Z!BO'!>5)!J I
M>M $UTO.]%H>*R%R$_6</8E8\]XA/A4/Z:$.K(VM5,3R;&R48".-X$QY!5TY
MAXH X3ED3KAL<!#.GE24>K>X'BB[[F_"J^CJQ>_;W5,[ZU6&!9,(]2 (9>"+
MF4$-NXZ4Y2&X)I&D[,E$M'>!9%\"Y\UX@G,P6DK&\.,"1><4K4W$]3HV]D7*
M6.;"?=\B</9HI8H(IH\<%<"2*4:ZK'%GYQY\5#19Q;7C3=P!^DD=SG0+;%],
MMNYMI]LPM1TWP'=7KK@2*CE"(%N/$I:7AXY5*N]5)I8HS9G')JEWGH3OO%,X
M^[LR?B\!1UD#YY-"\]E5<<INX:(=-2M%/2->:'#1!!"&EM$CI *';+VRSC9*
M'_TTHMZ[ [-'_7I\E0JIMP'Y^SSB5JM^I64,.?((/%H4QTP+4-9P4,K+$!,A
M)C5YB?IIA+]W#6EOF]LBG<MYOIOBY7S4*)G,MMVP_=ZJP+,7M@S.ET<V<R0@
MF(T0+27)<A6C/?G+[8\H><]I3.'M\CC:FTCCJR^3=(EE2F: .TI@_V\CW:5D
M*8]0^)WG[4;/EEJX X:<RPN$BZ<KB;/E_2N;@3DGK C&*%E+(^U]O#=,_Z'D
M!,&%/$..\_-9.>N^&)=7N,IYY'B(-'V^OHI[&$:']%1Y)7"MI0Q4Y00Z*@*.
MH"&M$@G!N* E/?D<4*WQS<-L=4?'^H_,84?AFNYG]S&F%UM&2_^,VJVQ^W^7
MST;<7@*_M8K/)H,I?O4*_T18%^I!C1VAJRXK1I,VBED0M.@<UI<\3$F7]RZ)
M<IZ:;!LD[>PID_H),? )351?RV$+_-WM\;4FTD2A?)(*LL"-SY2CWN1SA*P-
MTTX0%4B38X9^C.4C;.H=@7M\PV#E8<!OCV81(,:W?HDMO'^O7.5<%MG%!%E)
M!HJ59_<R81"D%4);(I6HY43\0VMJT8=UZ/P\1IWGOB^MA(X.1G,4![<K:GE<
MM"R',B1-KU\[NI889Z/8KI.T4RHJ[D7VU"84J[[<<\L.E&$"2)"$,8<\TR0Q
M8S],>BAK;76DGAKLO:G]U^[I6O)[3>G*J)"]C@X"D:A3!AW EJ'J;"AU.7OA
M3OX]VI/EA8>*>"OX]\Y;UY=RZW#6==DJ4B:H107,X#)&#= H7. <US:UG!->
M7K-OAZ^ZU',;3]@F!F@ 4U_3_S%-$_95//&OTM<T'"]>$=D<956K7H5#C2YK
M-!G+>X*,4%)^\\!\8)((Q2)K$#K<C[AI.(OC;O'JBS_^GD8(P[!<78U7@]%@
M.BN@?-T2AU>S9A6H5,&4I[Q]()!E5!"T3Q"%)$926=2&4_?_M,LC[2/6GQ2Y
MN8FS[F[7Z^\K7UBY1('_Q^TNQP-:JVS.)$N.2J;B&6+. :+C)5^$-DE*QP1O
MH#/WS$TM[4/]X-B?'7@W2>X-5EMMMK4U*J9B5%D*R)DK8)(*7$<EHX@-2@>I
MM<@G[WE^+,IP>W/0-Y_MWN$>IOO6Q"J*_X-RE ,G62!8S!4/I0TI$Y]<@PRA
M/:5$>VR,=3CXO0537?D48XJW3T;<GL#\_-WZ2Z$'MU493AD1P8#CAD,H,:]!
MRP!").MI8J91''$_@5"/A2?[F)T#;]0\M7S)_=S!.G7&.XUTRWU<J+A>2 =?
MJKANH)*1,%,LM$@T <,2JM41=1"KF=)>H27>))%:/Q? 3ITO.Y^27@-NWH]'
MX_NFV6[=<'O%2EB=K4FJN FPTR 16:(5I*2<<TDI$1KX3?M)J_98F+#UJ?CC
M9E#M]U3^8+]'?[$(D5LME55"_IVGY#_5J)1#I=9H S&[#(DK Y:K! &-,YZ3
M45FUXW'ITC)N]4B[#8S^N&!V:H^;=A+U\/BNC]V+4&H8B;EW6Y7BWB<C GA;
M_-C:6Y"4("[&&Z*YB=(T2:S6VT7%EH*\^@#P^/&5BP>I+L=#G*/I<L%LB+-<
MD=F0F*_E&3[$\%7RL]XZ>N&&;A12N65V\_D+!*;D47\_GJ7IJS1S@^'Q(DS?
MC4>?RW,\=U%9LZ3O%JNL3#FYXK?5R-])1 ;,*0::!AJ#0\ZNIQITI8)[7#W3
MV61>^.R-"ZF&[KV^2D5TUDS@2&G( 63V):Y?<) :1VF3#$&>? S6X5/WDU;<
M&DK]F6-W2?Y]Y)9/C*?X:C ->S'%FKH54T9K;2)$U/LA!:, -00'1#L=C$#!
MWRAG53^[5D?LT0Y>_?'),F7;F\&HB.N7X^ELNOU49T.-RJ?D) \2C(AA@1M(
MHW'(S''#3!0Q-7!5]G2@V")/M(72@6<H]YFRI&A/9?SG^<,D70WF5VMFN$ZU
M*@6NF'$6K03$0UF_N/]UG4-4)4Y\/'R:^SFB:SS+'2'58*H']RB9ESPA&ZV5
MG74JI[@Q7$0HC[]#L#:#DO'F9=0<0FS@<NOG.*RU26X3ICYLC[M:^'LW68;E
M;=>VVU?_/X7+%.=#U/]_<[/5@<H?&G^7([K%^6/ZXGZL3,T/D\$H#+ZXX<=T
MY08(].0\OT&UQ W_?W*3FB@<TG2EM&2RY-^D5N+B<%9"XC%"-IJC+F0<,2=_
M>ZTU=> (:/:E0>XQM+>C][C<+[ZEX=?TVW@TN]SFB&W4;L69UI$(-,JD%V!*
M0BRG<-HXH4*P+%P(#1Y<["=L\AC<UPJ4)\EZ91E=?!NWQ7&KYBIALC9>:H0C
M,!#1.A"22]"9,*&C2,;X4S\). ZC'8[@Z?(7]KXMT.*P!BO"=4@T4?"9"] 1
M]4RK4.W$SSP3@2F;&D2G/1*;JW<,3Y;+WHSG+6ENM^T5!8.Z;!B4F';(F3@@
MC#'P@7$G)0U"/WV3KV\(^S8'+\I16J=&(/;VP7U.'791Y@+KKIZ!6^0L&@["
MH--A;>RS<[/ZC1M,%L&ROR4WG4_2O?"%GKI;/D![-KK[$NCJ^W@VNZER;/-^
M]2+S#3EH/ W'A<@MLG)CG2JK1#AW$73):>45[AQ!,0^HJ+!<7DWR^8BI9-;%
MJNX9;5P1EQ+*0@M9Z^*XD@Z\50G5?,T4(5:&)J$'_1CH+<U?C4C@ ^#J+;/8
M,CGM@Y2T^RV$VFU4QD0G0W*@DZ.0@E"H39D$AK&D DO4\@8' /U8UMVP39<8
M]L5+9U]1AA<MX<UX\@D'<+L(%E[=F[^VR=2:3514)ZFT)R"21NO/X(I2(0D@
M66CBO=<D-'B(I!_3N1M.ZA#"OAAI>? Y<,,[2L-^(JEF"Y4563D=,U"N/([<
M<F!<9' JV^R<CYG7<C1W=<!^?86NWM-A:\M77# KO F@A,4N5%00HT0[5A$1
MD\L\T@8QR?WLU9W,YT_'[NV@U[EAME;1OOEPF9O=C7Y,?Q[0C^/8'/V=)*[M
MOFO+M:0S&4\O+M/$?4ESM/:F;T>AY^X>7+ZXM38[AWPM.3?S@'O<_.K+XI;*
M<2BY#21_.UH6. X=_:V!M=UWO@;&X_AM,!PN;AK-W.AS<1LM%9RC=-HCW)N)
MN YDV%+D<,?'VG">;8AL?(1[>Z4J)N83TP2X=@RBP;U0>V]6D2K2D*AJA?-V
MHR-=$[]%+;HN4DE-T'JR%G@6')3W&0+GY=V53!+U7'K2X+RM6TVH[8EZF)+K
M<(QZR]"V(O'OD^W7X^^5JT) @DV0$#+#H5AL-['LT5RVC$DJM6B2?:T?[?>P
MR=DPPX?"TJ/QAVB\0]%=4X35JU@%RH3+PD&@3H/T44-6W@)QAEH;J9#A9-/P
M=;SX6T?N!'AEEY385;42B@LE%043<%TXKQ)HZST$(7)@5$F?&[QLT)O9W-K$
MUN>90_$[ :Y!NVE^568KQ;/E38P%S(?QT8;&*F)U\#$ER)9$T)Q3$ K7:\B\
M.&]5IN[TW\PX#FNU!^F!\?);I/ FB5.G6F6=$-1J#48:!\FX$F+BW$I\,V&%
M;1!S>%35]( !=JZZG. FWARF3D5R1[[,+8!T[;)X>_7%E:<\/Z:01K/AC[?3
MZ1S%RHWG[!.2$]TD=DG";<J6[CIY5]Y#[;S]_APNR_X^E=4V^7&>W\QG\TGZ
M#7G_:GZU^.[#*M+JV$$E-TE@%U3=^."W*!,;:E3.>*6BSJ!9T"!R+L_$T@Q&
M>,N](\+$([I@-E#]<CZ9I*V7A;=7K+*,QBK)P0K* $67!69PCP]<:IM\(%HU
MN"G<<W+])C.ZZ=F%MF#K+<G<>L)+=HY#>>6V;DF,:Q01Y69T2;=,4L!Q>PU>
M.J=Y<$K&!F\Q])P9O7MV:81<;_'-)5][VC""&SD_WQHW7[.)RH5DRJL&H&))
M3,MH!.ZT!<=\"C0*8NH]'71$)/:^J'=PHY7@/BBO*;AL$RC-(RAK.7CE",M4
M"9H:I%ONZ8I>)ZSQ,!Z\3XQ/;5WN<V?OP":K*!D1DC&0N+&!#<& CT@UMYEK
M1[2FO!UWRG\$)[:#\*GQ88T+?/NU5$G/0TD2!MI$!C2:",))#<1&0AC:UK*E
M-Q#^4[CN<&!/DMEVW>;;MZV*$)3ZE"G4_HP&[C7J]K@-@$J6FDR43ZK!G?B>
M+O*=',,=".TILMRNJWU[-E4EIH476J%58(L):2P0&4NZ(:%DCI$$W2!/:4^W
M^DZ-X0Y$]L#3BJV478Q?I ]N$,_R+$VV,-!A#54O7IV]-O8,?XBS%]R^8(P+
M]D;8-XR_?O%:-6"=?IX>Z)1U>L&T<^?]TA/;M9_^?5HD&OZ0)I\NW:3#ZZ$/
M.KI-0W0VF@U>#8;SXMZ^>YVB8T?W WJZQOE\\MF-5@>J9Z-XFUZ^NRX_IL51
M[@<W08Z?N-'4A2/UV-_QQ>JQPH\IC#^/!G>C"_KHJ[]Q?KH<3V;E(OR:W.G]
M]';<L=X<4&V[D'7D6\\/*+M_0>SL.A5I24#YPDT'^US<V]5499+G@@0)EN.&
MJ0BW@$JX@Z""4RJQ3'*M=TR/@LQM%,KB8/W^2S_+USBVO_S:2ON5,UQ[3A-0
M00A$:1D$JC0D%]%N)I$I<OJ/DG?+.3LN1_:%^Q]7<$_3[WI4YGN$-W,/73]%
MC^U2+MYKO](I:\U2AD@<SI36'HB*M,Q9%M'AC]/WS3X*L=@4]LXMU'6*6==V
MU.*%#IR3Y5N4"4V,;I7\]?UUK_.N[;87<'MZ_N3GOGJT*'[J^]:>F,^0J\OR
M*T&3BZ!%G(&KA='^8;+*';^H?P0J.Y__N9^F?\UQ';_^VK%%^:"GW6"N9%CY
MX7%=_.U/_PM02P,$%     @ ]GT*4=&[ 7S];   )S8% !0   !I;F\M,C R
M,# V,S!?9&5F+GAM;.R]:W?C1I(F_'U_A=?[V7;>+W.F=T]>/;6GJE2GJMP]
M[W[!09&0Q#%%J$&R;/6O?Q,40=U($ 02("2/^^(J"9G(>"*0&1$9EW__/W_>
MS'_XGA7+6;[XVX_P9_#C#]EBDD]GBZN__?C;EY_4%_/NW8__YW__CW__GS_]
M])_Z\_L?;#Y9WV2+U0^FR-)5-OWAC]GJ^H=_3+/E[S]<%OG-#__(B]]GW].?
M?KH?],/F#_/9XO=_*__O6[K,?OAS.?NWY>0ZNTG?YY-TM7GW]6IU^V^__/+'
M'W_\_.>W8OYS7ES]@@# O^Q&'7RB_-M/U6,_E3_Z":*?,/SYS^7TQQ\"A8OE
MYMT-7E(]7OYVNMH->/PP_>7^E[M'7TS]!]X\"Z64OVQ^NWMT.=OW8)@4_O*?
M']Y_V4#RTVRQ7*6+2?;C__X?/_QPCUR1S[//V>4/Y;]_^_SNR22S1?Y]EO\\
MR6]^*7_]BTZ7L^7%Y:<B6P8V;= -[]],<UUDEW_[,0P(((67,@Q*B/Y7S8C5
MW6WVMQ^7LYO;><#FEV@KLMDJG<V7IR_LV<"^UO<IG\\FLZS% I^/C+)"D\_G
MZ;>\"&_XGJFK(LO*3_#8ZHZ,ZG-ES?C;;'"D=2ZFV6*93<,?EH%%TW+OTNF\
M_-"^7&=9 S";3M#?>K\$$;N'Z.+2I,MK/\__:+7NVHD&6G]^<UMDU^&9P/OW
M^;(['8<F'(:>B]NLV&P G0EY.=,P%'Q9Y9/?K_/Y-*@#[I_KV>JN*R6'9XQ%
M45!=5K-O\\QFWU;'5[OOZ3Y6LMT62IG<_5P'L)9J,?V8K[+&VV.G6?N@[&-:
MW._6K2@X-+J/E9;*U'0]#W!]2%?K8K::M82]P41]K/]K&OYPXE*?CHFTJO""
M3^E5=G0ESYZ+\_82[DDZ5Y-)OEZL@E724#$[/K#G]344M:;CHZS6I[/B[^E\
MG7W(TN6Z:*1#UH[I;U5JN0P:5=C8WL_2;[/YYJ/;_GZJ5KLAS5".^(;^*-[]
M\%Z321=W00:*8$B7^V6UQKL.!+=Z07_TGGB2G#1'?ZMNM"LW&!EEA;]FBRQ?
M?KT.ZN)MM@X;R?+=8G)D;;5C^EN5S28['3%HM@_[73/N=YJS/ZIVC Z;R?KF
M=J.S=R"HP73]T?(N:!++52FJ[Q;W#W2@Y.AD_=%QXKYRTAS]K;K1OM)@9)P5
MYOGTC]E\'@['=XM5NK@J]<O[\_+8"H^/['N%I_+_])GZIJ R.&H>Z4S;Z>_H
MF^IF7T#3\5%6^RYH29/5Q>7G;!)VLOG=N[ M!^5P=\Y\"2N8IL7TV*I/GB?.
MZA?AC]G7],^CJ.YY,LH*W@?UY^C+GSX4\;TG;@3U@R*NZ\OZYB8M[BXN_7H5
ME,,/L\7L9GVS^=VG].X$[WG;Z2+2TNBCW?=HE#5\S%:EG_=35GRY3HMC'HH#
M3_>QD@>7D0H?N)W-UZ5(?<DF)_FANDW:!UV-V%T[)LJJ+HJK=#'[U[W6OY@V
M]KP?'1=E=9^S>>D'_Y06J[NO1;I8AKV_P>*.#>MU;2?NE:=.$VGMW[/%.CP^
MR:\6LP;7VH<']+2>DU%L.D&4]7ZYSHO5UZRX>3#.CJVP;DAO:SH1Q5.FZ&W-
MNT-8?0_O*W<\GQ=?TOG)>WZ<R7NCL]$!<'Q@G/65EXLZW5P_WMQF81-JL"?4
M#^IQ70W9WV1LCZMLQM\&0^.M\90+Z9[OFU].?^I>U7B"GM;[L)6L5^$KG?TK
MF*'!E-[8HX&9-QN]Z%-8?%84Y55^&-^6LNZOZ@F#YC)>,RS.VM;?EMD_UV%_
M=-^;G,8''N]E+0W97C_JX,K28E(M;OO'Q^O;15O.%JM?IK.;7[;/_)+.YT\7
M="">LPK1+&-!Z6:ACT;&7E3X<QESE"]^FF:7Z7J^:KG$@_/TN.#\)ITMNJ_W
MR331E[N9_:>;[.9;5K1=Z[XY8B_T.LQ73-;?LI]VT+1<;LU,!Q<=A&9V;T6\
M#W_=/EVNJVVP\/V;LC]7V6*:3?MYU][]8O?*\H75*^?Y9!^6&QPOT^6W#9CK
MY4]7:7K[2[E'_9+-5\OJ)YM=ZR< MT'A_VO[X^1C]L>CT(LB7X0_3K;1:X6Y
M3A=7V;O%XR=FB\DL(!_(SMZMLIO=RH-:GLW_]F-891)M[D0@B8144"C&F,;8
M"&:TX1900H7 _"EL\S*4/B^VC!HG;IM#M ?,-O,FE"J()' .*\ZDLM!:M\4+
M:LI1$[P>1%L5DQ_R(B@ ?_L15B.WG_I))U69%'$VR<C/AV^ (OQ@L[/]VV2>
M!W/A;S^NBG7V\,-\L0K?NIMO%A VM>RJ_$,; 5X6JT?"&_[V7'##CY*+/Q9!
MF[N>W:H_9_L^W!?/) 1")0"FP' DH768*EH1;"20 PI4S9$03\!.9',>![>-
MH/3-<_M$1SG$]?NG$F0UP)(2K(2BPGBH>?5Y08(I3O9J:+WR_Z!V^,#]#GS8
MQ\E.6+P^GIZ'ET\H.#<K3V7A"W,P_"#9&Z3R\X<GFO<C5AT;DD!#$84&64(H
M]LYK@GBU:*'0D'OP7BOB --.A3SO!8Z6//S[K_^I%K.;=/X?63I?78?7U_+O
MT.,),A@)2Y'R4!#MO(!<;A>++-;M%3(T5MY%@J+E]GFR'E\F#;Q;+(-:5BH'
M!_2BPP\GA&@C)5+ ZK!!>2R\(155+- X((-'K"!% _ \8O$QO<D.'K7'AB10
M <V\EH8IP"D/\J_4CD+FQ#AUJ1@LJ^5^9X3>HBR,2@<;DPA$.=45^SFHCP\9
M8U^RQ2PO[C,'UUEXG-2>\DV')\HB8Y5D5"!#+.(*8;8E!EL.R7@TMGA\R7O'
MJ2W3UU?KY0H!*)]GC=8S^\BP!'O.@"&">(0PQ- +4]DCV'!-QZ/:]</DN/BT
M9*[-)INWG<S>XP,3SRT"2@8[TV!(K(085-HOEL'X:,U@_"H8'!VAH<[K]_GB
M:I45-YM\X/#F(TK]OL<3H9R@,/P?Q!Q29#@EMJ*,&-M>K3^=]Z] K8\ X;F$
MXZ@JMW] (B&'@.F BA60(885QA5UV'@_;J6^&\..<+\30F]-#D:IT(^!_>=A
M^[-R$0=5A-KG$^>QMTYXR+P$&D)C5&7]$.6'M>*::09=F93'AV4HEN_*\9AY
MNJQ*\AS1"0Z.24#X0#C#5BAD=#!;?/A6*AH=E>V_=_(6%8-8. ZV/3Q:YM$3
MX>7#B>64&H>,\5HC*9V#1E=44<K,N+6""-QZOD_$@NBM", HU8%1\/U<^D 9
MA[U99P-=X-FS"93A7,,2(D>D*^_(+$(535Y2,#X]H MC7N@ W> 8[/Q??UO.
MIK.TN"LSAAJ>_X?&)%9RA:0*7P-WV )"S4/<6?@^=&N6TS=Y_D?"<3!9>5AE
MZ3V[N'R4VWGT.#@^.(&"&X^=AEQ)B05PP,$=U1Z/_"HP C>?RT=?D/U5!&:<
M^L08Y23*=4.YCN5#F>;:&X:]SR9:<:4UQ,9IJQES&-(J"H9:-L:KP9C8YW'A
M&>HK_Q 67,Q6=^\6JZS(EJM=G-2G< "7F1Q7F;[[F"_*>.X ;7C_U?TC-1]_
MZSD3BXW@5DNH.&!06^^9WV+$L'1#!ODW%*'SA?L/A?)0DO@Q6]W7*GI<WGMO
M&LFCYQ)+M+>,>$^$U!!9ID3EVF5$<SN^J^IS)HBT1VXPJS6]G:W2>0W_MT\D
M' *$I03>2T0$)HK+W?J%8VQ\=]CGXWP[S(;B^><R47"135U:+ +=RP#!^F:]
MJ4)C X,FLU6-.!P?G @,F8<0.,$!$BA0JMG#?M<AT^=TQ_;H)24ZG,-M',OK
M\G]E0O_WH( M-O6?ZXK<[-U;FDZ2.*X!(<HA"0ER$@:ML *8*0C4@-Z2T0M5
M;[ .)5P!K4F639<^@%I6N:A:->S<A#4R=71LXI@&1A,5MF./F>5 F"KM@QN'
M&J4"[Q4E]O9$*3::YY6@Q[U*&HM..2CAB& N'<58F6#(2U;:E5LJG<3MM1_^
M5Y&9%C">)RR_,O ^AT-X<Y\U?;#P:H2G^20)4)0QY!46 D@'!(2[^!A. 6HO
M3.+M"5-OL)Y'N'PZR=1-"5-C47H8DG@M%/480@$LQ Y0!\GN\V$= L7E6Q><
MUB ^B,F___(,O[#&WWNHX[*_N4[$VC&-6AGV_[YSUZMYNJRB*&7Q9JLK;_QX
M^W_]N$;K^P:E:V*^)@F'IG)>6* M$MB1\%E(;:!76H6#532R@GJZOMI55(Y
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M.;#[;YD:E5?@=8C2F<+S#FS2#5)3ZP8FTDA! .,"@J" ,PA)J1/<4XNU&%1
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M_'M JGT _^&5/+]1KM\:VDR5<.RH8H"K\LAC$ !):$6DP!W"Q'IS^T;>+ 9
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M%9%3.+LY">\7N#S8@JOV^<0A$(Y(3# *&I;EP7PTJ**)4CC27FS=6?22U]'
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MKPIH)##?*5U:*-?^5KVW32&^1,3%Z&R'PRF'0N(,U5!J&,Q?KCQ&F'&WHXG
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M]/9^^-8%E>'B>9]%,V4K]^=DOI[.%E>[:*)ORU613NK"Q4^9)F")-9?,4:N
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M,6#$"^^V%"H0U+=Q>KUCL*R6^YT1>HNR,"H7])A$((J[2;&?*3#YXGM6K,H
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M$87X.Q2UL@/MF'0([<AVP9Y'3G*@-=AEY5[SBI^L45J?/1<B.%3)J(@#1)&
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MR^MU$?_RW?*Y>G=V:\O\Q6"EE#S=^EA+3:H@+KTM(6/4M"] G"_1LL>#=C+
MOK;3^/ML<9=N_N/BW&>!#G HO_QDL)0!3SS%TG@'C'*L"B_1V/D.6?BOQ.\[
M$60G+[NU6<Y5I8X'8'((\Z5S" (!:*%%7ED I>'<*'[@@;'4=V@8-W$O]]2A
M'B%Q:$_ PV+]L-MNMK/E?+&\/7MA5C,V&$FA0YIR*ZP 0 %3N8<-15T2BR;N
M2,\%T>1WP?V/?T2YC[0]E'.HK?#;TV<"B"@Z;9DV% !,A9>TC# R@K,.N>T3
M]^Q/ ,TN5DZ;&1]N(\UJN5W/KK>[V5VJ)WS.LNGO*P%B2*.:#05.>0$1'J_+
MB.^X>$D'07L-]PFC@CD;H);+LUHGGW?W][/UCP\W3ZX^E_.'NY*'S3WUF7F6
M1/@VJJ(H+Z-P,(Z8DUHX:;DB7$G' $G)D8W"'S*=31FJHFC- :&":8O3<6P8
M/M"J1-3.!@SU:E$5I3&G+JJ*<@DBL[].513FK4>,40.!->E.U.$2;$6=&S*D
MM\>\BH;,;EP5Y3*47DM1C.3IE9)!";3AA$AD/2^ILHY,/2VV.[?JJV.T@^BM
M", XC&]=%65 OH]DQ?9>,D-@AI@%/!(5CUO,+72R/&L]H1W\94-H_I<RZX*2
M&9<!,X)WZ[DW^N/LT)QC.=_[9>QBDQ2777)4?]GL#91FCJ^+7QM2LT@J4WT1
MPBCS0!EJ2Z0X\.TS,P>^"FNK=@X(W@AB%HGXL-YON?,],6=BV"X8'3@U<4=6
M1@-+HZELK:6^I)O"+A>HV81F$#:?EJV>H!Q!A"X(13HS*L0CG0MDG-.*(^>)
M<10<Z#1"^ DVN!Q;9#I".)JHG(R5KAD1N&-<X_1#8F\!3HD[)7W*T_;Z;+[+
MOTF(2"OX1A./BR_S?KZD<M$T\%)I2"'SQ'*GI2LIE4BV]WCGN\:;A*"TQW"P
M@@3/E/D6VDNS%P2!I-4$&!%M >T1L%+9BGK0H?1,OKNY,20H"YKCR-(%:LSY
M@4&HE'V@E4404>.5M9J5U&KHVA]3^:[;QI>=CBB.*3.U^LSI00%(@93W<4.U
M!MAHGRI3G<D.=:A:GB_+9RJRT@K!,>6DF6)3,S)8Q055#'AM$-46:FQ+>]#8
MJ-BUEIA\.4!3D9CV, Y^CY^['\ONRZ;X8U<LM^Y["@8<[$-C!QN\F,_[!O$&
MIX:$*#12 B,%!5XAP5S4<(QTRF-JC2*-H@4'H;(VUN#(X\$:81&U#'*CJ5+(
M"8L/U G&Z9!%UL\&&71GSY'JRAW1F'2 @2V^;!_C@&LB"WY^.& I==PE)4(B
MQ6$Y1CDJH; :P0$%X[*0@DY\7?6,RU"*R/.)-JKE=VI( !C&(Y*DHI8,"I"*
M)]F2P@@CF'9 01>6G>5^9X3>HBQ,,K9@"B+02R"RVMWN-EN4$C,>ZILMXF:F
M5\OYYGSYP)IA@5!I-#"4 0XIT29^E!\F+Q$F[3.[L]W;=>?#*AL^0ZWK]ZOE
M[;98WR<LKN*7:\[T8X\'2H&UFDMGN13*Z;@J2$E9)'G(Z[?Q3O4>D!F+Y[4[
M^?$!P4=56!C@C=2: *H,@;"D#@+AIWVF=V-8#?<[(?36Y&"2Y_D4V#_6K6EU
M/J7Y-FBB=N3Y@!"'\8RTAAGA/8#<5B:RYIQ,L&9L5R8=+1+:#9;!HD-[30QP
M4D%!M5,<(LH5Y\S8BD8 VT=HY6ZXT.=YWQ<\KR4@'%H%N:0&1:.'2NX9).76
MJ+WS;MJ'?0_<JH\,;P?16Q& 29[RD^#[Z,%1+?JD2AJM7X\UM<@+Q;$&NH+'
M:-+>IALR^K\Q8VK[I%X&QV#'^HL#K=Y^/S$B "&P0"RJ/UYP!IC%7!SH,\[K
M]D?ZY5%O(Q[IO8 S(O/K^QN>&A,DHBHJK%I!QHAU3+AJJ1C$Y,3]\YTY5R\)
MG7!ZFS(QS1-_,J(P"1&H3P$\]GQ0Q J'D) "0<!37W!;FK'&.S2H2Z=A^\3N
M?#K/^5;(C',]]\0U\=C*Y%.J7G*N0E'C=P2AB.:8>I0JJ@AG/&2ER\1QJP9M
MT=9*.MYWCO3(!=:0 O,XU:K3T9,;SGW7BSIY:?**$*FV% BO+=;.4ZSBAON
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M(UPMC)-RR0.9+W#^4I:;/_/MEF B%0@9OCDQVOF!\GJ]+2GX?4U"[)N^99G
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MBMBJ:VWL<*:MK,1HJ:"/21BIE86X6D95+ :]5-!7Q%2@+Z<QPI#D<DED.W9
M4CF(T; ,$;E>#$5T@/'3TRF!T/P;+U%\:J"!(V$]F&5.[241#)K R=BR5($7
M_!E=$.* I00#MFGYU\2EHLF_9M3<D(J800Q $F#/!<@#81#@80=%%#H)<PTF
M;$"S2E!8QAZ708&Q5Q3BK%VNPB8AC$\R3G E4(:)D\9>ATU"GE@A)D0B2R%V
MSN<SE9@T1?.78O(NE J[#)?8FL$I4Y"HN(4])P1![-I^XIH'74>1S;3K5,J
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M!:PN0XU4./+F#49%W(CE0-<%&=-9W7Q*FXQ.MF6;FXSTPJ))OV0K!\:19R<
MD__"V(?M+>@] (2PQ?>ZK$+#/&--Z*'9#I&1]R"-BOQ6)E^2HUDD@YJ,7\F<
M:L!I4*!71D_\ >N<B=88A\RIEY*&6(;\Z7!L-#U3R)V8/!Z=#CTL:7^B6QRL
M%028*'+D6,@%OA?Z41SV6V$]$X:V*UXSREB=8O(J/QJ_ZP/6X3?MUHV*PI61
M3"GJ111S*M8E!1,>$WZT5^;3*.$3J.4(?\QBJ:(-EJB52OP:E4IUS"E4RG;S
MC[7"KFD&,$:6X\( V=!W[+U]9"&FO3GJK<ZHE,="^=3N<?LA+XQ-N=VF56T\
M9951T\?8?U2NGZP-HDP_-;2%)OT<WR@[EWYV_,GI)V<;?#?ZR>L7OWX*,2>M
MG[>DC]4/Y?8HV?UX_[DIUW^T>&ZK_,N7]OY]'"-L1W84^Y'C1&;L6@.J$-H2
M:Q;JL<R:E3:##U19>R?H[%E-W>CUM^D<422XJEI04H9G:#R5XKR'?S0=0-NM
M]:#?&WY[H=VFU6TVPD747'%3+ESC57O+JOQ:6%87#VZK=),77U#Z7*_\V+=M
M$Q+60^ GV'= C <, 4!,YV'U6%Z(UC<=9&-#,*N6=:Z&4"7BNMI CV3W: TT
M1O],ZGS$I)06B[3(]Z*\0KYQZZPX@^I4E?Q9G:UW3?XU.X)CK8BJ0]?W8119
M'HS#,$ 6&/"X=J!F?E<:Q4+4=GV KU5YA1M+E0I/T4YZ%/D(^:+5^0S#4DHM
MVVK?BVI+^\FMX&J8%5/S3]DF>VQO,&S3\Z.UP3ATS-"*$C\$. 1VE)C#.33/
M],Q$XLE <9M3*W6U1]K/<3Q=7E372[J(!D_#MZ3B'D!VTQ)7"]G <)8\9C&5
MIW^)TJG JU&A5,6:_%)<6E7/1).[/:X?[V\?,OSW7=X\P_+QJ2S(#Z^B* +(
M0GX0V:8;D<0;X6%RVXH1D#AQHQ;'O!L;>OS]UGDZ"YFU^,F/]0ZH6JM3T&*R
MJW?3-I;2];RAG<"^G3KH!KS83A,O\5TD66C13UW3+5&W-7G*O#"HFEUV?;_/
M*I+/)7E!]P?#LF[J#UFS K&7 .#$9A#$&./$-GU_L.99-J=VB]G0K,N_%41R
M"?W_F6W:$P.'(P1K@I!7= 5I9!54_0R*B.5 6 OHRB"0IM; D[R,ZIL<DTO1
M+DDOWNB2"E;$<LJC88CR>MV>F,*NXT0!0*YEV70)S +FWFZ"L$3F*&)MZOQP
M=RQ,/4B9'%"(89%,3S>YDOG<L>"C2[Q.D+.=H(LY,Y.A>BD:ILR?T2Q+GBGY
M\T_X_CY;TXG,HWK=]$T/!@[P S, 9A*3DMW>YW/8X3JDJ=;RU'J7#1CUG(H2
M(E]$_J;D75(*7YV-VJ-=R.SB!2:955)5BRQ1,97YQGQ.2IY!5B4=K.)O3UE1
M9RL462;RXBC$20AA[)J(_*>W BT?\&@E[[<UJ^&'LGBW3NN'@_9E'3 ^^>-F
MC$W@=)+%)V%[Q<(7Z-$B3Z]X&!$@4<:6(3'"Z$LU_49*)MJC[3C&KA\D<0@<
M'SDNCOQX6 :Q LOR):2"Z?N:Y>+ZE4JTJPE-E:Z;7;K=:XB4=K#1**0?RAF4
MTY"K&:ZY.,$(NYIP\;=(1>'S8%Q5!-A@+^6J_&M*<YWW>7J7;_,FS^I5$@2>
M[V/'\TWDAI#> S_L([3, '&6;"(6M)=F RACVZ-ZYBW#A(AC+;=T<\9;5NWI
M>G^1+DUETPE&1LLC&0:7H2B2/KPI=^098545_'B7;3;9YF#SES0OWI=U_;%X
M^W=T MY%GF=9;FC;T/%##!#>GP^T QQS382KMZY9C> #O0F:)#7&?9I7QM=T
MN^NO]Y)5*0T-P:9@\[8!G[H->(P#H"N#PC5^H(!_-,K"./DSDR\#<K,ZHI#Z
M6F@9ZJG1OW*JOL[^H-?9#1=M*EFD6SJO]?'^4];LJF(5PR1,D!^'ON=BWP2)
M;PV36;8;)9#U:2^U5F?=GI;WB-L9>2J^50N:_6TJQ2TP+K/SDB\Y)_]BN]D
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M)NGD00 1</T($0$.8]],8(+P8!'"F.MM51D[$RX1[67A<U9]I1?;GUM:N#+
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MTQ++)\$O&;T^8K3#UZ7#TTKK1;Y&E%,=U\L01H7^E+IZY42)<)+FU5_ITT^
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M=2SF:^YERPC>BV5'U4+_)*VH/7SCO^_RYOFZJ)NJ?<^P_M@\9-7M0UH(^I=
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M+#/TL0,C*S)]+XA C#QGKW)6%/,>CQ$R,HWL'(&C]U2DPSCB/PLCQB2K[$Q
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M)4?F,G1)TH=29?=BTYJ:/@M,7\[*JB>J=/1:!? MKU=^[,>NY0$8^XD#S0B
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M\J2>(E$AFN<PTPL>6)2%C["%:0@G^'-J(<+!)5W(B_)XMC(NB\TP21E&3A
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M3V5#AQHM/=.J(%:'2[RR*C.*LJ$&RB]%>\=76N^':UY03/=E]4AW,K1Q]Q<
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M_;)C!$*3@! OI2XF:>;Z &&?C$!<!(G<(9 % -:/B;H1>-N-P*X5UO'=VOR
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MME4:JIRZ?QY+G)(DCJ(T0#[$ 0$^C9C>CC8A2(4N/)NQ-%5UY[:KLI8N[31
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MU?K\)B?Q*$4( IA%":0I22#R#]EM$ 1&#G9T $Q^L',[@C5^L*,5!RTEG2H
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M55O^,B5Z(I$/'TAV\P7ZG[]^_MS4#TU9[/+F\>M]WNQPP?>9QGY,, :A!S)
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M.5.5P684)2Y$,8AP&">1[_L!&I/@P/.IT$+?C"7+TCH"= :$_.FK(T9QY3!
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ML@0M)9V4QOTB<53S7&ZY^U1AOA3\(&K\U4W1W*]"!$+/3?W$C0$DR$L"BGT
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M'B ^KV**(/13-Z,0A?&((H6^9T-X16W;UUM@1V^%R34KLS9XG4!=&>1EJNO
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MTJK3#D/KZRE"]32V5]-,7F?[>2>OM098E+Y9NICGJTVQNC\\VMQ$R33R00A
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M(Y"J)HR7#DP(E1Q+$.7(ZY!"P^Q/0P1-.R5_%$*?,UGA:_7UT[K<\' U3%.
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MV9)F<8*2)(^]2VX4&9"N]<K6*RY8FYM\_5TDN$FV*>;B"HYBN1//$[?G+0+
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MQJF\N7(J?YS&H2MG[])QNSI_55XYH[W>;K91.N:-D5I_&O/)6,Z7DQB!JC4
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M2+R49(SI:2B:.7?D2FQT>9+9%C]7U7.;_Q*7QN,?F^V:_VCFXH!$'L,@]$-
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M&+AX,6T,9L,7O'U:<5/BU[O!+';AE^&W<CRJ:J<W'LU39-HQYE'":GS_NG.
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M,X)6\1K(*PGBWSYQVD;^3&+I]<6*WXI8<#3X6[3\YSX*O=XC'*12C9J!J3@
M.-; "66 PEA*O19! :7UE=S];)\\S6-])EUL(NSJY7QZ57I33(;%D2PA>\H'
MKR2T@#L0.1V_ 0.I;=7=.(OF['YZ=*VS?6HTA7!7!V INOS[F\?O*PX'L-U9
M/F@H!##*>1T77T6UQ&I+=B]HSOW-'IDS/=H[-ZF.KJCV$I_!;DB.!ML^L:5@
M-7)4*4ZU8PQ:BGC*7KO" T)_+9OKAC@Q[1+K2S_]JQ'7_5#%((T4!# N((@V
M(8.0I.5B+2W6XLJ8U1H7:IZSG05Z5Q1;AP/\//BAEHMOJUB41Y;2W16"(=8(
M32F5$ @EB7(IGNM&.H^O+-U6C];21O1Q.;8=#0B_KTI U .$F&?*6P[B7I;
MS<Y6(<O5E07_SE7S4=:<A6K75]?3CF=V?W3YVU4\1$"LP@@9)Y%@BGO%9"49
MC$/LVOERJH+W7#?/P+3-,Z\/L^EH.5R\GWTJ9M_+X:%SU%U%@R4L]=L"JP'1
M#F-5.6 5PE+D'.CWR,G4H_6K(4UTP*E5U,=U!^<'STWWE@_*I;OOE$.(J)-
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MX\1B8)"&FBB HNHJ<"S("EGTY\G+&5QO5X%GLGN]ZKR_>=@25E=.]O!T?X5
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MIG?%;''_83Q(C^I&:9NYN@8=K;V#"]G^:@'J= %'0:2Y<UP*99BJ)'64=GI
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MO]$Y4C,(C3P3R&NFJ>)"6VVWUB-C6:>PO;SGVL'<U23@;?D"#DY/)[80H/4
M2R,)LU811+C9GOE03Z_M_FMK#&H7]D[OR#[F?.V+LCLK!0H89=QHP0%C*FYN
M":T>J*0[PCDK8+_=32VM@$TA?0&74SU?4W*=(0@1=LX"+QA#S%>O)*FT*&=)
MZ[>3J?6K;"="VQ5%7@H=%]_UBZ0/T]E*A8O%K/RR7*1;4I^GJR0%DT4$.7;E
MZYM)'-;%O,X-RF:_*!A$@(XSM83,8^:MQ*XZ%J!"@JPHC"?GC;@*X^NB"NKN
MM?Y&KRMICT7HVU$Z>"YEVDQC3RS@W'&H*N\S!8ADY:3OWYIZ*5*\#$J3J8CN
M7*BWM]-)+78]+QHP-HAQ)(3S%'*E/135"L&<1YW&&^[F34(OR)6IA\YNF3\D
M4QZ4<8ML!G=E-) .W2C?72,8H2P%Q@I'-%0,,(BK;33#".6<^O3R)F=/>-:,
M.KJBV\=B,2@GQ<@-9I.(PEP-A\O;Y>IF<]QHE\/RD+%WO'(@Q&$DD658 RRH
M(*8*HVD8DC3GV4SO\EWWA("-:Z7#!S951]<1Q*:W4<'?BLF\_%ZLG85OI_/D
M(GQ_<S@U^XDM!8LYD ;%4>B9%UXX5>5(,,P(E+/-Z.5=TIXPM5TU76YO?=+^
M.!"GC*(.B*A'SZSG&FZE0A3GK-.G7S-MW1G3$^IEZZ$K=OU63J:S%4IKR0]P
MZWG1P#V0P LEJ;*$.>[U]MX31USE++Z]S&S=$VYEZN%U^01;]P4&JCWAT%@G
M"?7$64M=M4_C#,.<&Y&G'V_\<>?'#G37EP@4]4Y1=E8-D$#-D *8"LM=BH9J
M*M.:*R6R4M"=[CF\JK.5)@!_H%BWZ8RW@3GF[V]2FA(_GO[>B[3&V\Z<EL[X
M1;5@D:5&PVB>&R:I9\XZ;85#3$0C':%:TW0[TJ:$#+&['V913Q%???_W>;I\
MLKWII(:+\ON:8<<Q.+VQX 5Q#DH/XC1H $;:8E<A [3*>0[2RS .S=!DVC'N
MW9U-36_*1=K7'CR2J@H%Y:*U**+YZ+&5C#E*#*JDD#+K?F,OV=.FHE]&DCX/
MY>X. _[/<A.&-@6<B!;6L%PEF'EPCGR>-C>WM?%U <85'R-C).. "2.!QGR#
M+#,(YP24Z&%ZS0[9VP-M=7>Y-^IY6*[T?_ F[T.Q$$T_IT$<NY)J PDVWIM*
M$I$7R*27\^9EZ?#BBN_9FNAL;KU-^]C_6G7Q_<WSF,V'9LF#%0,B0DK'E6 &
M.P"I(PQ6TGK!<YQNO3S>[Q7O&M5-5TR,0,W28PM;K/]\,SGUR57-%@+D4E#G
MB(5Q" *&C,*VDA]9E7/UI(?O]WK%S'94U)FO^%M$7 ]63HW;%,WJV%*\NT)0
MB!@*.(/02R*9<D!69C9CVN7X<GOX"K!7!&Q$(V<^MGDWG20Q*[?P)B#:GG<U
MNPL'P@RDB$">@L,@+!&2E17!L5<YCM4>OO/K!74:T\:9M*F^="WS)K3>^\FN
M?+TFO:.^*:/2B_G[FVA^3N<[KRXUT6PT:*$AGFBO(X8.>:@DK81W*.O!30\#
M0_6&BAWKK:NU]6^#<I) ?#^IE_1I9_E J5*"0Z X2YFJ-3"&5+)YGW71KOY9
M__:BW==TYO'YCT'-)O5RYD3YJ5@LQAN7^T.^X!2=9+7JIS.GA]O/Z;'DDZQH
M^W*I9K8:B$(&4\P4,5PJ+X#3OA(]PI+SRJS^P?U32EX_&[M77'=.P.'V0#6R
M(0VW][,$:MST+P]'PSY<,T HA#50ID0I#!LOJ5"5O-+ZG-2*]9]#_J'GSF8U
M=.8L:KX-)E_CQGSU/"1YC[:S^)O)0T34M'L:3/;-F2>U$:#1TF/O) :8:80T
M$GPKEL^ZH'?"\\8_XA39IIXZ]!MN,'N8PT_)'EJK?K <6TV8\%A'<24Q0E<'
M]B*"FS,YGG"AZ0\].[:AJ*Y(NBO_[M\GLV(P+O\K*OWP-8CCE0.TDGHKH80.
M.P^-$ZY:&82)V[H<>O;P?+E7O&Q</6<NW$]C5FT\5JN?#WL:C]8+0G#&)-%8
M6>(0]BR.JJK["LFL0^0_3TSV+\]-:^9,8GT>_-#%I+@I%VGB?:!VLD_G"8VX
ME]KI?]I#N+/;"XY0@82SD%D<]V;I#?Q67(Q]%A'_/#G93\2N--;5<NRGLZ+\
M.EE'1A[>?YX-)O.(S6;/E032Q4TL<_A]Y0FM! HQ%919PKF3C@F--*AP<$2(
M'.;6/[CY0]N/[:GK<E<DMCAMWM?7N-Y8OY%@J5'2:&RYE81[*#"KD!;,T9QX
M?;"701][Q=?6%'4YNE9Y"!_<L2<1]67U(*V QF-$A;"4(L^DK>XR2<X[>E70
MH>NH#5(<Y5TV[GUBW-.,A9G\>]I8D-X[22(8DBG&332CMY!+([,N]M3?A7>]
MR/>$DEFJN!Q!/\R*NT$YJN*Y;C9V:C)ZE,;^))+6:3!0!*)!XZ#D<=QBIS@!
MU<4521W+2>I5?T-_[=-F"YHX^PK1GKYM^C2O.E6EGUGU[4D\X4T.O+V7B9KZ
M@F"%Y)!XR(753#K'";);0!#NYG+D=5#SHIJYX*8HB?-@D9\^A>YJ('"AG3 4
M*2DIP]Q3)*IK4Q)QGV-IGKN!?ZV\;!7YR]N:A[*LGV5O'FHP.,\]T%0#HPUV
M' &IMZ.2Z*REO)=[](N:FPUJHK&E_$"R[=JK]8$V@I%:J)1_PBCN,25 V\J%
MJQ2G.4??/<S:T/ERW!STO9GY&MAB[VPIH-@CP@&52GDD-:,25B-,0>IRJ'AR
M$*0_RER7I8++4?)@<L*3*'FPI8 )<<!0[5$<J,@8$7=M%1Y$9=TX/SV)Q&N>
M';M10&.K;K6K_UA\+R;+(FV8CDY[9[84'([@><4P].D, 3'M<"4B("XKFE8O
M\S]TO@@WK8/&:/;T"LC'\NNWQ?N;O\_73[F?):?;F=^MB6:C'0(5E9@1*IUE
M)DI-MY,^,5E^[3/"N;WF6>X"ZFB(B^7D0.;ZFL0[V$;PABKD(/"*,  @P!32
MK;7K:4X(X#Y>8NR894UBWRJE=J6YS^+7K@:#HBDQK)<*.!]%UHC"ZL6WYM9D
MW6WHX9W&7I"M 47TQ:M\KDMO;RM!6"\<B-;L*DTC,-YM+ZYK:U#6388>WFWL
M@7OY?/2[8F'].&H'2%B_D>"0M,XZIK1%$73-&&45"@S"G$GQ]#FQ]:B]'4:I
M:TT'%V;B^JIO0]%C#S06F.%&$(V@P\!+KX'?VB?:*Y-SRM'+>&)=1H]M#O>N
MV/AA<+^YI*F&_UJ6LZ+FZX.3Z@</H("<$8\$4E@PZ;:N3FWB[Z[M;F&;]'@>
M<[8%!71&OMET6!2CU1V)3X-Q\?[F5/;5:B ((2QQR2Y&#&,M$'&586R S7K3
MU\LIKTOZM:&!BTU^49IH1RSN/XSC5DM-1NE!XMWM[EWSZ8T$G)+'&P.T<<@I
MHZW6E?EM;#14KNVNX"6GP::TT!47$U"V3, 4HS28GD6P.$# (S4#MA0[JGS<
M^B'&+(K_5#:.(=SD)*/KX6ZX0\XU"WS_]A^-[#LBNM0+$<>9,!RIB#- U<T+
M(Y7,V0F?'F?Q4COA-NC7F@XNS$1?3@:384,[X0.-!0>]UUHA99A07CJA--X:
M)83DO('N:4+C[G;"S>%^B<W(F_E\&;L?K=FWT\G79,S:XLM!(_!HY>"4CR:P
M1UX8Y Q2@&\CG!K*2:=9>RZV##="BP-;D$:PORSC'H72.YEPC^H&815F3%'$
MF858(N-!!:>E"J,N-[U_ +Z=#_U%O"VIG^_ODE[G[D<Q&Y81KKJ.EEUU@\!&
M"HP<-=&D(/%?S*H=OL6 =O,.[MKIU@3T73M7-K>_/D\_#WZD>X<IVV(ZP9[.
M3DX"<&Z3P0/+$88ZCDH.I<0 D>HDR$HLNMD"=_V:N$N.=J.82\R45?+EE0";
M3*$U)\I=5=.A)#0<T!0RW! %9'+%;R1F2N1< .QAVH$+S9,-('\)KKV;+HKJ
ML4!-CCVN$J1EV&$+K*(40.VU1W$802:XAD2J3A^P72VW,A#OGV.E$8=*D!@2
MQD#RIU-J# "(;D<6$%E;V]/?M5W*Q=<&[UK305=,=#<WQ7#Q_L;]&*X")'^,
MYL'[5?#%]/]T)O-],%Y;#A&J<IAB),=?J,GHZ0>/2AZ@; O?%I0&S%D-H3;6
MRP@H4)7J'(N*O*[3DU9<A)=72Y>'>&?+]*&8E2D"\_.KEL/Q,AG1C]%;(WKD
M3+"[C@1/M87&:6XL08!3#TQUI.HPDCF9.7IXQM/*(.FUQE[%^&EK. 2(4UI9
M3#D#W@JB* +5Z9F+-E^.]^!DL_INI>G(P-GB#\;Q$]7PQZ:LMP0HR!GB# +I
ME5,4;)='E+43/-DB7U/63=J]:]1#PIZFA*X(^VEY=[=.YC085TB]F=Q,9[=K
M31\_:J_90A F;HBMX(I8#3B4BI'M@$T;H0P2GAQCXI6:SNU ?>&G7YFQG/:T
M$>)(@R+N"I 'VEF/)-C>ZW-:DJRGU3VD6]/,J/?D*QOW[KBW3N[Y85".=K_G
MWU,R<"VY)R8=12C'N.9458AY*[.\63T\.&^?1SGH=L669X$"WG]9#,I)<K55
M6R<_G3T-+5 G DY&JP%% T'*"$AZN&8$!9I6#@Z/'<VYOM'#\_2V6=B=)AX8
M^^^_OE#"V_C!ZE<[?[-IYP6PY63ZO9S^93B]7:O#3">C%-1L9+;7C8O1UOQ8
M9^.,;7^+9<KOQ>.46.LN%C\616QA]','QN:#4;3)LCP9/>G=YM,:1N=I+06#
MJ(>".0@@M0RDXQ@3YQH%//:0U'L$WMJ)WTVY.)*I[*%0X%X(&[<2$C),I$)4
M.U))XG1>PI,>S@1MZ?GED=YY '>U)*U#";^4/'4Y+J3O;SX/?NSV^]483?F-
M!QC7<2,13-YVA>/>1EE=H:84S$E:WT<SJ2-:=JZ82]/Y(076?ZPO"SVD/7](
M!*AFY3S^RL:_3KZNQ:_ .(/DN5\9H!88,XB(10 *JIA1L$*80)_C7>OAC-PE
M)6N.AHXUV)DO^:6D58^W9SD?IK,591:+6?EEN4BW4#Y/WTUCX<DB*C7VZ6NU
MY3KD76[VFX*5.AK@ B*H/:,PZAN#"D\LU)6%.^EJ,;BLEGK ^O987@LO)*V&
M2  8_W0&Q?\XNYTED,LYUNYE HT>\+H%O?2 Q^=Q-'@9!V4$$FL7%RBI"65R
MNVQ:D_- L=_7*B[%OA,1[X.O9^.UBK^]F)-GC>&V4_4R9^ZJ$32(ZY%ASGO@
MI;;$2V"-0D02S@VO=].B94?6YR.7LY\6#%$2K@'ABE"O#7$")#_B6B+KLFY&
M]7"KD*W7Y\>?.6">.>_/9XM'M(A_>TZ)^%'R'HV6P\7[V:=B]KT<%NI'N<N;
MMZ]HT)!A 3BB"*4 L2D=C]Y((K 35_88^%PU3AM%L0,^I!1@FP[.[?0V;DH/
MD^)E^> 0X!9@@A$TUG(@@$&53)3"*_$MY*OT)3>RP>S*4'P;>QB7]-^*VR_%
M[,!2\J1<X"A.G<3(.&H$=!$D3;?(*&2S8GKWDA@Y^IPVA^1Q5NR,T+WYRM_+
MQ;=GZ?_*8KY7]35K!H89]=@BR)@5Q%%#:;6@2F'1E3SN;Y8,[6#;X3O!A,,#
M#"O?Z-$YY%"UH'T< X!@0J70B&*JL*DDE:+; #BOA44M -O9S<_*#(L;T.)-
M_/'0 ?3+PH$YR8R) &%'K"/,.%C9;3(:\3ETZ=&DTY#1VAB.G5V!6B?LJ1-K
MZWG1X+R S'")J+"$ .NL\)5$ (L<9IQLFW0:2>L,I3Z_F92'9<?L2 ^@=R41
M<S\VQQ'I>E7\=W38Z7E&:\%)X'D<=MA@ P&Q/H*ZP44I0K)2=_618^<38S?#
M6@2[LSL$U0V];<;M&C==]M4)'&HJ" ;21&0)=$(Z5<GH%,XYL^QE5.@&)ZVF
M0.UN]IH7\;O2<QT;1\-XNHH$O#^U;ZUZ(4K$J5384T \)P3'G4(E*U"\TP<'
M71"H :V_F)J:P[<K+OVMF$08QBEQ]>BVG)0)@D7YO3C.IB,U W!848[2T9,!
M&@G,MUL1+93+28#:RPFI>3XUB_#%EK53EK/@#-50:BB@X\ICA!EW6YG(M64:
M:IXSN8AVSI*'VW=U>/)0.FC!L$<0*6^,])H;&?^WD4LZG7-CMX=,:</<.1O,
MSB(_32?3IYW=L+I.!.UC=0,B@FBGK!=>6TD=,J1R:VGOLPZS3XZ%\\HLYJ;!
M[?H9Y;K/VX%P\&['SAK!<8*<0MQS38UG #-;S<]:<Y1CW?3H_*H%?>]Y4)F'
M;]?\.6X=/RN9<A8 2)PFZ:(JHA9#5MEJ!L&.K.'.8[:V3IOSX.V*+N[V2S$:
M%7$W."N_KTSWAYO]+W]W^%WWR6T%P(@0R&F%D%8J0H-PM>$T&J)KBV'=&M?:
M1O[,(WFS>NG[9O*/P7A9I$NFV_QD;R8/I\'I>NA@LNM9]\EM!(6%(4HY+#
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MKJ)?!,QO M3N1Z8>C),?[,D!AIY.1G,U&;V;+HJY3:_(QO-7/X*=LI)"8*G
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M(TBV?I@],X-%\74ZNS]ZGKTM&2CFW&,OI'7&4LL% J(2P453..>ZTY7Z%G,
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M-\%0QKA2BALHK%,V56(KQZY95@:-5[ );;[FY*#8"P,N+BE/O@I(8.NDDT@
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MG>1^J-J_7L;)YW=Q:?O\5W'WO?@][DR^7C*H>1T'[AQ(FP;M$5&>6(;B[/>
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M[.Y32AA_J 1]W1*UTG\PV.\OVJ,0UBD*M.-'15+!.1LPYOU=>@D1.?M<E2^
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ME8:X%!T,7-SM2EX>?Q $6 XE1UA$<A2GUTW!;WCR>$[2%$&UF]U="/"IT3H
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MD6OZ<Q<!:H]0],&8X)8ZG7+7V=-T1C#GR'N$D5@]$K(EQ >*(=D?/?PZ\2$
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MZ@#\.E/[,&\]8HP:"*Q)=_,.DU)&ZMS$'IRTHNW*J7WJ8?M:4OND<WLI&91
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MT*FU'37.B=)2$5I&B.4%,G.]RE7Y?96;)9I*C>-3U90X;RG-@"QQQ?_QJ9
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MNVU8 KK%/EOUKXB7U4--SC7O !FR7J)Y/&^6Z[.%5I"N3POPOQUK98*M&6L
M=G"*IJP6:4"R;#;4J7EN>0LF2[PW .\[$(5M5+],>IV:BI>N?FLQOGUN6VK\
M)DRA'C[PVR+G+1.CK<E\YXE1Z08TS0UH4%IX>S&19J0I9J1ULPHRL]"JV&)K
M'2'#BY/2!%LXE-**-"3]5'/1Q1:B()5%:QF^M8&0CH T"C("/6@B>C?*7^[
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M3).L YPO;MB\,*(UXK46M7)I6T*NNFH>:BZW:*HZVX'<JJ<G>ZH4@$4DGI(
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M\*1!M[<-Y^0*D%;5C,D5("=;VBF1*I':2J3NLN %TB_XJIM"_K/S[>,D "4
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MXFC)GA_W$D5L_!3TYHI QA5D"E1_\'\LGV-MP@3^],2D0T_@)T^LWY].M?_
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M[MQKF!+BF:ZMVZXC-K+<2CX??E0NHY0EHDZH0E!E-F"UD*YFC6+(]-8\U51
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M+K.K:=!#AN9.MFWBMG=AV<3^5C:J>L>@L&,<QY2'C#:/ #>D<*X%!5A%)M8
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M:T!#-M"!JEK3,\,- R_L_5;@3%;V:A?Y,EI9^8DSY9*E5P]W_O>=6V,>)W>
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M?,D=;&9UT)\AL-Q-T#&T!IW@2J' G&!("F^0X'RYFA$)*39*_[8"W?-\VFU
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M F]TM83J&EZN+F'\=#[\9743EF&N/=8*LXQRE0G:B2I]"!1W $WUF)/&VI&
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M@Q2!*H J.DD5<IW](R1@CZBQ(0AGL&?!JN5*2.&)?A6CHN'2/9D))#-"P*B
MY4F[%!YL1CUZ>4VVR]F/2:C>U,2[-US(]Y[IJ='KW@+>>IRV:FU7V"GGC39:
M.1JI($+3Q5(%P3P2_!FTU98P"1,Z8T@>D*/VV[H#F=$V&C1=2YM@A-?&##=!
M*95><0C%R#138M$C+J36;B-SVC@K-!\1P1IGBN]O$/4S) 2 #\ _$E,!HUK<
MU#/AO.4<$\$L4\PANBQP#,'&_;/"7LHF!,TD!VL!2.-H2*,5O%"+DA)+M$=*
M!D%,0!A[K]PR2JJB?TZ4M"VA#B)PQOC^%M,?@[70K9J+ZN&]T>A/AR/.1N-/
MPW'O[76>1*5?W%5G/\W2\_V_O%@(&MI<<W3S(1K8>-\"N^GQT#!&"J^#+$8X
MZQ@-V#-+O%$,+P9%<(,">T["^3!U)C*Y2B+#7!]R;T\G(KTGD!,"A@.&*QD.
MHS7#:2^=#TQ$SGB4&N-H%@PGDE&HQ(L8;@_E,2K3C&="[2^3!00'!'<4-QD(
M[IL$1]8$AXP-G$07E46!6^/0JBDP$*<V=J8^VX3;P_ O(C+)@>& X8#A@.$>
M9CBV7C@K8PQ84&&HHHP0JX4BRP(FK3UYL0G7>#$232:<W&,O1%<)#O;4/N>8
M8$]MZU?"[NT;6[4 EC6V -9K9)GS%C%&.*76>A<EXTA9Y2.UKOR;G1; PCK6
M)W,.VZQCO7Q_X?Z_'R]^\N'=Y?_;"__XY>S]_[;]Q'9:R+K+H=8^[RM#]*3W
MI5+VW;>S=O/O(/S;6SMW6Z6ZVTNLZ0\\Y,$_<@T;_ZY#GI?LZ'FU[WZ]:E;]
MU09+OL:JLF]Z5GM>BYN/!KUO+DCM?6.IW4F*A3@)J7@[*:Z*R:0H;^RX_^_3
MC#B>V#UWX]O;<IXJW/#.#Q6&>]FI<^WZ^<&][,[YP;WLSOF=S+T\24_G-<9G
M;%Z+EJWJ/K^[_5!,JMS"^&I^&:?7^:0XU.[J%UV@MM+#24J2N1W?C;XQ(P(X
MYI0EXRN.Z0&] +T O1RS9+S"S4^'4):5Y3<5BWS,AX,WPU'U>S__.)REYT$P
M3E(P^OV[V[N;LM*KDH9!<37L#X$F0!HJ:Z-<)3!GB7JA;/7,5XM/05Y.4E[.
MQZ,W"_%833A8",=C$^] +CHN%^_'LX6E424/K].SQ63Z__R7(EC^K7J^^,_=
M</9EI\A:.O>VC)C<L9[=YC?YJ%_T\EG/%_VB=.[FXD1Q65N!]3ZJ_D]DY!,G
M1.@"([9>H<6=4T1(9H2*R$3NI3#SIA!C- X;;6^7E8-]-IW>%8-[72!G51<(
M^[^+M_[?RV5)?*CDN6PG&8_*"GGS>3A=O6M5/'%9HN'GZH;7NDCF#GV]D>3L
M/&ZY.8<TNH%^9QF"J4]MTT$ON]$[<<)>A:--;7-/RLU1,Z=@*^94EE//A>-2
M>F^)1@8OF1,YKS<&ZU[6M/V<$1L8 [X7SMUV4=GOQ60\R*?7)=B2]4+^!G0+
M= NVV<L81JY'=]NR94M3SZ0A-%#IF5[99AB+C8;=QFVS>9%C\X891CBC F>(
M,J ,H RPT,!":XP_:ZL/B+(*62\Q0EP33R-3:,&?6BI/6VRA/<:\N^Z1G9,N
M$"X0+A N$&Y3A(MK6R4,M<P&(ZTQ$6N"*==N:; B)C969+6(<-=% &_SX>!L
MY.:9_Z;(5S*2"28RJ?8W<AH(& @8"+B#!/RM&5]+!JYM\- D4BDC]QI;0ZAP
MBH554#*BS9!!>QCX73'+AZ-B$/+)*'WV]%G4N\U ,4EUR;^9V./8_UV$[ZA'
MC0%E V4#93_79N9KFYDQ9QF3C"%M(O..",J7C*TPW4S MX>Q:Q5Q%V4QW ,#
M(YNRGYE,]O,>%UB#[0Q$#$1\>D0LUZ:SD30R(1AC@?"(*3,^+H,7GCG68B)^
M^*,;"QQG6B3+^;"[8H!]@7V!?3O.OGI=AQHXL9Y3ZI12U@?OF%O4.BB"%%.'
M9-^74R;/&&*9XF"P?ILRMRMF/XJ:];+DIBI:'U\E@5H/!BM%I-?/I]<':O78
M-ZA797[//IO6*N8.Z-^MYP. 2(%(O=(LIC:8&X2MB[<YERR9%<C&J+6V6'&Q
M=/8TUGACG5UE;LPK*_W=I#0RTF&,!_.*R_/BM^JEZ8.+G_ _WON6U%TRFF&F
MLG1!&K1+ (= [;MCDNNU"Z )%<8S+X7'&@E,Z:JAPAC[L NPB<E_YC=WQ4$A
MN6M,NT1CDT$50"(@<7<DUAH/C$7:HTBP"!HE&:4AH%45 :,/MS8="HE[KM0B
M2&58JTRJ)GL3 )H 3?!_0*1 I$"D0*1 I$"DMK%)*5\GB'#42G,D D;!$JV1
M5FI5)X6D:]8F;<:.) QGFC8YA:3EV9KC'CT4/A>3_G!:I7'F^9OQQ_)^35=Y
MG&KUTZ=B.DO'5;[KW>4OTZPW*F;E@UG^N?<Q_U(M@7WM$H'V*H1OGF9K-467
M:S>VGRT-T@G2V:HTU%%)Y#;6#D/K6#BA5 G,F32(T, 4CWC928DXH_A9^:GJ
MI\VGQ: ,J16C:5Y^>]N353ACB&<8-SHB!.#=(GAW4_EL!76R3D4;0B(S6$K,
MD2*(4>O8LNZ8&O]PR]XW')O70_K.M<4)Y !P 'C7 ,[HNL-+2L,P5=ZA8+RG
M&#N]TN7(;UMK<@" [SFU1C.D=49THU6Q '@ /+B3()T@G2"=()T@G2"=()V-
MFO*<H'424DM&D[]NG2,T&B-=8*O".,X>[A%NQI1OPOS&"&42-;H5H74@[5!;
M624];SZ4(E*VE:UDI",]&U!4<M1$#R(%(M71;C(0HS:*$3 3B!2(U/.<%X%J
MX_"Y0<Q&$F5@)!HI51!+YR5&M=%?9P;_NIO.JG*V]^-OI 8J)^;#?2?F7;G!
M<#J<%9?%Y-.P7\R]GG=%?_SKJ/J4R@$ZDJP%RQ"6F6QT<CY@&C -:@)$"D0*
M1.H(16JKL>1"K&<K6J\0$<IB0X1C&A&#5IO,HJ/H6$V/!@8O;C.Y'(N,-#K\
M=A,,+Y&JUYLN#D30!B)X@@?4F@="Q"Z0J)A61#K.B<3+L3M((^5;PP.-N T(
M9YQ#]]>1='^9_EQB2@D>7_72'7M3X_;><$'NZ9?>#\6H&$./UQ%E!2%UW[74
M/4AG-Z03)!(DLET2"7P)T@G2"=()T@G2"=()T@G2"=()TKG/$+&B9)TJXMHI
MXZS0@43F=8QQ-7M6>[,Q^>+A%,S9J#\I\FD1)^/;R[L/T^%@F$^^+!;%++9U
MM"@)]-@<L0P+G6EHF@7<=P_W'*]P'WFPSL> M/)2*NJCP\N-#$2SC=30'G /
M8#VY%IOS8M:[&4^GO;RV+:PW&W^UQFFQ9@R*V]NJ'4Y)"8!(@4A!VPV($3 3
MB!2(%(@4B-3QB]16]=2:KUNYE%;::N6D),P':;DF81DD0T9NC)1[.QE?#6<_
M)4>GJ:#7NV*6#T?%(.234;I:T\9KGBG).,,9XDW.?X6Z9P LZ  0J1:*U'8Z
M0*]U (T&.2D(-5IK+'4PVJ]F$0DB]Z\##M3]PC7+*$>@!@"S1XA9@O :L]'$
M@"U"":0^,,681*NQ_HR*C<6:6V"V29.+9ICRC*%3-+E.H<7EE]&D2)_W>S&8
M)SW*!,?U>#)[DYC[MC<<E9N-=EY?-)X,BLGR]/#'S[WI^&8XZ/T7JOXYKN3E
M"TIJ=KT,K34,(?5^;*EW* CKAG2"1()$MDLB@2]!.D$Z03I!.D$Z03I!.MLN
MG5L%Z#!;#ZB)6B"IB6+4R^ "$VRUC \ACL/] -W%+'UQ&1Z?%-?%:#K\5)R-
M^N/;8AUI^7%\4Y[U#_EP5,;Q+D:71?\N'>NPF)K)<)I>JF\&."]F%U?O\\^-
MS<;L]^]N[V[26P??.M3FIU5EFNB,TX,401]+>!&XI6O< IH/I+.]TKF=YE-\
MI?DX\IPY&CBQ03K-I"=J.:(12QY?7?.!AFI# NPH\EPVORD;O7KYK/=S/NE?
M]RC.>J4@O3BA0S]^[@W&=V63T#*CTU[T/PY^@N2ZZ5983[54'%G)$5?1D%73
M;4#4;>RUJO:ZSQ=;W0/LV1RPS[13WTZ*JV(R*0;-[Y$GC>Z[>DH:6JO".Z"I
M#X_3Q8>6[]A,Y>Z9Q/ZPSXO0^#D?DKC(VE]'0DDB#$51^""%T$RO!LHR)3>Z
MAB]K_9R+KN!1_^:NO 9OQY/RRTRM$?3]^.$2MT-0WK8=R+\7D_$@GU[7')+#
ML5TC^  J["X5'I(6V'I/9W2>^-)R"113EOY+Y7+>/%*2;M3&-F[/N*I]O'EC
M!C.>:<S+39Z <\!Y:W .)L]^N4VLN<V((*VVG$HBN21&.!I6NS24WZ@A;I')
M\Q@K[CAQ94&(0(9 AD"&)T*&4J_)D!G-E0[""&88"XRSY=0HHPQY>"%[.\C0
M#/:ZME!SF6E!,D$:C7(#.0(Y CF^)CD^D=,CM191'4TR$9'W$E&F-3.6K<+Z
M$<>-,0$M8L>]SQ>0DF24B$PB?4A^W"D;^)I(.]&^5*!3H-.23BE>&YM2X."T
MCMAKSB)%R.JEL8D(,6U.-KQ.'2#C(M/TH)%*X%?@U_;=Y!/FUR?HE:[I%6M!
MD_>N#5<X1J.4X:LEP3H2TF)ZW>\(>)IQHC.L#VJH@B,/S C,^(K,6!OWA[TD
M'LO@E:.*.>.-MZMTMN$;Z]/WR8P-I&R4S!1G&48'K<QK)Z&=PMB9Y>*%<JUR
M?:Y^*22]?CZ]?NV.A)IH/*>DL[V-)#N>T&MK;V@S.;8V$VB"ZH9T=D<BM[&M
M&%K;5@&I*)!'E#(5#.=1.2L(99$15WJA#]I6\TK!>OO2O(+PO/BM>NGA<7WD
M^?V[>ZLC)!EB.,.RVYN*3AG2W50X6\&;T'5;(S$!RQBP4\Q01@BGLH*W$,21
MN-'6^ UX_S._N2L.BNY=G:L*V !J '770,W6.T*#QE@8JY14TA.FE5N 6DF=
M\/YP">RA0+WGNBY,<":1R)0"E /*CPGEX"N"=()T@G2"=()T@G1V23JWL=]Y
MK9#.&R:99]H9+$2,A$=.G:14)H><6KPY;N1%]GM#-C=6F2:DTS9WAT8 N?$H
M'?JTE,/Q5>_C<M;"(O%X;\%W1_;G;E70RFMM\II9YKP.45$C*>9&<"8\E8$0
ME?3-P]U3WXI]KZ_XQ=7\]]GPPTVQ'OK5E(/]TEE!6]6NGN(*G!,HKCKJ=5.P
M=;"-(G5T8K25M2;92DL0K:WFAJ47C>=66VQ=TA)E<UDY9N7AMH=7UQ+[RISR
M##/9H'( : +;[PY357>J)-6"*6\)$LF>4U&H.4RQP]P_7"3Z#:>J%2C=T5EK
M<A8(@!/ N;NK)6IE1CI($ZUPBE.O+9%(F3DZ=1#><MM*=#:1RMQJPR\X6X#P
MEB$<G"T0*1 I$"D0*1"IDQ*I;?S.Y%FN9^UZ1 U'E!EAC.>(8>KGEJV7G-EG
M5=CN;MFV;')VRU-XQ]U/&#X7D_YP6O43SO-YXX_E_9JN&@I[^6C0*[?9I^,J
MW_7N\I=IUAL5L_+!+/_<^YA_V7G1_3%EYJ%N!.I&0#I!.E\Q!794$KF-\2-K
M%10A,$<Y+4?4A$B5M]%Q4<YN$!A9;[>M9)KGQJJ?-I\6@S(>5XRF>?GM;4^(
M2<TRK42G"Z-.&=S=5#U; 9VOUR,Z);7'%'NMG$(N@="K"NB*&V?0L[)KKX?S
M'5-J4C<Z8!_@#?!N [QK-2XB>H=00IR4B#!F!#*Z@K=ASF!BV@/O)G)RCT"=
M98S@C+%&9\T!X 'PX$J"=()T@G2"=()T@G2"=#9JRBN.:RN!N<(*LV2[.^6L
M<B&@JKF0>F]P>%8^\IFF?#/F-\F2!])I\[M#?8:5]+SY4(I(V5*XDI&.](I
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MEX;51CHI$=?*<">\T!Q;31GR/@;K]7;1.U^LHW?W8C/'$:JG&58X$PS!XCC
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MK%L1KL'8(8Y:3+@F7?GR"_.;M_EP<#9R^<?A++]IC'PSI&0F&<\((T#!0,%
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MLZUJ($9M%*-V<!.(%(A4.T1JBPPG1PBO,R#,>^2)\"0R%#R10L:E_V.CV,B
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M":Q\.:ID$.1W6YO?!?D\<?ELH4Q"1<Q)2V3+&1.D$Z03I!.D$Z3SP/&*QT=
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M#+2FZ%/A-7T&$CVV%IE(,0^4.4_X@CZC=WRC#+5%!MICQ+MC#&S.N<"WP+?
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M7<!A%WO!W'A:-77E_;FDE)*;'J8[]:9&S;WA@IO3+[T?BE$QALXO2,]W2[.
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MF@J5O2MF^7!4#$(^&:6K-6U\P!S1&54R2^?>H*M]+!XU +;=@ 4= "+U&CI
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MBJO% "C9R@V"<Q_%4D+S##?:#P39V&/0M_N*)Q\MIA56*TR7JC9*$22+D<J
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M%$E/W3UX";9T"B^$+Z@P_7%WF/MFPG0?;L),B7HJQ]"=)+%\QPUM*[!-U[*
M:D#@CR/;-'P'[TFW6(8M;)^[""'Y^.7K[Q^_*M_^ZG__[(?Q;S\^AOZGDY'R
M\4O8W\(;QRH#G"VLK#L?^Y>O/^(3Y<=7)?SZ)8J_G,01_G7R]=/'R/\!'Y*/
M7_POX4?_DW+R [[X''_Y<;+O<WK[FZ"V=VLHB)\Y; /J!);IA!$V)4Q\S;<
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M"=Z\6W]-6$QR@'YV4-Z^\4]"N!*%%&K!G<^D10 MD((CA-9&TT-3=LG$9](
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M#KZ<U8MF>7M<H2%+>7OM.VXWZYKCT!L#2B)H5R"0H6L+-P0-S7F)G*$17P2
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MP@'5O4 D/(M\ 2''L;5=?T\E/%A]AI(JL+X4;4OQ(4T0-,U?=!+H+( <A\Q
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M^5G=\$Y)"-*(1/AB-T*T6E+OBSN>_HU5&^]6Q_$IP')-N[).Y4=-MZW(UIQ
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MZZ0+D=XX^>P'U/OU]KR.2HR<@2C_KBE> S#!%6XFX6Y,/Y%('O1XUN1;"H1
MTV$ZEHLE,&L4(M=%EDZ:(8Q:IVN-7DTJ6L,M@VV<='L_E_'%[=M,G"SF%[A_
MM!%R#9BJC2EL\(C7"6ENYV5GFLB.%K[Q&(J:*AN/ KSK*B,'K_158_!F@?RR
M!4\4"EG7<*K+GD'ZS[,K;L.D4D?5RJ(V+*A-I"W*GV+'LXE0HN"X\LC1UG&
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MG6.5HEDK(Z9_+TKQE$5ZGAV=PN1_'J5G,*;WZ?0JO:XP5/>B[$]G9;[$]G_
MO$ZR:4;<[LC4S= QD]#4?5--U$2S(Y[<&ENF$;I'^NYG'7[]_6-TI'G*^;0X
M!1J'^R?9+!\S<D&2Y4?GQGVO"A =D*:O\OH"3@VP^;-\+!'(L2)C\*2 \X?/
MQ0.(%%G I=,IGIBJ@P T@)QP#"\'\,H /GYF<)H)TO!+^*/N(-A5#H\ZS> D
M_FM)\"L]OO/P4U),X;HQ*@O7_,P"G/91$JGCZB(?7RBS]!H?#N^<\0"[8R6@
M-2D8Q/*E 32<<H AX-V"H>!$TA+'"/,&$:L#10K5[H$CTX(8G_#_^0]7UYP/
ME0(3 UKG=7O/EH2JX[2Z4% /(H8% \?$ SA[\%0BZOJBJ#)I%%UF<)I-<T#*
MBKY<]K 1!XM;(#$VW&I_/ 9Y"F!D>CW"A=H'1.PS.1PX;CU(?A-<;Q (BBN0
M@3-B:ITIP75DW" :P%.Y<3./MP"^QQ>Z_OQ_4X*@RE1-1_/L2-=<RXHC+3 \
M^&AIFNV&011$B&?I-M+:BKYE#B&OK8E_<8Z5_]N16KO*3,22O/[G1Z^4"0;.
M4)A,E%=CV$P@B0H!.)@6XY]OUN Q:&2V9SBN[T>>ZP>^[]F\5DILPW_^D=IH
M:IYA.Y&>^&;D69[JF:KMFUQ3"UT_=)C&!5N>3?SZSN_1W@ ]C],%<L)RF;$8
M((7FHGP&$(:9$(KUQ/G.IF]F0-L,Y"'SV,2_9 W>7LGR&E+^/U_F$Z+N,CM/
M"9UDT7DFK2CB*!!W7ET@Q %NE%EV!$1=RC=<P.>T'%]<"[X <E:!M/]OCI;Y
M?+&$9RTKDI?X"[IO):8(Z(O/%I)R]E[YA)(U@SUM!,!R!DLV(0GSM,K*2TIG
MXT^OEO#F%$7O N$)QC!FDAWJTB"%SRA:3&(M*2B\597C(SC7E&:N3 #D/LCO
MUSOOYR]E>@OQWZW?F^5TTP3X\;@&[@T(BTJ%^-1,[ ,Q-VD$1F<$RWE_#>"M
M; > W=;P-3QZ7O 1X(Q2)?N55S7C;*5@^2@:X&[ )%#] D9-^AR\MU@0QA=7
M<Q1LEK,%*17'VVNPCW&B?6!+7#R:YNEI/N5J"'+\*0P;Q"]8L5-9+@'NAJ(^
MT]M0[<'E8SL$XE4%<C95"H1C "NQHEG*Y-$5Y80&O7)#0Q[-<,8,@%"=0MFH
M!.$9=IX4T&,E;'42$I9H0K0E;+\S23GFVXYR&-<U\-PA*U]YTQF;:\7X>5;6
M*5PHZ]!P)OD+UXU\163-F21\D<)@\(NZ3.?5&9QIM!:PW8#7R)MQFM57639G
MIUD!4F9_Z.T15PPA'JY=N@D##%F/NO-!J?)?(#;/ZPN M3E*.BA3*0\6IW"N
M][Y9SHNZ\\W'/09W=ZG@9'R139;3[.M9(Q\P@O+GDT_M#G(V._DZ_XZG!C>#
MXK-^(/S<*D4X3A(9L1H$:N2&?J1'B=5PQ<350TF*,$'<BGW?"C3#TF,UU(.
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M4:&1B[PHBCR*2>!CMW2M4!3I5K^N?<D*ZU/Q,1&OEX\;#=((1L1S)0D#/XR
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M*((-8#[C),N X&;C%.X>YK-.1B:7-$K U@ 6F)DZG 7<%F<@^/.#1+_,#)^
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MA' P7 /FYW3BEO 7DM^'M_'D6U(DPB8U9)4Q^HN<W(_VMUS5+Z.PI[ "H'Y
MDQG\U^O'G,Z<#_9C*YM^B6?SB5%U/_SUPR\_#D!^?1M/K^%6@UYITH##^-Y(
M<&M)EJ*MA&A(9W?%<%,#&3U=C ?Y&SH'VBYI'2-'KB<]Y0K)%0^5"U06E2BI
M0.=1RTS=#[3=$GAGB7QW2Y6=$9)D&< #!F9@ER8@,H:&E.;6K"H,--M (+%
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M^T;GCRK#'9?&8&XHK)E9[K,TK4*0LHNL:JI3CRT#*1F#0V9&=Y/^GO<W:?9
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MR3BJ:GQEUXNPZR&" UN"S+E;6'$\#%F[W<:99=S+N)J"B3<AI'8+)+[V,W%
M4OB0+7O.:;]4:/T-GMAGO)9VB'IA0"GF# PX^+\"4BDMNB!J WKL(>T^3#["
M!+\^)./OR=^GIN[_@J-S?( 1/;7([!PL0"\QWJC$D'5Y._.8BV6 7$DI$C24
M(2M:[ A" D]W06)T.<2%^<G]OUY.]'*B&W*B<>[=CSS,/"4C7S&)2$!E5%H6
M(9%\X[GW9Y(3'0\44=T+BEY07*2@X+@!D!$@7[BN)-@ 6_O,$R&N:@3<4#RG
MH'@9UX'HG0Y1OFI.OZB2+8/L\#9#WA<!>+I%-K$&%@6-!*(T4@*''F$1J]"*
M>2!\TCK+NY=L,M'?KP_3/BJR%Q-UUE;IN?M5<'>C6S"2RD.8:U<*JG1 ?.VK
MTO)P=7!,JN=8[GY;$8R>IWN>/H:G95VB0C$C@?1HB (:A$J"DBPUMBL#?4R)
MRI$\_=:B#3U3]TQ]#%,W*FL#13TF@M#5?AB$&GFA%U4YAS!H86N=@:DO)3+0
M\0# !91:T#[.V<<Y"R$F"&OT3N$^U5I('(5A*,/ X,;EEDGD"7%<0L0*,0.U
MV$<37GF@M!<5;U14L!IMDFK,6*2](-+893STF0[+W*F0_ 2!B2-$Q=L*3?0"
MHA<0'1$0HH% Z1+,.?:(9&[H$<^7H2@CE[YN8XP^IX!X:W&.7D+T$J(C$D+5
M$L)U R'A8P3R(?)%B 4NX,BYASEK8=2>14)<2M"D>RQ^:>44K(_C[G)\ZJ0(
M3]T06A+)!K V]5CDNAP(@E#A(458&2+QM3K>[XFFBTO&B%%X@,X%$O,DZ776
MS.GEPT7(!U*7BC*M741](;@( ^Q*%D2EVT-</SKNM-J1\J'381$](/),L .]
M7.CEPHO(!<9KY"67<ADB7V%%@X!Y*!)^>8H5_"#O!>5"QZ,A?(!8+QAZP7!)
M@D'4@B%"+O4P(IA[C"/)A<NJG*O$I-6VZQR"X444/N(#*MZ,)_ V:DN>0D-^
MR^'>/>BU;]/=M^E>T12ZH2E"&1(<>IA25W).-0LKI&*&-E?G7'!$2:N!QN?5
M(Z^_T7<O@'L!W O@ P2PPG5YI-!",.%3ET9AP'6D:-DVE4=@NF\\!GZ9(3M0
M3[W@[05O+WA[P7MRP4MKP:M)1+@.J982RY I0G55*4+!"CZ]X.U\3!1+V4O>
M7O+VDK>7O">7O+PN\Y>88*8BZBFM0N1%GJ=+DS?TD+_QK'(7@\Z$#I0Z^0F=
M"Y.<-E;])]M_NOI\M&_7["4A0DU/ZQ.,^ ?\H^/>P4+.,V>6W,^2#)2V)3.S
MBXMX[,3%M\LMPVW(:N"DD^%X848%OP'I)=G<N8ZS9.0 #YC+;M+?X8]9/$^.
MZHF^$Y,U2N4%18%+9$2!S0@)J!:R,&^T1IB3529;MED^%%/Y#,/^,H<?HU^2
MF>EW&'][%4?M@$7M!S4W?_@85?S\GFQD:!AIBY'_N,+)>^^?<P]D\YC$LRMG
MA3OR-WV$Y9JEP_QOL\#I9!'G,F3E [OI7V']OR3CQ([NO2>%E(BZH0Q#CTF*
M(UE@R86"41&]Q^].SVC;AQ50'""JE8Z8C'BHD?!0.2RB!7_/<UJ"1R0C=[[W
M[>(@=B>'L7NS76\\&3EK6K9V3!@T@ 2H<CW!& *U&T08R:@L,!6A%]%6/OCL
MPN!90E!'"0%\1A'@W(\7F1,[0'QWZ>+.$$>V&-XZU[;O[WP*7TR_IZ,$Z"RG
MHPE094DTLV2^F$V<AW1^"[]G]\ LYA;[@+QQ\-DI2]:VG/ \Q#SN22D4@[W7
M :$E95$=52>R8-=7J*JQ>Q^*.1H"^W3SV4[P8@E+;"6LM@;8?QM/()Q!NCKQ
MW+G+ZT$>K]KC6J/)EL>]2>6LVI[V;],F9@(:1YS&M%MCC.ZC!5]NB/_Q_\1V
MRS*E)8J8#GF (TX%R&]%0N8S!1Y'Y'L1/.!/\3YS*QP*=HK1VS^76U=C!/;-
MDD6SS,=!SL?__-KR\K[,I\/?;N$IR2P+_[4 BC/&89!FP_$T6\P20[W>&*YY
MMX:879<+%6#JN6X8 EV#6"K2V*$,)/7?U^AWBB.F@\"E4B!&J>]'K&SF!CK2
M8QM-DJWOP>^<!.3 O7&N9HODW7\TI_5O_T<1+']V\NFU+;\F$1RVAL/;9+08
M@Q"UK_4>_7&<91M7#DLM&0NT"^N@"=,2)E;.2/HZ:*R<BSRF%:R SWR78"]"
MG)>RGMN(Z?+4=Q!"NZSG,=M!=K1["ZX0*W&IYQ("7XUI.!V/IP_6=#2V0;:X
MNXMGCT:9&\/1G][!0Q__';Y:S&^G,[AY9,W0-,M@:6"1[NY@A<TG8%7<)+-9
M8@(,L.E.?)Q%\)?%),G#@A0-EAJU[V\ F>$=?'=I<!>#P0-K>1_\N)^<W15#
M>XL;5R_Y2JBDF()"S-_-QTV,83!>(C*,\LBNC8TXPV0\+KZU@2?S-PQS6/Z]
M9HI?T[LD<SXF#\[GZ5W<B@,_I*/Y+?P*\RA"0T,@M?@^2WXJ?VD1^;NJKK"J
MK,6&EYXJ.\S?P<@??W[7BF\5[]_TW6%?G?Z)[.1/I#O=MKV0\XREVD\' =6^
MXDR]+()?IV;:E]SW._G*=I)WZ?"$"3 ELV-W=HV+\FDQS^9@B1A3R]I&!U76
M7PIQO^C)F3U6XFSDX%;V]!OG_K=* !^L!]5O?@<V_[#4]=DHXVG7MZ>2,\ZU
M8U2P.>[PYH[C^7FDR088!\Y]/'.^Q^-%XOP!72&$;8XKNXUGR4M7SW6[*$HH
MD@A60P IC$B@3!"6F$Y,GJ*<Y)%,C[I"M(X!Y+M@-^&+6>VL-F/69\X:Z2N[
M/=E3Z:O-Q4X"V6/SSP4TULU:IKX*M&=@R\ "-S"\0JYXB!GRE=*1"I@LTDIN
MR +9JK=J,7!NAIZ5>3%7 \G%@.%V=4//O#WSOBWFE?4I:.1Y*HJ([PL>>BZE
M$2YK(5R--8JV,F\CIM1S<,_!/0<_"P>KNL(QPCY'0H<X<%E 2, 5YJ7]')(V
M,OA^'(SU/]BI.!CA'**&LK?+P1<%X_L%/DZRG&E]YY>J^N(<'O)),RS/R:L2
MU=H6N])3(2:A1R7'(=,!+:K5/8(]W/)UJR7=P]VM:CEMP;*M-S6E4$5AU%*U
M9[Y__O);6C6?1_'\ .E3ZNO.:MY+5["OE_VP;K3_E4QP&6I)%7)1Y+LE^[EA
MA$*V"_MM<E9[UNM9KV>]FO5H?5K"\!<)71UH%'*IW+#JA>=)K9G>A?6VNIJ=
MXC_=\U[/>R_'>XT,BXM\&D92^AZH/U=['#RPTD.DD7<\[QDGL5.\9UJROG[F
M6W-P_"3/;AU66CV.82_+;UPM$&^GG;><,SC!^C@$K\S _KR=E4^YC[\E[Z]G
M2?S;^_@&QO13/'Z('S-38WP[:T_G!(<SR'&',^B)#F><]#!&_J>Y_*=T#EL\
MA&>L^/3['R@[\'@)4Z<Y7A(L9J;8T9PCF9OV5<X=7'&;.0F\9N28*A>G+' 9
MG.WHJ)7'C3/)2GM:>X1HETL>^8$4OD])(##'2GAB3<S=',K,X)F%-,U%<G%6
M,QGA=VM/2?WC:] IH8RWAOWVEPSY>%:."A6'S3)G.3ZU>CKH(9DE9N'R133'
MC:?FV''\[=LL^7;F<^J6)!J'B5D0:D(BYE(E*/-(X(<1D(040!^^=%O][I\@
MB=PY/0D]-,+$)Z4"/L!,/C<A%&?$[+Y?G5Z(G5T,-RN/GN=0+SY0X'Z8.'^/
M'TV=F!HTM\*QQD+%9LX7()7,<8'5+!GFA_KA75.P,\WY__MQ/,R_ =T./W\P
MSS+[2=#/OU3?N>8[^RG^^4>+!9",QPU:2.?+>U^\IN+P;[-IEAG,@6&2Y/ !
MBWOSF"/9_@^;^5XU^CY'RD,>TA%W"69<10*7_8U"-]2X"2*0\[E9MVK9_A[_
MGMXM[NJ0< [OL<S_@=F,?Q#8%@S_*#Y&"-3W+JYAG])X]FA&U+S7@!'\,DNG
MLY6A;L&<:DH0L26/A*[:)5@.;,P8?CE6D@R<F]GTSIFG=XFA!/-?0\BSZ>*;
M)=""!N/Y>Z#(]W?Q[+>DI$ GL:>;@8Q SQBS PCKVRR^*Z!4'F[3X:WEB14"
M=AZFB_'(@8F84QF9Y0Q+]5=.PWZY26?9W/G7(@9M-3.DFALM31XSATS7/7^%
M]_(GF8NS! @%W@S7CNSU9L;P@%7NM-SWSN[JZG?O+-^EDR&8WUEB[\Y19,P0
MEWAO?FLQ%1Z=Z\1DXT8-A)G5]]DM.#,3RIX).\N$YY?!NJY?\P/B8AD*K372
MGD=1Q'$)BQ"$XB3;7]A@^$@;K L[3_@Y=_[*<:T>_GL\ V&9EYP78@ZL]0>0
MCV<UR1O](0)72(\AI -7*^R;;J1,4A8$PA<H"L(M9/$YN8O3"0CO+821AZY?
M@3Q8-NO?@^HPE/$PG8VR9/+N/R;3TQOULW(-G6%L@ ! M]8Z8ZTVNG(^31SW
M?I:.'3HX7$-.DH<G=.#']C?O=K$\#U@$7##$X12_NA9V^L8\QV3=XMRDX\2
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M'H-'W2PX$F=T>^CC49AE>_(_#P/NMG4G.OAMP4/W(MCL5WU24+9O2@5AFZQ
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M7#N2^$09USGWNR7 +XQ[= L_!<9U&\9UO3 E)!%Q0'G,W,CGQ#.,RY,PB8Z
M<5'CGC#CNN=>%V[E#L;]IIIZ-]1>'$GDY]F8KX5<P@*'$M"/81BRD(3"DXW6
M%'X0]LI\]FA^KT_FE#Q5=U?V$WOU4[]UY?A-<9K7<)J@82*=Q/=CY@1!& 2.
M, 4^OJ2NH$?!:<?I6N[,:?R%T[Y73F,-ISE2QH2&81S)@ =^PE/'8)+[@E/1
MP:9X-IUV?";E[IRV5T_PA=-.B-/\H-7M[! 61V%"TX3&@L54V"Q'X$5I9U#0
ML^FT4^:T!^FT[R-KF:P4Q1?3P6V>S9\=EO+Y.=96M:\RK&A*QT,1>R).TU
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MA J'A6E 8\>&<8E'99LKWUA=KE*"&,:=5]?%[)-2"5TGG_W-!9KHT\F_>]S
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MQW.\0?N2",>'5THT=-UGN"8V9;X' BG&IO55__CT4DT*&00A!;JM\RLQZ2U
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ML)9,_;)H"[?+";S$2P4)><(I8U' F*CG'#!/WL^B:D9=/@YOT(#;Q)P>K)O
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M'K^MNUF*AD%<SC>Y#+W'Q[VFAY3[@D6")(F3A@ZEA+/0U%\PX4;I#N2[LT-
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M[U@; =82]/A->%'3L[KZ>*[F+U354@]7+*8*C;M<5G6+R4PU:FJ@"AUIMEA
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M(9(WWO6RP.=$Y.U96:F,S- (<T4TC<1&BV>45=>#2WCX=>&\Q5@PKI5(>1*
M7^^X 6-1P@7\Z7DR">$?0>(FCW6MO+Y<*?Y85^K=_"J;&HDAZZ(K>!%.Q^\Q
MYC+5TN7=96KW7<E5Y;SNZ'YY+N=I LY43((TH(X7R=1:(9X(V^Y7*+PX264
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M# ASF,O\U/,<&?@,9%S,TH23V!7479G=9.A%:G))++%(H)7-L;3>S !GQS
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M_.CJY>KP#"(>VR;RL8XM)I_OG=27IFD22NH%7 0^BQD)>6 IAHDT;+5VN%2
M#8U!EX2DU'%EZ+CZJ]+Q IK<*>'NO4^GM:-9QD"OXZD-&;L\PE-6X.[8OVCJ
MF/RU4J>:3RQ3[(6R7OWR&B/G8&;J)#^8%#B0SO0%JF0=FE*ZFS>[ OL"]3;&
M0J?83#AI99OZ4A7$$W[NM?#MD3=3PBB) Y_2,$VH\ +FAX'T TJ<#L''^<5"
MJG54<%UI5_2Z;KC2P[3)%N]M<JOJZB>WE-1NUJ_E] ICUGCI3I&AN4,!,A,_
M7_?A5MFO\^NUS^_50ZS60_[=J(S!>;< :P G,RE:$V@>Z[_!^;\%*[/2B<,5
M6GDZ:=Q#&0WT+Q5Q3$&[>?!)$G(2BI3]/_:^M+F-*]GRKR#Z><9V!,0FN(EL
MQ[P(<)'-:<M22^K6S'PK @6R+* *784BC?[UDR>7NQ0*)$6 $F3R1;RV2 *U
MW)LWUY,G27]OGYSU7N[V=XX_6S*$&>L<18SAY\C' [(V:Q.019ZM^Z=]=KO[
M>P?=[9=[ZX_PY;$:=>SO%T!AG^]$?'E]V:\OR4L)8%$MVA*MX/*J[M.]H\YQ
MD0^_QADY\G[VWO[1\?'V::^_<_CJ:']O_Q7M^.'!\=GVR?'VR=[^_B.<$5H!
M.B+XW^UO_H0 S+K3W3WX2B<$Y5[A&WA,>=G?]F[=+NSJ[N'.[JO> 2IE>P>[
MIT?]_LGI]MGN]LGI L4@3.,'-8UMB.2=6 [PL< 26U FAP9G)K"F?'H:LK Y
MEGBY#''O&\G1#5!A:2Z@EW5+SZ@N&3^WJ&Z*>@88'#2C$CVXXRR][P%41I51
M\(EOC?=D=_L+\YY\"<=_#0M3.+O56T<!?N?E_M;!(48JK:CN  SZ^[N/#W^2
MGI]V]]!'R?+%B.8'5"^OZ30C$UHPY8,[$P(% >8/Q$=_,$<%A5#_?'_ZN%'0
M?L]'02?[K_;V=HYV=E[M[Q\?]G?W][</1.SZ9WNGNZUVW"O:0#-ZX\[MB;WV
M-I(DW][YBDK[;G;ZG?NZN%N]1[#='MX6H=[2/P0O%.I96LHZ*2G@EF/XX]8J
M">Q'S(IMDD[OK:[3-<FWNWVX?=;;/^YM'QSM[[[:H_#P]'3G=.?X]*3?Z[_:
M;R;YEJW#E]N)Q[MC2UKQ_,/9Z\Z. N(6__=U_[?^SV>OSW[[H*78]YW3\_<G
M_WS__OS-;YW^;Z?T__U?_^_[\_>=-Z\ZK\Y_Z_]V<M[_M7/RYK?3\P_VF7=G
M[__YZP?^R)NW9^_Z^,/[1R*#6E_^M8'JY;Z,?]!)GC$8\1TCR5EU)ID@)=&<
M\&)<%)^8<<O!VYFO;YB.&(I*EN>]^!&RP#LO^^:+O7>,=YW^@#-LO:/=7?XV
M*79ZO:'P0<7?[YVU?/_,U)"_T%YX(78+T?+A,?A"725E.*Z^<4V0<8]%7=HO
M@PZ;M&2EFP]2[I6H@!Q'+P*][[RH4:XTD.3\EL5A2#"#0:5\6M6#*SPHQ&UG
M^Z=),N_R/WL_V:\ [&S^KKH"L+OY6R&C:OYV.D[RYN]0=66NM+3YEXMTG-%*
M+%Q:B:H6+EZFPZSEGE:0M=_3JNJ?+,/LOH*MS)$E $J8]HY7!$LD>\$^?X.-
M*@M*K_&N,HPS'Z-XRP\F#18D%37H&=T."TRXXE8C@==W\'8E-]*L"5>Q>%1W
M'NNH]L>S*P:@W@#8RQOH6Y]$*A(C;!LI5MLJ\\LE5;I-$M3KL?#.[N-X@%(+
MCF-T<1Q6<A=_3PVR?(,3DJ,@?DEZA(0N=;5NW0&$^]?IF/T&N"K73 H7G#7L
M5C*XPBOQ4VUU7A=EBMXPP <REHZ;E/Z-SZ'(SK\1F$%7J+'X9E-ZH$R;P S/
MFPSH-9*!P#,@8N.4Q#:M7+2X?'&V.A]37B!I>V0@-9?\X=*BYC_E2%/+_G<M
M-$RZXB3&2KTZ:]6^3,J7,]R"CTEP$;CP(N8FW 6W@H6X\KJ,-FSK87+>V[E#
MT/<>3="96;88CXL;+-,PJP9U56F[&&MMIZ[1A"7M9M)(ITL2-EYU1(M*;VLR
MU)Z,W^L\:,I@66_OY_+W"K=2$1U&C)ASS0"_%<$,Z?#$A^='G$[3I.0VIG&5
MWDCS5;Y$!OAB]%A)32]X[X>*'\A. ,B*.FPA.Z?I@ ,1\D6[DEQQC(\J.OT\
MAWCI8]!COX(<]K9?_!URB^90:V-A1L' /.,!G(E&VC/C7>M"1-^?G71QL==)
M20+=TZ"A\P/NJ":#GR:ZN]J.'[?HYX0STSB+%";1R2LOE;V2?C6JQ]Q?@I8Y
M/>6D!HP4]YK6O*@KEJ-Q@:X56(1A"AM=6YOE##UM$B$/K]$V:JVLJ73U9#ZC
MB;94-/?(%\FJP!FAU[@ @(C42E>7%!N-M2KJ66><3;*9J@WDIYJ/0FM_3D\@
MSD^/?2= 0>3G\_/EJJ)VW+^#1,D!=3G!"=)Y)<]J1AAKHW]^G>04;4!ROJ\Z
MI_Z(X2/]/!G/T9-&MWWE1.TD.FOO_%E[X\Y:-[S1LA?%6BWN]>*;W/4B>JD5
M#LA#78 [5>/CN>N\&)$$#EB[#1+&G\6F@:19W1[&O) H5JFY]O?R#50W<$,[
MCAYL/(LRG[V_\?H+&RL;0&FI^8E_C8YX(1=7>%W0^,Q8G!2;<0FZ2GR;,U#7
MR?@GD@,MWO.9XZ51/.R -H4;MF;PX)PC@LM3($+^13$UT.!EF4RB@X@WB)_>
MG65Y,O(DW?59A=@/H1.)*URDUH^KGJQ]0/P7=J(@FFP(]$E) 8Z<EVO?UG8O
M]=^J&3VH-&3IEX(;!JRPWE&B=ZZR,AUZ)VOA1>RBT0LU+L^02.:7X,VIZM$(
M' /P^O*2C# O*=WU(G7.DQ,=IK.5?BG<Q**-H3Z*K8RTPN7RDG-WYSS%2Y%V
M'L_%.IO3BH:\>@JMD&IS91K9=EY&:]G3=VR[)6J3.=)EC1O?<PNOZ@F?U_#Z
M?A41*X'RH-*N8ER*UYF^,TL^H46/W$*FF%2695Z[8,O),$AC\H@]R'B#<&%W
M%(0&(LG&\*EQ@P(^+7HG\47>A6%=&GRU<2$Z#@,V2Z*4$[%6G/?GEGDU2Q[K
MB\^=_M8GPSD8P*)U^:<0ZFPRA=^3[!1P'R9%7I"NS_G\S+*+8NBPM7CD(6OF
MBIV!X>O^\?LN;P=>BCM%KXH;;384H:Z243J39TDAD7#@9V62*>]"+,P27BI=
MN'C_M*@ WM*:_-2DAJ"-J7'PL9CZCL$3METKQ!XW[Q)VO_K5X6.<)MI*:HZ8
M<U=))!+R8%2^:Y>/8/[7"^P)Z?=0?P5W456J_!E,QZ$KQ&X.,-5%-7N1LF<B
M3\4'8>YPU^'#:0=YZAS.Z!$Z5^1(LQT1_2JZ/5A+U>6A_NU&>EUB+@>Z%F'C
M$%W!X [#+0Y _ A\J P-3EM#3C,??GP*A ]EELZ0A&:&+'$/4WC<@Y0/,60M
M'>%PZD_DCN.82+PY'J?D1([GP6]SNY*I&5G/1.($+C\*2[PP,>1DL3+:T;D(
M#3II)3-UB= UY_6]2FGOK@;2,D[GK6)Y-0?)?^7DS;_.3U^06T0/45=N.\)9
M&<POH[9?R,*9JJ1\M!!O76"3.Q"K)R][9P>]EV>'^SN[^Z=[IX=[Q\='VP='
MNR_W#\[VMD\_&[&J)<B]1P*M*L?.9C= :^8BZ5QD1:#<!XJ*'Q6#6C,]4%DX
M!A<X!&Q$"IN( F>"HB&F"4!?52HZ?X*L&TP#^U%0)5WDBM*N^60S!$73M)@:
MWIH"@1195.1J"E(%,PLDQ<A.Z1$HWI\DUUE)PO_#+V__]6-7>T.ZZNVS.M-
MCJ^UU7E#!R1\GLXTFPJC?\9X$R:5&TKT!/+,V7PJ<5R;85J'R<.G?H!YJW[D
M]''#3G&NC-VL@+Y(C7(2OPETS@4^-R8="(,X)+,XF+&V@CL!HG)SP]C67F?)
M@EJL:!O9-\ZD'Y7CXFHF? R<B$/ZJBPN4$]G'X,CZ9$F1^BY/_"=A$_&K+KF
MV; @ER@2S+PQDQU3USRA@.,RS=?5P?9H$S(@17F!00;-'5#9X(/$X:OT"#67
M>1/:V59L^ K]/W%T<:IQ6*8800$NG>DXJ2;9L+)12E@4)N82+[Q,&*0SXD64
M2^!@\T%+.]H !I$=IM.4-Y!E&7D:H!(@922A5^EX:BP,59%_7\DAI-!A3G([
M,8:I_XB_,@2%5S%7L5/OAU0($V6)QH!0XJP\EA"N2UU#",E/&]*#C/\L781.
M_[ .FZLBJJRK+Y"M>LHAD^9W8Q,#,Z&*#CO9-<HXF5;T*9V'V347'M(UK-LP
MB&QTP%=KZF>SH ([:X5_;9JT_\)6GY1KPL$%K)!D'ZY 5)906'A=2"%0XT#:
M-V2?VR7D_D;2]WC^R4X86WAZ4\_.>  L62<9TCG)V-&0XMV@1(MZ0.+('\,\
M+2YX;;Z2'!0E)RW2CKA/E]R.*XG[A/-8ZG\Z9U1T3:N1YR].4O)T45!0]CD*
M-DOV@R_'Q07Y0!+!,;^:5 2MN!W<E;_(T: 4!,DZELG<S&&;3R%I(':<.N3N
MOK#,M'FW]W!_X>)GD_ I9EPIC^XBG$6+,;C62=R+H$++XZO"B)-</5JX070A
M%YN[8C!]5*>A13D+<[(7VKJ_"6-L;Z4+%29%+"W>GZ)(>9P5G1,2RJUNIP^1
M_'\4'0Z2;N<XS7[',O2'&E5T&;5\# :O_YE,IC]U7B-6&2:=GWFK7H&47_;F
M!_X-14 G13*6F@M22&<4IZ63;-!Y6Z;T>.F0J]CG.<FU;L</)V=OS^E[IYSU
M2/G>)!=<KDFY]/96*O=5IT_R/IAW?CCMOWO;_U&>C2MZI[BVY(8@OGJE'TZ+
M4_H40M\W),B_9J.T\QYY8IRX7\[_U?F7ADZ=#YQU_"V=W13EIZZO%-J5/ES!
MM:0G@G#@U>1)'"G&:QP6U)N.W_WFOG2"Z@[IV'K2^>'UR>D)/<IOB<8H)WQ.
M.D!R9K,:*5;W)_<[]DQ_X8/<]F?\M3\>T[F7E-6Y/VZG[CR^'=>3"XXNP[>G
M/[Q++Y$1H%=Y>Y64DV3 _=<<[[TKR-OX*U8MAQ^BRY%G#%65!.+;-,^K^9@V
M*DOD[Q\YVT>7I8WKEY-Y_)RVE:(8L&T?2<$GP0)LN!;_F+:F.R6@$,3)F)-=
M+""(MTH$'SE3ZRS4-EH] IP6*-4@VX!4AD2GH8ZBGZ]QN6[GNJ8M4&V;0#B&
M\PHA3Y;\U+Q4RW6N "V04TVG_U,WN# N!K!+GH$6,+S-=4)F!C4O<5D;=R$]
MSQ2!=!^#C\F0.YQ,Q.!9*3E6ESR9%13=<X;]W;NW/Y'YRHH+>H,9_:DS 6$B
ML @I?^#GX]<_04%SL4]?Z"><XY\Z9Q?%F-[Y=38<DL-U1M^'R+F[4; [+ N]
MS.NS=^]_ZOQ*3TT^&PS(3YW_EWU*.IS&\5E.E]O4] [9<#I__$,3-[QIR8&^
M=,!IR-](&K'(JG]9FH:5P#0H1UZ1^F!CS2XNXZ0X@2CMR Q<2)DQ1ZNT<'K'
MKBQD!501F9NT,RSX&@+Q@>6VJ_''653\%0NN$HU3[*) \/Z8=2HV]6,I3O&3
M@?#8OB6/849[E&KBBY8)K*9YZCX7&\;L^I8U"$W_F_:E9&;+$MT*94S:C4U7
M?;WT^NF(WG06G4AZ4:W*+2WM:@UO"ZJ_[9%<:<2\JV*Q_A<]=DM!&TT6"M%R
M+ABX8KJ>?[_MI5'"D>U;\-QXP]J+PPJ)N'N95)3X*A &+T-!_==6Q/9;"'\X
M$N.)%IM^<A=Y833_*BP @T$]J=7G3O'.J[7_?W>TW=O:;G:B?_9EY#BZLQUZ
MZ"3;=1FRP0=S I3-U" =@KX<RO?$TDXFF1;\BMN%Q,,GY%)<1-4Y\4WKVVT%
M983'0-">ECV7(J@."!"9T^1R$*=>I\'7-ES(/K/7H84AYA%@0FT-$5QGK)J%
M1NCB8\6M;3SOS8?0DZ O2RQTQ;/+28(Z,N"*P>7AS =[\SQ"Z1E@0OD;7V.B
M 2E4TFLRA4#]=&@'[O$F47]?U+.KSM\+"E^$ZNV*O#=?TB&%DHY3J^@$,(SP
M<-'#G?_VYL7>X38I(_-;%T (@*E3W.!@2G1CSO5QRB/C+.?[_KOW+TZ*?[W8
MD7,JGI7FW6OH ELJ+D1IMQ8_K<-?V=B&2X"VW4EG\X\X,DPLV$-+8NU.C%'X
MRI8Y> L_J-/3BI^SO1]%(T\!WZ1XB[% X$X$)HV>D9^M"A[*L!2-57597U?#
M<]6IP#WEI[S;LX5;:V4., ,#<<JKRG -]% Z_Y4<I4]IL-:<'A)$%6327KH)
M[FD1,.9.)V]A;!D?L5V\88J%FI*#KS3K:&.82 ;5N8VCK(2;=P.S<05#;Y!5
MOJG,_E!GJNMW%/VSE>-V+P3N*D N/ 2=JR)_H67:DMM#.C_\]LO;'X$YIY 9
MN F!5]%U\%V[*0?]'@CQ?>6!HA3AEM/.^VG*S3^=W.)Q-3W(:FD=VM)WH=7[
M=YW8-!6<]62$J?,.[>)C#3U5$)@^<RDE.3?FN,[%;8PP^B@'@F-.LKL)PZ1Q
M,FWK9,?X+- ?P)#AETBGNP0NJJT\)\;&22Z&&^<,#KI>=.>ONR&JB7&J]<7O
M:O-?G?9A]R74&ZS)S7I,Q6RA#9\3>]E%Q&&@^[AAK$V=LI#J*>#C;GH D!A5
M5'2=[PZVCLS5PI(AU21X AZ!Z 1*DU)! L6\$+EO>R9(\D3J?K$+[ [R7W?D
M;0+MX$_>@N@U3KW$!-HNY]^>W]D;$TZ#^+!*4>2+Z<3.<03L."FV6I_8GG?F
MYO18H4S> ,??/1AS67OGC1ZQ4'!_)OQ:WP ;[3G@)"@!IV/?W1$:YU8KY4(C
M,^>DV))+UN&YI#+9!;:DL!L6@+P4?6J,1/X+[MP.\(7J.'NI!S>HX7>KMG"1
M9>&UI/=FMV9D.?]R6IQVW1%YPW) 4E%Q[BE%:GBP)2W_C!MK@A_=<]G;T.4:
MM*[U5"NMC<,<GM,;+-:,ZV^>$L@87%VWR,\I6KW\LP0/4G;>D232%5[\DHXG
M>(-?BTN,P/IY<O&+9M4@WG__6>HSH98FOR'](Y-8/%[XH"PALT@847R_G0JW
MX485FW.;3 \YN\LI??8LEB7T.0\3^H>:/6 4'S]*/;4TDZM,=G;?OG^[',]C
MFY9A08=8W;$OM3??!:Y$U^UQH%2_>]D+%:FM$M/@MJX4:\C&,YI2!=38IL)$
MG]I!D='*_VZP&0L9@TOYJ2,GTUZ)5,[&:YR/(N-D"RY+Z5D;N+I-J#0$895+
M3E?2/ZJ>G @/$HI6,@4^6[+7?(E<VESD_+C2G#,:59I^\FX3PVYJ%GTD[6R/
MAX5./7&+K0#[-&>@'+=EX8:][>W&E[)<7:8-AT[L;@)TXC'ES?G1,N?Q)L@L
M(W-49A)]A%'P,*O*6AO$#'&AQ+CA?+Z%\)I"X_/<(?Z:\6@WBKJ]K\]#E88F
M\MJL6U^,$:Z+;W6)":<(+'605"7SUS(T2> *4+,*54!"VT**."#WR5Z-IYAN
MWYBU<:X*.-GXJ"LSM22M:*%F+C]E8[PXNL P0M+Q'(+!]S%'-WI,<3[9&%RA
MG8.'=,Z9_)]U04H?+N9(H]/%!$L>?P'[09JW8)\2O>_<IP6X@9YF_CR]HGL)
M]$T,@,''4]I?R="-I.F+QY'([":_.XK&O4QX: GT[J5@Z=$0DDLOSY9+!J'7
M F )-\N@JJMIP-90Y%P(Y35#[%CD-OTO<$G1PJ(JGC$6%#"C/PV]FHFT1UWQ
M"$L%^_GU!1@L]Z(!NX3*5WIGXI)#*)\\M!5=6, L#<8T%.5EDC,,S:\=#^<,
MDV4\I4L[6C<\)_E!SK?DEV28,"P*#QJ&(R-U PP&4SZ&\5RS9+[=RI__4\N3
M]8XD>Y0PIAK +3[G%(P=[6UY)T)':'+743H,BEJ8H28#7!TS&[,C!=W3%R!9
M<OA2'"!Q4J)$>)R4YN1VFT-O:>Q&VB/HDZJR/P#AGEU5VAS=5BNX]F\<Q?G?
M[>YN^W3_8NG.LR!:^MUS'\K[83^,[2[-KP2G$6^9])--D=;U]GZKTUK9X-LD
MU95^B?[AF;^T7029B1=@UHCFW+'B_6[W96_KI;U.5ZDXY$A\=WBTM>_>5-B?
M%OK(OX' 4#LBT) ,D:<-R: *5!I\)TZK(;3\L=/FW29Z 2LL@9=EK5!<_<#<
M'#,MO/C)T>ZZ7 *TFX<):E:SGL: /R?8:3R+E7B\Q$<&D3.D=>EB_=AJJW*W
M"<@.R<78@S&<A9D.I&Q-5'JCSN.SQ:9:#. R<4:Q84,71:G?]X)VYJW[D;M,
MK*<<@)RNCR.N2+3&<]\NN07.@O"PABP,-LC3-?3) U=W[KSO[_\L_HDN_'*^
M\BW][)6."+V@S;S!&J'[OW-^WF5:@$ZO[Q@ C(WA'QMNA.YH^3K8VSGL]XZW
M#W8/CO;[)Z?]W:/MXY.7Q_N]O;,3^MVFM7R=( T&$].7D?$X&V]U&OMCM;>L
MJ?GNP^(XT AIH,PQ5BBV%TW\B]K8>9T)NJ#[N];M#G>.LVW#8FJ:)UBP]^B?
M3#!2_)]"G//#7_KO__F7'SN_%5NXT,&+WFYWG1.+/7F%IWFL7IR -&K6^95+
MYG_KO Y&V<+C"__*_"=M%^G\\*&8DF[8W3GX\:&/#+[YAP(%6E_WP<]A%1$W
M=ICU)]IK2!S<3MXI'DU&E%#,?J^'EYZ&PXC&JFA^U)1AK4ETO_NS\J#O&%P7
M),C@\._LFDB?N&N<A-?P^_I^@?%BN)28A_GF;K@GKA+E_+*[R*GBP*SK8E8Q
M0[&</P5?Y??>L?<V9I2[WSKB!&F__J,U\7V9%N/MD[V3[8/3EZ\.=D_W=\]>
M';_:/3DYW=E^>;R]>]K;?[5I]J8?:-!W7)Z,+$]9Y 7<'=Z^%3=F[8,%O*^%
ML0 E^Z-28HVT1O0.TK ;2"%$6>B/]OQTMWN?X^[=!WE5_^G+RN_I[MGA:?_5
MZ>E!GWRDDU?'O9W^_MG9Z<'A]DG_Y'!WT^2W58EML@9I,ZCO!/BX]7##^J&0
MT%T E"LQE7^W<_!R-7IP6(B'W[ZW=; RN+'+F60)#Y&YMA+6@R\H;?T<NMZ:
MS%GAB9,J2H:LL("[!U]S_W;7 $[]2OO7.UH!3JN'6+!+S#5E+ A#H7Y2J+S0
MS]P7SUZ6B)H6TB[A[Z6Z1^YP-A8\3*JHI6]![E<3MA6W[ /#^\! P$2,OC%!
MEXW>^06_LW*/"<$EJD_R+^A9O]U#ZV^L*G<E1R,P5'*RF'7(>$&C?KYB-*K2
M&1+DBZT0Z)\(K]7<]7GG[:_O'RMC\XCV;UD? 3.>A5WTG[W+=U[[6S@DDCI_
M^#'9V=I;62>O:!;V>CZWOS:[L#:;22NT^M.MND(!UO!)6<Y(#=L#\WT_7_MR
MG==K=$&QO%C>J"1*P _Q9<TJL"O?2Z9(T -?MO(ZNG'#85DW\6%.T5CGO:6+
MK " A_K7S__GQ2Z@,"U@5G*I/ A5(-MR0X;*.$X&<-VA9&_OA&\&G4(&:9/(
M-@4#5YK* _Z[SAR^_;N7!T<\(0B#?5#ZY(PKN(VYIKIDMQYD*1]OKUZ&>Y5$
M-KX!R5BV.3\?OY9*\9@L9&KCX\--V=G:B986161?MF.]1%=6'L)H2YPNMHD#
MK-X_1Z06>5;]BXC N!)K^&*1Q#7N\H[ACZ?^.ID P[E27V@_6#;,D+[5(??R
M-KU@I5LE9I.]D;_\]PFD+KNH;:"!8B]9M@P7MR!C4H3S<[_O*[J\T2MT_OG%
M_FK1^=X:GN';"\_7Z&FL(;T1[>&&@B/W5@='?MXS)I_S@!T2F-'_^LM_5;W^
M\<[9R<G.T=G9_O[)\>[1_L[.3O_E_O;)WL[1T<'I@PJAP@D[0OIX%B7.DW@Y
MULF>M89-(Q=G_2[ZM^* .ENXH@/J?3.8Q_VM0V\>OSO<WQ:R+'J9[_:/]OD'
M#>DE+=3L0NPJQ)]!_R>G)VVK"^/L0-9J>> 11GFD *K(J%-&1P8NA_>1V-<]
MV F?S8'.Y&'$'#8<IN'K_D6 R;S5?5Q8ZP>YC_%*'X:."+DEL7/VW5%OM_6-
M9)&QM/RYX 6KYEHW7GC-2QZ@XAYAV3?9!VO+"/V\O&5_#3FA>US=]=VYR136
MSMV20I*&%UIYVN7_.%A!EL\2BK)@"Y**-MVQU<9?73&WT^MM@%-X^.T:CLVH
MV>RO(?6SZB;N>%OUK6WBU[?^@5IN!-;C]+(9GO?\2H=?Y,X2_K2"VDD/5PJ.
MND#.9F&:5VE0H?B646J;>Q)T!%XZ#._G&2Z%A=UE%@I0(6=!BTM8E!4$+J"P
M8;I#61Y1C(>58@"Z\N(NS80<'KV\,].THJNP?%O6OT8[H:]W'R'86_^2!G[/
MTF7]UGR!]TM>? 4'8-DEW5K2V=*NH&%'X>#B?DG#2S2T>I1D6-]QG1JTF]M>
ME5VC"FN 2>5WZUJGD#$K%SK#.M?:K"N"3?+/H(Y('H1W&'.+[GJ#S3>?*\)4
M=K]^3>OEVG-A6YTW(R77I=-;<Q2R"I1F=8N^:E'K$=*%D)L0=G=7VE6;1KXN
M)&D#437-=;R%)\T'7=^"4EK!'5Q9*7WU8.Q@:W>CE=+.&IYO9:6T\^TKI<.7
M7Q6FN?,%%/O]%)(-'O8Q@/.\EP<#YFT+FABNF;+2>S<O=.S<C.\;;BOB#\DS
M:E.LI/6R7)C)I(BKR/I),>3FE$@3NNJAMJ14:&T?@G(,X'$AR.@=?7-YNW.=
M9HPM*":K()H;5_KS^[.;D,?;9(C6R_W]KPM+7SW<^.:S8S=)!)11'6HCS*UN
MH7W,K30 G:MBS'FM;U>UJ0I?AVY[,L'Z.G++*Q[@?5]@VSSEMK,&CW1EA^[I
MHD\C!:?EY07EM@ _U-K[P=;^_XAX9JHT!Q6_T,W@:G3R]IA&$6N!AD-77A0R
MJJJJ00[O&6.$YK/A#$8=P0N/Y5H"^O4EIFQR9^TQ>&Z$]0(4T-9/[_]VQW,(
M3173R15@D+%'JOPS18'BMZ;33YB3 #YXG,0=T@6N)= 89SJ%>NOA!Q,B-OB,
M6_WY[<'1RZ]O$'J]=<Q1:*9*/@(% J>'&XR9J:#]5+I EVZ(8SD<"OD 3VP"
M\4Z:,/,.7T*ZEC'#5$W-1<H DA;9D2D?.,$7V:@N->YT6))A>H&8R@@FE$Z(
MZ1!<N]),^;7PX&T,"*(T6YY5_$.6;5<W4;['-.%Y,:A7^AH'=S])][6.ML'T
M(-!3*EE(?%S*=*3TX3:GLY6U02[H'S?FR?GFE-3/H";Z 8,W?NSPOCA?&I1%
MBVU_J[01H\X5W,Z(AIST>"WF*E\ZP3LJ@(6T7_19&^8&67O[ZWMAJ>51(JM-
M0ME=%VKB4H<=K +-7G?6]5M P#0=8+^I*P":7NZN'N<__/9'.ZO=_EMT@3^:
M5\L:_X[#*VJ]<?"KN"0.ZCOAWLB4AU&X1IE=,S/.4TZH3J>DY60"+ZI'Y,^J
MCDEF8C,NDC$3N%97H/:4^CLWS:YD(SI_&O/P&X;*YA2^C!EB<!E;B^0ZR<98
MWA<DB"^8-!+^ ?D)?B]6-!CYR@_P+6BZE:S#WM?'*OQP<-2#8OMQ;9HM<@Z2
MA[@&R2*_Z#=W_-@[ W5YZM6+ H"E36X=[IC+.9 #C<(B%H]]ZS\&2GZY"$02
M"F,E.LJ+G'O4"I)!9ML,?4AMYS-BS4%2EG/&N7&QUZZ^< E-0#@@4\OWY,K?
MA_AG"U1XE)/?_Y[1RW*,DLPT-H[6]!N$KEWIX$[H2'.-5"Q62R=4RZ\<"HGD
MX1,9IF"[H3/\@CR/1F/<B76/5=^L3K/]YTZS+]II]J7*+5SVG25_="Y(;D?9
M[*\_O 7=<65S3C+WB;3Z<44MFRW<;36#W]O^NAQ:+[=7NWV4Y-[L\&71+;$
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MQ3O]I:'L39)_E/S^XADL8/Q@%(2J?,_K\ZZ#C _KP<PJS>[S+DB9)G/.+UP
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MHP?]G_]UN+.S_5.$+N3?]7XR8+X[QW2ORS*91&U++2_3N2GJ,2J9'"%;T P
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MO2$)%- 8^+N'6O OF$@]\1J)D1) IZEG+2K.^SGO;"SV9A_U#VP47%Z1)Z7
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M.)-Y,_]VTV*$\QX+,C3.Q82N._\/DY986QC[PXKDX(;P=FE0">"7+-T@%N7
M%GYK$8EO3G>=1+% 9-W_NKQJI(Q3"%DD25+<D#]27653%[HPN+8M:NFZ9C/O
MGM"&E*D.'7;C6KXI<E%EK=G9[8UVMKU-"-96&+Q+.5\M2_VP9:Z6KK/-/5"V
ML1M'Y/& ^#!\7CFJ\N@!G47DED4!I6(@B@A4T*H3F<H3S_T;>"6Q%C+N>U<=
M$N,5&&3EH)XP$9E0 KAA>/H4LK5X$($=V.$-7J!MN=?V.FT7I\<5?>3^N-NS
M*9=]T*8P)+V->]BN&I<X*>IGKXFWC,/U8-^6Z%QM2V?^@;N47L.U%E$B.4N#
MV:->"H  KA&*889/*2VF#%EQ0#E!IF53]EAIE8%W,0^@504Y2*#-*3!+*'>P
MMG5%EN5R<9YDL>2"=]E\@P@^2!=M%A!MY\_#['0O,_;1VCX =%W"[&1AV/+>
M[[M(E#SPO=DVTM+/M^%T=">^K54.(=@1)*B/"1(,2LZH^A=W<-\J"LNCDGUI
MK[5'%]^^*"USOF1L0AL!E6]VBD"MB3*DFA\:BH+0OX/V](\0>&ZSX2U!Q! -
MT_N)$4D'B+0&V^:$DP["LQJ ]2*0Q#,\XFDD.,5F%#P:MBE?D&1,96YK'3#=
M\MPY_BPY2+-5@V*:+J HA7W<J^ VU?LL04]9@AQQ$,PYVI"%D0DU9C;"2W@N
MGO7.DY8:%I8%@KK (7.#BI^)3I[%9D%L,,":.2OA]*88X3VPAC/AX>.?E!0.
M$7H.U32"D$GN5-M1@H$&%">/$6'5TK0Q34%>6.*-UBUS&RMC+_>^&1G#HSX*
MF<[%S*/U7,G!#0CCI,YJ).,N7=M>S7XPL?A#R=J;C\69PV=(V*8?@,?C!-*F
M8M_F:'Z_)C_"&1_/!%)/65A"/(I% #*FK,*69]65RHUB?X(AI-=A;VA2EHD:
MYJJ-@-G/T (-@O4KH<L;!GW!<71YNF^/=LI/BPK:N,*.=X<$+W*=?20(*^ <
M@W;WK<YI,4%T;MTP] $WL]PRC#9EDL%KPJR4R?AI_F\X-"08QW?-I-MNS\ES
MGQ09)MB%+ "8K8QO6#&D91#Z)&&*YVPFN 7/P9!I?G.05#;/*$0TA=5_+DAI
M;6AAJ.=6YU_^4;7&U7QU\"MSG]]B#[=S-[F,+^ON< $#C,Z9=?%?P<6@>1&X
M OV+NX%0(' A4?X@$R#IX4X*<!33[2\PYHW;!&=)C#RPBPCRSF:9RT?+-+^<
M74FW)--?VV%1R C/@>4N;R!2>$'' "!H-QX<XVQ6.Z <R,.*,I@6[B;X<@U9
M]F+ 8#BA]T#ML^L&CX!^HRC+XH;I[#\TJ\  3QH24':SK482;*S-25W85.U;
M%9D= OBB,U+=UZ$*6(-N_Y3,7M#%7L@R\N]Z/VG-,[DLTU3X?D!T9XCF@#6>
M]56>IP//S)WDVG[HF?[CHFVW43&W>N'R@KDK. 95 Y")<_U]R.B>L#^)RPD\
M-DIFSBX[#"1DHY0G(TF9L2@[ZMKZA11$7_#&PD#T"6> ]DE&VW+\T]7K29>G
MQ.79=39.T4R@S<8Z*# &-"GH0I-"\92.5'@&%+FA!-W=)2!(D_M+F1;)LW!<
MEZG')6AC T83,YO"N$8\IWVO>J<R(,/AH^]0GG;B*X,@\))Y/6P(5TYK;77>
MT1;@UTWY371*CU(#M(D,EL/,5GO@:90&4F+2+GE0%= OR*PR9Z#@%Y>'K;9J
M98K9%<F@Q-J'4\-DIB[SFJ&\+;]\;%3?.AD: 535R; 16Q\]CI1#\LL"Z^Q)
MYN.J6DAD'Q] U^!LC!YQRXPA97%D/,AYL:'0P7 7K;7 8E$\!K#0T<D)[  #
MZORT.@:XWLZ(T)PQ8GC8:&BV#,'QG6H-W>5)/Q0D#Y(2%)*&J<O.J63Q4&GX
M"B$7BJ<VZA13(.'J/)Q&:9=H,AH77*^:*48$/UFW[TK$AE\='*#E6L;*?$KG
M2K.2IV/,0.;=AAR0=A&@%88O\YQ+SD^QO=&>!<.$1K2#(B=77(#V\O9O4@,.
M+ZIW@U(L&5OM)-3IM"[Z"&'X M><TQV>T]"Q<2TIEV\Z!7T+[YMK;2!30Z]P
M.8_JZS@J\=SZ%,Z";.0L'N>MHX9Q86RQGZC0E:/A8N>*6QYPQ6!GV@[I3 :2
M2!VNJ4[:ME>,+.X;80%"<8,LL3<_RZ2986%P<#!L->3)B;+SW8!(-HS=Z+3"
MF]5NFH(;#]L%L9+)*56J. 7':$1>W2#AN"!T3,/T;#1\N5W[MBQ=?.S8D1]>
M9Y6@)F9-\J9 L08[$AD6/11=+GUV%UAAARU'95DAXT]!UOH1S2*#U.\KQPR.
MKV$02(7*Z3R MKD.JR:_"*VT<3C%-'$^)GWDY7L4XC(';&V^O^E:)S)R9!WE
M9\G,AK.Y#*T;\Z33<+&T\XP;TD+1ZR[E#U["<*E(:4=5'#^O_XZG*?81#-C*
M$+*\9]#QXDO&9#.+VQ_Y7[;];<@5<JKD?!H6S/6L= ,]VU170E4;3#;'8C$C
MM-=>>!@94-[8CS0IQUF*?FHQH$Q['DU]B$D==01S-S2D/C]E_80QOZ,\T>R*
M:;$8>QR1J,YYHKJ!#C$ABS-M?TS-BL0)VVB1.'B82 K.=3W^U+FB>/T:;[6<
MNE41\[(LX@HV;A8Y?O3OBZK@V<5,0)4']^OZ"4_L>6*'Q0\7#Q!2;129$DVV
MM#9L%N1U=V,@KX_1-_7:#^3QW(.06_89,\?&1.(_$1BZ;:E(1*KDPGP^=%2V
M[XN<@41TUJ \7&8@<->;HOPDS4:=QL 6@X V>4S!\8J,2.EI#YM,@ID1'MLX
M(2?(83?Z2?_=BP].39/VNYBWV[!%QG!1.W65"LCS?@K12*>%:+7! \F&E#6'
M9=GQ0%D1(%7==AD/8X,[LMW4+NE)#<RO?=([D]8#S6#;98S:;MY-X&;:Z#V[
ML/2ZPMWBT'&Y2E+2Y@7G-.3?;D.I=>_ (P7N6P;ZM0]7F6@][G'-T.Q592+M
M/"E0E&I%0<$P)O*U)9D5C+V$<@/OAD2T45C<5*+J/"IMVVO?!5.ED7A8XR^+
M1Y=I_%X@-9C>,N\W@I(O\+EY7]5DMRBE.===@0S[!'U$7I3<.$WAYE8*YN"J
MP3,WZ@.6*VM4A!;J0*T'P#\!;X5FW0;(C&FV-3:=M(:WI<F48KKU(%J"D$]C
M:XS2C5E&2>/3$4K#T$7[:BQMBHUSNQ2%-4: *8SK'@//MEY!+/3LL]3/C_2%
MMEM6,G!/XI/19!(/I/_=_3P"<T-6\PP>F&GL'7ZUN$?BSS%<M:)LQ*&L[<*,
M"A_9D@] SD$ZSI;9N"4?LD$E=!XYGYE20"V"8^YKX=A.)%I'P:&RO%$W2M8T
M]SF@?)0-\H.PU;NLR2DM-SVS\]%-CT5J7Q@Z?:=G.'V=/Z%_)T=D5F87M60X
M!L4+&5O#/]GJTU+2L9MB=FG95*HM)>M1K' 63!.'4^WIDS"JTI'=;J)PQ%,=
M!FF+HX:E%;H*)^KZ-=%ZA*%T@T2?+X.%0Q"ZM[3/N.DX]QF2(*4%U\).VZ]L
M:E&BBFX4S35B%M1LZ!K^HBE\2G$O_&C:.:3UH,!5H4.3A5Y:>,BXR@6S HY]
M?R<W#K@8;[K<-_((VNM1^ ZBZ'UUX+$82TLXRT@6O_M=FU1A[ "2Q8\6+]/Y
MZ->N/NK8]DG><XZ.ZS:)%KQF(ULPQ+Z)[TJWOA@7@T_<1@F1!D.'X[\-QS7A
MM3FJT+%VQCS2!7LP*MAYP$:":+.8)^/9O(VAI/%>_APL:&;\W:EEHT99".H7
MER-$8YS/>%""<0^IH0^WB?6N$+2I8M?D-+D.HV( E:ZI>GHC 7-<+]9?W!B3
MX#/!\(Q,<JFY44C<Y.KGQ5J!C8A8>5(U,KW#I9)X@$@YD/H#O$[O6FIH5S)C
MP74F<['5,6T[BPLCKJ"Z6!2#7)70*4EEW??X*?! U(%+H>1!DM^;6YX</>\*
ML,14<)2AE1DS\/6"'+";WL6.5L(=W8]%)K[.>;MIE94-J\>!R#*)W^K\8GF@
M]FQAE '/TTLREC;A+"QU+G= :0%Y%X* U> 'L?<2W-PG\C@?6(2*)9J>(.Z[
M']H;]M#;A%_ QD@<6B8R!VL4Z !_ #I7M*'C^0L9QL3**BI$<)2H4]H]A&DH
M;H?"KL::NM8?T.8ZPU0%NA'8R=*AGDAV)J.K2RHUBA&P1&SA*0CQ5%K)D+7I
M+(#6\<JRU1V5Y!F4M8R!X7<6/&9<\N-WGKC)3)+LP9(!"Z2L*DDNH!X!8W!1
M$OS_%"#'_D,H),BWD$X7YS.^*6T=\"HDG'QJ,4RKKBI^&C_\*B!LBYX7=OQ3
M#A6F>SYALE:.WR8(L>==O<I8M<+-52I8C"N])VT=:9>ZY$$W 9: U'>!"?+Q
M\X:'QMCMF?)G_GWEOF(!9]*F4@T_)-_2E*KE0XW&&OZ2%N 4&U8[OG1UEWC:
MNOJ$?@K] LOZIOLQIUE%SQZ#<9)2J.-F-\BDU9XZWL&GEO@Y# SCTBUFO:4"
MHIM@F'U<%HV37.UY ?V:1^^$G0#>A0A5J*39AO$;76!\@=9>=13H8J^[Q2M>
M$N(I(POCOMK\J\B:L:YD6@D9RR)BXO6L"F.T?M\>PJ+?J3@?Y8>J>=B5<]<X
MM]B:=!PP;%('L]W"ZZQ>P*:?)3+\?F8A\#K7'L&Y$!S*W\D&QSB']C<79'#B
M9A-^SGIK6E?$5I<>N26Y,,S)2"%ZS9RT6&Y-]ZNQT3BOGM(3Z6%H"P;$J2S*
M3RC]HS:A.,J V!#WBG&51KFCXJ'&\'=FN6M]2T8CNC<5)]-= )8E& $X5#"F
M97[8C*HZ<U\A)9&5XL6+2S%(@=Q5#]G/X&.7P>%0^*O\M'#Q8CR8;:!C7FMB
MR+ PW]JQMZ1/TUL+I,YRL.:V)#)YS@9E61!L)A-F6SB>;("*Q18;?^074SWW
M6I:(:/F\?W[:[9SVW[WM^XZTXM3%9@SM,$Y#R:CQ'1546ZCG.IM/%3(0A-(Q
M;6K$*FMS P7N[,CQ%B!6>H89V'PQUYNUO)5FBY3^F0Q=YJK?CD6V2J.4AW<*
M7'[5W]>0[9J$BO+Z<A\+>SE3P3N1%Y9"ZN !^8MQ <WAY1$IM[T%/($-+WKO
M;4S1>RT-G]<86>[$.)0/T1Z:\P@4"/GZ-1/TD,I5/U(^ZOLT]$LNWS94V6W=
M\P#CN>DZY^<E(FOF24_KYYY$O]*.HFVB]<1[+6&#-T[3&,V'$IMXKT?RU5=\
M*;JCTVX-LY*0*HG?I4!LZ8 %\S2!ZS":I6Y$95:P7I5OL);!-31R%Y0C^I/X
ME]E0TB$Q]@MEI_&XN-& OE+(E[C_.CD,X4Q:<F7SBLNI&CE:2DM@.4S,)?TL
MC@G;VE>V.GUZ<HU0PD1@G0=3+,TJB)>3IR2)F6:0^$]=,1=J9%O7=!7Q_S+N
M!VR8)WQ=X$46N6OW:3<_=8@X59.?BV^FY7TO\'X9[(4E:84ERM,9JJ,1@G?A
MBD:I:\XH#CA%%VF)R:*+[&9_:PC'<U?QG[.K&/D;S;6H XF1"V/IH>,NL<HE
M-TV5-:@1T>2CI=B6JJ3/(#WSH3T+GO]&FW0-BI*E*@T[^*+8H0"L$$4+FT4J
M%<SALQP]53DR1S2LN-MDV\7>-PL)%?CX+#9/5FSR^9)Z1,1<-4YNJCKC0H$;
M@QR1B L!W[,</64Y&J>7B/>$Y(R331JQH36>QUD;.9K,KPJ"W0)%Y;1\]H.>
MK  %L+^0ZTGC- //+/6YE_0[2LF<$;,+_1W/LO949>U>A'OM3'F=1V"JVUA)
M>:9F#(;7<E$IR4HE,%%](B1&"[6=X-<,LR'S-LXXO&,83O8\0GGS1>H1^>O2
M/YA'-IQ+&R"^NC&73Y71!9,8_=]UVLE#%!P407US;B'C-+O@F*.B0W"M9SK%
MIRR.683K=W N%9JJK1VCZ_.C7 %GP1HSU<XPG7#%N2@;O2/?&B?BN:S';567
M4<*5!' :"?$<ZACF2(P">CN<X8#P#,/YN&9VZ^ E-Z0)V9L&48'#QZ,%5(;!
MMM=%K+#66C(*YIKZ&571\\B#H'SFBTOQ<WP$;'+,#$\<\/G'8#QOF56Z&O&4
M3WL*5#.1Q32(?88J=IJ@0HCB'K=(7_$Z*$ ;;&2ITALE6,N@O\?=1M+L 89C
M\RM\MQ![A:P/S6,J,RYY'M1M7!M<V587)FYLVOCJ('-.14O@9N?%;16?'1FV
MKD<#LM>V!7X@TT-NZW?L(F[?Q+#$4 &W/9[5^:5=,H(N@C$N*YN-!FYZ-E2$
MM99L^*9S<T-@==#40\X"\RAY&2@&P9AF[96N.BE3%/K^K_2.*5Z:#V_8/B;[
M1&^.@-7BBQ8\4SN<'Z$/DWK8.!,)OP#2;.[QDOY+:5E]CU*SHD&Z@*6-F5F5
M='(,VW8P0>8W=1UISA##U:M!"A7,X,+M\TLFP)M(U\=,Y\N'B.,47*K MS'2
MEKOY%48& &ASB5BY/^B80:<Q'AUD0@*?==PS<!-XFFV@Q/$[15#:;M/R5&BW
M!QL 3T942DM#R=GG(IK%V7RJ73S2*=) Q(3=)$*'& Y>9(4)'_H:;5^1S>MV
M!/AK".'Y-.UJ_>T/HR?."W*-/*.NK@I;2^VP1@\)-_V5PLB(?63J8MOB5K((
M<ZMNWX1%=R[<#P_87J#[V>J\)G^BX*8L[K-R-S;Z%-6'UC$U8,!A,.?5B4W0
M=1OLJ)HX].\S -*)L6L>L$GU(=J(,>!Q;5Z05:-.GH#^-^[QO5&$D9!S)+7C
M%I23^")\-#X50&<INL3-91:_%OPIYSISE$'?W:4*UO7M\7'B;_A&/X-",Y,)
MCVP&V?%PH7?&?U)IK39=4Z=L&L'W'*H6M%25:4A4W%3<KO]$FT/+=%17ZKCD
M5>9Z7=!2'>@%=Q,^(&P6F,!DWC'\7P?\/(RQ'@F/FWQ(3@,=@,1KLO#B3!(8
M=+8!60>$VX+C];GJCQV*F:[3L-"BO7_)TKA/FH_DJ *-C=>.H+5)ATV0>NIB
M.IJB::?H-?!0&4<8WAK2HD[03X?K\PI=I",PRV1NXN2R/=GJG#8;)I1]VQ'(
M6)6'=UGOVHU6517-V)U)>U%]+BTA66,#2(5#3=XU"8A9B]F**D7.(ON:8/F-
MU=X:I855)NJ6#A;9/3QI;=?B8;U1 K[H1JVD'J,HNH>7D(>V.C%3;"ED8^1$
M0;8.ZD1<S4\+LF&$.?KPX>1J+'D]0TVV$B1H>P=U<D$/#@N:\Q;Q,JF$1_<)
MG\J!3-E.Q=XG]P9&FDR/ VO6C6=4V]\8</FCI#):: !RWOG%%CY(DFDQ%1QC
MV[$N_[C9F54$#J3Y!D[=3\M,#&.+(Q.TU---I1J\2)IA<2R\5'LH9C61.>*L
M$J*1?SH@FWX7F&CY:]<$&TO0^DQB>Y5 #L_$ECP,I)L=_%TS_Y)8"1KWA?7:
M&BTK\M"5 RRBO=G\M,1)(PPP3OW$XA7'CRHABYEW;3P.NIQ4*W6U2]S-^E2.
MR\@BZ<T"93K%& N)&>@[*GK\,;O6AKM*?B&5-9!.9!SIH2^1"=BY&UZB%#D
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M!2]<4.&-V7>.YL%?1DO#C49<3@Y[]V:ZA$SXM8SX:BY2QF+E2BJ;K?#>A.I
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MZD-1#KD]6V5O"7ZKC(66'*]902;PV7M_LC*6Y9+W\NP5#?%28)HRFH9J+B8
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ME*H;7K@'&RK(>ADCPSD@^#V?C66Y;0ED<>MJUB%51W*455>>2U%S/6[**OX
M*J0L9L:+^Q]&KNI-<7XIR/3+I&1-V3+<=JO3=WS18#$?,IDK$RX)Q9*_C@U4
M=O.J/7S#WMJH-;F[T/\Y&5)8F?&,%I$\3J5*&K6ZYQ!<D&<V7FS"%0KA@+)T
M73)KNXK/%@,S^^&J7?IM3FK;K3C?#8N3&D2(Z=,PCDBT"KR6Y**0@Z7K'=ZV
M?31!4I$ H"926<885\0HY=;#B29B>:AY9UC0]Y%73_.J+I>>YR0O!">);N3$
M$Q:7+:/>EUTCO"U6@O$6B>]=2Y4U-6]RRC57M/(SM>^<X]#< AWYZ0ALJW1V
M =1T] *2M[:K&,Y"2?NK!' 4RVAKS_7#-V^K\QYWLPN9>'BY<-.(;I^3X<H8
MAC\+YPAQ3KUB8$*('1'V7MQ*:H-+P5XXB;)=>>/5=;NR""#CBH:A:10'JQN6
MQ3A[;;WEOI+X^0K]HIC-B@GK]*\&D^6*O']S6T6@UZ1@D?Y!KPZAI=5DN$PP
M6$]+>Z@;73#NCTX99E232J^][23AJ'F2"6ID?!=W]0=8P6#1'H/<_H.(U?U8
MK4Y_ZY.Y&)!WG';YAVPRJ47G)%.Q-</7_>/&C/8F.,<@+E4R3F5^_-S[$'Z6
M%JI<HC0B+*"<4=XE<^3L%(9DY'Y#9=.V.F^7_$5-RT7;GB(V18425IDV^(HI
M^0?8?P79,J83D!L2JUK&R_K"J6&5*M)?,HS1?J.ESXDRD$CM,;$Z>^A4->K0
M2^_%Y_Z".XV"BF90BI[YC:Z*">+U(3F_%''9CN(:E30$# />B?SWNFR@Z"Y*
M[,HPF7 I'M@3#"3(T_(:GDLU)Q4VT3^+=T!/6TVZMO'RZN%S\XF!%4?' *-@
M'97Y,!VE_FNZE5(#59ABA,/2C],*TI)?0R?J7BZ3"SZU#B&UY-RROHO*S6(Z
MQK!WJ [B;/'H(91.44$F/Y#>,>TNO:^"8Y7$_;E.]S2"TV%J7/W#=(+CL+P4
M_)P0>ZI"DI%NS$IC8X-T7-05%#0\Q&DML_Z>Q>.IBD>,8FG2Z 5CG9]%Y*F*
MB'A/W&0I\S3@PUP^ZXTG+11#3LHY;@SI!(25^9Z\Y!D'Q(ZADSV2;(+,H-F>
M9\%YJH(31D23(D]GG#"^86IUIHA5FD37FL,1SOTLT,:U-QP^CVAY/A)W4W@4
ME=I7Z9=Z)G1YRM*0Y4$OW?+ZZ!><?+H^,@+.SUFC4TLV"W->2^YLX,8#I/PL
MI[% FH*JE$RM7_C.TE'B99I-+I#-0S9VI'4AZR!DWI*"AS%K[AU?3LNMSNNB
M3 ON8VFY68:><Y=]Y8P,_7-LU\VNF?P%V7^I!$D#7W=)I^B$ED;:7Q?OQ&3\
MTJDJ9Y^;*$N>]NE?,YF@\&7<#3,D;VN?N=07U&Y:7TKHO"$_;C!(*DY(CI.2
M[O=[/;R4VK#/![.EEAX@,LRDM]0''"<W59W11Z6-*YQ@RPGCJV38;  )^(NW
M.OVP,K(DS2FUNU+'9FCFLR7-+@E8SCVSA##MBA*R<!(8LO3_V_O:YK:-9-W/
M]_X*U&[M)CE%:4G)LJWDGJVB)3E1-K%]+6=S[D>0&))8@P 7+Y*YO_Y.O\WT
M@* LV[)#BW#59FV)!#"#GIZ>[J>?QY=D_##-NRDT,G=;U8"ON\'ZHG,JN]^%
M:E<A-PQE7([-"UT3@1ZW.,/5,(_S]#^QZRD'=A6 N^2.2L !#[J^/XU7+M^-
MV6Q%/-#B&MG@DW&@B02+'8'CV[9RMK(9[3A8)'@AW++/9?+-%X%.R[<641LC
M?@K+97 H2R>-G,H^AD %2Q,.O1+N/[JVYO$GDR;-:-&T'VH0/-& 3XE$&.LZ
MW?(B/[!>:D'>O6TUR_BMZ2"JV+ 81_R I9V*9*Z)<@:J84!+ ;;A3%;X&Z"7
MC280B5C(Q9BWU#?J>2[@OSG4WH!XO6V1A MQEW:3JWNT^6VT;Q<"A'RW*UDX
M7\#1<;D=A8I? 'RA>J*L//)0!'10%[3>N<FGB]L8"EIU+[IO#>V][HVL<39]
M(RZA(PHFH3":.*-56(3;3M("WS*(?*]5R0YW9100&41VPJ$[%@N"U-3>KM@Z
M[T(EQ=P *(=JMDC/4,/P;J&I:D=3#D&A%,:QAHSFC6,5V!I)GSA. ]1 (9:W
MX+)2750X-JX>MHI^_!YP%NWLUIDA3A3'E(*MEU+:1BZ3HJQ9X5P/C%%5N"<+
MV9@\#J]Y^BH^ $[5-<]4Z,_EM8NA=LV[6R6>:,9(#VBH87[[CD+SB^:ZJ1__
M7O(+*>K3]QE,E&&39SS=KDV]L3/L_&[-%$!M7JD UW ;+--!O4"7T5PC*B%.
MG,\A848;Y0P8?^6-&^W#S9RTM*8EOTMQ20@G,LF.[[%.=9JP2NSL/DE\[0ZP
M$M<'?!<68)S0Q&"33+-B0)Q_08P;U(YELHXF!7=("Q$ #++)4X9J<C(M6A4K
M;OD&YA4Y3:"#Y?.0WJ,Z!HPMZGHW7(>DZXH#POV2; >V$[N)X(:1&YAUR/?A
MH6X%G(Y9QWNA_30Q$"52<KEEK8+SX0?><.+!9"(W1L\8WR=66KN"$!LJ=5H#
M/V#[ZD \]T6+?34=VAPSPBS;^,QNDT0!C.81$Q!.8]7[TNA^&PLPIM@X24S$
MDYW0QL6$>T18B-&;RRL%>;'>B/;5B#"N]GVO-T3&41&T%[/G:<CY96/,@PU:
M(Q7E$#NEA_XZT#I.R?"'"1+)3XIW^._1#_Z6O0GNIPG&UW&:2< $CDN1P]:E
MB6MNC^WM8S_M PHJ/O$(C8BX:5GSZ!$^^VP7F&'4IN"2WU1O90;3@*GZ&U7%
M\)D4C*7-O&<3VF-K:IW:.=NFR_HJ,375R2VGB!-DN7IPS3Y;$_@F2 [:(8MG
M"@7JB1L=?EQ,B<25$K&3RK@L[*:]W2/'PY>2'[W\R-QW7*J^8\#@<,E:"@S8
M+<P++X."$H:./G4[64>KQ;JRBS?.6TV0F#C6B>NPUN^*$6KQ<\7"I=I5?KRC
MV@E-=-2>O&0RCUF*[Z=5FL.)X7(;X!SL]>"^VQ/MF\EQ:6F?V(>>I?5MC=9:
MV*+%\,S2![0K"H\&HIJD6ONQ):S1L,/.OA@"I<65V^1,!UR+VH7HEVVM5:R*
M#$R *X%8M85W/(NOK24+ZW[G? N.9P$+JB3"62J(ZA+;-YUUB=VN<KT23]9-
M& &IRJPRQ*'KJS-!M3RTX0 Q![^)O,X-R0I 9TA<5<64A.R%L3?%2:VF9;I"
MKP+TR6S&O'[\ ?(P&J-"*X+F!NW:[68U^(,]5@!MT)6A-.=!Y1I 8&]*M;V
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MJU1(5"WUN&CT2 IX<?3&O+.C0S35>4IX(SO7C7T'/S?)W,YHD^&QB_=:F!+
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M?PTH$4<I/2@*@TQN9%))*<,)U)0E^7,0#G0E1,3QH-XF/@.0ES&BF#]9F^7
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M6X1H+404S&8'J,V*],@J]VX(OA^0]@O>JT(88K\?[+5U(Z#Q.1=QSHJR;%;
MJRE@8F_;6U+>SF+]%F!#EX8H.0I[5- $SVC'$VN(W,&--RU0="MFP1F%KD7(
M6BPTQW1?J?+T1KNO1LN8\?@&!9I0#)U @0B@%&*OB34C=YREE)94)*"H>_!6
M3K)8PVSGO]B;8^EPM2(9DJ[TKI.Q@&H(A#OM/)-.I"DN8]%M$DYN> @JJ>+=
M*<J2Y%L).$^!BFXV "A]4V;_M$$,Y<M(D&:@H?9P>5IB<GE75<66;CZ'.#QD
M<+A(_>%BFI;39EDAKRUA+?%+-&^LFH"KG=X*KMTTI!"'U#^M;)0.@&0#=BV6
MAEG;[:3RJ:Y>-.1@,H1)TV3:?V!:AG&A7T7_=^\4/I.DN$=E=ZXH6?OX#VN'
M9_;VUFKR-"9R@KBJK)W:V*FNW5%>^DT[FDB]\?GV!?5#)H-B6F=CO<(4S#=Q
M:U&Z'K$[*FA8['KZP<;C_].4=B^V._.O($U!W_\US>W&6-@S2W!4XR,-9QWH
M\GZ/1<<Y3V<U#\#D%9>C_2/I,C6VV;@CUOUAAKX4G@7JSO8@.=/I&V3YRJ_3
MLF TN6*;(?_K4CAM5-$2RGM0\@]YW/%WY 0ICG&6P3A]_TYT?LAWTK .2U%5
M0CTF-4<,LM;4D=!8ISDK&H)RY801+1A_L^--<;\;IZ_",X#G<%P8 ?0*!55P
M<[,CQ'V8V1UP0C3NQVX@)32YDEGSV[/;,4EVF.H.<+ NX-)A](P;M3FT@/IU
M4B]\YXC[%K8_V:> =$55A0EN-#+'K-WFY%<M.Y57B6HE7?@@J<U)Y\2)]F[E
M&/&E=YJL*.,9VZ8]B18%Y/> A.J87-]>R+*\>C:9[@"+:*3!SEE];#%5.5*@
M%;:AQKQ)$WQ^+/1Q53W-KXOLFGO!M[R<PXC5A37J#FIX14.)G G.25!FY\BD
M%E!8@NV/$R@;8)#(XO'DZX+IT? U6G\2"S9>0'@2",X&.G.>!L$'@6&'SJ"K
M&JN^E\1+.V7V+S-X"X 1JN9%.6?U3/=FK6%E#::+69JJ9+T(#MHV:Z/*O=_>
MD[>TX6%5N#:;VLPE3_TW5UU%WB_J.)U8MR$O6XYO4/9Q [&>KZ&-%&YI UF7
M7 <KLJ%E)O)JJ.W20 :$,4OA>S^,QO:MX<;HX9F$M&S#++?A_D+OP<A.#^ D
M] ;?B/NTXSET3-8@706'U3:>@[W!(#)>[#%0B4W,##R<7 9JYO3,Y&(:Z;ML
M LTQ:/5";0 26V091@B\\)&IT0GF[9L*18_RVMD"-D'*I,DL>JCD_>T27Q+@
MZRR&+:S-=+LJ4#QG"9]%%6)!!%/.K%ON5S03XFZQ7TYC6!_5+ W[@QNW>R$K
MNT"L)W&5$HT6^(R,D'A=H&3*3JM%0[X%/HZ_!X>?STG>, 0J@^=!F+)7>"/>
M#*?JR61[7N0XL( /U3K>_7!"F0!U=L)$VY@A]Q+IM[UQDCJDIF%WP,=0O]/$
ML#'0WY#"Q*53V--W)K? ]T+%J#BKBE =.Z*4P?:;:</M,$[P1> _(!X W5>I
M85K[D>J?)ELC66:7C=#)8=(,]3*[_BZHL"IJRY.U#E]4'$'03CTW[2EPGK9C
M'*Z\I)T?N#V[H7%>FSM<5!6H#5;2BP#V_^0:8@W=X8^?A!IP^N_&KWC4/!1M
ML<. @5WD#6WT H@/I(UB%4#BMI3!X QZC3@DMHN E@1NV:S:,^^_A?-6X=9K
M=_1E):#T\$;H%?R71"?=/O\Z-5EB?<._[6Z;BBD5F9Z;JE:-0L@2^SZ!\\TF
MHIU#G![MC'KV/0Q'7IX2J[0VCI6A:@'@HSDY)?P<8E()?),#C;2JE[93$:X"
M92"9-_4D'#K_*.GXX.RSVVZ?H@%NJ U]Y@V0K>!I45:L/P=4K575>0$,;6_
MZWS SCUHAYHB;GK[GLL=+. W<F&G0SXB/&]L\?=M)T]JM-ZYV&]F<9-#XLA=
MXD8ZD?YE"GNW!(@;6IPD-TP+R!'%*JX@^LC V.PS__/'_[EL;W[G+\9 WE M
MTZ2Z19!8NR+XQ-G+?UZ>'XQ.H^MX.@7T@=]I+E^\/'CT=#@\C,X;IYK6E'1X
M9.?EOHZTU\MTBH\.*H)IT52HQY$7#3I^N-N\H!8).S9VQ3#I]J[6PC(,!@0I
M+3?WYW!!$AG,50.ODWTRG E[$*9UV%2.]VSM9[G)I4%)]F]B2(&=!JA%W*S!
MC!JC-&1A>0DM56S?X_0MW#G<P>Q.&$^MG=D#"F#!Z;CB7V %)%0UK8$Y*F#Z
M'*FN4VP/.D1YEX[.=OH/8"<SK<=04W88_53<&!$@12&)'.9A4W_WQN=_9(JP
M]F!H"M2C=H\9<4[:U"%M5O!TFW+)VN<8?A]& 3D:OC@@-0(,"O5;HV %OB80
M.Z8!"W(%$5BD;6B/PJ:&]T8$/P)=<5@R-%2=<7+L*Q)[M0,CF3C2;\>:JN8,
MP$=-*WV2AJ"1O [S5!8,U$'',X?:"8D7DY-:8L8$CDRE-D=,]69N-8N7DFRG
MW70VXB4>,V:5O#AD6K8]GB,_P>WF-L-K^=N2+^N9-R'P0\HHMR)0E"=XK*K!
MZC&,V>Z*@BT/II:;I5QUZF9[DF#SO(2L-'R6PJ]![ YY"_R\SV: &N2.[Y;<
M6@0IX@'NAC33V&YFUPP4_CE?A(<@VGS@"!1L-/0+L6[G+ NWP6*:1HATVAM7
M^Q7CGFKTR;2UK;78I3C@K:IBFN(2H#0\,R/(UM)Z8H$P$]>?D>(+I@EP>1(O
M'<J=VP<;M 3*T2C <P'ICIRHZN"(HBR<DS2X':-T.JNVRC=YQ-;P=CZZTEX3
MJ&=;"[8E_HJB7$%6^,=?7X7X5Q=^\H;Z_'SLV!+!QW(;(AVI2%JKR.7UR0DI
MN"*?DKJQ*1MGH<WX6C))3+XAI*9H4":G'/6, 8V<=RNFC2L&;IX26W-"">+0
M\:H8$E '&[,$=\$/T&CL)-T2IL/Q6W\;$PRX_]N1UID3RXZ(7+$=YGZS<5:H
M>9)]ZIO1 ]@["=E0#(B;<LMX@J$0<1;$)>!6,(E-OA2SWIHG&*4Q!?&L#]/Z
M-R5[#G_>=G0& _>3RJ3_:4KNEIU*^@V>,"GC&XH"V]_&71*]7CPS=$#6.9"4
MEFU9+%,(%#@N0T?7.:=J@N)DP2<15=7 .@2SLTF-%<(7G]OK%A37*1>A<<!K
ME&&666]C0<ZH<I+2;)D(F\T(33YC'Y[F4,TT*,0*MX5*B0\P*1WN#E(P:BA:
MZ2QV+#M+>^_PY2 L>C431KG#8_%X.!#8DK;TPX 5:$UH85TDTA$BL5^IC WS
MW ;]O%M].C;9/D>N"9=VRG36<3J4,R%K'^@ZL<ZZ!C')9H9XU905?$#%8(GK
M@E&K#\D:NX-=(G[4U2@_7#Q2V+,1NXW0-:$=X$O+@!C0AZA"/_0)*=\O4PMX
MV91ZI04K()[BNQA(,I"].BJ3AG27[0@%%H%D.=UDW=P2\,[+XN9K2(^K24GS
M Y))""?H;T6Y?8ZV%48HX<N3K^@4&0I!X1:1E-OW@C%7:P)%+0C:8"!%PKQ7
M%(*1TTWS^;;\Y#;^FIUD,Y0L,VU!JZ+"W)ZF3 V8!JD?D%\56B;,2I6ZTG9'
MEK[#?F'_ @6'>K&6JI"]P;O#Z&6]8"Y7IDQ4R6(HH5#RT*,Q[ N<8W>(*I,.
M%"X=(P6$(X( =U,R-'#-=+%\P<8?C+</;<O;WEB:.MXA_7)W:VU;U "%3984
MC0>W*_V*X(Q& .1TFX[434WKZ"_,0%0?YX!_213<>!YA?$2:S\I8JMK&!H]V
M@RDP7<+NVR[& C,2:@C>,ZMGKC8?&G,U34Z;C>MNSB$=XPX=U!/MZH>TA]DW
MZDI?\)X1.0!!.K69HK5BG9V!ECCE'4&*+%G<"Y&VIR6YV.5M<TK7N*R0M2M8
M_ "4(0B,JZ+N_ (/SDN,@PE>&<P9QRTY<.L64.J5VKS0*7GX05J]U4NRIQ/=
M#RBK>6?W!8YIFASZI7,G[]EW;^ZQ821I)3FZ%H[' X(J]=L %N1PE!X?A,<7
M#OZF?'1QP1ZFK_SVUEO=OEI=RF)6E G3T-S$3!"HE]@C&-*-0]\7]H/@)ZF5
MA%N"5S&A3O1^V-O4OMH49VULS)?[(H^.R'4P[7 NO;WLJ[UX=:%X"7T3G!04
M/&QO&/MJ& [&(XD-5*N%X^XD=0V.+89>!YF2++\+?M3QGNHOK48#_>6O4&WZ
M^$&I3?=+ZC/Y6DQR"WA6RV;QJGAKUH(!8-A&4]7%DLN?VQ84U\Q$A] N4G\\
M(42P<+STW/5[;7ZYJ@R4!LN>8'%FN<J*M3&W&=D]4MA_J9RAH_OMAMQ+5E12
MJUN$J#3B75225F7:1H1B;EXG^>V 6!78UVD)<*R2[?:'"J[!/Y=*=@<:(6@&
M&&>=:5]N,LO1)V"B$UZK*^:M5_@LJ@R@1MB&^W=TR6Y.)((-.5]=+2"E1LV"
M'CZ6<1<F%@JD3DQG5C4-V\;YD:GI/TXIX:5.'U'K)7<=<ZOK(OY/7":0HEY"
MP<?UD7#[%<1&V\%\&U@@U5\M+?FM/EMI=F7(*,7V+&U&O8#0^PH"P/8)DN*S
M]+!]CA4.$_W>"?L&ZZ77 GW"M^$[W(H,5)_M)EO&H,PL#$])6J%6XY:WM<'A
MN]$/M:7&1H@4?T7\8I,GW+S$8PE?.*JF^3;8CO8"1<;0EH8(^4A0#D)=?>!'
M;H.')!/OI(=/->>.24#L+V))KZ4=*(?R$M8%Y?$*WP2[T1%-/:EZ8="]PD7A
M )1A6E9WJWH8KIHG\/J2VU]KE(T#4I8?;#A(H]=E#AL9XRZM$@:1?%ZEDB_G
MXKB'%Z<S/,EEJ=U&$YAVH*D5 -/$OUDU=M*O1&#$+(/BK;H.(0>SR B)J)O+
MK\(U=4_0^R:C8[ R$2!9,2F0_X1XOP+]8MQ=L\K<("HN+JEOWW[LIB@S:V-G
M13ZUOJ BN&*:SS*F(X&+S]>4"!S8>Q6K NIAX%,@[0Q @WE63*#*'-LE;!\&
MM%_Q.(N'%.D2"=RB])#X'O1 3\NE% #(9D/-M-YLC2%<T3I0Z$2G#?V41JOH
M)M ['-?^TDF*5  +DW 2E"=?P!$TR6OW;&2!X"Z9/0VD0 "!BH;9K!8F1@ =
M/ Y1+N>RCI7\>=/E$\6Z$QL96<>2#QC=?JMM=/D(Q&11Z5MF#L)54A;!@H'T
M;\9<YZ^<XJW\1L9YRXT&;ALBCCE26Q1P.02S!G%)I4/%J>)9&B))&0&.+%=<
MY6B[7.F_$+I2=_QU?!3J$P-U.L:4D>OJ"EHP@&>GFJVYDTQS)1"O-3/"!$Z;
M!@@QJRE;72V(Z6!]P "9OB097M2&JQ;<0FO_HLG3@.Q#\<?X?2%EL0E%@5&B
M_0.5">&8>.?$3E<H6R<!J1%#3;"%-\4B4E9@/H"@]]@5##"HC\=OM9SEOVSD
MF<[67VB+^9UV= *YX6+* \(TU1SD#'9=(9$<A0T:#T0-_8XXN@7_(#J'Z1IX
M:X6E#=S;="&$$$!7FUE_9T.E^\$CREP&>\_PWB")V '/_6WEW-!IM":(8%6L
M%FE5LQ;REBF5J=Q"Z8&X<M9X9G96] >H"CP JN&:*MZ$NV4 )+:"D0L6!\ ]
MHK12K<],BI)BX2E$YM.:(E1N)B#R[IK'I)=?D<\(CH8+RXW(+11K15G!AL+#
M 0]>E@2EIH9UD5U#)&'2E!2\8<LZ]66R#^##@[NC;#J>PD507=N>"Y#^VI/@
M7@H;!!CE=5SAHT\+Z1L")"F9LH/4J:8BW$%EO[[];>)7];H80,0!+Q:$O;&!
M9$!G%$Y(B@RWT1N*7FKP5G/U*4KBBSO-S3QF3#CD/F&75&'[&]HGRP/>QA%0
MS@<P V0@COW%C23@?,R*)CF8X/8/YZB&NKF)8[MJ@?9DX[?_SAFD0>P,E<$^
M(C6Q[I=ZSK?;&!EH(KCXCE,%+P,X4?"T ;]026E69,_&+@,ZB05L%JHO3KGY
M6&<7O"%@8^BLOO59"]U7Y[B#R/\QJ1Y\Q50K^#TLLKJ.IV\1:IK=L-08'6+1
M71ZXWWM63]_.H2RE[8]),BWA1E'G7%U'(0XLIYY,1"ENG521G/?-U=?48RGQ
MAV/MPBXTN!GO#QTKY;W-M=ALSFE 3'RM2@KUF-@D>"-,:=K:412[4KB.2_Z(
MA$FRQFYA7NHX#GL>/&G70#1P02&%\Q3X9#E@ J[-K?8"SXBNN"&8*1"&K >J
M;3-H0A+@,K(J#<(S\08_%37VWW%#??)H5PZ_9[[04L?O*.]REW>T)2_PD0%%
M5W[S<T03-A0^-U,D]8^.AJ,G))_WQ@[\K.'.A9^+2242/? 1U PT>4S'"?(,
M:KO#+IMK;/>"2UWR4H]>4W>,/:@FAM1^GC[6JB,#CA3P X=__?/H\?"'-POJ
M'94DD]T>("SA]]+=NPB;.G"$!5NP5,_PC%DBD01>AN,(O^U87^\W!0H%U,<C
M_ M+TMG7!">N.5+/40PUBXY/8).<,C=%',$QW/WR:"2_'%"L'RC:P?43=_N9
M! +6W;G66'O)XZ&[ 5+T0*@)Y^ 8\X!5]"UQ)1+1!4?$U1*:4'UT]UW7[<-;
MY\;MYL"V2D</>_NGP>T9GG^P-J"$9*<3]CQ^292P2/W^.^NXJ'7%9;F>T":#
M58UTZ5\,NLK9#!A<C!\A3"@\*W0L,/?1W)[G,SY6W2P,VX,AP5OKF&+8^-!<
MO:"%&V\5S!68FV=(PG;:&K8R['$.OI$ 630T4RM$#65?8! #YMY,[#D@)?U2
M^R"&^(R0]-EY#G5=HC.$A(E]DRVKE#2O^QX8#&=7] @V*E*._8X1B6[SE _
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M;[ P3"T;F'>PGI?8$C,4K:>A9FOD2"A30/PG3,![#7R+65S.I1$$%A7CYC7
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MFMNB4=)"*$JU:7,+.+@9':IO;^S_BEW-V,[+ 9#:X@:'T5+%I+()DQ]/K6T
M8VQ23)NE8PP_MX<[)&^U_^?\=A;C+K!"10$@N*+4)=D5;:3ZH(51X1UCI]UW
M-_$2U#02X6NO\>Q[JP^".<$CGIIW15Y]I_G<W(-;I:E-Y^%)\0*K7R)! Y!
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M$4*?\"=_>L_9UD_KTP^UNJ==2[?K],R+8:ME_A%/A3])S)2K[=\C6A5L&G8
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M-#E*#_,]=[_]=K=@V:/6?,%__Y?\8U(DZ[__[__SMT6]S/[^_P%02P,$%
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MN$-P=W<G.(_O?'/GG+EWWMR9<\^];]ZZLUFKUX_:5?7?M?>N_N^J!<^SSZL
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M#"< )PVG 0>"<X#SA@N#2X$K@*N%ZX*;@%N#.X5[@D>')X5GA.>'EX'7AK>
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M8"/!=6("8('4 !AL("PV\+D+0/%2SKPH88%_K6J049!0$1"!</"P,"\=H%@
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M[RS1""5 6IN5_+V42XBTL%-^'<'(SH+&JB7CRTDB^T.'IOIF^ >$C V\G+V
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MH6FR3[+=I;BIBH\3YW,FJ32ML!*I4&_5ET.%#P1;ZU/N&1Q@LD:EZ?78_&=
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M@=T50.D\"1P*$=6=\029#2<[2%*2.D,E9OJC8X/)5]12IO#1C034UU>E("T
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M:E#R[V;9<YR<#9G/&#(L35D>065IBS()GS"RLIYX/%[YIPNMBXA?O#.9W^T
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M8&, HHVC$,;8\_DYYZSE"17T>[JT>ZX(:FMDV'-Q? & 2_@J\)U"..!AHE]
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M4>WGT.457Q W3MO9M]B.D3C@CEW<U7-MB,3+X&N-"(\03 /8@D1VE?DLV>C
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M#RP5FZS;^QXXH#0 E,Z^R=4H![TJ)NAE>7EA84X3^]<>9:3,1WR*++"_\*M
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MFW@9V>TCJBUN7?:UA,/,CZL??B]\5@)/I7C.9@/<*/EFX;:;DP/:V68YQ>5
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M]#32?YFLL9;EUR9/*S_L-C.3F! ?Z\N.NR56G\J\XRZ;NU&&Z?N64-0F4D"
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MS,>HAJ3U\U/Y10@?K=^3YL'V3Z+HYYS43JRK,41F,>B[6@(_O]\&B,5@\Z?
MUSY'F%7OM0&(K7;UWM&=!?(>I]SC+)[VU)5T35HRJD&RD&CWP=F6/H^_ZS%G
MCOC%>>\7E/@7,U?ZF_JXF":49TT_-2S^(O:?:Y21'+U3K[F"[@ZE2%>WUU9[
M\*=VZ1_M@@4'<QQ'>C?4O@Z/6UQKV>W<V$G= B1ET_*(1P<3EG:[EBF;9'4A
M)+)"TR(SVJ:,X4Z'JQ0Y QIC^(YOF??MVY3$CO44VNPJ'CJ^"M!38-]86$.U
M)CW+'L]"%CK--29<B*PKFUGBI ^JZRZU<VLH@Z(SHD=RI9QN.#^:@HT7S<-H
M5,^8(3R%272-^BO]:,NCM44->/+Q43=CP^Y1[79A[Q+OA)3""KVL-I1V(**Z
M9 6-^:SI47\KR<Y.TQ'//HP!G_TWZMXZ**[N6Q,F"0D0++B[>Z#Q1MY < ON
M$+2#TTUH'&*X!7=(<+?&&PG:0.,.C4/C[IK,^_[NO5/W3MVJ^;ZJF3_FU*DZ
MM?_99]O:>ZU:SWX>;1Z2PDMLGSA53:)E3P39\V+W=E=V3W"2GNVTIIZTT]GQ
M-_LU_D'M!0OSFIT-UGN_\KFD\,&9#H/Z/0.F1DVTM\M4O<5?Z6WI,RQ4/VHP
M:YHQJX>)OL4I8ZZ^E_L'ZM;^I=3RHY9WVH?68.F\V90YX7;%?H-QGTA-<TK:
MK.:E#"R(%X3RY):'^*M-@6@,K\N&>$'"--_7R?K<P@>O3@D3<O^3,Y(D-Y\-
M6\YZO BO79&3S,#A^J-%CDDO"AS5PY,B4IN]&T^TS8"GBJG%[F"9Z#[%J58K
M6^U6K'G",F=8I+JH+A'0Y4JY^YC_6[^#66BP*1O- U,AC)7_S I6OR%:9A=&
M-;PWPNHI]+HZ0T/3QQLKE9$Q_X6-NMW'(QN!?!$^ &+K) 74M^F //XR#0%#
MHC(&3<X)U2^+&++F*EAU^XZ( 16AJCA -!Q[H,Q]9=A493)>P["@^/L>-1D+
M<<([A](5:1Y\&H *O]H3&@TI>IJ;AAJ$8QG"V@A\BK"2PCEEN7#5F3@[0&$)
M]6Z.:"WU#::TM#PN5.WB/,X9#X#@%,Z9'!L"H67ZW3[>)[\?>V/%6MKV'6/-
M4\JRS.T8C)72:53.V+#-O]Q;F\]5^%,!.>P#R+*]P7<=-+A2Y2+^BH[S"V-^
M([^I^C?79;,7\MA:O@BI>LX)X 0/ZPWHEGS_:4V3Z&88LJ3F.63[9=B4**I:
M"^_+$0=I36HJ"1 6#JCP^CY KI,!=%?\M0@$'XK1_\&HZO9KUY0>]+U/\O.4
MD1PR92NK!..'<V2XN<TSWRYF85DO)TJ$WST5.MEN^T8E:=D+-!K[/JAN9Q7O
M'W""VM5K<WO9=B:XVIZ!7=EHT_FQPVYZ/I;LN/WLI^O"F77VYU6W,%?B1_PL
M?L-A9,S6[]Z*/Q@<LT=F=]UKH+<YJ?_@:;EM36"W3" 0R![ZSX/.RAF8GW_(
MRD&#],J.90\23:6;)RQ[_SK]T.;!U]KW_'-.%\+2)D9]F3#%%9/'J%IT)U87
MKMU(BS]:&B<]G<QXA3XHD_=NV!?,=Y9Z9YN6P5%82XPKV]D2$05IE_'BI_V"
M\Z#RP7SG*B(:SCQT=##*[JV-$)";=FJ !,GW+T3U5RSH#]RGN,PNYVKEY+K,
M;KT)@"F<$GZS*M]MV#@K\B>!T;6U+YA;=>36^'4\YS>6K=4^BLD?=!AJ9S%P
M0"G( X+;3#FB&QFD.EW+HZS[I&"T'-V]4IH'$[/QRI']#\?&\Q1UV0)0X1?/
M3&S$P\[(%&GK"7ZR](*X80I)".4#S:,Q$VON+74V:0F>.??8WAUJQ<.8A<5Z
M+\%/4YZ'ZZYKSEK1_;H">'SZ@S-):^GE,3;";JN)$,%$YS<L4B#26"H<TFHO
MLZ-6H%(EKP,\C496:&%O6#+99*WGLJ;E$VV9=2W3.*V&$;]W7G3_B.9?VB)4
M(,:(2%H_@;J<J$722_$="D?^2M8N(]B7&)$9&V,#?RM;L/-0*7$A\=E!&3>_
MBZ%)NB;82RVY_090:;LK0=(]M"SNM;"KDS$__=&2SR/1THA])4ETR@"E<E%!
M7FQ1L/!Z/L3QBAGG1PWI]U&\'QRD8X.$M#7*F",<M)\TV3%'>O@/#KNK; TO
M?EQ<[;4(FW;E!12)8C0D6"Y/>N:>7"S-^&>G@+>[:?G2E!6_PF$>_/P&DNP/
M"0.T[II'O<"P==&C'6^(7M&WX%:)C4W"&#/\MN)-5QFCX=3V#EK_4J7[BWO%
MZ;RJJQ6EOA.@]:F$<X.%HKW/CX WCM'J[G$!I.!/UNR9O6UI+^R9T6OTKX-P
MG86$+3B@'D2;,G#PUO#VXY;=""&Y(/C4.U(OBUSU;D8W!I2ZB,K6=V]'2Z@T
M:SGQ9;E"_"? *0"(1DMT;[J+T4*,!9O W@9(FJ$:33FB7W6AF_#EEJT9+\TQ
M?K)&VAB1ZWA&JB/V^"-0 A3DG> N9YE+ ;HU'/#IZ+AL.]KGAFON*);Q2GBC
MBHH7*@K/5MO#5U-^7\<I6OPV[;[^V&&H=T ?*[554("KJ-.KGG[Q@V5FZUW_
M,PMV\G/FY/$N%AK(UI+ZT,'(#WJ64NJ/$/Z4-@W]P1M9XUF8>\1CP^\J5_AH
MKJ#00)3@=IS(1+'*L._YFX"DR=;L0>G[W-TLY#WG@I:=(UG8D_(]WG8E#IMB
M'Y8(P5#J<=6>Q5<B$2FLL0-SN9G>7ECDKB0H +S^#X;(7@6\>!$^ZL97L,&\
MVI^%CI_!9"CYM)@Y:&;X3NY XR0H>&S:-LDE:8REH"XY<[)K48:%4#&Q?(1M
M..P'H7'@3WOKK>[^ TL>6?ZCWV[S^[DS-UCY^U(T^2=7C;'#@>PY:L9)G-T"
MN-H-3:BT0)%X'?=SH0*;VC2/:6=H<'4.KTFB^/W\^9L- LJ>L9NO9)H+@AM2
M_G>)3%E%(&,RX'%WBW9"J#3J=DI%-7(UD;_2K 9<4%XN]_8?]@;M5,HF6L@3
M<4IES"$K1AIQ2A*<)X(X *! YX Q8?WH>W^9CM/S5*%0K+(F")".U@:FV=W]
M0H>SNYS7CW'<UFI+V]Z]ANPSDW?9:).I3]9$FLK)0B0%B"2^:LNS/ Q.Z0D4
MOMP.RZ]R;8;+AMK7Q<OY^]# @6)L#\XGA*:KF8VT"]D&:<Z+[O6^3 *YRRUG
MLU[& 20"26Z\?K:W#1F(VALY7;/WIT[SAF:K_BL\0AV%#LG#"%PC1*D:!9-7
M%'_,N;>//[S9QI0#'K4LW3A+8=6].$LX8Z*8#(F;@#.\HZBGS4/S^9CNL'WK
MD),_@@;^U3D(('[*%*BN] =CJH-9=N'='PQ"L$Q@;$YHJ8-/&G5@WN< 'R/C
MU&35\BCGB/P"7,=:/A'6^Z)6._(U-LY!;6\+BG&WWO;,3(=Y1062Z$24J7MM
M<^\QE:(:S!+N&BW2PG+5:W84C SO%@M1F%X=PI_69=)3^Q+S873@,=Z-FN-V
M$]-96WD1P3,*@KA>O!LX8L_]R5NCTY8P@<4YF6Y/ ;.A2T8D1/,7V=?*/X>3
MW*B/6HOGI=Y),28KT$NF:.D.3L5GS;4J1[=FM<9PR<KS*B&8&/V#CZ";*F'F
M\R=YNCM#E4D=%FA3<NM+/Z+1Z"'=9-4KGKFHEC7&[*<XCF9A&:F;49U+\S$L
MH+U7Q]<PK3I#K)MY/B!A!$OD#^^B@NF!Z.*Q,D11^(?*YLY;(O_J]OXNG:P[
M=?1%E->6[2XT@-CXH\U%=Q<AZ8Q=JL?P-ZL2:Q65/CY#"VOM1#ON[&$Y5^)
M.U/I].TJ;P_%MLB#UM+!*_KCIG2XWJ0?<EH:ZKU:5OEA^OO!6SQIEG.EF%(A
MLI1]^VV.Z$^$/U$S'ZCPDO-KZ6-F4J/EH\M2.VUWT*>&N52[FX(SUHTZ/8J\
M<MI:.*]D$QKY1M_!3]1'D5S7D>(LVN.N9S '1_QZ@[=BR=+(#?,,_@[JK3S;
MP MB!_A2'O@%O[_$3HT$V_$T7]+?IBI)<W6CXD:Q<Y]ZC"I;]X+(3-7^P6@+
MUP=J!0W_&VD'ED'IX<9[EOEA!$L@95VE)ON9U]56=&YT:]MB6B3D >"!O!7C
MTW>1_4<(Y7'E8?K%56[0BHG;'=GOW[: ]>X_&#/B'7LZ?S#\W'Z_O;V6\K?<
M(VQ 67ZMV3,E5;F6>OA7,>CKZ9Z1$!7U)5/\<,E:A071?K(?,>;K'GST-&NM
M^"="_N$!$C'^P0%O%S9ZAHG%=!6KSH;E 3:X2^,X*[QQ+M&;J"#OO=@XMYC+
MA0J7&O0W#?WZU_8[8.R>GX=^2Q-OMF^G&-[J,9TJ$6'.^"5AA#\ @%L#[.#O
MJJ4)@D\(RZ32D-9U2"(%&<)IR.3%7WMNT2MD._]\N^%.V;JR^JN>JK%Z!J,9
M_%ES+*#@TGX+M&,Y=57V?1*G+T0R.L@ 8;.1NNZCV IBG4Q3&<.#S-=(%8W)
MH' !G&*] @SB;LRM,723L+P21PG]$4#RL^B;U#*&_8/SLPT!KN'2 I,J>D--
M<K^&TA0=@5.:7G/ZP>W<]<WRH:$T1;X-%WOIER5]N[>-A640Q\;G+[/B=7:M
MO^RYFYN9O8L*U,+Y@W%J1F/HA%?IJ'J./B,_$YHN,(G6J>=)_?O[*J1-LN96
MP:1.\!.F^U]$?<SX!^?(#J'90'T6AM^;*\A'W-)#_XYKTT>\YOMU>KV-S\%Z
M(!'<6B'GVGKVGV*&*>A!L)9#DT_"IHN,!0AF-E1L\1JM*2M?"(C_MI2029H>
MM>188)IHJ"+N,9K4=NN3C7(=$?% _[;4]G_R7>Z]T':^2DO3.=2M#(&\0QXO
MW0:E]"/#ET5=S9?2_@[]W2[;.Z;NRA37,OV1'C4\DZ>5R)&DRT<*&OI((;?V
MG0'5ECU$*:!A5XS^>R6_1D!V?L#/0<?!)3 D$T0EQR4AQEDW@3:WU)^G*TI=
M\CVQ:=/YI,**OM!5E7[5MPB$,&NM*SL?'[F_NO93.#(:MY=P5E9 IL4!,T..
MMXZ/(0)BYT$EHPS::1"<K/#?53F'LF=!03*6' P\VTHV[;]:$%ZNO=+BA+CY
M/Y.ZF4I=Y7Y7CN"->()%!GZ=I5@F,V2!=1JE#<J??)07T)%BNGHVXZFZ5GD3
ME_$'(T]2F+KC0D,H=-<Y2;A@P/YHKV[;>IY[F[9-X9#;0E1XT9GW16QW>G*9
MI^H-,L.VK*\4*-SBF6)0:E&;%>_*T\&]5^-A?2^]A^]3S.VPQ!<M56@Q^N+M
M0[ J66J?A-M*S<0;S40"F_4Y069TG_@7XRAFH!^4]8"D\"J($@"33YTQ=+KQ
M"5 $PX&"0**-4R(5Y$3?9P  #C!ND9M B=E'8 -1L%![#;;Z5,H328/0+^QC
MR6H<H.X4GK1Z;'&1UJP?,>S)FII*$91Y(04&R7^56& /]Y[AF,$OZ7@T)C>Z
M'[@*)W_ND+8M49ZB^Z=X53CB<OP@<.8!SLI&E$N\=FR&[2U/-'3RBQ00,;&&
MZQS%.XC*4_/6[BCPNTQ\9'/:WZ5+/M+^N9R0%^#GMF?W5T K 22_1UTJP;!5
MZ%U2\Z[7^U/V3P/-]IM/;L_6# >B30%UE5\#-'YX0O&P2IWF@,NE,AK#>^/2
M+;2/]LV8!)8":K($H]VEB0JR[VK %^JCV\?GKMYWB_S\?C[NDSWKK7RJ1.@J
M@XFRK>05-YZG\^->%^"B;SGK+?[>98]3 @3FM!Y%3OK=CO5M!*DC?K)! +66
M(:>62ZT4XB4)?X/](OO']@[TWX=BF]IEES?[%P/K&*/\B#>WV'AFRD'&O4LI
MES,=A7$Z_OYPKDR^BK-YO3P[B&D156>)G&EE&VO";LTP]H<K?7%32[@DFJI+
M>TE\A$]5P!.F(9R.JAI*6UYW&9!*'M(H<%;5,1F3+ -^7;WQ>&EXI))1WJ/^
MJ#!IP^3+.?^0%\*9BW7RZRU[FKYE,PM$YMER!7)LDN$M=<HKGQ9UM^/^U>,W
M E]IQ&26RNVATU^W?U?1'%.<<2T<3B[82]>,-=:*V$9?TNM'DA0ZY>08J+JO
M'K_R&\33]P).-/).9((-/+ R53H*8V1FP0NQKU15*4WZDHI.6=D;%O3VYH2W
M!Q N"9 6%!-F^U2#6HMLA0"!^$CF"-FD9Z1MGM[%HG]:>Q:+)),+..( S;UM
M\LUP 1)E:%A#1+<KG:]FN#<G>DWT/A(KWX5H*YO9[<7OPMWWG.'S*SUXK!QL
MKK'L-.>+5)@QK5JT4+1R63?^R[C,&9#XCPA*I4KC W4;VM=O\;<@*DQXX*\^
M<0FX?K-EA0ZD1&J!XXD-;"SIQG:!S>S9.CYLR7*/1&EQ5"DRMIKYDRWGL/"]
M"EV95?0:2Y>#PPC>:QK_HZL\SMYET![()I3(Q#XIU?MA15IG[V&8%31L*I/2
MEZF!G#8$MCSN:"L$MD<FIZ<@L_O:+_I]<3E,IQH/ UURHL U/]J ?O5Z[6;G
MIH]P2:2EM<RPMDMV6$%4-F?[!Z$ *G.U]W31HQS"\KUODMICVH7HT]W!/;9O
M>->7=#/:K03P6BL_[Z9[BGM?K(_3JWZH%#%D^/8^7J/#6.8L ,V.VD.J%:WJ
M1RH872"22ZTHW_C''ZV4YU\G%BSKN+27,_.:'$8NY.#"%BCXRB%')*/8TNKD
M7)O>Z.%M9\4@K UK,#$C#MY+4ZBDF:-.2.\7T,F<&N#S5ZC^I8W-+(]K>_^T
M/MATT"-#.\(R8V]Y@+\B/T/6K+QTI]++E.WEWK<B"62=#1G<[43M-"!%1^0>
M[><UD%N-WR"I>1Q:[NFBZ4'!HRPCFC-Q?A.G>;!^Y&X+<^;0R8/C=*O-\GV-
MBM;+KJ0<!%OO"L(!#$JUBWYI&2M_,%)F'NW-(K6=\$:JIR0JG$HK?+?<I#^>
M2?#P\A,E]C'1OC-\*O&2.XFG][GDN]:0$]TOV$;(;O194/6L;6;(C2N^,T_4
MV"XMEWS<C 1G3O<)N,WVQ'J? 7/X^]  T?37@4>+:E330QLXQB+8/99@S3TF
M5,)2G$,_2&5**, %GL1!Z09+M%XHHJ?A$)W4/N=+OG"+$AEJYYOY&1I))4D6
M45IV\4XKR,\UO"XK12T@CZSAH=I4)10R:C4Q@,+?F_:DW/WET?G#843@'"78
M[WFT9X-E3X%-RY87[K4'2IGE!P 0F@KVE12(R73?&!8&);*H,GQ:J&B!+RF7
MP8N8-E5/YI>79?(T/ICOY"D5GRZOD=M=Z5-O9+_N,)MR'8%[]VDET&==Z]GT
M=O#7[W88\K V;-7J)@\()R'69*CR5#J+"+ZU];8EH$ N%?P^'0FH#Q4KO*0V
M\#EFYLGA[YQTQW['M D*NAE.PGRS=$YIQ</%D&E;^C:ND$8*/DSVQ42?Q0H?
MRK)7%]F2X=(S3#4BS,;ZR^;+6$IV'SM*UF/JE[JG]-'X@A%IV4:[O5,G6L40
M\+/(NV#BO<L/RAO^T:O4G^0I3=-?NOVZ.C;KR!E&9?_6XH*,J+'X+L:R9<SC
MPN@R#$!QJ(1DGTT)5H%2,S'\B4'$#<.:X>1A2%6QX2-:_;JW$+R;\I'A+%[K
MT&::#76 <D3[=9%$_3BF>% +28GEY34^SOCH8[OZN&?#/QZSI-\@,/+*'UF>
MN_'@< =>6XL9)QRU8?I.LWPD=^#?89AQ=HA&GAUO[7-<BZ8N34K,A7YQ.)D=
M%+N&I92JL+(AD(?5)(&-";#;2I\Y0(V,8<"E7_=[%YTQ(R[K%+TM:_9H=)"U
M\L??HDI7.6S?HQ?SDP69$.,.O/U64HG6L+G' F$-9_K26>^7[YZ;4![,Y/Z,
M+969\CP=7ZBCO-M )GQ74%F-;LDIZ3$M6T!G9%DNY76\A-X$)+QMAM65+YE$
M%3UOJ:2JF3@#E]4ZY=9(T93K/Q;@DL)5R$A,UYP'+Q8NI5+K\?9=<FE1A5=5
M&4M:1P*^W.:94RD_+<KJ6]N0 GZ-]W+(>K^E'Y<V0^X;:OSB>#>"'WME<-_%
M=GI1([0Q$O79LBOU),._\6[\2+M+_WNOHMJ_Q[_L[1A;J6R*44P@>07W(0'*
MSJ*S.L9*^#^7&X<FQ2;I+@PYE;4PC)0ZJIWY.?_FZ2@A<,\A,@Y/B$Q1;VBD
MWG.KJEQ^U(V.T[HRC= Q3U^B,?@UEQ9F'J:2UCM_"P*Y&O^C^((:SFH[Z"CX
MVH8"SK.O'K@N.)H:J"ZKF@O$]-F74WFJB3KAD%B=>8S\P6"=.=2)7VML;K-J
MNHO.5"OUM?<7JBD>J*KP(9WV!\I"YQ3!AY,!!;-;GG\P5*;*AGK[D&6WO*5<
M_56P:_Y*4:6 1M,"MO;EGT04=?W_?3Z/$H%B@*%=QE !VGGVKYPDJ 5DF"%G
MOFE#/M$'"LFRS$0TU0ID(<0,U)D-3ADWNC32+R#>*-+R^0)7YBK7K/ ]DT^H
MKU^&'31QUD2#1#D+GCUUB^N=Z6?3S+YM'W;);7Q;+XTMQ2NZUFLC+(TW3.K[
MI42>_$=X$]$N4$A+EX]#6HOUEH;8,^$2[_U;[G]E65A@0/?#S=]:E_-$3SXN
M[Q),K SC.M1<',WY>-RQ*U^TZ^=#?0K*++ WNRRAUXE0\ A9JY+]?J/<ZFVK
MJP*G8PK=>$!!^WLQ&[KH-J#\IUEF:C?6+<UQPWYE!?87NX'!+1!^\5O\.T5Q
M(2%U>\$>LR6Z_[N",,]ILW:S\G-<16,E^( "EK*E&!<-F.LRD:]&$[YHMP5B
MN0DF,$33&# G-9U4^,+.CM;96!PS L[,\Q%FKOGI@=$A&;B-<0N_WJPU>X,R
MLXVTM)%;FCWN\V6&Y*Y=O(@H4?K"S2'L>')[>_MKL81 F'].76ONOR6KGEU5
MF:CDQU#:2!2F_Q5":4W!Q9ZL\SZ"L[=U4 7O&X9Q5G]66NOT.?PE%!KK=-6A
MYF 3(S@83'EF\FWCW,'C5I#&6-3F>H#..';*J?] @,VWAN83D7B])? G4(2\
M=2F"RN^[=RH^-DLQA$!.@"PJP[/W4^ZCA=;PUHVJHA4[)[@(I[INW<7CXG\9
MCO],^'&97?84/B;#> TXH)4-!N^\%/J/%!O?XZ+-*9?-X<J[P(ONDOAWJ/]2
M_/^ 1"&:;;DF+#B9IWM3+$168^2L8=,8^ C[L%J%#23D_WTF@?>%T^H%%RA;
M>>T;@3$&[HYCM%9LUT8E^FR69Z,F=6'2K,-W\2N^;[W3UP'AB7[-(48,_N.S
MCN:T@?GLU,=-NK5Y.O2P/UFH1/'A%C4RFS[\VW>C89/88AI@<MBBLOJWK)HI
MVZA PD^9^:!&X1$,?YF3RA/_Y?-MS0(N/AMA NZACB=6. M4 J]2_MJ"61%]
M'_9U)^>>UE3YT=NC14L[ESQUKO3R?][7OH\1$GKUA 7 A(%!P0+@L'KUA!S"
MS PE(@)!O.SMO3YBG>1G5%=!LRN7C=>0JNBBCZRZWTVF#)B]<AA/4M[6?[S4
MH<^8%(3UBLR_E J0HS+>K+$7T)6Z/+HX@F9P"GL6'DUD%V!YNZP+OXT9-VJE
MU^D&Z7Z$(TWRHR?D@XDCILH?)<2^2:GJS.?1Q%1IMI)QO\$WJ<^-^?L85J E
MV^]\5:V ]ZJ'A59;\2D3[7MF#-XNWJ&A?H*$@\OY(L5#Z$MIV;S7)QN.8BJH
M6LWSS=KDM[ZJ6SH/F:.NG;=P0?%.,[7.DN?>F,STM_\GK8Y6UN(#'GMQKUGG
M'JTY[PCS@Q9^:\#-TUZ?SZ@8,_RLKK_N.-'174:Q7Z-^S8>7#J!6FH\%<].W
MRE"O&W,FWGU+%GB/7=A8["X8V9PV?:6IOLS/V=J_N,)E))]FTTK(EEJ1'(;O
MDJM^\&]L!><@RXF&1F^ECU ."]^KOYVG?2N1G\(-;E;S:Q7!4^= B3197J+U
M<P!%@OG^2]&H#C$$59SYRX*]0Y:D7[9':Q[>^]Z9#9*0BB Z7^(O2RJ(4&]T
M5-MB9/CGR$1(WQM>17!JPF>$]K_WC(ICWK)>L62!3_=%X22YA/7)ZI U!_,-
M$!AMLR\I]J9YEWTSIJ!_OEPGZT$YZU=!B&D3U.Q0H>#:355_VL3:XR2JS90M
M"C8F0<NOC$'@[WGS*<SD+QN2D ^+/^J?(*1>K/L3=/0F9L7!C??,LZ<]+]F?
MZJ275]'Y'Q&K8#N !,LUMTW YQ\.NJ=TQIJZSO1KNN_=5:2$/@?VF+/,;]>1
M9RPN\<1,MUAL&".6HT,^X/=6V@A@/$/U;EJ!@IX> OC#GZ7@8.5Z$YB<]7)=
M0_Y_9?>+ZY==3J^;.T#<OY_UE$V4\GEE^ <<N<T/=GPZY<0C_;?=A;EMHD/=
M8OX/AMOT2N=1I?;4?R77Z,=M^^_U.2)B[@3"Z%2N0"J!0C9)@DDC?COMC)X<
M\UEL-P,Q>GW_OJ[,BUJ ZR0*05!9O&6]9$.'HYB;;^.62['=8M^)-?^N*J;R
M-*9+3RQ/M;%$Q-$$A4D\6GA6BT$8,S+B\;YJN)NA<_ZIO;L8AZ,A-8_U"+XU
M5[[^*^IU3_J,?JLSBAH)$ZC@O)1+\\XFIVGT.DQGR8&>:S5=[)PDJA>%)G;%
MH_WT=UQ=9N75=.WUL+!1[FH153!2V:V[+1U5SHLH 9,IY1B%,-F? HSZ?2-D
M1>,?7_E&K\]]253074'?K51=_E9RB_N?9J*V[0GR5L\PS\1G*'7I-WGV;HDP
M9Y0ET5>7QVI!-IAE?[N[UU0 #W(262UW,,_9&>5RU]OM9!SS82.9!<<Z\85R
M0=2WC7@ .6,\@ +\6A#*Q.1%3 $"0:&>%?/&',W;K0K(U<><F4;_'I.&X"'C
MN&9VT)5P?;/&+=?SK-_/OC=[1>%2HOO'HS[52OX_+)229YF?U<R6N'PH5H29
MM3YQ1YWV6A 0:3)J6VF2VK07F*9*G829-F?>)9X30Q=^S%F_Y%5GGZ-_U3);
M3[FL>GE)GSHY[C%Q],KFQ)NS*K1V<U'!N99_>'JZ6\STB2=&9_982V[?VKZ8
MG^)0Q-1=U>9><#.Q6R"<0]W/<\7ESO6]=P*;?J0$\@#AHW9;'57X!\.+?WM^
MX5!H;I&>.P$7T*W)D1"RD5;H1@T*JM3IMSV\M$2;(U2K_L%M[%=I)FE5(&;^
M8.S]MF3QX;?4J4KX#:M\M6^27]& LK].:M <D+X?A$!2CIVWEQH&4;PM 2#G
M;=N</MV$S(Y(EQ2^ \37EZ8./W9(;29?1$U^5Z%ZW13G3ZA=N.\JJ=8C)I8P
M,)>9M;)<AK]<L;3-/F//NJA!HE;D!A/=<*X4RF<=WWEH*Z$US7_V/51KLY"1
M6G.8UON^UI_^04&:W.#'W-8?C ,!Y<?RU8X7^F8( P<SJ!=5$'Y*@25+Y*!^
M=HQ<] \''E2)O5C$!S:LZ_#/0,A(CT#GLQH ,$@C$ =<J42@6V >.RP5-'XC
MO+DA5N>62VJ04CC>T%&OG^%7NRS@K0E.VIJY 5(83G!UMW");^A?^$&7ID7T
MK'-&\%F+Z(<]3544*KS35%]OEDG5G,XB6(>/M^_L;TU']_QR'F;>'WT[II/6
ML*B<=$)MF911&'U5 PEHCOAF4%GN@*'V<7/Y(QN,4,JP_H+!=Z%]'/%H/PY>
M&>C#@4K"7,![?-T9UQU\!?O.7>?\UD%/[$ _T:R!P:'A_0MK?L=1%MS-DF=S
M]/95'ZV[_.)&2>LA-QF \395;U?=9AW=+]- =QJUYQ'GB@=@-=(O"*K(1H(5
M'A_IW^M\N!H;^-3$E>!$E]"LX"2RXXW%A,BMV,!XS?((TWV8.0>EIHA8:'WF
M;X)I='0<E0^!(YS'Y4RSX5I%9JGMSMF2;)E?Y< 036KH9>T5/+.L(>GM__!]
M:M%<S()I1)\(FV5XTAX[=\I[[LV=B<0F-)+-0)#\I\]CZD:1?8Y>,: R:'^!
M7#,M!4IN[@K?2>%-\1[PBOZ>LES97\^IXA5IGKUK?LBCER=&7Y[I4\;=P*T=
M?W'3IS:A[=>G-IXW^!N/,JTG+4PE*\R\V1IT!H4&<?P3(SWD+.[?*X0*/1>_
MGX(3#=29#-0'9I6N_1!)NGV)_3ZZKSUC=/"Y]0QEIFFNI.$=KV6/X,?J2--<
M_$E- >+7M7%#6*8\T34B:O7L(=-JGK:<SE.-%F_2<?8'"1"T8X-,K(K\(ZR\
MAT>F&&)(NVI@:(&')%!G^K)5T?7G3%KP':B"Q]VS2C<E],1UO%9PH4R H%M8
M?H:#)M-.41H]EWDUZY19N.SH^G):XJ>O81X6I=!-9#SEA@>9PDK.R[$^&U;_
MCL\07+W^L%4QPXQ.6>*-TO>CSV1Z+X9>>GG4'%]DBO,EU:X<:A;4>QUE))_4
M-$N,)F=Y#__2G?1@*G<X!1>BQ&I?F?I .WRU3:%15QYE+HDFB9)L=(=I2TFH
MY/:SG<^TB=6(RKI6?<&[VE3X$Q.AJ(VB8J=N]*0N8.]<^2^Z-P8'T-++CPB2
MQ,12L0.-)5.8[SY)Y<?ZA9F0N@U+@:B4WB^TRSDUO%K?^X;6)R)56.4F)M-N
M+DU/9FI_,RJZTTU>P3T$J1%:Z_6B+_L7>NWVHM,G .Y66]K#%N[H!Z (+V:]
MR]O?8*,(Y944,G7OA+ FTW<C60\\Y6N.WE0OC8F*Z'6#;]S2>+AAU#OZ 9Y<
M SY"20X0%4-X(HW'<2BM)9\2L3":7_W!F^VC[<:PLR3G8H-;D/+"K()TCH)X
M7K5AJ(6VU0!CU8KOJ-U)EYWUDAG^FY!"@UX3R2[)T]=A=M@V9=$C:N/=6%5*
M=/YVS72IFD,?E7,0,"85,JJ(G]^+)Y\]G"BT9%I^(;9'1X<WL4.A9_^"MN0D
M0;(ZQU*'M;\-.AP,@^NCD!/IT7,, X-4B)@?_!(X-OQI5G&M&XD8J"%C/34(
MM)NCT:1;)/=<*F/C($&W[O"7;0V@.5N,A2$E8;Y\55=QR>+YSVQX7*NYEGI
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M)?^M-;(F5ZPARELA\B$?HMA"/@QT*1=$I6[$ ]P$Q8?>_LH84DE##2>=WK^
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M/[\[8&IY_6=*#C+D_7^&:F#_^]3_%RR&GL]_9>SX]#W_?PNZK+CVM4\064!
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M;W HQU^'_923D+!*CHX8CA@>B-[F<^?G!S'R\_USL+K]TQE K" 0R/C  P
M5#9BZ&G;<90&\6<T@7@,>*R,$=]CR2R1?10S^?@UNJC7YL'"6TZ^/H'H_Z9M
MD:UOI(&"DI;4I9?/DGU:_*GUQ+R7[\*-IT98#TYY>\GJE,4GA7O1Z9D@^/+H
M*J^F%^$5TQ1+4K%3%&:4DD: E*S.,DV,<R#)?N9(AME\E5JEBM92(T?T9VDF
MH.F.7^$UYO%?E"D8UP^B39RFQL'9R$:, K:L5!"0K]="?V&TFJ4M5[5?96X8
M8Z8=NS.XHWCE9!X-MW[^52HHG+T*@J]P\3&+(# B?"'>Y;:Z1KBNT0HYI(9A
M/P6MU%^7;\/_5/[?IEU2M]NP!C3A@E&8SJ;."(KK,X'R:.-#O[D).T3TF>,I
M4/-&>FOU]7VD(WHK9,[.,?J* ,89)OL234S?2W5&3*J<9<HWD9:$G*RT:Y>C
MRSQF=/S E5(')WN1?<O+'!8G\GJ$W5C_/C^U[<*2</[-HA^$)GTEAL-=V<ZW
MTE5I3 C B ^V>M]"1SM\1^6_*DLH;XPS?B4 X&A+<8CL9N<K>F-',VR89>MI
M F<O^^E,*%EVYB.,_B0#B&:D_T$O.Y(UD-'J, ?RL=6WK.'A9@!BB/W;-DZM
MY8U5W'VWZ45<&[\+KD@J 6[=Y3;?AIT5]>)#)>?)<34537/,G&P'\JV7(R7Y
M;[UL#%?LYQ/)&3/)F?ZUBR3J/V@R2Q9A9-0'5^'MZ(P('),(Q?30A84<8T@K
M#/KMN"_U%DW*.L]T3\ES<^AM#HK/XY?+N:I?# 3FA.DCP3C-\BCO5^G2+:.P
M&SN_I6S_[R)F\.]'S1@M0$2#7#Q&]13M?!U!!&D_.M,E$C+;?JHRVS<@77GT
M8&JNL;T&"SE=GYUDOP^\CH;7B+VSP\V;U?-H<GAMUW-N-'47AD%Q-\P_M/%R
MH!GT]5#AL#.^8DQ'V4'FZ(/G3NK3 9Z?DY=8YXE0#.3;@+? A0Z&O:&E^"G.
MU,9Y'.7[%I<-SO2#6(+NI!+"_@-\3+)X_>"V.E09;>,'CZ9ND8(K/"-E.R7"
M+7=](SG-*P.#1W"159@W[D*8;^JZ\)%6/<[90H6 EOPQ"^+;?PGGU$O5U]BN
MR#1D]M-6>-S5W<H2U]\.8BU6V[]A^JG'.RL<]"5:H:?4)O@=Z 4E#B&*(D[S
M>@1NZ -VNZ^?ZV4UJ[XMV-&>."5T0+:94N!(5IUX.&"^!11\Q/'"19WHL6!2
M?A<G82"@JXQ@!;'4?CUL5YW]?;$EW[U> :^P3UZ.<3(I =,30_*-;>X1W;5#
M-R66%;OGA^,+F<^%K<<YT]I\T^Q(7A#'-F_+Z_'E0M^B3HNJUB9&VR]UZ!,)
MZ'7*Y%BH8)B8&)WDY/_'4P2#7WO%)I'(M9]2(%5YV<]JLS6=,ZSL!XEB*3P=
M[?'_&EZFE*UY>X%+<75W07TJ0X5#;0!/J<DG**WE/Z O.B,9/?1_^3HNO\Q"
M]52I1MWG&2$OMSFQ[T%+;"/W;O>M*K5^&N<2W*2AOVF74%RQ#(J)@//ROS:6
M%!1)WC1Y'?X(E_4Y-&4%&.1DFW3-OE)'WZ$VOJUB7M1[D[H1GD9R_\I:XZGA
MC.J6Y]T,[+QD2KEIJMIQ\%'$1TBU<<WIB* &K+4]#JE<"E2R6EN'[_Y%\3A+
MZIKKT+7SVK*UG\>+_/BLNYOJ&N2=GH3U'8#'PJ"Z,UQ[(!+<4EP38[!<DF^^
M-EU%!"#L6[TMV5N7_@V8B'O1)ZZ$.W[<G:T1?->:I#2%F$R-F;_?2&F+;"N*
MDM\MT >O$LJ;CB<%K;"X@FR*);M-%Q9+0Q9WF5<#@S#MH+J-*RQ\JQZ(K[.-
M 4)\=OC3O#\3ZYNV3/-CWA2LL*F190BWP:?]E6K>,&@,@F%X"XZ>KDNYV- <
M]8)ZVHK6F 0UW%*$\,9WXE8 FTVM'FO_]EGJP3;OW-[0F6&A;^4/+C_\3Y(6
MK@.<1PAALBO42%3\E X_R$/_5V<:TG6N#YYU2PDAE6,I/R7>?\PM(T*1#'I#
M=#I"GL!O]14M8>N0E'%$\:>@^F$LWW'F  F ;HR)D#_%R(3[_=+WO%B%7'UK
M/'T@.(T-$7Z!]H)[:ZF*LJS.0%R^:;+%_;=575/F#@^KR<B1 E. Z\ 8IC#.
MC,./0<,9'ZNOCM.I^L5H80J$SRGBFINKF+/-"J^B>.8NEP,XA%J/)@3[141K
M<N7<F\C&J_%35>OK!1:KNV-XWD5..0N^;P)S<(Z%Y-*ME9H8%3A+*2.J3,AG
M3J2' ,HCJD>#CD;GC<RD[5?ZA4S3SOM@S >BZ[Z^XR;4-N<78=4],J82"N$O
MZ&GQ,[8<JH6MKL?(O3[PHUBF__GT7&IABU60V^?T3J]DW_LN62\)[,'3W^BN
MYP! )JXY36ID&]J62;M&;TY%;Y&SI.Q,-5*X[=4PTM@-5<4),'6XJTK6)1NZ
M)AMJ1B>!%0N$8-UBZ)8@=W(%0&SLN\P;9>R18/A CXA27<:H81 S0#FM7)7W
M[70Q:#-E\DSJI[J56JM@E&OB+"V7J9T!!?^(VHHRW=E\F5-+F]9<-NT?/!'T
M?UR(I51D3N_"ZKX=G=B@&#Y)88W0QI]%]0OUV- Q"7 I6G)K$BVZXUT!63YI
MHL,*V6]I%@(1YVE:G?62L)]M$ELW+X'VMV1I.IY-2X4Z'KRN62O28(>+JG-2
M3T&I@.Z@RBADU$XT(UMWCRDNB-U..'[U5L$ATZ)U6X>VXVWJ\?Y<J1]=D]$H
M;W3!23VI773LZ+Y%8G^,O0*0"65:>*"G6-@D79IS5I(W,, W/8ZPCS,0IMY3
M?=:VI:G/I5%RQ8S3)YFK1^J$?7L8^M5Q$J:_^(ES-IOB4TG$TN#OWQE+2&<A
M%@L;:Q6<@ &W&7WLTE[S=9/'N_NQJV?UQ2U$*-W**KR!::FMTI=5QP PT>+G
M;WFBGS(OT"??R>])-/#$N^&L='0@/8JJ- A?38TULBK@06O3\TZ*!9>-I99R
M&W)E[<DE!EE#%[.L#Q9;H*P-U@!J]>Y5?GVM6!K9FZY6,PVK/!5[EN?AO&(A
MQ:O#BJP=/WDMNZ&(#C9K(@(Z>EY>"T+"?[J3;$C&2K9BSC]M8>$Q+_2^(EW_
MQ_I^C* "?RP\8D@GZAC K-E+.<-*(ERIW4@@(\["<T(4/6#R='1B8P/TU#*=
MA*$%?;VJRI$"Q%BB^40=9PXJ'_D><PZV!%LZ4<ZY3B9--W!W*4P0YY/$#MNM
M8+]],/>RS&_UE1XE-,-KLLB0E%&SQB0?"M,5'I#%R6A3UVC#NW*6Y>F4E^''
M'C-\@0GM#7I3,=>PU\5KIMH?70J6C$24PF6S'IH<6D#VJ;VDK>#<>U8:EYH]
M*FMK]@!^2I_Q>QX^B5W9O*X1Z \_M_F"&PWWU2K]'.7DR99EW:JI)IHF+8*O
MW)-9(YTKZ<%V4V Q[Y2J#VXSC41WRJ:VJ$^/%19>7X]0(Y?AC#'3M]"OHRY?
M^=+/N:U[D?D$]@W6NR-](MC5;1TR%F7=PF>;8H+*=&5NH17W02*Z=N3BCF6_
M3$NMC%FJ_AGD;O(JQFX2,@.?N,\01"$3!'U?Y!(E8F J"XM<P*EE$?5/N[&O
M#6-_$<3K$@#L6IKIG:H=+/UESM+)8WO)6<!+\1RULU(OVSY 9*99B^T(77I;
M1Q4OCMNRM+9#1R27'"K@'HMBBB?((IEE[%ZS0K<61R=A'_[/ ]%0,X46O_)C
MO5DQP4&W!4DYV,K<6\.G(,)/=$RR*@R<V[)J70R<RRU$'4GO(6+_H<%F/]N_
M30<UQ=:QB1JQYU60^&=N)>P4)\)6?#N.H(Q7?IL0G^V&*IP.PX=!ZJO- G=]
MQ'T!:)8V H[/57KE;$,4K4]B$H1[.2)VO*_Z;Q.(%&F,/G<S)=1B86GW"D9N
MNXAYM"FG]8JKQQ1],<E+8D;.4&^@3Z9<"UYYZG7XZ-]S097$1A[J'&I]CUOD
M\\! G4GC!.5$]JNFP2!68Z$U$& _22/V(G4";,<(&Q=#%"]+;)IW&ODT7<@H
MVK^,(,M5BQZ&O&7,G7Y#[M*[953]WN*61IE6'FL^XT21RO]$T2XSC;>&J8F>
MHN95I6!2O#Q!9'=-KP_6/ : %#F0DP$_Z:KI'AA>!B2Y]N-V^P!F#:@A2_9E
M5^D*BN?DHJT6=;5C I"%=ZI31Q*^@E'RP;UA3L(DSJ^A6E2Q*]*OAD>%M^3B
M+SPE#/_,C#E/BL_>:RV^+VF<U=0(,3?1Z15IUTYTA.\]PWIRO>1:H"/N^MN'
M3R;MVPRM\ +X '=-"O>1DU=@\=1)2^OB[XV!'ZC@K^4+" ^/R$ZJHG/JP":G
M%H<$2JV8I3Q,P^$"NF,N"?AJ#MABML4N)3=#9WS1>LL_^\?OQD&%2/,>^4!U
M9G#1B<1=NEEWY7E"O*J$%W?&H?/\ZD[-@/;DO6F6Y>FT/SF_07CH=EBH.PLY
MYT+:@KV/L@6?A&$_G:+5[[ST\F[V7D>NTL5*;O#OB:GTUS_TJ#]0A_\QM>?/
MNE)W6XYFN#"$L/*IL@.R8)CO^U#0-DY9N[+'" 1]&X],P6P;N.^>_57L4\<,
M$66'A<R+WE?--<6JSB]I3]YEEXIGV0_>NG9ZG>%I\[MSN$S4<>Z4EW&E6D\$
M63I-5O/<^7@:!<@"DJN21:Z47#^^=>DFD\'A#=&0PX]0H-( H[OVO1BF0\'I
M>L$YS##,N<QC3> 9RZO(E*C(E6A"J%RO/,&P60R5;5(N4!YG8+B3E/Y?*EJ-
MG_ =_O&%?L(KZIUCA[0J%D$V>I81[ECLV-L58-?A<!6Y>@(T*0T<$H9H-8.0
MUTV.C'X+=_?9'&V*9.GQ\758_)%8_/CQ,)=-E6>UT='#PV>UL:Z*#F]::Q^A
M7:U494I4_\%],1+.+4Q&GE?$'N!>2$C\TJ^//WK8Z^!.S(*2O[X7O=/*1,Y!
MTX))..C[6AVY/R?;]L[9A^BUL!WITA1,[D]O'G3#K\&QG,D!#T#MORBTXCS5
M#ZE0.?NUSQ42<CR-;_/59/9N"A&J<1-]:5"X"!F-"5,/T_"FRJ;*XUTD 'WL
M*B<O-!QF4,WM> SKW'\'5[=7LGN7@4*R6^[]=9$P59*\/Z%%N2?B^TK(5D9/
M5E%DJH%@ZK.I/?%-UIMUY(MY0)T7*JO7C?>I_[%\T#\+'O/NR7Z@Q)#,\]9:
MI*>Y:QK^::IQ8O\FG *@8?P\TG+/V+[&PC&Q4+*SKZM:TU!7D+5'2'OZ%X5@
MW6J^(M'4+F1SKKA!<0C7?S)Y;3LFF$)&1W/4PM6GTJ/0DC:]7W-((YLV/C?G
M?L*HBDTJC9&)[SO_Z:KLJDH+46MHX/;HI'G9]7X KF^WI,V'(7R=6 /?DCQ5
M*Z9,!ZN$2'X"F;ALARV3D"*[\7YYP-?"U&8I=U"J5U< ]C=JYM(J?GLN=>/.
M?P#K6:V^C'O4Z.=TLTHN0]?$7)Z*PMW<.A?%U;A0'NDVA5!_@%<AU8+PW ^1
M<VA]RG@:/&8 )F*&I;L)8^6N8EJ$\T2Y;I0H:#89Z2'9E7@?U$[J]X*OLAI%
MYTHK[-@;:>#(ITJ$B1W&.(7;E&+Q)7+N%CC\<M@GYZ/Q*E]DD<U>8BQ9R&9<
M?BNP76M UM(4%NUKY: 04S[>MSRD,GS(N>V$W/[-*=XB!H.X<!YO/P+R<. .
M&'SBGF8TZH5>@;DU -!-2U(:M_I)$  $N@#=M":U'SX/*51 \D9(-70/IN;%
MF$1]JR*R"Q&[=)*O;\8D(MG-HZD^IN, !R]AG][$Q3/O4N4&4;J^>;>6J.NT
MIJ?S5N]1O-7R5HS3S^DPS_  <\?>,/;D62N-)RN,6US4XU9/6]179.0O2C*D
M,OC&XUJ.JWVJ-&=,;V]6-)6MN)7P?5NZ@QD:LXHPS'V*OV,G.ZG.3U=)]'A9
M^Q4[O2GE71#/K[:*AY]_TN^]F,GT:[=+(M@4H )Y/FJ.CFV[+$C6>J/V2*Y$
MR+U\BAJ>H'Z#@MU^[&!'([MD??::ZJX(@%TB<>52T2'!&V2JBWI]=92E9_\>
M5YU,Y^C >)M/X<=/*Y9I<Y!W\>AJ9 M+A79K9A&P"W"LL([E[6HHW&%BIEOX
MBF*Y+:-\KP3//>F9(.IA*FF1-VI_>U)A27N&O;M@.#OR7$?;I^BAZ4&>U\S7
MW4^>P,2:)2%4XIBZG<_7(F3)'"H'5#5)#RV8SBBG9_<?MN"2_HN2\6X^+HSJ
M6HV?%O=W:UWRIRI2N8P]F,X6;4D6&MK+")JVB6^UG73>5FB3*V_&#Y??J(]#
M %0!0(.GF+">BZ41(.>8'WU@SQSW,I1>&8B$89R/B)\/'"LP)1(E$%V<;#0#
M@2:E"XC:WJ>+N126AFNV/\9LX/W*;!,+KUPTV_)UWK 5AKEZ-,;&C)Z[_HF#
M^G4M8OW=,3_.AR\;2Q4KW0N&:D)X.'60^K\HRGJ>359K*6!:T6R_\F03M]V^
MF)GIBFS"%CU,:<U6-T_2Z,*\GCL//2SANZ;RO1XS(-F3<3:R0]$A^3AW2:"X
M7N-S%%)B.F?UW$G7@FM@=CJF00COTNU+W05$P!?"KV;!)_*/#R!.P^)=Z(=C
M\1[)+57&/V+8+LW7M/ZOG)9_9;6,; ^O[@"=W?D!+>URIQXE*7WK9\GOFWT%
MZYJS=41O'YTDLV5>&GJ4R[Z?K3+%!Y)MAM'AHP+/@??M]O%5T!X\T<&YB]T4
MK],2RFXBVH M.;%+LU<.USM-0;XF)#-]!#&YZZ,$_1.U%;WYK%S)-5"K8L<L
MSR V!1#%UHWEFH^(8MK(,/#=UKY!AV^/P)YFL+WNT4*\>8UAH_>0P6ZNI1=F
M010O8_S(O*S<RDI&6@=3,,/V/YAH5%;M<)AS! &#W?UC _<)LK]C4+L"_J,M
MS+%[8'EQ!=4_2\[2D3A -:OP2ZN@X_[NI/?^E/0AG^V0%I9 &)\B!O!W=#12
M"3-W;O>W_YN4&AL%4FIA'>K2E/C9T_[2@.P\)WOF:[LJ@5WNX_?1N[1+8.%2
MRD\]N;JRJ7N".GY''#90V78"DUVNIJC;P5[)N!.FH[\H?@&>9'L!_ (SUPC<
M0*G/&.3T:=I6FX"XC:5U!Z;I3;<M;&G]A0T2_Y##:YNH=]X);6Y7JDJU4#1T
M#">N,9QS_&^0A^<0ANO 0J(G/6,9Z<W-JB!:?5]_ ]970=S&&$(^9LM'NX<^
M=W<\C54[5]FA&1*;K!NO$(<]*V\>U!S4UG1R4GB>]Z'CIYYK;X3M7[]K;3 A
M-9[9I8G5S*U+"?^N,]LXJ[MTS\'>(I#D:L<NYU:MY/?Y%ASH19OA#S\\;-TO
M%VMHRS1J5R-P+G;-T>[D652%#B_].6CL,'I<O>IQFKFYXQZ'Z1UPT_M".P;=
MS8@8ZS0]JF2@9N$[RG]17'1SSJ!I(J"?9NM/!/&LW&D@C,:DOH^'23YOM$['
MQN!M6<O5+.4+?Z[VU.#J+7>YE!<8V"J;=X&B&><+.' H\,X[Z#LY(H[E6A2^
M6<72&G<X$3?8I:_K^-@N[PE[]'&K+ QZH.Y@; P<T']LPRU=@CY6\&C"@F:1
MPU#*(,2?QX[#$%FM#9O_8:SG-3S@ 9[YY(=;>J- C0;/)L#+F9;%?2(B"NPW
M95C.!HA/#"($33LF\#[+KD586)O+S2YU-Y&MV!<W8B0B^B:W&O%8CKG'&'HT
M!']]8H20<AWJE_'WVS7$=,I9D"%?6:)ZH9ET<8-:*4$)DQ1)8L7UOS6V&YXU
M=]XMX8L'N&FE%]K^-LO+7H@)'D8?E791I?H&1&<Q_J\0*?7$PIQO]=%L\Y3A
M'$V?UCJ?JV$JV5HP5/JC:(N2ZA&:5+6E3:-.>K1"!F75O8@1:D-817Y.KR6_
M=P6J,WEZ_]3@UI'"F%R4WD&_7>76]+#*9#<;)19FDGLGMIB84 NQ(_?6\V2'
M0.OKY^ !]9G4<<B/<=LW&9RVE1F#S JHK/M>?::4VD7F3A%?DJA63+0\(HC\
M_YLB_FA(&W=/UV0GJQH5XC++_7F86T]L-Q6Q79?[?/K@8SI#%#\?Z!Q(JHUU
M9-)^#>5WN5)KJ)<]0YYK^I,3> +*-VPC)KMG\'G>>Y^=?M "H,[9*>[0$25G
M&(RU0QNR;+D:<"GE^\,SELFM^P=X%:<$#-W G=Q."@1>+&&[8+VW#L_#XRL0
M6O3A ,%7_PY/N^40%)P;QO%'3=UZTXSJ"<:71??_'E;KM]ON1C<)>"'+BTH;
MR5N;)LM@TX_6]:+7I#LG"Y-NVJ\LH7KK ,_03$4$XO99^J.D[ZV/V*6B>;EE
M/G=)8&L&*IVK=\RA;VOXEVL_:N@]0.WKH=E++?7-\O&S>PK^%J#PPK%9,EED
MF/WLD+T;F  S>Y3AB8$3YO/_3.+X[RX5_:IG.C,VEI;6CRNY$9?*2:@8/'>L
M+X3Y;KJ"0-7"1_%IHA>?( G*T^W#WY%8&.[]RB'K8:3: 9F^':YL/MHG]LDR
MXA,-E8W^;0LE;]*=%=\NOB%D6Q*=2S?MY7XN9V+:FM%2W"P+5_:4T,KZ]_7&
M:J?9G%;KG&R;XI*\[@NO\(@:I.Q@>,\['6/,X($8]W\+K)M29<#_O"D-ZS8:
M6*Z(ZY_-/7J8-2]3*OXZ9$12I1]O46.*&9I=E&KP29K7V4?,+VO%+?!P].2U
MG]P/JN>?P91&D=F_<!-S5D4VIZ:W-^4[MZQ(7&W)EP.)6\B3C.O(^@GNBP@\
MM^(\;$ RMJ(Z(!FCK:6=4F8TY1)> (<K=V;??&3O.7^_\%5W]D W/4J<K-O6
M+W+I[0NC6ORQ=_]M7-A_DNR$#U;7,E.PP2*;J99\N[F#VZ:&8S?A^:H-OCC:
M3^JT+<@RRR+Z@2DW?*A)JP_65O#7^@E\BC,0U-H3;]7./S=A1B WUHR4 R=X
M=-=TQH>RNNJ>WV7$(F:@.;5M> 3AJ4#7+^#60ZU9?;'*-2]&#:<PRU0U#8-V
M]C,MNG/18>-^OQ>I]2$G[\FC#5B*0+J!^I=/JU&R'2VPWQ9,+]HPA@ZL]ECO
M&?0A>5-+"^/SW1C^55DR9BL3JY#%A@C-QLDH@7?O/<,+0A=)BO_41E^87]D;
M/=HI[S[ !5C.G*?[,;['NI+P2T$L0&-;7TB?3\'1<OQ0>IBZ')GDB12H?DP/
M?)L77( TT+SR$/!B-+#=H][;+J"OTU5XG(H>F MZ_<PW?\H]RSYO@5>=BK7I
M724S@WY&#JHOGO,,=SQ?#/@JG+W2'H-; 0PK,=]-#L/AEKN-"ON)9]8=*[Q6
MDJNQ5F0:$F,U5A[R!20=^Y'>@M""$$A/[T5/SX*,S&G+R6E;6!I<6O[V//&_
M$UWVKWPSM9O\&_]NF#[&M*A3P_MCO+QON0EW\HOAY)2*3.D<LL?T!]3._V"-
M3W]1A'.BZI+T&JR)A3AG4K&L@[V+@[V9$['6<_FBO%E#5D5^9C*:"Y=$?61#
M1O2HB:"'A$;FI ZDF#C=FAYOMI."0+(:_'!T&9:FKJD(DV/=N-0 =5U\8'S5
M;$P//^\/VA@UMI,(])1JQ2^OAQE.QQXS?/[+;+52#SUOOS^',29ULZ"8RVJ+
M)862>ET54PE :OW)7;"/XGQAMS6+*]G*\E;_MC6YJ$69W?3X1\/3S;'M(X14
M$G3&^=>W!8:HEV+YL)Y .UO=Q15[OQQ%<#GOGG%5F8C$1W %[9N8.MXTUO2^
M+L[Q!#^?U_2SQ[KV*EKJAO]_K+I<!O"/#;NE;#C^-FV!/F'/!>N(9J?RQN+:
M.TBJZ^L=P]#0A:D@$ NVWW.:-V::M%^#3H_,JFQ7RI;)+$%YTD[,QM8M;<T_
M7E9O@+'\<^"/_JQ&Z/)!T@3HL7]1&$(D"B])?YWJX6M@7AA083M7.:P96B!9
MIS;,Q-8<TZH1Y>-M&IVIZG@'.A^= 24[HI/'.[^RHI[^HCQA!D=+W9AN6Y[7
MK#/^15%_EKJM<2!WH6BF':NA.!,Z#KSIGW[>=^Q[I6/:9^Y)/VA$[D=O6M3R
M[HG+!O\&MQQ#\Y64S07J,(E-!!Q,O)G:<J>(<,L):LB UXRIYE\QO2#4"GD=
M\ROK@D6/;-M59W"2]>)T]U2U*+K=Q_0W KURE[+%=2XNP<O)*-4+"3\:&UK3
M6%H=ZM'U*GRY2&KC<=A"1-$R_]5C?$061[=.Y!$DX(2>XV##A>VNMP?7SX$#
MZT(CE$3ZJB).^NMGO<P(_OAVH!OD@5A>KMTK%JPO>.2*M@_T8VM]#LGCTDSR
MYOL1-A'3M";4WKJ0ZC<O%AFD,A9QZVC<G@?6$5U-,=Z=W!>992F+;<D=-[6Z
M/.!8^MJ'X$J>G56R@V<:Z>Y<FOK15@@T3A8G]0]-=M,]?)[_E@.WB)GWV:M3
M6C;N!A)NW&/W1!1F,R9SL2_P-\H3>7K,6Y\=3M<W+'/8G":2I41;'U.WAH9$
M[O0O[;'77;>UZ?O$FD=-"]%%56="%'8NG=SIBSQ-&(L3\SEZZ6 M'X&$;G8W
M?T:Z<:-T.S/U66A$2+V19*6Q^H4W7@CW1HPE.[M,F/(P(Y# VU$W 3%]/K^@
MQLZYQ?/>!^XS1!89DU4-C\B'D([1T]C$X8C+(S8J]_9:HZ!_ZNNZ%DLR4]S!
M2*\NGO(F2D<K49\$12G?]ZY_ %AG.JURYUHQ<23N2$2O;=F4A7]]$WZ 3OR2
M;;_UCIQ;A^][N^WH/ZU$D+2O55(MK4[M!;]55IUFSKT7<'./*1EXOR/B6G&Z
M.\%D@^C#7+B_\$0V0&CG)TUZW43<E5$5K1E]BU51.5X?3\C[E#VFS)ZO%JXX
M5[EU0'/89=D.Y0-E7:Y^?1H!F4&SL-*)PPDSM7/)WM"2H\7E%6JM4ER@;I;.
MIMV/L^A&=AB)6]$'<0S)P>9'9OP'0<Z\*LQ&V](K[_I&='*[:HLN30\_U6XI
M+=<3X(V4%,^,GAI,GA(?\3*B,!=K2]@F^ N6>2;[RZY/R.B%KD_;+US?"[GR
M@@AM;#9TL:&L5MABZKE4.Z_)2\8S8"Q7,2T)#4]WJB.GL\JQAOEU8ILVDKX;
M:&7LM^.H\V62HMZ?#Y(;X7Q4,$G_UB]-.H/M4#F>,RWG \)GM<#[&Z8[NC@"
M85Y+I>''K\Y@^[5WOZJ3#5BA.2_WM)=N9E>W5_^B6)CNF()LKI>2JG/G[#G"
M=%$S<:G3&BR>Q3\L8^2T\!*1ST<'[?@46?KD$Q6X"21H895RY6B"!:.Q:T/+
M>SZR-7]B)1!6?/OSZ2,3D+N?'!7R%LC=@\ZY>7@X6BFRLK;DM_- >\%>[M!/
M ^WN/%1R^GV?1(Z)^<A,*96TS0&%)'^COH>#)\ * @F=#=Z4FUVCY11J 5G6
MTRV\E7573;Q&/D3.-1GH[=7J=Y_\X,S$8^FGNS& [2F^W;;)I==W$H_SS).1
MT&<^K  MQXO^93\EWMUD)K.!#HY[7?V, 8,3M<-DO?+4/=NAM?-4AMK^BG?2
MXBF/LE0"!E^B#>ZK++[E5!/Y:6X9%/&\8QQF ?>FE(QUBP?3/G;WWZVTFY4/
M[0MQH/]T'4!C<L-28 )R_F/C"@L&TR@3$_?FYE$W!";F4YYU/;UPJ#;OY#A,
M\X99VM]+L]9F;^-G(TX+M93A=A^S])/PR$Z-:BDY-I% '5A5H8"[S*J**?QS
M0(&_9*CRY3-'J)$B)WS9G-A2W1[JR%6IG+H6D@BI$<_^0OM6&$@VY9OB7U=P
MQV;=7:#1:@:\FN&J7+(7VB])OK] .-<5P6;=EP -AG'HWC#1'R+@KQ5_.-P$
M%)2)2*058EU'"0;X%6.[R8G;O!6(RVP2O]8EWK>+8_@VFLV(UHA4N,_5WQF!
M(*W@S]LV<-_E%2]GJWH ,SLP95YN.7HX)U@XQ#*,GJP@5M@2A7QZ5N"KU98P
MIOBGTNC";$S*G]]Z>SKGVR-S<I96D.<!@?E3OMB*7PVUEJ-$]7\QON+P,;H
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M-B?.$=PTN]V_)U2->+2>6BOYBT)3>JFZKOOC'O"CV9F@VJ!?L:=U9LF^_L
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MQ+BDO](LHO/+\ ,J3'Z?J280.Y.ZEZBY9V3:ZK<Y_8-(>4X98[R*_6/*L3:
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ML?$_A^Q[+D09N?*\,NW^[9'2*' )X-+^-<K;W*XW*\04+@S7^Q.8;/9UWW&
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MKX1\F>Y9_,^2)J76O3]8&U^SKBS.^W!['U8.6[^I6$OZM6@2[I^QX!M#W;3
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M8*V/&I[-OI=W,Q'D&KF899$A>GOIN+YR<FRY)ZDG('HE>F;A*ZXBX,=5L=%
M?#\Z.[:90^?3NBPS%7%V'TQV=?R )I'5>*E->+A(\I-\5X7RL'\QJ#)Y@%Q@
MFLX-S'+L)ZY]90'TU79(JVMK6F-.V?NV-IUAMI7TRN:P+:QIKT1L*L%%X_W>
MZ_W@G"AOA." XP@)P&SBL^Z^0XG,T7*T0_X.--1%VOSS>CK/E)LV=L\>J[+0
MESDFQNGQR,3M_=13[BSV:H+NQZIFYFX@_>05/*K66T<>G),^6-^>?;ZN57-0
MSK2G*49QE4@1D>G)9;&V_!$L/STO9-H(([&EG%R#AJ1FE,F#8J ;P4SWP@08
MN1@5XT?O^V0YP*]0M!ZP7+I8(G?!!0)WWJB+9R7*LIU"_!B4N>G7@R$ZDD,=
MZ_<S'^?KW=%ONS_H<*\&YGJ&H:+WWO>*JG0VG37503GV##],O]$[+OB6/\5F
M)5S.F3"F5]S;E9]X=%()L%YFTV:*SS%;S\8HIN[R]HKK<=E)UI-UFN3E+BV?
M!\3;]*;FS\\PZ35\__E"-8&<R#%>KW4K_YHSQ[*5XJ;B >U"HWVI.^O '#5^
M"GJ^V&KC<DE-D3-U"A5R&LW2#$L"(B"""*1&HK1Q^_W;(Y8'-$NF2Y/5![2[
MP)\$*V)LKKUW%_I_'O)LTL2'0HF1<30&SJEJ)'0>#,'!_Y#19-BO/-3(;;'K
MZ^&^/+?NZ>&;?^!#LW6(,A"=/=;6[YHT\(X7HGH?D:-_FY(N7?G*#]]2^G)S
M9+5_Y* [<I%7Y1$7GFR$GJS)O$Z=HMM9D;K4;9Z2RX!$JE7F8(.L4B#<1/-^
M(GUFHX"-Y>JG2-U!DQ=T))DVCJ;VVG=R3##>E3>SL= 6)^)X42&MUCTKZ9K9
MU[.!!*"=8N&:-'892:6:\ZT'47GJ?QV<"8C2\U%E 8)D6C]FAV4% Y&!F4_2
MUO6B2-(*=SU2P-XM+>E)R]X1>XT/://R,J!(^6)==767BF_VD1+[N>[F2$)3
M_'?_'R&4PW/C'V]T O#51U:K/%(71=X*R1.#9<0,E%?X31*^9ET;;3.[6OQE
MFA7BV=?,;L8+DC:5_)1O#FM<+5NO[%X_&-4D6T@(R=1NE^JJCX-"F\4]?@Y:
M76^ 6&Z3>-DI[IZ<3SV@.:J*"ND ^1[08(@QMVN=;(N[K6K:DXR!F_>6BR5F
M?+U,&7.SK!;<T*?U@#N.*UL295DP/^CC8FOB2B-R.5!O_\U"SB.RVN"F%VZ@
M+&I](5%;N-*HGG'!BI,;GFSB=_*PV097"ZRT+[IB!BPVA[J<:DQ[U_LD$L,C
M+\ GP!<CV.-Y4RL3]X/QI.LYK'E7!""JSALCXYX,E5+FN-&XR+?=DK<G?=6>
MGDX6J[?+/;Z&PTT^L.WQ_>=S:( 2 ;ZR>SVJSEX5= (OB0_#.\(FN9',2\JC
M#'$"5(^9!D3G?UYEA5W?UB]_Z=>]KTC"ND$\GEFGZQ#^XF6L?M78OIO&;K?
MT-QL>AZ"_:W?*DK$TL4%5=@7V6\P9,:9H5-K+,3#KY,534SD!-$JKAKX+!,L
MAV!-%1(VL\4BU3Y:TFY<QMO_,KN5[U205S55A4Y$U&+LZ\A^)?3!8S4OKJ]
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M\_J]GA8:>:YQV;(<#8A;/.CZ,>!@1>UPKF^OKA9V=T,?.77R&GK5N32 F$-
MH9?1&^)O;%J7_F!(W_JYO&>*)BDY-VX->BUI9VTWDS1,">)^]4$V =<K?5.,
M(JQB$_@S\KH&SMO!_B"/:ET>3,]&+R\.+W-<GW1S(11/QL*!&<X"0FH&_L9:
MK^8*&_M<HF$!7/J9%]8C+0(BJ7,;@>0-N2?H0$Q-@>O?@4=05%UHU66CKNWN
MB=#;QE@:"@<Y'A"S:N;DV<;WWI>@="6R(=+3ZZU,3O&(]T"+Q\2/G:2"YX+2
M[T=[_C)YIV#A>;+YXC8-&X'QRC7.C5!=.U;#KZE*MK#*I!J\>\ #@?K:D&"K
ML^+QI+0=<CX2&1&B@J'U[,"V^A@\6+J@+EWGZ_UU_43%PI\OY+-(@X*><'.N
MVL:ORNA0<=O0 IF1+$T-V97(1\^^?]&/Q;_:TIVA+\[,$U&@@L58<GIJB<[L
MZ$3&MTOE,TWKX7*&YOO+(2(%4Q4F$K>&HU-DVU[.NQO U+,"JEX$[!HHKI"^
M%\A8B)HQ:BE12]#]@W'5M_*$^T*8,2O?8NL/1O.%O\XOOQE#J-Q!)((Z_>*C
M]7G6UOL#$1/\G8K&< NEW3)@JOS[N&I]5\PDS!*V#5LELI,)P28YEZMIR,@P
M)+I8CF)CFR8%8@IQ9H:<.HEV/\16M-C7&9(;QJ1W&)M^9"HE-"PT;1'1Y>Q<
M&GO?\72<YPRO!GX^P'*X^Y(Y"5ZWZU8*IV4N.\R;:T(IQVL$K1TG!(;L5-78
M*H#EF?,<6?J$EDO&E76CUU .]M"9C4VMX2G-J4:U#.7;\0_*_1XY]T=?T*@E
MM:]@F1WS85O[%[%3@B6[(17COR.C&G(;36D+4(OOW'0SF8GX\=K>L\\($U!D
MU,\Y:(9(">E'WX*AD3-@C?+CFS6)S<H5OBM?.DXW2<9H[7LG@QE7H0AS"U)5
M0A\Q\T:)22J943[I%?T0G%64*#IR2:W05\Y&%YYVI-.SAR?EN6?O2+<G5F.!
M$Q]?\+)><Y@^91.7]0-2C/T/QF? .U[-6J!1N3E=OC&7ES0DG"4[J-@IU7+"
M]W;&3(]E F'BK<$R49ZK.5^V[-\%TS?BT]0!R.]7F!!,FI <!U0&V!?MR*O3
ML[X=#OK/:,^I>Y-"LS (V/@U9H0SV."5DTZ2;EZ-]B++TS!&,FMS'+.X-2 4
MZLIB?>KY+F<ZD]C:$?1"<[L<DR4T9)#8HC!QWE?0-SYX43I%W".66:P'GPWT
M<PXG3RS=(@[;U+R:.^ /!F3,L'OG?J)?VZTF-(,+5#+*BD;^*I]0!##OKW-M
MX(ND9]/(W\5R8X(>]^P_-5?[=VA-ZY#Z@&WU?<DEG GLJ1V8X<_39VSUI.>G
M=0FV^!U.3O(5AC>]O<[@C<2CS7Y[XR/(P4%'H_">DKV2;V8.+IM^;\LO2WQ?
M4LC/#=?-@S&X.RU3F/2 <GY27O;'&#H#C/.JHL*,/HLS<E37J#B;0H-$<A@Z
MB[G<Z64.#@4*W58R;+20R[*1.Q)'Z__?RH_6*>_PK?LZT6T*K0KZ@Y'A'HM5
M.*46JR%HSKH [)I-7O@(;4XMY2^*77#UDZ,( W:IZQ)SIY;'EMK=HU;+59*]
M#Q;@0!Y)XTJ;"-NMI.4!^I W0HPLIX1DL%.K=S'3M_?6[K^QU??TYDV_<'B%
MDNB;PX2]]"MWK\JJQC8HHM_A,$?YQ]5P+@JY3[VS:/EWRFJ+K_!^\GW_S+R[
MM$7.NTS1^(B*2WHSAOP8+.]3&"HZ2ZA0 DSZ*#KK^;M'S%  :6<T1Q'K"C!M
M7X#W47E,KWIY3+ZNV.?G2;^>7ZS2^"WGL79Z!Q@VP5A@ 5HPWU $/X]L"<R$
M 9L)K%SH,2Y'(XGG]D/,YYS 6$5=-Z3J+3/6;NST*4F?"E,.O^6K_\FLF>KX
M8/?0;/I_"3VN$K4NZZPZ?Q$F.GR+_6+%T.=Q5-@_@0'<0!CYG8+N+6R*MHUG
MUS))X/=_O(W[+S7CBO]CEOR>[_/P+F==MPG%Y]XEY'):=G!^:6PE4RER;.F!
M2JIKR4EJGW/T</AC-5G ENU6X,>&7#*K])9O4_,5#&Z[S*1TG1:%T%]^()::
MI Q:QR&YFD2_@T\9=NBJN65'](#]@54I?XK:V"P_@?;(:8RDN\\T>O[U*^G%
MR+":<_I*&4+KG6?E'U_4#H],_4.]91L\5-Z/F2_61BU6C.AP,D=FT?VHZQS#
M/]#@='(4Y(-?-&"5!N=4,^/.LF:I6!NK/B?W8 X?W#6<X5 U*R=IK;*GTZ&(
MK>)47=5O9.TFTY&+QS/=6%5R8%KIP7(:[:I&H1+-7#.MO]5=1O;66=/0!*DM
M-KR,XDX84E@"J+*PO@#P&K>XJT[(TLE2R+X(<Z04QFQ7^V]:_?_WQ%>$L$6H
MK+]TX:X3E+0Z/'V"GI_OI(=KU6!B4I[.9S;14Q% NI\/4NS CZT/D EH8HB1
M1YMP@T)*XXN=:0-:M;>7*D7!R=98"93\#CT?YCY_"&2(T8U: P:R$$'?V7^1
M3C:J![_5GS?J'=V^]I,'GLBAN,3MM 'E&0%W"2D"LJ#3%/T#JJ9;]<CS["%M
MVH]G&+V:_V0Q+;O_P;#=_$E9:((3!__U"X0]57<PVEX<P3FI^F:G7&I8J7,#
MNC[7G]S;(\LRS1%E>BKKKE4Y@4LDR>@N8?7JYP!1-Z?3&J-ZGY+KP),E\W<.
M/8 EA_W1H:O[S[>R_2V^1D7U\FGM6N4I+!]Z>J=<MEQ5IIV:SS9'/$.HLO".
MQLJ6/B'G81!,X/^_<@#^AT@3HTIA?&#_ZN '25G*MY2VC,D^WA_FK9TG(WCC
ME(+RKVKB'WWB"\<!@\'BS].,-N\_5NP_%%R98#^!.S[DU0NM,CD3F7QT(FXM
M+JX:<I+J?*QR%4E,0=T2GZ0NSU0&STI5-+)M!<M^FO5QYBKDYWK3%CJLE5"9
M%AF2 &+>Y-"R6AEJ&THXURTW%12TCL+S7Q1\?1AO%>J0,RATD#6C?3ZC:P6/
M22U;RA[U,B(Y\\IC-DTS]'YV.,URX1!MK/OK.\V;R.F<BMI5GW\2@))M'-U3
M)H6R(%\[ES(IT[L70QZ$SU_TQ.E5.9@><@\H$AZ?C#W)^S#W<?VSJ6 !,( ]
M#'?J\ME!9?A2-@V%W#R[<";)BL:TH!K+W:!G3RNXGCPL1LE8ZEU1*0,B26I2
M,WW);ETV:\\D%D(S(1QJQQ\"UMWI-J_1*6N7I.4,(>$3+!UXO@DXDA47SNS&
M,4LM6*ILLE^(>K9BQO'STGOY0+0Y0Y6L_'PZEY8V/C;<%$2KWV\<'5RYQBT#
M>"!I<1.7^G+.#""6VL*K27^$+OG_<"K \S;J*Z-5WNT*T!GC>//CZG)/+F"F
MQCI[W-45/M VZG66.A]B=LBZ-P+([$Q:Q5:A\N+53*D*,>;\65T#@\WE;[6]
MB@ZI+V$%CM%?U;VD4T;FR"()(Z*N8$0(S[48^2?**]5KNML"X:B+L\TSX2^N
M]6+VVKL<5O8<V0-C"<AUG-QO^RIW]3Z=EBH\L^'YE2H$>:\OS$-  7$TI;>=
M'2]62JP4-8<_>^D2&QLR-L;(Z,^K*8LE5 6M64[NL V5.+(VYXFN/3#=,-'*
MEAD8^9GPJ5:P[V::X"@?D7=(%=R(IL^VF*@HV_2QGPB!7<=2,1XO&69VQ$5Z
MGXQ-09W\D0S?7P/:9(A2PS<A6ZG.V;A_,%!D:SGB1>*)BYS-17$31(K\2C*O
MHR-A7",D=DF[$E" 43W'=UDJUYY>QDDY0[YGD0B_J*XE;:%]5?0C[32-J86:
MEXNM:U07;PW='HT7J>R;ZNT1$O+?/D9S7NV>\K,J5C@H^Z:05RQ37'T*+E#;
MW# 8V.A(C#6>&!BPOZ";M'FH6U\S]&%33.\#X(U?P;@U$0D9OR/L<P;/RPKN
M+6\NKMZSL#1*USI4T=@6]&L5^AS8>^Y8&IOV&Z14G&BV>PYV=4[4,YKI#^HP
M[Z29)2W16Q-# IE.+9, TI-/0Z,'6U&Y7W-SXZ-;%Y![L6T.^%,+9L5\NNJ3
MZ0X$M P?624Z.F>!TRQ]>, 72L!^!3F%5F6,D]VCEX_>K7+C?HD$2P3:&J]6
MTJ5Q4!C5C.B/>_-Z6UT1G TF3YP-'&X2SNY"A\PI2Q>-UN !7_LZ"2U6H7R"
MW<&B7]]F[GON"C:8-C*7=V3N:+(V'EYG)7<-;30,UFO5+'L+O??0RP$<NVN>
M3M7MS\VM)B8;QA>Y)1A!W9*2UMIOI5$FRBD3]FY/!6@;: X/.&L:8J>U%\@H
M/$FSAVL@'N==FZ=4 =\L[Q24Z=PV .RC8F.,*GR-8?X:&ZCR#GO)+95V;K<:
M@3IF=?5GF5Q&A4A;6^4K&DC-2P'55SVJY]JVJC)OS,$4Y,&9:<3+[4.9Q763
MBC2-$XWTO3+^0#M.7S^.8LY(>-R D'"%LE)V6O,7%FI<R0G57UY.1#1"<(OJ
MV-K5)W\P*O:/CDZO Q,[4MODYK="6X5ZDNZ9>?(T:D!4]V)#:_:.L*P]]:H=
M;BT_SJ2 L9;?#/[</6+T*PMBL>E&$U4OK+6.L[[FY: 9N"JJQ+$UD_3WIAT<
M^,9;9E^4N$Z?SG$6B0.C&O"9?*^0+NA2GJ8:7^)9ONC!M,P2GY8?RY]) YF&
M2-O018L'G@W-+,AM+N6DR<MG/?O2,MTI K>8\.^6K@E>:;>=!P.-%;,)<KW(
M'X*#-TGK4-NCO026+V2(>8MN*!1[VD>%3S#+ZU0D)CMKU"8\N]U;C/?@4USD
M7-\,QF6Y,^FMZ&Z3R,S.:4RAQ![R2=E0Q)4W;V(T I"K85G,,JV)(,4.%K&;
MJ"<A1W-_6[PTOFLN=6X\#6<AZ-A@(.^'9W+6118UF-0)A"TJV6S4J13W[ H;
M@L*N;B6T[1+AXL$!03G4=WX'2$^=-OW6U0=I2L#ZQGL*P1D-(:V_&TZ(Z<U:
M,AFN,*$5B!34[']-6'8H_ZP%9KM%K3"U6N.PR<A?NB89*/M-BOIZK-2\BE-]
MY?Z>YY6[) ]>O")%HWS_W_Q]+,"JA-*JTM_%EO-PZVG=">;VW!J3)\R8E^QL
ME_0B1LF?.XI#?YPJP>K.$X)UO9-O"A)?,/.LN\=MV1,UQ2GQ<E9]Z6F^,5H*
MP-*:F_'8/-TXU$VU63!80EC<"LBH+5<MI-T;2/6,5DZGQFH=^^Y71#B!SY>(
M;C^D'KSOO1OB@W[9!R' PF[ZT[IT@SLESV7\-8J'#*L(\W;$"0R&CZ5]2<;P
M9X^C!>DP+R5Z\L?I5N:48P>QQ0;2K\^.B&!GL*W40-#9AH-> A#H0F=.9$WT
M=X,\YI6>X+OP[&9KZU-H(#]Q6QDX1P#ATNJ7\AQQ<%DDP( 7DU6)8<ZE<-<A
M9"3:\[:8"+:^\=4+&6-(C +NQ2B"?RR-'Z=R"2^)I]S([J35N%5?SZP=;M'.
M9_/FW.<KJ7-4D]Z*O6\VR5_:K0$Q24=+-QY'E]L@5\A1Y =[9JIDG<M]F2/1
M<*Z XEWFL+0\T.F98'@$0X!(,QUL#9EB$I"RI3@@F5C]*Q&!BPH=I?%;*.E$
MCS+_=ML_A8O7'3*<"UG/=]1@;3CX?5<MM9M!VD8VTH2 -5;63[9U:X]'+-D-
MBUG(:AH)VKPWG^U+::W'4!CCNK]RB_(*)VD->&>0BL%[DR78P74AUG%0O=#K
M;"U.X*?>6WL@B8O-P:]=7FTXL64L5A/.@K\;W:Q9Y2O2U.YEMJNUK 1;WMYI
M& I<%0\6U)M9B.T1UF1)E?AP$R"B)1Q--;[4K##'PF&:-[57=>&/+V;3;=T\
M5+5H[<QB;7ZM=_\'PRB[O1'Y!V.FJ+%IV6VHH6VJQ4W>Z\N''>A '^.#=$*G
M)4?_2M^2GSR34N6U\C7$I638L.D+*WL-63F&]%0/)Z!S_ZY1#@%WO: (+>PP
MR='VA9G:!WZ");[7\R9_O*F^1*,.@Y#&<JEL,)/MGEX6)- YB4NM'FSU4V5=
MRO[:SR%=^X-!Z$4)&%C<_EGOYRE83+YA9:.?0BJ3FU#N>%KN:NU_$G*:1%+&
MKKKD)'PI$G0.$!J<1&?]7*^-!0*T[(L!&2O6'/O%T9ZG&\Y>[HX=,LC:O&/D
M4%VH3==_*[WL2C_S@T[/6O4&5ZJRH2<85$'LBI34)LY1$<Y.'^RA#LY>2%UI
MU_JMC?L[ZO#%\,.TM12CS?X6I+"X[&R,^?<Z&U<8PKLF1J!^1_H/QFTN+4>E
M8JQ7WFOF\'*[2T=DT<ZU=[A 0M9VGGM5>WN#;KZA3D5!PNZ(?=359V'M^-)=
M==0]-C8'.S PP&-2:-9D!&4>172XF&"DIU\I7^8(J?6F&EG=1:2T.;/8HI:+
M^]N$4'&2.5XQO,E=/*>F45)/TX/3VSVL'CS/+)B-YX@>W*V3P=9@QZR*!M00
MDC-Q2:/6<<@]T7^##<0FKKVT=6;1E\&5HN?8(*2"9!)"6;8,N6>Z9:W?6_W]
M/-+AYHW)X*RRT["WW_!<&V71R:R[T(&T11X>1("XQLWKS:\!&9XSTKC0A+A%
MLYA6 <NDM1AZIH4 !EPA8O@S. +Q/XHD(1"WZ9DY =(Y]P.W+OJY^O;W4_6/
M?%+H6=]",Y/ZY[P=>-!#KU3'N!@]OE RML;2GC:^2SRG!+T3;UY;B>(WYD%$
MN+NN!:1V-IWOGE;U7NB]WI2NI@T]L;PMQFM:*'.F7@:DLK8U_U8GJPG])'ZC
MW*_;3/'RX?AGPUB+8>O@QNT?C'>AQA&>*%P^NA;[7"*>A-]C.K4ZKH69T2:@
M-K(A5OD,N7.5W+8WR'&D1W_6F):+X$!P4T(1D=-7(J<H..V'IQ&79X[?7RN2
M&& 7N5SMD])_/3&AC2HG41B_?M9\+L4PR\83&_XV6WU@=12BTEP+Z#]QIK'S
M0;=# J2*G[7M]8<<]Q5/[NXH5U[N;"J/HKB2BL:V0:&"BI@*U<CN//Z&A.QJ
M6R/(<K6%07V'L58=\<$K0K+N*?U,RM!B,5FNN,+(_NG'"2/[P25L&M7DC8SN
MJ%K7[I=P/D1\&IQ//&/*@HPY_]5B)HJQT;$]G+&EX>'9W&*"<D."D8$_D0G?
M(;?Q=,G7"/G-!$&S$+X4O4)@#&M>E.%Z@CS^W&,>4C<^%C-":S<HQ!.KK01\
M=HZ5:2^(;BQD7ME,CQ$\I=>PJ,NV39\3D1B0?U&YD8^]WEOCN5191$A>J_8D
M6G#VK [D@(]:8K.D-BOEE UF,_XP20Y+)"FFMX:Z4MCTLI'*=OWR$^*=7(I[
M9OR.CI?>NSA(!&?&4\R E^X&]-K(;SBM0TSQ;@EP C^&"9O/ZC9#&0C83ISE
M)QF8-BO*4Q>+%./%@RKW:+<Y:.Y?2R<CU&!CCMJ?P8*5X+>WP:7T>['3;^_B
M[W#4S4XA W840D7[O6.:NE\'Y\C(*"P^A2GO+<R#6IV]80[[4QU97, B!Z^/
MPA:*(FDWO<:J+)%,B=97.IRJE#P*DZB0\%M54C&L!!E.8&58_]J/EL5GP:T?
MO2#.E4B_7!8\9)U KMU%W^HZ)>'7MPT:'W0MGA4E!.&1WQA9=DY8NC4\IW)\
M%IJCH)BRZD09LLM"Z"O:'?#*Y>&3R81C-'1!73T'^HU]OK*Z[:F8/JO\?3KK
M=;@'M+UR5M2]UQ]F"-^>]]?6,8I-X5_KLQT4ET6V-9P?-J[[7^M83;]]V_8<
M8XE%4K#Q)R8H=>]X>.30L$/:#-Y2SD:**6MZ*K18]Z#VLV<J97$?<.<%%W%8
MT<>"_JK0$S0E.W6WAEKGBHT8=7<ZF[ A6A(4&8<GQ)(FX"(D?BI%US.JXF^-
MZ\T!*0%-KLG;<INKDG$NQ#'RA_.BL1/"N*3DCM3%-?J^5*( ES4[Z4<HH--K
M^P9RX]X%*F^OR\(,IQSLZL+T3*W5/Q@V_GPO,K(!C25+C<9.AQ5RR.O3V'3H
M6-5T'T_"+8@!W$WS"+(Q!-HC:S&_3"PO.+!?&<A--5D34I'_75%Y!*E:P]?(
M.N;-K,F.5?D@3J ]J0^U.;)6 9T)UE+(FXE !(Q%<Y_'62V/A%5(OTE2Y87#
M]!U>W0#Z/C4VI%%>X>90I<0<Z]9G9BR:2I+*;L;(+PMAR9#1LU_NKK\1+MB?
M]B/OP;!\FIJLVY38R^6N6:\7X%G71ZQ1EB4_]CJCD*R5B<0PJ5!0K*86A;(T
ML:4?.#["M/4Q?.7J:J^Q8.T9KVW$M'=4?UB\]WJ*_@^&9IZ)5W\^K+Q.SFC:
ME\%\J6GB9]0EP!:WC[L2^#+<\\4/]2#7V:D+"9"K8 =PT\(F*#^474/NXE=B
M+9F]J%4-.#AZUD=&LCRM>PP@#@QMXGV/94VV!VPP48:8TIU\PQF%/_+LWQ/<
M#_;B#/.Z\*%U<"]A/M([E!I?N-#>K)B(5I0Y;'WC'F-._IA3I8IUQ266MMPT
MA(4O[<;\.6KWX#A:%@,7WR=35#O5B[A?RT%<QI73(C'2C_H%?S=LD']H+=U0
M>^9][^GU=*&EV-2:A=/ S9F'8VYZS*(560?S'XP74\[P:['82<<&MT@4;;U*
MTE(TYJ=%46K;K9[-7X%$=4$O8,0)50\TLO@),;S,(0_"R%=\F"<S8E0G%^_?
M2NFQUU_ Q"[;I]N204.7XX>%E#[VRG;#=>2.>I%#35]LLU5,^8]?E]759"4[
MK%4A=/J,FK7EV=%]>L6)(8,AG.:YIFF)8#[XZ=CFZ)+#P2E8?&CL5'Q*C2S<
M\.6YLB2RS!B*I4FJDAM74$P)W)H7L_1'C59.63'>7[4<R,O,Y;,5;WI/'\Y,
M1F[4BC8D7,/D?U][&H>>AT6(BJ[\*]MY9N%'_=R(8^'9O"H/M=?^ ^^,P!C^
MH-0,O6M,3X#%V>[$%93N,KU5+C1U;1"J\(9_XE![R?(\YNN(K=^4,8'!HX3&
MB'9\Y)<Q=?7PC6!T\&C;)[,:?5G(B3WR518?T0J[/_@"S"_&HK$"XJ/&Q,=7
MQ%CA6R+GP],;=B'\V<P02^,MXLR/1C?9 AW6I: 4&8__(6AK+QR^/V X4VY,
M.6>6Z!Y,_@GU87L;/)RP4U$ U^V'@T\W!6\#FF-IW:4U6;M&.FM$Y4GM?OM!
MXQZL$.7%_-3I\WA<<%'Q4JKP/N8?&^M!+#6@M$89X<6WM5F(6[%")#SV0QP9
M0OKN$Y!/\-\(Y7\=UW!X8R*\L?E!VV3BOXV6'WE-#[&&02&0#?1=>GIF*BS0
MG0^$/'PG&>L/LM49OX6\5J45EW$VT1,Q^XX SD[6/RT:1IT&2.\G3O;VC8Y,
MD3G(]8ZX$16?<=X= 0[H#=(1^E\8]*&IF)\3-^U5PE(UK63)I4@/(V_#3_5
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MX[]QZ[4-9@;=!70-S;=)=.0;C(,Y5#XLSV847\0M7!IEWA&Z6ZJEHA+;,FU
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M(,DR$#?+;Y8N#K6$4TB0R(H=+@*<?5ME:V6JOQ/[<")Q(TT94%>LPU<IKBK
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MU XKAO/=UZEM[P'-RF,U&VJIYML6$-]S>1JV9$'MU#@G9WG'BV<)5%60>RZ
M-^RG?PYP?P\-OTKVT$V<)$9X[:9O6/<#7ZMRT> V4HW:[[A>WPM- ' VJTB8
M"J[&5@,+8Q9V$=]XCP\?_+C*\7K=.&LO(-*_+L;YMFB96C5A*RK3BAT3P-!F
M%I9AFUORVBPU\'P#"5E"5BAE7_@ZM;^DQ^' N=OZ\F]%!OI:Z3G^>/?U]<T
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M"E(X0RR*CI0F?QUK,CDW6\5)Q/AE7I+[\2?_L%Q3O_B-,R9_^\/IUHTZWNR
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MG.BW7Y\94''$U56A-6>?J"]8OUWM7-$M&9XGL#RWV T.]]S\6O)3JD8NV\3
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M=]N^/]"7[IM.Y-1@.7,F9[EQ7=&[7@W#R6SK3]OYC8/0.\FR!];H^8Y]HTQ
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M^N2^6OHWSMU7J]XI7).X9Z_>U#>W!UYC[FS]G<+7?[M[.\Q235F8>^2BX+3
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M8*_'*H^FF;7,J?V:' (6TG2YG)Q%I>3*:AK8+2_ZZYQ'#WS.V%@;OZLQ05)
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M$%%T[T<-)J;AD:ZI;E=9@X1-_[MFWWOS)6^NX"6:G8 $FR,/>T[UKQV57DZ
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M,@AF3^"K+,FIK+]W]ZBOWF5@S[-&,I*3I3LG[XO-<@H>SDZ,;0C<RPG[4PD
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M[FF]^T&'^K.W=8ZR&[;IIGRI:3D#K5Z7#<LU"#@M5+[MSDS&A_WTG3,??R%
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MOCJBF<^.IWZ^]7?R!RZ(@+3#N6RPH5DI$7RGBAF@;[N6P3CR/I#^X(XC[=8
M<=\ONIEV>@B^T]MC5T>=N>C6CYS1MA\-C-R8/L-+ +;7Q)7RAD 2OGLB3DQ%
MFX-:UD[DB!!H.&@3.?-_*F+O?_N)Q\4>,&IG?3T:JS65'&+B'"F3XG+4_*CX
MN>3[/_2-ILTLXC2B5Y6L75E=?A1912HS<JW+/86&3.1F">"/.^)<2VEAY/SF
M,^JUMB!YF9DC-Z;RXCA-="8W4C]&J5)V3\(X<;I\/81$R6^_QF(.7N?#&.#E
ME1&]*"J:0+YF.C93^HBA,"@L8-L@)*^AUSKK]3*44(SPM!L@":BBDJ"[P'P'
MX*]V92OE.[7I7:]%,G]/*A;"=S.(GLM+(:=/IY3N<CCIE<>+.9879])2>KSL
M=OJ/=3W]X".^9Y$_LV>CJ;,RK+S9IS4Y86#6_/)J4#:?=TJR6D;LO5@'T+N&
ML<;.,">OL=DB_82*I]T +[C$7;1!;8%J.@AF46>F^2J+Y)IR:RX6%'!A/P@W
MF_0X+\CBI37Q8T6&%!U 9,'HJIR)FK@A=8Z;T!\<"B)M@[P:!HZNXR\"(H%:
M=<J#](.4HK\COGA\:X 3&=68)W*5QVY8>DRZ3M8$I$5QZ;0^UG,PJGJM;C;D
M_],ZTH\%&"-BF<Y+$O^.%9/8DMPG1'_T_VF<,<G"O_59/O&X_R>XAG]PXC_#
M,>C2ZOZ33_,;$]N_)_Q"W_>;K]?8XAZOT.%W[<C5CZ]X?Z)L0Y]2%^MM)SM+
MI&2\RW$T%/)G,Z(7^NY;=%NA[H3_0?^KH3.!2?]X?=E@3]UD,/$Z$ *K'HM8
MF_4>%NMU#V8F&UT;^57!4C;JY5^1-5.C>YAJ7E1P#:L>>ME_IH#UZFN?>0]Z
MRZ 77>>S_CVY=SZJ8J[8H[5%'?=W/CX3TV)0(-=P+W6/>Z8[99'^YP.Q_>9>
M5P'&25&KR2,J4&R)UF2>PC/WMI)V^@,R1E$UKJ.!I=]',WJAQ-F@+V*J.I&1
MJ<8IWSP#]/F2QF=C27VQLF :9\<4[1$A-%G)X+Y[:Q)IQD#O*AD/:0 KI47Z
M.Q;6]EL2N$' OE"VJJ[U%&CLB#HEES=89&5F1FYINH[;NU/Y&.&\8_O"+:W-
M>Z0PE\09Z6 L?S_8P<B,]#LX28#,A2,8KOB4H/9%YA)A:,%X'D_>D,?RK;Z^
MUW&W+:X'55N<P"=N6TCP"'CH_AEB'QX,\3Z'V]Y3C%$2D-#8=:\,\03%FY!Y
MD+G?'IGF9X'#Y".;]?*_^K2<4.4T6><U3J7U7QSO2<JZ6(T@?Z$/'"!YS*R_
MR;?A,*<(K4<=L3/^&$?'R]1 ,^HO[^L\NGGDION<%0$O)_:[[9+PF5M_]2TZ
M8XGW$HQL+G0".QND%,5/D&@X/Q=5?W;"CZ']E>S(%45J_9]&&A5)NA>_)\_Z
M11;D;D%!C+.0'+T3T^8L]V:VUUTPVDA%DA[JRI<;"='6MM@L*77^B56=Q\62
MV1>;%U5@2$2^3A/DW8&+IKN P((6Z/OGWA&[A6^]6[<2U)*"<3X,;I'"V[+4
M8&945 DT*7UA:S ZQCW,HH9 07G?%7VFWQF"WOR7GMY&K)KC%V\DZ<N=F AZ
MB +19@&HVW7QPM5GCO_*>L8+;5/OF8,>8I/<Z]]?^A6"8PUAKMM$'-R;:P5M
M29JCCVL*N:%7P?(G1:&AQU=Z>@F7]UAM4,W+4TFGQ8/9!XQ?P7?8X*L._6RX
M_9 0L#5S&,#Q1=Q',$)3()N/TAW%N0O'E1UL=AK00E:8,-4!#+X!4=3YN['3
MON8' "?W %DR];@:87CVQ$7F\L_EPLT=UB:+2S%?)9.GG5QATQULB!?)BF8I
MFCXXM><O]T]^SY%&!EQ2X+"5<?\BM#WS41#.9TOF 3#6Z(8%\&2$9?^HL'(4
M:\!1\'4R:^:V6UN4/-+!D?U<SB5B%%%XYE<+4KDP94UCAJ:1GJ>%#DPWH[4B
MVOOZ3-B[A#::!',-^F^0RL%0H(.FB^\F^IP1Z8-J-:/QM?25M6@.%\T:,8H3
MOT<C'ODQ4Z4!)9-P_AIB=E+JZZ9I+Y7E]VGP>,>+*3Y9U_G$WDG9PX727U[9
M[VO4B8!)&7I]@;TZ7QZJI/]X+DY7MLF[VQ=!NCU?-%_,)O* H3%NWU/./_KD
MF>)):GYE*==QREQ%:/C,WSQCN!?_A0D6[AVF1>Z9NZ:W7("XH'1V-CT'_<W9
MI\DXNJ58V):)YB.#YC.OW(41)4I]:G)9F0NHCAD1]?)6+D?\<>M&/ 0//!9!
M*=Y\F,Z1KV;@M/7V9$QAC10W!0)W'Q9&'>X';1N7UWPI:QR6XI-99.=4:5:D
M2JQA-FYTD2.9:C#36U[-HJ0(@\UM@SEN2<1(^)IO?IJ$IGVW;D6>M8"$*ROU
MSN.2S$/ L^32KOT2S8X+6>Y[E>Y2..-EXP@ICTU6U'SZ/N?=#'>'2=X<W&M\
MARP_V#9%FHGEHZ4TDVLWN"5SYC8W%VK?DXV8W^V,R+J_Q'S4O\;G_HOJ,-3X
M1V9'M60%6.>V^@!1]OO@]7Y>GQU#:P6_B=[Q[*M%6#1LWLF:/S')+Z\F<8LH
M??VY$./S5D%LUD)<*UH]6<&S';<G6<6<]AILG]82_=#Y\WO'A-"6+W>[:OOS
M(0T5T.X<Y83\!.IVG,DTPWI[KUQ/<X>*B@,<1J@!HLU!RX48F&LZY>=@<-'&
MY[ZZ@5_K$9/L'EQJ<KY#&62)="Y*35&=0NS$PD>4WP;.Y8GFW]Z;KYMH8K8:
M?<5,_Y[7M>Y!43G,U>/K/O-&\#G.ARJ9_XN[KPYJJ]WZI09M@5*@N#LM#D6#
MM#C%BCL4"RZ!$APJN+M+<8>B 8(4E^!N"46"2PD:]/8]<N>\WWSWN^?<F3-G
MYNXD,_OY9^>QO9[U6_);1FK#]_!J&)\M2Z[^5.XGC0&$W[K[F<P:BIRGM^\"
M_);9S%W!+!1B%P,N@[P*O>^,* V-CVPJ(U]/&I$E3!S9E5D9,A@8O%Z-LZDL
M*6PN;%,=:]ATG\VG"Q]LQ65JJR"F8#?4+FM\729'C'F$YO89'ZN:N%!41PV=
M%^O$/P=V:\B$11>$=7OG+)#(6,.Y+V%J.TK*N *G:_4ZK&<K:3@)KEUKTY2J
MGUR2U.UB04SRQ:\W/U!%,3NOI^MFL3@508YA1EK?_,6%G*AE+[\PC09)G$4V
M77[:@WYC3'HE=&V@6\\,(!"0(WOGK<U2%D415W>N'T#0#](X;>JVJIO^PES-
MAQ-7G<Y73!,J^G0"5;,"9IKLJ-189B$O9GMEUWX.34@>7U^6HRHO86FA(Z)6
MD-?RR 2*J121(@V3QFK4;=Z>7<[$'PL<'M2S-$QD';KQM:Z(H=+R7-,0R6/^
MCZWA3^@4<%.;U[ZJV]K><%*1D>UFM#\R+T"._MPA%K7IRN=:C*-/2G^[$H[-
M]_ORY.-S_B.,:PBQ 00"+4\*T/XV/MO^R>=PQ6OAKD8OH"CH>W$D/V?-8OE>
MTI7PHOEY>?J-C6#- H]:F)K:@6-%;+I[9KQYC5/##<.C]OE*-GB GYJ1B4Y+
MNM,F#.7/-=:,CO,)WX9=TB O24R$>P:ZI>5#0@/>/.KO#YW[K?5FA(1D!LBD
M+H7.IV8N!]9-WF'0--Z\O%W>$U?^1+^-3\# ^P$#WY6/#_P<XYX5 Q^+Z3UB
M%WHPL96[CLB!X4'5+=!CRUW.Y#WQ$B6<A)*3&;S+01'82"\]>0_[L2U[@A+'
MQ^#RHSKXT=$@KVH,P39BTW%K@#LX$EXQV7,"U,N%YIYD;OW(?L[8Q4@>S'>O
M^J-E:(9%SY@X8R_VY? WNT-*S3W$8/'%[.I"O[;U@A%T(IL9K.6R[6I$S<%K
MM*.*MBFJK_ $^:EGI[]VML)NGG)!F=>=(=+RVSI/:NQ.LY?"C7=V;O:;E&"#
M]&7=<?^38'-+.MXW%C2T4;J-@WTEEI"(J(_*O/0*(\D2M+;O78*,VHZ,ZX6B
MJ1E#3)+6$N>+/\W*-"Y@,16X8=HI;=#_XDW!R5Q2OEA,IM$M$.Y4ES[HW'RX
MQR#F*01,>F(>F_[%LNO%N?OVF3V[;&FGH['(,Y[+7,RN34.RE \C:V96>1\N
M]5IJ=!L\FOP\DHE5I)$?'GV3^1M8<&Q;KYQ@*FU8[0WOG_-TN7P*TZI8)>&%
M%:(>,5X4^8LK%"O-'.5>\SVR/>E;X,SU"F-''FSN4U^9-E^Z"YKU?0X82+6!
MRTV/!OY2T9?_.L,(]*/X>34^T;[:/O;(4P:>&R=+RZ4=_B/^KU%N (#G'WR:
MV4@K-)7G_\OQX.'^1IK$9]-&9]S ^-*.!M"7,7O&V/GU'I\"YGW2:_O3(K2N
M942966#J7"A*AO84AZ"FR#:F[?A@PJG) ))5K^Y/<J\P]*0W>]ME*ZY-1)(R
M<,7*W0DM]>IL(R3 ?"-&G1 S 7=0[&]_:!@O9P.8OVYC>Q0>NCD K-$$"5WH
M92(,FBC4-$HI!;,?B?X8[1L87+,% :*@ M?C=BU)/Y<K92+&?O';FZ;4=G'F
MP]ZR.XP=(*92EO24>;ZC.]VW*2#,SW[HQ=>V#9F?'4O;5)!$X-O.X1B^'GSK
M*&:[(JP[8"S![)YT*VFG8^F'E<K"LDWCZB[Y3X#R/YD_:J?_%,EU3U;Z[S4_
MVJ'_6.O^'87W/S;E_TN@D0F)S?5AIW=\%>J9D:J3GJV"5Y/59D9]SF82Z@:O
MO^$)(KOSBXW_!4B!Y0Z#%M][>: 5<5H9;F1AO.$JZ+!<LK_ATI")-D/NF53S
MM6OP\;ALCFIX2K2VQ%#J_16&S)X__]#B"Q]9!EG9DI,P$ )N PZ!W!'="%@M
MB8P>5EFQ44"(7FCH1>"C#TYR=QADTZ40\C7("8?$UW*\Z3X\ =F]HO[KEKI[
M'3Y9]HB31[FQ_[F,T#]NW\CYSU#TC(L\N\++5-9R::+)CC'H'KJ1D.Y<R@2!
MW4G<MU<R])9+?:<XSG=7%XPR>_76XDHJ?EU+J'(RF 49T_M5C0GJ2$GTJ^PA
M;H7OYUK_927:A8-CF"]SE6_.P":YM +X8.O1:S:(/@GCX=1Y751FS?HUZI"3
M.<?E1FD4=KP)X[O1@L-PO*%\U*W5Z7J"[,;4$5T3[O@\9]7?!82:6U04AL/*
MZH(0W4'=(!#9 _:1_]^-(7]L,S'WTG//H"U3$UT;_=BHMLE37,3C//QX+;,/
M#P1[Y)4G-N,J-CP\\UUVW..I?1Z%Y%=Q%W^:03):/%3KQZ*,C7T8V_^(LCH%
M$-K'".PTI2442J'@N<<7R@=P;@\T1UPX'ASB'A[<AN;M$=8M[.)I^@5D7F)K
M3'XR6+K^M+$:'25DGR=[O<ZLU?F_^T1X!7^ H+_TF^8HFIE=_LEV]E2,+K75
M])(;4@1VGCQC2M[B22YTN>#NGWMIE#PMEC9#9SL3A[1SOL,0G+5:6=S]@W/8
M)PKA@&*S.E=P#_&!FW]8C#1WS;0,R&<('-#CV9VZ\(H]^4C6CL=L1_88JR+V
MF%.R2OG ,HNMEU;EZ;]FYJ/W_E.EH4J39:VC)QE78@42S[0TQ_XV)&.*YNQM
MO\7H:K1_K])@WN"?"Q$E/ S\;QXL"F!_NM\%AW\['R7\N6G7P**A\47^>W,7
ME3'+X-B.E7.%LU>.?2]3P7:2DF53@&Y*5&:81JH*>N^[2<.Y8ZM@K9 $^22F
M@>8Z@\2GNB7>[\.F%SQVZ >.[[*8'V#9E ,\XN6']8L5> !!_D'4.2=[_N..
MR/314\[D.JCWTN)5FPGGK5/JJ6$&PJJI*7@6];VDNWE84JN/@ <QZS2_."[C
M6R1PIE7L?>#-RND0)G_VX^ .8PDW=>J]*3^__IFU!;D-]T(RY28SQ<N'#X=9
M%/N'^15C>635Q^H8A*IK.[7I25(_ FE4.Z2%,'<34M,40M.+6V^E;FA=-R=&
M-R]9W!VUE<X^+SMH-"Z$S11-SROP>BI* /"XGF:2YTJKC?5.F=$6R6*Q_%JY
M3\_BDM1=J^+RSA?3'^V_6J7]3-:\KY"LME"/YXL>05]$CN;>*4C=8:^998(G
M(3[!]%&=%O=,?2G*L78KMJ9<D 4IV9L9)1[51YUY6<S"J57CDI',LYT-N[*;
MD/ Z5T7>U&_3M%JP_26"A$;UVN]X7,+EA/%<$'59MBSALDH>KJ'1VS<-5'6*
MDL0X*Y28H1F+%D>)/VHK/9\D/E-PO)4U(2A1><<=GI"UR CQ/[J1FR5E3.@4
MRA.VC.D56@UYJL 8 __$$,5MQ1?3G_+F4<9O55 //J_J_^%@K>)M6594,;S*
M<*+9OMM^=N(#BX&FY1J+562-M!%3D2WIE=R3/F;=G@7><$J?M+)*5Q>4ANJ+
M>GOEJ%-/\ZQJC31Y=IG7S'TX7;8L3V2M(Z37A/I%^8"T9_.ANG+0V0FBZ6:Y
MJ9.V7X\J'#Y'%Y(WA]%@N%FR7J:F 0B&.6Q3^W\870NT,AD@C)AB4GQ8I72/
M'N"97#ZXP=S1$7<2=FK02:XQ,!/V?5?;SA>OS9FE>"S 9$PT5LU6K5?R\AV;
MHZY<A9KW[SE#GN<GJX(!7:?G4<@1@4F[NH/(+O7)9AW<Z!^F/$<7;CR-@QWZ
M=4IW&+*.M'#U4;8KU_F4_&K1*/5AQCA\PN/IB46B!0I91V,"#JE<OI/:BUK0
M$XM2:>*7(V]Z3UU>%#VN?%_'?COM[2S%YGP+JW6!%KR/V#D,G)%C%NBC4S%V
M:54P+%_V] SSN\,0O[$<GO5#!O8E.CYW$Q)!ZS!4.:H8-;N@KEJ@X,5OTC)(
MB0__;L_ -;M6E/5ZD'6G;L'],-W\>T+K$3T_UKB90=P\[@3WK0BLP&"PNZ6!
MRM'MAK53CY.V@_(S$7U%DA,'H>#NRCU&*W.E!P"W7I5ET<D]A,7:+SWL([6]
M_)QDR+)W6_HB2U/!B;GFM->! *N]MPQS]F1<#-0UH?KA)QVG[FM",YO^;IH;
M*##OY"'T#B-8)*I:-H<H7U9;3ZSETA+:6Y-_M7ZJ%L#0#G4\RJ!8(-A(FI@2
MFFGE7QG43U@S BT/5OMS4)!O%1L(JZ@Z?E?H57#B'X1HQDZE4;#([B6P:\<)
MYS%8N3Z(,/B6H5A5+IWW>TQQ#/A)O([QF$P'JW4%7I43%*\G(=EZ>#7/#N\P
MM+G61^\P'&ZJ2B9'L5O.Y5SYFOL <5/-R;2>2@C]#OWVCRM5)KTI-P?\.S*/
MK#'T4B19Z:*XB8&FCB3ZV4W&^JCR!/.1O"?\U!Z=*B#U181:>@1E;M8.1R=N
M17J8+Y%F_U2!(.O,>BE\;T$M8ZU=[G4!$_',8B^O#7@CV7U[ '6[?$F2(]AZ
MA^%TAT%T^)<VF1>A]_+9'<:1<1KT=FTC^^*F;R@9>5-U33*2C/;WG1W_:X-T
M=//5VD\V@0U2,[S$Z_[LT4\1!@M\7#$RF;=5N!LU"1677!<[EB"S]372(F;$
M !/4R6^ <^^R\5JK[*Q,+4][>+%A(ZS^W<>?2=-0L)7_,_+3,DFLU\>#%AV4
M//?Z+?;H.0\[(:IN3JY:OB]T;WK@7FY5=IA;D$\3\0_!-C:2EZQ.%MFE\ERV
MSZBB6%.>-I"FO&/(.O:HM]V&=R$\(^;%1J,U-U_+X"H7<;PAA1%>T#&73M8/
MZGC6DMOJ%3YE<%X3Q$XH?,Z6F/?T%/4Z$\E&07B&YU\7M6EC:%PW-E^:>@-(
M"5TO\RJ1H*/U5%59Q^P28SMEW*#X6-Y'%8:J#?WJ"9@]I/;(T^TH)?4XT8O\
M'$]MX+K" 4<EN">]2O!:JXC?5+>%K36':[&]V$ \6='/G48#5"Y:5Z3V33I=
M3C+:M3C6L&;+ST 'LI9(? V4SO_UK>$Q:2BR:G27LC]5B:7#;'7\O-@Q8CJ[
MT[3G+=:B.7S)_*"6=*9ZO"-1D1C#* .M2=\NZ14_JCW%8CRM5U !;"E?8R2F
MY0VSMB!9Z5Z-D<=MDR1QBK4/U)P]C-R;6*!Q8[=]2G1-2=P>98@$4_NP\H$\
MU&R?KB&[/&8LPEF[IFZ88F/N?2%=([[/]%<MS8/.RNJ/ HKSB[L2\56LGZ#^
M;OXV3AO1=8UF39:;H]NRN!P91Q:[M2_7=GM^N:&;SH8/U]ZU! N?BLZ80Z8L
M616[8_A*[=V%P?$.>,WUOTC*1864?T3AX-RH(%YX-D;IO3[9A$'P.%*+>CX+
M<JU:?"UI%@EQ?/__(&]^J* 0$TX-!LK%+FXLI*[HXFSE[65[V??]2',ABU9"
M"4ZY\+Q=O>=  I*L%CJ&UT!9X;.2FV6-!853OPV9?&L]3^Z%^RT)C!%4+2_=
MJ Z?&;:,K)U8:I-NFP>7P*:105O!4J-\0L]7KASO,+3@</CM'W[?]E;X]3+B
M[[0C> >L49*D:Q'(),GG4:R?\I/T<.?,PU@[,M;CI$!_6#)83(E=P)8^QAUB
M&5)V#5!EFU2SQZA-39>%D,_I\2/KW>S&]P7<C\B3>=;6Q(W"R&,;OW_]CFOL
MG7?%?X?Q&G>ASQAJ5/##.J1/?7VI+Z6P]446]=/H;/9-3JGP7LX1+@,J(<)0
M!8K6R9A_1@/^-U1&P**>GL&D5%'7H,,(IP)+\C$_O_=T(A8_%O XI!802UC+
MQP>%\LZ2X2!9<8I.7+#E?3SY\"%JSLL,+H?K#8R',F,5>?66H2(M0J]'O,RW
M'15SV8WR.)/<@2[;)"M-CB9(R\J16A"EPRD&Q1U&CP76P5\]7?U^T2,2"TN+
M/EC)0W!'#_1FNB736I;X5UB6\"67N+B600^P70[1Z(/;- DZ'@W\N&1DV#[&
MSYYZU"?J2P@][I,P"7@4JO:?18G2V;Z)//&FJ#A .W\]<W**Q[DPM9(=@"0>
M_7&.Q<F]H6L3)=K "CU,B BOG:D!68%Q@B(9P(ZZ,J=9#\E@.WRIGVKO,)0D
MEU_=3[+^>T)6R[GB^HU3+0*N,&6Y,C-%)!R/0.24N9YX&0S?@JFKQ@F]T^@P
M@4"4#8G:UZ4U81*K"@*N@["#:@S4^1,[Y;=\M3<FCAI^)NM@)U?>^/7_LV=9
MIO+8*;IU^$I8YQ<UDW&BFEW+XMJAJ]^(UC56Z)L/N7_912^)#A(OS<Y&K_PJ
M;_'<7*(*Z%LGVI6,YW\?1]/+'0>5;XSV_WL:&4WW<9\W.ZJU(HI'\90E$96N
MRS)'#TK$A[:Y>I5<"GG_YNS<%QM??I[&=E5] 43EUT!5/[IW,X?=[OF1M7R*
M^_@OK =-8-KX*&7,,*DRS@^0XHMOO'+L+MB??T.\$69,SM4/2JN2!R,CHYU%
M<EY.[MU0G2Q?K<)7BLS+.VPN,0\=9LA-V'A:JD+2@W:B*:R*1W%YW#!P7,82
M?JR6GCF*-HJO[_>2Z/QT:;9[/Q[,%#0TF19Y&2_(P,B'1Z66[NT\%] ,K "R
MD)7I1@FO<"=Q,S\P$F$?W8?-+?+7D@_Z,+43;SR@12U-S/=1/V"*W"'Q8 $Y
MIJ \-F/LEH,'0M( :J[&0SZF?_/^8A_:.*C&=%H<H3-D!H[02EJ#:!RWG=ZC
M476D@JSM<;?# >OZ/3^:6)YUW#!>.O\O(=@=Y^"S[3XGV7C".K>277M&4$?)
MKR,*/D)HB]NQIADG[E$3,[$@T,I6D-J6&3C>\QI%7K][YKO<*M/@5456=M*3
M_8 A6I#L@R"7YL#[A,\'9H>?VGDG&VG9'4[4Y)_/A8=^"PDZ\4V^>K<-GQV_
MN#$I8D+W)'GPDJ(9(PY,:[Y_(FHQVHB\L/EY=%]^]#,%OV65(X_UYD-,R=S_
M<-F"W[=/!ME!^PH+!ECU7NJ(@J'D<"[QLI">7GN!6C*%AUE/W>:ON\D"D1#3
MQ:X*7<8$-/BY!##[,UCKU-Q\ELVI#519^A.2L,E2HWAE,"_CN*@@X'&*<PFR
MAK#0]T_+/$],FA>L,WU<L>@_E[3?&J=<%U6SW[0(P*_S\BA$]TII6>3&?+S%
M60<?*33='S"V1L>Q6TJ!/14RGDU%3+.EI%)^GS3PA-#PE]6F<L@45PW'P=8W
M/??U4Y?7'5-^?A'W8INN((W@+Y/I?B]Y'V-H"%KK>>XM5EFK1Z5:?$ TE"0K
M)WA>[Y48N#R]I1X.?_0J%BKW4&KC=JHF(7Z /3C<<]G[]K?FC'YWZLP5=&)-
M:I>>!)>\8$F,:2Z81[^ U$9R^[52U1A;G"T\KPP C88V44IEG6T4J>0ZF)F+
M1YZKTI] U-NZ+SFK"_%@0?OS )&&.XR!R]\/K/KR!VYM.[W#B/^#,M+DX1T&
MZK=$!Q:<%5QDV1OWGXS^!J%;2DKLTBJ=M)RRTGOT].*.TJI=V(*_C]M4]Z3^
M/=G\)3$I164;'WLT>^:J.ZFI([G0O9XBB)F9T],*D3VI-?CWM\8DW"3T2?*Y
M<9-7=DMV]720F;JVQ@KF;U/"NBM)MP4YC@AQ'^7^U/X'JC$Q'V>^R/E!VA\.
MQS@^';9>^[4K57XD2+E]*1%_,C \,DNM;Q-AY9Z$F&CJ5?\2"=JM34@&J'"K
M@Y(FY![_$@>6M)2%588X#;NE%PO"):DH$I95E7.S4+[J'UVG%POWD)B"!?--
M) W*HSJSE8]0KJ,$%)Y7W3YH(SSPRJ E8Y"ZO.I :GPLX8V.N_OFKJ^L>BN"
M'VZ:,3?4) [0W+ZQ*MS78RTA\LD2J:SL>T)XH77<;%'A-1DC.++,%$[QH@!T
MQ!),CL(UC;3UUDFM[1LQ_YR-3%.A:C/AB<SG0IZ^2.^Z#&(&\GL*:>AHV"($
MF!B7>][QJ64PMIJS]E0%C;J"=5_85$Q;,?%%+[@F>"(AE5>GJI5+;8>Y<CK#
MK]!\L%NW^$;$*&'_WIE#_!W&_!?.[%F@,&7F;>W)T[TA.>"U-6243<%T&9FF
MYS\=D4>SL+)X#3,-=/KIP2NTJ-RGFG;KVTK;?EM$&'2FMI]7+E#U7G/(9N]T
MC[_1*->N?BA*F.VH:QRF+EXZ;VC:3CE;_P)Q[_LHGE)U#Z-[R,'E8=1$>C[I
M/J!\,"AA9N;^8ULEOI/M8;4/\P&J^$ =KO=-'S*S1)4'UAEX?VT;-!IWJ?,9
MG,F_M!TPQU3%+>X9*-'E$V+_B&X!#3FJ2_%%)_@Z@F+Y[HG:.]&:,R\YUK<*
MVFS#R?*_\36JZJ'M7C _H;2(PW2W(HR8O];U"LSXW"_"B%Q^NU:%<W+C4G02
M=EU>W&=;^TK!"+=MR'+>2-^I0F.[UL^P+'V#KX6CEPA1#E5HU2^+\Q3B\V89
M7G@GYM,TP *SH&%<6#!H;$QW;)+1N-VG1NO]^F56E[6QOC%LH_"#KG-70[ ^
MIK-7I0O7?KY]%"54G#K(W*PJH$C=R?-.H"R:G\,J:D '8HSMQA(T;/"^QZP^
M#14PO:>302YO]<5Z*2_M91Y=G# #_8/[! 0@L)N,Q^@7OCK1; 9.BDZ?D8@0
MQ^TV?%]#@UVR/K<-+8XBS)GMGE[UU#IEKXC+I1T'%3&.0E_V4I,G<BO-W@H?
MO?G'"Y.;0\)5^=[^^W2>1ZC:U 7=0; +&9M;\?L"G"1'HZ;7;J735<^;%%X?
M#[U]H2;+O@ZTH.?8.&@C;E_"X4SJ0HSN4$8:JM!08(^ZG Z0"YEBK@2VJ0M;
M")*N! D( Q.^"'T:"C#.N%GU19+M+S=QXN&<_3+PUC9F6S6\!J1NFXE+,62Q
MPKY@@9^\7$T)>YH]SN)-W*R"._OE@H9-KZETLHJ\B<E/*>E7<!4CB2KO#/2M
M6-R"!BAJ>)O2ID^WF?_EW/52F<:E^&OCR2RX\,9O235-@G!P1!Q]28 L,D.[
MO5</=R3;\P32X!'&&>!JU9?E#$=VEJYFU]V@#\N;KF;50>(,8INF T8/[@=6
MCW_V&O931=QAF PO[T"OX+=E?V (M/%Z-OH.HR"YT._4V<,IZ.AU,[$XDRW^
MO/#PWGZS79%8[;RK8AO,DK0R)L*\YE52?;>>5^8A ^>(I]@4;;..IK]ZL2/:
M?-SQW"79<U!]QXOE#B/YEFU<PN4\^@Z#ZUHGUQA9-[M]AT%=E%2U)R8L;K)X
MAR'%)>GDM9]9-G^C6.GJ]OH@OLMH>(,+'X?HI30*@%'K43O*DN"V\T-\Z<R*
M]6> Z#H/RBIC*3H/4N*T7]^%;BF)7-K^Y##9UW=/L2 /,[CDET[-&[Q8"@%&
M]R>NFCEQ3X/H>=ZW8K^87.6OY)[\V*1%N=>\E3@1%J"?L#F(0%CD&%JR3I.T
MG2FP?K01F^G=[KKF2\U:/]I.* NZGFD'UT_NE8C'9<%SJ):UVF ENE1V32^.
MS-2"E<LB#SYA?XZ\<*3VI$C"BY^CM@"CL;*T*7>&%5Q9S/N:V%)Y +*X>SV/
M?Y_J+^P/Z)>UKOL;'7,Y*:+.]HF^D\/LW63EY'9;B/8P_:F5U+6;*"ZT=_N7
MNF)[EQSMUH]F]-!!I\), 9'Y7R2CAO@ZJ 66SB$W2,;M6\W=P'H5@<[^DEE[
MQH(GG0I"@P11V[T*!VD._#L*^@+AQIRWN^#*N(R9"=5:!8GO;6SM>?;HP]_+
M</DBXMSI/&DW:G@!LI)Q3R%UHHD/8SJ-?GJ MA?X$_C<;AH[E*'/]JD:9(,]
M17J?5;#$^$GI\PN>H=\'I7^.A[*J8M]P'X2$,\4D^J,G1ZE-XZ#856$!F4P!
MJPHG7T!< F-^O &3]B"!>C@HSKNP56)M]IS"#O#JK'!\<2 71'XNM1[,$#C8
MT]&KU.%.XL>)><#RTB#Y52HY ;3+C #EAZD;)L\8IM[?4[;6?-52I@EVFE5#
M;B6@Q?#3L^K(-Q4N G^NESRX,$_J>] >;/!^-9<^+C&)FN,'2T3]$$$?DT.R
MMV +N;O)MCUU[82G$.^ENYKYRH!9#=%R3%9+2WAH]+B,64L7DYU;_JIM0TY:
M2R=OM]D45@\7+N?*==W*,#@S]J6H4O!TS[G'^>LX'>WF$L8\>Q)1=5NWV9;M
MY@BG:*/$6.,3_R.N^%N\HHZV(6D98C+N_UD-9/UYJ+(W?CT!3N>A$KD5\'_7
M9)M!V(NC,< IWC(<FT.!)A.0(@6;6S^"%]13\7Z(DS>S9-CM@H@;WV&4?YI!
M,'</[6^,#.WM7?_%,RTQY8:TDO"8!<XL[,].D8K4WYA@)8"FTD !1CGVLMHV
MR].F?J2ZH-D<:+3U8O0SD2,)*BPR8IR_]NG!8HZ?5VV';7G1H[1:&;.ZHW8L
MW!!&,M,$FG6A]7L\_C&!F2:NU:K6'H)R#J][J^X3MSK&:PS_X()-CZQE3_/&
M KSG&*LI%BJFAN34ASV]#+I7BKF+JAHA=3EF_,96#KQ\1]'31*,\7X]P4^A&
MS1F((=H\+$"G@"-?#4%%"*%9MR[.'HI6/_%?%M7F17945R4-!MXEIYF0R%'"
M:*ZOWV)2TS:,YR-%M7B<QD7/-S[)&\!)]* AH<_'N'A2ZF.;7.F\/#F,^PUJ
M_?93%48,!#F5P ZZ"0-+40J;20H6O.X,O"[^@MKW#A'[3+OSY9@S:YL;;01"
M]9RYSUFV+U1.>'N"BMCXCE:U^A3%5N\#?_)JX3;M.*:=_8T1M05P8^*"JL7^
M;F5%".<8F]0WTUTZPI^G[,T%[P#MGW'*[QE][O=P]OGLH3LF0.?,%O'AX /]
M3WV69D"MQO[9I'GE\N?5*?(9V:EY69[MI%8#_ @/)>^KS*"VU^:UM.V<@EP&
M0!;,Z$(UG35CC##N,-K'JQ&R0FL1TO>%.E+>8#SZ_=,+D-9+D4E-3?7K_Z?X
M..Y#Q\1IS_GV*"4"0;MBVO]H;!E[8?'WF3:X:NQ;5>];;/MVLQVLP9@#^5/S
MSP]^4'0E>8<QA@LZRRYIOP_71WV[Q+C#:);8LOR^6?=0AOGKS/BGV-1M*GF,
M^R/2TKIVY?3T"$?I@Z$AA.-AYVSD@ZM[=QC._F/]>--_)3G(:*7Q1X>[M@UM
MMR/(F'2GK;CDUF[-EI9K19S.@Q3NF:[_9TPA?[]52UW&/VEVQ#J[(;RFLY%A
MMN7Q7K-_#':??7-]S-]*0NJ,,)*J/!DZG-Y8$I1FV5BZ,A2DE&!_].KOEAP2
MY0.'2Y/7[GLW)A?+&>I!N<=-D&V?\>7:4_\U/] [\O_?Z4?^MSFYK-[?$@Z
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M.XQH%XA5:E&O $=RJJ9#2?VOI(,M6)'CHI=]LY#@CM5E2*&!<+4NS'&?_ZF
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M7KK!/9[_B)"4MT,&MK3FY#!H#5( (#*V$!PCV">1D)JYHV)G(MXZSC7>YW+
M*,F*,!VV07:U4?TI&9PCTG;V55 J-MJG]%-F\=FK@X7=&[7< Y[&E9KX()&.
MK\%5IO:$<UT(8G?FC5YQ>6I3PABS&KZ.58INZ9\?"?[2)4Y+2-H52X'KG(-B
M8.HWV <7+=Y&-'8R9JV*:0)#BO2GJ"<IQMCXU7BAQ@H,.]25.KC2F-W*:7 E
M1\A$(ZY!B'@+^%O/U(".HU<8C6YHF/X$B;PKAU[+NXDK>@2C3!>HJW)("W%
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M;FS'7F?.8@2F'%(LT<&'#N\.90':3<]F'*5-I%CQ^]15B(,6!$9".B _>#M
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MV0)JS@)AIIXO2EUFJ]9O#J:TR:(GS4 ?NU4&M66^UD[5#!..9%-*&6MSD
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M_ JIVU'F%KPGEO#L ;PAJ6:5H^UW5I1NE'NB7W&6ILAL<7-Q&\=YLIZF<&8
MM=.'Z5_Y;%Z(IC";$[LH(%EXW3=!8D"2T9BHM%9XTHT&70(\/(1F-3+') $.
MV1[46CT@:<GIN:HLD3(U$7IK)3+TTDZ@G*._^"A;3*\%:#(Q#4NE-<X(U1F8
MEM!$1\+$:.?=27,Z%P7<'^<@*>VTV8H:)M:J"WMM9[G8KL]9]ZO^5*<IV&>N
MAV;R?LW+^6+&=H?3\S9%<&L30X;MO\8^$[)86[77=/KF7(?O7@B? QLRX7 /
MBW;[III);/GZ4-SO723"#&[,95,U8N=3S5ZX 'G%:IEXS0(("="+=SC]4UW1
MB\]3U2IJ:X0W5SFUI$DF$!8T^L5/SD+JUI\QQ0=MIP,DHW/V=Z&S='8K,^4?
M806"81.:":.G:!HJE>MVH15V7&]CH[C@^%X&L@*P@HOR"(^DVUEM&_>%5=G[
M>?GMW>[$MN);WG(I!%?DN9*7^E+&<Z>V83\)XV(0I*W2$'2BOK\>)LQRAT-I
MT'!.>MX!W+/F?:RMA=U;/B1J3/:"451@P)_C>.E$7ZGC+40ACO?!@[O7;GL#
M\:BT/1=T /ZR?K]MV=:"F12N_J1GBT9XC^PWVA.VZH3DO*$!LP2;(B_,/ A$
M%I\UNJ#?9"2:NA@\T>@"-*+-%O 1N\@9>B'4$/IBB-&HTS@] X6<XK5>H9>*
M;@+IF#<##*N/'Q99FOVYWLU[(1HW!1%F\7=/H, 1L&4\@-6<QZ(!]I5I$7N/
M^7Q3RB;%32.^?ETO61]0M]4?C89@KOM,R@>JEX=,(@,3;?RD 5&-4"V=2[4R
M/B^.)K74=D?]IE&^V/'K453K >K/4!L $#;VVX'KTN(48*@SO)[I'Z,1RM9M
M\@&L5SAS%4RZVV^_A[9^Y8&1$_\&$FB2@ GI#U!JR5.N1&-3Y2A7(@4@B<8:
MZ<R1 F"SPGC4QT=9B4P@5QERL]-RU!\A0ZL.C*])K'CVKAKM@1WSSI/7 49E
M2KNT%S -R &6L@G; 'EB2[A6/<>L^ ;2I/WQ]QG3 O>6D&RHI1#YEMFOB8QS
M=PX71]E@DT'B>_+@9.BFVB )HJ)*)J_$;2HM\:#\P[*U,K/@V_7L^30^0+2=
M39'H&H9Z2S=I$T.'O-?A,Q?[+2H.6D"&5WXZ1UM&'*.Y8PI3MB]5=07.\A2P
M9*YI4M3MEFVG7_' J GEY\+EQ2DOA)H+S]DD1'CS<S7:=(4\K,1H?8SCB$PK
M<'I2)7]0"N"6$BJ8H2<]N3P$(8)[_M,V*)?3]NB=K.QZBR@?YS2;>O5\-L?R
MM]%6])&<BH'/G(.9^.Z=_:>@"[>\ >XH,+>NZDC'F/KX%?5G"B<Z ?$3*7;^
M0+M:?*1LE&Y?IR.%-3&5U7UB"A!TA_2U4]X"#V["V,7V5!:R8]^67T)])NH
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M7.5J21_")?P<P\R0HUX*F<2&BM%[4['T8 BZ@QE<?Z9BG^5\7'SPVC@+'CN
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M?XF /?RHL7U[AR-#ES$[V[;RWU8L^]?7<-YSBPXLPN2IQPSU%]'&WZ/F?2O
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MC8,L!H@$SSMF>ECL#;$[0DZ7 ,^ZP8*$8\'F'D>?ZH8RR3Y!94%_Q3:74W5
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M&Y4_R0L-?:02=6%\<4BV,S,^6:^2GWQYU;RP;QT1-;%L)P+%M/(E3W;!T5U
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M4Q/= 3P:-[)%([]H_-K?]C[>ZTS%XW)9'*_V4=J]\=V]494L%%W70 ZEY]B
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MJVV(QT.N ^6(K<D"HU(%,Z=/-O2Z.QI?VX JZ0.-S^-05Z;=Q]PV@Z CPMS
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M[&<,LK^8@UWE+.YI'TNRD(FB-PX>#%>Y(,\13:!&V[.ES&PNBI$P:OZ2=>(
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MH=@X# S>< S,IMC8!-YP3&@-)E2H1524%UJ+H"A_M/P,B3P2N_1T>C\>^/5
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MVTK^AK_1>+5#&1(KS'ZC<3<-X0D2</.2J'YO(XS2GTM++7EWF)":+_B=V#R
M=*4"8BI002'DMF"WRS1!I-N.;!BJ8G<V!J 6YE]I9N:3O-DU')5XSI]FP+M>
M6=^QKV@*>F52F["=8CG=D)>A/_ZG\RQIT"C$(MI:VO>Y>:=F?2(2*WN-* )\
M"X^3:4$[F8@YM^1<0>8GY<3TDY0S(1VD?A:D@R,L8=#JQG='PTLJZW>" TN;
MO]%V34.>O.3/9]7]$ 4?&-Y@8F&(10Z,RL0M#@]D#:PSN=)ZTGHR>6IZ(!OG
M< [.K18T4$*,D(;F@"/L?D:A'!W3+_/RG>H".Y[YU&B(\C@"+CD'.5A]*8-(
MRJ'BI'LESK@E"URZS'PLSDUI= @>CW"@O$Q*B%<O*KBH)&=BSQ=]J5)AZQ-#
MBMJE"KZK=-1."##FESV83"DP:]NU:CCQ3S[@%IUMSF@I.#^_\2VL*G'++YFS
M.:M\O6A_C/(]+_SEZDD3EU7P0R-=T)J6:WL00&4\&.W]' EI,I7$"R^7AMAJ
MEW=K9@G10G0A7EW,K+.?7PM]"GD#1%^+X'Z%1OP)#P@$6I[IO%X;%1J<A1:G
MQ"ZR@H]Z^]6\S"?;4:R-?!L3NHA:MQ1+4KE7T3V_#O#[QJO+>_HBD/0'C1:%
M'AD>"5>RH&!!6^YS5]<$3LS!GB7$/<09P)M[\KJ1:\UL5B*_^&B$[EG4IJ/7
M<-G/H"695]64D0VD1K:3(3:1(Y^5="?/;FL/R\FI8 #_"[GF\H@ES<QLN!_^
MN<->7J-#08: 6$79=J4G@/_E;F3F%D<$=P2RXRX>M?P^@_:P@[4N(+)WQQIT
M8/0\<ZIY2W.*]O/)5;JP05W 2QLJ%BB7$I ,)T3UN)_=7K2;WI4O3K]9>D7_
MN6'?CI^0>L5)2C42:U$0>[H_0Y#*Y/ T8'Y=),/ JGZT8&B77<_KA*P5"><T
MJ?6+<CF7'+6=CD;.O]3./4)-5$H,$ZV")92;HVJ9:JTL]_K.=\M\Y DU)[HF
MK ]140-RFZ29S(J=3"&J2P3KKCB]>F1X'8V"X9^Z/KQ5'?G9CK-2H4KR<X.B
M/(7=8XA)Y%I1E<I<*4V'"M5D7UZ$IZBK5,699JX:[Y)#!#QFA.IR9!<EVD<Q
M1X&6N#61PI+0,?',"H>F/G&JH_"85BE;$I*/Z1AK;[@844^B>GMZ,C:L2$",
M&C;-OB OK-YTF6G4O0HPN/7(27]DD,3F14QVE\Q*7(S25=PY%)=MQ/WA0J)K
M3H6[R'VS;EPHC#MU1%"-O!":6-H[2;H6'%))P"JIY'?R0S^1>V9_Z'27"JJP
MR7.4UE?=EG?FO-SS_-VC5C\#F"C45U;3%2_5>"$4%#4O#,CV,2@ [9@Q!<H_
M/@9)0"*QABV99RVVM'<S3"QUI?;A$B:9HQP\IJ0&)+LUM/(X]W3"JR:36NJ7
M:\W!4\E'M1CG"SGIC1W PB.F?IAG>X-R[II J/?)ZC7/=F'>^8R<+O4W].BO
M#5E3R4J?*2*Y^?0SZ[(I/*6Y\MWO_7]EG]?H%K(<[]U!&U-.UI /R:=6IWJ*
M!WR''U, TZ50WX0$;_YLD9:0Z#%D5K:Q7D2Q\;J8+)R1 U9/S%''HTH@3+;A
M4I-90 >,#F=_M\3O)?5:IWDT28]=R9>WAC6FQ;2BMB3"F-7XH)+5]F:!L%Q+
M/<W+*>QZT>4PI?5"1W]Y/B V(=#WG'KIEM/;H2UU'$\GP?N_.$=H7@9YNJE:
MVS^7UT)50.PE"$@>J=ANI'ANA7B"7_X,HKCDT&<\*ILH)YR!**]A>Q7$!IO.
M+#FL3S8_4;'T )8-]$9UK;XYKE"CBS&*)ZCS0&E'#YB,+"0D>I3IOMA-]T9[
M 3:>CS&&M7C9^A]..?E<JT1.S.U88@L6KF5&M#%3(-/W+W!2*X$5?=V[ F$?
M[* W$(G49TL&@MV!V*[\NXL92:2$"FQ16<G[^R/K&LWS>HJB O,N9>RJ-HWH
M!J7':H33Q7JUBL-I1:CR@'#0*=M"V5?_%'F!!C!<46/_X2C@Q%BVC8R5U.>9
M!+ECZ0(&=ZK )BN9*Z0_*&'*$?\5(J</5:-&M9Q:XF)T)WPHM5M(EGRBKO,B
MWNT5=4(.#]/-9W8XP0-4<G8%9F3'66)>@J0=H3]8DAJ+=3OP%CIUBIL#A(+6
M%L<&=\F3BVJ=Z/LVU<Y-!P W&D[.D7Y1B_YZ>L72/UW<[VR/N=]&DYZSYY-6
M^:CEN66VC,+W6_<27%/Z\U@O0,8(3\6[<-BH6GE Y 2W<3[1=HKL-;2]KO '
M?&@XQ&/7=>\1>?68('S*JI-/:FS;_'KM^/X5 'XMQ^G$USC"@5=O!!/QT54N
M%)@2Y*K W\CK(<R;92Q>D[?J2:7UY-SF'>P:^]7-UH:7PK1WC:!SX0?&3-]^
M*3Y*0$S<<#RJB:M3>4,Y\=B\C?@U8U0.#2-C!M%=<; *I>'JL)P6P?NE!H%A
M \5H\J:XLQ/<(4GVPY5VZ%TD>W1<3 )%.DLSQR"@Z#<:HPMHW&)72Z'#-[X7
MH[0[79S:8SR/?]4HZIY7D)K'Q+P':B,-8WEK:62QNC&8OF4$[W/RG_>?F.MH
M_^'0'C71+/,B;.%&?]Y0F7D6&G[%WF4X:V<8(IP/)ZIQ8PN^S'^3#3A58+O(
M3)=)A!D/E[,LPA8*CANZ+?G]EX=/X6P9_K'UK)@RK#4C=HJ9\2VN^!TZ%6\\
M//BJK"C)"2B9OX[892[Z=R%\Y$H3(E-8%EA4D";*"TYOR^D7G5R3]T?5/&P=
MFA;(^CT;#G:<4UZMV7H16IJ[]N&\Y2D3]5=>3>'WY8"[.V\W!D4U /8(&3T;
M/-W;U\QBG.N,I?T#BZUS*LUWT6"H._Y/N^<<,99C_. H>C$IS/.%J,*^U$$K
MV5V5=#93K&-&W80,51#%-7N1<?9=\LP#4I=^EA_$$6_\VE>1@S?*HO;U4K1<
M;K0CA[(PJD%4,LKRTNK%#G-[Z<6936_=^=A*+0WH<?FG3(87;USB,G%8'BVJ
M"J,UO:%A='G#:(9O904$@31SD X+%\:Y4]BYYP[Y#U:&$;_1M 4*O>DI&=+J
M]LF-PYMSNKLMZ+?M*]Z)$Q6!X&'0I*T,^MN5VQ9,;+.+4VL1CBE@7-%LZEMU
M7WX&"=)Z'68S)V!KX01B.Y@R/[&=^.1QN_G3=^H;94(ISSCE4\0D 2X'-[_1
MKEDO@U+^V#TA4RG\>OWQ\Y>J>V(E[#?BS0 M6X\Q1\";21?GS.\[ B".W,[T
MB8:&NU )BXL XSKXN4- P81+IN<2@4I1IG=T1/T6ACF&.5>\\%,+\ <X6!@-
M$8:%9=SS^=M<\#=D>%963JAI+23&;=8K,0ZN!.3?7]V->M[^><PXJ]V75+1Z
M1Q2JK*S&]V;M5)(N,9OML5>CUV"[&%.M:QZ%51>9(:-_D[!2@*E/AN8\&:'
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M5= NUISJW(+$?Z,-_4:S=.5 &A>[4!:W,*,&.&3UR%I$U?4AGFZX [R6W$V
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M IL!WE 'O8&2:O%>!.!#56X8P,)?- O_D@<<R$(NAF4-A&5=N](&? C+^NO
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MN2?QR?#]LV]Z__*$/LD3CA"6YY=YD+EP$'QX<;8[7,Q[1>Y/14IK%UW@%="
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MI/[Z]H;QPQ3,EO I(BU3HH.6FM;]I$_(])55W?MY0Q>D;H'+]9*1) ZXC/C
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MFR:;)LJ1QF$]+[>URPMGV2M\6=DD4V]&7'L-W5M<AK8Z-,X9#XJ_5>TT]/;
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MSO-"6<N2G#7->%E?'"M8P-_;QM5TJJ2OXJ H)45TR;OQB-5^NV6[ TZ<&+G
M3)2$1<$:=16VXC00$SM<"'6N;.(;]RN+8_<H6G%\;E0>$;M@"'9$:IGV1;8[
MK9/+*)AP*WGD'W?#+TY<.N36J!1.102'YH7.!6GYRXBHJ(G:'4^D3TY1K*#+
M/61U0PQV:9^X::^W$M!YSG_[#3F+A 4J0?H:'[OC8ZSV-;E&MFT5.9'%F6K"
M(TQ34A0&FL'Y-LQ/2E1%M@?>4&)HX0B4HX.VE(R6T=?*<7B^\ </,KO_D?63
M*NQ_]'FPK\)U&KM/4P9T4>D<O4FTJCU4,-RZ/]GIMD%D=U$ FF8E/AS/EH?:
MZ(0B6%6%HQLJ->.MRBQI+J/C5<@4R(%-75E934;SGSH9P_[J2P0:T5;B--GB
M_]H_9]AJO"HB.N8>(-HIVG@G?D/!Y,OKA$OQ#;H@K#=K\G*JQ9<\&?Q.K*;*
MU:=K_USGK@6M=3Q7CNAQ/1%NY;D&>C%1GP4"LTY;)5,FD@80;I*V=GQY#T&>
M]OP^#$.;,:ME8)*VZ_0?(D!%]_XP#N.(%8/ES3>D9Z"2K)#&\7R&@5E,J$IV
MV/4DDSB\X355[EFYB%_LX5 >XN[\<*Z3N>1=>/XPE-%;>M7>@32,ZTN=7N.(
M)X0X_T1-6I?YVBE+=W#H\,2DIO)P] +),\SD<1.CGXC35].BG)"4Y<?E_*>.
MYI;J=V73(<;5J=Z$>$8]Z7/0/@-$?1$"T20>6BQZO1_G+7?0(>?3>$L'=3B3
MJQ/C$6SQV@-S;K'/Y$K_E!$M@UI%5LA72X^J*9GV;A'T$.!X4":2?85F) '3
MOXW.BJ)?OY5/B9:>_XP7F$I5O,I'AU*;X!UIR]RL?9D"WX]"/_O\>JK 4=$U
M9J*+WL/WBV>PH^7%<L8VA$D'S<U3GXI^$T%3\;T0<+1.G.#(9LD!'$]IRTQR
M'T9JA&8J47*M4TCUX_6W(IS*[@%A2']-FR;@+Q$](LZ9BANEY;>_BS/SX_2/
MACW&$;7SG#HS^Q6\LWPUO@DO.C<T,E*\%!) IS^3RP,%8$=DG)G)!76&[^ P
M),7BCL>EFK>"UCYET@8\9G,R-8/0E'=+0F6+/K*(S<588#$AMD_U2"\FO$_P
M*]U[/V&[<6EX-\?!DG.W*/NMP0G&$G-S9R2.N.M,XI LJH^)3HY^*>(2U[R5
ME"UFG/O2BB:P8FM5<U['$/@BVF=3FD%40Y,JH3)RTX!T#/R<U7.Y'>K0.$^T
MI[<JMYKD]B<C"SRDYAO "<)@<W;1KH/=,_Z8DMP#VI2-MRW?SEYB%NZ,576=
M<JT7[P'M@8'3IQZ7#1Q);.Y9^.^'=_II7E %EF\90"'3* .Y#5UL.1B2ODZ<
M4O'F,-BAXK1;P6O8$FH<G&AW274Y(MIW*1*X]O<U?&<U-^EWM=$?W@L28L(-
M=#,0.V$[^]=NYY#- EZ0MFB B!8.:<*(!<-IU)OP BM:GX^(M ';R4B;-BY/
MQQ(1L6\[B0Q.?&"?_6JM?6M1H+&!W1M&,^4O5@,:L%^ZPLEF \..QPKL+E<<
MK-PKL<!G=+2)UGF ]>!VZ*Z1L(>B7D5I1E5>F5-B")^N@W/CO$)M)5Z)4J=2
MDFAMZ:"Z1\,T<U^QO%JF77+N"XT55**^S*GUWEJ/>5!1!<7OA Q,^?->\[]P
M8YQ %GX/J!3A>/.BHYSA9#Y4!]>PM\6P\"GH9G-">>3<1V3>4Z/S5.6O&77-
M\LLPNC7I(M  .1,W<P.>J88F3:5Z<4-9-$>T<F,C;> W>4$"7%4V^99/2?::
MI(X"O$&[/2=04IL;8F)SR[*VUG+4C^*P-$8Q.96Z9%,(F['6Q=*O*R=E1ZBC
M(?LLHZ2K$E(MFBA9[5)]M<S8HS/-H-Q2KZ)PNSV\8'.D5ZZE'W/FU!6W'W]\
M#Z!MV=(<+@I;S]D7#N0\906-'S(=K.+@"VF+\@8=(@7W_0TI.YRVEC3AVA$M
M^H.9IE:@&T;&4T/?=G3?HF]\'Z'#A23SSU."?ICSX);3'JY4G96G28LNMCWB
MBYO5[GGD#-S,\M6YG&%$+!?LY/1#5DV0]QFS:!;43*LT;E0Y,ZI\\;@$N==(
MUW8/>'Z:Y;IL9M2X.J2ED'67/Z9!W7FK>DT<UANLWBE[RXBF/1[%&.=B,N)2
M,L;VZCA,C/'N 5;_V#6/C&G=&Q>9\QJ4W62WVYZ=^CC>;J)HU3RSGZ;E1?;R
M:&=UTR:V1TY*6C9G?AY<EZ=B^SP (PNX<OABRDX<^V;Q#_UZVM7U:V4QXUO%
MU<NV:WJ!#5OGQB8E.642"9[* =%- 646U42[?+4H979WFZ.Y2DKU;F_>5L:H
M$7HLIL5/G2F5J@YR,@%U")L2J=N3Q2./Q?1-YF$MG8,NMI3R3XJJ*H]#'H\3
M.A^HCE $?T4B>B)XZJ[_PE5FNCF.,_;^WT@\Q8*C#'L1PT=[/D'PHL18:M"6
MW<Z-51ML<B!B%3<^ZN270)Q$5)3N4>5PG.ZH[]T]8.RN6<<P4'&RX766X%P]
M0OM/12@J%KT,8B\O53DO2Z8_Y6-_I#WMS*&];FD<8556JB1M_,3"0;[5[)9?
MPN5/"ZGRP<C?-><$%,TMBAD,I565Y9PNK./NT:>Q9)^F-1NK^C7T-4H08\J3
M:F8E^",D>,[-PZ[U.@_,3)M.;AYJ'4T?:OV3"1&I,QA.%_G!16#KH>6[]R N
MAG_4GM$8!;T_RAK9=2TK@HK/G'-DFT8^OXDDZU:2# L#Q[2[/]FT1S#)?*<-
MO#9X\-,EB28 #U2:Z;*65)1#*Y-96>'$;*)/=QBY>B>515SB(^&K6SNO/"\:
MY?(K0,![*75ABE8ISKJ?OQBIF'-]T]*2<5[;OK=\'L*E#RZ6Z@9=NCC[U+U4
M$"]$)9\*^ 4K\8F$8(?:HL+^9( O\A.Y+^B#M+!S$R(%/^ :0O@U#X<0V *C
M'-Q1+LGFF1;DC'5*HNDV9S85DVQ*(&F7Z'5ZID%F:55;U62]98&&%IO*DLJ8
M)Y/^/RXA;Z$MC!IV!OEA);MM?/ T::OQ?4))P@9Y4Z-[P"MD;6BY/9NT#%,U
M=D9UIRO+QHUD5F['BPD]=?M=Y4TK]:T.ZSI5K+;J.1J37".CMT/"@FDFC6R*
MO6JFWWYE2G_45WGDO#_=8,]&U08QR!KQC!6UF?<UQD)(R(O7C\?,\A%'1/AC
MJK]OK<X,^E8;3]@%@A$ZYX[5@WL&,\:?M^WEG-@S!Y:'MY"RRE)\!S%I[',<
M_MU4=#^YI'&Y8(2/5<.E'[*CI-_^U1(WD)-'N%_8,/< [X!6*(;JZ+32[FE*
M:C'>3@ 8 @FG&)NS IERWBZYLJ,9GXS5#^<NQ0YZN\.8M*ET8.SY9/WFC8:-
M?Q(7:^>);K6F3<A+=,4T!5$?!]'-[2NW-]"ZI, GTYDJN1FK]X#96WGWV]!;
MH%0I\"USY=&,C4NKO_S;SX)FIJ%*<IFQTSX%+TD?NIF=5*_4^HM:Z"!5XX.?
M6^-]R"I3?J%H-!PG<HIR.0H\8MWQE $%.'3.(>DIC[T$_;5U/+)-PKTR^L=Z
M\"+?CX[U1#=PX<56T'VB^3Q(WJNX_5@*WVNX%_^1=&/38-_!+OH5A;M+I=PP
M-7+5B5F^Z!@$RS@*$V*<:'A]D*[<IGD6P2DC<%80(&:FQ1E9$0];59H;/],J
M"0.Y([7CE/=Q3J:F&LJZD4\9-2CI3K;>Y%L]8]DC6^-)ER2(J/M(FQQBQOI,
M1'#K(W(V=MF;+G3J\:M^$095%=P:@DSU'C9';BDV:1J3=P2I9!%1=75"<Q1M
M&7+!LS[&?#\]WA@;]%@5#TL?*/7(XOH1:=EEU%UIE2ISZ94!Y;RTJ*-OC(O"
M<@L/#[;=;,\[W#[:2ILUA]=NXN5B/>-N:L5%F=4V]+;U44S[F'O-#T_OV.P+
MIOU2QN0\\+H'G,7B3*"*.HR>N&@VBRY?^5-CG8+%6Q7O 2:3G#[*#G;9@LXB
M-=PFY2;]8'ZE(1C1+/VJK0URUW7%!=W 5ROGY%BY7[GPJ'4Q\)E%>9_/JAR>
M@5AI!-S/-WB<8/,<*V1KD\26C"Y1C>0XC/;)E1F(+/6U0@JN+Q,H9>"@8V/#
MHX DW4_DIP!2-3:DOXRQR$'II4'L>T;K(20WH#W.E=I)K_)]<HT4[\_9BHGT
MLC>9L,U3G0SG51C"9F; [/"7X>>%(D?J[+:3UF,T]R=3Q5&XTI@<C[ P7^!)
MSE=QB3W'!>K&IVY93;><H PAX9H.^1?RFAQ10\FFS9ET@]#N2F!L7>$L\Z!(
MN5=?ZPS:O*58_VJ0H0CCRNU+SY09XK*L_[,F[<#PCL,RQ0_,RJSF(_B:)-_&
M;K'$$ACI11^#WOBBO 1]S-GU*()'V)7N\QW#QE3>D@5) ;E4_<;D,N^LQN1>
M^EX:HSQS8;H2[Z228[K_:[MI<0U5PL8B<WAV[^'C!5>).C=%"P!*3X9'@#!F
M25?^(X-8[YV(54I/CI+=^O0&I9IZAVJP=I[%Q&MQ_6W>T-P>.T-V'T60%9:]
M*U&YY)@<I80*/<6')=XIUY>"XZT/4(0:-4R$XBP'_LV^U!O0# FC29*5UVF1
ML.-L"#S3WB)\5)OTF(Y__4X>^'$T5KDU(KI^1Q#P>HJX(#(>?)*F!$P=V165
MD9GBT?&]<!&TK:WAFH'JR<2J1H61Q6(+D)>.43J2L P3_2;L81+J#"!T0?M)
M%HZ1\H"]Z[6W++7Y2&I9,KU)9&@-*DGZO0R)TK7<G,BZAR8+ EB=E5I(<HU*
MOHT\9Q3GILRHXE"%\)1Y3,OCVVBL+/9,-PV6C8/$D0K?E]%XD3-D5F06F?*%
M=D0HKKENRWUG8$VC_D#&SZRB$N9G#:4\6O54O=VUWU1WJL7M%7S)JX+0S?8C
MN0TX/9):F^ND*7G?2](+?Y3A^*IX$GR2-GO+:/>&O66$,DE4)O+0RQYF$"($
M_3,7N<S:L 95GGK*_=&R(K7/]H(ZWK!/MC"\6Q9NV!N<FK%2FA.Y\E;EPY3%
M,V817(CP^W+?]KSTG?[,'%^F;07_Q2S7ROX9-=7:%<J3=KV5QQQJ<1.LJJ&*
M),,KBP4)1O%UEK-[@_*BB4Z[>311,7??'"\/#_.FD^T=&T-^_#5BF^1=%4IJ
MB%C:DO;:I&1[TY>]OCB1^&$8GL5UQ3)MUZ0478<_5/BL^K#<B.-,4&B$O*GY
M[)8#$Q#@!]P7OP3#H!CC6[2%AM%E[)':.+FP?D/NG_A=^X8Q0FU3YF\B/I[,
M-HME/$8OK;RJFX4IV[M(CVNN*7!5@S7*PZ<;,(^]2J"07%L2]X##++^%W>.>
MS)S^>P#(X2SP<XNWJF9/7PXN6)&^=%T2?(.^"__HX1L8%VD,R6SE.X\[@O:W
M%MYVF2_:PRG,*CAD;VB%_?L?)$.%K_04N)R;;/O4Q0F^<#<*F+VDCGJ3E(8\
MXR7E&"9N_)4VG]4$ B&RVN;GT:-CAR#0);O[S+OO[*IW(2/?YN?O 9]665U0
MU[Z8,M?RA*7K%7H&4Y9%\2K.!"N7Z05VPK1F1E7+DX:/_6L4;FE<5/H4@&]F
M6V*U Y]C9;?B'33P]=%MGL=5@3R&DV5[4'#^)U+WUFT)UNG (Q;6VM-5NY]W
MF.=7&3O20F*Y'/K[EUQ%P%7'*?[;(@Q]YUE@<11VJ;*/KOA9JREFYI+B.#M"
MVQ2A&C=1.X;;6M*0VA<@'[IJX93D:L!C<4X^2[H+VG4LZH9P<$[]M9Y['OO!
M5AYT=3!V!\07":D<>VG/=$:/?_& HI'B?6^[70+G-/-A'! JPY"[)=WED.7V
MT<TS#B1*G!(ZT,P?T0N6Y(GX23MU4<N[OFN)6%+^Q547>)FE$%D>?U!4N(*I
MS>7"?[^QWA / 0<(];VJTFUV<N'+>*G(AKD(QN1U\JN N0.?=>[MWLGNB]T#
M6*+*D8,&B.OB#LTK:*UQ@L?*.ARHY>E:]1ZJQ":6\G.LQW7UF<$HO'ML>NS%
M7(=<JEQ6K^& %XDP?3''(<L$OK'TOM\N_A/P5'W-"63(XWAN/-DXIWB&>^9;
MQI8+X[7&GTI/KZ[DB@WVCY6E^%0%5[-1B@R=NT0C^3U[;WRD:?RW*NI061?R
MXN>4$C1,\*7N_T4Z8DN&/RCN395[0-[XO,FK_&(N$)/L)]R *JXX0X6OG(?I
M,0-KS0]P:A[_?O#M07@2:.@=W\C^"''\I"Y\-&M80A/EQ59P)W45;4#I8%8^
MJ&5%$NBG1F1$QXU/S<9(69,@;:K2.X7TW $Y7.'HFD IWN@7O2G_PN9HONED
M^D8J,I2_@JX"T67!I;A""-5FC*C=F4"\-7CUSVAQ3UG()2<([&_1R%E0RT]V
MFOYT8,-+4&>GH>@ *RZD<0.S2OQWA9NJ#*1EO,4M]-?2>9I=^O&V1E@6O'"X
M\A!1AO_BD>I;>%\N*>AXH5$VE>L2.P=,VF^1GO(](:.BY&;K(YI\_E>;/"?N
M/4!]^1R2_-]C*X3HX^4"?0D'I7)V5BH23^.L&$'9#S<,<<1K-7L407"T$9&[
M1125-!N:QX*UKNF\AH\GXVY(07A66+YQXW#&B$7]:@[O-6K77C@J0DIDJHAA
MQ#BF)^%]0S)Y;I 6K<WN9-G[I,?1CU[_<Q(X/OX\:S_85J<(@?W2<M7U/>>J
M9_TN2#3+J4Q<U@=GVT*K#;#=\;0".>!W'&*%D\WX=3I[_K]:J[B)%Q2-OH>$
MAH6+P#A^#G7Q\D6DH9/80*('"YMA7FPJTH'F?30?=,OJC 9^+V;A%/(:B89L
M=)F6S=0(1#U:'DB]NA8)#AHUD/.E9L_XM/RI:^/J"_HA6^O@_W2\\#\HR[I[
MU:SMCS;PW<2Z>JZTJ;[FT_RKTN'J<I_X*[#8\CG6D:)0&CU>^[]WZ?[OOO%%
MQBO,3,AW,)?=[,LSZNE4$PCM3Q1W%%!J_:7WB=O $L$X7(I"(^W:I4J\=,4+
MX1-#E.PSLG9HQK'4MV4[)D,=UV":LJ=EQE2N =52#QJQV>0WC=6Q?!@-6P13
M@_3?$KL*[]P^N3H9:Q.2C[\Z#F]LS3<PS+8]^0HS5I,BJXL:U/E@A[@R86:]
M(I5;WI^C?5@_\,_5A TXO$2.)<\[:$W*7W!:+TU5=Y4<_S)'4P_+4-F](>P,
MGI<'W)W\ND&KLJ@-X*\I/9FO%X/V[BF* <6#VHT9PX8G0R^$T.HV[^JTG,UB
M/S"<6IVZ)'*;)#(_WDB6^$#MX,:B)UQSVU?AP*#AWE>4[:OO :F#YW6?RA6@
M"'.@D)\/.9G'LY9SV*7%BD D[6K\M80P=YQDFNLYOW:#$/G9XKE0!&N\E&5!
M*>KQ],%LYE-9JU"=Y6[9@NC@7[ E6<.LG)"SS_\;SS20GM %/=Q2[J89_?3I
MH)MF9#A!^)J'!\AQM#6RO7^K675D=<2]?Z5@"SI]I\AVNGG>F%?JQP7$)=Q=
MDDH=@UP.OK!=\\:I,?L!Y-1_]^AMZ]QM_ULCHQJH$,-^1Q1L@63$HE1GFUTW
MH?( :?0J+C3I26Q6,WXVI:YP34QEG':9FESN R]+2Y23FS=P:G,?.-#V3X9W
M[)TO>J!@K"6PVO<PM/BZ;,K]YHPA&8J;) 54ERIV2Q 8TWY%L^0U9>M,4GL'
M"?UR7DPV1'+ ^T$>XN9D8CH^Q[F=5LK4IE>DKNYUK('LFC1[4L3HS)76)[T?
MA''YRIB0*J'#-6+TD(&5/Y=\V'C@$<[[J/?A=>^C@+CPD1X>'N]_W, D8"(F
M_G]P//__=OK@)<';1YHV]B G"E]\2-%32?+$,C[6LPKIB=D&K5\B;I),XDD1
MWX1=EP@Z'W/TPI%R5,>C/>3LX.FX)RX-GE+;D0JOS;@XQRC)PR/MWUSKA]F#
M>7W>_.0B:5=<;R#/['$5NHPQI%Y@K+O(6D+2)X_?I)>I2-)2B/ _"*G8Y.Q&
MNZ/<Z4';%!X,:S#8G&4,HDQ83L\[[SW?$<W BTG_3+X7T[9WX/@IYQ-126:7
MV4W2<\51%CE<&POFI'O ].BCWNK6JQ0VW(:"BXVM&O0_3\/,"W]LU5W&+G$1
MJE,R8!',9 ?7:6GM>160OHJ%";M@XY>KM3X8U%MV!=GDQH>!.1*I&C\]N?0E
MOVC\=4054U3BPOG&/ECIC9)4\(F?W'$:*";2MN^P6TTS8]3/O^@!A::LPM=D
MADBV.@WJ YN%5>&Z]*'* I@7N&:R39./BA!VG#MBZJ><_QU"^*QR9D^P9B83
M>W]N2RX2NRCZB+5>O^';K) ;<6G]]!\4F3W,Y.]>Y+*/A>CV:30SY7R(D N5
MG]E/.N\R9:;ES$7\.DC^+U6Y?&Y,D#96MZ!^C-!4>N**N:D*5]R91S)?N986
M!OVST._Q\M0]0.%BR3]N&,-MJ4FEN=Y:@H$@FV[?0N[,X3_HF/^?) $KS!+T
MUZS];SG6YS$R%E51T([^X4;?X<KZ_N 3LU4^*^ W1%;PL> U/G/LLV9/U]?L
MIHJJ%,<[[-CXL=C@+H3>/4!6H8X-4IVN#^)RYADI*A#E*Q5Y[YFHJ*S\!8+C
M(T-R@^LH5ZZ>,)@UP/.2L*E?5UD,<"+4-3/#GH@H4JOZ@_9E"P=:\MQ9</C0
MM%NXKF[DK[YR-R[8/1RHV(GBY+.'.C8V.Q@'&32*IUC85U_C>^9 ,(%HNVVK
M;^W68_> \&X_3%.=^/6\2Z:8Y/+.72?D>I:YQ8$Q-% UT_ >H'OM=-;2#D3G
M])1H5S.A7"\/BK E;PH[#P_<EKD]]GZ?Y^^>"'*M8R1(=TKN 38PE4MWJ"==
MVJ(.>G6)Y:G 'JJA';^HZI.H(/F3U!_3Y*]1/$E3P<O#6'K2^#I@_L%!\AE;
M+/XGGO(@Y<F,FB90R5XKUUCH1-.?!J(6Y]3KJ;#]&O5GC*#U#NPBD?AL-;%"
M5D[3+.7$(%\Z4I._<_A0X*M9+!=!['L20#1 YP/@2>JGQ[JIGW2#=?]1LELK
MA[)-K>X5_J<NM\I;EJB1@?G^X<*YLT+(I/<B5CN8(_[[5I1;<ENS< \^+@O8
MXF;4<E9F+*.GI($NTZ)39#:OU) ::WK0;="U^#1@(+QDWD*"IB][IKWXO;!D
M'G?+F B&:0I?NW?SX<?8&2<^@;==5^F5BFC&+[]BO5OH;.LWZNR_=F.].O^R
MKI_DH7.FS>K8XE)9N@9-WN'/)ZN"=1SE'2[(;"8E/;?+:AR4:-G8$1S.BS:%
M.F!P[@&Y0?[(-VMX#4*&]860YK>GGZ938H547KIQ9'8/[.!5?*3%J>NW7C(O
M"WE%O=>\8; A6RQ'E$(^J>-2\5*W>DMJV]R5,$&.6CCAY4O?3Y^4M\SOF@E1
M&,?FV+8EPX]-"U5<%>>&G?KP[?+V#$8D+_&7!]9[9KO?A*]XK;7(]C5#.D*9
MYJ+2< =:3VN=+''[SNQ*7XL3R:CC:_>TE_(\Y%B/Z.IGBNZE=*6/;^^9ZNLU
MP)[G?*7\+LB,ZOLQ$'O].#O&(HTGV%X3S:@ZY)^Y27KX$3G"LK<\^TEMNU9I
M4$IY)E*ROTT%TGO3X$6FFE&5,UC:A)X3]$AN.2BR7)H1^QVIWZ'C:/76?=;D
M^Y*_'-7F7HN_'J/BLE6/1@T%T>NDSU/)LD+Y"9GTO>M;;U_-TJC.=W!I7.0'
M_2ZSX^$@;%QT"YT0H%1.FYPR[5MWKL_-C2O <2;HPO$=Q$3*%0 %RY4=43K9
M<HS)D7+/<C)9U#<8*5>K]O@MYD>>4[=[N0/O8K#/ECFR'7(<YSE0?B4H:6Q]
M9:RU&U[%YS7,<F,6;%%J^PZM'G9U6W'S%3XR99<%# /A]9+.0JN>E_HXN6=]
M;MJVK&8*.$4GDUM5RD86Z]UBO02/7-7UH#S]6@7.IN"1DMP@:F:ZESXD3I9G
MEE [8ZN&0^\!JV'=C1@@(Y,+F>WHR<:)YK6G262!(Y7VVS^7= W6'=XBL:C^
M5;M%]G.MO#!KWN7*-H:T&KQE,U-LH;P!6Q*03U/8GRUY7 ("G88IHQFU7]VJ
MWS93"T*&'POLV0,X3F7A-(#1[4.#]X HH.K+UKKW4 [E _CH47?KR@-GK-_O
ML\N2\&I/?[05T,]D NM_=*@-V.ASGMJF'':X[ZG$9KJQ'H4F17!88*-&^H^,
MIQ4"HVV58 &+.1Y#YG$6L2/7;S:7V,1"^Z^.3>?1@6I;:U@@F,U-\)BKIYB0
MQ$C=N_[?5J>LC1L<.<\%PSGE\GD#@"JF+JEL?++%ILYGMILN4VLD9&7J1<\^
M&A&07#]\1^(::)V3R.CJZ1D[NB\&.ZIO ;!MVX7O.^@=(\XI@W$GS7*]KOMV
M3VBV@EWB*5(:42?<(/:DNX-W9%N(#RN\)_> W0JYR4^7D\<&I?WSMU#]CEGS
MNZF%SR47J+R?B2 5[[ANQZ>Q484]\-AY;Q9^<_[V/PS0$/T[LT[>>\"H7&4I
M%ZU,>Y4]QOK"&&@J<*<@9$P=/75^#SC@$Z3+]\)4@5GI P>;3S>'X_CS.LH*
MULT=P^X!;;+&E7UHOWO U;!YY8&-O.XR5[%S,[-)4*@Z3E*^(RP($%I/PCQ"
M!"[@ 0&>PXV$TUJ?>?DK'XP,S9)7FC@9DNL7],'T)NOB4B&?W<]Y[LH/7QS<
M UA=^MOE,&,M9=DY&9$WY?;%NF]NF1!:LRR!S)NC^GY6G26E5PWA9<-] _K^
M_MS?,1ZO#(TW*4RAZ)R$67I\%,;([M@+,NO5:1,@];I:M3YRTT9(+*YRS^]E
MRT*8_"#KX]>M"H.\[Z0F&.,G9Z2G)!X="K;+'WX(:<>0R2,/UP_YI>&CAP=P
M^.'A/UBM&:VMMVE-IS<Q1WI'K<\=X7KX7HW[FO.U1'\V/?@$7!LMQ%^0O;_^
M L%+S38-P.JNBAG0RVRY:X[(20"9VE >21ZEM%;][/P!:D2T*8?'2E:D3L63
M3P_N;9LX)[9S.V:0(44^'8WA$Q]4?6@;,XIXH\\'[<W!<ST/H"[TJMDJ8GQ5
M@K!0$F=)4V=6NT3[TFO8:,Z2C@!;_:JC#Z(GN_R,I1E23#OT1S-V7I?$+=;R
M2^DT7DDIS8\P'L(<EIM@.T!O4O\4/US(&0-<KR1Y]'N68E^S%8Y7)EW0)Q*6
M+U+S:T,(6A>OK0X,AU!$,ZZ)XT!GV704>SPTN=.3'=QNQPX>U 5OR] G9.MK
M<^AG9B)J3+VCM])UL:_=X@?OTC)"+2W7XO5>6O[CLC3Y1[:MR[\P N\\K>DF
M1Q>D#)X@0:DFP\V, %15KZ1=W3:W8OG7!]O:MSZ(JZXN%780K+49TL3EVYP[
M"!;L;,DQ)B30[UMD$7W)F2^E;) ,&%562[:!+9F 5/BNM5F8HA8(E% ]GK5R
M]"/,XH9)R>W^RXG7^*0SQAG]?]4W1N%FX/MT9J[;_BZ:$*C"?@_PA&PN_14F
M3,N=Q*9X9]SB/6!?GRB?J4.KI3*NZBY0MT)"J8#N,CK1YN"F:+\.LYRVEG<S
MW,P_*IZ+N0=@6.?FVH.F;U/2\<3SJK7=TDA)$OO+L)04_1T+29N3VAF5#/P_
M>EJ>E ]140M+/1MF!HC'5%(+!'T^?1A7KA#F^.E[24[8^E_CZ&X^JR-OT+KY
M?5;C3!&IA6JEEM;/S'4*[SNH0%&;QETSRHU^9) =BK#L[&-QF2QB)&=25HNF
MFU3-"+J<TM=72,H6601MZU_*."/QS=%V;>G%]3/A_;-0QWJQUD0H".DC<*<E
MNOW\R.>@-@GN<C7QV.')ZUGV >5EXB4R.!OK?/[XW>\FZ>^TS;K#-Y-T-+TZ
M]BY4I$H?.=7%QYXS^O7)P=+2,@]52R5<<>L9-@0I<H6#7#H8FI;VR\=@_L+?
MRJ;742/[WL*G/%X=:XCBSI?W@!D>P<#I,JG2NDVG"*%*_HJ$0E-S?Y+(LOQT
M=P[];60>2?NAPQ"V&_(MX_#N1684]CKI,Q/=GR:(5>TL^^D,Z?YVU<^UG_6U
M$M56(9[;;N=(J&0%J-/RK#"BOY%5=G>)/[._KB[%0$RL@2 YK45/X<EC4Y"%
MR86?S:B<85K:<*BE*OOJ] EGS*W/KX"+(>:ZSVG_UF6*ZU$HLGIEPU/KFHG(
M4D_>8626:[QT3<YPN%M<2A08?1D;5RS-I1K9V\ $HTM$'"3^@:QI*MX#MN,6
M \^$6N\!H,Y>L1ETR?@]0$]3]M$](%W<X1[P>^\(O7 /(+C5ORB20=MHQE^D
MW0.>[*[NK]ZUPT 7KO< \%X.//#HA]5#&A8#?;5XPUT!<-&"C+-"K&B DJ@W
M)FIA?](KO>WZVK>4QU=L##*]I^.F3FRZ(M_!$:*O[;A$\]J#Y2-[&3^NF6"D
MP(]@<[ $67ZB\F.<N8>!OUL2E&_8K$HO0J$\P$>^<KL1]X!/=YD./C6=]4O
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M']="-7V,LL/&,,1&R7L2UF?ZX# TNSDK7N%-;E+EI&UY_/I0,M:U="]M1>I
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MEC6!*=;84MLT[AXT7H[S$[RH]0R_(QKR.M(";7@(/CV:" NXEVDW)'I"E)7
MK E#Y@BMSP[\0@C5$DLVBA3<S<CF>4>G&,U6.?M(.( "\77D _DK9C%5ML T
M'\C/C-+KXL[6A*9YW'OGO%MK7QLVP83%(EN;B72;;NV-ZF'ZU1U+_J/:*IO
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M\S^2UR,0S</'O4RU"317:$,/E)7WAE;+4UGEV!YI/@"5T-KZQ<RG_+W;^X5
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M"-"V\#!F7Y%<BJYW$4;1U !5_-+MRBP@X HU/GF05*.1$H90Q$9LQ[KE-IS
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MIDV3?>8*,BR%+#;OU7ZG?]!G%ED.>"_(5G74KJB]"*.+$G@VV;-8DUI[1HA
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M,9^E+)&5F$6^V?F5T&U?FR%SK'!D:QO>XW1@]( 8.#\R;\MN-^3YDHLAC)-
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MSGG6B-D<:)X.$PB8'XX,W4U[9Y_T9?+U%ST+YRNVUG+;)^93;NNSD+=.(*?
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M3YZL-[]L?S!%5_BUXW>X<B4S-^X&X%LVV7UP?O7H?,&DS.V$E)EK\R(6+1?
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MJLXG#G &S[\MOIL\][5\9>"?=+H?T"G'F=61:K,>G]UH2F;R'/+*]\.;-0@
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MR:9-(01M:GJ7*;WE&91[,5O"I"APRD?8'Z6$-SUUK9X=%V/L'5@;6R[LU-Q
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M..4]MJKV/&> :P"Z^Q0S$S'.Q) Q/=>KQE<5]PJ38T>ZE1.;JC-RCXX'GWD
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MD0> \^CUW,<("X/Y=RMY4=#>Q;M*:O'^!4])I5,*[ZX;"H6QMGSKQ>E[0UC
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MV%95["[HY%GU")80UYH/C\%7XNYP?6/WVBA0%+"O8PM1L;K&'.^&:2)H<GA
M!2'>'E3W#2_$TBU[3YL0V7$;P8-?HBBJDBZ]I-BC4]6!;_^>6 J#TU]%BOA'
M'QDH#"#]&,'Q%9TC&/*7=)=N[//_=+_^]QW'_QV4PK8VV&9M1]37IW3TOF+6
M4APVB^OM&&:DY\="7GF^)G,>>,]XM7XM5NH$O_H!;J(%)*R]53:I632^ZYP5
M;JLLX\@G)P&^MK D \EZ*)FB9<$MK["?$?EJH\SX%DB\T-1O:JA$4BHRLT:]
M\E-2AJE"(@942V/ZYOU+YW+!S\L_U3ZJ1\4_V\ +U8*MXQ'9.1[!7K/LZ2-<
M"B!]YIRU5X1C*8+/U^.43 WDA"P=P2Y&^:^?IF (QUSA0!8+!E=^39;]O*<B
MT)&:OUF&-^OMM;T[2IU6,+57:Q3H$%G"6[6%"'*38^2_SZ*TE\N?3R5%>7VX
MR@)*CL;^\(><!%WU8HJ(^@D#E4<(89-9;/TON2_'W)N5/Q,+; >1QT$(E!@W
M@W*DG09E[X,5&]'J8R#UL;$*10=-"WI$081>AZ^F?K37N;&8:H7'H/-CT#H^
MY2G^;4"<R8:F2OAPQ5PY8W_X6G,^YW+])<P 7P<BM6/-$O"+T0J;35CP ]I\
MTUJL8)EQ1=_SJW:<=V!S(/ +=''@[?ENRXB)L_ 39029J&S><FJ=M<UGZY,1
MK 4*@U9%5Q]&$ VE8Y5 L_"HVV\K]L75=S[![3WU,-C/J2K!-R0?*_L(0=/,
M\]^N;'5#2F59[&!N]2@;L -6>V*]GD&;KXT1]7;DMN(">ZO(D8\3=F<F55HK
MR90C"PPP5B<95[XSBPU GZUB82S5-C",R1GR69YED$4J*1(YC.#FOCW+N+WR
MX7]KR$0@Q)/D-75IXJZ#2)43H9D7,7.ZC<&K3TK+)*4-\:YD]SB!M=-U5[M\
MN'Z;ZLL'&+&IH]C\51.W?(:"\,&\9GSA H*+5>AN:55B8RV8ZET],L]3IB\4
MOCNE&V2-'WT%H=#C5]'(PO-F\*;<TD=.)MS>MA8%0:^NR^97_0^:9VX4AXQ[
MB_N$3V"SX]7]3[KP;K9FZI3V@=?8;E']W2M/VV@BRI0\"LUAGOQ#)QK\YMYA
MJ78:FL#EE,42U0Y1L(\828NY"]B;Y+8166;GAM4]"W2]D)'M&Y'9;#YX=U=W
MO%XIHS\7-7H\M'R3M^WTS":G9T>_'FP+BYZ>5VA-Z4F!YDP1XX',O4D6"TX.
M$14R,K6V,]I$0C<A.4!<[]C7M=+X\+!(5Q?2BL%;M\.O!VOZY+<G'J!KK]%%
MSP:?.^-;EO/\N0\F3&8(<B*RSXB8S(*NYV'"$.Y&T6'2(7C+O>9;ETX6D\8Y
M3?/=H!"QK;U;ZHFN:8:*GU_/Q-F&H ; =7@&O,V "&O )<3:3+$2SYGG4P86
MRWUA:GGT9FFDD.C;LLMPQ(TBN3R%EZV(. !H^7H7YE)U[I4/DVU(8&!P0TE-
MQ/YD:/SZ#LFEUJE ]/0!\&LPCSCOQ)Z+D-&V=,AE"BFE"?9C+JK6\\B,3&W#
M,/!T6'SN'@3=\] 74[CCCWVL@_O.(.=@;\[R3B%BS+V/?NT.RRCD.]NMF[-K
M_1JUK6?&C"R\$?S2AS[J%60,M>'.Q'?NU>HF4BEY8DPXS#/#:=OHDLT'N?#,
M5LS \VOU[!L_R^';NXVV7N)K(<9GV'<8V\O51"Q^/K-QC,GU>M#6>05%3O =
MJI@5_EF[6^35YDSOU/(&4P^CJ/*R;R*95^6V:;8.Z:.^+7=&"M&]#<1W=FX?
M6H,\+JU:$=[23E&'$>.W@<1^\Y-TU3A?L47<8K@]$AGWQ>TBTL<R:8$NV I/
MJ^IK=2*687,N=JX!UFIZR1%MRI\=S-<S4FX3"'B]&X<M2>[,E8$G)',L^PHF
MO/&M"1D9=W=<BYD=42R#"$YN^T&$_5 ?@1'P& BT*T-0L18WBM[,:8<[ABE^
M/@,6QWO[=GTJ]NW]L&"S+O81MOZT$0C>Z>)H:!?UK/\8>3=Q,(]H^0[%2OAI
M,<2,RQT\^P-O\Y@*<45F9UJRNAK3DA92-!<5Z16IG_[Y"(>$O2FC^D)3M\:O
MA'<_!_J>.4N?HT%@T+$FW3G,!(3[JR\<.#AX5 N,Z$E)=[4EY'[^HQYC<.B,
MI,'6V]#E:G'=<.RO+8D;<QYULT$:ILM=%N%L<J()6=?D9/JR-DKCFR=0$4Y[
M7\)E1&'ZBC])QO [H(O:*OQ]0]->86GR_&#VZHJQKT\*!DJ163U5?9TSA*1_
M]@L5ZG&HJWT/2QX[8^EZ-@,:V7-V>'GD9)I?,@961,?\\%J&_WKD=_YOBB_9
M JNB&VD#= BN6UJLU"2?(I%8DL,# Z)1'K%.^YEG\AL[2KKJ&R94F:*"'^6>
M%%A\&!Q^ I9X,06)E38PQQ^=[HWA#W1F[9TWYR'5K'EE(FE,U6$APB".$NHW
M:/GKJ[$%'1C(A(1N\I8^&QP$LT!9>@<'I9$T0S-;V'(DX>4?6WB9IGWS=8["
M>7<U@JDJG[Z=I\;GZ*8E _GQ/P:PT"S(PQ;^&0WI_]4$&+\SC.&0[W@MC.Y'
M8IR!$PN)=^]$%66(<QX]F11HT%[WE.]!5JTQ0SZXND5<N6$4]=O@CR:XNVM5
MTG')8HQ",49)>GBXOO6PJ/8JOI1B4>6 DL4D-\B2!">3"N!Q0\IC/M:U'K;.
MAR^T-L_2^#4WBEP?8'\2:7(7+5=1Q#U><W_J:-^-B",U$W(C/<8A:/Q=^_[H
MQ5=T_$=#UR/J#_\*%T>VK$76X+'FB$)V"QNCX,JD;GTL"D&IP!YAC)&EQ3Y=
MX%'18ID>@8=Z/QWJFEP)K0"L ==[!LZG9LI:XE@RNU:HGP#MM$\W.(JG)TPW
MS?HTKL!]TI2L32+1WVN?"HJGB\]]W1;!<Z' .\\5*=K67'F6.3 #2>OCS5"O
MS^=V;_M>KA6Z3TQ_\F(VM8S&1B57/%TF"?N*;^Z2G7:LUI2)QU1]Z*:U<NI$
MEYWM4VBW:H>(RLC3T72U]QP857+XOLMT#KW6RW1 MI7/UBL2^W3#PZ63<UD-
MI:C%'\\+X%<[%GJG&6#&L23%#Z=M'VWUUCP]?^(I?(5P-Q_A/+W,B<M/;25D
M,M=8[&K_\@*IOF)5KF[WH4LY'%PR(G6:+.7UZ9ZOPTW):_-5K(.].<&E<GW"
MK/M&V#R,I-U=?,OT8L.PBK6@E5YT3-W-CV,8(7P\LH:\_VU^:,(0MY6JKJA;
M.=Y2EVO>*M=#9[JWR-:A%?B\>3U)"L]]_3B<53 !51R+]/ (\T=$3ZBGUTSH
M1^U7]S/"2M+=1_Q:#@H3@PT$>M-)[0\ %*!E75GHLHV&Q, FP9N]"I5T1J)9
MY73=\)Q[III^EU.;F42Y+P.8HH5Z<5%VLE+(B:3<_39,T?!+I,M<G)YUK^$T
MSWI??4#]:T)SN<58B6[3;L/9:-19%N]W03%1M,HZ!@+HCX"$APF='E3@NU_"
ML+?H**Z@IE !"KW(F $Y#+<2+ZPNEMJ.$#^FMX9!I!--/Y^N6($FDF\??5^W
M_DY$=MO.?@]+W4;NM7@UP<G,8#QV:O&,Q>X1(<PZY1QW&#^T_'VU(EKFBI[K
MPQ&&,8SFP;?O#I-0M56;[7+,;?;7)\DGTUCC'9@7WDS6095<Y_!CU4!1M#$"
MAI$.''5!NE]N9DZ\C(Z<E2K9#9JMEQ9N>F3KZJ1_%XO:PXP0]5S^H&M"BZ,\
M:%[$,S67G-3_73$GJ.-9CB\#+N70*>)[=A((Y'*4R^*58^Y#.I6WMMCJ@;A1
MVA(=F DWNR,J!L&_VU@5 JL4!2G:5*,S]+(@/@1?C/K5J!FWQ2D:T/'JGR+?
MKANX6G4-:4JOB#)NN^Y_8KG^Y+"],&CAO-T:PJCK'=W$.W3-T!2KT=@CH'TM
MEKTVFY E6=O$,DM8Z5+9M-B2M/MN0)Q04^#O)=%&$_^;U]ENY!\ OJ<'9P?W
M!BL$?\BAS?Z>,:%4NJ5N'^Z;KX5:X<%7$-GJ^C[1MA$8[RO0EP3<X?I-ZVI4
M<9XU;\N"1$YA_ +ROXCTX,:+YLL<Y90M.>YY?7+2*$<R'=K;#,'S;PS/%'JR
MO8WV 2%90IB0 S37*NGJZ1^HNAMT-[<RY(<2#22Y,%G'[LQ*555OO;,3E&9>
M94@ZBRTJBEEX%'Z&-4I::EB86ZH6,4SVBA\,-0:E4!0 C\%\M5-]!S%AY;?0
M:<@<\Y@S0E21T/Y&M'!G[_R-1BK>A%N5GV"I67#/*EZVGOZAJZS7Y@J,T!9D
M O3?&<%35+8(W@LI6JMW9"RF:RR!).W)V2Z8,\5DZD7<X&6IB4+7T!1EGJT0
M:PD0E_9AX$KC=M-,W?P\P*A5H*2YO7NG_K&_YY@VO*"LC75>O00L8/=)-<+&
MH1>JY%9AAIEJOQCFZCCI-!D6A,TW@RB<4BX7N )+(9'Q7F84-TZ+)HS"6@,J
MVXA<_VK)XX OAEW1N4>YJ7M&B8VG<:XQ<D2ZLGC'SS#TC5>&!YC<[B^N$BTW
M[74#&AU[6)LXC:HXDSZ]%Y95+?/D/]6,5&R>+MSVCF$(-C;W8?#7"S&5AH.U
MQB\E(B>7/:?>"E#'S@2/^_\FIWS3'+#DD0ARW^2T4W+LR4FCBH$*TK/Y [BG
MMUWU[77EMQQ[S]P<B^B>@6K"M9./4+4H>F,_D+^Z0Y5'2(7"VAVI9\NV[6&6
MA8<@\$P0)>71D6L0>*<5R+6;3AJI$^&P[39_M01D?(6\;2:+9,/FT$^Y8=7N
M-_VRC8GBFT6=V)^,$43L/,*,C4E_FS]-$3I1"FF$L?20ZRS=<49I!U-8G4L@
MT<LO'";P3$K%*#_Z5Q Y*TK0O)+ ;9>/7OE^3C<PMV9 _>)6W5<:7&N)E?BR
M]@!( =41MOC1CF(1RK[+]XP?!BP_A27 AC$> *+UPMP<$G1KAVH5HY,5[#]E
MIC:I.^YI+SO"\GM=3QM,-Y$3H&76G1R#V(%4Y.HB5&DP$2K.*JME(P0,R2H?
MX&Y.(U)2W8#;9A3;C-5,3_'/#<4>KT[V<L6"A!A_^'S&H!A9U3DKK$R>)GFQ
M0*@K--K<HXC'%WVDI9*0J7,JU<L ,;IFA,H]5Q)X3]RAT1)"2Y/O/@R)*S+5
M3DBRKFB;;LEG@[I+X.I3/Z^(]E<-UY0,@2B.%W<7X)M,E9:@FQ'LW)DQ+JC&
M[3*)SGEUTK!H[_\;#Q_\;7@I5"BO,F3"1>R9\;D^<D 5$M6NH>C.HM:(-EV%
M!NJ"R.)&'[-U(X[9A@?W*C=K;/L6Y[SLBDXUI-9B];"D=2:1_5@H'J2T/)>P
M.Q%N_@KEQ):-CD$3ZN1'.%%J2#KU[H-EY-C8^\)Z0W+4EQI?G"H*J)8#=N5X
MQI?8!ECW!?:4[,CI]H=5,4MP2(Z> KZ6_R[?%-;4S%!N_^Z\42$/^+7A-"^6
M3H%HOA'-JX2\F-"S*RW/VU?X@3W0AA/791#EEX"LS\!OOR[W>/V[MY'RF+HD
M 7T3O2K^KL 7$\O/C<V74]+3WP7# G?X:5:'-/D;?"!J0W8J^YD?VSG54<=?
M?0[WS.S.X-ZL#)H.95?M^ZD $X^(?FDK25[V\U_0Q2R_MV:5G?W!1>>M2LQ_
MZ(QV^ZN4(7*4MM=^%P7D\K&!"W\@_R_R3?:A#U )%-3^:M"7C:P*FB!.!]L1
M6(L("R#+A2ZVA\7.+9CAD1]">N#!<H5%:,D],RD9WT]J+D"124,B5Z+5L+:X
M?KST+,"ZEPEU82&CMZ?0N58>=$5W)-";RQZ=&S 9T5J0N?96F;&&TJ2U;_8&
MFZ)JG&A+S4U$@-LYUV,&G;Z/AM-LEW,23;817/ZE=!;\DN%;3U,B%Z0\VHW,
MQB-:3F/>E54C_85@*3R8T?<+K#\WD40R-QK]5,)XY0' _#I[CP0Q5W,]4=CN
M6VXN 5S?8:SZ"F*1/&X^F;1",1KX[G8RH3761R(H^/$$#YT#?U:*J?7[3=:%
MGR3^>57#[/4J.J4*YAV7I!L@6*:T9./9B-3ER#=&=F7/],==T&&&SR_8JP5V
M\9$*BNMNVX@R._+0Q.78VI)C_C;!W6%J'B[^)&HJ-+?ZI-0GXW]7V;^=/CP*
MN^GV:8'=2*)N+J.>YCX !A:O&/W%QZ(NTAX ]-<T3[K0^1N3XO_N=L&5!KB:
M]-OBFI9TT=R.,72F/P]/25O81U")Y(Q0C-S--G<T5!IX:B2F88=D?6\CF\1R
ME7>4\-[."?V2!YVG2%P3E:$T"@DF"Z;EBRE4@_2!$GU_MA#5GJONU_7+=+3Q
M/8[#+)2$SU_&OCKV9'0.@H,M*KL,E*S-BU_C/?^FM9<[<V=8R?4^9'36A;G(
MMCGL@\!.K*Q!4=SAV&*3/$_5X96PZ[3U.])FIRI!X1>9;(,9W1IT[E<*4R/A
MN,V<MP/;N;LI=R/C,2/]@[BW9<Y5M707(5@*K46383R*WSHMRCP%,D1#^HQ
M"?#45P(#T:IE9-S8K/B QVLK--VFPZ:#B+BC=5@TN3A$^$DNWP6Q0 1)(6?R
M"P,I9I4*6N!:.K?(%7K?-/@NR C7;5^)IXP&T/T30(MX_D^+OC^<.2L=*YI>
M8-MAS9G6R>(NA9QQ'P,=ZR3F3THSJC0:Y<B_O GKT:,%!7N^.H*$"1_+KQ\X
MH="/ZGD<OZQCOPY2N_M+W/&MN#]0T?C+4J"#_H\S[3OD2A=0JP= CM(?J+=J
M 7]T 4GP]:%F-GX %#F++])7WH> >WM=M&WXYG<&Q6K&G;E'-SG,7(O(!]?#
MG/VK!4IG/,1832)\#2Q,K8,YA9T^+-.Z^5'16?S-$?;TD\L?G$;J<,_]D0^
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MRQ0R_6O.Q"R_;GEY3-*6Y#';!F:H)75B3VOO7 M?><?:Z4)V-I82>G(QO4@
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M#W D>OUBS/-ONT.'4CGS2"7)\CNBO2IGRTV/<M%Y)I=[8AK(%)(25S1:M",
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MT=;^26IP&:^P@*&C,=<G$XHN]2%>-6=BAQN[.,H$LKH68?G]4:/][[T,QUI
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M'A?9C$4FN-X@ YMXCV_MHI0+E]H3)HS9&ZL^]'#S'<H>+C(SID&.I(]<;R_
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MVV=]IJ]_G@^\:@ S4_LD/'-=EYUD-V1'\VJT3/Y7PJN+!^CV\3IR>C%*JPR
MS_F</GW)9 '0*2\(/?PP\*$4B^[:7IFV.M2_ 8%YEJZ65Q*;+!A.O_OJUK:'
M*QT@:0CUR,_J"]M&R0E $=U.LBG@P8Y^FX?+1\=A H=+ [+<L3V[#&HY<01%
MS=9SKSO5<O34+ '?/U>8UNUB-)'<,YU3Y#6S-P:F@:(":BA2"JB5":I1H/AY
M9#^G V(IA=M/I]!F,_.KMB^1UA5CI_0(7HPA3KK$)_FYO*H(8!LZ="?1+OWQ
MYNW1PH"-X6=JCX!Q6WE"]+??*_YWYFIL>W1MUZEX9/CZW73:Z)E&!?I<Q7+6
M:^A[S6!YPHJE&JH>PPK=[V%CEF-AD=15AMA\EE^#>3M' S]0-$\X]@HNI.\M
MT?^"*X4I?1G<=:E1XKIXW4!C$CB9$G_D$G=RR/A$L)=$D4JV;TH[;$&^&8OP
M.2466M:2^43 WH3$ZO*@,ALK9AR^2VNY%6^[#:<XC__;EZ'5]"CPS-#WG+I$
M,0U9(JLX0MJ10ANW9F[K/- 7$E8ZB*1G4#)FYS(I".\VKIEEY\UPX/_!+JH9
MS1_(IEYB2-QK%DU,'<T&;X)C:2FB!JB9R&G*K>F1?]?>$I,QJR49H/=:6;3:
M)E-PT[57H\JJ0M1-9?US2A; 6^=@*'0+%6$@T IQ40U2]7'>\JDD''Z2E"_'
MI=ZNFM>">>/]+D22"@U-6Z#=VFG;<*2Z02.X>BH[/:XESHUZW_\9CE@R4"=0
M,C50)S5%LC5%YP^5Y,^K;>1^PU,"WN/W&_*6::,<,OXWW#XJ7EFR  8R?X5-
M8V.%WV#RA.XWE!P_ANWF.=7%N$U8.BP$N\RE<^7:+U?CAEFR$Z?4S8$ *<T[
M663C6;< *L+(]&3(5NLC!"@[ JA+I$&(>:I^PO#AL68QOV9P<UV0E[B0-Y(]
MH7/>/7ML(8F2 R<0J"999C IDK%3R!6".Q&_)BQF! 66+"Z+MWSQ\A(R7R9O
MX4=D+OR1Y?:%O-C$@^->GFW3!R>)1W5S&Q)%FYE!%QZT:+W320</C:[B41=O
M5G16'%EZXBD_\R0'E%7S1BD6N5[E%WWMMG*Y<DUIN2H@0J6&RFVK:7TESQXI
M)N^[I0;16QES6M"T*'M7Y?:9*<R..CI9\C=P>-AV.;W)7"+![#NN%VHU51L1
M6E^*VVM(#.:V(:EKFP;V$/=14*P6'7R;233=RZ8APJ6BIG9F8V/ B^Q,4:"+
M7/#O[%5 T9=-^0W8,GUW*1ZC7!;5^/00_>:N-(=W7#'H<R:C+9C;A#05G^P^
M6(?$BX9'G0/L=,@ EUL0>UQ/]2'%H].Z/6/W&YF3Z.A..QAJ>E%Q76'A0%]<
MKX7UT"S9]\'Q ?S.1WE-F&RP7,/^ @I,I0E]UKX/_UP&,:]+&S().TUI6FPP
M&LCCJE12711T\^5U$[55>[]$)&PKDUM1?@"XNJ_G5^9?RFTUGI37SAUI&>#F
M=Z]%FI$P"K)C'R-S$Z>2Q__&(<EDSD 6EU+S(BZE)>QS1 TJ6F-L"Q (@52M
M_C% MB]/3^]='D1\FM0?M3N9.^0_L/KY3<<L(<*&BS;[X>%QWI_Y!O$\T<*H
MKXEL_/P<Y?+^!Z5.\ GK$\7X4_"P[WFFVYL>=Z+G&"O?'@MACW'_29-_*&L8
M]TS^'H5K#X>+ 'Y:=^^O[SFF#X01?3#B^L;EZZ1BT]K[M5B!8S]RCHB5GI62
MPA&4Y9Q.62) (D^>0&PK:GC&_?[[?5\:AVX7W<L2'U*E!^2%,44]"W=:*O$Z
M\#3'Z9>1I=APP;;9)IT7Q&.CS293S<%;_MN]I'E$R9FU)\R&NZK6UV9];U/"
M/J-^CL F;L&.37#]O4>.Q12.-X]/_E#-)<*^8/\;I/D3=7DL,];*0UWW!J<5
MLD*DCG?&%67#"Z^NBS0L'#D3;!44V6D<<'P];^,5UEZE0'[0Q<MN#YO8R7\(
MM=_LF8=K$?LK^)K/.\CWMCP67F*!/@I_46_3$KN<$@* *&%$NL^47:6&W^@'
M)H?N02"BX\K&YU?0S65?*!683UAIO/LI<9ZR2[-5S^E/ 0K""BRYHX.!&4JW
ML?8GV%<]^;E_'1#1O%-<=W8'G7R!2;:"OSC=8%&7NC3J&ZZ;7VG87$9+DT8.
M$<HE>2EMT83;7'AXKR K'NW8Q_42F"7N$,L6XB @!DK:38AW'&3,";M$_H+;
M\@T749[X/Y10_G]BCAS*G.E%Y]2^*\M;Y^/C1UL8S9KRSNFSU>&(8!9(&*<^
MC506]HQ@'Q1)']UE5G?-XEW^77M(49Y$GU$K_O*J3+6*.3Z29"?^=>(6[4XW
MMN/+EK@_<6IQ/Y\J\#AC;>64S@Q!6K2TRY56Q8_K:67]<TQ2S_K*/B$WAA<O
M\ @1%?J8=-#ST*%MKF(%(>&K=CK\%\$%%9.K&)(55_1NVK;';6.BI5PL4OUZ
MP+1!F:F5P?5:_2'._-%N.(0N# \:[( *ZYP*0]X?P;S]&L ;8"<##&V)4=OJ
MW2+?1\OP)B\1:UY=)]R:C<MGL3[]8%!C&#;6F) A(]\'ZA\CY&?Z;J$C\' ]
M(6\1=G2)Q*RXE*S(BSC'2=\50Y$,.V?Z3-B^VIO7-J'1'S,3R&F(R1: 7*UB
M4[QYQ5/I>;=PN7=7LZ])-1R3&J9)/^6<AZ3,-G>\HV! B\'UZ-SU*(!:SC:E
MT%W9@[B#O'28,FL17J?<)]G')DA_US-HR6U)JE^NK4\)D.-Z=Z@X-6)V)%W.
M@[NCR3C'L']8$S9M ASVP.#"[S<C?Q]"=D>(XF#YIL&4UT?_53X(X5*,!U%+
MHRA[_4F+?M&L_*,"/T VB9&G@J+I8PN2&L"8@]\.V5;$U;U*MS[W_<DDY_8T
M_FS9LG+MA/.IA4%N>(T-K*#3LA:ZV#2CN\F:+K ]\!W!E2#C2+<*60=1\8=J
MB6J^&C 1? 9!B6P_:_TF!*+%4:/4?:7^?KY J<Z,P#:1*AQJ>X[UO>\%=J@D
MONF:&(Y_A'=D>\#%?R>XA+X;^(/D/YG64&S #(-FXW7<WU5:?-SEUD]-_PE[
M?$^P-5@3T:&=H&M%0JS85D-DWR;Q$@BTOJ<DE2\Q@R8N,AME+PL,8>GKNO.]
M.X3A<6:T-/9?KW!)O=D^<G>/X8DKH S!_U23V+=-D^_NF 53W#M>ST!G.;:^
M.R> 3=#Q.JA%)6\XD!=[\]PS"8%1NH6)N_J5OW#$F@%4X-VXN=D=BU91FD-\
M0$12)XY)(_N9/D7LNF7R5HSD^EFD[)I #4L$)U/K^_3>,M>F<T'&*_-@&",U
M>6E"CRE5K,CD4D<"$KT+O2FNE2FN)0CDQV!E=?&'/.''H+:U7K:2EW)<4&9G
M>7F9#/!B+W?EF)M*+5.FF[]<T\Y-6A]US*N%37,55F&DGO&)T3/U"Q5\KH;W
MC0J (*"@[8'95F\U+U0W6P".)S;'>M%U^"!W=7-+ ,3U51RV'^"QHBDRS8OS
M4!KMX-W8DAW^1C8.(&.VF"!BDAD_A>SI4?'15P\/U ]@#NN09PP?4HO;:(@>
MVK+O<Z?T+<_K&3!-'*2&P#=\'\+N&-IK-&J::'@DSZ_'DCIAJB![G4*3K607
M#K=U%Z-E3'=%EO&-=IL  ,?U<V'C)@J]P"/?.(LO#^X-SF]O/F*UX?E-@]^)
M4=4O./R+D;>:?Q&QT#PTLF[>Z#PU(O\ RWE\Q?P760IB_L,_ZT2"LJ7GG\,=
M>98Q\<X4PFU:_L??0M$-85AA38MN=?4\>IMVLA1ALW/VVP7E"%NJ"IJJG9)E
MSF=UOB.*H5 !'6]OIA6Q@2C,^,_C'% D(H 6K5*A6.3Y8@&XCNB]=FA*;A8T
M)=B:/C)]/T [4L%HQ\KBL^!N9M+RQ^L&5KE$EW15FXT$%9NB R="O3H3#FA4
M9(?8G:V0(-7.PNM)C7CI_; YVILWUV4^*GG,#OVZKMZ[@9%&KP$)T A=P]YM
M;"S9<]I'9/ME$JH67\LR%@Z:K6(=>)YMA=&3D]'1OV7\ 9XM+1U-J1KNNHIF
M4".;X=O2<3?8[A<('>X$WN.F@6#P(.(.4T1' F'Y<#^^G1SSIA!GF<)FGT'G
M&[^V;*B-0^&"?E%$[7=;'_,+8^==^C'F]Y9,=ZW?8N( LP-QFA6TSI/K+:I:
M9L3C'%NK$T]??\&EGBR)9P^I>W!QM[_V;%ECXUTL"R;.9Q:.2@Q+V7I[I)M-
MS2G=^]F*ELF-+<, #EG%_:=F-'G&U*0$/)F*HQ0A;QZ\"<H6!D-Y(!R<3J#(
MRQ0)R=04G=0D'W>PMPPL9BF+YTE,FV1]_5RTT/? PZ_/P!(R\?])E+)PLV_W
M*.(HO0JZV4Q*TMT@_%>1"<):\5\"DXBY#XH@\'1+3<-]A\.5A9'N]/T$?%RG
M^>=F;VO3#OW-Z!TU:OIP&.H:L*[P@/75#([LU). 4&+4U:+WW(J=@U[#4J@.
M)(U1Q:)N3J&7@JW&#,]1K@?T=F0Y&CT2$5.LD;*>32<L8B*QU6:NA%7VIPWU
M5&:M.X+M]TB"JV!D*3L1'$O'%J*S7W"(YO0L0J&%@S^8A[>/)X8NSXZ9)%[Z
M:52T84=/$=9U6,.D&Z86#[I/0.OKPAH,EK@S]RQ7^EFO.^.$$?N):$O+R$S'
MU3*N*$O26E!GW\C>N-;O4"3 +*KY7&BPDYW/4][URHG:4,]<5=KT1TO%C';M
M#8OXO!A'-T92&"570-HB-%3!?DF\>D*^=:LT2@K(6F'L>ODD;?8L]CW-5T>7
M9_QP^5QFACHAF-8>Q(N@7VGX ??M^6_O?=>&&C<AL>1FZOTI'<MWKX>O>0&#
M;6V-2R6L^V,4;#J>-8L"F5Z2A.6SG^XE:'A&S.V"N3-CS\7LI2@BKXIXF9N(
ML?-:2,N*H7/%,Z^GM2SLK;BD2D;TQ_9<Y\+6[%+1IEIK$P M=1J;%.$S1XBW
MZ@>BAOE,;)WHJ[X1&0Y)2WO0K+S. PS&R)JTF>9L9FGD@#X-HG>GYA> */#W
M!G08OH+$Q6*UMZ1JN9MN1@"*.3<B2TN35\O5C4W%\(##6E#Y]_XUC">=$AAB
M.ZVT30=I#R1E$.BLR338\\:;^SW#562]="[2^RL$V*&7);"]I8U["V*X;G:)
MM&HF0&Q&?&QUA3$9K"A>!C$@TQX[1)L<H"S735P)@'KT\_,V.Q "20VA;VE"
MP5;-M"U$"M>Z2_J6D?U!>DL-[PE<'\)*:8("',1+AEO0>\B"9H$F-11T=6P:
M=''];5)\S0A](RRN*?\60,?,7U<,G7Q(+7![36MH\P@JFFHZ+%)F#!X6W]*L
MP>&)"T,+G"WOUI?7W-&A;E!U03U2Q/]&OU3:<@Q,NA(VAYE@A.,:S:2+EC(-
M\O-H:1LG[?*O-U ?,&LZ2Z.[6!YV,S.318B^9((QG#->FC.:OQ>M[S++MA,:
MON<!7]^HPK+:^P82I_FS(F:@.#R*X2 SMIJ8X:TBIRRU8=,JR9>//HT9Y@&C
M. G F ^QKZ7F0YS<,<6.-\5$E)"07O3B2ID>B])9=KL,8O8CT9@>*XPO9JXA
M+H1H7+NO1FE P76O](CE+<R04ZS7^)?2Y5:33#L/7\5,4=_5Y_N2WR(.1VNB
M71HE5=)[F/LO">^OWC0/+5':[WY?6J8](FVJQS^_A'!;F9! 02FQ<I5$FFBA
M_HI^:5-F4.Q^)I/8<-(I-.E$__!A1GE6=R<'^U.KBJU)O:H (!(O>JAH<8VS
M/)U),6>P1%Y5"9M;Z"?.,<L8[N+(N&$VRW=FCI%.S-JW*VW0Y>3 .; =?%G=
MZBU'FI_:1DW3([U436"U89]%20\XJC@_,A2%OD+ <IP.MC? VHV814.#$/.<
M&F/!#2T$Y7F]53_,1DZ#-H##1XT%@EF%=>>L7G(E$QZ=&8^8PM2BU=RCWUW4
MB(S-VVL@SNVQ7%8.U3B%6#U-+4M_+FS+GKIYT_5XVL<+I2?+&SU8_(&IE[HY
M^KU0Q1D&.UL[T4P)11E\N1V9FQ!\3L,->IM_0R;5.RKFDL"+AUT#@$ @0" ;
M95Y&7E<7;9^ (X<HH_,I?N>QB]SHL]+Y((W#59]C\,D(3 _IQIY^WM%;C7..
MBSLQW],7(S)G1KL[ :/X<%AA=$U0_T28VA!D:4EBQN[D.G59CWG_>K54FN$;
M#]#2R>"H(9^+[O4\O*KX]E:G[0)2O1+_DRNP%=L6W2)=51+EHRBWQG9B%TQR
M$_X3YS_X)Y09M2BH)"TH<$TXP+-NFI4XX&/DZ$K+DV1A0]L(U,1)RX9Y9>7M
M<6*Y 4R%&TL)+P%?Y2"3X06_'>8L&&73]CJWGT(QG,&X1DC,*Y"9.95OL6N]
M:FGQVJYV[MC6UCV"LICC'C0>/I5$$YL+Q<R=$]%^Q?,NPW$JJ%S;()OQQ;=>
MMB$)BQ1O[-CT#^CLZ,;L7YRI:!!66LYH1D=7.E@> 3SI'6^Q)O7=OQ\<AX*_
M?&Q \[S@O*_Q\O.ORKM\2B5=2%"W[;9+U?J25?B.7=<WR"5S]?/6W;?2\U0W
MMBA>] 6)T,Q R8S0S%M+RY_N[G]KY_.I?G[RQW&PE^BBLD.)4=X;#.D*:Z$M
M6VU[L3/]\),JXR&S@Y5HF<T:@DA'E!I.RPKSU^"$+F8W$X][[5<Z8$V?6&7'
M!T7%BN(YC\OG\X/[M%P^R?:/_&6O)G] %97 F8_BP62$)H.-9@*M7:0?YWT9
M.>K][[7(8^6=']A7YA:6?&NR%E=V,,Q9R7PTT11T6#]S6:-!(F[571IZA(55
ML*'>3.,XLL#>$:T+Q"8O_M-G.UNNZ\B557ZEQ4SDXG-PUE=#:C$B4A)CB]^.
MI(@I547R0%NK1BX.S>OY-U2.]40.RWJ>5>QI1?"!,XTZ2W.T'S9=[LH-DBR=
M*()5\[5L93;'#>B<%3!%1QJ):)[MCZ00EMCWRT =S,/'7=)RV_:<34]9$RO?
M-25V2!C2E0G BVUO?+K:JK_\&(U,>3LL?90TE]U"ZX5)]MDB\!]+B,Q,SXX,
ME-F]<X5D./KQG)?)X+%?=:6J5\-E83A^M<52VM*7-J .=]BIYXSF65[6W5;I
M>Q/&TDJ%>].=%%M+Y962GJJ *G;<;!&XYY% 8H4/F9^X^$"5 =F9IG*;Y?BQ
M?6Q=]@B:X!!BP:P566:R,792<*]G$T&\394]"V%;:BDN0HY,Z:2:]ECY]K5R
M#6^$"SP%)"A.@:I#7$XN+"_,D1-!?N)ZM:3KLRTY[9ZOUU,OG]^W+Q_H8(7@
M#>X6E&3.:L&A\)F52 4C4^KVN@)YMUVO(E\N9I0P"/00DP4__MX=PAV?"7<>
MVTZWUW9_^KDQM[?U/,70+;*,>!D5N!*,M^>-;"KK'79^)::/^&#'%P$T#<QE
M@<T'E=@F862&I@R\GOJ$EXKWF>WW <+,Z+.UKF!EK=S2?OX+#N4^T3%?5_-A
MH#UE_'NVN\_6,\[5>T3TN6XGL?G-'F_? U[AOO?RAL-_43U\S/^?&MJI0:;Y
M;Z.6A%N(?:F/WE2&V1O\*]U?Q(+2I"-Z-?VA%+:WY4CM.*:KT(+Q"#I>7]5R
M$B9U00/9_EOR7?CO0(GH7X"2%[-XYN-3".,QD4V%>R';97]6S,QS42/_^[?K
M>Q],H,*1.DS.:#S8F SJ,S/XC'.FK%@DA-R:U@&]S@,-B1]&IA67]A'FNNU<
MX.WPO!</2&2TB;?#\GIW-\\I8["7<,,U(Y)=L%X;DB:XBZBX6,:X4UK;7!?Y
M@=R=3:LUODVWA!3*,QDS.8+=&.-#4$LV]MUQ7-.5S6M%\1(N!X2_L+-S^K &
MC9Q!G8_Z0;1;O943ID+>R[U?]G)&7,>/>]%/1F$CWN7^:R<1I?4,'X:2)E_S
M,+)_4DR8:O:B?N<RH-[@@G\\J._ZZ*K:<CYR/D'6#%.'US2:FK__P.'WT:'M
MD?D]1*R\HZ#J\IOY\_ZRUZVN.E+5IY\0RDQFWX'L&QHC2>_C@3UYHYJ]I\%8
MTK6C7W#B,<\_?L&5CEP;1?GMN_R"6Z&\TO$=_/UTN<[!-MG$>B^OTZLZ, Z"
MY/H^"2L"MM",VZ<_W6RTL95H^Z=C28L?3"QBU8+SSBE5RR+!,@:#'6/SBD.M
MI%:1R&ODE%'&@YM'*%)>(04EJ*FF0[<X":HFFV[IRA/O $N!%MTC5.B7.V5*
M?O\\2T4C"@;.L_U)+]T+.A$3JJ^NTE1X@7%#)-49KE*FO_T#&I>46.(:- C!
MBB!#UM;Y]+7K4R$H 9,ZL(6IX<9/WO1@@$R[;'KT0GM%P)LK4&_6%7?8U0XE
MB_N,&7"(_'5I3C(O'XS@]1 $W&:]UEE!Z+6U(V0Z;F\:$OUI)R*E,Z&X\ZKU
MH^U1I*+'?5-:G?-T6;$=')\Y&[1;YA<<EYEM9(MV767Q@!5[RO$<Q95]%@.K
M5*$\45S!6^TB/THPRO%TDZ;'2H#MM=T(V?=AS$V7E 0@I'92OU)GO^]F-2EP
M>.N!]V3<(43"$B:N9WM%H=13IRL/!'D2UUD\J"4$ZGH!+:TCE,F"\+7MFQ2C
M7?E3=4VB$4UI_F71LR]#;_I8]I_&KQHVYQ1MD/^1[+^%^9S+-PN[M3G<0A-T
M1<_^.=G_UYK_4"'F:M](Y2GAVO5:'N5;RQ7.%]>YO^_0CE0Z2_Q(S_HF;42O
M*J;/9%]_V/QTZ2M5F31E3-6;EOKC,6ITYR[=.HXQSEKL0)?/.'@ 8#4V\P'Z
M#239TJ<HAJ2 &>ZD?UMPE"7*Q(5V>N'VFU_P5?X/!=AD* GC3+_4(T'&[+T^
M3]E<$Q-_$4,-4ZTLY]28J>=.O.>Q=NQNC:EG9$%67U@^3;S-WM=PG<+8<%D+
MCMC!R,PU"> <T'N[1<XINGKE"$]I ?6X'D]TR\*3F.V> 7L'B8(X-]:,MW X
M.::8PY#.9?2.#.K/%LUK$D!\*$)0V$9>N>D"0_SZQ?U&Z7/[R,%C9OAM!ED5
M'6N3SK'^!$;:5.-E]F@PS;&5$8M*@I#M(YY);W Y"24AW4-!2Y.;8#%/-GR#
MQJM99BZ]O ^.2* Z\YW@R4O[;IX 5-*%$,;TV &,$#[R8$:0W%%DEYP,W0I6
M/:F%_R38'36_KOY]%I:2S:B% #<>3DR@W?3 EK4(P>%L%38 )= %KD'(W&(H
M/2X.[_/068JNQY(&^\(]=/][CNZKCR7JP?Q7[]4KL'L,H;;G*'TO/:CAPHGS
M<%"V<. )"2V-_JUOK$;5%/,)7U'':\.3$X=*-JJU3.KP>'G\=Y%L2-L']TP
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M_*:$IBA-0,DWU]O?6)=^;XV-EHA?<-*0#I/:[%8K_2'GU;Y?<'F+Z]6+RFN
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M?[WRSC).GX_K;]SU;4ZT9\G#0P^_J>OM%@>0FJVJ?7N6_6]EQU?\=HNRS@*
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M\QD""*E<P6Y:>L"!6^6^%NWS)EBVU@?:GOU,;5<=#&D5_-:,7BD<4H#A>L@
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M_PX*.FWJ$R$SQ;-DT8][ELP3;\ 5\Z6("WV\9_K M32B6(5P6S1._(G$;[1
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M7BB)%H9NY,L7Q="QLM^ C-F&@+T6RK=E$^^J/B.^OYG1#K)%C7&]%?U$$2Y
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MU [A;$$S1,1/&Z\WEB:2K-\];4^.U\S%R@!B.F(/1).US@3^KV3/P2(XXD<
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M>IA=%TA> ]&;(/6L!#F1([C^\.&E!6T'N:[O 3X+"/T3PNG_"M7N_\3PK']
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MW5TS#O$!M.KEA86P&$6@B(,^[7( ?41$K1'S_L'F/*WF(7/=Y,*GSX!7WR]
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M9+??_"S5CL5_"Q&R:W3<A1A.YP8O!,WM'G7;[\8EN+VW791,6N,.&IMU/A2
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M;\Q=L_JUP;MUP_[U,D0(AX#-I%'@;?<C-6,!WZ"<'+4DB*!8U]^<RO;SYGD
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MV@@K0S$E([KN,MT-*&#;F*/Z4VUR?8#L!N21GP@H.@[ V_87.]_S36J484B
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MPTYXGZ^MATP/TD(I>%;MT]LZXS5U>7;2][S>@X7*ZT\5HM^VZDY7C?NZA\H
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M_#1LWL136P!;A3$L*B=\8K!3 J,6WFLK1KLF>CA\B RGQSH-]'\T_G0?%O&
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M)+5PJO(SI1WK+%<:<,?JFP%/[HS^\<[58HEA5=C09ED7N/=C6/; 1A5H&#M
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M<+CG>L)U"7$;0^%Y&ST \6MM9AC7)<*:"< MA$8C8&O+KQ'5ULP&(2-RF>H
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MW6%)?7940Q"4VX)CG_=DJ<;'1;_YWJ:;9>%?#\*P&#\F@^G?P,O8IZ1GYGP
M7$*-M]E)%N*J>[LLXS!>F>M7.:[ 'TM[;]WH 0OCD/Q;HVO'D-KEJ-:3AJB'
MM X---+41<W>7;BI(VJT\%#G A\L.WCW)"3$.WGE>4X)R2WCS9?B)0K%7EO%
MO5LD0U7R)* Q;UED-;/>7<@9[[MZUNE.F/UA24P!=&)JQN?IY<B"M!-J'V/<
MM)L:S6KJXE;LJ#(A9W-LS:LZQ@Y"+Y+8F  I"84U9!B^@0KV,VT?><,=T8&'
MB;JKX]IO(\^K'Y/:)OWB[_)LCE8M/A"WS(T.>SM#[LA]8&%>>&<U%)DLWGW9
M5]2B=I[_X#^\N7\BY/3]1+#WF3&[^_U YGK^A#_PIA^XQB)9_.\4Y[X'GW?F
M&S^Q%B+#*A0Q%1[8C>[VDJM;89%^!(=,95=3F%Y(KPGGZ]K_Y<6Y*%WO)R7#
MHJB*G-_6=DV/6=BH1&7CI7;#0^E^K:\7,L-2NIN9N L(RR9K2165-K!URXW>
ML:?LBAYY'Y;-""74"_<F][^ZL<$LHH/&+7GI?=HGBF1V#"-GH/8V(L^?6GV'
MQS'AV.7\#J/%B/#M*[SZYZ6X1P2']^/P?% ?9]WB6@G;PLN60LYCB6>)DSI)
MJ&88ME^Z!^_Y1K2^OBZ;H;[XG"2LJ[5G[+*?3LG54NY0)YA>Q*7QM</R@2$1
M$C"]"&12YO8;FN0 CV DHNE8GB&%8>F9[I]HE]L>+Y707@!Q_2T0H!%U#*:*
M-E6"4467;?;FF"R2A=9(7,=<%9$C:Z41 Y'3A/*XTD1+W6:4P#@T/:V5+,&/
MS&QZ^<:4O1^1IQ\[O0Z)/2% L\SA09F/[(+9^75S&N,P+QH#,3O59@_@6SS.
MZR* #[D^?Q$R&LN'Y-2TQ-CZD*IW246D<9;9?R^:FQ8"O*<]YLPA>&7*.=51
M4?VFSH^N<F8K:1Q5X.$=N+28@K<:7D+!I,3L%RJ^@QE7=H%48@A+K])QLZ,)
MQ)SX]7JHNT/D$W;7]>1/^/BNJZF-J\W7 %MO"93]_T6NY-?P5&>5(V@R'CT[
MV%3\/IY27]^HJRLW8&JNYK?14N*,@JL[8+R*&K11D]"^X!-LOZ)@:R]L$*C
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MV[^"G/<F]%6.98XM\1+XXU?HAC>L5NX3.&F<-%SWRI8]-8L@1A+]P6W@BE7
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M<+X3<18)X;),ITN,:QZ<'(O<A4WI!#3&5WMB5*97K%3NL1Y(OQ:+MF )CK"
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MGL1C\7--PM"468RHS^+N!2'=]^+*GS(D @-\;2#Z_ND@R7!OK63F0(YAZ!3
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M=50,:LVF67BK,F-(YQ<,QM,'*-2#?ZPR#';\FK!#>Q86RRDM8$_V;51&GP;
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MLTE>_-C:&K".?6A]YO:T?BIGE58+)X@V]71 C?/HMQ 5E7E>UEO:(I1>J^Q
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MF@ME$9WLMM^(#!B:;QV1.VQ_-4WOR;IU@PR([#O0'LZDB2_ >)5(G/)&Y $
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M<X77--R##B_<,BIY]>L3K.1@6.M7M)WG^^0S6E'7L*C6>5L9!=.BBE?Y_:/
MM<.WT6F)(JK&Z_:QOD[U#;7%4C3^6*GMCWNU=V?"(KCQ6PTEIFL'DYL52P%O
M-_=JVQL"2AK.13&/TGALY]%#RLHZ-1\X?^YAEM;SM:]VNF##6W5Y05&2\?.
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M/[>>5H9=),1]Z\#R(H0 O)>0:UIP0T*D#QTP6S9>2N5+S!"B">=C*XOCP$#
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MB6N9<X_#$V=%LATC&Q.]8QMW9;4M.S$)]:UFB90QKS1\.WH1H?PC? [/MS<
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M)OP81)79C4;>C5>7=6GV+(6**+MPJS]/-AV[#IMVUB@:,Z$8G/'1-!C41KA
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M^#IW*_VS123]RV'^N9F8 0P!:B[]DZT-@-*[+W[N%:6O9;RH,11L[]>C :I
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ME(?R_TN:?63\'5!+ 0(4 Q0    ( /9]"E%*JJ=04V@  ":[!  :
M      "  0    !A,C P-C$X9&]D;F%T:6-K87=A<F1E+FAT;5!+ 0(4 Q0
M   ( /9]"E'FAC\E%F<  .W) @ :              "  8MH  !A,C P-C(R
M9&]D;F%T:6-K;W1A86=R+FAT;5!+ 0(4 Q0    ( /9]"E%6<R5IF!,  ([5
M   0              "  =G/  !I;F\M,C R,# V,S N>'-D4$L! A0#%
M  @ ]GT*47I-">%J)   2H<! !0              ( !G^,  &EN;RTR,#(P
M,#8S,%]C86PN>&UL4$L! A0#%     @ ]GT*4=&[ 7S];   )S8% !0
M         ( !.P@! &EN;RTR,#(P,#8S,%]D968N>&UL4$L! A0#%     @
M]GT*4>UUE1$1YP  B>$+ !0              ( !:G4! &EN;RTR,#(P,#8S
M,%]L86(N>&UL4$L! A0#%     @ ]GT*46NDZID(D@  ,2<' !0
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4!08     #  , !X#  "?R L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
